doc_id,curated_by,assay_category,src_id,src_assay_id,assay_tax_id,assay_id,confidence_score,tid,assay_cell_type,assay_test_type,assay_tissue,description,variant_id,relationship_type,cell_id,assay_organism,bao_format,tissue_id,chembl_id,assay_strain,assay_subcellular_fraction,assay_type
11087,Autocuration,,1,,,1,8,12052,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,H,,,BAO_0000019,,CHEMBL615117,,,B
684,Autocuration,,1,,,2,0,22226,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,U,,,BAO_0000219,,CHEMBL615118,,,F
15453,Autocuration,,1,,,3,0,22226,,,,,,U,,,BAO_0000019,,CHEMBL615119,,,B
17841,Autocuration,,1,,9913.0,4,4,104729,,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,H,,Bos taurus,BAO_0000249,,CHEMBL615120,,,B
17430,Intermediate,,1,,9606.0,5,1,80001,143B,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615121,,,F
17430,Intermediate,,1,,9606.0,6,1,80001,143B,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615122,,,F
13799,Intermediate,,1,,10090.0,7,1,80001,143B,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,N,163.0,Mus musculus,BAO_0000219,,CHEMBL615123,,,F
17774,Expert,,1,,9606.0,8,1,80001,143B,,,In vitro cell cytotoxicity was determined against 143B cell line,,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615124,,,F
3801,Intermediate,,1,,9606.0,9,1,80001,143B,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615125,,,F
17430,Intermediate,,1,,9606.0,10,1,80001,143B,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615126,,,F
17430,Intermediate,,1,,9606.0,11,1,80001,143B,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615127,,,F
17774,Expert,,1,,9606.0,12,1,80001,143B,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,N,163.0,Homo sapiens,BAO_0000219,,CHEMBL615128,,,F
11324,Intermediate,,1,,1280.0,13,1,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,,Staphylococcus aureus,BAO_0000218,,CHEMBL857900,,,F
11324,Intermediate,,1,,1280.0,14,1,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,,Staphylococcus aureus,BAO_0000218,,CHEMBL615129,,,F
11324,Intermediate,,1,,1280.0,15,1,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,,Staphylococcus aureus,BAO_0000218,,CHEMBL615130,,,F
11324,Intermediate,,1,,1280.0,16,1,50185,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,N,,Staphylococcus aureus,BAO_0000218,,CHEMBL615131,,,F
11347,Expert,,1,,10116.0,17,9,100122,,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL884521,,,A
16474,Autocuration,,1,,,18,8,12054,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,H,,,BAO_0000357,,CHEMBL615132,,,B
10091,Autocuration,,1,,,19,8,12054,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,H,,,BAO_0000019,,CHEMBL615133,,,B
16474,Autocuration,,1,,,20,8,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,H,,,BAO_0000357,,CHEMBL615134,,,B
16474,Autocuration,,1,,,21,8,12054,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,H,,,BAO_0000357,,CHEMBL615135,,,B
16474,Autocuration,,1,,,22,8,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,H,,,BAO_0000357,,CHEMBL615136,,,B
16474,Autocuration,,1,,,23,8,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,H,,,BAO_0000357,,CHEMBL615137,,,B
16474,Autocuration,,1,,,24,8,12054,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,H,,,BAO_0000357,,CHEMBL615138,,,B
14352,Autocuration,,1,,,25,0,22226,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,U,,,BAO_0000219,,CHEMBL836324,,,B
5646,Autocuration,,1,,9986.0,26,8,12054,,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL615139,,,B
5646,Autocuration,,1,,9986.0,27,8,12054,,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL615140,,,B
10997,Autocuration,,1,,,28,8,12426,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,H,,,BAO_0000219,,CHEMBL615141,,,B
6309,Autocuration,,1,,3847.0,29,8,12054,,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,H,,soya bean,BAO_0000357,,CHEMBL615142,,,B
167,Autocuration,,1,,3847.0,30,8,12054,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,H,,Glycine max,BAO_0000357,,CHEMBL615143,,,B
167,Autocuration,,1,,3847.0,31,8,12054,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,H,,Glycine max,BAO_0000357,,CHEMBL615144,,,B
11087,Autocuration,,1,,3847.0,32,8,12054,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,H,,Glycine max,BAO_0000357,,CHEMBL872867,,,B
11087,Autocuration,,1,,3847.0,33,8,12054,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,H,,Glycine max,BAO_0000357,,CHEMBL615145,,,B
13622,Autocuration,,1,,3847.0,34,8,12054,,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,H,,Glycine max,BAO_0000357,,CHEMBL615146,,,B
13622,Autocuration,,1,,3847.0,35,8,12054,,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,H,,Glycine max,BAO_0000357,,CHEMBL615147,,,B
11347,Autocuration,,1,,10116.0,36,0,22226,,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615148,,,A
5926,Autocuration,,1,,562.0,37,0,22226,,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,U,,Escherichia coli,BAO_0000019,,CHEMBL615149,,,B
4567,Autocuration,,1,,,38,0,22226,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,,U,,,BAO_0000019,,CHEMBL615150,,,B
3782,Intermediate,,1,,,39,3,22222,,,,Dissociation constant towards 16S rRNA construct A,,M,,,BAO_0000225,,CHEMBL615151,,,B
3782,Intermediate,,1,,,40,3,22222,,,,Dissociation constant towards 16S rRNA construct B,,M,,,BAO_0000225,,CHEMBL615152,,,B
4466,Expert,,1,,562.0,41,3,100263,,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,M,,Escherichia coli,BAO_0000225,,CHEMBL615153,,,B
6592,Expert,,1,,562.0,42,3,100263,,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,M,,Escherichia coli,BAO_0000225,,CHEMBL615154,,,B
898,Autocuration,,1,,,43,8,13053,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,H,,,BAO_0000019,,CHEMBL615155,,,B
898,Autocuration,,1,,,44,8,13053,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,H,,,BAO_0000019,,CHEMBL615156,,,B
13163,Autocuration,,1,,9606.0,45,8,20001,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,H,,Homo sapiens,BAO_0000019,,CHEMBL615157,,,B
13163,Autocuration,,1,,9606.0,46,8,20001,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,H,,Homo sapiens,BAO_0000019,,CHEMBL615158,,,B
10691,Expert,,1,,10116.0,47,9,12971,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615159,,,B
10691,Expert,,1,,10116.0,48,9,12971,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615172,,,B
10691,Expert,,1,,10116.0,49,9,12971,,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615173,,,B
10691,Expert,,1,,10116.0,50,9,12971,,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615174,,,B
898,Autocuration,,1,,,51,8,13053,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,H,,,BAO_0000019,,CHEMBL884518,,,B
912,Autocuration,,1,,,52,8,11512,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,H,,,BAO_0000357,,CHEMBL615175,,,B
912,Autocuration,,1,,,53,8,11512,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,H,,,BAO_0000357,,CHEMBL615176,,,B
912,Autocuration,,1,,,54,8,11512,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,H,,,BAO_0000357,,CHEMBL615177,,,B
15103,Autocuration,,1,,10116.0,55,5,104740,,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL615178,,Membranes,B
5116,Intermediate,,1,,9606.0,56,1,80002,1A9,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615179,,,F
14578,Autocuration,,1,,10116.0,57,7,104835,Oocytes,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL615180,,,F
14578,Autocuration,,1,,10116.0,58,7,104821,Oocytes,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL615181,,,F
14578,Autocuration,,1,,10116.0,59,7,104848,Oocytes,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL615182,,,F
4787,Expert,,1,,9606.0,60,1,80002,1A9,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615183,,,F
4787,Intermediate,,1,,9606.0,61,1,80002,1A9,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615184,,,F
3547,Intermediate,,1,,9606.0,62,1,80002,1A9,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615185,,,F
3547,Intermediate,,1,,9606.0,63,1,80002,1A9,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615186,,,F
6726,Intermediate,,1,,9606.0,64,1,80002,1A9,,,Effective dose of compound against replication of 1A9 cell line was evaluated,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615187,,,F
3455,Expert,,1,,9606.0,65,1,80002,1A9,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL885343,,,F
5726,Intermediate,,1,,9606.0,66,1,80002,1A9,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615188,,,F
5726,Intermediate,,1,,9606.0,67,1,80002,1A9,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615189,,,F
5726,Intermediate,,1,,9606.0,68,1,80002,1A9,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615190,,,F
3395,Intermediate,,1,,9606.0,69,1,80002,1A9,,,Inhibitory activity against Taxol resistant 1A9 cell lines,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615191,,,F
3415,Expert,,1,,9606.0,70,1,80002,1A9,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615192,,,F
3415,Expert,,1,,9606.0,71,1,80002,1A9,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL827083,,,F
17099,Expert,,1,,9606.0,72,1,80002,1A9,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615193,,,F
17099,Intermediate,,1,,9606.0,73,1,80002,1A9,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615194,,,F
17099,Intermediate,,1,,9606.0,74,1,80002,1A9,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615195,,,F
17099,Intermediate,,1,,9606.0,75,1,80002,1A9,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,N,506.0,Homo sapiens,BAO_0000219,,CHEMBL615196,,,F
17721,Intermediate,,1,,9606.0,76,1,81072,Jurkat,,,Inhibitory concentration against Jurkat cells,,N,503.0,Homo sapiens,BAO_0000219,,CHEMBL615197,,,F
1229,Intermediate,,1,,,77,0,22226,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,U,,,BAO_0000019,,CHEMBL615198,,,F
11347,Expert,,1,,10116.0,78,9,100121,,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615199,,,A
17117,Expert,,1,,,79,8,11231,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,H,,,BAO_0000357,,CHEMBL615200,,,B
17117,Expert,,1,,,80,8,11231,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,H,,,BAO_0000357,,CHEMBL615201,,,B
17117,Expert,,1,,,81,8,11231,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,H,,,BAO_0000357,,CHEMBL615202,,,B
11375,Autocuration,,1,,5476.0,82,8,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,H,,Candida albicans,BAO_0000251,,CHEMBL615203,,Microsomes,B
11375,Autocuration,,1,,5476.0,83,8,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,H,,Candida albicans,BAO_0000251,,CHEMBL615204,,Microsomes,B
11375,Autocuration,,1,,4932.0,84,8,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,H,,Saccharomyces cerevisiae,BAO_0000251,,CHEMBL615205,,Microsomes,B
11375,Autocuration,,1,,4932.0,85,8,11231,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,H,,Saccharomyces cerevisiae,BAO_0000251,,CHEMBL615206,,Microsomes,B
11375,Autocuration,,1,,9823.0,86,8,12083,,,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,H,,Sus scrofa,BAO_0000251,2107.0,CHEMBL615207,,Microsomes,B
791,Autocuration,,1,,10116.0,87,8,11231,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,H,,Rattus norvegicus,BAO_0000019,,CHEMBL827084,,,B
791,Autocuration,,1,,10116.0,88,8,11231,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,H,,Rattus norvegicus,BAO_0000019,,CHEMBL615208,,,B
791,Autocuration,,1,,10116.0,89,8,11231,,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,H,,Rattus norvegicus,BAO_0000019,,CHEMBL615209,,,B
11375,Autocuration,,1,,10116.0,90,9,12083,,,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615210,,Microsomes,B
11375,Autocuration,,1,,10116.0,91,9,12083,,,Liver,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615211,,Microsomes,B
153,Autocuration,,1,,10116.0,92,9,12083,,,Liver,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615212,,Microsomes,B
8269,Expert,,1,,,93,8,11377,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,H,,,BAO_0000357,,CHEMBL615213,,,B
8269,Expert,,1,,,94,8,11377,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,H,,,BAO_0000357,,CHEMBL615273,,,B
17653,Expert,,1,,9606.0,95,1,81020,HepG2,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615274,,,F
14277,Intermediate,,1,,9606.0,96,1,81020,HepG2,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615275,,,F
1717,Intermediate,,1,,9606.0,97,1,81020,HepG2,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615276,,,F
14091,Intermediate,,1,,9606.0,98,1,81020,HepG2,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615277,,,F
14091,Intermediate,,1,,9606.0,99,1,81020,HepG2,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615326,,,F
17653,Expert,,1,,10407.0,100,1,50606,,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,N,,Hepatitis B virus,BAO_0000218,,CHEMBL883130,,,F
13105,Intermediate,,1,,9606.0,101,1,81020,HepG2,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL884519,,,F
1717,Intermediate,,1,,9606.0,102,1,81020,HepG2,,,Concentration required to inhibit 50% of 2.2.15 cell line,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615327,,,F
13105,Intermediate,,1,,9606.0,103,1,81020,HepG2,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615328,,,A
13600,Intermediate,,1,,9606.0,104,1,50587,2.2.15,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,N,,Homo sapiens,BAO_0000218,,CHEMBL615329,,,F
13467,Intermediate,,1,,9606.0,105,1,50587,2.2.15,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,N,,Homo sapiens,BAO_0000218,,CHEMBL615330,,,F
17477,Expert,,1,,10407.0,106,1,50606,2.2.15,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,N,,Hepatitis B virus,BAO_0000218,,CHEMBL615331,,,F
1593,Intermediate,,1,,9606.0,107,1,50587,2.2.15,,,In vitro anti-HBV activity in 2.2.15 cells,,N,,Homo sapiens,BAO_0000218,,CHEMBL615332,,,F
1593,Intermediate,,1,,9606.0,108,1,50587,2.2.15,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,N,,Homo sapiens,BAO_0000218,,CHEMBL615333,,,F
15089,Intermediate,,1,,9606.0,109,1,50587,2.2.15,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,N,,Homo sapiens,BAO_0000218,,CHEMBL615334,,,F
15089,Intermediate,,1,,9606.0,110,1,50587,2.2.15,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,N,,Homo sapiens,BAO_0000218,,CHEMBL615335,,,F
1593,Intermediate,,1,,9606.0,111,1,50587,2.2.15,,,Cytotoxicity in 2.2.15 cells,,N,,Homo sapiens,BAO_0000218,,CHEMBL615336,,,F
1593,Intermediate,,1,,9606.0,112,1,50587,2.2.15,,,Cytotoxicity in 2.2.15 cells; Not determined,,N,,Homo sapiens,BAO_0000218,,CHEMBL615337,,,F
13600,Intermediate,,1,,9606.0,113,1,50587,2.2.15,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,N,,Homo sapiens,BAO_0000218,,CHEMBL615338,,,F
13467,Intermediate,,1,,9606.0,114,1,50587,2.2.15,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,N,,Homo sapiens,BAO_0000218,,CHEMBL615339,,,F
13467,Intermediate,,1,,9606.0,115,1,50587,2.2.15,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,N,,Homo sapiens,BAO_0000218,,CHEMBL615340,,,F
14764,Intermediate,,1,,9606.0,116,1,81020,HepG2,,,Antiviral activity against HBV was determined in 2.215 cell line,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615341,,,F
6531,Autocuration,,1,,9606.0,117,0,22226,,,,Inhibition of 20-HETE synthesis in human renal microsomes,,U,,Homo sapiens,BAO_0000251,,CHEMBL615342,,Microsomes,B
17322,Autocuration,,1,,,118,0,22226,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,U,,,BAO_0000019,,CHEMBL615343,,,B
17072,Intermediate,,1,,9606.0,119,1,80612,2008,,,Inhibitory concentration against 2008 (ovarian) cells,,N,388.0,Homo sapiens,BAO_0000219,,CHEMBL615344,,,F
16936,Intermediate,,1,,9606.0,120,1,80612,2008,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,N,388.0,Homo sapiens,BAO_0000219,,CHEMBL615345,,,F
16936,Intermediate,,1,,9606.0,121,1,80612,2008,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,N,388.0,Homo sapiens,BAO_0000219,,CHEMBL615346,,,F
17146,Intermediate,,1,,9606.0,122,1,80612,2008,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,N,388.0,Homo sapiens,BAO_0000219,,CHEMBL615347,,,F
17146,Intermediate,,1,,9606.0,123,1,80612,2008,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,N,388.0,Homo sapiens,BAO_0000219,,CHEMBL615348,,,F
10797,Intermediate,,1,,9606.0,124,1,80613,2008/R,,,In vitro inhibition of 2008/R ovarian cancer cell line,,N,561.0,Homo sapiens,BAO_0000219,,CHEMBL827085,,,F
10797,Intermediate,,1,,9606.0,125,1,80613,2008/R,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,N,561.0,Homo sapiens,BAO_0000219,,CHEMBL615349,,,F
10797,Intermediate,,1,,9606.0,126,1,80614,2008/S,,,In vitro inhibition of 2008/S ovarian cancer cell line,,N,389.0,Homo sapiens,BAO_0000219,,CHEMBL615350,,,F
10797,Intermediate,,1,,9606.0,127,1,80614,2008/S,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,N,389.0,Homo sapiens,BAO_0000219,,CHEMBL615351,,,F
4823,Expert,,1,,9606.0,128,2,100256,,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,S,,Homo sapiens,BAO_0000220,,CHEMBL615352,,,B
12912,Intermediate,,1,,9606.0,129,2,100256,,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,S,,Homo sapiens,BAO_0000220,,CHEMBL615353,,,B
2957,Expert,,1,,,130,2,100256,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,,S,,,BAO_0000220,,CHEMBL615354,,,B
2957,Expert,,1,,,131,2,100256,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,S,,,BAO_0000220,,CHEMBL615355,,,B
3260,Intermediate,,1,,,132,2,100256,,,,Inhibitory activity against 20S proteosome,,S,,,BAO_0000220,,CHEMBL615356,,,B
3451,Autocuration,,1,,9606.0,133,0,22226,,,,Compound was tested for inhibitory activity against tryptase,,U,,Homo sapiens,BAO_0000019,,CHEMBL615357,,,B
13885,Intermediate,,1,,9606.0,134,1,81020,HepG2,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL615358,,,F
13885,Intermediate,,1,,9606.0,135,1,81020,HepG2,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,N,726.0,Homo sapiens,BAO_0000219,,CHEMBL827086,,,F
3676,Autocuration,,1,,,136,0,22226,,,,Compound was tested for the inhibition of Alpha-glucosidase,,U,,,BAO_0000019,,CHEMBL615359,,,B
6043,Autocuration,,1,,,137,8,235,,,,Inhibitory concentration against human neutrophil elastase (HNE),,H,,,BAO_0000357,,CHEMBL615360,,,B
11140,Autocuration,,1,,10116.0,138,0,22226,,,Heart,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,U,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL615361,,,F
10543,Autocuration,,1,,,139,8,19640,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,H,,,BAO_0000019,,CHEMBL615362,,,F
10543,Expert,,1,,,140,8,19640,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,H,,,BAO_0000019,,CHEMBL615363,,,F
10543,Autocuration,,1,,,141,8,19640,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,H,,,BAO_0000357,,CHEMBL615364,,,B
10543,Expert,,1,,,142,8,19640,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,H,,,BAO_0000019,,CHEMBL615365,,,F
11365,Intermediate,,1,,10090.0,143,1,80360,P338,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,N,524.0,Mus musculus,BAO_0000219,,CHEMBL615366,,,F
11365,Intermediate,,1,,10090.0,144,1,80360,P338,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,N,524.0,Mus musculus,BAO_0000219,,CHEMBL615367,,,F
11803,Intermediate,,1,,9606.0,145,1,80384,PBL,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,N,554.0,Homo sapiens,BAO_0000219,,CHEMBL615368,,,F
11803,Autocuration,,1,,9940.0,146,0,22226,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,U,,Ovis aries,BAO_0000019,,CHEMBL615369,,,F
11803,Autocuration,,1,,9940.0,147,0,22226,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,U,,Ovis aries,BAO_0000019,,CHEMBL615370,,,F
12278,Autocuration,,1,,,148,8,191,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,H,,,BAO_0000357,,CHEMBL615673,,,B
8249,Autocuration,,1,,9606.0,149,0,22226,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,U,,Homo sapiens,BAO_0000019,,CHEMBL615674,,,F
8249,Autocuration,,1,,9606.0,150,0,22226,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,U,,Homo sapiens,BAO_0000019,,CHEMBL615675,,,F
8249,Autocuration,,1,,9606.0,151,0,22226,CCRF-CEM,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,U,635.0,Homo sapiens,BAO_0000219,,CHEMBL615676,,,F
8249,Autocuration,,1,,9606.0,152,0,22226,CCRF-CEM,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,U,635.0,Homo sapiens,BAO_0000219,,CHEMBL615677,,,F
8249,Autocuration,,1,,9606.0,153,0,22226,CCRF-CEM,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,U,635.0,Homo sapiens,BAO_0000219,,CHEMBL615678,,,F
8249,Autocuration,,1,,9606.0,154,0,22226,CCRF-CEM,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,U,635.0,Homo sapiens,BAO_0000219,,CHEMBL615679,,,F
8249,Autocuration,,1,,9606.0,155,0,22226,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,U,,Homo sapiens,BAO_0000019,,CHEMBL615680,,,F
8249,Autocuration,,1,,9606.0,156,0,22226,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,U,,Homo sapiens,BAO_0000019,,CHEMBL615681,,,F
16992,Autocuration,,1,,,157,6,104290,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,H,,,BAO_0000249,,CHEMBL857972,,,B
10543,Intermediate,,1,,1314.0,158,1,50264,,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,N,,Streptococcus pyogenes,BAO_0000218,,CHEMBL857899,,,F
17833,Intermediate,,1,,10335.0,159,1,50527,,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,N,,Human herpesvirus 3,BAO_0000218,,CHEMBL615371,,,F
17290,Expert,,1,,10335.0,160,1,50527,HEL,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,N,468.0,vericilla zoster virus,BAO_0000218,,CHEMBL615372,,,F
17290,Intermediate,,1,,10335.0,161,1,50527,,,,Antiviral activity against 07/1 strain of VZV; ND: No data,,N,,vericilla zoster virus,BAO_0000218,,CHEMBL615373,,,F
17290,Intermediate,,1,,10335.0,162,1,50527,,,,Antiviral activity against 07/1 strain of VZV; ND=No data,,N,,vericilla zoster virus,BAO_0000218,,CHEMBL615374,,,F
10932,Intermediate,,1,,561.0,163,1,50145,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,N,,escherichia cloac,BAO_0000218,,CHEMBL615375,,,F
9707,Autocuration,,1,,,164,0,22226,,,,Ratio of Ki at A2 to Ki at A1 receptors,,U,,,BAO_0000019,,CHEMBL615376,,,B
2346,Expert,,1,,5476.0,165,8,11143,,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,H,,Candida albicans,BAO_0000249,,CHEMBL615377,,,B
2205,Expert,,1,,284593.0,166,8,18077,,,,"Inhibition of 1,3-beta-glucan synthase",,H,,Candida glabrata CBS 138,BAO_0000357,,CHEMBL615378,,,B
11900,Intermediate,,1,,9606.0,167,1,80609,1-87 tumor cell line,,,Inhibition of growth of 1-87 human tumor cell line,,N,832.0,Homo sapiens,BAO_0000219,,CHEMBL615379,,,F
14864,Expert,,1,,10116.0,168,9,12166,,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL615380,,,B
16474,Autocuration,,1,,3847.0,169,9,100171,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,D,,Glycine max,BAO_0000357,,CHEMBL615381,,,B
16474,Autocuration,,1,,3847.0,170,9,100171,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,D,,Glycine max,BAO_0000357,,CHEMBL615382,,,B
16474,Autocuration,,1,,3847.0,171,9,100171,,,,% inhibition against soybean 1-lipoxygenase (SLO),,D,,Glycine max,BAO_0000357,,CHEMBL615383,,,B
16474,Autocuration,,1,,3847.0,172,9,100171,,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,D,,Glycine max,BAO_0000357,,CHEMBL615384,,,B
3094,Autocuration,,1,,3847.0,173,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,D,,Glycine max,BAO_0000357,,CHEMBL615385,,,B
3094,Autocuration,,1,,3847.0,174,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,D,,Glycine max,BAO_0000357,,CHEMBL615386,,,B
3094,Autocuration,,1,,3847.0,175,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,D,,Glycine max,BAO_0000357,,CHEMBL615387,,,B
3094,Autocuration,,1,,3847.0,176,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,D,,Glycine max,BAO_0000357,,CHEMBL615388,,,B
3094,Autocuration,,1,,3847.0,177,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,D,,Glycine max,BAO_0000357,,CHEMBL615214,,,B
3094,Autocuration,,1,,3847.0,178,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,D,,Glycine max,BAO_0000357,,CHEMBL827087,,,B
3094,Autocuration,,1,,3847.0,179,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,D,,Glycine max,BAO_0000357,,CHEMBL615215,,,B
3094,Autocuration,,1,,3847.0,180,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,D,,Glycine max,BAO_0000357,,CHEMBL615216,,,B
3094,Autocuration,,1,,3847.0,181,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,D,,Glycine max,BAO_0000357,,CHEMBL615217,,,B
3094,Autocuration,,1,,3847.0,182,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,D,,Glycine max,BAO_0000357,,CHEMBL615218,,,B
3094,Autocuration,,1,,3847.0,183,9,100171,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,D,,Glycine max,BAO_0000357,,CHEMBL615219,,,B
10413,Autocuration,,1,,10090.0,184,0,22226,,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,U,,Mus musculus,BAO_0000019,,CHEMBL615220,,,B
16929,Intermediate,,1,,10090.0,185,1,80049,C3H 10T1/2,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,N,294.0,Mus musculus,BAO_0000219,,CHEMBL615221,,,F
1229,Intermediate,,1,,,186,0,22226,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,U,,,BAO_0000019,,CHEMBL615222,,,F
16587,Autocuration,,1,,,187,8,11489,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,H,,,BAO_0000357,,CHEMBL615223,,,B
16587,Autocuration,,1,,,188,8,11862,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,H,,,BAO_0000357,,CHEMBL615224,,,B
16587,Autocuration,,1,,,189,8,11862,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,H,,,BAO_0000357,,CHEMBL615225,,,B
16587,Autocuration,,1,,,190,8,11489,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,H,,,BAO_0000357,,CHEMBL615226,,,B
16587,Autocuration,,1,,,191,8,11862,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,H,,,BAO_0000357,,CHEMBL615227,,,B
8058,Expert,,1,,9913.0,192,9,12347,,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,D,,Bos taurus,BAO_0000019,,CHEMBL615228,,,F
9065,Expert,,1,,10116.0,193,9,100120,,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615229,,,B
8865,Expert,,1,,10116.0,194,9,100120,,,Adrenal gland,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,D,,Rattus norvegicus,BAO_0000357,2369.0,CHEMBL615230,,,B
9066,Expert,,1,,10116.0,195,9,100120,,,,Inhibition of rat adrenal 11-beta-hydroxylase,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615231,,,B
8394,Expert,,1,,10116.0,196,9,100120,,,,Inhibition of rat adrenal 11-beta-hydroxylase,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL884520,,,B
8394,Expert,,1,,10116.0,197,9,100120,,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615232,,,B
6431,Autocuration,,1,,,198,8,10328,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,H,,,BAO_0000019,,CHEMBL615233,,,B
6431,Autocuration,,1,,,199,8,11490,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,H,,,BAO_0000357,,CHEMBL827088,,,B
6431,Autocuration,,1,,,200,8,11490,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,H,,,BAO_0000357,,CHEMBL615234,,,B
9295,Autocuration,,1,,,201,8,11134,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,H,,,BAO_0000019,,CHEMBL615235,,,F
10193,Autocuration,,1,,,202,8,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,H,,,BAO_0000019,,CHEMBL615236,,,B
13622,Autocuration,,1,,,203,8,11134,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,,H,,,BAO_0000019,,CHEMBL615237,,,B
12079,Autocuration,,1,,,204,8,11134,,,,Inhibitory concentration against human platelet 12-lipoxygenase,,H,,,BAO_0000019,,CHEMBL615238,,,F
13622,Autocuration,,1,,,205,8,11134,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,H,,,BAO_0000019,,CHEMBL615239,,,B
12079,Autocuration,,1,,9606.0,206,9,11134,,,,Inhibitory concentration against human platelet 12-lipoxygenase,,D,,Homo sapiens,BAO_0000019,,CHEMBL615240,,,F
13500,Expert,,1,,,207,8,11835,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,H,,,BAO_0000019,,CHEMBL615241,,,B
13723,Expert,,1,,,208,8,11601,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,H,,,BAO_0000357,,CHEMBL615242,,,B
16474,Autocuration,,1,,,209,8,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,H,,,BAO_0000019,,CHEMBL615243,,,B
1630,Autocuration,,1,,,210,8,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase,,H,,,BAO_0000019,,CHEMBL615244,,,B
167,Autocuration,,1,,,211,8,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,H,,,BAO_0000019,,CHEMBL615245,,,B
16474,Autocuration,,1,,,212,8,11134,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,H,,,BAO_0000019,,CHEMBL615246,,,B
167,Autocuration,,1,,,213,8,11134,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,H,,,BAO_0000019,,CHEMBL615247,,,B
16474,Autocuration,,1,,,214,8,11134,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,H,,,BAO_0000019,,CHEMBL615248,,,B
10091,Autocuration,,1,,,215,8,11601,,,,Inhibitory activity towards porcine 12-lipoxygenase,,H,,,BAO_0000357,,CHEMBL615249,,,B
11966,Autocuration,,1,,,216,8,11601,,,,Tested for inhibition against porcine 12-LO,,H,,,BAO_0000357,,CHEMBL615250,,,B
951,Autocuration,,1,,,217,8,12052,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,H,,,BAO_0000019,,CHEMBL615251,,,B
10997,Autocuration,,1,,,218,8,12052,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,H,,,BAO_0000019,,CHEMBL615252,,,B
10193,Expert,,1,,,219,8,12052,,,,In vitro inhibition of rat platelet 12-lipoxygenase,,H,,,BAO_0000019,,CHEMBL828340,,,B
10193,Autocuration,,1,,,220,8,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,H,,,BAO_0000019,,CHEMBL615253,,,B
10193,Autocuration,,1,,,221,8,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,H,,,BAO_0000019,,CHEMBL615254,,,B
10193,Autocuration,,1,,,222,8,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,H,,,BAO_0000019,,CHEMBL615255,,,B
10193,Autocuration,,1,,,223,8,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,H,,,BAO_0000019,,CHEMBL615256,,,B
10193,Autocuration,,1,,,224,8,12052,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,H,,,BAO_0000019,,CHEMBL615257,,,B
11087,Autocuration,,1,,,225,8,12052,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,H,,,BAO_0000019,,CHEMBL615258,,,B
15569,Intermediate,,1,,9606.0,226,1,80007,41M,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL615259,,,F
12989,Expert,,1,,9606.0,227,1,80007,41M,,,In vitro antitumor activity against 41M cell line.,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL615260,,,F
16745,Intermediate,,1,,9606.0,228,1,80007,41M,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL615261,,,F
15569,Intermediate,,1,,9606.0,229,1,80007,41M,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL615262,,,F
12989,Expert,,1,,9606.0,230,1,80007,41M,,,In vitro antitumor activity against 41McisR cell line.,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL615263,,,F
12989,Expert,,1,,9606.0,231,1,80007,41M,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL838393,,,F
16745,Intermediate,,1,,9606.0,232,1,80007,41M,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,N,621.0,Homo sapiens,BAO_0000219,,CHEMBL615264,,,F
6210,Expert,,1,,9606.0,233,9,84,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,D,,Homo sapiens,BAO_0000357,,CHEMBL615265,,,B
6210,Expert,,1,,9606.0,234,9,68,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,D,,Homo sapiens,BAO_0000357,,CHEMBL615266,,,B
6226,Expert,,1,,,235,8,68,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,H,,,BAO_0000357,,CHEMBL615267,,,B
17855,Expert,,1,,,236,8,10201,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,H,,,BAO_0000357,,CHEMBL615268,,,B
17855,Expert,,1,,,237,8,10201,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,H,,,BAO_0000357,,CHEMBL615269,,,B
17855,Expert,,1,,,238,8,10201,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,H,,,BAO_0000357,,CHEMBL615270,,,B
10413,Autocuration,,1,,,239,8,12220,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,H,,,BAO_0000357,,CHEMBL615271,,,B
10413,Autocuration,,1,,562.0,240,8,11303,,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,H,,Escherichia coli,BAO_0000357,,CHEMBL615272,,,B
10413,Autocuration,,1,,562.0,241,8,11303,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,H,,Escherichia coli,BAO_0000357,,CHEMBL615103,,,B
10413,Autocuration,,1,,562.0,242,8,11303,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,H,,Escherichia coli,BAO_0000357,,CHEMBL615104,,,B
10413,Autocuration,,1,,,243,8,12220,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,H,,,BAO_0000357,,CHEMBL615105,,,B
10413,Autocuration,,1,,,244,8,12220,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,H,,,BAO_0000357,,CHEMBL872866,,,B
7587,Autocuration,,1,,9823.0,245,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,H,,Sus scrofa,BAO_0000357,,CHEMBL615106,,,B
7587,Autocuration,,1,,9823.0,246,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,H,,Sus scrofa,BAO_0000019,,CHEMBL615107,,,B
7587,Autocuration,,1,,9823.0,247,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,H,,Sus scrofa,BAO_0000357,,CHEMBL615108,,,B
7587,Autocuration,,1,,9823.0,248,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,H,,Sus scrofa,BAO_0000357,,CHEMBL615109,,,B
7587,Autocuration,,1,,9823.0,249,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,H,,Sus scrofa,BAO_0000357,,CHEMBL615110,,,B
7587,Autocuration,,1,,9823.0,250,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,H,,Sus scrofa,BAO_0000019,,CHEMBL840105,,,B
7587,Autocuration,,1,,9823.0,251,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,H,,Sus scrofa,BAO_0000019,,CHEMBL615111,,,B
7587,Autocuration,,1,,9823.0,252,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,H,,Sus scrofa,BAO_0000019,,CHEMBL615112,,,B
7587,Autocuration,,1,,9823.0,253,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,H,,Sus scrofa,BAO_0000019,,CHEMBL615113,,,B
7587,Autocuration,,1,,9823.0,254,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,H,,Sus scrofa,BAO_0000019,,CHEMBL615114,,,B
7587,Autocuration,,1,,9823.0,255,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,H,,Sus scrofa,BAO_0000357,,CHEMBL615115,,,B
7587,Autocuration,,1,,9823.0,256,8,11303,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,H,,Sus scrofa,BAO_0000019,,CHEMBL615116,,,B
7323,Autocuration,,1,,,257,8,11303,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,H,,,BAO_0000357,,CHEMBL615698,,,B
7587,Autocuration,,1,,9823.0,258,0,22226,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,U,,Sus scrofa,BAO_0000019,,CHEMBL615699,,,B
7587,Autocuration,,1,,9823.0,259,0,22226,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,U,,Sus scrofa,BAO_0000019,,CHEMBL615700,,,B
13750,Expert,,1,,4932.0,260,8,100249,,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,H,,Saccharomyces cerevisiae,BAO_0000357,,CHEMBL615701,,,B
7662,Autocuration,,1,,10116.0,261,0,22226,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615702,,,B
7662,Autocuration,,1,,10116.0,262,0,22226,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615703,,,B
7662,Autocuration,,1,,10116.0,263,0,22226,,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615704,,,B
12211,Autocuration,,1,,,264,6,104698,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,H,,,BAO_0000019,,CHEMBL615705,,,F
12211,Autocuration,,1,,,265,6,104698,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,H,,,BAO_0000019,,CHEMBL615706,,,F
12211,Intermediate,,1,,10141.0,266,9,20033,,,Ileum,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615707,,,F
12211,Expert,,1,,,267,8,10623,,,,Stimulatory activity of intragastric pressure was tested in the rat,,H,,,BAO_0000019,,CHEMBL615708,,,F
15453,Autocuration,,1,,,268,8,121,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,H,,,BAO_0000357,,CHEMBL615709,,,B
11884,Autocuration,,1,,10116.0,269,0,22226,,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615710,,,F
7185,Autocuration,,1,,,270,8,12688,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,H,,,BAO_0000019,,CHEMBL615711,,,F
6876,Expert,,1,,9606.0,271,9,121,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,D,,Homo sapiens,BAO_0000357,,CHEMBL615712,,,B
6876,Expert,,1,,9606.0,272,9,121,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,D,,Homo sapiens,BAO_0000357,,CHEMBL836325,,,B
11863,Autocuration,,1,,,273,8,12198,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,H,,,BAO_0000019,,CHEMBL615713,,,F
11863,Autocuration,,1,,,274,8,12198,,,,Inhibition constant of high-affinity 5-HT uptake,,H,,,BAO_0000357,,CHEMBL615714,,,B
11863,Autocuration,,1,,,275,8,12198,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,H,,,BAO_0000019,,CHEMBL615715,,,F
11863,Autocuration,,1,,,276,8,12198,,,,Maximum rate was determined for high affinity transport of 5-HT,,H,,,BAO_0000019,,CHEMBL615716,,,F
4639,Autocuration,,1,,,277,4,104714,,,,Compound was tested for agonistic activity against 5-HT uptake,,H,,,BAO_0000019,,CHEMBL615717,,,F
15796,Expert,,1,,,278,8,10577,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,H,,,BAO_0000019,,CHEMBL881818,,,B
15796,Expert,,1,,9913.0,279,8,105,,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,H,,Bos taurus,BAO_0000357,,CHEMBL884540,,,B
12801,Autocuration,,1,,10116.0,280,5,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL615718,,,B
12801,Autocuration,,1,,,281,4,104744,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,H,,,BAO_0000224,,CHEMBL615719,,,B
12120,Autocuration,,1,,,282,4,104744,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,H,,,BAO_0000249,,CHEMBL615720,,Membranes,B
12120,Autocuration,,1,,,283,4,104744,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,H,,,BAO_0000249,,CHEMBL615721,,Membranes,B
11963,Autocuration,,1,,,284,4,104744,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL615722,,,B
11701,Autocuration,,1,,,285,8,51,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,H,,,BAO_0000019,,CHEMBL615723,,,F
9995,Autocuration,,1,,,286,8,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615724,,,B
9995,Autocuration,,1,,,287,8,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615725,,,B
9995,Autocuration,,1,,,288,8,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615726,,,B
16394,Autocuration,,1,,,289,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,H,,,BAO_0000218,,CHEMBL615727,,,F
11574,Intermediate,,1,,10141.0,290,9,105570,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,D,,Cavia porcellus,BAO_0000019,,CHEMBL615728,,,F
15779,Autocuration,,1,,,291,8,279,CHO,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL857971,,,B
15363,Autocuration,,1,,,292,8,107,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL615729,,,B
15363,Expert,,1,,10116.0,293,9,12687,,,,Efficacy against 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615730,,,F
15329,Expert,,1,,,294,8,12687,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,H,,,BAO_0000019,,CHEMBL615731,,,F
15329,Expert,,1,,,295,8,12687,,,,Relative potency towards 5-HT2A receptor of rat tail artery,,H,,,BAO_0000019,,CHEMBL615732,,,F
15329,Expert,,1,,,296,8,12687,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,H,,,BAO_0000019,,CHEMBL615733,,,F
15329,Expert,,1,,,297,8,12687,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,H,,,BAO_0000019,,CHEMBL615734,,,F
15329,Autocuration,,1,,,298,8,12687,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,H,,,BAO_0000019,,CHEMBL615735,,,F
15329,Expert,,1,,,299,8,12687,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,H,,,BAO_0000019,,CHEMBL615736,,,F
273,Intermediate,,1,,10141.0,300,9,20033,,,Ileum,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615737,,,F
273,Intermediate,,1,,10141.0,301,9,20033,,,Ileum,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615738,,,F
273,Intermediate,,1,,10141.0,302,9,20033,,,Ileum,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615739,,,F
12092,Autocuration,,1,,,303,8,10623,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,H,,,BAO_0000357,,CHEMBL615278,,,B
1317,Expert,,1,,10116.0,304,9,10623,,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615279,,,F
12409,Expert,,1,,,305,8,168,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL615280,,,B
11126,Autocuration,,1,,9031.0,306,0,22226,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,U,,Gallus gallus,BAO_0000019,,CHEMBL615281,,,B
11126,Autocuration,,1,,9606.0,307,0,22226,,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,U,,Homo sapiens,BAO_0000019,,CHEMBL615282,,,F
11126,Autocuration,,1,,9606.0,308,0,22226,,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,U,,Homo sapiens,BAO_0000019,,CHEMBL615283,,,F
11126,Autocuration,,1,,9606.0,309,1,80156,HL-60,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,N,649.0,Homo sapiens,BAO_0000219,,CHEMBL615284,,,B
11126,Autocuration,,1,,9606.0,310,0,22226,,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,U,,Homo sapiens,BAO_0000019,,CHEMBL615285,,,B
11126,Autocuration,,1,,9606.0,311,0,22226,,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,U,,Homo sapiens,BAO_0000019,,CHEMBL615286,,,B
17807,Autocuration,,1,,9606.0,312,7,104703,Oocytes,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,D,,Homo sapiens,BAO_0000219,,CHEMBL615287,,,B
16575,Intermediate,,1,,,313,2,100256,,,,Chymotryptic inhibitory activity against 26S proteasome,,S,,,BAO_0000220,,CHEMBL615288,,,F
15407,Intermediate,,1,,,314,2,100256,,,,Inhibitory activity against 26S proteasome degradation of IkB,,S,,,BAO_0000220,,CHEMBL615289,,,B
10797,Intermediate,,1,,9606.0,315,1,81034,A2780,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL615290,,,F
10797,Intermediate,,1,,9606.0,316,1,81034,A2780,,,In vitro inhibition of 2780/S ovarian cancer cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL884522,,,F
3469,Autocuration,,1,,9606.0,317,0,22226,,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,U,,Homo sapiens,BAO_0000019,,CHEMBL615291,,,F
16037,Intermediate,,1,,,318,3,22222,,,,Association constant for binding to AATT 28-mer AATT hairpin,,M,,,BAO_0000225,,CHEMBL615292,,,B
16037,Intermediate,,1,,,319,3,22222,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,M,,,BAO_0000225,,CHEMBL615293,,,B
16037,Intermediate,,1,,,320,3,22222,,,,Reaction Rate Parameter for 28-mer AATT hairpin,,M,,,BAO_0000225,,CHEMBL615294,,,B
16037,Intermediate,,1,,,321,3,22222,,,,Reaction Rate Parameter for 28-mer AATT hairpin,,M,,,BAO_0000225,,CHEMBL615295,,,B
16524,Autocuration,,1,,9606.0,322,0,22226,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,U,,Homo sapiens,BAO_0000019,,CHEMBL825021,,,F
16524,Autocuration,,1,,9606.0,323,0,22226,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,U,,Homo sapiens,BAO_0000019,,CHEMBL615296,,,F
16524,Autocuration,,1,,9606.0,324,0,22226,,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,U,,Homo sapiens,BAO_0000019,,CHEMBL615297,,,F
16758,Autocuration,,1,,10029.0,325,0,22226,,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,U,,Cricetulus griseus,BAO_0000019,,CHEMBL615298,,,F
16758,Autocuration,,1,,10029.0,326,0,22226,,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,U,,Cricetulus griseus,BAO_0000019,,CHEMBL615299,,,F
16758,Autocuration,,1,,10029.0,327,0,22226,,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,U,,Cricetulus griseus,BAO_0000019,,CHEMBL615300,,,F
14360,Autocuration,,1,,,328,8,241,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,H,,,BAO_0000357,,CHEMBL615301,,,B
14360,Expert,,1,,9606.0,329,9,241,,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,D,,Homo sapiens,BAO_0000357,,CHEMBL615302,,,B
9964,Autocuration,,1,,10116.0,330,0,22226,,,,Selectivity ratio of ID50 in liver and heart,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615303,,,B
9964,Autocuration,,1,,,331,8,12132,,,,"Selectivity, ratio of relative ID50 in liver and heart",,H,,,BAO_0000019,,CHEMBL615304,,,B
9964,Autocuration,,1,,,332,8,12132,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,H,,,BAO_0000019,,CHEMBL615305,,,B
9964,Autocuration,,1,,,333,8,12132,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000218,,CHEMBL615306,,,B
9964,Autocuration,,1,,,334,8,12132,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000218,,CHEMBL615307,,,B
9964,Autocuration,,1,,,335,8,12132,,In vivo,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000218,,CHEMBL615308,,,B
9964,Autocuration,,1,,,336,8,12132,,In vivo,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000218,,CHEMBL615309,,,F
9964,Autocuration,,1,,,337,0,22226,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,U,,,BAO_0000019,,CHEMBL615310,,,B
9964,Autocuration,,1,,,338,8,12132,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,H,,,BAO_0000019,,CHEMBL615311,,,B
9964,Autocuration,,1,,9606.0,339,0,22226,,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,U,,Homo sapiens,BAO_0000019,,CHEMBL615312,,,B
9964,Autocuration,,1,,,340,8,12132,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,H,,,BAO_0000019,,CHEMBL615313,,,B
9964,Autocuration,,1,,,341,8,12132,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,H,,,BAO_0000019,,CHEMBL615314,,,F
9964,Autocuration,,1,,,342,8,12132,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000019,,CHEMBL615315,,,B
9964,Autocuration,,1,,10116.0,343,0,22226,,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615316,,,B
9964,Autocuration,,1,,,344,8,12132,,In vivo,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,H,,,BAO_0000218,,CHEMBL615317,,,B
9964,Autocuration,,1,,,345,8,12132,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000218,,CHEMBL615318,,,B
9964,Autocuration,,1,,10116.0,346,0,22226,,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615319,,,B
9964,Autocuration,,1,,,347,8,12132,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000019,,CHEMBL615320,,,B
9964,Autocuration,,1,,,348,8,12132,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,H,,,BAO_0000019,,CHEMBL615321,,,F
3796,Autocuration,,1,,10116.0,349,0,22226,,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615322,,,B
4251,Autocuration,,1,,562.0,350,8,19690,,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,H,,Escherichia coli,BAO_0000357,,CHEMBL615323,,,B
4251,Autocuration,,1,,562.0,351,8,19690,,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,H,,Escherichia coli,BAO_0000357,,CHEMBL615407,,,B
4251,Autocuration,,1,,562.0,352,8,19690,,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,H,,Escherichia coli,BAO_0000357,,CHEMBL857267,,,B
4251,Autocuration,,1,,562.0,353,8,19690,,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,H,,Escherichia coli,BAO_0000357,,CHEMBL615408,,,B
166,Autocuration,,1,,,354,8,19690,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,H,,,BAO_0000357,,CHEMBL615409,,,B
17861,Autocuration,,1,,,355,8,19690,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,H,,,BAO_0000357,,CHEMBL615410,,,B
166,Autocuration,,1,,,356,8,19690,,,,Inhibition constant against 3-dehydroquinate synthase,,H,,,BAO_0000357,,CHEMBL615411,,,B
166,Autocuration,,1,,,357,8,19690,,,,Association rate constant against 3-dehydroquinate synthase,,H,,,BAO_0000357,,CHEMBL615412,,,B
166,Autocuration,,1,,,358,8,19690,,,,Rate constant against 3-dehydroquinate synthase,,H,,,BAO_0000357,,CHEMBL615413,,,B
3548,Autocuration,,1,,,359,0,22226,,,,Inhibitory activity against fuc-TVII,,U,,,BAO_0000019,,CHEMBL615414,,,B
9877,Autocuration,,1,,10116.0,360,9,12236,,,Liver,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615415,,Microsomes,B
9877,Autocuration,,1,,10116.0,361,9,12236,,,Liver,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615416,,Microsomes,B
9877,Autocuration,,1,,10116.0,362,9,12236,,,Liver,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615417,,Microsomes,B
9877,Autocuration,,1,,10116.0,363,9,12236,,,Liver,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615418,,Microsomes,B
9877,Autocuration,,1,,10116.0,364,9,12236,,,Liver,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615419,,Microsomes,B
9877,Autocuration,,1,,10116.0,365,9,12236,,,Liver,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615420,,Microsomes,B
9877,Autocuration,,1,,10116.0,366,9,12236,,,Liver,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615421,,Microsomes,B
9877,Autocuration,,1,,10116.0,367,9,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615422,,Microsomes,B
9877,Autocuration,,1,,10116.0,368,9,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615423,,Microsomes,B
9877,Autocuration,,1,,10116.0,369,9,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL872868,,Microsomes,B
9877,Autocuration,,1,,10116.0,370,9,12236,,,Liver,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,D,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL615424,,Microsomes,B
3003,Autocuration,,1,,,371,4,104832,,,,Inhibitory activity against 3-phosphoglycerate kinase.,,H,,,BAO_0000224,,CHEMBL825022,,,B
3003,Autocuration,,1,,,372,4,104832,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,H,,,BAO_0000224,,CHEMBL615425,,,B
3003,Autocuration,,1,,,373,4,104832,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,H,,,BAO_0000224,,CHEMBL615426,,,B
17185,Expert,,1,,9606.0,374,9,10612,,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,D,,Homo sapiens,BAO_0000357,,CHEMBL615427,,,B
6072,Intermediate,,1,,9606.0,375,1,80616,3677 melanoma cell line,,,Cytotoxicity on 3677 melanoma cells,,N,844.0,Homo sapiens,BAO_0000219,,CHEMBL615428,,,F
6072,Intermediate,,1,,9606.0,376,1,80616,3677 melanoma cell line,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,N,844.0,Homo sapiens,BAO_0000219,,CHEMBL615429,,,F
5018,Intermediate,,1,,10090.0,377,1,80617,MC-38,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,N,700.0,Mus musculus,BAO_0000219,,CHEMBL615430,,,F
2852,Intermediate,,1,,9606.0,378,0,22226,,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,U,,Homo sapiens,BAO_0000019,,CHEMBL615431,,,F
8663,Autocuration,,1,,,379,0,22226,B16,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,U,798.0,,BAO_0000218,,CHEMBL615432,,,F
8663,Autocuration,,1,,,380,0,22226,B16,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,U,798.0,,BAO_0000218,,CHEMBL615433,,,F
3245,Expert,,1,,12131.0,381,9,12464,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,D,,Human rhinovirus 14,BAO_0000019,,CHEMBL615434,,,F
3245,Intermediate,,1,,169066.0,382,1,50085,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,N,,Human rhinovirus sp.,BAO_0000218,,CHEMBL615435,,,F
3877,Intermediate,,1,,169066.0,383,1,50679,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,N,,human rhinovirus type 14,BAO_0000218,,CHEMBL615436,,,F
3877,Intermediate,,1,,169066.0,384,1,50679,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,N,,human rhinovirus type 14,BAO_0000218,,CHEMBL615437,,,F
5861,Expert,,1,,12131.0,385,9,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,D,,Human rhinovirus 14,BAO_0000019,,CHEMBL615438,,,F
5861,Expert,,1,,12131.0,386,9,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,D,,Human rhinovirus 14,BAO_0000019,,CHEMBL615439,,,F
5861,Expert,,1,,12131.0,387,9,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,D,,Human rhinovirus 14,BAO_0000019,,CHEMBL615440,,,F
5861,Expert,,1,,12131.0,388,9,12464,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,D,,Human rhinovirus 14,BAO_0000019,,CHEMBL615441,,,F
13748,Intermediate,,1,,12059.0,389,1,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,N,,Enterovirus,BAO_0000218,,CHEMBL615641,,,F
13748,Intermediate,,1,,12059.0,390,1,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,N,,Enterovirus,BAO_0000218,,CHEMBL872065,,,F
13748,Intermediate,,1,,12059.0,391,1,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,N,,Enterovirus,BAO_0000218,,CHEMBL825023,,,F
13748,Intermediate,,1,,12059.0,392,1,50665,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,N,,Enterovirus,BAO_0000218,,CHEMBL615642,,,F
13748,Expert,,1,,147712.0,393,8,12464,,,,Inhibition of human rhinovirus 3C protease,,H,,Human rhinovirus B,BAO_0000357,,CHEMBL615643,,,B
17699,Autocuration,,1,,9606.0,394,0,22226,,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,U,,Homo sapiens,BAO_0000019,,CHEMBL615644,,,B
7145,Intermediate,,1,,10090.0,395,1,80619,3EM 37,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,N,833.0,Mus musculus,BAO_0000218,,CHEMBL615645,,,F
7145,Intermediate,,1,,10090.0,396,1,80619,3EM 37,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,N,833.0,Mus musculus,BAO_0000218,,CHEMBL615646,,,F
7145,Intermediate,,1,,10090.0,397,1,80619,3EM 37,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,N,833.0,Mus musculus,BAO_0000218,,CHEMBL615647,,,F
7145,Intermediate,,1,,10090.0,398,1,80619,3EM 37,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,N,833.0,Mus musculus,BAO_0000218,,CHEMBL615648,,,F
7145,Intermediate,,1,,10090.0,399,1,80619,3EM 37,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,N,833.0,Mus musculus,BAO_0000218,,CHEMBL615649,,,F
7145,Intermediate,,1,,10090.0,400,1,80619,3EM 37,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,N,833.0,Mus musculus,BAO_0000218,,CHEMBL615650,,,F
5325,Intermediate,,1,,10090.0,401,1,80620,3LL cell line,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,N,847.0,Mus musculus,BAO_0000218,,CHEMBL615651,,,F
5325,Intermediate,,1,,10090.0,402,1,80620,3LL cell line,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,N,847.0,Mus musculus,BAO_0000218,,CHEMBL615652,,,F
5325,Expert,,1,,10090.0,403,1,80620,3LL cell line,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,N,847.0,Mus musculus,BAO_0000218,,CHEMBL615653,,,F
16169,Intermediate,,1,,10090.0,404,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615654,,,F
16169,Intermediate,,1,,10090.0,405,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615655,,,F
16169,Intermediate,,1,,10090.0,406,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL825024,,,F
16169,Intermediate,,1,,10090.0,407,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615656,,,F
16169,Intermediate,,1,,10090.0,408,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615657,,,F
16169,Intermediate,,1,,10090.0,409,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615658,,,F
16169,Intermediate,,1,,10090.0,410,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615659,,,F
16169,Intermediate,,1,,10090.0,411,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615660,,,F
16169,Intermediate,,1,,10090.0,412,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615661,,,F
16169,Intermediate,,1,,10090.0,413,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615662,,,F
16169,Intermediate,,1,,10090.0,414,1,80620,3LL cell line,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615663,,,F
16169,Intermediate,,1,,10090.0,415,1,80620,3LL cell line,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615664,,,F
16169,Intermediate,,1,,10090.0,416,1,80620,3LL cell line,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615665,,,F
16169,Intermediate,,1,,10090.0,417,1,80620,3LL cell line,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615666,,,F
16169,Intermediate,,1,,10090.0,418,1,80620,3LL cell line,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615667,,,F
16169,Intermediate,,1,,10090.0,419,1,80620,3LL cell line,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615668,,,F
16169,Intermediate,,1,,10090.0,420,1,80620,3LL cell line,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615669,,,F
16169,Intermediate,,1,,10090.0,421,1,80620,3LL cell line,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615670,,,F
16169,Intermediate,,1,,10090.0,422,1,80620,3LL cell line,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL836739,,,F
16169,Intermediate,,1,,10090.0,423,1,80620,3LL cell line,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615671,,,F
16169,Intermediate,,1,,10090.0,424,1,80620,3LL cell line,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615672,,,F
16169,Intermediate,,1,,10090.0,425,1,80620,3LL cell line,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615791,,,F
16169,Intermediate,,1,,10090.0,426,1,80620,3LL cell line,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615792,,,F
16169,Intermediate,,1,,10090.0,427,1,80620,3LL cell line,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615793,,,F
16169,Intermediate,,1,,10090.0,428,1,80620,3LL cell line,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615794,,,F
16169,Intermediate,,1,,10090.0,429,1,80620,3LL cell line,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,N,847.0,Mus musculus,BAO_0000219,,CHEMBL615795,,,F
15547,Intermediate,,1,,9606.0,430,1,80621,3LLD122,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,N,971.0,Homo sapiens,BAO_0000219,,CHEMBL615590,,,F
8663,Autocuration,,1,,,431,0,22226,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,U,,,BAO_0000218,,CHEMBL615591,,,F
8663,Autocuration,,1,,,432,0,22226,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,U,,,BAO_0000218,,CHEMBL615592,,,F
8663,Autocuration,,1,,,433,0,22226,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,U,,,BAO_0000218,,CHEMBL615593,,,F
8663,Autocuration,,1,,,434,0,22226,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,U,,,BAO_0000218,,CHEMBL615594,,,F
4504,Intermediate,,1,,10090.0,435,1,80951,NIH3T3,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615595,,,F
4504,Intermediate,,1,,10090.0,436,1,80951,NIH3T3,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615596,,,F
12695,Expert,,1,,,437,8,11169,NIH3T3,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,H,723.0,,BAO_0000219,,CHEMBL615597,,,F
12695,Intermediate,,1,,10090.0,438,1,80951,NIH3T3,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615598,,,F
12695,Intermediate,,1,,10090.0,439,1,80951,NIH3T3,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615599,,,F
17642,Expert,,1,,10090.0,440,1,80951,NIH3T3,,,Effective dose against murine 3T3 fibroblasts cells,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615600,,,F
17642,Expert,,1,,10090.0,441,1,80951,NIH3T3,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615601,,,F
12340,Expert,,1,,10090.0,442,1,80951,NIH3T3,,,Cytotoxic effect on 3T3 cells,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615602,,,F
12340,Expert,,1,,10090.0,443,1,80951,NIH3T3,,,Cytotoxic effect on 3T3 cells,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615603,,,F
12716,Intermediate,,1,,10090.0,444,1,80951,NIH3T3,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615604,,,F
6277,Intermediate,,1,,10090.0,445,1,80951,NIH3T3,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615605,,,F
6277,Intermediate,,1,,10090.0,446,1,80951,NIH3T3,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615606,,,F
6277,Expert,,1,,10090.0,447,1,80951,NIH3T3,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL884526,,,F
6277,Expert,,1,,10090.0,448,1,80951,NIH3T3,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615607,,,F
6277,Intermediate,,1,,10090.0,449,1,80951,NIH3T3,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615608,,,F
6277,Expert,,1,,10090.0,450,1,80951,NIH3T3,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615609,,,F
6277,Expert,,1,,10090.0,451,1,80951,NIH3T3,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615682,,,F
6277,Intermediate,,1,,10090.0,452,1,80951,NIH3T3,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615683,,,F
17780,Expert,,1,,10090.0,453,1,80951,NIH3T3,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,N,723.0,Mus musculus,BAO_0000218,,CHEMBL615684,,,F
12751,Autocuration,,1,,10090.0,454,7,104860,,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,D,,Mus musculus,BAO_0000219,,CHEMBL615685,,,F
12380,Expert,,1,,10090.0,455,1,80951,NIH3T3,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615686,,,F
14892,Intermediate,,1,,10090.0,456,1,80951,NIH3T3,,,Inhibitory activity against 3T3 cell line,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615687,,,F
12695,Intermediate,,1,,10090.0,457,1,80951,NIH3T3,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL884523,,,F
12695,Expert,,1,,,458,8,11169,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,H,,,BAO_0000019,,CHEMBL615688,,,F
12695,Intermediate,,1,,10090.0,459,1,80951,NIH3T3,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615689,,,F
12695,Intermediate,,1,,10090.0,460,1,80951,NIH3T3,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615690,,,F
12695,Expert,,1,,,461,8,11169,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,H,,,BAO_0000019,,CHEMBL615691,,,F
12695,Expert,,1,,,462,8,11169,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,H,,,BAO_0000019,,CHEMBL615692,,,F
6277,Intermediate,,1,,10090.0,463,1,80951,NIH3T3,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615693,,,F
6277,Expert,,1,,10090.0,464,1,80951,NIH3T3,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615324,,,F
4959,Expert,,1,,9606.0,465,9,9,NIH3T3,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,D,723.0,Homo sapiens,BAO_0000219,,CHEMBL615325,,,F
4959,Expert,,1,,9606.0,466,9,9,NIH3T3,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,D,723.0,Homo sapiens,BAO_0000219,,CHEMBL615490,,,F
4959,Expert,,1,,9606.0,467,9,188,NIH3T3,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,D,723.0,Homo sapiens,BAO_0000219,,CHEMBL615491,,,F
4959,Expert,,1,,9606.0,468,9,188,NIH3T3,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,D,723.0,Homo sapiens,BAO_0000219,,CHEMBL615492,,,F
12082,Intermediate,,1,,10090.0,469,1,80951,NIH3T3,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615493,,,F
12082,Intermediate,,1,,10090.0,470,1,80951,NIH3T3,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615494,,,F
12082,Intermediate,,1,,10090.0,471,1,80951,NIH3T3,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615495,,,F
12082,Intermediate,,1,,10090.0,472,1,80951,NIH3T3,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615496,,,F
2643,Intermediate,,1,,10090.0,473,1,80951,NIH3T3,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615497,,,F
11926,Expert,,1,,10090.0,474,1,80951,NIH3T3,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615498,,,F
15204,Intermediate,,1,,10090.0,475,1,80951,NIH3T3,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615499,,,A
15992,Expert,,1,,10090.0,476,1,80951,NIH3T3,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL835522,,,F
16279,Intermediate,,1,,10090.0,477,1,80951,NIH3T3,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615500,,,F
16279,Intermediate,,1,,10090.0,478,1,80951,NIH3T3,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615501,,,F
16279,Intermediate,,1,,10090.0,479,1,80951,NIH3T3,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615502,,,F
16279,Intermediate,,1,,10090.0,480,1,80951,NIH3T3,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615503,,,F
16279,Intermediate,,1,,10090.0,481,1,80951,NIH3T3,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615504,,,F
16279,Intermediate,,1,,10090.0,482,1,80951,NIH3T3,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615505,,,F
12831,Expert,,1,,10090.0,483,1,80951,NIH3T3,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615506,,,F
13497,Intermediate,,1,,10090.0,484,1,80951,NIH3T3,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,N,723.0,Mus musculus,BAO_0000219,,CHEMBL615507,,,F
13715,Intermediate,,1,,,485,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615508,,,F
13618,Intermediate,,1,,10090.0,486,1,80006,3T3-L1,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615509,,,F
11902,Intermediate,,1,,10090.0,487,1,80006,3T3-L1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615510,,,F
11902,Intermediate,,1,,10090.0,488,1,80006,3T3-L1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615511,,,F
11902,Intermediate,,1,,10090.0,489,1,80006,3T3-L1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615512,,,F
14840,Intermediate,,1,,10090.0,490,1,80006,3T3-L1,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,N,620.0,Mus musculus,BAO_0000218,,CHEMBL615513,,,F
14840,Intermediate,,1,,10090.0,491,1,80006,3T3-L1,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,N,620.0,Mus musculus,BAO_0000218,,CHEMBL615514,,,F
13715,Intermediate,,1,,,492,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,N,620.0,,BAO_0000219,,CHEMBL615515,,,F
13715,Intermediate,,1,,,493,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,N,620.0,,BAO_0000219,,CHEMBL615516,,,F
13715,Intermediate,,1,,,494,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,N,620.0,,BAO_0000219,,CHEMBL615517,,,F
13715,Intermediate,,1,,,495,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,N,620.0,,BAO_0000219,,CHEMBL615518,,,F
13715,Intermediate,,1,,,496,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,N,620.0,,BAO_0000219,,CHEMBL615519,,,F
13715,Intermediate,,1,,,497,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615520,,,F
13715,Intermediate,,1,,,498,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615521,,,F
13715,Intermediate,,1,,,499,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615522,,,F
13715,Intermediate,,1,,,500,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615523,,,F
13715,Expert,,1,,,501,1,80006,3T3-L1,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615524,,,F
13715,Expert,,1,,,502,1,80006,3T3-L1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615525,,,F
13715,Intermediate,,1,,,503,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615526,,,F
13715,Intermediate,,1,,,504,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615527,,,F
13715,Intermediate,,1,,,505,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615528,,,F
13715,Expert,,1,,,506,1,80006,3T3-L1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615529,,,F
13715,Expert,,1,,,507,1,80006,3T3-L1,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615530,,,F
13715,Expert,,1,,,508,1,80006,3T3-L1,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615531,,,F
13715,Intermediate,,1,,,509,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,N,620.0,,BAO_0000219,,CHEMBL615532,,,F
13715,Intermediate,,1,,,510,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,N,620.0,,BAO_0000219,,CHEMBL615533,,,F
13715,Intermediate,,1,,,511,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,N,620.0,,BAO_0000219,,CHEMBL615534,,,F
13715,Intermediate,,1,,,512,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615535,,,F
13715,Intermediate,,1,,,513,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615536,,,F
13715,Intermediate,,1,,,514,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615537,,,F
13715,Intermediate,,1,,,515,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL615538,,,F
13715,Intermediate,,1,,,516,1,80006,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,N,620.0,,BAO_0000218,,CHEMBL836166,,,F
6411,Expert,,1,,,517,8,11214,3T3-L1,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,H,620.0,,BAO_0000219,,CHEMBL615539,,,F
6411,Intermediate,,1,,10090.0,518,1,80006,3T3-L1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615540,,,F
6411,Expert,,1,,,519,8,11214,3T3-L1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,H,620.0,,BAO_0000219,,CHEMBL615541,,,F
3966,Expert,,1,,10090.0,520,1,80006,3T3-L1,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615542,,,F
3966,Intermediate,,1,,10090.0,521,1,80006,3T3-L1,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615543,,,F
15556,Expert,,1,,10090.0,522,1,80006,3T3-L1,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615544,,,F
5845,Expert,,1,,10090.0,523,1,80006,3T3-L1,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615545,,,F
14422,Expert,,1,,10090.0,524,1,80006,3T3-L1,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615546,,,F
5845,Expert,,1,,10090.0,525,1,80006,3T3-L1,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615547,,,F
14508,Expert,,1,,10090.0,526,1,80006,3T3-L1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615548,,,F
14508,Expert,,1,,10090.0,527,1,80006,3T3-L1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615549,,,F
14508,Expert,,1,,10090.0,528,1,80006,3T3-L1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,N,620.0,Mus musculus,BAO_0000219,,CHEMBL615550,,,F
6349,Intermediate,,1,,10116.0,529,1,80622,3Y1 cell line,,,Inhibitory activity against rat fibroblast (3Y1) cell line,,N,1118.0,Rattus norvegicus,BAO_0000219,,CHEMBL615551,,,F
15899,Expert,,1,,10116.0,530,1,80622,3Y1 cell line,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,N,1118.0,Rattus norvegicus,BAO_0000219,,CHEMBL615552,,,F
15899,Expert,,1,,10116.0,531,1,80622,3Y1 cell line,,,Cytotoxicity in 3Y1 cells.,,N,1118.0,Rattus norvegicus,BAO_0000219,,CHEMBL615553,,,F
15899,Expert,,1,,10116.0,532,1,80622,3Y1 cell line,,,Cytostatic effect in 3Y1 cells.,,N,1118.0,Rattus norvegicus,BAO_0000219,,CHEMBL615554,,,F
15899,Intermediate,,1,,10116.0,533,1,80622,3Y1 cell line,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,N,1118.0,Rattus norvegicus,BAO_0000219,,CHEMBL615555,,,F
17038,Expert,,1,,10116.0,534,1,80622,3Y1 cell line,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,N,1118.0,Rattus norvegicus,BAO_0000219,,CHEMBL615556,,,F
12421,Autocuration,,1,,,535,0,22226,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,U,,,BAO_0000019,,CHEMBL615557,,,B
12947,Autocuration,,1,,,536,0,22226,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,U,,,BAO_0000019,,CHEMBL615558,,,B
12947,Autocuration,,1,,,537,0,22226,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,U,,,BAO_0000019,,CHEMBL872066,,,B
4896,Expert,,1,,9823.0,538,9,11607,,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,D,,Sus scrofa,BAO_0000019,,CHEMBL615559,,,B
6148,Autocuration,,1,,,539,8,11607,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,H,,,BAO_0000019,,CHEMBL615560,,,B
16432,Autocuration,,1,,,540,8,11607,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,H,,,BAO_0000019,,CHEMBL615561,,,B
4978,Expert,,1,,,541,8,11607,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,H,,,BAO_0000019,,CHEMBL857062,,,B
4978,Expert,,1,,,542,8,11607,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,H,,,BAO_0000019,,CHEMBL615562,,,B
3723,Autocuration,,1,,,543,8,11607,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,H,,,BAO_0000019,,CHEMBL615563,,,B
3518,Autocuration,,1,,,544,8,11607,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,H,,,BAO_0000357,,CHEMBL615564,,,B
4164,Autocuration,,1,,,545,8,11607,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,H,,,BAO_0000019,,CHEMBL615565,,,B
3518,Autocuration,,1,,,546,8,11607,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,H,,,BAO_0000019,,CHEMBL615566,,,B
4164,Expert,,1,,9823.0,547,9,11607,,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,D,,Sus scrofa,BAO_0000019,,CHEMBL615567,,,B
3518,Autocuration,,1,,,548,8,11607,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,H,,,BAO_0000019,,CHEMBL615568,,,B
3518,Autocuration,,1,,,549,8,11607,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,H,,,BAO_0000357,,CHEMBL615569,,,B
4978,Autocuration,,1,,,550,8,11607,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,H,,,BAO_0000019,,CHEMBL615570,,,B
4978,Autocuration,,1,,,551,8,11607,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,H,,,BAO_0000019,,CHEMBL615571,,,B
6455,Autocuration,,1,,,552,4,104733,,,,Binding affinity against melatonin (MT1) receptor (pC1),,H,,,BAO_0000224,,CHEMBL615572,,,B
2222,Autocuration,,1,,,553,0,22226,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,U,,,BAO_0000019,,CHEMBL615573,,,B
13020,Autocuration,,1,,,554,0,22226,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,U,,,BAO_0000019,,CHEMBL615574,,,B
13021,Autocuration,,1,,,555,0,22226,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,U,,,BAO_0000019,,CHEMBL615575,,,B
14532,Autocuration,,1,,,556,8,10619,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,H,,,BAO_0000357,,CHEMBL615576,,,B
14118,Autocuration,,1,,,557,8,10619,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL615577,,,B
11884,Autocuration,,1,,,558,8,51,,,Hippocampus,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,H,,,BAO_0000221,10000000.0,CHEMBL615578,,,B
13969,Expert,,1,,,559,8,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615579,,,B
13392,Expert,,1,,,560,8,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615580,,,B
14430,Expert,,1,,,561,8,51,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,H,,,BAO_0000019,,CHEMBL615581,,,B
12248,Autocuration,,1,,,562,8,51,,,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615582,,,B
12249,Autocuration,,1,,,563,8,51,,,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615583,,,B
9995,Autocuration,,1,,,564,8,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615584,,,B
9995,Autocuration,,1,,,565,8,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL833691,,,B
9995,Autocuration,,1,,,566,8,51,,,Hippocampus,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615585,,,B
9995,Autocuration,,1,,,567,8,51,,,Hippocampus,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615586,,,B
9995,Autocuration,,1,,,568,8,51,,,Hippocampus,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL884524,,,B
12249,Autocuration,,1,,,569,8,51,,,Hippocampus,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615587,,,B
11799,Autocuration,,1,,,570,8,51,,,Hippocampus,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,H,,,BAO_0000221,10000000.0,CHEMBL615588,,,B
14331,Expert,,1,,10116.0,571,9,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL615589,,Membranes,B
11884,Expert,,1,,9913.0,572,8,51,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,H,,Bos taurus,BAO_0000221,10000000.0,CHEMBL615442,,,B
14331,Autocuration,,1,,,573,8,51,,,Hippocampus,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,H,,,BAO_0000221,10000000.0,CHEMBL615443,,,B
11701,Autocuration,,1,,,574,8,51,,,Hippocampus,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615444,,,B
11701,Expert,,1,,,575,8,51,,,Hippocampus,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,H,,,BAO_0000221,10000000.0,CHEMBL615445,,,B
12248,Autocuration,,1,,,576,8,51,,,Hippocampus,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615446,,,B
12248,Autocuration,,1,,,577,8,51,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615447,,,B
12248,Expert,,1,,,578,8,51,,,Hippocampus,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615448,,,B
12249,Expert,,1,,,579,8,51,,,Hippocampus,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615449,,,B
12248,Autocuration,,1,,,580,8,51,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615450,,,B
11799,Expert,,1,,,581,8,51,,,Hippocampus,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,H,,,BAO_0000221,10000000.0,CHEMBL615451,,,B
634,Autocuration,,1,,,582,8,51,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,H,,,BAO_0000357,,CHEMBL615452,,,B
9995,Autocuration,,1,,,583,8,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615453,,,B
9995,Autocuration,,1,,,584,8,51,,,Hippocampus,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615454,,,B
9995,Autocuration,,1,,,585,8,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615455,,,B
9995,Autocuration,,1,,,586,8,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615456,,,B
9995,Autocuration,,1,,,587,8,51,,,Hippocampus,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615457,,,B
12210,Expert,,1,,,588,8,51,,,Hippocampus,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,H,,,BAO_0000218,10000000.0,CHEMBL615458,,,B
13311,Expert,,1,,,589,8,51,,,Hippocampus,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615459,,,B
2331,Expert,,1,,9606.0,590,9,51,CHO,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615460,,,B
1375,Autocuration,,1,,10141.0,591,8,51,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,H,,Cavia porcellus,BAO_0000019,,CHEMBL615461,,,F
1375,Autocuration,,1,,10141.0,592,8,51,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,H,,Cavia porcellus,BAO_0000019,,CHEMBL615462,,,F
11574,Autocuration,,1,,10141.0,593,8,51,,,Hippocampus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,H,,Cavia porcellus,BAO_0000221,10000000.0,CHEMBL615463,,,F
12867,Autocuration,,1,,10141.0,594,8,51,,,Ileum,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615464,,,B
12867,Autocuration,,1,,10141.0,595,8,51,,,Ileum,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615465,,,B
12867,Autocuration,,1,,10141.0,596,8,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615466,,,B
12867,Autocuration,,1,,10141.0,597,8,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615467,,,B
12867,Autocuration,,1,,10141.0,598,8,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615468,,,B
12867,Autocuration,,1,,10141.0,599,8,51,,,Ileum,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL615469,,,B
11574,Autocuration,,1,,10141.0,600,8,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,,Cavia porcellus,BAO_0000357,,CHEMBL615470,,,B
13114,Autocuration,,1,,10141.0,601,8,51,,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,H,,Cavia porcellus,BAO_0000357,,CHEMBL615471,,,B
13181,Autocuration,,1,,10141.0,602,8,51,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,H,,Cavia porcellus,BAO_0000357,,CHEMBL615472,,,B
10639,Autocuration,,1,,10141.0,603,8,106,,,Hippocampus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,H,,Cavia porcellus,BAO_0000221,10000000.0,CHEMBL883242,,,B
10639,Autocuration,,1,,10141.0,604,8,106,,,Hippocampus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,H,,Cavia porcellus,BAO_0000221,10000000.0,CHEMBL615473,,,F
11883,Autocuration,,1,,10029.0,605,8,11863,CHO,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,H,449.0,Cricetulus griseus,BAO_0000218,,CHEMBL615474,,,B
17785,Autocuration,,1,,,606,8,51,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615475,,,B
1558,Autocuration,,1,,,607,8,51,HeLa,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,H,308.0,,BAO_0000219,,CHEMBL615476,,,F
1558,Autocuration,,1,,,608,8,51,HeLa,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,H,308.0,,BAO_0000219,,CHEMBL615477,,,F
15740,Autocuration,,1,,,609,8,51,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL615478,,,F
17624,Autocuration,,1,,,610,8,51,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,H,449.0,,BAO_0000219,,CHEMBL615160,,,F
17624,Expert,,1,,,611,8,51,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,H,449.0,,BAO_0000219,,CHEMBL615161,,,F
17624,Autocuration,,1,,,612,8,51,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,H,449.0,,BAO_0000219,,CHEMBL615162,,,F
17624,Autocuration,,1,,,613,8,51,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,H,449.0,,BAO_0000219,,CHEMBL615163,,,F
17624,Expert,,1,,,614,8,51,CHO,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615164,,,B
17624,Expert,,1,,,615,8,51,CHO,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615165,,,B
17624,Autocuration,,1,,,616,8,51,CHO,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,H,449.0,,BAO_0000219,,CHEMBL615166,,,B
14256,Autocuration,,1,,,617,8,51,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,H,,,BAO_0000219,,CHEMBL615167,,,F
3445,Expert,,1,,9606.0,618,9,51,HeLa,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL615168,,,B
3445,Expert,,1,,9606.0,619,9,51,HeLa,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL615169,,,B
17200,Expert,,1,,9606.0,620,9,51,CHO,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615170,,,B
17200,Expert,,1,,9606.0,621,9,51,CHO,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615171,,,B
15180,Autocuration,,1,,,622,8,51,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL615694,,,F
15180,Autocuration,,1,,,623,8,51,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL615695,,,F
16026,Autocuration,,1,,,624,8,51,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000019,,CHEMBL615696,,,F
2759,Autocuration,,1,,,625,8,51,CHO,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,H,449.0,,BAO_0000219,,CHEMBL615697,,,F
2759,Expert,,1,,9606.0,626,9,51,CHO,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL859410,,,F
2759,Autocuration,,1,,,627,8,51,CHO,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,H,449.0,,BAO_0000219,,CHEMBL615841,,,F
2759,Expert,,1,,9606.0,628,9,51,CHO,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615842,,,F
2759,Autocuration,,1,,,629,8,51,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,H,449.0,,BAO_0000219,,CHEMBL835003,,,F
2759,Autocuration,,1,,,630,8,51,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,H,449.0,,BAO_0000219,,CHEMBL615843,,,F
2759,Expert,,1,,9606.0,631,9,51,CHO,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615979,,,F
2759,Autocuration,,1,,,632,8,51,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,H,449.0,,BAO_0000219,,CHEMBL615980,,,F
2759,Expert,,1,,9606.0,633,9,51,CHO,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615981,,,F
3445,Expert,,1,,9606.0,634,9,51,,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,D,,Homo sapiens,BAO_0000019,,CHEMBL615982,,,F
5272,Expert,,1,,9606.0,635,9,51,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,D,,Homo sapiens,BAO_0000019,,CHEMBL615983,,,F
5272,Expert,,1,,9606.0,636,9,51,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,D,,Homo sapiens,BAO_0000019,,CHEMBL615984,,,F
5272,Expert,,1,,9606.0,637,9,51,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,D,,Homo sapiens,BAO_0000019,,CHEMBL615985,,,F
17624,Autocuration,,1,,,638,8,51,CHO,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615986,,,F
17624,Autocuration,,1,,,639,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615987,,,F
17624,Autocuration,,1,,,640,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,H,449.0,,BAO_0000219,,CHEMBL615988,,,F
17624,Expert,,1,,,641,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615989,,,F
17624,Autocuration,,1,,,642,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,H,449.0,,BAO_0000219,,CHEMBL615990,,,F
17624,Autocuration,,1,,,643,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,H,449.0,,BAO_0000219,,CHEMBL615991,,,F
17624,Autocuration,,1,,,644,8,51,CHO,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,H,449.0,,BAO_0000219,,CHEMBL615992,,,F
17624,Autocuration,,1,,,645,8,51,CHO,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,H,449.0,,BAO_0000219,,CHEMBL615993,,,F
17624,Expert,,1,,,646,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,H,449.0,,BAO_0000219,,CHEMBL615994,,,F
17624,Autocuration,,1,,,647,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,H,449.0,,BAO_0000219,,CHEMBL615995,,,F
17624,Autocuration,,1,,,648,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,H,449.0,,BAO_0000219,,CHEMBL615996,,,F
17624,Autocuration,,1,,,649,8,51,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,H,449.0,,BAO_0000219,,CHEMBL615997,,,F
6563,Autocuration,,1,,,650,8,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,,,BAO_0000019,,CHEMBL615998,,,F
6563,Autocuration,,1,,,651,8,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,,,BAO_0000019,,CHEMBL615999,,,F
6563,Autocuration,,1,,,652,8,51,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,H,,,BAO_0000019,,CHEMBL616000,,,F
17296,Autocuration,,1,,,653,8,51,HEK293,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,722.0,,BAO_0000219,,CHEMBL616001,,,F
6876,Expert,,1,,9606.0,654,9,51,,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,D,,Homo sapiens,BAO_0000019,,CHEMBL616002,,,F
6876,Expert,,1,,,655,8,51,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,H,,,BAO_0000019,,CHEMBL616003,,,F
5272,Expert,,1,,9606.0,656,9,51,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000019,,CHEMBL616004,,,F
5272,Expert,,1,,9606.0,657,9,51,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,D,,Homo sapiens,BAO_0000019,,CHEMBL616005,,,F
5548,Autocuration,,1,,,658,8,51,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,H,,,BAO_0000019,,CHEMBL616006,,,F
5548,Expert,,1,,,659,8,51,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,H,,,BAO_0000019,,CHEMBL616007,,,F
5548,Autocuration,,1,,,660,8,51,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,H,,,BAO_0000019,,CHEMBL616008,,,F
5548,Autocuration,,1,,,661,8,51,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,H,,,BAO_0000019,,CHEMBL616009,,,F
5929,Expert,,1,,,662,8,51,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,H,,,BAO_0000019,,CHEMBL616010,,,F
5929,Expert,,1,,9606.0,663,9,51,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,D,,Homo sapiens,BAO_0000019,,CHEMBL616011,,,F
5929,Expert,,1,,9606.0,664,9,51,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,D,,Homo sapiens,BAO_0000019,,CHEMBL615740,,,F
16245,Autocuration,,1,,,665,8,51,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000019,,CHEMBL615741,,,F
5640,Expert,,1,,,666,8,51,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,H,,,BAO_0000019,,CHEMBL615742,,,F
5640,Autocuration,,1,,,667,8,51,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,H,,,BAO_0000019,,CHEMBL615743,,,F
14509,Autocuration,,1,,,668,8,51,CHO,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,H,449.0,,BAO_0000219,,CHEMBL615744,,,F
14509,Expert,,1,,,669,8,51,CHO,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,H,449.0,,BAO_0000219,,CHEMBL615745,,,F
15331,Autocuration,,1,,,670,8,51,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,H,,,BAO_0000357,,CHEMBL615746,,,B
15331,Autocuration,,1,,,671,8,51,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,H,,,BAO_0000357,,CHEMBL615747,,,B
6563,Autocuration,,1,,,672,8,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,,,BAO_0000019,,CHEMBL615748,,,F
6563,Autocuration,,1,,,673,8,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,H,,,BAO_0000019,,CHEMBL615749,,,F
6563,Autocuration,,1,,,674,8,51,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,H,,,BAO_0000019,,CHEMBL615750,,,F
6563,Expert,,1,,9606.0,675,9,51,,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000019,,CHEMBL616259,,,F
6563,Autocuration,,1,,,676,8,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,,,BAO_0000019,,CHEMBL616260,,,F
5272,Expert,,1,,9606.0,677,9,51,,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,D,,Homo sapiens,BAO_0000019,,CHEMBL616261,,,F
5272,Expert,,1,,9606.0,678,9,51,,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,D,,Homo sapiens,BAO_0000019,,CHEMBL616262,,,F
5272,Expert,,1,,9606.0,679,9,51,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,D,,Homo sapiens,BAO_0000019,,CHEMBL616263,,,F
5272,Expert,,1,,9606.0,680,9,51,,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,D,,Homo sapiens,BAO_0000019,,CHEMBL616264,,,F
5272,Expert,,1,,9606.0,681,9,51,,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,D,,Homo sapiens,BAO_0000019,,CHEMBL616265,,,F
5272,Expert,,1,,9606.0,682,9,51,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,D,,Homo sapiens,BAO_0000019,,CHEMBL616266,,,F
5272,Expert,,1,,9606.0,683,9,51,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,D,,Homo sapiens,BAO_0000019,,CHEMBL616267,,,F
5272,Expert,,1,,9606.0,684,9,51,,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,D,,Homo sapiens,BAO_0000019,,CHEMBL616268,,,F
16146,Expert,,1,,9606.0,685,9,51,,,,Inhibition of human 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616269,,,B
17624,Autocuration,,1,,,686,8,51,CHO,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL884528,,,B
13706,Expert,,1,,,687,9,105,HEK293,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,D,722.0,,BAO_0000219,,CHEMBL616270,,,B
15250,Autocuration,,1,,,688,8,51,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616271,,,B
17624,Autocuration,,1,,,689,8,51,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,H,449.0,,BAO_0000219,,CHEMBL616272,,,F
6861,Expert,,1,,,690,8,51,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,H,,,BAO_0000357,,CHEMBL616273,,,B
17200,Expert,,1,,9606.0,691,9,51,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616274,,,B
17624,Autocuration,,1,,,692,8,51,CHO,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616275,,,B
17624,Autocuration,,1,,,693,8,51,CHO,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616276,,,B
12058,Autocuration,,1,,10116.0,694,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616277,,,F
12058,Autocuration,,1,,10116.0,695,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616278,,,F
12058,Autocuration,,1,,10116.0,696,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616279,,,F
12058,Autocuration,,1,,10116.0,697,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616280,,,F
12058,Autocuration,,1,,10116.0,698,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616281,,,F
12058,Autocuration,,1,,10116.0,699,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616282,,,F
12058,Autocuration,,1,,10116.0,700,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616283,,,F
12058,Autocuration,,1,,10116.0,701,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616284,,,F
12058,Autocuration,,1,,10116.0,702,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616285,,,F
12058,Autocuration,,1,,10116.0,703,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616286,,,F
12058,Autocuration,,1,,10116.0,704,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616287,,,F
12058,Autocuration,,1,,10116.0,705,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616288,,,F
12058,Autocuration,,1,,10116.0,706,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL616289,,,F
12058,Autocuration,,1,,10116.0,707,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615610,,,F
12058,Autocuration,,1,,10116.0,708,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615611,,,F
12058,Autocuration,,1,,10116.0,709,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615612,,,F
12058,Autocuration,,1,,10116.0,710,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615613,,,F
12058,Autocuration,,1,,10116.0,711,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615614,,,F
12058,Autocuration,,1,,10116.0,712,0,22226,,In vivo,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL615615,,,F
11440,Autocuration,,1,,,713,4,105093,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,H,,,BAO_0000019,,CHEMBL615616,,,B
6238,Autocuration,,1,,,714,8,11923,,,Hypothalamus,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,H,,,BAO_0000249,1898.0,CHEMBL615617,,,B
10046,Autocuration,,1,,,715,8,10577,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,H,,,BAO_0000019,,CHEMBL615618,,,B
10046,Autocuration,,1,,,716,8,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,H,,,BAO_0000019,,CHEMBL615619,,,B
10046,Expert,,1,,,717,8,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,H,,,BAO_0000019,,CHEMBL615620,,,B
167,Autocuration,,1,,,718,8,55,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,H,,,BAO_0000357,,CHEMBL615621,,,B
167,Autocuration,,1,,,719,8,55,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,H,,,BAO_0000357,,CHEMBL615622,,,B
11520,Autocuration,,1,,,720,8,12166,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,H,,,BAO_0000019,,CHEMBL615623,,,F
11520,Autocuration,,1,,,721,8,12166,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,H,,,BAO_0000019,,CHEMBL615624,,,F
11520,Autocuration,,1,,,722,8,12166,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,H,,,BAO_0000019,,CHEMBL615625,,,F
11520,Autocuration,,1,,,723,8,12166,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,H,,,BAO_0000019,,CHEMBL767045,,,F
135,Autocuration,,1,,10141.0,724,8,55,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,H,,Cavia porcellus,BAO_0000019,,CHEMBL615626,,,F
135,Autocuration,,1,,10141.0,725,8,55,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,H,,Cavia porcellus,BAO_0000019,,CHEMBL615627,,,F
11311,Autocuration,,1,,10141.0,726,8,55,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL615628,,,B
10193,Autocuration,,1,,10141.0,727,8,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL615629,,,B
12281,Expert,,1,,9606.0,728,9,55,,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,D,,Homo sapiens,BAO_0000357,,CHEMBL615630,,,B
11311,Autocuration,,1,,,729,8,55,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000219,,CHEMBL615631,,,B
12576,Autocuration,,1,,,730,8,17087,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,H,,,BAO_0000218,,CHEMBL615632,,,F
12281,Autocuration,,1,,,731,8,17087,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,H,,,BAO_0000357,,CHEMBL615633,,,B
12576,Autocuration,,1,,,732,8,17087,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,H,,,BAO_0000218,,CHEMBL615634,,,F
11089,Expert,,1,,9823.0,733,8,55,,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,H,,Sus scrofa,BAO_0000019,,CHEMBL615635,,,B
11006,Expert,,1,,,734,8,12166,,,,In vitro inhibition of rat 5-Lipoxygenase,,H,,,BAO_0000357,,CHEMBL615636,,,B
11481,Expert,,1,,10116.0,735,9,12166,,,,Inhibitory activity against 5-Lipoxygenase,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615637,,,B
10864,Expert,,1,,,736,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,H,702.0,,BAO_0000219,,CHEMBL615638,,,B
3595,Autocuration,,1,,,737,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,H,702.0,,BAO_0000219,,CHEMBL615639,,,B
11311,Autocuration,,1,,,738,8,12166,RBL-1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,H,702.0,,BAO_0000219,,CHEMBL615640,,,B
11311,Autocuration,,1,,,739,8,12166,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,H,,,BAO_0000019,,CHEMBL615796,,,B
11311,Autocuration,,1,,,740,8,12166,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000219,,CHEMBL615845,,,B
11006,Autocuration,,1,,,741,8,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,H,,,BAO_0000357,,CHEMBL615846,,,B
3595,Autocuration,,1,,,742,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL615847,,,B
11311,Autocuration,,1,,,743,8,12166,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,H,,,BAO_0000357,,CHEMBL615848,,,B
11481,Autocuration,,1,,10116.0,744,0,22226,,,,Ratio of IC50 against 5-LO and COX,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615849,,,B
11006,Autocuration,,1,,,745,8,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,H,,,BAO_0000357,,CHEMBL615850,,,B
11006,Autocuration,,1,,,746,8,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,H,,,BAO_0000357,,CHEMBL615851,,,B
11311,Autocuration,,1,,,747,8,12166,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,H,,,BAO_0000219,,CHEMBL615852,,,B
11006,Autocuration,,1,,,748,8,12166,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,H,,,BAO_0000019,,CHEMBL615853,,,F
4288,Autocuration,,1,,,749,8,120,,,Prostate gland,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,H,,,BAO_0000357,2367.0,CHEMBL884527,,,B
7587,Autocuration,,1,,8932.0,750,0,22226,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,U,,Columba livia,BAO_0000019,,CHEMBL872871,,,B
7587,Autocuration,,1,,8932.0,751,0,22226,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,U,,Columba livia,BAO_0000019,,CHEMBL615854,,,B
7587,Autocuration,,1,,8932.0,752,0,22226,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,U,,Columba livia,BAO_0000019,,CHEMBL767046,,,B
11249,Autocuration,,1,,,753,8,10732,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,H,,,BAO_0000357,,CHEMBL615855,,,B
8003,Expert,,1,,10116.0,754,9,12198,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615856,,,F
8003,Expert,,1,,10116.0,755,9,12198,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615857,,,F
8003,Expert,,1,,10116.0,756,9,12198,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615858,,,F
12416,Expert,,1,,,757,8,10576,,,Hippocampus,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615859,,,B
16293,Autocuration,,1,,,758,8,51,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,H,,,BAO_0000357,,CHEMBL615860,,,B
13047,Autocuration,,1,,9986.0,759,0,22226,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL615861,,,B
13047,Autocuration,,1,,9986.0,760,0,22226,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL615862,,,B
13047,Autocuration,,1,,9986.0,761,0,22226,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL615863,,,B
13047,Autocuration,,1,,9986.0,762,0,22226,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL615864,,,B
10085,Autocuration,,1,,,763,4,104744,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,H,,,BAO_0000221,10000000.0,CHEMBL615865,,,B
10085,Autocuration,,1,,,764,4,104744,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,H,,,BAO_0000221,10000000.0,CHEMBL615866,,,B
10085,Autocuration,,1,,,765,4,104744,,,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,H,,,BAO_0000221,10000000.0,CHEMBL615867,,,B
9841,Autocuration,,1,,,766,4,104744,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,H,,,BAO_0000249,,CHEMBL615868,,Membranes,B
8822,Autocuration,,1,,10116.0,767,5,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL615869,,,B
9806,Autocuration,,1,,10116.0,768,5,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615870,,,B
9806,Autocuration,,1,,10116.0,769,5,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615871,,,B
8868,Autocuration,,1,,,770,4,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,H,,,BAO_0000224,,CHEMBL615872,,,B
9036,Autocuration,,1,,,771,4,104744,,,Hippocampus,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,H,,,BAO_0000221,10000000.0,CHEMBL833492,,,B
11374,Autocuration,,1,,,772,4,104744,,,Hippocampus,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615873,,,B
10881,Autocuration,,1,,,773,4,104744,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,H,,,BAO_0000224,,CHEMBL615479,,,B
8822,Autocuration,,1,,,774,4,104744,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,H,,,BAO_0000019,,CHEMBL615480,,,B
9806,Autocuration,,1,,10116.0,775,5,104744,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL615481,,,B
15463,Autocuration,,1,,,776,4,104744,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL872869,,,B
15463,Autocuration,,1,,,777,4,104744,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL615482,,,B
14542,Autocuration,,1,,,778,4,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,H,,,BAO_0000221,955.0,CHEMBL615483,,,B
14542,Autocuration,,1,,,779,4,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,H,,,BAO_0000221,955.0,CHEMBL615484,,,B
8569,Autocuration,,1,,,780,4,104744,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,H,,,BAO_0000019,,CHEMBL615485,,,B
10062,Autocuration,,1,,10116.0,781,5,104744,,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL615486,,,B
4771,Autocuration,,1,,,782,4,104744,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,H,,,BAO_0000224,,CHEMBL615487,,,B
10062,Autocuration,,1,,,783,4,104744,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,H,,,BAO_0000224,,CHEMBL615488,,,B
10062,Autocuration,,1,,,784,4,104744,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,H,,,BAO_0000224,,CHEMBL615489,,,B
10062,Autocuration,,1,,,785,4,104744,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,H,,,BAO_0000224,,CHEMBL615389,,,B
15463,Autocuration,,1,,,786,4,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,H,,,BAO_0000019,,CHEMBL615390,,,B
15463,Autocuration,,1,,,787,4,104744,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,H,,,BAO_0000019,,CHEMBL615391,,,B
9098,Autocuration,,1,,,788,4,104744,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,H,,,BAO_0000224,,CHEMBL615392,,,B
3070,Autocuration,,1,,10116.0,789,0,22226,,,,Affinity for 5-hydroxytryptamine 1 receptor,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615393,,,B
14542,Autocuration,,1,,,790,4,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,H,,,BAO_0000221,955.0,CHEMBL615394,,,B
14542,Autocuration,,1,,,791,4,104744,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,H,,,BAO_0000221,955.0,CHEMBL615395,,,B
6398,Autocuration,,1,,,792,4,104744,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,H,,,BAO_0000224,,CHEMBL615396,,,B
1344,Autocuration,,1,,,793,4,104744,,,Brain,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,H,,,BAO_0000221,955.0,CHEMBL615397,,,B
11963,Autocuration,,1,,,794,4,104744,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL615398,,,B
8908,Autocuration,,1,,10116.0,795,0,22226,,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615399,,,B
9098,Autocuration,,1,,,796,4,104744,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,H,,,BAO_0000019,,CHEMBL615400,,,B
8841,Autocuration,,1,,10116.0,797,5,104744,,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615401,,,B
8814,Autocuration,,1,,10116.0,798,0,22226,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL615402,,,B
11752,Autocuration,,1,,,799,4,104744,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL615403,,,B
11642,Autocuration,,1,,,800,4,104744,,,Brain,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,H,,,BAO_0000221,955.0,CHEMBL615404,,,B
11642,Autocuration,,1,,,801,4,104744,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL615781,,,B
9231,Autocuration,,1,,,802,4,104744,,,Brain,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,H,,,BAO_0000220,955.0,CHEMBL615782,,,B
11351,Autocuration,,1,,,803,4,104744,,,Brain,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,H,,,BAO_0000221,955.0,CHEMBL615783,,,B
4639,Autocuration,,1,,,804,0,22226,,,,Compound was tested for binding affinity against 5-HT1 receptor,,U,,,BAO_0000019,,CHEMBL873481,,,B
1205,Autocuration,,1,,,805,0,22226,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,U,,,BAO_0000019,,CHEMBL615784,,,B
10025,Expert,,1,,,806,8,10576,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,H,,,BAO_0000357,,CHEMBL615785,,,B
13241,Autocuration,,1,,,807,8,10576,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000249,,CHEMBL615786,,,F
16245,Autocuration,,1,,,808,8,10576,,In vivo,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,H,,,BAO_0000218,,CHEMBL615787,,,F
16245,Autocuration,,1,,,809,8,10576,,In vivo,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,H,,,BAO_0000218,,CHEMBL615788,,,F
12438,Autocuration,,1,,,810,8,10576,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL767044,,,F
16245,Autocuration,,1,,,811,8,10576,,In vivo,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,H,,,BAO_0000218,,CHEMBL615789,,,F
16245,Autocuration,,1,,,812,8,10576,,In vivo,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,H,,,BAO_0000218,,CHEMBL615790,,,F
15740,Autocuration,,1,,,813,8,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,H,,,BAO_0000019,,CHEMBL615813,,,F
15535,Autocuration,,1,,,814,8,10576,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,H,,,BAO_0000219,,CHEMBL615814,,,F
15535,Expert,,1,,,815,8,51,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,H,,,BAO_0000219,,CHEMBL615815,,,F
15535,Autocuration,,1,,,816,8,10576,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,H,,,BAO_0000219,,CHEMBL615816,,,F
9888,Expert,,1,,,817,8,10576,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,H,,,BAO_0000249,,CHEMBL615817,,,B
10085,Autocuration,,1,,,818,8,10576,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,H,,,BAO_0000221,10000000.0,CHEMBL615818,,,B
10085,Autocuration,,1,,,819,8,10576,,,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,H,,,BAO_0000221,10000000.0,CHEMBL615819,,,B
17331,Expert,,1,,,820,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,H,,,BAO_0000249,,CHEMBL615820,,Membranes,B
10845,Expert,,1,,10116.0,821,9,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL615821,,,B
10845,Expert,,1,,10116.0,822,9,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL615822,,,B
10845,Expert,,1,,,823,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL615823,,,B
10845,Expert,,1,,10116.0,824,9,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL615824,,,B
10845,Expert,,1,,10116.0,825,9,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL615825,,,B
13730,Expert,,1,,,826,8,10576,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615826,,,B
13508,Expert,,1,,,827,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000249,,CHEMBL615827,,,B
13508,Expert,,1,,,828,8,10576,,,Hippocampus,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000249,10000000.0,CHEMBL615828,,,B
12073,Expert,,1,,,829,8,10576,,,Hippocampus,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615829,,,B
4671,Autocuration,,1,,,830,8,10576,,,Hippocampus,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL615830,,,B
13631,Expert,,1,,,831,8,10576,,,Hippocampus,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,H,,,BAO_0000221,10000000.0,CHEMBL615831,,,B
12438,Autocuration,,1,,,832,8,10576,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615832,,,B
10483,Autocuration,,1,,,833,8,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL615833,,,B
10483,Autocuration,,1,,,834,8,10576,,,Hippocampus,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL615834,,,B
12352,Intermediate,,1,,,835,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,H,,,BAO_0000249,,CHEMBL615835,,,B
14732,Autocuration,,1,,,836,8,10576,,,Hippocampus,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,H,,,BAO_0000249,10000000.0,CHEMBL615836,,,B
11049,Expert,,1,,10116.0,837,9,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615837,,,B
11049,Expert,,1,,10116.0,838,9,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615838,,,B
13657,Expert,,1,,,839,8,10576,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,H,,,BAO_0000249,,CHEMBL615839,,,B
11473,Autocuration,,1,,,840,8,10576,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL884525,,,B
2014,Autocuration,,1,,,841,8,10576,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,H,,,BAO_0000249,,CHEMBL615840,,,B
3086,Expert,,1,,,842,8,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615405,,,B
15854,Expert,,1,,,843,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,H,,,BAO_0000019,,CHEMBL615406,,,B
10922,Expert,,1,,,844,8,10576,,,Hippocampus,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,H,,,BAO_0000221,10000000.0,CHEMBL615900,,,B
13346,Expert,,1,,,845,8,10576,,,Hippocampus,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,H,,,BAO_0000221,10000000.0,CHEMBL615901,,,B
15311,Expert,,1,,,846,8,10576,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,H,,,BAO_0000357,,CHEMBL615902,,,B
10922,Autocuration,,1,,,847,8,10576,,,Hippocampus,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,H,,,BAO_0000221,10000000.0,CHEMBL615903,,,B
10025,Autocuration,,1,,,848,8,10576,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,H,,,BAO_0000357,,CHEMBL615904,,,B
10025,Expert,,1,,,849,8,10576,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,H,,,BAO_0000357,,CHEMBL615905,,,B
9742,Autocuration,,1,,,850,8,10576,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,H,,,BAO_0000019,,CHEMBL615906,,,B
9742,Autocuration,,1,,,851,8,10576,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,H,,,BAO_0000019,,CHEMBL615907,,,F
12304,Expert,,1,,,852,8,10576,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL615908,,,B
15789,Autocuration,,1,,,853,8,10576,,,Hippocampus,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615909,,,B
9912,Autocuration,,1,,,854,8,10576,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,H,,,BAO_0000019,,CHEMBL615910,,,B
9912,Autocuration,,1,,,855,8,10576,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,H,,,BAO_0000019,,CHEMBL615911,,,B
9912,Autocuration,,1,,,856,8,10576,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,H,,,BAO_0000019,,CHEMBL615912,,,B
16693,Expert,,1,,,857,8,10576,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL615913,,,B
13276,Expert,,1,,,858,8,10576,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000357,,CHEMBL615914,,,B
12678,Autocuration,,1,,,859,8,10576,,,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,H,,,BAO_0000221,10000000.0,CHEMBL615915,,,B
11825,Autocuration,,1,,,860,8,10576,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,H,,,BAO_0000357,,CHEMBL615916,,,B
12443,Expert,,1,,,861,8,10576,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,H,,,BAO_0000357,,CHEMBL615917,,,B
13830,Expert,,1,,,862,8,10576,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615918,,,B
14286,Expert,,1,,,863,8,10576,,,Hippocampus,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,H,,,BAO_0000249,10000000.0,CHEMBL615919,,,B
14356,Expert,,1,,10116.0,864,9,10576,,,Hippocampus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL615920,,,B
15306,Autocuration,,1,,,865,8,10576,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615921,,,B
15306,Expert,,1,,,866,8,10576,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,H,,,BAO_0000357,,CHEMBL615922,,,B
16616,Expert,,1,,10116.0,867,9,10576,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,D,,Rattus norvegicus,BAO_0000249,,CHEMBL881290,,,F
3651,Autocuration,,1,,,868,8,10576,,,Hippocampus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,H,,,BAO_0000221,10000000.0,CHEMBL615923,,,B
14331,Autocuration,,1,,,869,8,10576,,,Hippocampus,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615924,,,F
14331,Autocuration,,1,,,870,8,10576,,,Hippocampus,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615925,,,F
14178,Expert,,1,,10116.0,871,9,10576,,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615926,,,B
10639,Expert,,1,,10116.0,872,9,10576,,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615927,,,B
12306,Autocuration,,1,,,873,8,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL615928,,,B
1348,Expert,,1,,10116.0,874,9,10576,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615929,,,B
13605,Autocuration,,1,,,875,8,10576,,,Hippocampus,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615930,,,B
17624,Autocuration,,1,,,876,8,51,CHO,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615931,,,B
17624,Autocuration,,1,,,877,8,51,CHO,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,H,449.0,,BAO_0000219,,CHEMBL615932,,,F
17624,Autocuration,,1,,,878,8,51,CHO,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,H,449.0,,BAO_0000219,,CHEMBL615933,,,F
15267,Autocuration,,1,,,879,8,51,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615934,,,B
16532,Autocuration,,1,,,880,8,51,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,H,,,BAO_0000357,,CHEMBL615935,,,B
6563,Autocuration,,1,,,881,8,51,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,H,,,BAO_0000019,,CHEMBL615936,,,F
4751,Autocuration,,1,,,882,8,51,CHO,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,H,449.0,,BAO_0000219,,CHEMBL615937,,,B
15463,Autocuration,,1,,,883,8,51,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615938,,,B
3805,Autocuration,,1,,,884,8,51,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL615797,,,B
5640,Autocuration,,1,,,885,8,51,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615798,,,B
6563,Autocuration,,1,,,886,8,51,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,H,,,BAO_0000357,,CHEMBL872870,,,B
5548,Autocuration,,1,,,887,8,51,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL615799,,,B
6347,Autocuration,,1,,,888,8,51,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615800,,,B
17296,Autocuration,,1,,,889,8,51,HEK293,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,722.0,,BAO_0000219,,CHEMBL615801,,,F
13047,Autocuration,,1,,,890,8,51,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,H,,,BAO_0000019,,CHEMBL615802,,,B
15740,Autocuration,,1,,,891,8,51,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,H,,,BAO_0000357,,CHEMBL615803,,,B
5640,Expert,,1,,,892,8,51,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,H,,,BAO_0000019,,CHEMBL835002,,,F
5640,Autocuration,,1,,,893,8,51,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,H,,,BAO_0000019,,CHEMBL615804,,,F
17211,Expert,,1,,,894,8,51,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,H,308.0,,BAO_0000219,,CHEMBL615805,,,B
4751,Autocuration,,1,,,895,8,51,CHO,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,H,449.0,,BAO_0000219,,CHEMBL615806,,,B
6491,Expert,,1,,9606.0,896,9,51,,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL615807,,,B
4707,Autocuration,,1,,,897,8,51,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,H,,,BAO_0000357,,CHEMBL615808,,,B
13910,Expert,,1,,9606.0,898,9,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL615809,,,B
16190,Autocuration,,1,,,899,8,51,HeLa,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,H,308.0,,BAO_0000219,,CHEMBL615810,,,B
16633,Autocuration,,1,,,900,8,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615811,,,B
11898,Autocuration,,1,,,901,8,51,CHO,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615812,,,B
11898,Autocuration,,1,,,902,8,51,CHO,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615751,,,B
14331,Autocuration,,1,,,903,8,51,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615752,,,B
17624,Expert,,1,,,904,8,51,CHO,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,H,449.0,,BAO_0000219,,CHEMBL615753,,,B
17624,Autocuration,,1,,,905,8,51,CHO,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,H,449.0,,BAO_0000219,,CHEMBL615754,,,B
3307,Autocuration,,1,,,906,8,51,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615755,,,B
6563,Expert,,1,,9606.0,907,9,51,CHO,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615756,,,B
14165,Autocuration,,1,,,908,8,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL615757,,,B
5732,Autocuration,,1,,,909,8,51,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL615758,,,B
13366,Expert,,1,,,910,8,51,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,H,,,BAO_0000357,,CHEMBL615759,,,B
17626,Autocuration,,1,,,911,8,51,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615760,,,B
6588,Expert,,1,,,912,8,51,HeLa,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,H,308.0,,BAO_0000219,,CHEMBL615761,,,B
16209,Autocuration,,1,,,913,8,51,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL872104,,,B
15463,Autocuration,,1,,,914,8,51,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615762,,,B
15463,Autocuration,,1,,,915,8,51,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615763,,,B
14770,Autocuration,,1,,,916,8,51,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL615764,,,B
16245,Autocuration,,1,,,917,8,51,Cell line,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,H,1167.0,,BAO_0000219,,CHEMBL615765,,,B
16245,Autocuration,,1,,,918,8,51,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,H,,,BAO_0000019,,CHEMBL615766,,,B
5548,Autocuration,,1,,,919,8,51,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615767,,,B
5548,Expert,,1,,,920,8,51,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615768,,,B
5548,Autocuration,,1,,,921,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615769,,,B
6876,Expert,,1,,,922,8,51,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL615770,,,B
2598,Autocuration,,1,,,923,8,51,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615771,,,B
17785,Expert,,1,,,924,8,51,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,H,,,BAO_0000357,,CHEMBL615772,,,B
6013,Autocuration,,1,,,925,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL615773,,,B
5929,Expert,,1,,,926,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615774,,,B
16633,Autocuration,,1,,,927,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615775,,,B
1558,Autocuration,,1,,,928,8,51,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL615776,,,B
16026,Expert,,1,,,929,8,51,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615777,,,B
12469,Autocuration,,1,,,930,8,51,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,H,,,BAO_0000219,,CHEMBL615778,,,B
15874,Expert,,1,,9606.0,931,9,51,,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,D,,Homo sapiens,BAO_0000357,,CHEMBL615779,,,B
15874,Autocuration,,1,,,932,8,51,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL615780,,,B
3935,Autocuration,,1,,,933,8,51,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616298,,,B
15818,Autocuration,,1,,,934,8,51,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616299,,,B
13706,Autocuration,,1,,,935,8,51,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL616300,,,B
13729,Expert,,1,,,936,8,51,CHO-K1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,H,485.0,,BAO_0000219,,CHEMBL616301,,,F
15413,Autocuration,,1,,,937,8,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616302,,,B
15413,Autocuration,,1,,,938,8,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,H,,,BAO_0000019,,CHEMBL616117,,,B
15413,Autocuration,,1,,,939,8,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,H,,,BAO_0000019,,CHEMBL616118,,,B
15413,Autocuration,,1,,,940,8,51,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,H,,,BAO_0000019,,CHEMBL616119,,,B
3445,Expert,,1,,9606.0,941,9,51,HeLa,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL616120,,,B
15740,Autocuration,,1,,,942,8,51,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616121,,,B
15740,Autocuration,,1,,,943,8,51,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,H,,,BAO_0000357,,CHEMBL616122,,,B
17626,Autocuration,,1,,,944,8,51,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616123,,,B
4234,Expert,,1,,9606.0,945,9,51,,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616124,,,B
5640,Expert,,1,,,946,8,51,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,H,,,BAO_0000357,,CHEMBL616125,,,B
5272,Expert,,1,,10116.0,947,8,51,,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,H,,Rattus norvegicus,BAO_0000357,,CHEMBL616126,,,B
4622,Autocuration,,1,,,948,8,51,CHO,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616127,,,B
17085,Expert,,1,,,949,8,51,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616128,,,B
3025,Autocuration,,1,,,950,8,51,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,H,,,BAO_0000357,,CHEMBL616129,,,B
15315,Expert,,1,,,951,8,51,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616130,,,B
15267,Autocuration,,1,,,952,8,51,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,H,,,BAO_0000357,,CHEMBL616131,,,B
17158,Autocuration,,1,,,953,8,51,HeLa,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,H,308.0,,BAO_0000219,,CHEMBL616132,,,B
14214,Expert,,1,,9606.0,954,9,51,HeLa,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL616133,,,B
17133,Autocuration,,1,,,955,8,51,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616134,,,B
16532,Autocuration,,1,,,956,8,51,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,H,,,BAO_0000357,,CHEMBL616135,,,B
2391,Expert,,1,,9606.0,957,9,51,,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,D,,Homo sapiens,BAO_0000357,,CHEMBL616136,,,B
14447,Autocuration,,1,,,958,8,51,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,H,,,BAO_0000019,,CHEMBL616137,,,B
14447,Autocuration,,1,,,959,8,51,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,H,,,BAO_0000019,,CHEMBL872105,,,B
15086,Autocuration,,1,,,960,8,51,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,H,,,BAO_0000357,,CHEMBL616138,,,B
13051,Expert,,1,,9606.0,961,9,51,,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616139,,,B
16026,Autocuration,,1,,,962,8,51,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,H,,,BAO_0000019,,CHEMBL616140,,,F
17085,Expert,,1,,,963,8,51,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,H,,,BAO_0000019,,CHEMBL616141,,,B
17133,Autocuration,,1,,,964,8,51,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616142,,,B
17133,Autocuration,,1,,,965,8,51,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,H,,,BAO_0000357,,CHEMBL616143,,,B
17211,Autocuration,,1,,,966,8,51,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,H,308.0,,BAO_0000219,,CHEMBL616144,,,B
17211,Autocuration,,1,,,967,8,51,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,H,308.0,,BAO_0000219,,CHEMBL616145,,,B
17211,Autocuration,,1,,,968,8,51,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,H,308.0,,BAO_0000219,,CHEMBL616012,,,B
17211,Autocuration,,1,,,969,8,51,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,H,308.0,,BAO_0000219,,CHEMBL616013,,,B
16394,Autocuration,,1,,,970,8,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,H,,,BAO_0000019,,CHEMBL616014,,,F
16394,Autocuration,,1,,,971,8,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,H,,,BAO_0000019,,CHEMBL616015,,,F
16394,Autocuration,,1,,,972,8,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,H,,,BAO_0000019,,CHEMBL616016,,,F
16394,Autocuration,,1,,,973,8,51,,In vivo,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,H,,,BAO_0000218,,CHEMBL616017,,,F
16394,Autocuration,,1,,,974,8,51,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,H,,,BAO_0000019,,CHEMBL616018,,,B
15740,Autocuration,,1,,,975,8,51,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,H,,,BAO_0000019,,CHEMBL616019,,,F
15740,Autocuration,,1,,,976,8,51,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,H,,,BAO_0000019,,CHEMBL616020,,,F
15740,Autocuration,,1,,,977,8,51,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL858018,,,B
17296,Autocuration,,1,,,978,8,51,HEK293,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,722.0,,BAO_0000219,,CHEMBL616021,,,F
5640,Expert,,1,,,979,8,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,H,,,BAO_0000019,,CHEMBL616022,,,F
5640,Autocuration,,1,,,980,8,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,H,,,BAO_0000019,,CHEMBL616023,,,F
5640,Autocuration,,1,,,981,8,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,H,,,BAO_0000019,,CHEMBL616024,,,F
5640,Autocuration,,1,,,982,8,51,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,H,,,BAO_0000019,,CHEMBL616025,,,F
2759,Autocuration,,1,,,983,8,51,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,H,449.0,,BAO_0000219,,CHEMBL616026,,,F
16394,Autocuration,,1,,,984,8,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,H,,,BAO_0000019,,CHEMBL616027,,,F
16394,Expert,,1,,9606.0,985,9,51,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,D,,Homo sapiens,BAO_0000019,,CHEMBL616028,,,F
3445,Expert,,1,,9606.0,986,9,51,,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,D,,Homo sapiens,BAO_0000019,,CHEMBL616029,,,F
4316,Expert,,1,,,987,8,51,CHO,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,H,449.0,,BAO_0000219,,CHEMBL616030,,,B
4316,Expert,,1,,,988,8,51,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,H,,,BAO_0000019,,CHEMBL616031,,,B
15180,Expert,,1,,9606.0,989,9,51,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,D,,Homo sapiens,BAO_0000019,,CHEMBL616032,,,F
15180,Expert,,1,,9606.0,990,9,51,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,D,,Homo sapiens,BAO_0000019,,CHEMBL616033,,,F
15042,Autocuration,,1,,,991,8,51,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,,,BAO_0000019,,CHEMBL616034,,,F
15042,Autocuration,,1,,,992,8,51,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,,,BAO_0000019,,CHEMBL616035,,,F
15042,Autocuration,,1,,,993,8,51,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616036,,,F
15042,Autocuration,,1,,,994,8,51,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,,,BAO_0000019,,CHEMBL616037,,,F
15042,Autocuration,,1,,,995,8,51,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,,,BAO_0000019,,CHEMBL616038,,,F
15042,Autocuration,,1,,,996,8,51,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,H,,,BAO_0000019,,CHEMBL616039,,,F
15042,Autocuration,,1,,,997,8,51,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616040,,,F
15180,Expert,,1,,9606.0,998,9,51,HeLa,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL616041,,,F
15180,Expert,,1,,9606.0,999,9,51,HeLa,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL616042,,,F
15180,Expert,,1,,9606.0,1000,9,51,HeLa,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL616043,,,F
16245,Autocuration,,1,,,1001,8,51,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000019,,CHEMBL616044,,,F
16026,Autocuration,,1,,,1002,8,51,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000019,,CHEMBL616045,,,F
17296,Autocuration,,1,,,1003,8,51,HEK293,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,H,722.0,,BAO_0000219,,CHEMBL616046,,,F
2759,Autocuration,,1,,,1004,8,51,CHO,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,H,449.0,,BAO_0000219,,CHEMBL616047,,,F
2759,Autocuration,,1,,,1005,8,51,CHO,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616048,,,F
2759,Expert,,1,,9606.0,1006,9,51,CHO,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616049,,,F
2759,Autocuration,,1,,,1007,8,51,CHO,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,H,449.0,,BAO_0000219,,CHEMBL616050,,,F
15419,Expert,,1,,,1008,8,51,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,H,,,BAO_0000219,,CHEMBL616051,,,F
15419,Autocuration,,1,,,1009,8,51,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,H,,,BAO_0000219,,CHEMBL616212,,,F
16026,Autocuration,,1,,,1010,8,51,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000019,,CHEMBL616213,,,F
1414,Expert,,1,,,1011,8,51,,In vitro,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,H,,,BAO_0000219,,CHEMBL616214,,,B
1414,Expert,,1,,,1012,8,51,,In vitro,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,H,,,BAO_0000219,,CHEMBL616215,,,B
12861,Autocuration,,1,,,1013,8,51,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL616216,,,B
12861,Autocuration,,1,,,1014,8,51,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,,,BAO_0000019,,CHEMBL616217,,,B
5104,Autocuration,,1,,,1015,8,51,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616218,,,B
5105,Autocuration,,1,,,1016,8,51,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616219,,,B
16312,Autocuration,,1,,,1017,8,51,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616220,,,B
15180,Expert,,1,,9606.0,1018,9,51,,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL833493,,,B
5033,Autocuration,,1,,,1019,8,51,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616221,,,B
16909,Expert,,1,,9606.0,1020,9,51,CHO,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616222,,,B
2590,Autocuration,,1,,,1021,8,51,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616223,,,F
2590,Autocuration,,1,,,1022,8,51,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,H,,,BAO_0000019,,CHEMBL616224,,,F
16394,Expert,,1,,,1023,8,51,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,H,,,BAO_0000019,,CHEMBL616225,,,B
4540,Expert,,1,,9606.0,1024,9,51,HEK293,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL616226,,,B
17296,Autocuration,,1,,,1025,8,51,HEK293,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,H,722.0,,BAO_0000219,,CHEMBL616227,,,B
17296,Autocuration,,1,,,1026,8,51,HEK293,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,H,722.0,,BAO_0000219,,CHEMBL616228,,,B
15779,Autocuration,,1,,,1027,8,51,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,H,722.0,,BAO_0000219,,CHEMBL616229,,,B
15779,Autocuration,,1,,,1028,8,51,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,H,722.0,,BAO_0000219,,CHEMBL616230,,,B
15779,Autocuration,,1,,,1029,8,51,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,H,722.0,,BAO_0000219,,CHEMBL616231,,,B
6166,Autocuration,,1,,,1030,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616232,,,B
15779,Autocuration,,1,,,1031,8,51,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,H,722.0,,BAO_0000219,,CHEMBL616233,,,B
4199,Autocuration,,1,,,1032,8,51,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,H,722.0,,BAO_0000219,,CHEMBL857973,,,B
15316,Autocuration,,1,,,1033,8,51,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,H,,,BAO_0000219,,CHEMBL616234,,,B
14875,Autocuration,,1,,,1034,8,51,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616235,,,B
14727,Expert,,1,,,1035,8,51,HeLa,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,H,308.0,,BAO_0000219,,CHEMBL616236,,,B
14727,Expert,,1,,,1036,8,51,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,H,,,BAO_0000019,,CHEMBL616237,,,B
15146,Autocuration,,1,,,1037,8,51,HEK293,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,H,722.0,,BAO_0000219,,CHEMBL616238,,,B
5213,Autocuration,,1,,,1038,8,51,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,H,722.0,,BAO_0000219,,CHEMBL616239,,,B
16429,Autocuration,,1,,,1039,8,51,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,H,,,BAO_0000219,,CHEMBL616240,,,B
15042,Expert,,1,,9606.0,1040,9,51,HeLa,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL616241,,,B
14818,Autocuration,,1,,,1041,8,51,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,H,722.0,,BAO_0000219,,CHEMBL616242,,,B
4829,Autocuration,,1,,,1042,8,51,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,H,722.0,,BAO_0000219,,CHEMBL616243,,,B
17200,Expert,,1,,,1043,9,51,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,D,,,BAO_0000357,,CHEMBL616244,,,B
13051,Autocuration,,1,,9606.0,1044,9,51,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616245,,,B
5486,Autocuration,,1,,,1045,8,106,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,H,,,BAO_0000357,,CHEMBL616246,,,B
5254,Autocuration,,1,,,1046,8,105,,,,Binding affinity against 5-HT1D receptor,,H,,,BAO_0000357,,CHEMBL616247,,,B
5254,Autocuration,,1,,,1047,8,105,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616248,,,B
15331,Autocuration,,1,,,1048,8,107,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,H,,,BAO_0000357,,CHEMBL616249,,,B
13506,Autocuration,,1,,9606.0,1049,8,10576,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,H,,Homo sapiens,BAO_0000357,,CHEMBL616250,,,B
15267,Autocuration,,1,,,1050,8,51,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616251,,,B
16616,Autocuration,,1,,,1051,8,11863,,In vivo,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,H,,,BAO_0000218,,CHEMBL616252,,,F
16616,Autocuration,,1,,,1052,8,11863,,In vivo,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,H,,,BAO_0000218,,CHEMBL616253,,,F
16616,Autocuration,,1,,,1053,8,11863,,In vivo,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,H,,,BAO_0000218,,CHEMBL616254,,,F
16616,Expert,,1,,10090.0,1054,9,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,D,,Mus musculus,BAO_0000218,,CHEMBL616255,,,F
16616,Expert,,1,,10090.0,1055,9,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,D,,Mus musculus,BAO_0000218,,CHEMBL832872,,,F
16616,Expert,,1,,10090.0,1056,9,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,D,,Mus musculus,BAO_0000218,,CHEMBL616256,,,F
16616,Expert,,1,,10090.0,1057,9,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,D,,Mus musculus,BAO_0000218,,CHEMBL616257,,,F
16616,Expert,,1,,10090.0,1058,9,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,D,,Mus musculus,BAO_0000218,,CHEMBL616258,,,F
16616,Expert,,1,,10090.0,1059,9,11863,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,D,,Mus musculus,BAO_0000218,,CHEMBL616384,,,F
10297,Autocuration,,1,,,1060,8,11863,,,Hippocampus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616385,,,B
13704,Expert,,1,,,1061,8,11863,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,H,,,BAO_0000357,,CHEMBL616386,,,B
10297,Expert,,1,,10090.0,1062,9,11863,,,Hippocampus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,D,,Mus musculus,BAO_0000221,10000000.0,CHEMBL616387,,,B
10297,Autocuration,,1,,,1063,8,11863,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616388,,,B
10297,Expert,,1,,10090.0,1064,9,11863,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,D,,Mus musculus,BAO_0000221,10000000.0,CHEMBL616389,,,B
10297,Autocuration,,1,,,1065,8,11863,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616390,,,B
217,Autocuration,,1,,,1066,8,11863,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,H,,,BAO_0000357,,CHEMBL616391,,,B
10297,Expert,,1,,10090.0,1067,9,11863,,,Hippocampus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,D,,Mus musculus,BAO_0000221,10000000.0,CHEMBL616392,,,B
4921,Autocuration,,1,,9823.0,1068,8,51,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL616393,,,B
4921,Autocuration,,1,,9823.0,1069,8,51,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,H,,Sus scrofa,BAO_0000357,,CHEMBL616394,,,B
4996,Autocuration,,1,,9823.0,1070,8,51,,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,H,,Sus scrofa,BAO_0000019,,CHEMBL616395,,,B
12918,Autocuration,,1,,9823.0,1071,8,51,,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL616396,,,B
5333,Autocuration,,1,,9823.0,1072,8,51,,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,H,,Sus scrofa,BAO_0000019,,CHEMBL872907,,,B
4437,Autocuration,,1,,9823.0,1073,8,51,,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,H,,Sus scrofa,BAO_0000019,,CHEMBL616397,,,B
1742,Autocuration,,1,,9823.0,1074,8,51,,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,H,,Sus scrofa,BAO_0000019,,CHEMBL616398,,,B
16688,Expert,,1,,9823.0,1075,8,51,,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL616399,,,B
12861,Autocuration,,1,,9823.0,1076,8,51,,,,Binding activity radioligand.,,H,,Sus scrofa,BAO_0000357,,CHEMBL857065,,,B
12861,Expert,,1,,9823.0,1077,8,51,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,H,,Sus scrofa,BAO_0000019,,CHEMBL616400,,,B
12861,Autocuration,,1,,9823.0,1078,8,51,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,H,,Sus scrofa,BAO_0000019,,CHEMBL616401,,,B
12490,Expert,,1,,,1079,8,10624,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,H,,,BAO_0000019,,CHEMBL616402,,,B
11828,Expert,,1,,9823.0,1080,8,51,,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,H,,Sus scrofa,BAO_0000019,,CHEMBL616403,,,B
11866,Autocuration,,1,,9823.0,1081,8,51,,,Hippocampus,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,H,,Sus scrofa,BAO_0000221,10000000.0,CHEMBL616404,,,B
12827,Autocuration,,1,,9823.0,1082,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,H,,Sus scrofa,BAO_0000249,,CHEMBL616405,,,B
12918,Autocuration,,1,,9823.0,1083,8,51,,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,H,,Sus scrofa,BAO_0000019,,CHEMBL616406,,,B
12919,Expert,,1,,9823.0,1084,8,51,,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,H,,Sus scrofa,BAO_0000019,,CHEMBL616407,,,F
13047,Autocuration,,1,,9986.0,1085,8,51,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616408,,,B
15796,Expert,,1,,10116.0,1086,9,10576,,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616409,,,B
3651,Expert,,1,,10116.0,1087,9,10576,,,Hippocampus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616410,,,B
188,Autocuration,,1,,,1088,8,10576,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,H,,,BAO_0000357,,CHEMBL616411,,,B
16616,Expert,,1,,10116.0,1089,9,10576,,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616412,,Membranes,F
16616,Expert,,1,,10116.0,1090,9,10576,,,Hippocampus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,D,,Rattus norvegicus,BAO_0000249,10000000.0,CHEMBL616413,,Membranes,F
12306,Autocuration,,1,,,1091,8,10576,,,Hippocampus,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL616414,,,B
17167,Expert,,1,,10116.0,1092,9,10576,,,Hippocampus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616415,,,B
14776,Autocuration,,1,,,1093,8,10576,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,H,,,BAO_0000019,,CHEMBL616416,,,B
12158,Expert,,1,,,1094,8,10576,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,H,,,BAO_0000357,,CHEMBL616417,,,B
13481,Autocuration,,1,,,1095,8,10576,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,H,,,BAO_0000357,,CHEMBL616418,,,B
13427,Autocuration,,1,,,1096,8,10576,,In vitro,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,H,,,BAO_0000219,,CHEMBL616419,,,B
10210,Autocuration,,1,,,1097,8,10576,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616420,,,B
10205,Autocuration,,1,,,1098,8,10576,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,H,,,BAO_0000249,,CHEMBL616421,,Membranes,B
10205,Autocuration,,1,,,1099,8,10576,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,H,,,BAO_0000249,,CHEMBL616422,,Membranes,B
10205,Expert,,1,,,1100,8,10576,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,H,,,BAO_0000249,,CHEMBL616423,,Membranes,B
12280,Expert,,1,,10116.0,1101,9,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616424,,,B
17386,Expert,,1,,,1102,8,10576,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616425,,,B
13654,Expert,,1,,,1103,8,10576,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,H,,,BAO_0000357,,CHEMBL616426,,,B
14423,Autocuration,,1,,,1104,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,H,,,BAO_0000221,10000000.0,CHEMBL616427,,,B
15412,Autocuration,,1,,,1105,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,H,,,BAO_0000221,10000000.0,CHEMBL616428,,,B
12073,Autocuration,,1,,,1106,8,10576,,,Hippocampus,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616290,,,B
4101,Expert,,1,,10116.0,1107,9,10576,,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616052,,,B
10062,Autocuration,,1,,,1108,8,10576,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616053,,,B
6238,Autocuration,,1,,,1109,8,10576,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000249,,CHEMBL616054,,,B
16273,Autocuration,,1,,,1110,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616055,,,B
11139,Autocuration,,1,,,1111,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,H,,,BAO_0000357,,CHEMBL616056,,,B
16796,Expert,,1,,,1112,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,H,,,BAO_0000019,,CHEMBL616057,,,B
9548,Expert,,1,,10116.0,1113,9,10576,,,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,D,,Rattus norvegicus,BAO_0000221,955.0,CHEMBL616058,,,B
10381,Autocuration,,1,,,1114,8,10576,,,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,H,,,BAO_0000221,955.0,CHEMBL616059,,,B
13408,Autocuration,,1,,,1115,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000249,,CHEMBL616060,,,B
13825,Expert,,1,,10116.0,1116,9,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616061,,,B
11147,Expert,,1,,,1117,8,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616062,,,B
10552,Autocuration,,1,,,1118,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000249,,CHEMBL616063,,,B
10552,Autocuration,,1,,,1119,8,10576,,,Striatum,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,H,,,BAO_0000249,2435.0,CHEMBL616064,,,B
17136,Expert,,1,,10116.0,1120,9,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616065,,Membranes,B
5778,Expert,,1,,10116.0,1121,9,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616066,,Membranes,B
13481,Autocuration,,1,,,1122,8,10576,,,Hippocampus,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616067,,,B
13481,Autocuration,,1,,,1123,8,10576,,,Hippocampus,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,H,,,BAO_0000221,10000000.0,CHEMBL616068,,,B
13630,Intermediate,,1,,,1124,8,10576,,,Hippocampus,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616069,,,B
16245,Expert,,1,,,1125,8,10576,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,H,,,BAO_0000249,,CHEMBL616070,,,B
14509,Autocuration,,1,,,1126,8,10576,,,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616071,,,B
14509,Expert,,1,,,1127,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000221,10000000.0,CHEMBL616072,,,B
14509,Autocuration,,1,,,1128,8,10576,,,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616073,,,B
14509,Autocuration,,1,,,1129,8,10576,,,Hippocampus,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616074,,,B
14256,Expert,,1,,,1130,8,10576,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,H,,,BAO_0000019,,CHEMBL616075,,,B
11139,Autocuration,,1,,,1131,8,10576,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616076,,,B
11047,Expert,,1,,10116.0,1132,9,10576,,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616077,,,B
11047,Expert,,1,,10116.0,1133,9,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616078,,,B
11047,Expert,,1,,10116.0,1134,9,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616079,,,B
2395,Expert,,1,,10116.0,1135,9,10576,CHO-K1,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,D,485.0,Rattus norvegicus,BAO_0000219,,CHEMBL616080,,,B
9699,Autocuration,,1,,,1136,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616081,,,B
12028,Expert,,1,,10116.0,1137,9,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616082,,,B
12028,Autocuration,,1,,,1138,8,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,H,,,BAO_0000221,10000000.0,CHEMBL616083,,,B
5815,Autocuration,,1,,,1139,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616084,,,B
16616,Expert,,1,,,1140,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,H,,,BAO_0000019,,CHEMBL616085,,,B
5815,Autocuration,,1,,,1141,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,H,,,BAO_0000019,,CHEMBL616086,,,B
2761,Autocuration,,1,,,1142,8,10576,,,Hippocampus,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,H,,,BAO_0000221,10000000.0,CHEMBL616087,,,B
13133,Expert,,1,,,1143,8,10576,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,H,,,BAO_0000357,,CHEMBL616088,,,B
10444,Autocuration,,1,,,1144,8,10576,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,H,,,BAO_0000019,,CHEMBL616089,,,B
13278,Expert,,1,,10116.0,1145,9,10576,,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616090,,,B
15874,Autocuration,,1,,,1146,8,10576,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616091,,,B
10552,Autocuration,,1,,,1147,8,10576,,,Striatum,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,H,,,BAO_0000249,2435.0,CHEMBL616092,,Membranes,B
11130,Autocuration,,1,,,1148,8,10576,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,H,,,BAO_0000357,,CHEMBL616093,,,B
11130,Autocuration,,1,,,1149,8,10576,,In vivo,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,H,,,BAO_0000218,,CHEMBL616094,,,B
14542,Autocuration,,1,,,1150,8,10576,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,H,,,BAO_0000221,955.0,CHEMBL616095,,,B
13670,Expert,,1,,10116.0,1151,9,10576,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616096,,,B
9888,Expert,,1,,,1152,8,10576,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,H,,,BAO_0000249,,CHEMBL616097,,,B
3678,Expert,,1,,10116.0,1153,9,10576,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616098,,Membranes,B
11332,Autocuration,,1,,,1154,8,10576,,,Hippocampus,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616099,,,B
11332,Autocuration,,1,,,1155,8,10576,,,Hippocampus,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616100,,,B
1185,Expert,,1,,,1156,8,10576,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616101,,,B
2014,Expert,,1,,,1157,8,10576,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,H,,,BAO_0000249,,CHEMBL616102,,,B
1185,Autocuration,,1,,,1158,8,10576,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616103,,,B
14429,Expert,,1,,,1159,8,10576,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616104,,,B
16288,Expert,,1,,,1160,8,10576,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,H,,,BAO_0000019,,CHEMBL616105,,,B
5432,Expert,,1,,10116.0,1161,9,10576,,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616106,,,B
14429,Autocuration,,1,,,1162,8,10576,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616107,,,B
13672,Expert,,1,,,1163,8,10576,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,H,,,BAO_0000357,,CHEMBL616108,,,B
11296,Expert,,1,,,1164,8,10576,,,Hippocampus,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616109,,,B
11296,Autocuration,,1,,,1165,8,10576,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,H,,,BAO_0000357,,CHEMBL616110,,,B
14749,Expert,,1,,,1166,8,10576,CHO,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,H,449.0,,BAO_0000219,,CHEMBL616111,,,B
15086,Expert,,1,,,1167,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL616112,,,B
13462,Autocuration,,1,,,1168,8,10576,,,Hippocampus,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,H,,,BAO_0000221,10000000.0,CHEMBL616113,,,B
15363,Autocuration,,1,,,1169,8,10576,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616114,,,B
15363,Autocuration,,1,,,1170,8,10576,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616115,,,B
10796,Autocuration,,1,,,1171,8,10576,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616116,,,B
12816,Expert,,1,,,1172,8,10576,,,Brain,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,955.0,CHEMBL615844,,,B
13542,Expert,,1,,,1173,8,10576,,,Hippocampus,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000221,10000000.0,CHEMBL615939,,,B
13308,Expert,,1,,,1174,8,10576,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,H,,,BAO_0000019,,CHEMBL615940,,,B
13541,Expert,,1,,,1175,8,10576,,,Hippocampus,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,H,,,BAO_0000221,10000000.0,CHEMBL615941,,,B
10058,Autocuration,,1,,,1176,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,H,,,BAO_0000221,10000000.0,CHEMBL615942,,,B
10058,Autocuration,,1,,,1177,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL615943,,,B
10058,Autocuration,,1,,,1178,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,H,,,BAO_0000221,10000000.0,CHEMBL615944,,,B
10058,Autocuration,,1,,,1179,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,H,,,BAO_0000221,10000000.0,CHEMBL615945,,,B
10058,Autocuration,,1,,,1180,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,H,,,BAO_0000221,10000000.0,CHEMBL615946,,,B
10058,Autocuration,,1,,,1181,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,H,,,BAO_0000221,10000000.0,CHEMBL615947,,,B
10058,Autocuration,,1,,,1182,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,H,,,BAO_0000221,10000000.0,CHEMBL615948,,,B
10058,Autocuration,,1,,,1183,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,H,,,BAO_0000221,10000000.0,CHEMBL615949,,,B
10058,Autocuration,,1,,,1184,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,H,,,BAO_0000221,10000000.0,CHEMBL615950,,,B
10058,Autocuration,,1,,,1185,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,H,,,BAO_0000221,10000000.0,CHEMBL615951,,,B
10058,Autocuration,,1,,,1186,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,H,,,BAO_0000221,10000000.0,CHEMBL615952,,,B
10058,Autocuration,,1,,,1187,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,H,,,BAO_0000221,10000000.0,CHEMBL615953,,,B
10058,Autocuration,,1,,,1188,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,H,,,BAO_0000221,10000000.0,CHEMBL615954,,,B
10058,Expert,,1,,10116.0,1189,9,10576,,,Hippocampus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL615955,,,B
10058,Autocuration,,1,,,1190,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,H,,,BAO_0000221,10000000.0,CHEMBL615956,,,B
10058,Autocuration,,1,,,1191,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,H,,,BAO_0000221,10000000.0,CHEMBL615957,,,B
12879,Expert,,1,,,1192,8,10576,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,H,,,BAO_0000019,,CHEMBL615958,,,B
11964,Expert,,1,,,1193,8,10576,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,H,,,BAO_0000019,,CHEMBL615959,,,B
11964,Autocuration,,1,,,1194,8,10576,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,H,,,BAO_0000019,,CHEMBL615960,,,B
11964,Autocuration,,1,,,1195,8,10576,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,H,,,BAO_0000019,,CHEMBL615961,,,B
9548,Expert,,1,,,1196,8,10576,,,Brain,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,H,,,BAO_0000221,955.0,CHEMBL615962,,,B
9098,Expert,,1,,,1197,8,10576,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,H,,,BAO_0000019,,CHEMBL615963,,,B
9098,Autocuration,,1,,,1198,8,10576,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,H,,,BAO_0000019,,CHEMBL615964,,,B
9098,Autocuration,,1,,,1199,8,10576,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,H,,,BAO_0000019,,CHEMBL615965,,,B
13248,Expert,,1,,,1200,8,10576,CHO,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL615966,,,B
3147,Expert,,1,,,1201,8,10576,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,H,,,BAO_0000249,,CHEMBL615967,,,B
13949,Expert,,1,,,1202,8,10576,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000019,,CHEMBL615968,,,B
11883,Autocuration,,1,,,1203,8,10576,CHO,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,H,449.0,,BAO_0000218,,CHEMBL615969,,,B
11883,Autocuration,,1,,,1204,8,10576,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,H,,,BAO_0000218,,CHEMBL615970,,,B
11883,Expert,,1,,10116.0,1205,9,10576,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL615971,,,B
15535,Expert,,1,,,1206,8,10576,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,H,,,BAO_0000249,,CHEMBL615972,,Membranes,B
15535,Autocuration,,1,,,1207,8,10576,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,H,,,BAO_0000249,,CHEMBL615973,,,B
15535,Autocuration,,1,,,1208,8,10576,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,H,,,BAO_0000249,,CHEMBL615974,,,B
16372,Expert,,1,,9606.0,1209,9,51,CHO,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL615975,,,B
14608,Expert,,1,,,1210,8,10576,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,H,,,BAO_0000249,,CHEMBL615976,,,B
4795,Expert,,1,,10116.0,1211,9,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL872106,,,B
13863,Autocuration,,1,,,1212,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL615977,,,B
13863,Autocuration,,1,,,1213,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,H,,,BAO_0000357,,CHEMBL615978,,,B
13863,Autocuration,,1,,,1214,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,H,,,BAO_0000357,,CHEMBL616166,,,B
13863,Autocuration,,1,,,1215,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,H,,,BAO_0000357,,CHEMBL616167,,,B
13863,Autocuration,,1,,,1216,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,H,,,BAO_0000357,,CHEMBL616168,,,B
13863,Autocuration,,1,,,1217,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,H,,,BAO_0000357,,CHEMBL616169,,,B
13863,Autocuration,,1,,,1218,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,H,,,BAO_0000357,,CHEMBL616170,,,B
13863,Autocuration,,1,,,1219,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,H,,,BAO_0000357,,CHEMBL616171,,,B
13863,Autocuration,,1,,,1220,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,H,,,BAO_0000357,,CHEMBL616172,,,B
13863,Autocuration,,1,,,1221,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,H,,,BAO_0000357,,CHEMBL616173,,,B
13863,Autocuration,,1,,,1222,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,H,,,BAO_0000357,,CHEMBL616174,,,B
13863,Autocuration,,1,,,1223,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,H,,,BAO_0000357,,CHEMBL616175,,,B
13863,Autocuration,,1,,,1224,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,H,,,BAO_0000357,,CHEMBL616176,,,B
13863,Autocuration,,1,,,1225,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,H,,,BAO_0000357,,CHEMBL616177,,,B
13863,Autocuration,,1,,,1226,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,H,,,BAO_0000357,,CHEMBL616178,,,B
9742,Autocuration,,1,,,1227,8,10576,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,H,,,BAO_0000019,,CHEMBL616179,,,B
12073,Autocuration,,1,,,1228,8,10576,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616180,,,B
4101,Autocuration,,1,,,1229,8,10576,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616181,,,B
15360,Autocuration,,1,,,1230,8,10576,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,H,,,BAO_0000019,,CHEMBL616182,,,B
11576,Autocuration,,1,,,1231,8,10576,,,Hippocampus,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000221,10000000.0,CHEMBL616183,,,B
5834,Expert,,1,,,1232,8,10576,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,H,,,BAO_0000019,,CHEMBL615874,,,B
2395,Expert,,1,,10116.0,1233,9,10576,CHO-K1,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,D,485.0,Rattus norvegicus,BAO_0000219,,CHEMBL615875,,,B
1375,Autocuration,,1,,,1234,8,10576,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,H,,,BAO_0000019,,CHEMBL615876,,,B
1375,Autocuration,,1,,,1235,8,10576,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,H,,,BAO_0000019,,CHEMBL615877,,,B
3967,Autocuration,,1,,,1236,8,10576,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,H,,,BAO_0000357,,CHEMBL615878,,,B
12884,Expert,,1,,,1237,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,H,,,BAO_0000357,,CHEMBL615879,,,B
2343,Expert,,1,,,1238,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,H,,,BAO_0000357,,CHEMBL615880,,,B
11511,Autocuration,,1,,,1239,8,10576,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,H,,,BAO_0000019,,CHEMBL615881,,,B
11511,Expert,,1,,10116.0,1240,9,10576,,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL615882,,,B
16394,Autocuration,,1,,,1241,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,H,,,BAO_0000218,,CHEMBL615883,,,F
16394,Autocuration,,1,,,1242,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,H,,,BAO_0000218,,CHEMBL615884,,,F
16394,Autocuration,,1,,,1243,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,H,,,BAO_0000218,,CHEMBL615885,,,F
16394,Autocuration,,1,,,1244,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,H,,,BAO_0000218,,CHEMBL615886,,,F
16394,Autocuration,,1,,,1245,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,H,,,BAO_0000218,,CHEMBL615887,,,F
16394,Autocuration,,1,,,1246,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,H,,,BAO_0000218,,CHEMBL615888,,,F
16394,Autocuration,,1,,,1247,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,H,,,BAO_0000218,,CHEMBL615889,,,F
16394,Autocuration,,1,,,1248,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,H,,,BAO_0000218,,CHEMBL615890,,,F
16394,Autocuration,,1,,,1249,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,H,,,BAO_0000218,,CHEMBL615891,,,F
16394,Autocuration,,1,,,1250,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,H,,,BAO_0000218,,CHEMBL615892,,,F
16394,Autocuration,,1,,,1251,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,H,,,BAO_0000218,,CHEMBL615893,,,F
16394,Autocuration,,1,,,1252,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,H,,,BAO_0000218,,CHEMBL615894,,,F
16394,Autocuration,,1,,,1253,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,H,,,BAO_0000218,,CHEMBL615895,,,F
16394,Autocuration,,1,,,1254,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,H,,,BAO_0000218,,CHEMBL615896,,,F
16394,Autocuration,,1,,,1255,8,10576,,In vivo,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,H,,,BAO_0000218,,CHEMBL615897,,,F
16616,Expert,,1,,10116.0,1256,9,10576,,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,D,,Rattus norvegicus,BAO_0000249,,CHEMBL615898,,Membranes,F
16796,Autocuration,,1,,,1257,8,10576,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,H,,,BAO_0000019,,CHEMBL615899,,,B
16796,Autocuration,,1,,,1258,8,10576,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,H,,,BAO_0000019,,CHEMBL616291,,,B
15629,Autocuration,,1,,,1259,8,10576,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,H,,,BAO_0000357,,CHEMBL616292,,,B
13241,Autocuration,,1,,,1260,8,10576,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,H,,,BAO_0000249,,CHEMBL616293,,,F
12073,Expert,,1,,,1261,8,10576,,,Hippocampus,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616294,,,B
14286,Autocuration,,1,,,1262,8,10576,,,Hippocampus,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,H,,,BAO_0000249,10000000.0,CHEMBL616295,,,B
14542,Autocuration,,1,,,1263,8,10576,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,H,,,BAO_0000221,955.0,CHEMBL616296,,,B
13630,Autocuration,,1,,,1264,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616297,,,F
13630,Autocuration,,1,,,1265,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616605,,,F
13630,Autocuration,,1,,,1266,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616606,,,F
13630,Autocuration,,1,,,1267,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,H,,,BAO_0000019,,CHEMBL616607,,,F
13630,Expert,,1,,,1268,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,H,,,BAO_0000019,,CHEMBL616608,,,F
13630,Autocuration,,1,,,1269,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616609,,,F
13630,Expert,,1,,10116.0,1270,9,10576,,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616610,,,F
13630,Autocuration,,1,,,1271,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616611,,,F
13630,Expert,,1,,,1272,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616612,,,F
13630,Autocuration,,1,,,1273,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616613,,,F
13630,Expert,,1,,,1274,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,H,,,BAO_0000019,,CHEMBL616614,,,F
13630,Autocuration,,1,,,1275,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616615,,,F
13630,Expert,,1,,,1276,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,H,,,BAO_0000019,,CHEMBL616616,,,F
13630,Autocuration,,1,,,1277,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616617,,,F
13630,Autocuration,,1,,,1278,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616618,,,F
13630,Autocuration,,1,,,1279,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616619,,,F
13630,Expert,,1,,,1280,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616620,,,F
13630,Expert,,1,,,1281,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616621,,,F
13630,Autocuration,,1,,,1282,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,H,,,BAO_0000019,,CHEMBL616622,,,F
13630,Expert,,1,,,1283,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,H,,,BAO_0000019,,CHEMBL616146,,,F
13630,Autocuration,,1,,,1284,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL832873,,,F
13630,Autocuration,,1,,,1285,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,H,,,BAO_0000019,,CHEMBL616147,,,F
13630,Autocuration,,1,,,1286,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL872872,,,F
13630,Autocuration,,1,,,1287,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,H,,,BAO_0000019,,CHEMBL616148,,,F
9783,Autocuration,,1,,,1288,8,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,H,,,BAO_0000221,10000000.0,CHEMBL616149,,,B
9783,Expert,,1,,,1289,8,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,H,,,BAO_0000221,10000000.0,CHEMBL616150,,,B
14331,Expert,,1,,10116.0,1290,9,10576,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616151,,Membranes,B
15260,Expert,,1,,,1291,8,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,H,,,BAO_0000221,10000000.0,CHEMBL872873,,,B
15260,Autocuration,,1,,,1292,8,10576,,,Hippocampus,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,H,,,BAO_0000221,10000000.0,CHEMBL616670,,,B
15260,Autocuration,,1,,,1293,8,10576,,,Hippocampus,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,H,,,BAO_0000221,10000000.0,CHEMBL616671,,,B
16616,Expert,,1,,10116.0,1294,9,10576,,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,D,,Rattus norvegicus,BAO_0000249,,CHEMBL884861,,,F
15629,Autocuration,,1,,,1295,8,10576,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,H,,,BAO_0000357,,CHEMBL616672,,,B
15086,Autocuration,,1,,,1296,8,10576,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,H,,,BAO_0000019,,CHEMBL616673,,,B
5717,Expert,,1,,,1297,8,10576,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000019,,CHEMBL616674,,,F
12652,Autocuration,,1,,,1298,8,10576,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616675,,,B
14608,Autocuration,,1,,,1299,8,10576,,,Hippocampus,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,H,,,BAO_0000221,10000000.0,CHEMBL616676,,,B
12306,Autocuration,,1,,,1300,8,10576,,,Hippocampus,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL616677,,,B
12306,Autocuration,,1,,,1301,8,10576,,,Hippocampus,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL616678,,,B
15247,Expert,,1,,10116.0,1302,9,10576,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616679,,,B
17529,Expert,,1,,,1303,8,10576,,,Hippocampus,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616680,,,B
14826,Autocuration,,1,,,1304,8,10576,,,Hippocampus,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616681,,,B
14826,Autocuration,,1,,,1305,8,10576,,,Hippocampus,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616682,,,B
13241,Autocuration,,1,,,1306,8,10576,,,Hippocampus,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000221,10000000.0,CHEMBL616683,,,B
14093,Autocuration,,1,,,1307,8,10576,,,Hippocampus,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000221,10000000.0,CHEMBL616684,,,B
14093,Autocuration,,1,,,1308,8,10576,,,Hippocampus,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,H,,,BAO_0000221,10000000.0,CHEMBL616685,,,B
14442,Autocuration,,1,,,1309,8,10576,,,Brain,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,H,,,BAO_0000221,955.0,CHEMBL616686,,,B
9919,Autocuration,,1,,,1310,8,10576,,,,Affinity for 5-hydroxytryptamine 1A receptor site,,H,,,BAO_0000357,,CHEMBL616687,,,B
9919,Autocuration,,1,,,1311,8,10576,,,,Affinity for 5-hydroxytryptamine 1A receptor site,,H,,,BAO_0000357,,CHEMBL616688,,,B
11440,Autocuration,,1,,,1312,8,10576,,,Hippocampus,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,H,,,BAO_0000221,10000000.0,CHEMBL616689,,,B
11257,Autocuration,,1,,,1313,8,10576,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616690,,,B
10330,Expert,,1,,,1314,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616691,,,B
17331,Expert,,1,,10116.0,1315,9,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616692,,,B
16567,Expert,,1,,,1316,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,H,,,BAO_0000249,,CHEMBL616693,,,B
12058,Expert,,1,,10116.0,1317,9,10576,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616694,,,B
9699,Autocuration,,1,,,1318,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,H,,,BAO_0000221,10000000.0,CHEMBL616695,,,B
9547,Autocuration,,1,,,1319,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,H,,,BAO_0000357,,CHEMBL616696,,,B
10330,Autocuration,,1,,,1320,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL616697,,,B
14331,Autocuration,,1,,,1321,8,10576,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616698,,,B
14060,Expert,,1,,10116.0,1322,9,10576,,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616949,,,B
14744,Autocuration,,1,,,1323,8,10576,,,Hippocampus,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL616950,,,B
13506,Autocuration,,1,,,1324,8,10576,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,H,,,BAO_0000357,,CHEMBL832875,,,B
10862,Expert,,1,,,1325,8,10576,,,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,H,,,BAO_0000221,955.0,CHEMBL616951,,,B
10862,Expert,,1,,,1326,8,10576,,,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,H,,,BAO_0000221,955.0,CHEMBL616952,,,B
10062,Expert,,1,,,1327,8,10576,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,H,,,BAO_0000357,,CHEMBL616953,,,B
12073,Autocuration,,1,,,1328,8,10576,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,H,,,BAO_0000357,,CHEMBL616954,,,B
14875,Autocuration,,1,,,1329,8,106,,,,GTPgammaS radioligand binding assay,,H,,,BAO_0000357,,CHEMBL616955,,,B
2391,Autocuration,,1,,,1330,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,H,,,BAO_0000357,,CHEMBL616956,,,B
2391,Autocuration,,1,,,1331,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,H,,,BAO_0000019,,CHEMBL616957,,,F
2391,Autocuration,,1,,,1332,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,H,,,BAO_0000019,,CHEMBL616958,,,F
2391,Autocuration,,1,,,1333,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616959,,,B
2391,Autocuration,,1,,,1334,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,H,,,BAO_0000357,,CHEMBL616960,,,B
2391,Autocuration,,1,,,1335,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,H,,,BAO_0000019,,CHEMBL616961,,,F
17211,Expert,,1,,,1336,8,106,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,H,308.0,,BAO_0000219,,CHEMBL616962,,,B
17211,Autocuration,,1,,,1337,8,106,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,H,308.0,,BAO_0000219,,CHEMBL616963,,,B
6491,Expert,,1,,9606.0,1338,9,106,,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616524,,,B
16190,Autocuration,,1,,,1339,8,106,CHO,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616525,,,B
14165,Autocuration,,1,,,1340,8,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,H,,,BAO_0000019,,CHEMBL872908,,,B
14165,Autocuration,,1,,,1341,8,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,H,,,BAO_0000019,,CHEMBL616526,,,B
4234,Expert,,1,,9606.0,1342,9,106,,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616527,,,B
6328,Expert,,1,,,1343,8,106,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,H,,,BAO_0000219,,CHEMBL616528,,,B
14770,Autocuration,,1,,,1344,8,106,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL616529,,,B
2598,Autocuration,,1,,,1345,8,106,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,H,,,BAO_0000357,,CHEMBL616530,,,B
6897,Expert,,1,,,1346,8,106,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616531,,,B
6897,Autocuration,,1,,,1347,8,106,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616532,,,B
6013,Autocuration,,1,,,1348,8,106,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616533,,,B
5843,Expert,,1,,,1349,8,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616534,,,B
14454,Expert,,1,,,1350,8,106,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,H,,,BAO_0000357,,CHEMBL616535,,,B
16209,Autocuration,,1,,,1351,8,106,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,H,,,BAO_0000357,,CHEMBL616536,,,B
3935,Autocuration,,1,,,1352,8,106,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616537,,,B
13729,Expert,,1,,,1353,8,106,CHO-K1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,H,485.0,,BAO_0000219,,CHEMBL616538,,,F
14251,Expert,,1,,,1354,8,106,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000019,,CHEMBL616539,,,F
17085,Expert,,1,,,1355,8,106,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000019,,CHEMBL616540,,,B
3025,Autocuration,,1,,,1356,8,106,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,H,,,BAO_0000357,,CHEMBL616429,,,B
15315,Expert,,1,,,1357,8,106,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616430,,,B
14214,Expert,,1,,9606.0,1358,9,106,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,D,,Homo sapiens,BAO_0000219,,CHEMBL616431,,,B
3804,Expert,,1,,9606.0,1359,9,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616432,,,B
2391,Expert,,1,,9606.0,1360,9,106,,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,D,,Homo sapiens,BAO_0000357,,CHEMBL616433,,,B
4175,Expert,,1,,9606.0,1361,9,106,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616434,,,B
17296,Autocuration,,1,,,1362,8,106,CHO,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,H,449.0,,BAO_0000219,,CHEMBL616435,,,B
17085,Expert,,1,,,1363,8,106,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,H,,,BAO_0000019,,CHEMBL616436,,,B
17211,Autocuration,,1,,,1364,8,106,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,H,308.0,,BAO_0000219,,CHEMBL616437,,,B
17211,Autocuration,,1,,,1365,8,106,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,H,308.0,,BAO_0000219,,CHEMBL616438,,,B
17211,Autocuration,,1,,,1366,8,106,HeLa,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,H,308.0,,BAO_0000219,,CHEMBL616439,,,B
15926,Expert,,1,,9606.0,1367,9,106,,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,D,,Homo sapiens,BAO_0000357,,CHEMBL616440,,,B
16312,Autocuration,,1,,,1368,8,106,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,H,485.0,,BAO_0000219,,CHEMBL616441,,,B
5843,Expert,,1,,,1369,8,106,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,H,,,BAO_0000357,,CHEMBL616442,,,B
5843,Autocuration,,1,,,1370,8,106,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616443,,,B
16312,Expert,,1,,,1371,8,106,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,H,485.0,,BAO_0000219,,CHEMBL616444,,,B
15926,Expert,,1,,9606.0,1372,9,106,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616445,,,B
15926,Expert,,1,,9606.0,1373,9,106,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616446,,,B
4540,Expert,,1,,9606.0,1374,9,106,CHO,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616447,,,B
6166,Autocuration,,1,,,1375,8,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,H,,,BAO_0000357,,CHEMBL616448,,,B
17296,Autocuration,,1,,,1376,8,106,CHO,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616449,,,B
17296,Autocuration,,1,,,1377,8,106,CHO,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616450,,,B
17296,Autocuration,,1,,,1378,8,106,CHO,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL857974,,,B
15779,Autocuration,,1,,,1379,8,106,CHO,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616451,,,B
15779,Autocuration,,1,,,1380,8,106,CHO,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616452,,,B
15779,Autocuration,,1,,,1381,8,106,CHO,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,H,449.0,,BAO_0000219,,CHEMBL616453,,,B
4199,Autocuration,,1,,,1382,8,106,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,H,449.0,,BAO_0000219,,CHEMBL616454,,,B
14875,Expert,,1,,9606.0,1383,9,106,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616455,,,B
15146,Autocuration,,1,,,1384,8,106,CHO,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,H,449.0,,BAO_0000219,,CHEMBL616456,,,B
5213,Autocuration,,1,,,1385,8,106,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,H,,,BAO_0000357,,CHEMBL616457,,,B
14818,Autocuration,,1,,,1386,8,106,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,H,449.0,,BAO_0000219,,CHEMBL616458,,,B
4829,Autocuration,,1,,,1387,8,106,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL616459,,,B
14454,Expert,,1,,,1388,8,106,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,H,,,BAO_0000019,,CHEMBL616460,,,F
14454,Expert,,1,,,1389,8,106,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,H,,,BAO_0000019,,CHEMBL616461,,,F
14875,Autocuration,,1,,,1390,8,106,CHO,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,H,449.0,,BAO_0000219,,CHEMBL616462,,,F
14875,Autocuration,,1,,,1391,8,106,CHO,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,H,449.0,,BAO_0000219,,CHEMBL616463,,,F
15250,Autocuration,,1,,,1392,8,105,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,H,,,BAO_0000019,,CHEMBL616464,,,F
15250,Autocuration,,1,,,1393,8,105,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,H,449.0,,BAO_0000219,,CHEMBL616465,,,B
15086,Autocuration,,1,,,1394,8,17105,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL832874,,,B
3025,Autocuration,,1,,9986.0,1395,8,106,,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616184,,,F
14998,Autocuration,,1,,9986.0,1396,8,106,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616185,,,B
14998,Intermediate,,1,,9986.0,1397,8,106,,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616186,,,B
14998,Autocuration,,1,,9986.0,1398,8,106,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616187,,,B
13969,Expert,,1,,,1399,8,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616188,,,B
13392,Intermediate,,1,,,1400,9,10577,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,,D,,,BAO_0000357,,CHEMBL873475,,,B
3651,Expert,,1,,10116.0,1401,9,10577,,,Striatum,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,D,,Rattus norvegicus,BAO_0000019,2435.0,CHEMBL616189,,,B
10025,Expert,,1,,,1402,8,10577,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,H,,,BAO_0000357,,CHEMBL616190,,,B
13863,Autocuration,,1,,,1403,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,H,,,BAO_0000357,,CHEMBL616191,,,B
13863,Autocuration,,1,,,1404,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,H,,,BAO_0000357,,CHEMBL616192,,,B
13863,Autocuration,,1,,,1405,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,H,,,BAO_0000357,,CHEMBL616193,,,B
13863,Autocuration,,1,,,1406,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,H,,,BAO_0000357,,CHEMBL616194,,,B
13863,Autocuration,,1,,,1407,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,H,,,BAO_0000357,,CHEMBL616195,,,B
13863,Autocuration,,1,,,1408,8,10576,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,H,,,BAO_0000357,,CHEMBL616196,,,B
4622,Autocuration,,1,,,1409,8,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,H,,,BAO_0000249,10000000.0,CHEMBL616197,,,B
14911,Intermediate,,1,,,1410,8,10576,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL616198,,,B
12678,Autocuration,,1,,,1411,8,10576,,,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,H,,,BAO_0000221,10000000.0,CHEMBL616199,,,B
12678,Expert,,1,,,1412,8,10576,,,Hippocampus,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,H,,,BAO_0000221,10000000.0,CHEMBL616200,,,B
14235,Expert,,1,,,1413,8,10576,,,Hippocampus,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616201,,,B
14949,Expert,,1,,,1414,8,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL616202,,,B
14949,Expert,,1,,,1415,8,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL616203,,,B
14949,Expert,,1,,,1416,8,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616204,,,B
14949,Expert,,1,,,1417,8,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616205,,,B
14949,Expert,,1,,,1418,8,10576,,,Hippocampus,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,H,,,BAO_0000221,10000000.0,CHEMBL616206,,,B
16118,Expert,,1,,,1419,8,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,H,,,BAO_0000249,,CHEMBL616207,,,B
3268,Autocuration,,1,,,1420,8,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,H,,,BAO_0000249,,CHEMBL616208,,,B
3268,Autocuration,,1,,,1421,8,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,H,,,BAO_0000249,,CHEMBL616209,,,B
16117,Expert,,1,,,1422,8,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616210,,,B
9783,Expert,,1,,,1423,8,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,H,,,BAO_0000221,10000000.0,CHEMBL616211,,,B
9783,Autocuration,,1,,,1424,8,10576,,,Hippocampus,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,H,,,BAO_0000221,10000000.0,CHEMBL616504,,,B
14356,Expert,,1,,10116.0,1425,9,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616505,,,B
15740,Autocuration,,1,,,1426,8,10576,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000019,,CHEMBL616506,,,F
12306,Autocuration,,1,,,1427,8,10576,,,Hippocampus,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,H,,,BAO_0000221,10000000.0,CHEMBL872107,,,B
13348,Expert,,1,,10116.0,1428,9,10576,,,Hippocampus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616507,,,B
10394,Autocuration,,1,,,1429,8,10576,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,H,,,BAO_0000249,,CHEMBL616303,,,B
15260,Autocuration,,1,,,1430,8,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,H,,,BAO_0000221,10000000.0,CHEMBL616304,,,B
10046,Expert,,1,,,1431,8,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,H,,,BAO_0000221,10000000.0,CHEMBL616305,,,B
15260,Intermediate,,1,,,1432,8,10576,,,Hippocampus,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000221,10000000.0,CHEMBL616306,,,F
12851,Autocuration,,1,,,1433,8,10576,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616307,,,B
2148,Expert,,1,,10116.0,1434,9,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL881829,,,B
13134,Expert,,1,,,1435,8,10576,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,H,,,BAO_0000357,,CHEMBL616308,,,B
12462,Autocuration,,1,,,1436,8,10576,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,H,,,BAO_0000019,,CHEMBL616309,,,B
12462,Expert,,1,,,1437,8,10576,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,H,,,BAO_0000019,,CHEMBL616310,,,B
12462,Autocuration,,1,,,1438,8,10576,CHO,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616311,,,B
11933,Expert,,1,,,1439,8,10576,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616312,,,B
11933,Autocuration,,1,,,1440,8,10576,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,H,,,BAO_0000357,,CHEMBL616313,,,B
403,Expert,,1,,10116.0,1441,9,10576,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616314,,,B
15538,Autocuration,,1,,,1442,8,10576,,,Hippocampus,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616315,,,B
15538,Autocuration,,1,,,1443,8,10576,,,Hippocampus,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,H,,,BAO_0000221,10000000.0,CHEMBL616567,,,B
15538,Autocuration,,1,,,1444,8,10576,,,Hippocampus,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,H,,,BAO_0000221,10000000.0,CHEMBL616568,,,B
12464,Intermediate,,1,,,1445,8,10576,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,H,,,BAO_0000019,,CHEMBL616569,,,B
1455,Expert,,1,,,1446,8,10576,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,H,,,BAO_0000357,,CHEMBL616570,,,B
12652,Autocuration,,1,,,1447,8,10576,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616571,,,B
12639,Autocuration,,1,,,1448,8,10576,,,Hippocampus,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,H,,,BAO_0000221,10000000.0,CHEMBL616572,,,B
13949,Expert,,1,,,1449,8,10576,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,H,,,BAO_0000249,,CHEMBL616573,,,B
12463,Expert,,1,,10116.0,1450,9,10576,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616574,,,B
14829,Expert,,1,,,1451,8,10576,,,Hippocampus,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,H,,,BAO_0000221,10000000.0,CHEMBL616575,,,B
14829,Autocuration,,1,,,1452,8,10576,,,Hippocampus,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,H,,,BAO_0000221,10000000.0,CHEMBL872108,,,B
12092,Autocuration,,1,,,1453,8,10576,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,H,,,BAO_0000357,,CHEMBL616576,,,B
403,Autocuration,,1,,,1454,8,10576,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,H,,,BAO_0000249,,CHEMBL616577,,,B
403,Autocuration,,1,,,1455,8,10576,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,H,,,BAO_0000249,,CHEMBL616578,,,B
3967,Expert,,1,,,1456,8,10576,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,H,,,BAO_0000357,,CHEMBL616579,,,B
12771,Expert,,1,,10116.0,1457,9,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616580,,,B
15086,Autocuration,,1,,,1458,8,10576,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,H,,,BAO_0000019,,CHEMBL616581,,,B
14909,Autocuration,,1,,,1459,8,10576,,,Hippocampus,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616582,,,B
14949,Expert,,1,,,1460,8,10576,,,Hippocampus,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616583,,,B
2309,Expert,,1,,10116.0,1461,9,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616584,,,B
4170,Expert,,1,,,1462,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616585,,,B
11642,Expert,,1,,10116.0,1463,9,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616586,,,B
11642,Autocuration,,1,,,1464,8,10576,,,Hippocampus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616587,,,B
12953,Autocuration,,1,,,1465,8,10576,,,Hippocampus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616588,,,B
12953,Autocuration,,1,,,1466,8,10576,,,Hippocampus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000221,10000000.0,CHEMBL616589,,,B
12953,Expert,,1,,,1467,8,10576,,,Hippocampus,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616590,,,B
12903,Expert,,1,,,1468,8,10576,CHO,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,H,449.0,,BAO_0000219,,CHEMBL616591,,,B
12536,Expert,,1,,,1469,8,10576,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616592,,,B
10058,Autocuration,,1,,,1470,8,10576,,,,The inhibition activity of 5-HT1A at 1 uM,,H,,,BAO_0000357,,CHEMBL616593,,,B
12902,Expert,,1,,,1471,8,10576,CHO-K1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,H,485.0,,BAO_0000219,,CHEMBL616594,,,B
14057,Expert,,1,,,1472,8,10576,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,H,,,BAO_0000249,,CHEMBL616595,,,B
11296,Autocuration,,1,,,1473,8,10576,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,H,,,BAO_0000357,,CHEMBL616596,,,B
11296,Autocuration,,1,,,1474,8,10576,,,Hippocampus,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616597,,,B
11296,Expert,,1,,,1475,8,10576,,,Hippocampus,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616598,,,B
16616,Expert,,1,,10116.0,1476,9,10576,,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616599,,Membranes,F
16616,Expert,,1,,10116.0,1477,9,10576,,,Hippocampus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,D,,Rattus norvegicus,BAO_0000249,10000000.0,CHEMBL616600,,Membranes,F
16567,Autocuration,,1,,,1478,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,H,,,BAO_0000019,,CHEMBL616601,,,B
16567,Autocuration,,1,,,1479,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,H,,,BAO_0000019,,CHEMBL616602,,,B
16567,Autocuration,,1,,,1480,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,H,,,BAO_0000019,,CHEMBL616603,,,B
16567,Autocuration,,1,,,1481,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,H,,,BAO_0000019,,CHEMBL616604,,,B
17136,Autocuration,,1,,,1482,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,H,,,BAO_0000249,,CHEMBL616316,,,B
17136,Autocuration,,1,,,1483,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,H,,,BAO_0000249,,CHEMBL616317,,,B
16616,Expert,,1,,10116.0,1484,9,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616318,,,B
17331,Autocuration,,1,,,1485,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,H,,,BAO_0000221,10000000.0,CHEMBL616319,,,B
17331,Autocuration,,1,,,1486,8,10576,,,Hippocampus,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,H,,,BAO_0000221,10000000.0,CHEMBL616320,,,B
17167,Expert,,1,,10116.0,1487,9,10576,,,Hippocampus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616321,,,B
15740,Autocuration,,1,,,1488,8,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,H,,,BAO_0000019,,CHEMBL616322,,,F
15740,Autocuration,,1,,,1489,8,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,H,,,BAO_0000019,,CHEMBL616323,,,F
4671,Autocuration,,1,,,1490,8,10576,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,H,,,BAO_0000357,,CHEMBL616324,,,B
10058,Autocuration,,1,,,1491,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,H,,,BAO_0000221,10000000.0,CHEMBL616325,,,B
10058,Autocuration,,1,,,1492,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,H,,,BAO_0000221,10000000.0,CHEMBL616326,,,B
10058,Autocuration,,1,,,1493,8,10576,,,Hippocampus,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,H,,,BAO_0000221,10000000.0,CHEMBL616327,,,B
12073,Autocuration,,1,,,1494,8,10576,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616328,,,B
2759,Autocuration,,1,,,1495,8,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,H,,,BAO_0000249,,CHEMBL858110,,,B
2759,Autocuration,,1,,,1496,8,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,H,,,BAO_0000249,,CHEMBL616329,,,F
2759,Autocuration,,1,,,1497,8,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,H,,,BAO_0000249,,CHEMBL616330,,,B
2759,Autocuration,,1,,,1498,8,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,H,,,BAO_0000249,,CHEMBL616331,,,F
2759,Autocuration,,1,,,1499,8,10576,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,H,,,BAO_0000249,,CHEMBL616332,,,F
9737,Autocuration,,1,,,1500,8,10576,,,Brain,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,H,,,BAO_0000249,955.0,CHEMBL857063,,,B
9737,Autocuration,,1,,,1501,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,H,,,BAO_0000019,,CHEMBL616333,,,B
5717,Expert,,1,,,1502,8,10576,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,H,,,BAO_0000019,,CHEMBL616334,,,F
12253,Autocuration,,1,,,1503,8,10576,,,Hippocampus,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616335,,,B
14025,Autocuration,,1,,,1504,8,10576,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,H,,,BAO_0000019,,CHEMBL616336,,,B
10425,Expert,,1,,,1505,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,H,,,BAO_0000249,,CHEMBL616337,,,B
14998,Autocuration,,1,,,1506,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,H,,,BAO_0000019,,CHEMBL616338,,,B
13694,Autocuration,,1,,,1507,8,10576,,,Hippocampus,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,H,,,BAO_0000221,10000000.0,CHEMBL616339,,,B
13694,Autocuration,,1,,,1508,8,10576,,,Hippocampus,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,H,,,BAO_0000221,10000000.0,CHEMBL616340,,,B
4342,Autocuration,,1,,,1509,8,10576,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL616341,,,B
12936,Expert,,1,,10116.0,1510,9,10576,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616342,,,B
13144,Expert,,1,,10116.0,1511,9,10576,,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616343,,,B
13343,Expert,,1,,,1512,8,10576,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,H,,,BAO_0000019,,CHEMBL616344,,,B
12132,Expert,,1,,,1513,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000357,,CHEMBL616345,,,B
15419,Expert,,1,,,1514,8,10576,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,H,,,BAO_0000019,,CHEMBL616346,,,B
1479,Autocuration,,1,,,1515,8,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616347,,,B
14287,Expert,,1,,,1516,8,10576,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,H,,,BAO_0000019,,CHEMBL616348,,,B
13116,Expert,,1,,,1517,8,10576,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616349,,,B
2759,Expert,,1,,10116.0,1518,9,10576,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616152,,Membranes,B
2759,Autocuration,,1,,,1519,8,10576,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,H,,,BAO_0000249,,CHEMBL616153,,,B
14748,Expert,,1,,,1520,8,10576,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,H,,,BAO_0000019,,CHEMBL616154,,,B
12304,Autocuration,,1,,,1521,8,10576,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616155,,,B
12409,Expert,,1,,10116.0,1522,9,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616156,,,B
12409,Expert,,1,,10116.0,1523,9,10576,,,Hippocampus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL616157,,,B
13267,Autocuration,,1,,,1524,8,10576,,,Hippocampus,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL616158,,,B
15194,Autocuration,,1,,,1525,8,10576,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,H,,,BAO_0000357,,CHEMBL616159,,,B
14256,Expert,,1,,,1526,8,10576,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,H,,,BAO_0000357,,CHEMBL616160,,,B
16567,Autocuration,,1,,,1527,8,10576,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,H,,,BAO_0000019,,CHEMBL616161,,,B
15740,Autocuration,,1,,,1528,8,10576,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,H,,,BAO_0000019,,CHEMBL616162,,,F
13278,Expert,,1,,10116.0,1529,9,12687,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616163,,,B
1970,Expert,,1,,,1530,8,10626,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,H,,,BAO_0000249,,CHEMBL616164,,Membranes,B
10034,Autocuration,,1,,,1531,8,10576,,,Brain,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,H,,,BAO_0000221,955.0,CHEMBL616165,,,B
13348,Autocuration,,1,,10116.0,1532,8,51,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,H,,Rattus norvegicus,BAO_0000019,,CHEMBL616355,,,B
13630,Autocuration,,1,,,1533,8,10576,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,H,,,BAO_0000019,,CHEMBL616356,,,F
10862,Autocuration,,1,,,1534,8,10576,,,Brain,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,H,,,BAO_0000221,955.0,CHEMBL616357,,,B
12058,Autocuration,,1,,,1535,8,10576,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,H,,,BAO_0000019,,CHEMBL616358,,,B
4639,Autocuration,,1,,,1536,8,51,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616359,,,B
15453,Expert,,1,,,1537,8,51,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,H,,,BAO_0000357,,CHEMBL616360,,,B
4820,Expert,,1,,,1538,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616361,,,B
1089,Autocuration,,1,,,1539,8,51,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616362,,,B
386,Autocuration,,1,,,1540,8,51,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,H,,,BAO_0000249,,CHEMBL616363,,Brain membranes,B
6011,Autocuration,,1,,,1541,8,51,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL616364,,,B
5014,Autocuration,,1,,,1542,8,51,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616365,,,B
4402,Expert,,1,,,1543,8,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616366,,,B
17066,Expert,,1,,,1544,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL872906,,,B
17515,Autocuration,,1,,,1545,8,51,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,H,,,BAO_0000357,,CHEMBL616367,,,B
2474,Autocuration,,1,,,1546,8,51,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616368,,,B
4775,Autocuration,,1,,,1547,8,51,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL616369,,,B
14294,Expert,,1,,9606.0,1548,9,51,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,D,,Homo sapiens,BAO_0000357,,CHEMBL616370,,,B
14294,Expert,,1,,9606.0,1549,9,51,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,D,,Homo sapiens,BAO_0000357,,CHEMBL616371,,,B
12249,Autocuration,,1,,,1550,8,51,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616372,,,B
11376,Expert,,1,,,1551,8,51,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,H,,,BAO_0000219,,CHEMBL616373,,,B
2474,Autocuration,,1,,,1552,8,51,,In vivo,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000218,,CHEMBL616374,,,B
13311,Autocuration,,1,,,1553,8,51,,,Hippocampus,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL616375,,,B
4373,Autocuration,,1,,,1554,8,51,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL616376,,,B
1633,Expert,,1,,,1555,8,51,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,H,,,BAO_0000357,,CHEMBL857064,,,B
11866,Autocuration,,1,,,1556,8,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL616377,,,B
4373,Autocuration,,1,,,1557,8,51,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,H,,,BAO_0000357,,CHEMBL616378,,,B
4687,Autocuration,,1,,,1558,8,51,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616379,,,B
16946,Autocuration,,1,,,1559,8,11863,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616380,,,B
13291,Autocuration,,1,,,1560,8,11863,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,H,,,BAO_0000357,,CHEMBL616381,,,B
14159,Autocuration,,1,,,1561,8,11863,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616382,,,B
10812,Autocuration,,1,,,1562,8,11863,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616383,,,B
3032,Expert,,1,,10090.0,1563,9,11863,CHO,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,D,449.0,Mus musculus,BAO_0000219,,CHEMBL616350,,,B
16655,Autocuration,,1,,,1564,8,11863,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616351,,,B
14532,Autocuration,,1,,,1565,8,11863,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,H,,,BAO_0000357,,CHEMBL616352,,,B
13944,Autocuration,,1,,,1566,8,11863,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616353,,,B
13033,Autocuration,,1,,,1567,8,11863,,,,Binding affinity against serotonergic 5-HT1a receptor,,H,,,BAO_0000357,,CHEMBL616354,,,B
10321,Autocuration,,1,,,1568,8,11863,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616508,,,B
2968,Expert,,1,,10090.0,1569,9,11863,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,D,,Mus musculus,BAO_0000357,,CHEMBL616559,,,B
13964,Autocuration,,1,,,1570,8,11863,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616560,,,B
15527,Autocuration,,1,,,1571,8,11863,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,H,,,BAO_0000357,,CHEMBL616561,,,B
12248,Autocuration,,1,,,1572,8,11863,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616562,,,B
12249,Autocuration,,1,,,1573,8,11863,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616563,,,B
15120,Autocuration,,1,,,1574,8,11863,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616564,,,B
13313,Autocuration,,1,,,1575,8,11863,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616565,,,B
2613,Autocuration,,1,,,1576,8,11863,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000218,,CHEMBL616566,,,B
16700,Autocuration,,1,,,1577,8,11863,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,H,,,BAO_0000357,,CHEMBL616989,,,B
2201,Autocuration,,1,,,1578,8,11863,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL857975,,,B
1274,Expert,,1,,10090.0,1579,9,11863,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,D,,Mus musculus,BAO_0000357,,CHEMBL616990,,,B
1317,Autocuration,,1,,,1580,8,11863,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,H,,,BAO_0000357,,CHEMBL616991,,,B
12146,Autocuration,,1,,,1581,8,11863,,,,Tested against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616992,,,B
14059,Autocuration,,1,,,1582,8,11863,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL616993,,,B
14025,Expert,,1,,9986.0,1583,8,106,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616994,,,B
14025,Autocuration,,1,,9986.0,1584,8,106,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616995,,,B
14447,Intermediate,,1,,9593.0,1585,9,105571,HEK293,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,D,722.0,Gorilla gorilla,BAO_0000219,,CHEMBL616996,,,B
3025,Autocuration,,1,,10141.0,1586,8,106,,In vivo,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,H,,Cavia porcellus,BAO_0000218,,CHEMBL616997,,,F
3025,Autocuration,,1,,10141.0,1587,8,106,,In vivo,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,H,,Cavia porcellus,BAO_0000218,,CHEMBL616998,,,F
15329,Autocuration,,1,,10141.0,1588,8,106,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,H,,Cavia porcellus,BAO_0000019,,CHEMBL616999,,,F
15329,Autocuration,,1,,10141.0,1589,8,106,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617000,,,F
15847,Autocuration,,1,,10141.0,1590,8,106,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617001,,,F
15847,Autocuration,,1,,10141.0,1591,8,106,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,H,,Cavia porcellus,BAO_0000019,,CHEMBL858111,,,F
14165,Autocuration,,1,,,1592,8,106,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,H,,,BAO_0000019,,CHEMBL617002,,,F
14214,Autocuration,,1,,,1593,8,106,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,H,,,BAO_0000019,,CHEMBL617003,,,F
14214,Autocuration,,1,,,1594,8,106,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,H,,,BAO_0000019,,CHEMBL617004,,,F
14214,Expert,,1,,9606.0,1595,9,106,,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,D,,Homo sapiens,BAO_0000019,,CHEMBL617005,,,F
13729,Expert,,1,,9606.0,1596,9,106,CHO-K1,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,D,485.0,Homo sapiens,BAO_0000219,,CHEMBL616623,,,F
3025,Autocuration,,1,,,1597,8,106,CHO,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,H,449.0,,BAO_0000219,,CHEMBL616624,,,F
2391,Autocuration,,1,,,1598,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL883243,,,B
2391,Autocuration,,1,,,1599,8,106,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,H,,,BAO_0000019,,CHEMBL616625,,,F
14956,Expert,,1,,,1600,8,106,CHO,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,H,449.0,,BAO_0000219,,CHEMBL616626,,,F
2598,Autocuration,,1,,,1601,8,106,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,H,449.0,,BAO_0000219,,CHEMBL616627,,,F
2598,Autocuration,,1,,,1602,8,106,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,H,449.0,,BAO_0000219,,CHEMBL616628,,,F
2598,Autocuration,,1,,,1603,8,106,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,H,449.0,,BAO_0000219,,CHEMBL616629,,,F
2598,Autocuration,,1,,,1604,8,106,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,H,449.0,,BAO_0000219,,CHEMBL616630,,,F
14956,Expert,,1,,,1605,8,106,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,H,,,BAO_0000019,,CHEMBL616631,,,F
14956,Autocuration,,1,,,1606,8,106,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,H,,,BAO_0000019,,CHEMBL616632,,,F
14214,Expert,,1,,9606.0,1607,9,106,,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616633,,,B
3463,Expert,,1,,,1608,8,106,CHO,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,H,449.0,,BAO_0000219,,CHEMBL616634,,,B
15331,Autocuration,,1,,,1609,8,106,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,H,,,BAO_0000357,,CHEMBL616635,,,B
16146,Expert,,1,,9606.0,1610,9,106,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL885358,,,B
14159,Expert,,1,,9606.0,1611,9,106,CHO,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616636,,,B
14158,Expert,,1,,,1612,8,106,CHO,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,H,449.0,,BAO_0000219,,CHEMBL616637,,,B
14159,Autocuration,,1,,,1613,8,106,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616638,,,B
15250,Expert,,1,,,1614,8,106,CHO,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616639,,,B
15250,Expert,,1,,,1615,8,106,CHO,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,H,449.0,,BAO_0000219,,CHEMBL616640,,,B
15331,Expert,,1,,,1616,8,106,CHO,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616641,,,B
15332,Expert,,1,,,1617,8,106,CHO,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,H,449.0,,BAO_0000219,,CHEMBL616642,,,B
14956,Expert,,1,,,1618,8,106,CHO,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616643,,,B
3805,Autocuration,,1,,,1619,8,106,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL616644,,,B
14875,Autocuration,,1,,,1620,8,106,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,H,,,BAO_0000357,,CHEMBL616645,,,B
14454,Autocuration,,1,,9986.0,1621,8,105,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616646,,,F
14454,Expert,,1,,9986.0,1622,8,105,,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616647,,,F
16288,Autocuration,,1,,,1623,8,105,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,H,,,BAO_0000357,,CHEMBL616509,,,B
16288,Autocuration,,1,,,1624,8,105,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,H,,,BAO_0000357,,CHEMBL616510,,,B
16312,Autocuration,,1,,,1625,8,105,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616511,,,B
1348,Expert,,1,,9913.0,1626,8,105,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,H,,Bos taurus,BAO_0000357,,CHEMBL616512,,,B
5834,Autocuration,,1,,9913.0,1627,8,105,,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,H,,Bos taurus,BAO_0000357,,CHEMBL616513,,,B
13366,Autocuration,,1,,9913.0,1628,8,105,,,Striatum,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,H,,Bos taurus,BAO_0000019,2435.0,CHEMBL616514,,,B
1414,Expert,,1,,9913.0,1629,8,105,,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,H,,Bos taurus,BAO_0000357,,CHEMBL616515,,,B
14998,Autocuration,,1,,9913.0,1630,8,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,H,,Bos taurus,BAO_0000019,,CHEMBL616516,,,B
11473,Autocuration,,1,,9913.0,1631,8,105,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL616517,,,B
11473,Autocuration,,1,,9913.0,1632,8,105,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL616518,,,B
10639,Autocuration,,1,,9913.0,1633,8,105,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL616519,,,B
10639,Autocuration,,1,,9913.0,1634,8,105,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL616520,,,B
1375,Autocuration,,1,,9913.0,1635,8,105,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL616521,,,B
1375,Autocuration,,1,,9913.0,1636,8,105,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,H,,Bos taurus,BAO_0000357,,CHEMBL616522,,,B
16532,Autocuration,,1,,9913.0,1637,8,105,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,H,,Bos taurus,BAO_0000357,,CHEMBL884531,,,B
11147,Autocuration,,1,,9913.0,1638,8,105,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL616523,,,B
13366,Autocuration,,1,,9913.0,1639,8,105,,,Striatum,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,H,,Bos taurus,BAO_0000019,2435.0,CHEMBL616731,,,B
10444,Autocuration,,1,,9913.0,1640,8,105,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,H,,Bos taurus,BAO_0000019,,CHEMBL616732,,,B
16532,Autocuration,,1,,9913.0,1641,8,105,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,H,,Bos taurus,BAO_0000357,,CHEMBL616733,,,B
16532,Autocuration,,1,,9913.0,1642,8,105,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,H,,Bos taurus,BAO_0000357,,CHEMBL616734,,,B
12827,Autocuration,,1,,9913.0,1643,8,105,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,H,,Bos taurus,BAO_0000249,,CHEMBL616735,,,B
12827,Autocuration,,1,,9913.0,1644,8,105,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,H,,Bos taurus,BAO_0000249,,CHEMBL616736,,,B
12919,Expert,,1,,9913.0,1645,8,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,,Bos taurus,BAO_0000019,,CHEMBL616737,,,F
14025,Autocuration,,1,,9913.0,1646,8,105,,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,H,,Bos taurus,BAO_0000019,,CHEMBL616738,,,B
12919,Expert,,1,,9913.0,1647,8,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,,Bos taurus,BAO_0000019,,CHEMBL616739,,,F
12919,Expert,,1,,9913.0,1648,8,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,,Bos taurus,BAO_0000019,,CHEMBL616740,,,F
12919,Expert,,1,,9913.0,1649,8,105,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,H,,Bos taurus,BAO_0000019,,CHEMBL616741,,,F
14447,Autocuration,,1,,9593.0,1650,8,105,HEK293,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,H,722.0,Gorilla gorilla,BAO_0000219,,CHEMBL616742,,,B
1375,Intermediate,,1,,10141.0,1651,9,105570,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616743,,,B
1375,Intermediate,,1,,10141.0,1652,9,105570,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616744,,,B
12409,Intermediate,,1,,10141.0,1653,9,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616745,,,F
12409,Intermediate,,1,,10141.0,1654,9,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616746,,,F
12409,Intermediate,,1,,10141.0,1655,9,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616747,,,F
12409,Intermediate,,1,,10141.0,1656,9,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616748,,,F
12409,Intermediate,,1,,10141.0,1657,9,105570,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616648,,,F
11574,Intermediate,,1,,10141.0,1658,9,105570,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,D,,Cavia porcellus,BAO_0000357,,CHEMBL616649,,,B
1558,Intermediate,,1,,10141.0,1659,9,105570,,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,D,,Cavia porcellus,BAO_0000357,,CHEMBL616650,,,B
12409,Intermediate,,1,,10141.0,1660,9,105570,,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,,Cavia porcellus,BAO_0000218,,CHEMBL616651,,,F
12409,Intermediate,,1,,10141.0,1661,9,105570,,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,,Cavia porcellus,BAO_0000218,,CHEMBL616652,,,F
12409,Intermediate,,1,,10141.0,1662,9,105570,,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,D,,Cavia porcellus,BAO_0000218,,CHEMBL616653,,,F
12409,Intermediate,,1,,10141.0,1663,9,105570,,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,D,,Cavia porcellus,BAO_0000218,,CHEMBL616654,,,F
12253,Intermediate,,1,,10141.0,1664,9,105570,,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,D,,Cavia porcellus,BAO_0000019,,CHEMBL616655,,,B
12936,Intermediate,,1,,10141.0,1665,9,105570,,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,D,,Cavia porcellus,BAO_0000357,,CHEMBL616656,,,B
13181,Autocuration,,1,,10141.0,1666,8,105,,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL616657,,,B
12409,Intermediate,,1,,10141.0,1667,9,105570,,,Striatum,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL616658,,,B
10639,Intermediate,,1,,10141.0,1668,9,105570,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,D,,Cavia porcellus,BAO_0000357,,CHEMBL616659,,,B
5254,Autocuration,,1,,,1669,8,51,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616660,,,B
13051,Autocuration,,1,,,1670,8,106,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,H,,,BAO_0000357,,CHEMBL616661,,,B
3463,Expert,,1,,,1671,8,105,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL616662,,,F
15315,Autocuration,,1,,,1672,8,105,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL616663,,,F
6011,Autocuration,,1,,,1673,8,105,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL616664,,,F
14159,Expert,,1,,9606.0,1674,9,105,CHO,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL881820,,,F
14159,Autocuration,,1,,,1675,8,105,CHO,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,H,449.0,,BAO_0000219,,CHEMBL616665,,,F
15250,Expert,,1,,,1676,8,105,CHO,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,H,449.0,,BAO_0000219,,CHEMBL616666,,,B
15250,Autocuration,,1,,,1677,8,105,CHO,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,H,449.0,,BAO_0000219,,CHEMBL616667,,,B
15331,Expert,,1,,,1678,8,105,CHO,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,H,449.0,,BAO_0000219,,CHEMBL616668,,,F
15332,Expert,,1,,9606.0,1679,9,105,CHO,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616669,,,F
15332,Expert,,1,,,1680,8,105,CHO,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,H,449.0,,BAO_0000219,,CHEMBL617040,,,F
3294,Autocuration,,1,,,1681,8,105,CHO,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,H,449.0,,BAO_0000219,,CHEMBL617041,,,F
14158,Expert,,1,,,1682,8,105,CHO,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,H,449.0,,BAO_0000219,,CHEMBL617042,,,F
14956,Expert,,1,,,1683,8,105,CHO,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,H,449.0,,BAO_0000219,,CHEMBL617043,,,F
12469,Autocuration,,1,,,1684,8,105,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL617044,,,F
3463,Expert,,1,,,1685,8,105,CHO,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,H,449.0,,BAO_0000219,,CHEMBL617045,,,F
15250,Expert,,1,,9606.0,1686,9,105,CHO,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617046,,,F
15250,Expert,,1,,9606.0,1687,9,105,CHO,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617047,,,F
14956,Expert,,1,,,1688,8,105,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,H,,,BAO_0000019,,CHEMBL617048,,,F
14159,Autocuration,,1,,,1689,8,105,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,H,,,BAO_0000019,,CHEMBL616897,,,F
14159,Expert,,1,,9606.0,1690,9,105,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,D,,Homo sapiens,BAO_0000019,,CHEMBL616898,,,F
14499,Expert,,1,,9606.0,1691,9,105,CHO,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL858201,,,F
15315,Autocuration,,1,,,1692,8,105,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL616899,,,F
3294,Autocuration,,1,,,1693,8,105,,In vitro,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,H,,,BAO_0000219,,CHEMBL616900,,,B
3463,Expert,,1,,,1694,8,105,CHO,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,H,449.0,,BAO_0000219,,CHEMBL616901,,,B
15331,Autocuration,,1,,,1695,8,105,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,H,,,BAO_0000357,,CHEMBL616902,,,B
14159,Expert,,1,,9606.0,1696,9,105,CHO,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616903,,,B
14158,Expert,,1,,,1697,8,105,CHO,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,H,449.0,,BAO_0000219,,CHEMBL616904,,,B
14159,Autocuration,,1,,,1698,8,105,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616905,,,B
15250,Expert,,1,,,1699,8,105,CHO,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,H,449.0,,BAO_0000219,,CHEMBL616906,,,B
15250,Expert,,1,,,1700,8,105,CHO,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616907,,,B
15331,Expert,,1,,,1701,8,105,CHO,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616908,,,B
15332,Expert,,1,,9606.0,1702,9,105,CHO,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616909,,,B
14499,Expert,,1,,9606.0,1703,9,105,CHO,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616910,,,B
15332,Expert,,1,,,1704,8,105,CHO,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616911,,,B
14956,Expert,,1,,,1705,8,105,CHO,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616912,,,B
3805,Autocuration,,1,,,1706,8,105,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL616913,,,B
6011,Expert,,1,,9606.0,1707,9,105,CHO,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616914,,,B
16190,Autocuration,,1,,,1708,8,105,CHO,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616915,,,B
14165,Autocuration,,1,,,1709,8,105,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,H,,,BAO_0000019,,CHEMBL616916,,,B
4234,Expert,,1,,9606.0,1710,9,105,,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616917,,,B
15527,Autocuration,,1,,,1711,8,105,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,H,,,BAO_0000357,,CHEMBL616918,,,B
6328,Expert,,1,,,1712,8,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,H,,,BAO_0000219,,CHEMBL616919,,,B
16209,Autocuration,,1,,,1713,8,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616920,,,B
14770,Autocuration,,1,,,1714,8,105,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL872914,,,B
2598,Autocuration,,1,,,1715,8,105,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,H,,,BAO_0000357,,CHEMBL616921,,,B
6897,Expert,,1,,,1716,8,105,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616922,,,B
6013,Autocuration,,1,,,1717,8,105,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616923,,,B
5843,Expert,,1,,,1718,8,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616924,,,B
14454,Expert,,1,,,1719,8,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,H,,,BAO_0000357,,CHEMBL875909,,,B
14454,Autocuration,,1,,,1720,8,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,H,,,BAO_0000357,,CHEMBL616925,,,B
14454,Autocuration,,1,,,1721,8,105,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,H,,,BAO_0000357,,CHEMBL616926,,,B
15818,Autocuration,,1,,,1722,8,105,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616927,,,B
13729,Expert,,1,,,1723,8,105,CHO-K1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,H,485.0,,BAO_0000219,,CHEMBL616928,,,F
6011,Expert,,1,,9606.0,1724,9,105,,In vitro,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,D,,Homo sapiens,BAO_0000219,,CHEMBL616929,,,B
4234,Expert,,1,,9606.0,1725,9,105,,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616930,,,B
17085,Expert,,1,,,1726,8,105,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL616931,,,B
3025,Autocuration,,1,,,1727,8,105,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,H,,,BAO_0000357,,CHEMBL616932,,,B
15315,Expert,,1,,,1728,8,105,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616933,,,B
14214,Expert,,1,,9606.0,1729,9,105,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,D,,Homo sapiens,BAO_0000219,,CHEMBL616934,,,B
3804,Expert,,1,,9606.0,1730,9,105,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616935,,,B
16700,Autocuration,,1,,,1731,8,105,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,H,,,BAO_0000357,,CHEMBL616936,,,B
2391,Expert,,1,,9606.0,1732,9,105,,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,D,,Homo sapiens,BAO_0000357,,CHEMBL616937,,,B
4175,Expert,,1,,9606.0,1733,9,105,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616938,,,B
17085,Autocuration,,1,,,1734,8,105,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL616939,,,B
17085,Expert,,1,,,1735,8,105,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,H,,,BAO_0000019,,CHEMBL616940,,,B
15926,Expert,,1,,9606.0,1736,9,105,,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,D,,Homo sapiens,BAO_0000357,,CHEMBL616941,,,B
16312,Autocuration,,1,,,1737,8,105,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,H,485.0,,BAO_0000219,,CHEMBL616942,,,B
16312,Autocuration,,1,,,1738,8,105,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,H,485.0,,BAO_0000219,,CHEMBL616943,,,B
14956,Autocuration,,1,,,1739,4,104802,CHO,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616944,,,B
3294,Autocuration,,1,,,1740,8,105,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,H,,,BAO_0000019,,CHEMBL616945,,,F
12861,Autocuration,,1,,,1741,8,105,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL616946,,,B
12861,Autocuration,,1,,,1742,8,105,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,,,BAO_0000019,,CHEMBL616947,,,B
16312,Expert,,1,,,1743,8,105,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,H,485.0,,BAO_0000219,,CHEMBL616948,,,B
5104,Autocuration,,1,,,1744,8,105,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616851,,,B
5105,Autocuration,,1,,,1745,8,105,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616852,,,B
14499,Autocuration,,1,,,1746,8,105,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616853,,,B
15926,Expert,,1,,9606.0,1747,9,105,,,,Binding activity against human 5-hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616854,,,B
4540,Expert,,1,,9606.0,1748,9,105,CHO,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616855,,,B
15779,Autocuration,,1,,,1749,8,105,CHO,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL616856,,,B
15779,Autocuration,,1,,,1750,8,105,CHO,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL616857,,,B
6166,Autocuration,,1,,,1751,8,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616858,,,B
15779,Autocuration,,1,,,1752,8,105,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL616859,,,B
15779,Autocuration,,1,,,1753,8,105,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,H,449.0,,BAO_0000219,,CHEMBL616860,,,B
17451,Autocuration,,1,,,1754,8,105,HEK293,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,H,722.0,,BAO_0000219,,CHEMBL616861,,,B
17451,Autocuration,,1,,,1755,8,105,HEK293,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,H,722.0,,BAO_0000219,,CHEMBL616541,,,B
17451,Autocuration,,1,,,1756,8,105,HEK293,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,H,722.0,,BAO_0000219,,CHEMBL616542,,,B
4199,Autocuration,,1,,,1757,8,105,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,H,449.0,,BAO_0000219,,CHEMBL616543,,,B
14875,Expert,,1,,9606.0,1758,9,105,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616544,,,B
15146,Autocuration,,1,,,1759,8,105,CHO,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,H,449.0,,BAO_0000219,,CHEMBL616545,,,B
5213,Autocuration,,1,,,1760,8,105,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,H,,,BAO_0000357,,CHEMBL616546,,,B
14818,Autocuration,,1,,,1761,8,105,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,H,449.0,,BAO_0000219,,CHEMBL616547,,,B
4829,Autocuration,,1,,,1762,8,105,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL616548,,,B
14454,Expert,,1,,,1763,8,105,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,H,,,BAO_0000019,,CHEMBL616549,,,F
14454,Expert,,1,,,1764,8,105,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,H,,,BAO_0000019,,CHEMBL616550,,,F
5254,Autocuration,,1,,,1765,8,108,,,,Binding affinity against 5-HT2C receptor,,H,,,BAO_0000357,,CHEMBL857066,,,B
5254,Autocuration,,1,,,1766,8,108,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616551,,,B
10639,Autocuration,,1,,,1767,8,10577,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,H,,,BAO_0000357,,CHEMBL616552,,,B
10639,Autocuration,,1,,,1768,8,10577,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,H,,,BAO_0000019,,CHEMBL832876,,,F
12352,Expert,,1,,,1769,8,10577,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,H,,,BAO_0000019,,CHEMBL616553,,,B
9098,Autocuration,,1,,,1770,8,10577,,,,Binding affinity towards 5-HT1B was determined,,H,,,BAO_0000357,,CHEMBL616554,,,B
14430,Expert,,1,,,1771,8,10577,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,H,,,BAO_0000019,,CHEMBL616555,,,B
13657,Expert,,1,,,1772,8,10577,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,H,,,BAO_0000019,,CHEMBL616556,,,B
13657,Autocuration,,1,,,1773,8,10577,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,H,,,BAO_0000019,,CHEMBL616557,,,B
15854,Expert,,1,,,1774,8,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,H,,,BAO_0000019,,CHEMBL616558,,,B
10639,Expert,,1,,10116.0,1775,9,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616749,,,B
10025,Autocuration,,1,,,1776,8,10577,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,H,,,BAO_0000357,,CHEMBL616750,,,B
10025,Autocuration,,1,,,1777,8,10577,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,H,,,BAO_0000357,,CHEMBL616751,,,B
14286,Autocuration,,1,,,1778,8,10577,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,H,,,BAO_0000249,,CHEMBL616752,,,B
3651,Autocuration,,1,,,1779,8,10577,,,Striatum,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,H,,,BAO_0000019,2435.0,CHEMBL616753,,,B
14178,Expert,,1,,10116.0,1780,9,10577,,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616754,,,B
10639,Autocuration,,1,,,1781,8,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,H,,,BAO_0000019,,CHEMBL616755,,,B
13605,Autocuration,,1,,,1782,8,10577,,,Striatum,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,H,,,BAO_0000019,2435.0,CHEMBL616756,,,B
5834,Autocuration,,1,,,1783,8,10577,,,Striatum,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,H,,,BAO_0000019,2435.0,CHEMBL616757,,,B
10922,Autocuration,,1,,,1784,8,10577,,,Striatum,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,H,,,BAO_0000357,2435.0,CHEMBL616758,,,B
14286,Autocuration,,1,,,1785,8,10577,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,H,,,BAO_0000249,,CHEMBL616759,,,B
11825,Autocuration,,1,,,1786,8,10577,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,H,,,BAO_0000357,,CHEMBL616760,,,B
14826,Autocuration,,1,,,1787,8,10577,,,Striatum,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,H,,,BAO_0000019,2435.0,CHEMBL616761,,,B
9699,Autocuration,,1,,,1788,8,10577,,,Striatum,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,H,,,BAO_0000019,2435.0,CHEMBL616762,,,B
14423,Autocuration,,1,,,1789,8,10577,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616763,,,B
10062,Expert,,1,,,1790,8,10577,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,H,,,BAO_0000357,,CHEMBL872909,,,B
10062,Autocuration,,1,,,1791,8,10577,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616764,,,B
12280,Expert,,1,,10116.0,1792,9,10577,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616765,,,B
15412,Autocuration,,1,,,1793,8,10577,,,Striatum,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,H,,,BAO_0000357,2435.0,CHEMBL616766,,,B
15412,Autocuration,,1,,,1794,8,10577,,,Striatum,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,H,,,BAO_0000357,2435.0,CHEMBL616767,,,B
10062,Autocuration,,1,,,1795,8,10577,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616768,,,B
11147,Autocuration,,1,,,1796,8,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616769,,,B
9547,Autocuration,,1,,,1797,8,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,H,,,BAO_0000019,,CHEMBL616770,,,B
10444,Autocuration,,1,,,1798,8,10577,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,H,,,BAO_0000019,,CHEMBL616771,,,B
12469,Autocuration,,1,,,1799,8,10577,,,Striatum,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,H,,,BAO_0000019,2435.0,CHEMBL616772,,,B
9098,Expert,,1,,,1800,8,10577,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,H,,,BAO_0000019,,CHEMBL616773,,,B
9098,Autocuration,,1,,,1801,8,10577,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,H,,,BAO_0000019,,CHEMBL616774,,,B
9699,Autocuration,,1,,,1802,8,10577,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616775,,,B
10394,Autocuration,,1,,,1803,8,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,H,,,BAO_0000249,,CHEMBL616776,,,B
12092,Autocuration,,1,,,1804,8,10577,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,H,,,BAO_0000357,,CHEMBL616777,,,B
16700,Autocuration,,1,,,1805,8,10577,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,H,,,BAO_0000357,,CHEMBL616778,,,B
403,Expert,,1,,10116.0,1806,9,10577,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616779,,,B
12771,Expert,,1,,10116.0,1807,9,10577,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616780,,,B
11642,Autocuration,,1,,,1808,8,10577,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616781,,,B
12953,Autocuration,,1,,,1809,8,10577,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616782,,,B
12953,Autocuration,,1,,,1810,8,10577,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL616783,,,B
12953,Expert,,1,,,1811,8,10577,,,Striatum,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,H,,,BAO_0000019,2435.0,CHEMBL616784,,,B
12953,Autocuration,,1,,,1812,8,10577,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,H,,,BAO_0000357,,CHEMBL616785,,,B
9737,Autocuration,,1,,,1813,8,10577,,,Brain,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,H,,,BAO_0000249,955.0,CHEMBL857067,,,B
9737,Autocuration,,1,,,1814,8,10577,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,H,,,BAO_0000019,,CHEMBL616786,,,B
9737,Autocuration,,1,,,1815,8,10577,,,Brain,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,H,,,BAO_0000249,955.0,CHEMBL616787,,,B
12827,Autocuration,,1,,,1816,8,10577,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,H,,,BAO_0000357,,CHEMBL616788,,,B
5033,Autocuration,,1,,,1817,8,10577,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616789,,,B
9786,Expert,,1,,10116.0,1818,9,10577,,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616790,,,B
13116,Expert,,1,,,1819,8,10577,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616791,,,B
16429,Autocuration,,1,,,1820,8,10577,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,H,,,BAO_0000019,,CHEMBL616792,,,B
12409,Expert,,1,,10116.0,1821,9,10577,,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616793,,,B
15194,Autocuration,,1,,,1822,8,10577,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616794,,,B
15194,Autocuration,,1,,,1823,8,10577,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL616795,,,B
5486,Autocuration,,1,,,1824,4,104686,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616796,,,B
4639,Autocuration,,1,,,1825,8,106,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616797,,,B
386,Autocuration,,1,,,1826,8,106,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,H,,,BAO_0000249,,CHEMBL616798,,Brain membranes,B
2474,Autocuration,,1,,,1827,8,106,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,H,,,BAO_0000357,,CHEMBL616799,,,B
6011,Autocuration,,1,,,1828,8,106,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL616800,,,B
5014,Autocuration,,1,,,1829,8,106,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616801,,,B
17515,Autocuration,,1,,,1830,8,106,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,H,,,BAO_0000357,,CHEMBL616802,,,B
4373,Autocuration,,1,,,1831,8,106,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,H,,,BAO_0000357,,CHEMBL616803,,,B
1633,Expert,,1,,,1832,8,106,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,H,,,BAO_0000357,,CHEMBL857068,,,B
1633,Autocuration,,1,,,1833,8,106,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,H,,,BAO_0000357,,CHEMBL616804,,,B
4373,Autocuration,,1,,,1834,8,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,H,,,BAO_0000357,,CHEMBL616805,,,B
4687,Autocuration,,1,,,1835,8,106,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616806,,,B
11574,Autocuration,,1,,,1836,8,106,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,H,,,BAO_0000357,,CHEMBL616807,,,B
10321,Autocuration,,1,,,1837,8,106,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616808,,,B
15527,Autocuration,,1,,,1838,8,106,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL616809,,,B
17200,Autocuration,,1,,,1839,8,106,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,H,,,BAO_0000357,,CHEMBL616810,,,B
14423,Autocuration,,1,,,1840,4,104802,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,H,,,BAO_0000224,,CHEMBL616811,,,B
5834,Autocuration,,1,,9913.0,1841,8,108,,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,H,,Bos taurus,BAO_0000357,,CHEMBL616812,,,B
11473,Autocuration,,1,,9823.0,1842,8,108,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,H,,Sus scrofa,BAO_0000357,,CHEMBL616813,,,B
11473,Autocuration,,1,,9823.0,1843,8,108,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,H,,Sus scrofa,BAO_0000357,,CHEMBL616814,,,B
10639,Autocuration,,1,,9823.0,1844,8,108,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,H,,Sus scrofa,BAO_0000357,,CHEMBL616815,,,B
10639,Autocuration,,1,,9823.0,1845,8,108,,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,H,,Sus scrofa,BAO_0000357,,CHEMBL616816,,,B
14331,Autocuration,,1,,9823.0,1846,8,108,,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,H,,Sus scrofa,BAO_0000357,,CHEMBL616817,,,B
10796,Autocuration,,1,,9823.0,1847,8,108,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL616818,,,B
9098,Expert,,1,,9823.0,1848,8,108,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,H,,Sus scrofa,BAO_0000357,,CHEMBL616819,,,B
14331,Expert,,1,,9823.0,1849,8,108,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,H,,Sus scrofa,BAO_0000357,,CHEMBL616820,,,B
11828,Expert,,1,,9823.0,1850,8,108,,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,H,,Sus scrofa,BAO_0000019,,CHEMBL616821,,,B
11866,Autocuration,,1,,9823.0,1851,8,108,,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,H,,Sus scrofa,BAO_0000357,,CHEMBL616822,,,B
13047,Autocuration,,1,,9986.0,1852,8,108,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616823,,,B
188,Autocuration,,1,,10116.0,1853,9,12689,,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616824,,,B
11825,Autocuration,,1,,10116.0,1854,9,12689,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616825,,,B
11825,Autocuration,,1,,10116.0,1855,9,12689,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616826,,,B
11624,Expert,,1,,10116.0,1856,9,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616827,,,B
11139,Autocuration,,1,,10116.0,1857,9,12689,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616828,,,B
11147,Autocuration,,1,,10116.0,1858,9,12689,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616829,,,B
10444,Autocuration,,1,,10116.0,1859,9,12689,,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616830,,,B
11624,Expert,,1,,10116.0,1860,9,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616831,,,B
11662,Autocuration,,1,,10116.0,1861,9,12689,,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616832,,,B
11662,Autocuration,,1,,10116.0,1862,9,12689,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616833,,,B
11662,Expert,,1,,10116.0,1863,9,12689,,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616834,,,B
11662,Autocuration,,1,,10116.0,1864,9,12689,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL829595,,,B
9098,Autocuration,,1,,10116.0,1865,9,12689,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616835,,,B
10394,Autocuration,,1,,10116.0,1866,9,12689,,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL872910,,,B
11933,Expert,,1,,,1867,8,12689,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL616836,,,B
12092,Autocuration,,1,,10116.0,1868,9,12689,,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL616837,,,B
12253,Autocuration,,1,,10116.0,1869,9,12689,,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616466,,,B
12253,Autocuration,,1,,10116.0,1870,9,12689,HEK293,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,D,722.0,Rattus norvegicus,BAO_0000219,,CHEMBL616467,,,B
1558,Autocuration,,1,,,1871,8,108,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,H,,,BAO_0000357,,CHEMBL616468,,,B
2474,Autocuration,,1,,,1872,8,108,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL616469,,,B
2474,Autocuration,,1,,,1873,8,108,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL616470,,,B
11574,Autocuration,,1,,,1874,8,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,H,,,BAO_0000357,,CHEMBL616471,,,B
1558,Autocuration,,1,,,1875,8,12689,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,H,,,BAO_0000357,,CHEMBL616472,,,B
13944,Autocuration,,1,,,1876,8,12689,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,H,,,BAO_0000357,,CHEMBL616473,,,B
13033,Autocuration,,1,,,1877,8,12689,,,,Binding affinity against serotonergic 5-HT1c receptor,,H,,,BAO_0000357,,CHEMBL616474,,,B
10321,Autocuration,,1,,,1878,8,12689,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL616475,,,B
11866,Autocuration,,1,,,1879,8,12689,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,H,,,BAO_0000357,,CHEMBL616476,,,B
14454,Autocuration,,1,,9986.0,1880,8,105,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616477,,,B
11574,Autocuration,,1,,,1881,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,H,,,BAO_0000224,,CHEMBL616478,,,B
11574,Autocuration,,1,,,1882,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,H,,,BAO_0000224,,CHEMBL616479,,,B
13631,Autocuration,,1,,,1883,4,104686,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,H,,,BAO_0000019,,CHEMBL616480,,,B
9630,Autocuration,,1,,10116.0,1884,5,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL616481,,,B
8822,Autocuration,,1,,10116.0,1885,5,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL616482,,,B
9064,Autocuration,,1,,10116.0,1886,5,104686,,,Brain,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,D,,Rattus norvegicus,BAO_0000221,955.0,CHEMBL884713,,,B
8868,Autocuration,,1,,,1887,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,H,,,BAO_0000224,,CHEMBL616483,,,B
9064,Autocuration,,1,,,1888,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,H,,,BAO_0000224,,CHEMBL616484,,,B
9806,Autocuration,,1,,,1889,4,104686,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,H,,,BAO_0000019,,CHEMBL616485,,,B
9098,Autocuration,,1,,,1890,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,H,,,BAO_0000224,,CHEMBL616486,,,B
8868,Autocuration,,1,,,1891,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,H,,,BAO_0000224,,CHEMBL616487,,,B
12765,Autocuration,,1,,,1892,4,104686,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,H,,,BAO_0000224,,CHEMBL616488,,,B
11049,Autocuration,,1,,,1893,4,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,,,BAO_0000019,,CHEMBL616489,,,B
11049,Autocuration,,1,,,1894,4,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,,,BAO_0000019,,CHEMBL616490,,,B
11049,Autocuration,,1,,,1895,4,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,H,,,BAO_0000019,,CHEMBL616491,,,B
11049,Autocuration,,1,,,1896,4,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,H,,,BAO_0000019,,CHEMBL616492,,,B
11049,Autocuration,,1,,,1897,4,104686,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,,,BAO_0000019,,CHEMBL616493,,,B
11473,Autocuration,,1,,,1898,4,104686,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,H,,,BAO_0000019,,CHEMBL616494,,,B
11473,Autocuration,,1,,,1899,4,104686,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL616495,,,B
3086,Autocuration,,1,,,1900,4,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,H,,,BAO_0000019,,CHEMBL616496,,,B
11049,Autocuration,,1,,,1901,4,104686,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,,,BAO_0000019,,CHEMBL616497,,,B
11049,Autocuration,,1,,,1902,4,104686,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,H,,,BAO_0000019,,CHEMBL616498,,,B
10639,Autocuration,,1,,,1903,4,104686,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,H,,,BAO_0000019,,CHEMBL616499,,,B
10922,Autocuration,,1,,,1904,4,104686,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,H,,,BAO_0000019,,CHEMBL616500,,,B
9064,Autocuration,,1,,10116.0,1905,5,104686,,,Brain,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,D,,Rattus norvegicus,BAO_0000221,955.0,CHEMBL616501,,,B
10748,Autocuration,,1,,,1906,4,104686,,,Brain,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,H,,,BAO_0000221,955.0,CHEMBL616502,,,B
11614,Autocuration,,1,,,1907,4,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,H,,,BAO_0000249,,CHEMBL884529,,Membranes,B
11615,Autocuration,,1,,,1908,4,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,H,,,BAO_0000249,,CHEMBL616503,,Membranes,B
11615,Autocuration,,1,,,1909,4,104686,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL616964,,,B
11614,Autocuration,,1,,,1910,4,104686,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,H,,,BAO_0000249,,CHEMBL616965,,Membranes,B
11702,Autocuration,,1,,,1911,4,104686,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,H,,,BAO_0000224,,CHEMBL616966,,,B
11702,Autocuration,,1,,,1912,4,104686,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,H,,,BAO_0000224,,CHEMBL616967,,,B
11702,Autocuration,,1,,10116.0,1913,5,104686,,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL616968,,,B
11702,Autocuration,,1,,,1914,4,104686,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,H,,,BAO_0000224,,CHEMBL616969,,,B
13346,Autocuration,,1,,,1915,4,104686,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,H,,,BAO_0000019,,CHEMBL884530,,,B
10025,Autocuration,,1,,,1916,4,104686,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL616970,,,B
10025,Autocuration,,1,,,1917,4,104686,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,H,,,BAO_0000224,,CHEMBL616971,,,B
10025,Autocuration,,1,,,1918,4,104686,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,H,,,BAO_0000224,,CHEMBL616972,,,B
9036,Autocuration,,1,,,1919,4,104686,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,H,,,BAO_0000224,,CHEMBL616973,,,B
9036,Autocuration,,1,,,1920,4,104686,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,H,,,BAO_0000224,,CHEMBL616974,,,B
9161,Autocuration,,1,,,1921,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,H,,,BAO_0000019,,CHEMBL616975,,,B
12304,Autocuration,,1,,,1922,4,104686,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL616976,,,B
13276,Autocuration,,1,,,1923,4,104686,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,H,,,BAO_0000224,,CHEMBL616977,,,B
11825,Autocuration,,1,,,1924,4,104686,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,H,,,BAO_0000224,,CHEMBL616978,,,B
12443,Autocuration,,1,,,1925,4,104686,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,H,,,BAO_0000224,,CHEMBL616979,,,B
13830,Autocuration,,1,,,1926,4,104686,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL616980,,,B
9592,Autocuration,,1,,,1927,4,104686,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,H,,,BAO_0000249,,CHEMBL616981,,Membranes,B
9592,Autocuration,,1,,,1928,4,104686,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,H,,,BAO_0000249,,CHEMBL616982,,Membranes,B
10881,Autocuration,,1,,,1929,4,104686,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,H,,,BAO_0000224,,CHEMBL616983,,,B
13605,Autocuration,,1,,,1930,4,104686,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL616984,,,B
11624,Autocuration,,1,,10116.0,1931,5,104686,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL616985,,,B
4101,Autocuration,,1,,,1932,4,104686,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,H,,,BAO_0000224,,CHEMBL616986,,,B
4101,Autocuration,,1,,,1933,4,104686,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,H,,,BAO_0000224,,CHEMBL616987,,,B
15360,Autocuration,,1,,,1934,4,104686,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,H,,,BAO_0000019,,CHEMBL616988,,,B
11576,Autocuration,,1,,,1935,4,104686,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL617243,,,B
5834,Autocuration,,1,,,1936,4,104686,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,H,,,BAO_0000019,,CHEMBL617244,,,B
2395,Autocuration,,1,,10116.0,1937,5,104686,CHO-K1,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,D,485.0,Rattus norvegicus,BAO_0000219,,CHEMBL617245,,,B
11965,Autocuration,,1,,,1938,4,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,H,,,BAO_0000249,,CHEMBL617246,,Membranes,B
3967,Autocuration,,1,,,1939,4,104686,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,H,,,BAO_0000224,,CHEMBL617546,,,B
11130,Autocuration,,1,,,1940,4,104686,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,H,,,BAO_0000249,,CHEMBL617547,,Brain membranes,B
13427,Autocuration,,1,,,1941,4,104686,,In vitro,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,H,,,BAO_0000219,,CHEMBL617548,,,B
9443,Autocuration,,1,,,1942,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617549,,,B
9443,Autocuration,,1,,,1943,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,H,,,BAO_0000224,,CHEMBL617550,,,B
11825,Autocuration,,1,,,1944,4,104686,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,H,,,BAO_0000224,,CHEMBL617551,,,B
12120,Autocuration,,1,,,1945,4,104686,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,H,,,BAO_0000249,,CHEMBL617552,,Membranes,B
12120,Autocuration,,1,,,1946,4,104686,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,H,,,BAO_0000249,,CHEMBL617553,,Membranes,B
11963,Autocuration,,1,,,1947,4,104686,,,Thoracic aorta,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,H,,,BAO_0000019,1515.0,CHEMBL617554,,,F
9069,Autocuration,,1,,,1948,4,104686,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000019,,CHEMBL617555,,,B
8868,Autocuration,,1,,,1949,4,104686,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,H,,,BAO_0000224,,CHEMBL617556,,,B
17200,Autocuration,,1,,,1950,8,10624,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,H,,,BAO_0000357,,CHEMBL617557,,,B
17200,Autocuration,,1,,,1951,8,10624,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,H,,,BAO_0000357,,CHEMBL617558,,,B
13969,Expert,,1,,,1952,8,17106,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617559,,,B
13392,Expert,,1,,,1953,9,17106,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,,D,,,BAO_0000357,,CHEMBL617560,,,B
1742,Autocuration,,1,,,1954,8,17106,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,H,,,BAO_0000249,,CHEMBL617561,,,B
1742,Autocuration,,1,,,1955,8,17106,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,H,,,BAO_0000249,,CHEMBL617562,,,B
14331,Autocuration,,1,,,1956,8,17106,,,Striatum,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,H,,,BAO_0000357,2435.0,CHEMBL617563,,,B
12861,Autocuration,,1,,,1957,8,17106,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL617564,,,F
12861,Expert,,1,,,1958,8,17106,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,H,,,BAO_0000019,,CHEMBL617565,,,B
12861,Autocuration,,1,,,1959,8,17106,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL856076,,,B
12861,Autocuration,,1,,,1960,8,17106,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,H,,,BAO_0000019,,CHEMBL617566,,,B
12861,Expert,,1,,,1961,8,17106,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,,,BAO_0000019,,CHEMBL875911,,,B
12861,Autocuration,,1,,,1962,8,17106,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,H,,,BAO_0000019,,CHEMBL617567,,,B
675,Autocuration,,1,,,1963,8,17106,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,H,,,BAO_0000249,,CHEMBL617568,,,B
12490,Expert,,1,,,1964,8,17106,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,H,,,BAO_0000019,,CHEMBL617569,,,B
11828,Expert,,1,,,1965,8,17106,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,H,,,BAO_0000249,,CHEMBL617570,,,B
11866,Autocuration,,1,,,1966,8,17106,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,H,,,BAO_0000357,,CHEMBL617571,,,B
773,Autocuration,,1,,9823.0,1967,8,105,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,H,,Sus scrofa,BAO_0000357,,CHEMBL617572,,,B
13047,Expert,,1,,9986.0,1968,8,105,,,,The compound was tested for intrinsic activity against 5-HT1D receptor,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL617573,,,B
13047,Autocuration,,1,,9986.0,1969,8,105,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617574,,,B
13047,Expert,,1,,9986.0,1970,8,105,,,,The compound was tested for binding affinity against 5-HT1D receptor,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL617575,,,B
188,Autocuration,,1,,,1971,8,10578,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,H,,,BAO_0000357,,CHEMBL617576,,,B
10639,Autocuration,,1,,,1972,8,10578,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,H,,,BAO_0000019,,CHEMBL617577,,,F
12438,Autocuration,,1,,,1973,8,10578,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000019,,CHEMBL617578,,,F
12438,Autocuration,,1,,,1974,8,10578,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL617579,,,B
15854,Expert,,1,,,1975,8,10578,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,H,,,BAO_0000019,,CHEMBL617580,,,B
10394,Autocuration,,1,,,1976,8,10578,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,H,,,BAO_0000249,,CHEMBL617581,,,B
12092,Autocuration,,1,,,1977,8,10578,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,H,,,BAO_0000357,,CHEMBL617582,,,B
3389,Expert,,1,,,1978,8,10578,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,H,,,BAO_0000019,,CHEMBL617583,,,B
6011,Autocuration,,1,,,1979,8,105,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL617584,,,B
4639,Autocuration,,1,,,1980,8,105,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL617585,,,B
2474,Autocuration,,1,,,1981,8,105,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL875912,,,B
5014,Autocuration,,1,,,1982,8,105,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL617586,,,B
17515,Autocuration,,1,,,1983,8,105,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,H,,,BAO_0000357,,CHEMBL617587,,,B
11866,Autocuration,,1,,,1984,8,105,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,H,,,BAO_0000357,,CHEMBL617588,,,B
4687,Autocuration,,1,,,1985,8,105,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL857980,,,B
12146,Autocuration,,1,,,1986,8,105,,,,Tested against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL617589,,,B
10321,Autocuration,,1,,,1987,8,105,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617590,,,B
13267,Autocuration,,1,,,1988,8,105,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617591,,,B
1274,Expert,,1,,9606.0,1989,9,105,,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617592,,,B
15250,Autocuration,,1,,,1990,8,105,,,,,,H,,,BAO_0000357,,CHEMBL617593,,,B
13706,Autocuration,,1,,,1991,8,106,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL617594,,,B
13706,Autocuration,,1,,,1992,8,105,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL617595,,,B
13706,Autocuration,,1,,,1993,8,105,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,H,722.0,,BAO_0000219,,CHEMBL617596,,,B
13706,Autocuration,,1,,,1994,8,105,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,H,722.0,,BAO_0000219,,CHEMBL617597,,,B
13047,Autocuration,,1,,,1995,8,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,H,,,BAO_0000019,,CHEMBL617598,,,B
13366,Autocuration,,1,,,1996,8,105,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,H,,,BAO_0000357,,CHEMBL872916,,,B
13366,Expert,,1,,,1997,8,105,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,H,,,BAO_0000357,,CHEMBL617599,,,B
1558,Autocuration,,1,,,1998,8,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,H,,,BAO_0000357,,CHEMBL617091,,,B
12902,Expert,,1,,,1999,8,105,CHO-K1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,H,485.0,,BAO_0000219,,CHEMBL617092,,,B
13706,Autocuration,,1,,,2000,8,105,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL617093,,,B
13706,Autocuration,,1,,,2001,8,105,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,H,,,BAO_0000019,,CHEMBL617094,,,F
13706,Autocuration,,1,,,2002,8,105,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,H,,,BAO_0000019,,CHEMBL617095,,,F
14251,Autocuration,,1,,,2003,8,105,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,H,,,BAO_0000019,,CHEMBL617096,,,F
14251,Autocuration,,1,,,2004,8,105,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,H,,,BAO_0000019,,CHEMBL617097,,,F
14251,Autocuration,,1,,,2005,8,105,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,H,,,BAO_0000019,,CHEMBL617098,,,F
13313,Autocuration,,1,,,2006,8,105,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617301,,,B
13313,Autocuration,,1,,,2007,8,105,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617302,,,B
13366,Autocuration,,1,,,2008,8,105,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617303,,,B
13051,Expert,,1,,,2009,8,105,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617304,,,B
12903,Expert,,1,,,2010,8,105,CHO,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL617305,,,B
12469,Autocuration,,1,,9606.0,2011,9,105,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,D,,Homo sapiens,BAO_0000219,,CHEMBL617306,,,B
5619,Autocuration,,1,,,2012,8,17106,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,H,,,BAO_0000357,,CHEMBL617307,,,B
13047,Autocuration,,1,,9986.0,2013,8,105,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617308,,,B
16633,Autocuration,,1,,,2014,8,105,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617309,,,B
16633,Autocuration,,1,,,2015,8,105,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617310,,,B
16633,Autocuration,,1,,,2016,8,105,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617311,,,B
16633,Autocuration,,1,,,2017,8,105,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL617312,,,B
3269,Autocuration,,1,,,2018,8,105,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617313,,,B
12409,Expert,,1,,,2019,8,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,H,,,BAO_0000357,,CHEMBL617314,,,B
13706,Autocuration,,1,,,2020,8,106,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,H,,,BAO_0000019,,CHEMBL617315,,,F
13706,Autocuration,,1,,,2021,8,106,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,H,722.0,,BAO_0000219,,CHEMBL617316,,,B
13706,Autocuration,,1,,,2022,8,106,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,H,722.0,,BAO_0000219,,CHEMBL617317,,,B
12903,Autocuration,,1,,,2023,8,106,CHO,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL617318,,,B
13047,Autocuration,,1,,,2024,8,106,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,H,,,BAO_0000019,,CHEMBL617319,,,B
13366,Expert,,1,,,2025,9,106,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,D,,,BAO_0000357,,CHEMBL617320,,,B
13366,Expert,,1,,,2026,9,106,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,D,,,BAO_0000357,,CHEMBL617321,,,B
13366,Expert,,1,,,2027,9,106,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,D,,,BAO_0000357,,CHEMBL617322,,,B
13366,Autocuration,,1,,,2028,8,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616862,,,B
13366,Autocuration,,1,,,2029,8,106,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000357,,CHEMBL616863,,,B
12469,Autocuration,,1,,,2030,8,106,CHO,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,H,449.0,,BAO_0000219,,CHEMBL616864,,,B
13706,Autocuration,,1,,,2031,8,106,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL616865,,,B
13706,Autocuration,,1,,,2032,8,106,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL616866,,,B
13706,Autocuration,,1,,,2033,8,106,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,H,,,BAO_0000019,,CHEMBL616867,,,F
12902,Expert,,1,,,2034,8,106,CHO-K1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,H,485.0,,BAO_0000219,,CHEMBL616868,,,B
13051,Expert,,1,,,2035,8,105,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,H,,,BAO_0000357,,CHEMBL616869,,,B
12903,Expert,,1,,,2036,8,106,CHO,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL616870,,,B
1558,Autocuration,,1,,,2037,8,105,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,H,485.0,,BAO_0000219,,CHEMBL616871,,,F
1558,Autocuration,,1,,,2038,8,105,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,H,485.0,,BAO_0000219,,CHEMBL616872,,,F
1558,Autocuration,,1,,,2039,8,105,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,H,485.0,,BAO_0000219,,CHEMBL616873,,,F
1558,Autocuration,,1,,,2040,8,105,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,H,485.0,,BAO_0000219,,CHEMBL616838,,,F
1558,Autocuration,,1,,,2041,8,105,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,H,,,BAO_0000357,,CHEMBL616839,,,B
13047,Autocuration,,1,,9986.0,2042,8,106,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL616840,,,B
13313,Autocuration,,1,,,2043,8,105,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616841,,,B
13313,Autocuration,,1,,,2044,8,105,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616842,,,B
12409,Expert,,1,,,2045,8,105,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,H,,,BAO_0000357,,CHEMBL857976,,,B
15250,Autocuration,,1,,,2046,8,10618,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616843,,,B
1348,Expert,,1,,9606.0,2047,9,10618,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,D,,Homo sapiens,BAO_0000357,,CHEMBL616844,,,B
1348,Autocuration,,1,,,2048,8,10618,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,H,,,BAO_0000357,,CHEMBL616845,,,B
4234,Expert,,1,,9606.0,2049,9,10618,,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616846,,,B
16209,Autocuration,,1,,,2050,8,10618,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616847,,,B
10444,Autocuration,,1,,,2051,8,10618,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,H,,,BAO_0000019,,CHEMBL616848,,,B
3935,Autocuration,,1,,,2052,8,10618,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,H,,,BAO_0000357,,CHEMBL616849,,,B
15818,Autocuration,,1,,,2053,8,10618,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,H,,,BAO_0000357,,CHEMBL872911,,,B
17085,Autocuration,,1,,,2054,8,10618,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,H,,,BAO_0000019,,CHEMBL616850,,,B
12936,Expert,,1,,9606.0,2055,9,10618,CHO,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616699,,,B
6166,Autocuration,,1,,,2056,8,10618,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,H,,,BAO_0000357,,CHEMBL616700,,,B
15779,Autocuration,,1,,,2057,8,10618,CHO,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL616701,,,B
15779,Autocuration,,1,,,2058,8,10618,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL616702,,,B
15779,Autocuration,,1,,,2059,8,10618,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,H,449.0,,BAO_0000219,,CHEMBL616703,,,B
13181,Autocuration,,1,,,2060,8,10618,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,H,,,BAO_0000357,,CHEMBL616704,,,B
4199,Autocuration,,1,,,2061,8,10618,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,H,449.0,,BAO_0000219,,CHEMBL616705,,,B
14875,Autocuration,,1,,,2062,8,10618,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,H,,,BAO_0000357,,CHEMBL616706,,,B
15146,Autocuration,,1,,,2063,8,10618,CHO,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,H,449.0,,BAO_0000219,,CHEMBL616707,,,B
5213,Autocuration,,1,,,2064,8,10618,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,H,,,BAO_0000357,,CHEMBL616708,,,B
12146,Autocuration,,1,,,2065,8,10618,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL616709,,,B
13267,Autocuration,,1,,,2066,8,10618,CHO,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,H,449.0,,BAO_0000219,,CHEMBL616710,,,B
14818,Autocuration,,1,,,2067,8,10618,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,H,449.0,,BAO_0000219,,CHEMBL616711,,,B
4829,Autocuration,,1,,,2068,8,10618,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL616712,,,B
4373,Autocuration,,1,,,2069,8,10618,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,H,,,BAO_0000357,,CHEMBL616713,,,B
4373,Autocuration,,1,,,2070,8,10618,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,H,,,BAO_0000357,,CHEMBL616714,,,B
14159,Autocuration,,1,,,2071,8,10618,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,H,,,BAO_0000357,,CHEMBL616715,,,B
16633,Autocuration,,1,,,2072,8,10618,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,H,,,BAO_0000357,,CHEMBL616716,,,B
17085,Autocuration,,1,,,2073,8,279,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,H,,,BAO_0000019,,CHEMBL616717,,,F
17085,Expert,,1,,,2074,8,279,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,H,,,BAO_0000019,,CHEMBL616718,,,F
16209,Autocuration,,1,,,2075,8,279,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000019,,CHEMBL875905,,,F
16209,Autocuration,,1,,,2076,8,279,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000019,,CHEMBL616719,,,F
17085,Expert,,1,,,2077,8,279,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,H,,,BAO_0000019,,CHEMBL616720,,,F
14159,Autocuration,,1,,,2078,8,279,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000357,,CHEMBL616721,,,B
15250,Autocuration,,1,,,2079,8,279,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL616722,,,B
3805,Autocuration,,1,,,2080,8,279,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL616723,,,B
16190,Autocuration,,1,,,2081,8,279,CHO,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,H,449.0,,BAO_0000219,,CHEMBL616724,,,B
16190,Autocuration,,1,,,2082,8,279,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,H,,,BAO_0000357,,CHEMBL616725,,,B
16209,Autocuration,,1,,,2083,8,279,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000357,,CHEMBL616726,,,B
16209,Autocuration,,1,,,2084,8,279,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,H,,,BAO_0000357,,CHEMBL616727,,,B
16209,Autocuration,,1,,,2085,8,279,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,H,,,BAO_0000357,,CHEMBL616728,,,B
6866,Autocuration,,1,,,2086,8,279,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000357,,CHEMBL616729,,,B
17085,Expert,,1,,,2087,8,279,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000019,,CHEMBL616730,,,B
16312,Autocuration,,1,,,2088,8,279,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000357,,CHEMBL617125,,,B
6166,Autocuration,,1,,,2089,8,279,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,H,,,BAO_0000357,,CHEMBL857977,,,B
15779,Autocuration,,1,,,2090,8,279,CHO,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,H,449.0,,BAO_0000219,,CHEMBL617126,,,B
4199,Autocuration,,1,,,2091,8,279,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,H,449.0,,BAO_0000219,,CHEMBL617127,,,B
14875,Autocuration,,1,,,2092,8,279,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000357,,CHEMBL617128,,,B
15146,Autocuration,,1,,,2093,8,279,CHO,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,H,449.0,,BAO_0000219,,CHEMBL617129,,,B
5213,Autocuration,,1,,,2094,8,279,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,H,,,BAO_0000357,,CHEMBL617130,,,B
14818,Autocuration,,1,,,2095,8,279,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,H,449.0,,BAO_0000219,,CHEMBL617131,,,B
4829,Autocuration,,1,,,2096,8,279,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL617132,,,B
4829,Autocuration,,1,,,2097,8,279,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,H,449.0,,BAO_0000219,,CHEMBL617133,,,B
4373,Autocuration,,1,,,2098,8,279,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,H,,,BAO_0000357,,CHEMBL617134,,,B
4373,Autocuration,,1,,,2099,8,279,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,H,,,BAO_0000357,,CHEMBL617135,,,B
5014,Autocuration,,1,,,2100,8,279,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,H,,,BAO_0000357,,CHEMBL617136,,,B
11662,Autocuration,,1,,,2101,4,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,H,,,BAO_0000019,,CHEMBL617137,,,B
11662,Autocuration,,1,,,2102,4,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,H,,,BAO_0000019,,CHEMBL617138,,,B
11662,Autocuration,,1,,,2103,4,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,H,,,BAO_0000019,,CHEMBL617139,,,B
14093,Autocuration,,1,,,2104,8,12687,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617140,,,B
11200,Autocuration,,1,,,2105,4,104686,,In vivo,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,H,,,BAO_0000218,,CHEMBL617141,,,F
11200,Autocuration,,1,,,2106,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,,,BAO_0000019,,CHEMBL858112,,,F
12352,Intermediate,,1,,,2107,8,17005,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,H,,,BAO_0000019,,CHEMBL617142,,,B
13657,Autocuration,,1,,9913.0,2108,0,22226,,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,U,,Bos taurus,BAO_0000019,,CHEMBL617143,,,B
14331,Autocuration,,1,,9913.0,2109,0,22226,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,U,,Bos taurus,BAO_0000019,,CHEMBL617144,,,B
14331,Autocuration,,1,,9913.0,2110,0,22226,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,U,,Bos taurus,BAO_0000019,,CHEMBL617145,,,B
14331,Autocuration,,1,,,2111,0,22226,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,U,,,BAO_0000019,,CHEMBL617146,,,B
12685,Autocuration,,1,,10141.0,2112,4,104784,,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617147,,,B
14389,Autocuration,,1,,10141.0,2113,4,104784,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617148,,,B
14386,Autocuration,,1,,10141.0,2114,4,104784,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617149,,,B
5732,Autocuration,,1,,,2115,4,104784,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,H,,,BAO_0000224,,CHEMBL617150,,,B
16293,Autocuration,,1,,,2116,4,104784,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,H,,,BAO_0000224,,CHEMBL617151,,,B
2078,Autocuration,,1,,,2117,4,104784,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617201,,,B
5486,Autocuration,,1,,,2118,8,10209,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,H,,,BAO_0000357,,CHEMBL617202,,,B
11820,Autocuration,,1,,,2119,4,104826,,In vivo,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,H,,,BAO_0000218,,CHEMBL617203,,,B
10297,Autocuration,,1,,,2120,4,104826,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,H,,,BAO_0000019,,CHEMBL617204,,,B
13704,Autocuration,,1,,,2121,4,104826,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,H,,,BAO_0000224,,CHEMBL617205,,,B
10297,Autocuration,,1,,10090.0,2122,5,104826,,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,D,,Mus musculus,BAO_0000019,,CHEMBL617206,,,B
11820,Autocuration,,1,,,2123,4,104826,,In vivo,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,H,,,BAO_0000218,,CHEMBL617207,,,B
10297,Autocuration,,1,,10090.0,2124,5,104826,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,D,,Mus musculus,BAO_0000019,,CHEMBL617208,,,B
11555,Autocuration,,1,,,2125,4,104826,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617209,,,B
11555,Autocuration,,1,,,2126,4,104826,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,H,,,BAO_0000224,,CHEMBL617210,,,B
11555,Autocuration,,1,,,2127,4,104826,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,H,,,BAO_0000224,,CHEMBL617211,,,B
10297,Autocuration,,1,,10090.0,2128,5,104826,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,D,,Mus musculus,BAO_0000019,,CHEMBL617212,,,B
16688,Autocuration,,1,,9823.0,2129,4,104784,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,H,,Sus scrofa,BAO_0000224,,CHEMBL617213,,,B
16688,Autocuration,,1,,9823.0,2130,4,104784,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,H,,Sus scrofa,BAO_0000224,,CHEMBL617214,,,B
5333,Autocuration,,1,,,2131,0,22226,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,U,,,BAO_0000221,,CHEMBL617215,,,B
4437,Autocuration,,1,,,2132,0,22226,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,U,,,BAO_0000221,,CHEMBL617216,,,B
5033,Autocuration,,1,,9823.0,2133,8,17005,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL617217,,,B
15267,Autocuration,,1,,,2134,4,104686,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000019,,CHEMBL617218,,,B
15267,Autocuration,,1,,,2135,4,104686,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000019,,CHEMBL872913,,,B
11820,Autocuration,,1,,,2136,4,104826,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,H,,,BAO_0000019,,CHEMBL617219,,,B
9069,Autocuration,,1,,,2137,4,104686,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL873482,,,B
9162,Autocuration,,1,,10116.0,2138,5,104686,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617220,,,B
9162,Autocuration,,1,,,2139,4,104686,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,H,,,BAO_0000019,,CHEMBL617221,,,B
9162,Autocuration,,1,,,2140,4,104686,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,H,,,BAO_0000019,,CHEMBL617222,,,B
10428,Autocuration,,1,,,2141,4,104686,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,H,,,BAO_0000019,,CHEMBL875906,,,F
9628,Autocuration,,1,,,2142,4,104686,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,H,,,BAO_0000019,,CHEMBL617223,,,B
12704,Autocuration,,1,,,2143,4,104686,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617224,,,B
15453,Autocuration,,1,,10116.0,2144,5,104686,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617225,,,B
188,Autocuration,,1,,,2145,4,104686,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,H,,,BAO_0000224,,CHEMBL617226,,,B
10349,Autocuration,,1,,,2146,4,104686,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,H,,,BAO_0000224,,CHEMBL617227,,,B
10349,Autocuration,,1,,,2147,4,104686,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,H,,,BAO_0000224,,CHEMBL617228,,,B
8868,Autocuration,,1,,,2148,4,104686,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,H,,,BAO_0000224,,CHEMBL617229,,,B
10025,Autocuration,,1,,,2149,4,104686,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,H,,,BAO_0000224,,CHEMBL617230,,,B
10025,Autocuration,,1,,,2150,4,104686,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,H,,,BAO_0000224,,CHEMBL617231,,,B
11702,Autocuration,,1,,,2151,4,104686,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,H,,,BAO_0000224,,CHEMBL617232,,,B
11702,Autocuration,,1,,,2152,4,104686,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617233,,,B
11702,Autocuration,,1,,,2153,4,104686,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,H,,,BAO_0000224,,CHEMBL617234,,,B
11702,Autocuration,,1,,,2154,4,104686,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,H,,,BAO_0000019,,CHEMBL617235,,,F
11702,Autocuration,,1,,,2155,4,104686,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,H,,,BAO_0000019,,CHEMBL617236,,,F
10085,Autocuration,,1,,,2156,4,104686,,,Hippocampus,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,H,,,BAO_0000221,10000000.0,CHEMBL617237,,,B
10085,Autocuration,,1,,,2157,4,104686,,,Hippocampus,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,H,,,BAO_0000221,10000000.0,CHEMBL617238,,,B
9630,Autocuration,,1,,10116.0,2158,5,104686,,,Brain,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,D,,Rattus norvegicus,BAO_0000221,955.0,CHEMBL617239,,,B
11070,Autocuration,,1,,,2159,4,104686,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL617240,,,B
9841,Autocuration,,1,,,2160,4,104686,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,H,,,BAO_0000249,,CHEMBL617241,,Membranes,B
9841,Autocuration,,1,,,2161,4,104686,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,H,,,BAO_0000249,,CHEMBL875907,,Membranes,B
13291,Autocuration,,1,,,2162,4,104686,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,H,,,BAO_0000019,,CHEMBL617242,,,B
10590,Autocuration,,1,,,2163,4,104686,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,H,,,BAO_0000019,,CHEMBL617152,,,F
9064,Autocuration,,1,,10116.0,2164,5,104686,,,Brain,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,D,,Rattus norvegicus,BAO_0000221,955.0,CHEMBL617153,,,B
12268,Autocuration,,1,,10116.0,2165,5,104686,,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL617154,,Membranes,B
13508,Autocuration,,1,,,2166,4,104686,,,Brain,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,H,,,BAO_0000221,955.0,CHEMBL617155,,,B
11279,Autocuration,,1,,,2167,4,104686,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,H,,,BAO_0000019,,CHEMBL617156,,,F
11200,Autocuration,,1,,,2168,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,H,,,BAO_0000019,,CHEMBL617157,,,F
11200,Autocuration,,1,,,2169,4,104686,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,,,BAO_0000019,,CHEMBL617158,,,F
11200,Autocuration,,1,,,2170,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,H,,,BAO_0000019,,CHEMBL617159,,,F
11200,Autocuration,,1,,,2171,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,H,,,BAO_0000019,,CHEMBL617160,,,F
11200,Autocuration,,1,,,2172,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,,,BAO_0000019,,CHEMBL858113,,,F
9231,Autocuration,,1,,,2173,4,104686,,,Brain,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,H,,,BAO_0000220,955.0,CHEMBL617247,,,B
9737,Autocuration,,1,,,2174,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617248,,,B
9737,Autocuration,,1,,,2175,4,104686,,,Brain,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,H,,,BAO_0000249,955.0,CHEMBL617249,,,B
9737,Autocuration,,1,,,2176,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617250,,,B
9737,Autocuration,,1,,,2177,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617251,,,B
11828,Autocuration,,1,,10116.0,2178,5,104686,,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617252,,,B
12253,Autocuration,,1,,,2179,4,104686,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617006,,,B
12253,Autocuration,,1,,,2180,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617007,,,B
11279,Autocuration,,1,,,2181,4,104686,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,H,,,BAO_0000019,,CHEMBL617008,,,F
11866,Autocuration,,1,,,2182,4,104686,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,H,,,BAO_0000019,,CHEMBL617009,,,B
14424,Autocuration,,1,,10116.0,2183,5,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617010,,,B
15180,Autocuration,,1,,10116.0,2184,5,104686,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL857978,,,B
15180,Autocuration,,1,,10116.0,2185,5,104686,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617011,,,B
9786,Autocuration,,1,,10116.0,2186,5,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617012,,,B
12132,Autocuration,,1,,,2187,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,H,,,BAO_0000224,,CHEMBL617013,,,B
5486,Autocuration,,1,,,2188,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,H,,,BAO_0000249,,CHEMBL617014,,,B
15316,Autocuration,,1,,,2189,4,104686,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000019,,CHEMBL617015,,,B
16429,Autocuration,,1,,,2190,4,104686,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,H,,,BAO_0000019,,CHEMBL617016,,,B
14617,Autocuration,,1,,,2191,4,104686,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,H,,,BAO_0000224,,CHEMBL617017,,,B
11351,Autocuration,,1,,,2192,4,104686,,,Brain,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,H,,,BAO_0000221,955.0,CHEMBL617018,,,B
11279,Autocuration,,1,,,2193,4,104686,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,H,,,BAO_0000019,,CHEMBL617019,,,F
9523,Autocuration,,1,,,2194,4,105075,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617020,,,B
9523,Autocuration,,1,,,2195,4,105075,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617021,,,B
9523,Autocuration,,1,,,2196,4,105075,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617022,,,B
9523,Autocuration,,1,,,2197,4,105075,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617023,,,B
9523,Autocuration,,1,,,2198,4,105075,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617024,,,B
9523,Autocuration,,1,,,2199,4,105075,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617025,,,B
9523,Autocuration,,1,,,2200,4,105075,,,,Hill coefficient of compound was determined,,H,,,BAO_0000224,,CHEMBL617026,,,B
4771,Autocuration,,1,,,2201,0,22226,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,U,,,BAO_0000019,,CHEMBL617027,,,B
5033,Autocuration,,1,,10116.0,2202,5,104686,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617028,,,B
10845,Expert,,1,,,2203,8,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,H,,,BAO_0000019,,CHEMBL617029,,,B
10845,Expert,,1,,,2204,8,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,H,,,BAO_0000019,,CHEMBL875908,,,B
16288,Autocuration,,1,,,2205,8,12687,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,H,,,BAO_0000357,,CHEMBL617030,,,B
16288,Autocuration,,1,,,2206,8,12687,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,H,,,BAO_0000019,,CHEMBL617031,,,B
16190,Autocuration,,1,,,2207,8,12687,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,H,,,BAO_0000019,,CHEMBL617032,,,B
12463,Autocuration,,1,,10116.0,2208,5,104686,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617033,,,B
9699,Autocuration,,1,,,2209,4,104686,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,H,,,BAO_0000224,,CHEMBL617034,,,B
9699,Autocuration,,1,,,2210,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,H,,,BAO_0000224,,CHEMBL617035,,,B
11662,Autocuration,,1,,,2211,4,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,H,,,BAO_0000019,,CHEMBL617036,,,B
1205,Autocuration,,1,,,2212,4,104784,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617037,,,B
11376,Autocuration,,1,,,2213,0,22226,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,U,,,BAO_0000219,,CHEMBL617038,,,B
11376,Autocuration,,1,,,2214,4,104784,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,H,,,BAO_0000219,,CHEMBL617039,,,B
4639,Autocuration,,1,,,2215,4,104784,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617161,,,B
2222,Autocuration,,1,,,2216,4,104784,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617162,,,B
1558,Autocuration,,1,,,2217,4,104784,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617163,,,B
1089,Autocuration,,1,,,2218,4,104784,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617164,,,B
386,Autocuration,,1,,,2219,4,104784,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,H,,,BAO_0000249,,CHEMBL617165,,Brain membranes,B
2474,Autocuration,,1,,,2220,4,104784,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,H,,,BAO_0000224,,CHEMBL617166,,,B
17066,Autocuration,,1,,,2221,4,104784,,,,Binding affinity towards 5-HT2 receptor,,H,,,BAO_0000224,,CHEMBL617167,,,B
959,Autocuration,,1,,,2222,4,104784,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL872912,,,B
6398,Autocuration,,1,,,2223,4,104784,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,H,,,BAO_0000224,,CHEMBL617168,,,B
11889,Autocuration,,1,,,2224,4,104686,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,H,,,BAO_0000224,,CHEMBL617169,,,B
4221,Autocuration,,1,,,2225,4,104784,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617170,,,B
11026,Autocuration,,1,,,2226,4,104784,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,H,,,BAO_0000224,,CHEMBL617171,,,B
11866,Autocuration,,1,,,2227,4,104784,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,H,,,BAO_0000224,,CHEMBL617172,,,B
4221,Autocuration,,1,,,2228,4,104784,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617173,,,B
13950,Autocuration,,1,,,2229,0,22226,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,U,,,BAO_0000019,,CHEMBL617174,,,B
1263,Autocuration,,1,,,2230,4,104784,,,,5-hydroxytryptamine 2 receptor binding affinity,,H,,,BAO_0000224,,CHEMBL617175,,,B
13291,Autocuration,,1,,,2231,8,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,H,,,BAO_0000357,,CHEMBL617176,,,B
10812,Autocuration,,1,,,2232,8,17005,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617177,,,B
13020,Autocuration,,1,,,2233,4,104784,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,H,,,BAO_0000224,,CHEMBL617178,,,B
13021,Autocuration,,1,,,2234,4,104784,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,H,,,BAO_0000224,,CHEMBL617179,,,B
13020,Autocuration,,1,,,2235,4,104784,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,H,,,BAO_0000224,,CHEMBL617180,,,B
14532,Autocuration,,1,,,2236,8,17005,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,H,,,BAO_0000357,,CHEMBL617181,,,B
13944,Autocuration,,1,,,2237,8,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000357,,CHEMBL617182,,,B
14331,Autocuration,,1,,,2238,8,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000357,,CHEMBL617183,,,B
14118,Autocuration,,1,,,2239,8,17005,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617184,,,B
13033,Autocuration,,1,,,2240,8,17005,,,,Binding affinity against serotonergic 5-HT2 receptor,,H,,,BAO_0000357,,CHEMBL617185,,,B
10321,Autocuration,,1,,,2241,8,17005,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617186,,,B
12918,Autocuration,,1,,,2242,8,17005,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,H,,,BAO_0000357,,CHEMBL617187,,,B
15120,Autocuration,,1,,,2243,8,17005,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000357,,CHEMBL617188,,,B
2613,Autocuration,,1,,,2244,8,17005,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000218,,CHEMBL617189,,,B
13378,Autocuration,,1,,9606.0,2245,5,104784,,,,Inhibitory activity against cloned human 5-HT2 receptor,,D,,Homo sapiens,BAO_0000224,,CHEMBL617190,,,B
2331,Autocuration,,1,,9606.0,2246,5,104784,CHO,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617191,,,B
2331,Autocuration,,1,,9606.0,2247,5,104784,CHO,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617192,,,B
2331,Autocuration,,1,,9606.0,2248,5,104784,CHO,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617193,,,B
2331,Autocuration,,1,,9606.0,2249,5,104784,CHO,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617194,,,B
4170,Autocuration,,1,,,2250,4,104784,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617195,,,B
15453,Autocuration,,1,,,2251,4,104784,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,H,,,BAO_0000224,,CHEMBL881830,,,B
1479,Autocuration,,1,,,2252,8,17005,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000357,,CHEMBL617196,,,B
11139,Autocuration,,1,,,2253,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,H,,,BAO_0000224,,CHEMBL617197,,,B
13969,Expert,,1,,,2254,8,17005,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617198,,,B
13392,Expert,,1,,,2255,8,17005,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL873476,,,B
14430,Expert,,1,,,2256,8,17005,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,H,,,BAO_0000019,,CHEMBL617199,,,B
13181,Autocuration,,1,,10141.0,2257,8,107,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,H,,Cavia porcellus,BAO_0000357,,CHEMBL617200,,,B
17200,Autocuration,,1,,,2258,8,51,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,,,BAO_0000357,,CHEMBL617484,,,B
17200,Autocuration,,1,,,2259,8,107,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,,,BAO_0000357,,CHEMBL617485,,,B
17200,Autocuration,,1,,,2260,8,51,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,,,BAO_0000357,,CHEMBL617486,,,B
13463,Autocuration,,1,,,2261,8,107,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL858022,,,B
6347,Autocuration,,1,,,2262,8,107,CHO,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,H,449.0,,BAO_0000219,,CHEMBL617049,,,B
6857,Expert,,1,,9606.0,2263,9,107,CHO,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617050,,,F
4176,Autocuration,,1,,,2264,8,107,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,H,,,BAO_0000219,,CHEMBL617051,,,F
4176,Autocuration,,1,,,2265,8,107,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,H,,,BAO_0000219,,CHEMBL617052,,,F
4176,Autocuration,,1,,,2266,8,107,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,H,,,BAO_0000219,,CHEMBL617053,,,F
6347,Autocuration,,1,,,2267,8,107,CHO,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,H,449.0,,BAO_0000219,,CHEMBL617054,,,B
6347,Autocuration,,1,,,2268,8,107,CHO,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,H,449.0,,BAO_0000219,,CHEMBL617055,,,B
15331,Autocuration,,1,,,2269,8,107,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,H,,,BAO_0000357,,CHEMBL882924,,,B
16146,Expert,,1,,9606.0,2270,9,107,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617056,,,B
15250,Autocuration,,1,,,2271,8,107,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617057,,,B
13631,Expert,,1,,,2272,8,107,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,H,,,BAO_0000219,,CHEMBL617058,,,B
3805,Autocuration,,1,,,2273,8,107,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL617059,,,B
4011,Autocuration,,1,,,2274,8,107,CHO,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,H,449.0,,BAO_0000219,,CHEMBL617060,,,B
4012,Expert,,1,,,2275,8,107,CHO,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,H,449.0,,BAO_0000219,,CHEMBL617061,,,B
6366,Expert,,1,,,2276,8,107,L929,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,H,307.0,,BAO_0000219,,CHEMBL617062,,,B
15949,Expert,,1,,,2277,8,107,CHO,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617063,,,B
14093,Autocuration,,1,,,2278,8,107,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,H,,,BAO_0000019,,CHEMBL617064,,,F
13481,Autocuration,,1,,,2279,8,107,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,,,BAO_0000019,,CHEMBL617065,,,F
6347,Autocuration,,1,,,2280,8,107,CHO,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,H,449.0,,BAO_0000219,,CHEMBL617066,,,B
6347,Autocuration,,1,,,2281,8,107,CHO,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,H,449.0,,BAO_0000219,,CHEMBL617067,,,B
14093,Autocuration,,1,,,2282,8,107,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,H,,,BAO_0000019,,CHEMBL617068,,,F
14093,Autocuration,,1,,,2283,8,107,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,H,,,BAO_0000019,,CHEMBL617069,,,F
13481,Autocuration,,1,,,2284,8,107,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617070,,,F
14442,Autocuration,,1,,,2285,8,107,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617071,,,B
14442,Autocuration,,1,,,2286,8,107,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL872915,,,B
14755,Autocuration,,1,,,2287,8,107,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,H,,,BAO_0000357,,CHEMBL617072,,,B
16441,Autocuration,,1,,,2288,8,107,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,H,,,BAO_0000357,,CHEMBL617073,,,B
14744,Autocuration,,1,,,2289,8,107,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,H,,,BAO_0000357,,CHEMBL617074,,,B
16659,Expert,,1,,,2290,8,107,CHO,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617075,,,B
3307,Autocuration,,1,,,2291,8,107,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617076,,,B
6857,Expert,,1,,9606.0,2292,9,107,,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,D,,Homo sapiens,BAO_0000019,,CHEMBL617077,,,B
5635,Expert,,1,,,2293,8,107,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,H,,,BAO_0000357,,CHEMBL617078,,,B
4234,Expert,,1,,9606.0,2294,9,107,,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617079,,,B
15527,Autocuration,,1,,,2295,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL617080,,,B
6588,Expert,,1,,,2296,8,107,CHO,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617081,,,B
13631,Expert,,1,,,2297,8,107,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,,H,,,BAO_0000219,,CHEMBL617082,,,B
17723,Autocuration,,1,,,2298,8,107,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617083,,,B
14770,Autocuration,,1,,,2299,8,107,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,H,,,BAO_0000357,,CHEMBL617084,,,B
16293,Expert,,1,,9606.0,2300,9,107,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617085,,,B
16209,Autocuration,,1,,,2301,8,107,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617086,,,B
12469,Autocuration,,1,,,2302,8,107,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,H,,,BAO_0000219,,CHEMBL617087,,,B
15363,Autocuration,,1,,,2303,8,107,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617088,,,B
15363,Autocuration,,1,,,2304,8,107,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617089,,,B
16441,Expert,,1,,,2305,8,107,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,H,,,BAO_0000019,,CHEMBL617090,,,B
8,Autocuration,,1,,,2306,8,107,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617513,,,B
4176,Autocuration,,1,,,2307,8,107,HEK293,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617514,,,B
17085,Autocuration,,1,,,2308,8,107,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617515,,,B
17200,Autocuration,,1,,,2309,8,107,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,H,,,BAO_0000357,,CHEMBL617516,,,B
17200,Expert,,1,,9606.0,2310,9,107,,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL617517,,,B
4013,Expert,,1,,9606.0,2311,9,107,CHO,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617518,,,B
5088,Autocuration,,1,,,2312,8,107,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617519,,,B
5088,Expert,,1,,9606.0,2313,9,107,,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617520,,,B
5088,Autocuration,,1,,,2314,8,107,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,H,,,BAO_0000357,,CHEMBL617521,,,B
5088,Expert,,1,,9606.0,2315,9,107,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617522,,,B
5088,Autocuration,,1,,,2316,8,107,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617523,,,B
5088,Autocuration,,1,,,2317,8,107,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL617524,,,B
9786,Autocuration,,1,,,2318,4,104686,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,H,,,BAO_0000019,,CHEMBL617525,,,B
9205,Autocuration,,1,,10116.0,2319,5,104686,,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617526,,,B
11257,Autocuration,,1,,,2320,4,104686,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,H,,,BAO_0000224,,CHEMBL617527,,,B
9362,Autocuration,,1,,,2321,4,104686,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,H,,,BAO_0000019,,CHEMBL617528,,,B
9362,Autocuration,,1,,,2322,4,104686,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,H,,,BAO_0000019,,CHEMBL617529,,,B
10590,Autocuration,,1,,,2323,4,104686,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,H,,,BAO_0000224,,CHEMBL617530,,,B
10468,Autocuration,,1,,,2324,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,H,,,BAO_0000019,,CHEMBL617531,,,B
13050,Autocuration,,1,,,2325,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,H,,,BAO_0000019,,CHEMBL617532,,,B
11624,Autocuration,,1,,,2326,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617533,,,B
10468,Autocuration,,1,,,2327,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,H,,,BAO_0000019,,CHEMBL617534,,,B
10330,Autocuration,,1,,,2328,4,104686,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000224,,CHEMBL617535,,,B
10062,Autocuration,,1,,,2329,4,104686,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,H,,,BAO_0000224,,CHEMBL617536,,,B
11642,Autocuration,,1,,,2330,4,104686,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617537,,,B
10062,Autocuration,,1,,,2331,4,104686,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617538,,,B
13427,Autocuration,,1,,,2332,4,104686,,In vitro,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,H,,,BAO_0000219,,CHEMBL617539,,,B
12280,Autocuration,,1,,10116.0,2333,5,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617540,,,B
4101,Autocuration,,1,,10116.0,2334,5,104686,,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617541,,,B
10062,Autocuration,,1,,,2335,4,104686,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617542,,,B
11147,Autocuration,,1,,,2336,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,H,,,BAO_0000224,,CHEMBL617543,,,B
2395,Autocuration,,1,,10116.0,2337,5,104686,CHO-K1,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,D,485.0,Rattus norvegicus,BAO_0000219,,CHEMBL617544,,,B
2395,Autocuration,,1,,10116.0,2338,5,104686,CHO-K1,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,D,485.0,Rattus norvegicus,BAO_0000219,,CHEMBL617545,,,B
9098,Autocuration,,1,,10116.0,2339,5,104686,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617413,,,B
9098,Autocuration,,1,,,2340,4,104686,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,H,,,BAO_0000019,,CHEMBL617414,,,B
9098,Autocuration,,1,,10116.0,2341,5,104686,,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617415,,,B
9443,Autocuration,,1,,,2342,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617416,,,B
9443,Autocuration,,1,,,2343,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,H,,,BAO_0000224,,CHEMBL617417,,,B
9699,Autocuration,,1,,,2344,4,104686,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,H,,,BAO_0000019,,CHEMBL617418,,,B
9699,Autocuration,,1,,,2345,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617419,,,B
9098,Autocuration,,1,,,2346,4,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,H,,,BAO_0000224,,CHEMBL617420,,,B
3070,Autocuration,,1,,10116.0,2347,5,104686,,,,Affinity for 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617421,,,B
9547,Autocuration,,1,,,2348,4,104686,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,H,,,BAO_0000224,,CHEMBL617422,,,B
10444,Autocuration,,1,,,2349,4,104686,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,H,,,BAO_0000019,,CHEMBL617423,,,B
14617,Autocuration,,1,,,2350,4,104686,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,H,,,BAO_0000019,,CHEMBL617424,,,B
14617,Autocuration,,1,,,2351,4,104686,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,H,,,BAO_0000019,,CHEMBL617425,,,B
11130,Autocuration,,1,,,2352,4,104686,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,H,,,BAO_0000224,,CHEMBL617426,,,B
11130,Autocuration,,1,,,2353,4,104686,,In vivo,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,H,,,BAO_0000218,,CHEMBL617427,,,B
14542,Autocuration,,1,,,2354,4,104686,,,Brain,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,H,,,BAO_0000221,955.0,CHEMBL617428,,,B
2797,Autocuration,,1,,,2355,4,104686,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,H,,,BAO_0000224,,CHEMBL617429,,,B
11332,Autocuration,,1,,,2356,4,104686,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,H,,,BAO_0000019,,CHEMBL617430,,,B
11332,Autocuration,,1,,,2357,4,104686,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,H,,,BAO_0000019,,CHEMBL617431,,,B
10752,Autocuration,,1,,,2358,4,104686,,,Frontal cortex,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,H,,,BAO_0000019,1870.0,CHEMBL617432,,,B
1185,Autocuration,,1,,,2359,4,104686,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617433,,,B
1185,Autocuration,,1,,,2360,4,104686,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617434,,,B
11624,Autocuration,,1,,10116.0,2361,5,104686,,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617435,,,B
1344,Autocuration,,1,,,2362,4,104686,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,H,,,BAO_0000019,,CHEMBL617436,,,B
15453,Autocuration,,1,,10116.0,2363,5,104686,,,Striatum,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,D,,Rattus norvegicus,BAO_0000019,2435.0,CHEMBL617437,,,B
11662,Autocuration,,1,,,2364,4,104686,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,H,,,BAO_0000019,,CHEMBL617438,,,B
11662,Autocuration,,1,,,2365,4,104686,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,H,,,BAO_0000019,,CHEMBL617439,,,B
10796,Autocuration,,1,,,2366,4,104686,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617440,,,B
9069,Autocuration,,1,,,2367,4,104686,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617441,,,B
8814,Autocuration,,1,,10116.0,2368,5,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL872918,,,B
8908,Autocuration,,1,,10116.0,2369,5,104686,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617442,,,B
9098,Autocuration,,1,,,2370,4,104686,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,H,,,BAO_0000019,,CHEMBL617443,,,B
9098,Autocuration,,1,,,2371,4,104686,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,H,,,BAO_0000019,,CHEMBL617444,,,B
9098,Autocuration,,1,,,2372,4,104686,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,H,,,BAO_0000019,,CHEMBL617445,,,B
9098,Autocuration,,1,,,2373,4,104686,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,H,,,BAO_0000019,,CHEMBL617446,,,B
9098,Autocuration,,1,,,2374,4,104686,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,H,,,BAO_0000249,,CHEMBL617447,,,B
9098,Autocuration,,1,,,2375,4,104686,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,H,,,BAO_0000019,,CHEMBL617448,,,B
9098,Autocuration,,1,,,2376,4,104686,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,H,,,BAO_0000019,,CHEMBL617449,,,B
9161,Autocuration,,1,,,2377,4,104686,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,H,,,BAO_0000019,,CHEMBL617450,,,B
9161,Autocuration,,1,,,2378,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,H,,,BAO_0000019,,CHEMBL617451,,,B
9161,Autocuration,,1,,,2379,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,H,,,BAO_0000019,,CHEMBL617452,,,B
9161,Autocuration,,1,,,2380,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,H,,,BAO_0000019,,CHEMBL617453,,,B
9161,Autocuration,,1,,,2381,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,H,,,BAO_0000019,,CHEMBL617660,,,B
9161,Autocuration,,1,,,2382,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,H,,,BAO_0000019,,CHEMBL617661,,,B
9161,Autocuration,,1,,,2383,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,H,,,BAO_0000019,,CHEMBL617662,,,B
9161,Autocuration,,1,,,2384,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,H,,,BAO_0000019,,CHEMBL872919,,,B
9161,Autocuration,,1,,,2385,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,H,,,BAO_0000019,,CHEMBL617663,,,B
9161,Autocuration,,1,,,2386,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,H,,,BAO_0000019,,CHEMBL617664,,,B
9161,Autocuration,,1,,,2387,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,H,,,BAO_0000019,,CHEMBL617665,,,B
9161,Autocuration,,1,,,2388,4,104686,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,H,,,BAO_0000019,,CHEMBL617666,,,B
12094,Autocuration,,1,,,2389,4,104686,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,H,,,BAO_0000019,,CHEMBL617667,,,B
12018,Autocuration,,1,,,2390,4,104686,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,H,,,BAO_0000249,,CHEMBL617668,,,B
10394,Autocuration,,1,,,2391,4,104686,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,H,,,BAO_0000249,,CHEMBL617669,,,B
15260,Autocuration,,1,,,2392,4,104686,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617670,,,B
11624,Autocuration,,1,,10116.0,2393,5,104686,,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617671,,,B
13654,Autocuration,,1,,,2394,4,104686,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617672,,,B
9541,Autocuration,,1,,,2395,4,104686,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,H,,,BAO_0000019,,CHEMBL617673,,,B
11933,Autocuration,,1,,,2396,4,104686,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,H,,,BAO_0000224,,CHEMBL617674,,,B
15538,Autocuration,,1,,,2397,4,104686,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL617675,,,B
15538,Autocuration,,1,,,2398,4,104686,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,H,,,BAO_0000019,,CHEMBL617676,,,B
15538,Autocuration,,1,,,2399,4,104686,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,H,,,BAO_0000019,,CHEMBL617677,,,B
8841,Autocuration,,1,,,2400,5,104686,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,D,,,BAO_0000019,,CHEMBL617678,,,B
1455,Autocuration,,1,,,2401,4,104686,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,H,,,BAO_0000224,,CHEMBL617679,,,B
1455,Autocuration,,1,,,2402,4,104686,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,H,,,BAO_0000224,,CHEMBL617680,,,B
11752,Autocuration,,1,,,2403,4,104686,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,H,,,BAO_0000019,,CHEMBL617681,,,B
11642,Autocuration,,1,,,2404,4,104686,,,Brain,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,H,,,BAO_0000221,955.0,CHEMBL617682,,,B
12092,Autocuration,,1,,,2405,4,104686,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,H,,,BAO_0000224,,CHEMBL617683,,,B
3967,Autocuration,,1,,,2406,4,104686,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,H,,,BAO_0000224,,CHEMBL617684,,,B
12771,Autocuration,,1,,10116.0,2407,5,104686,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617685,,,B
11642,Autocuration,,1,,,2408,4,104686,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL617686,,,B
11628,Autocuration,,1,,,2409,4,104686,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,H,,,BAO_0000224,,CHEMBL617687,,,B
13654,Autocuration,,1,,,2410,4,104686,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,H,,,BAO_0000224,,CHEMBL617688,,,B
11200,Autocuration,,1,,,2411,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,,,BAO_0000019,,CHEMBL617689,,,F
11200,Autocuration,,1,,,2412,4,104686,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,H,,,BAO_0000019,,CHEMBL617690,,,F
11200,Autocuration,,1,,,2413,4,104686,,In vivo,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,H,,,BAO_0000218,,CHEMBL617691,,,F
11200,Autocuration,,1,,,2414,4,104686,,In vivo,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,H,,,BAO_0000218,,CHEMBL617692,,,F
11200,Autocuration,,1,,,2415,4,104686,,In vivo,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,H,,,BAO_0000218,,CHEMBL617693,,,F
11200,Autocuration,,1,,,2416,4,104686,,In vivo,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,H,,,BAO_0000218,,CHEMBL617694,,,F
15436,Expert,,1,,,2417,8,12687,,,Brain,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,H,,,BAO_0000221,955.0,CHEMBL857985,,,B
15436,Expert,,1,,10116.0,2418,9,12687,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617695,,,B
14025,Autocuration,,1,,,2419,8,12687,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,H,,,BAO_0000019,,CHEMBL617696,,,B
4342,Autocuration,,1,,,2420,8,12687,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,H,,,BAO_0000357,,CHEMBL617697,,,B
13735,Expert,,1,,10116.0,2421,9,12687,,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617257,,,B
5816,Expert,,1,,10116.0,2422,9,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617258,,,B
14287,Expert,,1,,,2423,8,12687,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,H,,,BAO_0000019,,CHEMBL617259,,,B
15738,Autocuration,,1,,,2424,8,12687,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,H,,,BAO_0000357,,CHEMBL617260,,,B
15738,Expert,,1,,10116.0,2425,9,12687,,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617261,,,B
15026,Autocuration,,1,,,2426,8,12687,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617262,,,B
16647,Expert,,1,,,2427,8,12687,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,H,,,BAO_0000019,,CHEMBL617263,,,B
16647,Autocuration,,1,,,2428,8,12687,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,H,,,BAO_0000019,,CHEMBL617264,,,B
13345,Expert,,1,,10116.0,2429,9,12687,,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617265,,,B
1543,Autocuration,,1,,,2430,8,12687,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000249,,CHEMBL617266,,Membranes,B
12444,Autocuration,,1,,,2431,8,12687,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,H,,,BAO_0000019,,CHEMBL617267,,,B
16404,Expert,,1,,,2432,8,12687,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,H,,,BAO_0000019,,CHEMBL617268,,,B
16404,Autocuration,,1,,,2433,8,12687,CHO,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617269,,,B
15577,Expert,,1,,,2434,8,12687,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,H,,,BAO_0000357,,CHEMBL617323,,,B
15577,Autocuration,,1,,,2435,8,12687,,,,Serotonergic activity of the compound.,,H,,,BAO_0000357,,CHEMBL617324,,,B
2495,Autocuration,,1,,,2436,8,12687,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,H,,,BAO_0000249,,CHEMBL617325,,,B
15042,Expert,,1,,10116.0,2437,9,12687,,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617326,,,B
15026,Expert,,1,,,2438,8,12687,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,H,,,BAO_0000249,,CHEMBL617327,,,B
12919,Expert,,1,,10116.0,2439,9,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617328,,,F
12919,Expert,,1,,10116.0,2440,9,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617329,,,F
12919,Expert,,1,,10116.0,2441,9,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617330,,,F
15194,Autocuration,,1,,,2442,8,12687,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617331,,,B
15194,Autocuration,,1,,,2443,8,12687,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,H,,,BAO_0000357,,CHEMBL617332,,,B
4820,Expert,,1,,,2444,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617333,,,B
6736,Autocuration,,1,,,2445,8,107,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,H,,,BAO_0000357,,CHEMBL617334,,,B
5163,Autocuration,,1,,,2446,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,H,,,BAO_0000357,,CHEMBL617335,,,B
5163,Autocuration,,1,,,2447,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,H,,,BAO_0000357,,CHEMBL617336,,,B
6011,Autocuration,,1,,,2448,8,107,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL617337,,,B
14294,Expert,,1,,9606.0,2449,9,107,,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,D,,Homo sapiens,BAO_0000357,,CHEMBL617338,,,B
5014,Autocuration,,1,,,2450,8,107,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617339,,,B
17066,Expert,,1,,,2451,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617340,,,B
17515,Autocuration,,1,,,2452,8,107,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,H,,,BAO_0000357,,CHEMBL617341,,,B
6736,Expert,,1,,,2453,8,107,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617342,,,B
5163,Expert,,1,,,2454,8,107,,,,Affinity for 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617343,,,B
16911,Expert,,1,,,2455,8,107,NIH3T3,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,H,723.0,,BAO_0000219,,CHEMBL617344,,,B
6841,Expert,,1,,,2456,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,H,,,BAO_0000357,,CHEMBL617345,,,B
6119,Expert,,1,,,2457,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,H,,,BAO_0000357,,CHEMBL617346,,,B
3962,Autocuration,,1,,,2458,8,107,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617347,,,B
4373,Autocuration,,1,,,2459,8,107,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,H,,,BAO_0000357,,CHEMBL617348,,,B
4373,Autocuration,,1,,,2460,8,107,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,H,,,BAO_0000357,,CHEMBL617349,,,B
3962,Autocuration,,1,,,2461,8,107,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617350,,,F
1633,Expert,,1,,,2462,8,107,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,H,,,BAO_0000357,,CHEMBL872339,,,B
4373,Autocuration,,1,,,2463,8,107,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,H,,,BAO_0000357,,CHEMBL617351,,,B
6576,Expert,,1,,,2464,8,107,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617352,,,B
4687,Autocuration,,1,,,2465,8,107,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617353,,,B
16946,Autocuration,,1,,,2466,8,107,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617354,,,B
14159,Autocuration,,1,,,2467,8,107,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617355,,,B
3032,Expert,,1,,10090.0,2468,8,107,CHO,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,H,449.0,Mus musculus,BAO_0000219,,CHEMBL617356,,,B
16655,Autocuration,,1,,,2469,8,107,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617357,,,B
13964,Autocuration,,1,,,2470,8,107,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617358,,,B
16989,Expert,,1,,,2471,8,107,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617359,,,B
16117,Autocuration,,1,,,2472,8,107,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,H,,,BAO_0000357,,CHEMBL617360,,,B
16700,Autocuration,,1,,,2473,8,107,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,H,,,BAO_0000357,,CHEMBL875913,,,B
3269,Autocuration,,1,,,2474,8,107,,,,Affinity against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617361,,,B
1274,Expert,,1,,9606.0,2475,9,107,,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617362,,,B
1317,Autocuration,,1,,,2476,8,107,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,H,,,BAO_0000357,,CHEMBL617363,,,B
12146,Autocuration,,1,,,2477,8,107,,,,Tested against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617364,,,B
12652,Autocuration,,1,,,2478,4,105075,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,H,,,BAO_0000224,,CHEMBL617365,,,B
12652,Autocuration,,1,,,2479,4,105075,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,H,,,BAO_0000224,,CHEMBL617366,,,B
12652,Autocuration,,1,,,2480,4,105075,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,H,,,BAO_0000224,,CHEMBL617367,,,B
12652,Autocuration,,1,,,2481,4,105075,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,H,,,BAO_0000224,,CHEMBL617368,,,B
16647,Autocuration,,1,,,2482,8,107,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,H,,,BAO_0000357,,CHEMBL617369,,,B
15851,Expert,,1,,9606.0,2483,9,227,HEK293,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617370,,,B
6857,Expert,,1,,9606.0,2484,9,227,CHO,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617371,,,F
3805,Autocuration,,1,,,2485,8,227,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL617372,,,B
6491,Expert,,1,,9606.0,2486,9,227,,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617373,,,B
14093,Autocuration,,1,,,2487,8,227,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,H,,,BAO_0000019,,CHEMBL617374,,,F
13481,Autocuration,,1,,,2488,8,227,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,H,,,BAO_0000019,,CHEMBL617375,,,F
14093,Autocuration,,1,,,2489,8,227,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,H,,,BAO_0000019,,CHEMBL617376,,,F
14093,Autocuration,,1,,,2490,8,227,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,H,,,BAO_0000019,,CHEMBL617377,,,F
14093,Autocuration,,1,,,2491,8,227,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,H,,,BAO_0000019,,CHEMBL617378,,,F
13481,Autocuration,,1,,,2492,8,227,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,H,,,BAO_0000019,,CHEMBL617379,,,F
14442,Autocuration,,1,,,2493,8,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,H,,,BAO_0000357,,CHEMBL617380,,,B
14442,Autocuration,,1,,,2494,8,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,H,,,BAO_0000357,,CHEMBL617381,,,B
14442,Autocuration,,1,,,2495,8,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,H,,,BAO_0000357,,CHEMBL617382,,,B
12369,Autocuration,,1,,,2496,8,107,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617383,,,B
12369,Expert,,1,,,2497,8,107,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,H,,,BAO_0000357,,CHEMBL617384,,,B
12369,Expert,,1,,,2498,8,107,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,H,,,BAO_0000357,,CHEMBL617385,,,B
14447,Autocuration,,1,,,2499,8,107,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,H,,,BAO_0000019,,CHEMBL617386,,,B
14447,Autocuration,,1,,,2500,8,107,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,H,,,BAO_0000019,,CHEMBL617387,,,B
17451,Autocuration,,1,,,2501,8,107,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,723.0,,BAO_0000219,,CHEMBL617388,,,B
6857,Autocuration,,1,,,2502,8,107,CHO,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,H,449.0,,BAO_0000219,,CHEMBL617389,,,F
6857,Expert,,1,,9606.0,2503,9,107,CHO,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617390,,,F
5635,Autocuration,,1,,,2504,4,104817,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,H,,,BAO_0000224,,CHEMBL617391,,,B
12861,Autocuration,,1,,,2505,8,107,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL617392,,,B
12861,Autocuration,,1,,,2506,8,107,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,H,,,BAO_0000019,,CHEMBL617393,,,B
5105,Autocuration,,1,,,2507,8,107,L929,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,H,307.0,,BAO_0000219,,CHEMBL617394,,,B
5104,Expert,,1,,,2508,8,107,L929,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,H,307.0,,BAO_0000219,,CHEMBL617395,,,B
5105,Expert,,1,,,2509,8,107,L929,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,H,307.0,,BAO_0000219,,CHEMBL617396,,,B
5105,Autocuration,,1,,,2510,8,107,L929,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,H,307.0,,BAO_0000219,,CHEMBL617397,,,B
5254,Autocuration,,1,,,2511,8,107,,,,Binding affinity against 5-HT2A receptor,,H,,,BAO_0000357,,CHEMBL617398,,,B
5254,Autocuration,,1,,,2512,8,107,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617399,,,B
13267,Autocuration,,1,,,2513,8,107,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617400,,,B
13267,Autocuration,,1,,,2514,8,107,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617401,,,B
14157,Expert,,1,,9606.0,2515,9,107,HEK293,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617402,,,B
12936,Expert,,1,,9606.0,2516,9,107,HEK293,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617403,,,B
14068,Expert,,1,,,2517,8,107,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,H,,,BAO_0000357,,CHEMBL617404,,,B
12936,Expert,,1,,9606.0,2518,9,107,HEK293,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL857981,,,B
12936,Expert,,1,,9606.0,2519,9,107,HEK293,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617405,,,B
4540,Expert,,1,,9606.0,2520,9,107,HEK293,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617253,,,B
6166,Expert,,1,,,2521,8,107,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,H,,,BAO_0000357,,CHEMBL617254,,,B
17296,Autocuration,,1,,,2522,8,107,HEK293,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617255,,,B
17296,Autocuration,,1,,,2523,8,107,HEK293,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617256,,,B
17296,Autocuration,,1,,,2524,8,107,HEK293,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL616874,,,B
15779,Expert,,1,,9606.0,2525,9,107,HEK293,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL616875,,,B
14391,Expert,,1,,,2526,8,107,HEK293,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,H,722.0,,BAO_0000219,,CHEMBL616876,,,B
15851,Expert,,1,,,2527,8,107,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,H,722.0,,BAO_0000219,,CHEMBL616877,,,B
15851,Expert,,1,,9606.0,2528,9,107,HEK293,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL616878,,,B
3832,Expert,,1,,,2529,8,107,HEK293,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,H,722.0,,BAO_0000219,,CHEMBL616879,,,B
3833,Expert,,1,,,2530,8,107,HEK293,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,H,722.0,,BAO_0000219,,CHEMBL616880,,,B
12936,Expert,,1,,9606.0,2531,9,107,HEK293,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL616881,,,B
17451,Autocuration,,1,,,2532,8,107,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,H,723.0,,BAO_0000219,,CHEMBL616882,,,B
17451,Autocuration,,1,,,2533,8,107,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,723.0,,BAO_0000219,,CHEMBL616883,,,B
17451,Autocuration,,1,,,2534,8,107,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,723.0,,BAO_0000219,,CHEMBL616884,,,B
4199,Autocuration,,1,,,2535,8,107,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,H,722.0,,BAO_0000219,,CHEMBL616885,,,B
1883,Autocuration,,1,,,2536,8,107,CHO-K1,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,H,485.0,,BAO_0000219,,CHEMBL616886,,,B
1883,Expert,,1,,,2537,8,107,CHO-K1,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL616887,,,B
14875,Expert,,1,,9606.0,2538,9,107,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL616888,,,B
15146,Autocuration,,1,,,2539,8,107,HEK293,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,H,722.0,,BAO_0000219,,CHEMBL616889,,,B
5213,Autocuration,,1,,,2540,8,107,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,H,722.0,,BAO_0000219,,CHEMBL616890,,,B
16404,Expert,,1,,9606.0,2541,9,107,CHO,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL616891,,,B
14818,Autocuration,,1,,,2542,8,107,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,H,722.0,,BAO_0000219,,CHEMBL616892,,,B
4829,Autocuration,,1,,,2543,8,107,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,H,722.0,,BAO_0000219,,CHEMBL616893,,,B
12652,Autocuration,,1,,,2544,8,10620,NIH3T3,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,H,723.0,,BAO_0000219,,CHEMBL616894,,,F
4682,Expert,,1,,,2545,8,107,NIH3T3,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,H,723.0,,BAO_0000219,,CHEMBL616895,,,B
12652,Autocuration,,1,,,2546,8,10620,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL616896,,,F
4921,Autocuration,,1,,,2547,8,10621,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617099,,,B
4921,Autocuration,,1,,,2548,8,10621,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,H,,,BAO_0000357,,CHEMBL617100,,,B
16312,Autocuration,,1,,9986.0,2549,8,107,,,,Binding affinity against rabbit aorta 5-HT2A receptor,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL884532,,,B
14998,Expert,,1,,9986.0,2550,8,107,,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL617101,,,B
14025,Expert,,1,,9986.0,2551,8,107,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL617102,,,B
13047,Autocuration,,1,,9986.0,2552,8,107,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617103,,,B
13047,Expert,,1,,9986.0,2553,8,107,,,,The compound was tested for binding affinity against 5-HT2A receptor,,H,,Oryctolagus cuniculus,BAO_0000357,,CHEMBL617104,,,B
1883,Autocuration,,1,,,2554,8,10576,CHO-K1,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL857979,,,B
13463,Autocuration,,1,,,2555,8,12687,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,H,,,BAO_0000019,,CHEMBL857502,,,B
13463,Autocuration,,1,,,2556,8,12687,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,H,,,BAO_0000019,,CHEMBL617105,,,B
13463,Autocuration,,1,,,2557,8,12687,,,Stomach,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,H,,,BAO_0000019,945.0,CHEMBL858021,,,B
13463,Expert,,1,,10116.0,2558,9,12687,,,Stomach,Binding affinity for 5-HT 2A in rat stomach fundus,,D,,Rattus norvegicus,BAO_0000019,945.0,CHEMBL875910,,,B
13463,Autocuration,,1,,,2559,8,12687,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,H,,,BAO_0000019,,CHEMBL617106,,,B
16326,Expert,,1,,,2560,8,12687,NIH3T3,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,H,723.0,,BAO_0000219,,CHEMBL617107,,,B
14093,Autocuration,,1,,,2561,8,12687,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617108,,,F
14093,Autocuration,,1,,,2562,8,12687,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617109,,,F
15740,Autocuration,,1,,,2563,8,12687,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617110,,,B
16633,Autocuration,,1,,,2564,8,12687,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,H,,,BAO_0000357,,CHEMBL617111,,,B
17200,Expert,,1,,10116.0,2565,9,12687,,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617112,,,F
17133,Autocuration,,1,,,2566,8,12687,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617113,,,B
17133,Autocuration,,1,,,2567,8,12687,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617114,,,B
17133,Autocuration,,1,,,2568,8,12687,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617115,,,B
17200,Autocuration,,1,,,2569,8,12687,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,H,,,BAO_0000219,,CHEMBL617116,,,F
15363,Autocuration,,1,,,2570,8,12687,,,,Efficacy at 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617117,,,F
17200,Autocuration,,1,,,2571,8,12687,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,H,,,BAO_0000357,,CHEMBL617118,,,B
17200,Expert,,1,,10116.0,2572,9,12687,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617119,,,B
17200,Expert,,1,,10116.0,2573,9,12687,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617120,,,B
17200,Expert,,1,,10116.0,2574,9,12687,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL617121,,,F
17200,Autocuration,,1,,,2575,8,12687,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,H,,,BAO_0000219,,CHEMBL617122,,,F
17211,Autocuration,,1,,,2576,8,12687,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617123,,,B
17331,Expert,,1,,,2577,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,H,,,BAO_0000019,,CHEMBL617124,,,B
13565,Expert,,1,,,2578,8,12687,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,H,,,BAO_0000249,,CHEMBL617600,,,B
13730,Expert,,1,,,2579,8,12687,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617601,,,B
12416,Expert,,1,,,2580,8,12687,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,H,,,BAO_0000019,,CHEMBL882923,,,B
15295,Autocuration,,1,,,2581,8,12687,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617602,,,B
1742,Autocuration,,1,,,2582,8,12687,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,H,,,BAO_0000019,,CHEMBL617603,,,B
15295,Autocuration,,1,,,2583,8,12687,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617604,,,B
14970,Expert,,1,,,2584,8,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617605,,,B
16693,Expert,,1,,,2585,8,12687,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617606,,,B
14776,Expert,,1,,10116.0,2586,9,12687,,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617607,,,B
14286,Autocuration,,1,,,2587,8,12687,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617455,,,B
17200,Expert,,1,,10116.0,2588,9,12687,,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617456,,,B
15306,Expert,,1,,,2589,8,12687,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,H,,,BAO_0000357,,CHEMBL617457,,,B
14178,Expert,,1,,10116.0,2590,9,12687,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617458,,,B
14229,Expert,,1,,10116.0,2591,9,12687,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617459,,,B
12884,Expert,,1,,,2592,8,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,H,,,BAO_0000357,,CHEMBL617460,,,B
13149,Expert,,1,,,2593,8,12687,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,H,,,BAO_0000357,,CHEMBL617461,,,B
15295,Expert,,1,,10116.0,2594,9,12687,,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617462,,,B
15740,Autocuration,,1,,,2595,8,12687,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,H,,,BAO_0000357,,CHEMBL617463,,,B
15185,Autocuration,,1,,,2596,8,12687,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,H,,,BAO_0000019,,CHEMBL617464,,,B
15185,Autocuration,,1,,,2597,8,12687,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,H,,,BAO_0000019,,CHEMBL617465,,,B
17529,Expert,,1,,,2598,8,12687,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,H,,,BAO_0000019,,CHEMBL617466,,,B
14826,Autocuration,,1,,,2599,8,12687,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,H,,,BAO_0000019,,CHEMBL617467,,,B
17211,Expert,,1,,,2600,8,12687,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,H,,,BAO_0000019,,CHEMBL617468,,,B
14826,Autocuration,,1,,,2601,8,12687,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,H,,,BAO_0000019,,CHEMBL617469,,,B
14093,Autocuration,,1,,,2602,8,12687,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000019,,CHEMBL617470,,,B
14093,Autocuration,,1,,,2603,8,12687,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,H,,,BAO_0000019,,CHEMBL617471,,,B
13246,Expert,,1,,,2604,8,12687,NIH3T3,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,H,723.0,,BAO_0000219,,CHEMBL617472,,,B
13246,Expert,,1,,,2605,8,12687,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,H,,,BAO_0000357,,CHEMBL617473,,,B
15436,Expert,,1,,10116.0,2606,9,12687,,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617474,,,B
15436,Expert,,1,,10116.0,2607,9,12687,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617475,,,B
14442,Autocuration,,1,,,2608,8,12687,,,Brain,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,H,,,BAO_0000221,955.0,CHEMBL617476,,,B
12457,Expert,,1,,,2609,8,12687,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617477,,,B
12457,Expert,,1,,,2610,8,12687,NIH3T3,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,H,723.0,,BAO_0000219,,CHEMBL617478,,,B
14755,Autocuration,,1,,,2611,8,12687,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,H,,,BAO_0000221,,CHEMBL617479,,,F
4707,Autocuration,,1,,,2612,8,12687,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617480,,,B
13297,Expert,,1,,,2613,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617481,,,B
17331,Expert,,1,,,2614,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,H,,,BAO_0000019,,CHEMBL617482,,,B
4664,Autocuration,,1,,,2615,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617483,,,B
16633,Autocuration,,1,,,2616,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL621528,,,B
4664,Expert,,1,,10116.0,2617,9,12687,NIH3T3,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,D,723.0,Rattus norvegicus,BAO_0000219,,CHEMBL621529,,,B
16133,Expert,,1,,,2618,8,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL621530,,,B
16133,Expert,,1,,,2619,8,12687,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL621531,,,B
14060,Expert,,1,,10116.0,2620,9,12687,,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL621532,,,B
16326,Expert,,1,,,2621,8,12687,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL621533,,,B
16659,Expert,,1,,,2622,8,12687,CHO,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL621534,,,B
14776,Autocuration,,1,,,2623,8,12687,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,H,,,BAO_0000019,,CHEMBL621535,,,B
13481,Autocuration,,1,,,2624,8,12687,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,H,,,BAO_0000357,,CHEMBL621536,,,B
17386,Autocuration,,1,,,2625,8,12687,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL621537,,,B
6611,Expert,,1,,10116.0,2626,9,12687,,,,Binding affinity for 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL621538,,,B
14423,Autocuration,,1,,,2627,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,H,,,BAO_0000019,,CHEMBL621539,,,B
15412,Autocuration,,1,,,2628,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,H,,,BAO_0000019,,CHEMBL621540,,,B
15412,Autocuration,,1,,,2629,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,H,,,BAO_0000019,,CHEMBL621541,,,B
6238,Autocuration,,1,,,2630,8,12687,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL621542,,,B
6648,Expert,,1,,,2631,8,12687,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,H,,,BAO_0000357,,CHEMBL621543,,,B
5667,Expert,,1,,,2632,8,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL621544,,,B
6611,Expert,,1,,10116.0,2633,9,12687,,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL621545,,,B
13481,Autocuration,,1,,,2634,8,12687,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL621546,,,B
13481,Autocuration,,1,,,2635,8,12687,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,H,,,BAO_0000357,,CHEMBL621547,,,B
15558,Expert,,1,,,2636,8,12687,NIH3T3,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,H,723.0,,BAO_0000219,,CHEMBL618692,,,B
6013,Autocuration,,1,,,2637,8,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL618693,,,B
16633,Autocuration,,1,,,2638,8,12687,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL872922,,,B
6013,Autocuration,,1,,,2639,8,12687,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL618694,,,B
6013,Expert,,1,,10116.0,2640,9,12687,,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL618695,,,B
6013,Autocuration,,1,,,2641,8,12687,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,H,,,BAO_0000357,,CHEMBL618696,,,B
6013,Expert,,1,,,2642,8,12687,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,H,,,BAO_0000357,,CHEMBL618697,,,B
6013,Autocuration,,1,,,2643,8,12687,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL618892,,,B
6013,Autocuration,,1,,,2644,8,12687,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL618893,,,B
16293,Autocuration,,1,,,2645,8,12687,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL618894,,,B
17175,Expert,,1,,,2646,8,12687,NIH3T3,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,H,723.0,,BAO_0000219,,CHEMBL618895,,,B
13278,Expert,,1,,10116.0,2647,9,12687,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL618896,,,B
3682,Autocuration,,1,,,2648,8,12687,,,Caudate-putamen,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,H,,,BAO_0000019,5383.0,CHEMBL618897,,,B
2014,Autocuration,,1,,,2649,8,12687,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,H,,,BAO_0000357,,CHEMBL618898,,,B
2014,Autocuration,,1,,,2650,8,12687,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,H,,,BAO_0000357,,CHEMBL618899,,,B
4932,Autocuration,,1,,,2651,8,12687,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,H,,,BAO_0000357,,CHEMBL618900,,,B
4932,Autocuration,,1,,,2652,8,12687,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,H,,,BAO_0000019,,CHEMBL618901,,,B
3935,Autocuration,,1,,,2653,8,12687,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL618902,,,B
5432,Expert,,1,,10116.0,2654,9,12687,,,Hippocampus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000221,10000000.0,CHEMBL618903,,,B
15818,Autocuration,,1,,,2655,8,12687,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL618904,,,B
13672,Autocuration,,1,,,2656,8,12687,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,H,,,BAO_0000357,,CHEMBL618905,,,B
13672,Autocuration,,1,,,2657,8,12687,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,H,,,BAO_0000357,,CHEMBL618906,,,B
14749,Expert,,1,,,2658,8,12687,NIH3T3,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,H,723.0,,BAO_0000219,,CHEMBL618907,,,B
13462,Autocuration,,1,,,2659,8,12687,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,H,,,BAO_0000019,,CHEMBL618908,,,B
15740,Autocuration,,1,,,2660,8,12687,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617909,,,B
16647,Expert,,1,,,2661,8,12687,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,H,,,BAO_0000019,,CHEMBL617910,,,B
13345,Autocuration,,1,,,2662,8,12687,,,Brain,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,H,,,BAO_0000221,955.0,CHEMBL617911,,,B
16740,Autocuration,,1,,,2663,8,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL872923,,,B
16740,Autocuration,,1,,,2664,8,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617912,,,B
15535,Expert,,1,,10116.0,2665,9,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617913,,,B
16740,Expert,,1,,,2666,8,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617914,,,B
16740,Autocuration,,1,,,2667,8,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617915,,,B
16740,Autocuration,,1,,,2668,8,12687,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617916,,,B
4795,Expert,,1,,10116.0,2669,9,12687,,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617917,,,B
8,Expert,,1,,,2670,8,12687,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,H,,,BAO_0000019,,CHEMBL617918,,,B
8,Autocuration,,1,,,2671,8,12687,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,H,,,BAO_0000019,,CHEMBL617919,,,B
17200,Expert,,1,,10116.0,2672,9,12687,,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617920,,,B
2148,Expert,,1,,10116.0,2673,9,12687,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617921,,,B
13345,Expert,,1,,10116.0,2674,5,105102,,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,D,,Rattus norvegicus,BAO_0000224,,CHEMBL617922,,,B
5088,Autocuration,,1,,,2675,8,12687,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL617923,,,B
5088,Autocuration,,1,,,2676,8,12687,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,H,,,BAO_0000357,,CHEMBL617924,,,B
17133,Autocuration,,1,,,2677,8,12687,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617925,,,B
17133,Expert,,1,,10116.0,2678,9,12687,,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617926,,,B
16532,Autocuration,,1,,,2679,8,12687,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,H,,,BAO_0000357,,CHEMBL617927,,,B
15086,Autocuration,,1,,,2680,8,12687,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,H,,,BAO_0000357,,CHEMBL617928,,,B
2309,Expert,,1,,10116.0,2681,9,12687,,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617929,,,B
12953,Expert,,1,,,2682,8,12687,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,H,,,BAO_0000019,,CHEMBL617930,,,B
12953,Autocuration,,1,,,2683,8,12687,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,H,,,BAO_0000019,,CHEMBL617931,,,B
12953,Autocuration,,1,,,2684,8,12687,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,H,,,BAO_0000019,,CHEMBL617932,,,B
16659,Autocuration,,1,,,2685,8,12687,CHO,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,H,449.0,,BAO_0000219,,CHEMBL617933,,,B
16740,Autocuration,,1,,,2686,8,12687,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,H,,,BAO_0000019,,CHEMBL617934,,,B
16740,Autocuration,,1,,,2687,8,12687,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,H,,,BAO_0000019,,CHEMBL617935,,,B
17133,Autocuration,,1,,,2688,8,12687,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,H,,,BAO_0000357,,CHEMBL617936,,,B
17211,Autocuration,,1,,,2689,8,12687,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,H,,,BAO_0000019,,CHEMBL617937,,,B
17331,Autocuration,,1,,,2690,8,12687,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,H,,,BAO_0000019,,CHEMBL617938,,,B
16633,Autocuration,,1,,,2691,8,12687,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,H,,,BAO_0000218,,CHEMBL617939,,,B
16633,Autocuration,,1,,,2692,8,12687,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,H,,,BAO_0000218,,CHEMBL617940,,,B
16633,Autocuration,,1,,,2693,8,12687,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,H,,,BAO_0000218,,CHEMBL617941,,,B
15026,Expert,,1,,,2694,8,12687,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,H,,,BAO_0000357,,CHEMBL617942,,,B
15026,Expert,,1,,,2695,8,12687,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,,H,,,BAO_0000357,,CHEMBL617943,,,B
16404,Expert,,1,,,2696,4,105093,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000224,,CHEMBL617944,,,B
16404,Expert,,1,,,2697,4,105093,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000224,,CHEMBL617945,,,B
16404,Expert,,1,,,2698,4,105075,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000224,,CHEMBL617946,,,B
16404,Autocuration,,1,,,2699,8,12687,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,H,,,BAO_0000357,,CHEMBL617947,,,B
16326,Expert,,1,,,2700,8,12687,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,H,,,BAO_0000357,,CHEMBL617948,,,B
15847,Autocuration,,1,,,2701,8,12687,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,H,,,BAO_0000019,,CHEMBL858116,,,F
15847,Autocuration,,1,,,2702,8,12687,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,H,,,BAO_0000019,,CHEMBL617949,,,F
15329,Autocuration,,1,,,2703,8,12687,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,H,,,BAO_0000019,,CHEMBL617950,,,F
16404,Expert,,1,,,2704,8,12687,,,Thoracic aorta,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,H,,,BAO_0000019,1515.0,CHEMBL617951,,,F
16404,Expert,,1,,,2705,8,12687,,,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,H,,,BAO_0000019,1515.0,CHEMBL617952,,,F
16404,Autocuration,,1,,,2706,8,12687,,,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,H,,,BAO_0000019,1515.0,CHEMBL617953,,,F
12861,Autocuration,,1,,,2707,8,12687,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL617954,,,B
12861,Expert,,1,,,2708,8,12687,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,H,,,BAO_0000019,,CHEMBL617955,,,B
12861,Autocuration,,1,,,2709,8,12687,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,H,,,BAO_0000019,,CHEMBL857071,,,B
12490,Expert,,1,,,2710,8,12687,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,H,,,BAO_0000019,,CHEMBL617270,,,B
12827,Autocuration,,1,,,2711,8,12687,N1E-115,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,H,339.0,,BAO_0000219,,CHEMBL617271,,,B
12827,Autocuration,,1,,,2712,8,12687,N1E-115,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,H,339.0,,BAO_0000219,,CHEMBL617272,,,B
12918,Autocuration,,1,,,2713,8,12687,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,H,,,BAO_0000019,,CHEMBL617273,,,B
12919,Expert,,1,,10116.0,2714,9,12687,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617274,,,F
17723,Autocuration,,1,,,2715,8,108,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617275,,,B
6013,Autocuration,,1,,,2716,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617276,,,B
16293,Autocuration,,1,,,2717,8,108,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617277,,,B
3857,Expert,,1,,,2718,8,108,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000019,,CHEMBL617278,,,B
3857,Expert,,1,,,2719,8,108,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,H,,,BAO_0000019,,CHEMBL617279,,,B
3857,Expert,,1,,,2720,8,108,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000019,,CHEMBL617280,,,B
15363,Autocuration,,1,,,2721,8,108,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617281,,,B
15363,Autocuration,,1,,,2722,8,108,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617282,,,B
16441,Expert,,1,,,2723,8,108,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,H,,,BAO_0000019,,CHEMBL617283,,,B
16441,Expert,,1,,,2724,8,108,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,H,,,BAO_0000019,,CHEMBL617284,,,B
4176,Autocuration,,1,,,2725,8,108,HEK293,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617285,,,B
17085,Autocuration,,1,,,2726,8,108,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000019,,CHEMBL617286,,,B
17200,Expert,,1,,9606.0,2727,9,108,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL617287,,,B
5088,Expert,,1,,,2728,8,108,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,H,,,BAO_0000357,,CHEMBL617288,,,B
5088,Autocuration,,1,,,2729,8,108,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,H,,,BAO_0000357,,CHEMBL617289,,,B
5088,Autocuration,,1,,,2730,8,108,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL872917,,,B
5088,Autocuration,,1,,,2731,8,108,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617290,,,B
16659,Autocuration,,1,,,2732,8,108,CHO,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617291,,,B
16659,Autocuration,,1,,,2733,8,108,CHO,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,H,449.0,,BAO_0000219,,CHEMBL617292,,,B
17451,Autocuration,,1,,,2734,8,108,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,H,723.0,,BAO_0000219,,CHEMBL617293,,,B
6857,Expert,,1,,9606.0,2735,9,108,CHO,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617294,,,F
3857,Expert,,1,,,2736,8,108,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,H,,,BAO_0000019,,CHEMBL617295,,,B
12861,Autocuration,,1,,,2737,8,108,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL617296,,,B
12861,Autocuration,,1,,,2738,8,108,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,H,,,BAO_0000019,,CHEMBL617297,,,B
5104,Expert,,1,,,2739,8,108,CHO,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,H,449.0,,BAO_0000219,,CHEMBL617298,,,B
5105,Expert,,1,,,2740,8,108,CHO,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,H,449.0,,BAO_0000219,,CHEMBL617299,,,B
5105,Autocuration,,1,,,2741,8,108,CHO,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,H,449.0,,BAO_0000219,,CHEMBL617300,,,B
5254,Autocuration,,1,,,2742,8,108,,,,Binding affinity against 5-HT2C receptor,,H,,,BAO_0000357,,CHEMBL617454,,,B
13267,Autocuration,,1,,,2743,8,108,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617505,,,B
14157,Expert,,1,,9606.0,2744,9,108,HEK293,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617506,,,B
12936,Expert,,1,,9606.0,2745,9,108,HEK293,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617507,,,B
14068,Expert,,1,,,2746,8,108,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,H,,,BAO_0000357,,CHEMBL617508,,,B
12936,Expert,,1,,9606.0,2747,9,108,HEK293,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL857982,,,B
4540,Expert,,1,,9606.0,2748,9,108,HEK293,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617509,,,B
4540,Expert,,1,,9606.0,2749,9,108,HEK293,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617510,,,B
6166,Autocuration,,1,,,2750,8,108,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,H,,,BAO_0000357,,CHEMBL617511,,,B
17296,Autocuration,,1,,,2751,8,108,HEK293,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617512,,,B
17296,Autocuration,,1,,,2752,8,108,HEK293,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617749,,,B
15779,Autocuration,,1,,,2753,8,108,HEK293,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL617750,,,B
15779,Autocuration,,1,,,2754,8,108,HEK293,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL617751,,,B
14391,Expert,,1,,,2755,8,108,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,H,722.0,,BAO_0000219,,CHEMBL617752,,,B
15779,Autocuration,,1,,,2756,8,108,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,H,722.0,,BAO_0000219,,CHEMBL617753,,,B
15851,Expert,,1,,,2757,8,108,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,H,722.0,,BAO_0000219,,CHEMBL617754,,,B
15851,Expert,,1,,9606.0,2758,9,108,HEK293,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617755,,,B
15779,Autocuration,,1,,,2759,8,108,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,H,722.0,,BAO_0000219,,CHEMBL617756,,,B
3832,Expert,,1,,,2760,8,108,HEK293,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,H,722.0,,BAO_0000219,,CHEMBL617757,,,B
3833,Expert,,1,,,2761,8,108,HEK293,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,H,722.0,,BAO_0000219,,CHEMBL617758,,,B
17451,Autocuration,,1,,,2762,8,108,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,H,723.0,,BAO_0000219,,CHEMBL617759,,,B
4199,Autocuration,,1,,,2763,8,108,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,H,722.0,,BAO_0000219,,CHEMBL617760,,,B
1883,Expert,,1,,,2764,8,108,CHO-K1,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,H,485.0,,BAO_0000219,,CHEMBL617761,,,B
4321,Expert,,1,,9606.0,2765,9,108,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617762,,,B
14875,Autocuration,,1,,,2766,8,108,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617763,,,B
15146,Autocuration,,1,,,2767,8,108,HEK293,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,H,722.0,,BAO_0000219,,CHEMBL857983,,,B
5213,Autocuration,,1,,,2768,8,108,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,H,722.0,,BAO_0000219,,CHEMBL617764,,,B
16404,Autocuration,,1,,,2769,8,108,HeLa,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,H,308.0,,BAO_0000219,,CHEMBL617765,,,B
13267,Autocuration,,1,,,2770,8,108,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000019,,CHEMBL617766,,,F
13267,Autocuration,,1,,,2771,8,108,,,Hippocampus,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,H,,,BAO_0000221,10000000.0,CHEMBL617767,,,F
14818,Autocuration,,1,,,2772,8,108,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,H,722.0,,BAO_0000219,,CHEMBL617768,,,B
4829,Autocuration,,1,,,2773,8,108,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,H,722.0,,BAO_0000219,,CHEMBL617769,,,B
13463,Autocuration,,1,,,2774,8,11864,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL858023,,,B
13463,Autocuration,,1,,,2775,8,11864,,,Stomach,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,H,,,BAO_0000019,945.0,CHEMBL617770,,,B
13463,Autocuration,,1,,,2776,8,11864,,,Stomach,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,H,,,BAO_0000019,945.0,CHEMBL617771,,,B
12652,Autocuration,,1,,,2777,8,11864,A9,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,H,625.0,,BAO_0000219,,CHEMBL617772,,,F
4682,Autocuration,,1,,,2778,8,11864,NIH3T3,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,H,723.0,,BAO_0000219,,CHEMBL617773,,,B
4682,Autocuration,,1,,,2779,8,11864,NIH3T3,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,H,723.0,,BAO_0000219,,CHEMBL617850,,,B
4682,Autocuration,,1,,,2780,8,11864,NIH3T3,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,H,723.0,,BAO_0000219,,CHEMBL617851,,,B
12652,Autocuration,,1,,,2781,8,11864,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000019,,CHEMBL617852,,,F
13463,Autocuration,,1,,10090.0,2782,8,12689,,,Stomach,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,H,,Mus musculus,BAO_0000019,945.0,CHEMBL858024,,,B
13463,Expert,,1,,10116.0,2783,9,12689,,,Stomach,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,D,,Rattus norvegicus,BAO_0000019,945.0,CHEMBL617853,,,B
13969,Expert,,1,,,2784,8,108,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL617854,,,B
13392,Expert,,1,,9823.0,2785,8,108,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL873477,,,B
13392,Expert,,1,,,2786,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617855,,,B
14430,Expert,,1,,,2787,8,108,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,H,,,BAO_0000019,,CHEMBL617856,,,B
1742,Autocuration,,1,,,2788,8,108,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,H,,,BAO_0000019,,CHEMBL617857,,,B
14286,Autocuration,,1,,,2789,8,108,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,H,,,BAO_0000249,,CHEMBL617858,,,B
5619,Autocuration,,1,,,2790,8,108,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617859,,,B
15086,Autocuration,,1,,,2791,8,108,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617860,,,B
12861,Autocuration,,1,,,2792,8,108,,,,Binding activity radioligand.,,H,,,BAO_0000357,,CHEMBL617861,,,B
12861,Expert,,1,,,2793,8,108,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,H,,,BAO_0000019,,CHEMBL617862,,,B
12861,Autocuration,,1,,,2794,8,108,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,H,,,BAO_0000019,,CHEMBL617863,,,B
12827,Autocuration,,1,,,2795,8,108,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,H,,,BAO_0000249,,CHEMBL617864,,,B
12827,Autocuration,,1,,,2796,8,108,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,H,,,BAO_0000249,,CHEMBL617649,,,B
12919,Expert,,1,,9823.0,2797,8,108,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,H,,Sus scrofa,BAO_0000019,,CHEMBL617650,,,F
12919,Expert,,1,,9823.0,2798,8,108,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,H,,Sus scrofa,BAO_0000019,,CHEMBL617651,,,F
16429,Autocuration,,1,,9823.0,2799,8,108,,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,H,,Sus scrofa,BAO_0000357,,CHEMBL617652,,,B
773,Autocuration,,1,,9823.0,2800,8,108,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,H,,Sus scrofa,BAO_0000019,,CHEMBL857072,,,B
5033,Autocuration,,1,,9823.0,2801,8,108,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL617653,,,B
12861,Autocuration,,1,,,2802,8,12687,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,H,,,BAO_0000019,,CHEMBL617654,,,B
14093,Autocuration,,1,,,2803,8,12689,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000019,,CHEMBL617655,,,F
14970,Expert,,1,,,2804,8,12689,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL617656,,,B
14970,Autocuration,,1,,,2805,8,12689,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL617657,,,B
14970,Autocuration,,1,,,2806,8,12689,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,H,,,BAO_0000357,,CHEMBL617658,,,B
14178,Expert,,1,,10116.0,2807,9,12689,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617659,,,B
14178,Expert,,1,,10116.0,2808,9,12689,,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL617838,,,B
14229,Expert,,1,,10116.0,2809,9,12689,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL617839,,Brain membranes,B
16532,Autocuration,,1,,,2810,8,12689,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,H,,,BAO_0000357,,CHEMBL617840,,,B
14826,Autocuration,,1,,,2811,8,12689,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL617841,,,B
17211,Autocuration,,1,,,2812,8,12689,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,H,,,BAO_0000019,,CHEMBL875915,,,B
17211,Expert,,1,,,2813,8,12689,,In vitro,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,H,,,BAO_0000219,,CHEMBL617842,,,B
13246,Expert,,1,,,2814,8,12689,NIH3T3,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,H,723.0,,BAO_0000219,,CHEMBL617843,,,B
13246,Expert,,1,,,2815,8,12689,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,H,,,BAO_0000357,,CHEMBL617844,,,B
12457,Expert,,1,,,2816,8,12689,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617845,,,B
12457,Expert,,1,,,2817,8,12689,NIH3T3,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,H,723.0,,BAO_0000219,,CHEMBL617846,,,B
4707,Autocuration,,1,,,2818,8,12689,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617847,,,B
13297,Expert,,1,,,2819,8,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617848,,,B
16633,Autocuration,,1,,,2820,8,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617849,,,B
16133,Expert,,1,,,2821,8,12689,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL621507,,,B
16326,Expert,,1,,,2822,8,12689,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL621508,,,B
14423,Autocuration,,1,,,2823,8,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,H,,,BAO_0000019,,CHEMBL621509,,,B
15412,Autocuration,,1,,,2824,8,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,H,,,BAO_0000019,,CHEMBL621510,,,B
15412,Autocuration,,1,,,2825,8,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,H,,,BAO_0000019,,CHEMBL621511,,,B
15558,Expert,,1,,,2826,8,12689,A9,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,H,625.0,,BAO_0000219,,CHEMBL621512,,,B
16633,Autocuration,,1,,,2827,8,12689,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL621513,,,B
6013,Expert,,1,,,2828,8,12689,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,H,,,BAO_0000357,,CHEMBL621514,,,B
17175,Expert,,1,,,2829,8,12689,,In vitro,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,H,,,BAO_0000219,,CHEMBL621515,,,B
12469,Autocuration,,1,,,2830,8,12689,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,H,,,BAO_0000219,,CHEMBL621516,,,B
3682,Autocuration,,1,,,2831,8,12689,,,Caudate-putamen,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,H,,,BAO_0000019,5383.0,CHEMBL621517,,,B
4932,Autocuration,,1,,,2832,8,12689,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,H,,,BAO_0000357,,CHEMBL621518,,,B
4932,Autocuration,,1,,,2833,8,12689,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,H,,,BAO_0000019,,CHEMBL621519,,,B
3935,Autocuration,,1,,,2834,8,12689,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL621520,,,B
15818,Autocuration,,1,,,2835,8,12689,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL621521,,,B
15818,Autocuration,,1,,,2836,8,12689,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL621522,,,B
14749,Expert,,1,,,2837,8,12689,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,H,,,BAO_0000219,,CHEMBL621523,,,B
15740,Autocuration,,1,,,2838,8,12689,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL621524,,,B
17133,Expert,,1,,10116.0,2839,9,12689,,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL621525,,,B
16532,Autocuration,,1,,,2840,8,12689,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,H,,,BAO_0000357,,CHEMBL872921,,,B
12369,Autocuration,,1,,,2841,8,12689,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL621526,,,B
12369,Expert,,1,,,2842,8,12689,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,H,,,BAO_0000219,,CHEMBL621527,,,B
2309,Expert,,1,,10116.0,2843,9,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617865,,,B
12953,Autocuration,,1,,,2844,8,12689,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617866,,,B
12953,Autocuration,,1,,,2845,8,12689,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,H,,,BAO_0000019,,CHEMBL617867,,,B
12953,Autocuration,,1,,,2846,8,12689,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,H,,,BAO_0000357,,CHEMBL617487,,,B
12953,Expert,,1,,,2847,8,12689,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617488,,,B
17133,Autocuration,,1,,,2848,8,12689,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,H,,,BAO_0000357,,CHEMBL617489,,,B
17211,Autocuration,,1,,,2849,8,12689,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,H,,,BAO_0000019,,CHEMBL617490,,,B
17211,Autocuration,,1,,,2850,8,12689,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,H,,,BAO_0000019,,CHEMBL617491,,,B
14025,Autocuration,,1,,,2851,8,12689,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,H,,,BAO_0000019,,CHEMBL617492,,,B
14998,Autocuration,,1,,,2852,8,12689,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,H,,,BAO_0000019,,CHEMBL617493,,,B
4342,Autocuration,,1,,,2853,8,12689,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,H,,,BAO_0000357,,CHEMBL617494,,,B
13735,Expert,,1,,10116.0,2854,9,12689,,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617495,,,B
13181,Autocuration,,1,,,2855,8,12689,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617496,,,B
1883,Autocuration,,1,,,2856,8,12689,CHO-K1,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,H,485.0,,BAO_0000219,,CHEMBL617497,,,B
15194,Autocuration,,1,,,2857,8,12689,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL617498,,,B
15194,Autocuration,,1,,,2858,8,12689,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,H,,,BAO_0000357,,CHEMBL617499,,,B
14579,Autocuration,,1,,,2859,8,12689,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000019,,CHEMBL617500,,,F
4639,Autocuration,,1,,,2860,8,108,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617501,,,B
4820,Expert,,1,,,2861,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617502,,,B
14442,Autocuration,,1,,,2862,8,227,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,H,,,BAO_0000357,,CHEMBL617503,,,B
14755,Autocuration,,1,,,2863,8,227,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,H,,,BAO_0000357,,CHEMBL617504,,,B
14744,Autocuration,,1,,,2864,8,227,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,H,,,BAO_0000357,,CHEMBL617406,,,B
6857,Expert,,1,,9606.0,2865,9,227,,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,D,,Homo sapiens,BAO_0000019,,CHEMBL617407,,,B
16209,Autocuration,,1,,,2866,8,227,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL617408,,,B
15363,Autocuration,,1,,,2867,8,227,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617409,,,B
15363,Autocuration,,1,,,2868,8,227,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617410,,,B
15363,Autocuration,,1,,,2869,8,227,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617411,,,B
17085,Autocuration,,1,,,2870,8,227,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000019,,CHEMBL617412,,,B
17200,Expert,,1,,9606.0,2871,9,227,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL617774,,,B
15851,Expert,,1,,9606.0,2872,9,227,HEK293,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617775,,,B
15851,Expert,,1,,9606.0,2873,9,227,HEK293,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617776,,,B
6857,Expert,,1,,9606.0,2874,9,227,CHO,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617777,,,F
6857,Expert,,1,,9606.0,2875,9,227,CHO,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617778,,,F
15779,Autocuration,,1,,,2876,8,227,HEK293,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,H,722.0,,BAO_0000219,,CHEMBL617779,,,B
15851,Expert,,1,,,2877,8,227,HEK293,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL617780,,,B
15779,Autocuration,,1,,,2878,8,227,HEK293,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,H,722.0,,BAO_0000219,,CHEMBL617781,,,B
14157,Expert,,1,,9606.0,2879,9,227,HEK293,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617782,,,B
4540,Expert,,1,,9606.0,2880,9,227,HEK293,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617783,,,B
6166,Autocuration,,1,,,2881,8,227,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,H,,,BAO_0000357,,CHEMBL617784,,,B
15779,Autocuration,,1,,,2882,8,227,HEK293,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL617785,,,B
14391,Expert,,1,,,2883,8,227,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,H,722.0,,BAO_0000219,,CHEMBL857984,,,B
3832,Expert,,1,,,2884,8,227,HEK293,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,H,722.0,,BAO_0000219,,CHEMBL617786,,,B
3833,Expert,,1,,,2885,8,227,HEK293,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,H,722.0,,BAO_0000219,,CHEMBL617787,,,B
15851,Expert,,1,,9606.0,2886,9,227,HEK293,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617788,,,B
15851,Expert,,1,,9606.0,2887,9,227,HEK293,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL617789,,,B
4199,Autocuration,,1,,,2888,8,227,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,H,722.0,,BAO_0000219,,CHEMBL617790,,,B
1883,Expert,,1,,,2889,8,227,CHO-K1,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,H,485.0,,BAO_0000219,,CHEMBL617791,,,B
4321,Expert,,1,,,2890,8,227,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617608,,,B
15146,Autocuration,,1,,,2891,8,227,HEK293,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,H,722.0,,BAO_0000219,,CHEMBL617609,,,B
5213,Autocuration,,1,,,2892,8,227,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,H,722.0,,BAO_0000219,,CHEMBL617610,,,B
14818,Autocuration,,1,,,2893,8,227,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,H,722.0,,BAO_0000219,,CHEMBL617611,,,B
4829,Autocuration,,1,,,2894,8,227,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,H,722.0,,BAO_0000219,,CHEMBL617612,,,B
4829,Autocuration,,1,,,2895,8,227,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,H,722.0,,BAO_0000219,,CHEMBL617613,,,B
14025,Autocuration,,1,,9986.0,2896,8,227,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617614,,,B
13463,Expert,,1,,,2897,8,12688,,,Stomach,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,H,,,BAO_0000019,945.0,CHEMBL617615,,,B
7259,Expert,,1,,,2898,8,12688,,,Stomach,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,H,,,BAO_0000357,945.0,CHEMBL858114,,,B
7259,Autocuration,,1,,,2899,8,12688,,,Stomach,Affinity against serotonergic receptor in the isolated rat stomach fundus,,H,,,BAO_0000357,945.0,CHEMBL617616,,,B
7185,Expert,,1,,10116.0,2900,9,12688,,,Stomach,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,D,,Rattus norvegicus,BAO_0000019,945.0,CHEMBL617617,,,F
7185,Expert,,1,,10116.0,2901,9,12688,,,,Antagonistic against 5-hydroxytryptamine 2B receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL875914,,,F
13267,Autocuration,,1,,,2902,8,12688,,,Stomach,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,H,,,BAO_0000019,945.0,CHEMBL617618,,,F
13735,Expert,,1,,10116.0,2903,9,12688,,,Stomach,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,D,,Rattus norvegicus,BAO_0000357,945.0,CHEMBL617619,,,B
15738,Autocuration,,1,,,2904,8,12688,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,H,,,BAO_0000019,,CHEMBL617620,,,F
15738,Autocuration,,1,,,2905,8,12688,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,H,,,BAO_0000019,,CHEMBL617621,,,F
15738,Autocuration,,1,,,2906,8,12688,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,H,,,BAO_0000019,,CHEMBL617622,,,F
12936,Expert,,1,,10116.0,2907,9,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,D,,Rattus norvegicus,BAO_0000357,945.0,CHEMBL617623,,,B
12936,Expert,,1,,10116.0,2908,9,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,D,,Rattus norvegicus,BAO_0000357,945.0,CHEMBL617624,,,B
12936,Expert,,1,,10116.0,2909,9,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,D,,Rattus norvegicus,BAO_0000357,945.0,CHEMBL617625,,,B
12936,Expert,,1,,10116.0,2910,9,12688,,,Stomach,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,D,,Rattus norvegicus,BAO_0000357,945.0,CHEMBL617626,,,B
16404,Autocuration,,1,,,2911,8,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,H,,,BAO_0000019,945.0,CHEMBL617627,,,F
16404,Expert,,1,,,2912,8,12688,,,Stomach,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,H,,,BAO_0000019,945.0,CHEMBL617628,,,F
16404,Autocuration,,1,,,2913,8,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,H,,,BAO_0000019,945.0,CHEMBL617629,,,F
16404,Autocuration,,1,,,2914,8,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,H,,,BAO_0000019,945.0,CHEMBL858115,,,F
16404,Expert,,1,,10116.0,2915,9,12688,,,Stomach,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,D,,Rattus norvegicus,BAO_0000019,945.0,CHEMBL617630,,,F
16404,Autocuration,,1,,,2916,8,12688,,,Thoracic aorta,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,H,,,BAO_0000019,1515.0,CHEMBL617631,,,F
7483,Autocuration,,1,,,2917,8,12688,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,H,,,BAO_0000357,,CHEMBL617632,,,B
7483,Expert,,1,,,2918,8,12688,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,H,,,BAO_0000357,,CHEMBL617633,,,B
7483,Autocuration,,1,,,2919,8,12688,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,H,,,BAO_0000357,,CHEMBL617634,,,B
7483,Autocuration,,1,,,2920,8,12688,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,H,,,BAO_0000357,,CHEMBL617635,,,B
16404,Autocuration,,1,,10116.0,2922,9,12688,,,Stomach,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,D,,Rattus norvegicus,BAO_0000019,945.0,CHEMBL617637,,,F
6347,Autocuration,,1,,,2923,8,227,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,H,,,BAO_0000357,,CHEMBL617638,,,B
4373,Autocuration,,1,,,2924,8,227,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,H,,,BAO_0000357,,CHEMBL617639,,,B
4373,Autocuration,,1,,,2925,8,227,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,H,,,BAO_0000357,,CHEMBL617640,,,B
4687,Autocuration,,1,,,2926,8,227,,,,Evaluated for the binding affinity to 5-HT 2B receptor,,H,,,BAO_0000357,,CHEMBL617641,,,B
16946,Autocuration,,1,,,2927,8,227,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617642,,,B
16633,Autocuration,,1,,,2928,8,227,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617643,,,B
16633,Autocuration,,1,,,2929,8,227,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,H,,,BAO_0000357,,CHEMBL617644,,,B
16633,Autocuration,,1,,,2930,8,227,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617645,,,B
15026,Expert,,1,,,2931,8,108,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,H,,,BAO_0000357,,CHEMBL617646,,,B
15738,Autocuration,,1,,9913.0,2932,8,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,H,,Bos taurus,BAO_0000357,,CHEMBL617647,,,B
15738,Autocuration,,1,,9913.0,2933,8,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,H,,Bos taurus,BAO_0000357,,CHEMBL617648,,,B
15738,Autocuration,,1,,9913.0,2934,8,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,H,,Bos taurus,BAO_0000357,,CHEMBL617875,,,B
15738,Autocuration,,1,,9913.0,2935,8,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,H,,Bos taurus,BAO_0000357,,CHEMBL617876,,,B
16404,Expert,,1,,9913.0,2936,8,108,,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,H,,Bos taurus,BAO_0000357,,CHEMBL617877,,,B
15026,Expert,,1,,9913.0,2937,8,108,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,H,,Bos taurus,BAO_0000357,,CHEMBL617878,,,B
15738,Autocuration,,1,,9913.0,2938,8,108,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,H,,Bos taurus,BAO_0000357,,CHEMBL617879,,,B
16312,Autocuration,,1,,10141.0,2939,8,108,,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617880,,,B
5486,Intermediate,,1,,10141.0,2940,9,20033,,,Striatum,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL617881,,,B
5254,Autocuration,,1,,,2941,8,51,,,,Binding affinity against 5-HT1A receptor,,H,,,BAO_0000357,,CHEMBL857073,,,B
3857,Expert,,1,,,2942,8,108,CHO,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,H,449.0,,BAO_0000219,,CHEMBL617882,,,F
6857,Expert,,1,,9606.0,2943,9,108,CHO,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL617883,,,F
4176,Autocuration,,1,,,2944,8,108,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,H,,,BAO_0000219,,CHEMBL617884,,,F
6347,Autocuration,,1,,,2945,8,108,CHO,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,H,449.0,,BAO_0000219,,CHEMBL617885,,,B
6347,Autocuration,,1,,,2946,8,108,CHO,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,H,449.0,,BAO_0000219,,CHEMBL617886,,,B
16146,Expert,,1,,9606.0,2947,9,108,,,,Inhibition of human 5-hydroxytryptamine 2C receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617887,,,B
3805,Autocuration,,1,,,2948,8,108,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL617888,,,B
3857,Autocuration,,1,,,2949,8,108,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,H,,,BAO_0000019,,CHEMBL617889,,,B
5635,Autocuration,,1,,,2950,8,108,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL617890,,,B
5635,Autocuration,,1,,,2951,8,108,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,H,,,BAO_0000357,,CHEMBL617891,,,B
5635,Autocuration,,1,,,2952,8,108,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,H,,,BAO_0000357,,CHEMBL617892,,,B
4012,Expert,,1,,,2953,8,108,CHO,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,H,449.0,,BAO_0000219,,CHEMBL617893,,,B
6366,Expert,,1,,,2954,8,108,CHO,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617894,,,B
15949,Expert,,1,,,2955,8,108,CHO,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL617895,,,B
17211,Autocuration,,1,,,2956,8,108,CHO,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,H,449.0,,BAO_0000219,,CHEMBL617896,,,B
6491,Expert,,1,,9606.0,2957,9,108,,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL617897,,,B
14093,Autocuration,,1,,,2958,8,108,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,H,,,BAO_0000019,,CHEMBL617898,,,F
13481,Autocuration,,1,,,2959,8,108,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,H,,,BAO_0000019,,CHEMBL617899,,,F
6347,Expert,,1,,10116.0,2960,8,108,CHO,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,H,449.0,Rattus norvegicus,BAO_0000219,,CHEMBL617900,,,B
14093,Autocuration,,1,,,2961,8,108,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,H,,,BAO_0000019,,CHEMBL617901,,,F
14093,Autocuration,,1,,,2962,8,108,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,H,,,BAO_0000019,,CHEMBL617902,,,F
13481,Autocuration,,1,,,2963,8,108,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,,,BAO_0000019,,CHEMBL617903,,,F
14442,Autocuration,,1,,,2964,8,108,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,H,,,BAO_0000357,,CHEMBL617904,,,B
14442,Autocuration,,1,,,2965,8,108,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL617905,,,B
14442,Autocuration,,1,,,2966,8,108,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,H,,,BAO_0000357,,CHEMBL617906,,,B
14755,Autocuration,,1,,,2967,8,108,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,H,,,BAO_0000357,,CHEMBL617907,,,B
14744,Autocuration,,1,,,2968,8,108,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,H,,,BAO_0000357,,CHEMBL617908,,,B
16659,Expert,,1,,,2969,8,108,CHO,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL620617,,,B
6857,Expert,,1,,9606.0,2970,9,108,,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,D,,Homo sapiens,BAO_0000019,,CHEMBL620618,,,B
5635,Expert,,1,,,2971,8,108,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,H,,,BAO_0000357,,CHEMBL620619,,,B
4234,Expert,,1,,9606.0,2972,9,108,,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620620,,,B
16209,Autocuration,,1,,,2973,8,108,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,H,,,BAO_0000357,,CHEMBL620621,,,B
5778,Autocuration,,1,,10116.0,2974,7,104698,,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL872920,,Membranes,B
5094,Autocuration,,1,,,2975,6,104698,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,H,,,BAO_0000223,,CHEMBL620622,,,B
809,Autocuration,,1,,10116.0,2976,7,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL620623,,,B
1578,Autocuration,,1,,,2977,6,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,H,,,BAO_0000019,,CHEMBL620624,,,B
809,Autocuration,,1,,,2978,6,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,H,,,BAO_0000019,,CHEMBL620625,,,B
12469,Autocuration,,1,,,2979,6,104698,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,H,,,BAO_0000219,,CHEMBL620626,,,B
14290,Autocuration,,1,,,2980,6,104698,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,H,,,BAO_0000019,,CHEMBL621307,,,B
14290,Autocuration,,1,,,2981,6,104698,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,H,,,BAO_0000019,,CHEMBL621308,,,B
10609,Autocuration,,1,,,2982,6,104698,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,H,,,BAO_0000223,,CHEMBL621309,,,B
10609,Autocuration,,1,,,2983,6,104698,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,H,,,BAO_0000223,,CHEMBL621310,,,B
10609,Autocuration,,1,,,2984,6,104698,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,H,,,BAO_0000223,,CHEMBL621311,,,B
15253,Autocuration,,1,,,2985,6,104698,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,H,,,BAO_0000249,,CHEMBL621502,,,B
15253,Autocuration,,1,,,2986,6,104698,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,H,,,BAO_0000249,,CHEMBL621503,,,B
11683,Autocuration,,1,,,2987,6,104698,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,H,,,BAO_0000249,,CHEMBL621504,,Membranes,B
12092,Autocuration,,1,,,2988,6,104698,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL621505,,,B
1946,Autocuration,,1,,,2989,6,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,H,,,BAO_0000019,,CHEMBL621506,,,B
11623,Autocuration,,1,,,2990,6,104698,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,H,,,BAO_0000223,,CHEMBL619781,,,B
11623,Autocuration,,1,,,2991,6,104698,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,H,,,BAO_0000223,,CHEMBL619782,,,B
14788,Autocuration,,1,,,2992,6,104698,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL619783,,,B
5432,Autocuration,,1,,10116.0,2993,7,104698,,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619784,,,B
14826,Autocuration,,1,,,2994,6,104698,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL619785,,,B
2222,Autocuration,,1,,,2995,6,104698,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL619786,,,B
11963,Autocuration,,1,,,2996,6,104698,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL619787,,,B
14145,Autocuration,,1,,,2997,6,104698,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,H,,,BAO_0000019,,CHEMBL872925,,,B
17819,Autocuration,,1,,,2998,6,104698,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,H,,,BAO_0000019,,CHEMBL619788,,,B
10394,Autocuration,,1,,,2999,6,104698,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,H,,,BAO_0000249,,CHEMBL619789,,,B
10394,Autocuration,,1,,,3000,6,104698,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,H,,,BAO_0000249,,CHEMBL619790,,,B
15034,Autocuration,,1,,,3001,6,104698,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,H,,,BAO_0000019,,CHEMBL619791,,,B
691,Autocuration,,1,,,3002,6,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,H,,,BAO_0000019,,CHEMBL619792,,,B
12092,Autocuration,,1,,,3003,6,104698,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,H,,,BAO_0000249,,CHEMBL619793,,Membranes,B
11752,Autocuration,,1,,10116.0,3004,7,104698,,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL619794,,,B
11752,Autocuration,,1,,,3005,6,104698,,,Brain,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,H,,,BAO_0000221,955.0,CHEMBL619795,,,B
301,Autocuration,,1,,,3006,6,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,H,,,BAO_0000019,,CHEMBL619796,,,B
16532,Autocuration,,1,,,3007,6,104698,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,H,,,BAO_0000223,,CHEMBL620448,,,B
16532,Autocuration,,1,,,3008,6,104698,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,H,,,BAO_0000223,,CHEMBL620449,,,B
12092,Autocuration,,1,,,3009,6,104698,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,H,,,BAO_0000223,,CHEMBL620450,,,B
11684,Autocuration,,1,,,3010,6,104698,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,H,,,BAO_0000223,,CHEMBL620451,,,B
11684,Autocuration,,1,,,3011,6,104698,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,H,,,BAO_0000223,,CHEMBL620631,,,B
12953,Autocuration,,1,,,3012,6,104698,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,H,,,BAO_0000019,,CHEMBL620632,,,B
12953,Autocuration,,1,,,3013,6,104698,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,H,,,BAO_0000019,,CHEMBL620633,,,B
12953,Autocuration,,1,,,3014,6,104698,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,H,,,BAO_0000223,,CHEMBL620634,,,B
12861,Autocuration,,1,,,3015,6,104698,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,H,,,BAO_0000019,,CHEMBL620635,,,B
11454,Autocuration,,1,,,3016,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620636,,,F
11454,Autocuration,,1,,,3017,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620637,,,F
11454,Autocuration,,1,,,3018,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620638,,,F
11454,Autocuration,,1,,,3019,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620639,,,F
11454,Autocuration,,1,,,3020,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620640,,,F
11454,Autocuration,,1,,,3021,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620641,,,F
11454,Autocuration,,1,,,3022,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620642,,,F
11454,Autocuration,,1,,,3023,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620643,,,F
11454,Autocuration,,1,,,3024,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620644,,,F
11454,Autocuration,,1,,,3025,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620645,,,F
11454,Autocuration,,1,,,3026,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620646,,,F
11454,Autocuration,,1,,,3027,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620647,,,F
11454,Autocuration,,1,,,3028,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620648,,,F
11454,Autocuration,,1,,,3029,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620649,,,F
11454,Autocuration,,1,,,3030,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620650,,,F
11454,Autocuration,,1,,,3031,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620651,,,F
11454,Autocuration,,1,,,3032,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL872875,,,F
11454,Autocuration,,1,,,3033,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL620652,,,F
10609,Autocuration,,1,,,3034,6,104698,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,H,,,BAO_0000019,,CHEMBL620653,,,F
12861,Autocuration,,1,,,3035,6,104698,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,H,,,BAO_0000019,,CHEMBL857076,,,B
12861,Autocuration,,1,,10116.0,3036,7,104698,,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL620654,,,B
12861,Autocuration,,1,,,3037,6,104698,,,,Binding activity radioligand.,,H,,,BAO_0000223,,CHEMBL620655,,,B
10728,Autocuration,,1,,,3038,6,104698,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,H,,,BAO_0000249,,CHEMBL620656,,Brain membranes,B
10728,Autocuration,,1,,,3039,6,104698,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,H,,,BAO_0000249,,CHEMBL620657,,Brain membranes,B
5163,Autocuration,,1,,,3040,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,H,,,BAO_0000357,,CHEMBL620658,,,B
5163,Autocuration,,1,,,3041,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,H,,,BAO_0000357,,CHEMBL620659,,,B
6011,Autocuration,,1,,,3042,8,108,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL620660,,,B
5014,Autocuration,,1,,,3043,8,108,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620661,,,B
5635,Autocuration,,1,,,3044,8,108,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620662,,,B
5163,Expert,,1,,,3045,8,108,,,,Affinity for 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620663,,,B
6841,Autocuration,,1,,,3046,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,H,,,BAO_0000357,,CHEMBL620664,,,B
6119,Expert,,1,,,3047,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,H,,,BAO_0000357,,CHEMBL620665,,,B
4373,Autocuration,,1,,,3048,8,108,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,H,,,BAO_0000357,,CHEMBL620666,,,B
1633,Autocuration,,1,,,3049,8,108,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,H,,,BAO_0000357,,CHEMBL620667,,,B
1633,Expert,,1,,,3050,8,108,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,H,,,BAO_0000357,,CHEMBL620668,,,B
4373,Autocuration,,1,,,3051,8,108,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,H,,,BAO_0000357,,CHEMBL620669,,,B
6576,Expert,,1,,,3052,8,108,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620670,,,B
4687,Autocuration,,1,,,3053,8,108,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620671,,,B
12146,Autocuration,,1,,,3054,8,108,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,H,,,BAO_0000357,,CHEMBL620672,,,B
12146,Autocuration,,1,,,3055,8,108,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,H,,,BAO_0000357,,CHEMBL620673,,,B
16946,Autocuration,,1,,,3056,8,108,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620674,,,B
14159,Autocuration,,1,,,3057,8,108,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL620675,,,B
16700,Autocuration,,1,,,3058,8,108,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,H,,,BAO_0000357,,CHEMBL620676,,,B
3269,Autocuration,,1,,,3059,8,108,,,,Affinity against 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL621382,,,B
1274,Expert,,1,,9606.0,3060,9,108,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL621383,,,B
1317,Autocuration,,1,,,3061,8,108,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,H,,,BAO_0000357,,CHEMBL621384,,,B
5834,Autocuration,,1,,9913.0,3062,8,144,,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,H,,Bos taurus,BAO_0000357,,CHEMBL621385,,,B
11147,Autocuration,,1,,9913.0,3063,8,144,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,H,,Bos taurus,BAO_0000357,,CHEMBL617989,,,B
14145,Expert,,1,,10141.0,3064,4,104714,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617990,,,F
10561,Autocuration,,1,,10141.0,3065,4,104714,,,Ileum,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL875085,,,B
15847,Autocuration,,1,,10141.0,3066,4,104714,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617991,,,F
15847,Autocuration,,1,,10141.0,3067,4,104714,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617992,,,F
10561,Autocuration,,1,,10141.0,3068,4,104714,,,Ileum,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617993,,,B
11454,Autocuration,,1,,10141.0,3069,4,104714,,,Ileum,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617994,,,B
4639,Autocuration,,1,,10141.0,3070,4,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617995,,,F
4639,Autocuration,,1,,10141.0,3071,4,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617996,,,F
4639,Autocuration,,1,,10141.0,3072,4,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617997,,,F
4639,Autocuration,,1,,10141.0,3073,4,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617998,,,F
4639,Autocuration,,1,,10141.0,3074,4,104714,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL617999,,,F
4639,Autocuration,,1,,10141.0,3075,4,104714,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618000,,,F
15253,Autocuration,,1,,10141.0,3076,4,104714,,,Ileum,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617815,,,F
15253,Autocuration,,1,,10141.0,3077,4,104714,,,Ileum,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617816,,,F
11963,Autocuration,,1,,10141.0,3078,4,104714,,,Ileum,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617817,,,F
1946,Autocuration,,1,,10141.0,3079,4,104714,,,Ileum,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617818,,,B
1946,Autocuration,,1,,10141.0,3080,4,104714,,,Ileum,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617819,,,B
12045,Autocuration,,1,,10141.0,3081,4,104714,,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,H,,Cavia porcellus,BAO_0000223,,CHEMBL617820,,,B
1559,Autocuration,,1,,10141.0,3082,4,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617821,,,B
273,Autocuration,,1,,10141.0,3083,4,104714,,,Ileum,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617822,,,F
273,Autocuration,,1,,10141.0,3084,4,104714,,,Ileum,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617823,,,F
188,Autocuration,,1,,10141.0,3085,4,104714,,,Ileum,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617824,,,F
12919,Autocuration,,1,,10141.0,3086,4,104714,,,Ileum,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617825,,,F
12918,Autocuration,,1,,10141.0,3087,4,104714,,,Ileum,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617826,,,F
1559,Autocuration,,1,,10141.0,3088,4,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617827,,,B
273,Autocuration,,1,,10141.0,3089,4,104714,,,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617828,,,F
1559,Autocuration,,1,,10141.0,3090,4,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617829,,,B
1559,Autocuration,,1,,10141.0,3091,4,104714,,,Ileum,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617830,,,B
1559,Autocuration,,1,,10141.0,3092,4,104714,,,Ileum,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617831,,,B
14424,Autocuration,,1,,10141.0,3093,4,104714,,,Ileum,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617832,,,B
13181,Autocuration,,1,,10141.0,3094,0,22226,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,U,,Cavia porcellus,BAO_0000019,,CHEMBL617833,,,B
5486,Autocuration,,1,,,3095,8,51,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,H,,,BAO_0000357,,CHEMBL617834,,,B
6491,Expert,,1,,9606.0,3096,5,104714,,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,D,,Homo sapiens,BAO_0000223,,CHEMBL617835,,,B
6013,Autocuration,,1,,,3097,4,104714,,,,Binding affinity towards 5-HT3 receptor,,H,,,BAO_0000223,,CHEMBL617836,,,B
12861,Autocuration,,1,,,3098,4,104714,,,,Binding activity radioligand.,,H,,,BAO_0000223,,CHEMBL617837,,,B
12861,Autocuration,,1,,,3099,4,104714,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,H,,,BAO_0000019,,CHEMBL620392,,,B
5104,Autocuration,,1,,,3100,4,104714,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL620393,,,B
5105,Autocuration,,1,,,3101,4,104714,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL620394,,,B
5104,Autocuration,,1,,,3102,4,104714,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,H,,,BAO_0000223,,CHEMBL620395,,,B
3935,Autocuration,,1,,,3103,0,22226,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,U,,,BAO_0000019,,CHEMBL620396,,,B
13657,Expert,,1,,,3104,4,105030,NG108-15,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,H,433.0,,BAO_0000219,,CHEMBL620582,,,B
10369,Autocuration,,1,,,3105,4,105030,,In vivo,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,H,,,BAO_0000218,,CHEMBL620583,,,B
10369,Autocuration,,1,,,3106,4,105030,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,H,,,BAO_0000019,,CHEMBL620584,,,B
12918,Autocuration,,1,,,3107,4,105030,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,H,,,BAO_0000224,,CHEMBL620585,,,B
12918,Autocuration,,1,,,3108,4,105030,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,H,,,BAO_0000224,,CHEMBL620586,,,B
10369,Autocuration,,1,,,3109,4,105030,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,H,,,BAO_0000019,,CHEMBL620587,,,B
773,Autocuration,,1,,,3110,4,105030,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,H,,,BAO_0000019,,CHEMBL620588,,,B
12918,Autocuration,,1,,,3111,4,105030,,,,5-hydroxytryptamine 3 receptor agonism in mouse,,H,,,BAO_0000218,,CHEMBL620589,,,F
10561,Autocuration,,1,,,3112,4,105030,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,H,,,BAO_0000219,,CHEMBL620590,,,B
12827,Autocuration,,1,,,3113,4,105030,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,H,,,BAO_0000019,,CHEMBL617956,,,B
12827,Autocuration,,1,,,3114,4,105030,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,H,,,BAO_0000019,,CHEMBL617957,,,B
12918,Autocuration,,1,,,3115,4,105030,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,H,,,BAO_0000224,,CHEMBL617958,,,B
273,Autocuration,,1,,,3116,4,105030,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,H,,,BAO_0000219,,CHEMBL617959,,,B
273,Autocuration,,1,,,3117,4,105030,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,H,,,BAO_0000219,,CHEMBL617960,,,B
10561,Autocuration,,1,,,3118,4,105030,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,H,,,BAO_0000224,,CHEMBL617961,,,B
5033,Autocuration,,1,,,3119,4,105030,,In vitro,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,H,,,BAO_0000219,,CHEMBL617962,,,B
16429,Autocuration,,1,,,3120,4,105030,N1E-115,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,H,339.0,,BAO_0000219,,CHEMBL617963,,,B
10322,Autocuration,,1,,,3121,8,11765,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,H,,,BAO_0000019,,CHEMBL617964,,,B
14331,Autocuration,,1,,,3122,8,11765,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,H,,,BAO_0000219,,CHEMBL617965,,,B
13462,Autocuration,,1,,10090.0,3123,9,10630,,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,D,,Mus musculus,BAO_0000357,,CHEMBL617966,,,B
12861,Autocuration,,1,,,3124,8,17106,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,H,,,BAO_0000019,,CHEMBL857074,,,B
15086,Autocuration,,1,,9823.0,3125,8,144,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,H,,Sus scrofa,BAO_0000357,,CHEMBL617967,,,B
12861,Autocuration,,1,,9823.0,3126,8,144,,,,Binding activity radioligand.,,H,,Sus scrofa,BAO_0000357,,CHEMBL617968,,,B
10561,Autocuration,,1,,9986.0,3127,4,104714,,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,H,,Oryctolagus cuniculus,BAO_0000223,,CHEMBL617969,,,B
10561,Autocuration,,1,,9986.0,3128,4,104714,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,H,,Oryctolagus cuniculus,BAO_0000223,,CHEMBL617970,,,B
10561,Autocuration,,1,,9986.0,3129,4,104714,,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,H,,Oryctolagus cuniculus,BAO_0000223,,CHEMBL617971,,,B
10561,Autocuration,,1,,9986.0,3130,4,104714,,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617972,,,B
273,Autocuration,,1,,9986.0,3131,4,104714,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617973,,,F
273,Autocuration,,1,,9986.0,3132,4,104714,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617974,,,F
273,Autocuration,,1,,9986.0,3133,4,104714,,,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,H,,Oryctolagus cuniculus,BAO_0000221,2116.0,CHEMBL617975,,,F
273,Autocuration,,1,,9986.0,3134,4,104714,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617976,,,F
273,Autocuration,,1,,9986.0,3135,4,104714,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617977,,,F
273,Autocuration,,1,,9986.0,3136,4,104714,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617978,,,F
273,Autocuration,,1,,9986.0,3137,4,104714,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL617979,,,F
13047,Autocuration,,1,,9986.0,3138,4,104714,CHO,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,H,449.0,Oryctolagus cuniculus,BAO_0000219,,CHEMBL617980,,,B
1650,Autocuration,,1,,10116.0,3139,7,104698,,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617981,,,B
16288,Autocuration,,1,,,3140,8,12020,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,H,,,BAO_0000019,,CHEMBL617982,,,B
16288,Autocuration,,1,,,3141,8,12020,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,H,,,BAO_0000357,,CHEMBL617983,,,B
10254,Autocuration,,1,,10116.0,3142,7,104698,,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617984,,,B
14532,Autocuration,,1,,,3143,6,104698,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,H,,,BAO_0000019,,CHEMBL617985,,,B
13392,Autocuration,,1,,,3144,6,104698,,In vivo,Heart,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,H,,,BAO_0000218,948.0,CHEMBL617986,,,F
13392,Autocuration,,1,,,3145,6,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,H,,,BAO_0000019,948.0,CHEMBL617987,,,F
13392,Autocuration,,1,,,3146,6,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,H,,,BAO_0000019,948.0,CHEMBL617988,,,F
13392,Autocuration,,1,,,3147,6,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,H,,,BAO_0000019,948.0,CHEMBL617792,,,F
13392,Autocuration,,1,,,3148,6,104698,,,Heart,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,H,,,BAO_0000019,948.0,CHEMBL617793,,,F
13392,Autocuration,,1,,,3149,6,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,H,,,BAO_0000019,,CHEMBL617794,,,F
13392,Autocuration,,1,,,3150,6,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,H,,,BAO_0000019,,CHEMBL617795,,,F
13392,Autocuration,,1,,,3151,6,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,H,,,BAO_0000019,,CHEMBL617796,,,F
13392,Autocuration,,1,,,3152,6,104698,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,H,,,BAO_0000019,,CHEMBL617797,,,F
1089,Autocuration,,1,,10116.0,3153,7,104698,,In vivo,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,D,,Rattus norvegicus,BAO_0000218,,CHEMBL617798,,,F
1089,Autocuration,,1,,,3154,6,104698,,In vivo,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,H,,,BAO_0000218,,CHEMBL617799,,,F
11454,Autocuration,,1,,10116.0,3155,7,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,D,,Rattus norvegicus,BAO_0000218,,CHEMBL617800,,,F
11454,Autocuration,,1,,10116.0,3156,7,104698,,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617801,,,F
12205,Autocuration,,1,,10116.0,3157,7,104698,,In vivo,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,D,,Rattus norvegicus,BAO_0000218,,CHEMBL617802,,,F
1089,Autocuration,,1,,10116.0,3158,7,104698,,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617803,,,F
5094,Autocuration,,1,,,3159,6,104698,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,H,,,BAO_0000019,,CHEMBL617804,,,B
2622,Autocuration,,1,,10116.0,3160,7,104698,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617805,,,B
245,Autocuration,,1,,,3161,6,104698,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL617806,,,B
14788,Autocuration,,1,,,3162,6,104698,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,H,,,BAO_0000019,,CHEMBL617807,,,B
14788,Autocuration,,1,,,3163,6,104698,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,H,,,BAO_0000019,,CHEMBL617808,,,B
3020,Autocuration,,1,,,3164,6,104698,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,H,,,BAO_0000249,,CHEMBL617809,,,B
1742,Autocuration,,1,,,3165,6,104698,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,H,,,BAO_0000019,,CHEMBL617810,,,B
17394,Autocuration,,1,,,3166,6,104698,,,Brain,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,H,,,BAO_0000249,955.0,CHEMBL617811,,,B
17394,Autocuration,,1,,,3167,6,104698,,,Brain,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,H,,,BAO_0000221,955.0,CHEMBL617812,,,B
17394,Autocuration,,1,,,3168,6,104698,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617813,,,B
14286,Autocuration,,1,,,3169,6,104698,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,H,,,BAO_0000249,,CHEMBL617814,,,B
14178,Autocuration,,1,,,3170,6,104698,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,H,,,BAO_0000019,,CHEMBL617698,,,B
14178,Autocuration,,1,,10116.0,3171,7,104698,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617699,,,B
14178,Autocuration,,1,,10116.0,3172,7,104698,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617700,,,B
14178,Autocuration,,1,,10116.0,3173,7,104698,,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL617701,,,B
15034,Autocuration,,1,,,3174,6,104698,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,H,,,BAO_0000019,,CHEMBL617702,,,B
1089,Autocuration,,1,,,3175,6,104698,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,H,,,BAO_0000249,,CHEMBL617703,,Membranes,B
1089,Autocuration,,1,,10116.0,3176,7,104698,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617704,,,B
16532,Autocuration,,1,,,3177,6,104698,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,H,,,BAO_0000223,,CHEMBL617705,,,B
12801,Autocuration,,1,,10116.0,3178,7,104698,,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL617706,,,B
15194,Autocuration,,1,,,3179,6,104698,NG108-15,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,H,433.0,,BAO_0000219,,CHEMBL617707,,,B
15194,Autocuration,,1,,,3180,6,104698,NG108-15,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,H,433.0,,BAO_0000219,,CHEMBL617708,,,B
15194,Autocuration,,1,,,3181,6,104698,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,H,,,BAO_0000019,,CHEMBL617709,,,B
15194,Autocuration,,1,,,3182,6,104698,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,H,,,BAO_0000019,,CHEMBL617710,,,B
15194,Autocuration,,1,,,3183,6,104698,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,H,,,BAO_0000019,,CHEMBL882925,,,B
15194,Autocuration,,1,,,3184,6,104698,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,H,,,BAO_0000019,,CHEMBL617711,,,B
10610,Autocuration,,1,,,3185,6,104698,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,H,,,BAO_0000019,,CHEMBL617712,,,F
10355,Autocuration,,1,,10116.0,3186,7,104698,,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL617713,,,F
691,Autocuration,,1,,,3187,6,104698,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,H,,,BAO_0000019,,CHEMBL617714,,,F
10611,Autocuration,,1,,,3188,6,104698,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,H,,,BAO_0000218,,CHEMBL617715,,,F
12801,Autocuration,,1,,,3189,6,104698,,In vivo,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,H,,,BAO_0000218,,CHEMBL617716,,,F
10609,Autocuration,,1,,,3190,6,104698,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,H,,,BAO_0000218,,CHEMBL617717,,,F
11454,Autocuration,,1,,,3191,6,104698,,In vivo,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617718,,,F
11454,Autocuration,,1,,,3192,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617719,,,F
11454,Autocuration,,1,,,3193,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,H,,,BAO_0000218,,CHEMBL617720,,,F
11454,Autocuration,,1,,10116.0,3194,7,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,D,,Rattus norvegicus,BAO_0000218,,CHEMBL617721,,,F
11454,Autocuration,,1,,,3195,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617722,,,F
11454,Autocuration,,1,,,3196,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,H,,,BAO_0000218,,CHEMBL617723,,,F
11454,Autocuration,,1,,,3197,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617724,,,F
11454,Autocuration,,1,,,3198,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617725,,,F
11454,Autocuration,,1,,,3199,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617726,,,F
11454,Autocuration,,1,,,3200,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617727,,,F
11454,Autocuration,,1,,,3201,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617728,,,F
11454,Autocuration,,1,,,3202,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617729,,,F
11454,Autocuration,,1,,,3203,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617730,,,F
11454,Autocuration,,1,,,3204,6,104698,,In vivo,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617731,,,F
11454,Autocuration,,1,,,3205,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617732,,,F
11454,Autocuration,,1,,,3206,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617733,,,F
11454,Autocuration,,1,,,3207,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617734,,,F
11454,Autocuration,,1,,,3208,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,H,,,BAO_0000218,,CHEMBL872874,,,F
11454,Autocuration,,1,,,3209,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,H,,,BAO_0000218,,CHEMBL617735,,,F
11454,Autocuration,,1,,,3210,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,H,,,BAO_0000218,,CHEMBL617736,,,F
11454,Autocuration,,1,,,3211,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,H,,,BAO_0000218,,CHEMBL617737,,,F
11454,Autocuration,,1,,,3212,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,H,,,BAO_0000218,,CHEMBL617738,,,F
11454,Autocuration,,1,,,3213,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617739,,,F
11454,Autocuration,,1,,,3214,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617740,,,F
11454,Autocuration,,1,,,3215,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617741,,,F
11454,Autocuration,,1,,,3216,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617742,,,F
11454,Autocuration,,1,,,3217,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617743,,,F
11454,Autocuration,,1,,,3218,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617744,,,F
11454,Autocuration,,1,,,3219,6,104698,,In vivo,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,H,,,BAO_0000218,,CHEMBL617745,,,F
670,Autocuration,,1,,,3220,6,104698,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,H,,,BAO_0000218,,CHEMBL617746,,,F
670,Autocuration,,1,,,3221,6,104698,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,H,,,BAO_0000218,,CHEMBL617747,,,F
10321,Autocuration,,1,,,3222,6,104698,,In vivo,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,H,,,BAO_0000218,,CHEMBL617748,,,F
10321,Autocuration,,1,,,3223,6,104698,,In vivo,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,H,,,BAO_0000218,,CHEMBL618909,,,F
10321,Autocuration,,1,,,3224,6,104698,,In vivo,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,H,,,BAO_0000218,,CHEMBL618910,,,F
10321,Autocuration,,1,,,3225,6,104698,,In vivo,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,H,,,BAO_0000218,,CHEMBL618911,,,F
10321,Autocuration,,1,,,3226,6,104698,,In vivo,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,H,,,BAO_0000218,,CHEMBL618912,,,F
10322,Autocuration,,1,,,3227,6,104698,,In vivo,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,H,,,BAO_0000218,,CHEMBL618913,,,F
15412,Autocuration,,1,,,3228,6,104698,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,H,,,BAO_0000019,,CHEMBL618914,,,F
15412,Autocuration,,1,,,3229,6,104698,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,H,,,BAO_0000019,,CHEMBL618915,,,F
15412,Autocuration,,1,,10116.0,3230,7,104698,,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL618916,,,B
15412,Autocuration,,1,,,3231,6,104698,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,H,,,BAO_0000019,,CHEMBL618917,,,F
15412,Intermediate,,1,,,3232,7,104698,,,Hippocampus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,D,,,BAO_0000221,10000000.0,CHEMBL618918,,,B
15412,Autocuration,,1,,10116.0,3233,7,104698,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL618919,,,B
17394,Autocuration,,1,,10116.0,3234,7,104698,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL618920,,,B
12457,Autocuration,,1,,,3235,6,104698,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL618921,,,B
12457,Autocuration,,1,,,3236,6,104698,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000019,,CHEMBL618922,,,B
12205,Autocuration,,1,,,3237,6,104698,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,H,,,BAO_0000019,,CHEMBL618923,,,B
14532,Autocuration,,1,,,3238,6,104698,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,H,,,BAO_0000019,,CHEMBL618924,,,B
1122,Autocuration,,1,,,3239,6,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,H,,,BAO_0000019,,CHEMBL618925,,,B
5094,Autocuration,,1,,,3240,6,104698,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,H,,,BAO_0000019,,CHEMBL618926,,,B
809,Intermediate,,1,,10141.0,3241,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL618927,,,F
809,Intermediate,,1,,10141.0,3242,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL618928,,,F
14290,Intermediate,,1,,10141.0,3243,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL618929,,,F
14290,Intermediate,,1,,10141.0,3244,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL618930,,,F
14290,Intermediate,,1,,10141.0,3245,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL618931,,,F
14290,Intermediate,,1,,10141.0,3246,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619594,,,F
14290,Intermediate,,1,,10141.0,3247,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619595,,,F
13961,Intermediate,,1,,10141.0,3248,9,20033,,,Ileum,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619596,,,F
13961,Intermediate,,1,,10141.0,3249,9,20033,,,Ileum,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619755,,,F
809,Intermediate,,1,,10141.0,3250,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619756,,,F
809,Intermediate,,1,,10141.0,3251,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619757,,,F
809,Intermediate,,1,,10141.0,3252,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619758,,,F
14290,Intermediate,,1,,10141.0,3253,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619759,,,F
14290,Intermediate,,1,,10141.0,3254,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619760,,,F
14290,Intermediate,,1,,10141.0,3255,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619761,,,F
14290,Intermediate,,1,,10141.0,3256,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619762,,,F
14290,Intermediate,,1,,10141.0,3257,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619763,,,F
14290,Intermediate,,1,,10141.0,3258,9,20033,,,Ileum,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL617868,,,F
15034,Intermediate,,1,,10141.0,3259,9,20033,,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,D,,Cavia porcellus,BAO_0000357,,CHEMBL617869,,,B
5094,Intermediate,,1,,10141.0,3260,9,20033,,,Striatum,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,D,,Cavia porcellus,BAO_0000249,2435.0,CHEMBL882926,,,B
5094,Intermediate,,1,,10141.0,3261,9,20033,,,Striatum,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,D,,Cavia porcellus,BAO_0000249,2435.0,CHEMBL617870,,,B
5399,Intermediate,,1,,10141.0,3262,9,20033,,,Striatum,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL617871,,,B
17394,Intermediate,,1,,10141.0,3263,9,20033,,,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL617872,,,B
17394,Intermediate,,1,,10141.0,3264,9,20033,,,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL617873,,,B
17394,Intermediate,,1,,10141.0,3265,9,20033,,,Striatum,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL617874,,,B
13961,Intermediate,,1,,10141.0,3266,9,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619067,,,F
13961,Intermediate,,1,,10141.0,3267,9,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619068,,,F
13961,Intermediate,,1,,10141.0,3268,9,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619069,,,F
16946,Intermediate,,1,,10141.0,3269,9,20033,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619070,,,B
16946,Intermediate,,1,,10141.0,3270,9,20033,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619071,,,B
15034,Intermediate,,1,,10141.0,3271,9,20033,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619072,,,F
15034,Intermediate,,1,,10141.0,3272,9,20033,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619073,,,F
12918,Intermediate,,1,,10141.0,3273,9,20033,,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619074,,,F
16946,Intermediate,,1,,10141.0,3274,9,20033,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619075,,,B
17394,Intermediate,,1,,10141.0,3275,9,20033,,,Striatum,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL619076,,,B
15034,Intermediate,,1,,10141.0,3276,9,20033,,,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL619077,,,B
5094,Intermediate,,1,,10141.0,3277,9,20033,,,Striatum,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,D,,Cavia porcellus,BAO_0000249,2435.0,CHEMBL619078,,,B
5094,Intermediate,,1,,10141.0,3278,9,20033,,,Striatum,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,D,,Cavia porcellus,BAO_0000249,2435.0,CHEMBL619079,,,B
17358,Intermediate,,1,,10141.0,3279,9,20033,,,Ileum,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619080,,,B
12953,Expert,,1,,10141.0,3280,9,20033,,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619081,,,B
12953,Intermediate,,1,,10141.0,3281,9,20033,,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619082,,,B
12953,Intermediate,,1,,10141.0,3282,9,20033,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619083,,,B
12953,Intermediate,,1,,10141.0,3283,9,20033,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619084,,,B
273,Intermediate,,1,,10141.0,3284,9,20033,,,Ileum,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL859397,,,F
12918,Intermediate,,1,,10141.0,3285,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619085,,,F
12919,Intermediate,,1,,10141.0,3286,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619086,,,F
273,Intermediate,,1,,10141.0,3287,9,20033,,,Ileum,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619087,,,F
273,Intermediate,,1,,10141.0,3288,9,20033,,,Ileum,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619088,,,F
13181,Intermediate,,1,,10141.0,3289,9,20033,,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619089,,,B
13181,Autocuration,,1,,10141.0,3290,8,168,,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,H,,Cavia porcellus,BAO_0000357,,CHEMBL619090,,,B
15034,Intermediate,,1,,10141.0,3291,9,20033,,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619091,,,F
5033,Intermediate,,1,,10141.0,3292,9,20033,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619092,,,B
1980,Intermediate,,1,,10141.0,3293,9,20033,,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619093,,,B
13181,Autocuration,,1,,10141.0,3294,8,168,HEK293,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,H,722.0,Cavia porcellus,BAO_0000219,,CHEMBL619094,,,B
14287,Intermediate,,1,,10141.0,3295,9,20033,,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619095,,,B
1317,Intermediate,,1,,10141.0,3296,9,20033,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,D,,Cavia porcellus,BAO_0000357,,CHEMBL857988,,,B
15316,Intermediate,,1,,10141.0,3297,9,20033,,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619096,,,B
16429,Intermediate,,1,,10141.0,3298,9,20033,,,Striatum,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,D,,Cavia porcellus,BAO_0000357,2435.0,CHEMBL619097,,,B
14818,Intermediate,,1,,10141.0,3299,9,20033,,,Hippocampus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,D,,Cavia porcellus,BAO_0000221,10000000.0,CHEMBL619098,,,B
15194,Intermediate,,1,,10141.0,3300,9,20033,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619751,,,B
15194,Intermediate,,1,,10141.0,3301,9,20033,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619752,,,B
13961,Intermediate,,1,,10141.0,3302,9,20033,,,Ileum,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL875096,,,F
5486,Autocuration,,1,,,3303,8,108,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,H,,,BAO_0000357,,CHEMBL619004,,,B
16209,Autocuration,,1,,,3304,8,168,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL619005,,,B
17085,Autocuration,,1,,,3305,8,168,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000019,,CHEMBL619006,,,B
4199,Autocuration,,1,,,3306,8,168,HeLa,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,H,308.0,,BAO_0000219,,CHEMBL619007,,,B
15146,Autocuration,,1,,,3307,8,168,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL619008,,,B
5213,Autocuration,,1,,,3308,8,168,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL619009,,,B
4829,Autocuration,,1,,,3309,8,168,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,H,308.0,,BAO_0000219,,CHEMBL619010,,,B
17358,Autocuration,,1,,,3310,8,10622,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,H,,,BAO_0000357,,CHEMBL619011,,,B
17358,Autocuration,,1,,,3311,8,10622,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,H,,,BAO_0000357,,CHEMBL619012,,,B
16946,Autocuration,,1,,,3312,8,10622,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,H,,,BAO_0000219,,CHEMBL619013,,,B
17358,Autocuration,,1,,,3313,8,10622,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,H,,,BAO_0000357,,CHEMBL619014,,,B
268,Autocuration,,1,,,3314,8,11249,,,Cardiac atrium,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,H,,,BAO_0000019,2081.0,CHEMBL857503,,,F
268,Autocuration,,1,,,3315,8,11249,,,Cardiac atrium,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,H,,,BAO_0000019,2081.0,CHEMBL619015,,,F
15086,Autocuration,,1,,,3316,8,11249,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL619016,,,B
14875,Autocuration,,1,,,3317,8,11249,,,Hippocampus,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000221,10000000.0,CHEMBL619017,,,B
13267,Autocuration,,1,,9823.0,3318,8,168,,,Hippocampus,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,H,,Sus scrofa,BAO_0000221,10000000.0,CHEMBL619018,,,B
13047,Autocuration,,1,,9986.0,3319,8,168,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL619019,,,B
1650,Expert,,1,,10116.0,3320,9,10623,,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL619020,,,B
567,Autocuration,,1,,,3321,8,10623,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,H,,,BAO_0000019,,CHEMBL619021,,,F
17358,Autocuration,,1,,,3322,8,10623,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,H,,,BAO_0000357,,CHEMBL619022,,,B
188,Autocuration,,1,,,3323,8,10623,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,H,,,BAO_0000357,,CHEMBL619023,,,B
670,Autocuration,,1,,,3324,8,10623,,,,lntrinsic activity relative to 5-HT receptor,,H,,,BAO_0000019,,CHEMBL619024,,,F
204,Autocuration,,1,,,3325,8,10623,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,H,,,BAO_0000019,,CHEMBL619025,,,F
1946,Expert,,1,,,3326,8,10623,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,H,,,BAO_0000019,,CHEMBL619026,,,F
6398,Autocuration,,1,,,3327,8,10623,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,H,,,BAO_0000019,,CHEMBL619027,,,F
6398,Autocuration,,1,,,3328,8,10623,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,H,,,BAO_0000019,,CHEMBL619028,,,F
17358,Autocuration,,1,,,3329,8,10623,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,H,,,BAO_0000019,,CHEMBL619029,,,F
6398,Autocuration,,1,,,3330,8,10623,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,H,,,BAO_0000019,,CHEMBL619030,,,F
11752,Expert,,1,,,3331,8,10623,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,H,,,BAO_0000357,,CHEMBL619031,,,B
809,Autocuration,,1,,,3332,8,10623,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,H,,,BAO_0000019,,CHEMBL619032,,,F
14178,Expert,,1,,10116.0,3333,9,10623,,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL619033,,,B
567,Autocuration,,1,,,3334,8,10623,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,H,,,BAO_0000357,,CHEMBL619034,,,B
1946,Autocuration,,1,,,3335,8,10623,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,H,,,BAO_0000357,,CHEMBL619035,,,B
1946,Autocuration,,1,,,3336,8,10623,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,H,,,BAO_0000357,,CHEMBL619036,,,B
13961,Expert,,1,,10116.0,3337,9,10623,,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619037,,,B
6238,Autocuration,,1,,,3338,8,10623,,,Striatum,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,H,,,BAO_0000249,2435.0,CHEMBL619038,,,B
14290,Autocuration,,1,,,3339,8,10623,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,H,,,BAO_0000249,,CHEMBL619039,,,B
14290,Expert,,1,,,3340,8,10623,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,H,,,BAO_0000249,,CHEMBL619040,,,B
809,Expert,,1,,10116.0,3341,9,10623,,,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,D,,Rattus norvegicus,BAO_0000019,2435.0,CHEMBL619041,,,B
1578,Autocuration,,1,,,3342,8,10623,,,Striatum,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,H,,,BAO_0000019,2435.0,CHEMBL619042,,,B
16709,Expert,,1,,,3343,8,10623,,,Striatum,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,H,,,BAO_0000249,2435.0,CHEMBL619043,,,B
1946,Expert,,1,,,3344,8,10623,,,Striatum,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,H,,,BAO_0000019,2435.0,CHEMBL619044,,,B
15253,Expert,,1,,,3345,8,10623,,,Striatum,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,H,,,BAO_0000249,2435.0,CHEMBL619045,,,B
4535,Expert,,1,,,3346,8,10623,,,Striatum,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,H,,,BAO_0000249,2435.0,CHEMBL619046,,,B
13961,Expert,,1,,,3347,8,10623,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,H,,,BAO_0000249,,CHEMBL619047,,,B
17358,Autocuration,,1,,,3348,8,10623,,,Brain,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,H,,,BAO_0000221,955.0,CHEMBL619048,,,F
15847,Autocuration,,1,,,3349,8,10623,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,H,,,BAO_0000019,,CHEMBL859398,,,F
15847,Autocuration,,1,,,3350,8,10623,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,H,,,BAO_0000019,,CHEMBL619049,,,F
670,Autocuration,,1,,,3351,8,10623,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,H,,,BAO_0000019,,CHEMBL857886,,,F
670,Autocuration,,1,,,3352,8,10623,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,H,,,BAO_0000019,,CHEMBL619050,,,F
1317,Autocuration,,1,,,3353,8,10623,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,H,,,BAO_0000019,,CHEMBL620591,,,F
12936,Expert,,1,,10116.0,3354,9,10623,,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL620592,,,B
4535,Expert,,1,,,3355,8,10623,,,Striatum,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,H,,,BAO_0000249,2435.0,CHEMBL620593,,,B
14424,Expert,,1,,10116.0,3356,9,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL620594,,,F
14424,Expert,,1,,,3357,8,10623,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,H,,,BAO_0000019,,CHEMBL875079,,,F
14424,Expert,,1,,,3358,8,10623,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,H,,,BAO_0000019,,CHEMBL620595,,,F
14424,Expert,,1,,10116.0,3359,9,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL620596,,,F
14424,Autocuration,,1,,,3360,8,10623,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,H,,,BAO_0000019,,CHEMBL620597,,,F
14424,Expert,,1,,,3361,8,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,H,,,BAO_0000019,,CHEMBL620598,,,F
14424,Expert,,1,,,3362,8,10623,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,H,,,BAO_0000218,,CHEMBL620599,,,F
14424,Autocuration,,1,,,3363,8,10623,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,H,,,BAO_0000019,,CHEMBL620600,,,F
1980,Autocuration,,1,,10116.0,3364,8,168,,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,H,,Rattus norvegicus,BAO_0000019,,CHEMBL620601,,,F
4639,Autocuration,,1,,,3365,8,168,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,H,,,BAO_0000019,,CHEMBL620602,,,F
17358,Autocuration,,1,,,3366,8,168,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620603,,,B
17358,Autocuration,,1,,,3367,8,168,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,H,,,BAO_0000357,,CHEMBL620604,,,B
17358,Autocuration,,1,,,3368,8,168,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,H,,,BAO_0000357,,CHEMBL620605,,,B
1558,Autocuration,,1,,,3369,8,168,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620606,,,B
17358,Autocuration,,1,,,3370,8,168,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,H,,,BAO_0000019,,CHEMBL620607,,,F
16117,Autocuration,,1,,,3371,8,168,,,,In vitro binding affinity towards 5-HT4 receptor was determined,,H,,,BAO_0000357,,CHEMBL620608,,,B
17358,Autocuration,,1,,,3372,8,168,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,H,,,BAO_0000019,,CHEMBL620609,,,F
17358,Autocuration,,1,,,3373,8,168,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000019,,CHEMBL620610,,,F
17358,Autocuration,,1,,,3374,8,168,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620611,,,B
17358,Autocuration,,1,,,3375,8,168,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,H,,,BAO_0000357,,CHEMBL620612,,,B
17358,Autocuration,,1,,,3376,8,168,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,H,,,BAO_0000357,,CHEMBL620613,,,B
17358,Autocuration,,1,,,3377,8,168,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,H,,,BAO_0000357,,CHEMBL620614,,,B
1274,Expert,,1,,,3378,8,168,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620615,,,B
10728,Autocuration,,1,,,3379,6,104698,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,H,,,BAO_0000249,,CHEMBL857075,,Brain membranes,B
11695,Autocuration,,1,,,3380,6,104698,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,H,,,BAO_0000249,,CHEMBL620616,,Brain membranes,B
11695,Autocuration,,1,,,3381,6,104698,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,H,,,BAO_0000249,,CHEMBL619411,,Brain membranes,B
12490,Autocuration,,1,,,3382,6,104698,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,H,,,BAO_0000019,,CHEMBL619412,,,B
11828,Autocuration,,1,,10116.0,3383,7,104698,,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619413,,,B
12253,Autocuration,,1,,,3384,6,104698,,,Hippocampus,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,H,,,BAO_0000221,10000000.0,CHEMBL619414,,,B
10561,Autocuration,,1,,,3385,6,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,H,,,BAO_0000019,,CHEMBL619415,,,B
10561,Autocuration,,1,,,3386,6,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,H,,,BAO_0000019,,CHEMBL619416,,,B
14432,Autocuration,,1,,,3387,6,104698,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,H,,,BAO_0000019,,CHEMBL619417,,,F
12936,Autocuration,,1,,10116.0,3388,7,104698,,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL619418,,,B
1274,Autocuration,,1,,10116.0,3389,7,104698,,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL619419,,,B
1980,Autocuration,,1,,,3390,6,104698,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,H,,,BAO_0000019,,CHEMBL619420,,,B
670,Autocuration,,1,,,3391,6,104698,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,H,,,BAO_0000249,,CHEMBL619421,,,B
968,Autocuration,,1,,10116.0,3392,7,104698,,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619422,,,B
14287,Autocuration,,1,,,3393,6,104698,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,H,,,BAO_0000019,,CHEMBL619423,,,B
567,Autocuration,,1,,,3394,6,104698,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,H,,,BAO_0000019,,CHEMBL875080,,,B
13267,Autocuration,,1,,,3395,6,104698,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,H,,,BAO_0000019,,CHEMBL619424,,,B
14826,Autocuration,,1,,,3396,6,104698,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,H,,,BAO_0000249,,CHEMBL619425,,,B
15194,Autocuration,,1,,,3397,6,104698,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,H,,,BAO_0000223,,CHEMBL619426,,,B
15194,Autocuration,,1,,,3398,6,104698,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,H,,,BAO_0000223,,CHEMBL619427,,,B
10394,Autocuration,,1,,10116.0,3399,7,104698,,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,D,,Rattus norvegicus,BAO_0000223,,CHEMBL619645,,,B
13657,Expert,,1,,,3400,9,10576,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,D,,,BAO_0000249,,CHEMBL619646,,,B
1879,Autocuration,,1,,,3401,8,12020,,,Brain,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,H,,,BAO_0000221,955.0,CHEMBL619647,,,F
1879,Autocuration,,1,,,3402,8,12020,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000019,,CHEMBL619648,,,F
1879,Autocuration,,1,,,3403,8,12020,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,H,,,BAO_0000019,,CHEMBL619165,,,F
204,Autocuration,,1,,,3404,8,12020,,In vivo,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000218,,CHEMBL620719,,,F
1879,Autocuration,,1,,,3405,8,12020,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,H,,,BAO_0000019,,CHEMBL872924,,,B
1879,Autocuration,,1,,,3406,8,12020,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL620720,,,B
1879,Autocuration,,1,,,3407,8,12020,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,H,,,BAO_0000019,,CHEMBL620721,,,B
1879,Autocuration,,1,,,3408,8,12020,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,H,,,BAO_0000019,,CHEMBL620722,,,B
10641,Autocuration,,1,,,3409,6,104698,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,H,,,BAO_0000019,,CHEMBL620723,,,B
773,Autocuration,,1,,,3410,8,12020,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,H,,,BAO_0000019,,CHEMBL620724,,,B
11952,Autocuration,,1,,,3411,6,104698,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,H,,,BAO_0000249,,CHEMBL620725,,,B
14145,Autocuration,,1,,10116.0,3412,9,12020,,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL620726,,,F
17066,Expert,,1,,,3413,8,144,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL620727,,,B
6398,Autocuration,,1,,,3414,4,104714,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,H,,,BAO_0000223,,CHEMBL620728,,,B
10321,Autocuration,,1,,,3415,0,22226,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,U,,,BAO_0000019,,CHEMBL620729,,,B
511,Autocuration,,1,,,3416,4,104714,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,H,,,BAO_0000019,,CHEMBL858288,,,F
4639,Autocuration,,1,,,3417,4,104714,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL620730,,,B
4639,Autocuration,,1,,,3418,4,104714,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL620731,,,B
4639,Autocuration,,1,,10141.0,3419,4,104714,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL620732,,,F
4639,Autocuration,,1,,10141.0,3420,4,104714,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618042,,,F
4639,Autocuration,,1,,10141.0,3421,4,104714,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618043,,,F
1558,Autocuration,,1,,,3422,4,104714,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL618044,,,B
268,Autocuration,,1,,,3423,4,104714,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,H,,,BAO_0000019,,CHEMBL618045,,,F
2474,Autocuration,,1,,,3424,4,104714,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,H,,,BAO_0000223,,CHEMBL618046,,,B
5067,Autocuration,,1,,,3425,4,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,H,,,BAO_0000019,,CHEMBL618047,,,F
5067,Autocuration,,1,,,3426,4,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,H,,,BAO_0000019,,CHEMBL875084,,,F
5067,Autocuration,,1,,,3427,4,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,H,,,BAO_0000019,,CHEMBL618048,,,F
5067,Autocuration,,1,,,3428,4,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,H,,,BAO_0000223,,CHEMBL618049,,,B
5067,Autocuration,,1,,,3429,4,104714,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,H,,,BAO_0000019,,CHEMBL619764,,,F
5067,Autocuration,,1,,,3430,4,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,H,,,BAO_0000019,,CHEMBL619765,,,F
5067,Autocuration,,1,,,3431,4,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,H,,,BAO_0000019,,CHEMBL619766,,,F
5067,Autocuration,,1,,,3432,4,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,H,,,BAO_0000223,,CHEMBL619767,,,B
5067,Autocuration,,1,,,3433,4,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,H,,,BAO_0000223,,CHEMBL619768,,,B
5067,Autocuration,,1,,,3434,4,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,H,,,BAO_0000019,,CHEMBL619769,,,F
5067,Autocuration,,1,,,3435,4,104714,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,H,,,BAO_0000223,,CHEMBL619770,,,B
5067,Autocuration,,1,,,3436,4,104714,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL619771,,,B
14331,Autocuration,,1,,,3437,4,104714,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,H,,,BAO_0000219,,CHEMBL619772,,,B
5067,Autocuration,,1,,,3438,4,104714,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,H,,,BAO_0000223,,CHEMBL619773,,,B
6179,Autocuration,,1,,,3439,4,104714,NG108-15,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,H,433.0,,BAO_0000219,,CHEMBL619774,,,B
4265,Autocuration,,1,,,3440,4,104714,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,H,,,BAO_0000019,,CHEMBL875083,,,B
4265,Autocuration,,1,,,3441,4,104714,NG108-15,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,H,433.0,,BAO_0000219,,CHEMBL620718,,,B
17358,Autocuration,,1,,,3442,4,104714,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,H,,,BAO_0000223,,CHEMBL618127,,,B
17358,Autocuration,,1,,,3443,4,104714,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,H,,,BAO_0000223,,CHEMBL618128,,,B
13628,Autocuration,,1,,,3444,4,104714,,In vitro,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,H,,,BAO_0000219,,CHEMBL618129,,,B
4612,Autocuration,,1,,,3445,4,104714,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,H,,,BAO_0000223,,CHEMBL618130,,,B
17358,Autocuration,,1,,,3446,4,104714,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,H,,,BAO_0000019,,CHEMBL618131,,,F
4639,Autocuration,,1,,10141.0,3447,4,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618132,,,F
4639,Autocuration,,1,,10141.0,3448,4,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618133,,,F
4639,Autocuration,,1,,10141.0,3449,4,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618134,,,F
4639,Autocuration,,1,,10141.0,3450,4,104714,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618135,,,F
511,Autocuration,,1,,,3451,4,104714,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,H,,,BAO_0000223,,CHEMBL618136,,,B
1479,Autocuration,,1,,,3452,4,104714,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL618137,,,B
1317,Autocuration,,1,,,3453,4,104714,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,H,,,BAO_0000223,,CHEMBL618138,,,B
12146,Autocuration,,1,,,3454,4,104714,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,H,,,BAO_0000223,,CHEMBL618139,,,B
12146,Autocuration,,1,,,3455,4,104714,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,H,,,BAO_0000223,,CHEMBL618140,,,B
13969,Autocuration,,1,,,3456,4,104714,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,H,,,BAO_0000223,,CHEMBL618141,,,B
13392,Expert,,1,,,3457,8,108,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,H,,,BAO_0000357,,CHEMBL873478,,,B
13392,Autocuration,,1,,,3458,6,104698,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL618142,,,B
14159,Autocuration,,1,,,3459,8,144,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL618143,,,B
1558,Autocuration,,1,,,3460,8,144,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL618144,,,B
16655,Autocuration,,1,,,3461,8,144,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL618145,,,B
13020,Autocuration,,1,,,3462,4,104714,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,H,,,BAO_0000223,,CHEMBL618146,,,B
13021,Autocuration,,1,,,3463,4,104714,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,H,,,BAO_0000223,,CHEMBL618147,,,B
13020,Autocuration,,1,,,3464,4,104714,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,H,,,BAO_0000223,,CHEMBL618148,,,B
10321,Autocuration,,1,,,3465,8,144,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,H,,,BAO_0000019,,CHEMBL618149,,,B
15818,Autocuration,,1,,,3466,8,144,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL872927,,,B
15818,Autocuration,,1,,,3467,8,144,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL618150,,,B
17358,Autocuration,,1,,,3468,8,144,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,H,,,BAO_0000357,,CHEMBL618151,,,B
2222,Autocuration,,1,,,3469,8,144,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000357,,CHEMBL875094,,,B
10322,Autocuration,,1,,,3470,8,144,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,H,,,BAO_0000019,,CHEMBL618152,,,B
16117,Autocuration,,1,,,3471,8,144,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,H,,,BAO_0000357,,CHEMBL618153,,,B
17200,Autocuration,,1,,,3472,8,144,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,H,,,BAO_0000357,,CHEMBL618888,,,B
17358,Autocuration,,1,,,3473,8,144,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,H,,,BAO_0000019,,CHEMBL618889,,,F
16700,Autocuration,,1,,,3474,8,144,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,H,,,BAO_0000357,,CHEMBL618890,,,B
1980,Autocuration,,1,,,3475,8,144,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,H,,,BAO_0000019,,CHEMBL618891,,,B
1980,Autocuration,,1,,,3476,8,144,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,H,,,BAO_0000019,,CHEMBL619054,,,B
12409,Autocuration,,1,,,3477,4,104714,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,H,,,BAO_0000223,,CHEMBL619055,,,B
4365,Autocuration,,1,,,3478,8,144,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,H,,,BAO_0000357,,CHEMBL619056,,,B
4365,Autocuration,,1,,,3479,8,144,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,H,,,BAO_0000019,,CHEMBL619057,,,F
4365,Autocuration,,1,,,3480,8,144,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,H,,,BAO_0000357,,CHEMBL619058,,,B
6769,Expert,,1,,10116.0,3481,9,12020,Oocytes,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL619059,,,F
6769,Expert,,1,,10116.0,3482,9,12020,Oocytes,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL619060,,,F
6769,Expert,,1,,10116.0,3483,9,12020,Oocytes,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,D,,Rattus norvegicus,BAO_0000219,,CHEMBL875095,,,F
809,Intermediate,,1,,10141.0,3484,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619061,,,F
809,Intermediate,,1,,10141.0,3485,9,20033,,,Ileum,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619062,,,F
14290,Intermediate,,1,,10141.0,3486,9,20033,,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,D,,Cavia porcellus,BAO_0000019,,CHEMBL619063,,,F
17358,Intermediate,,1,,10141.0,3487,9,20033,,,Ileum,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619064,,,B
17358,Intermediate,,1,,10141.0,3488,9,20033,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,D,,Cavia porcellus,BAO_0000357,,CHEMBL619065,,,B
17358,Intermediate,,1,,10141.0,3489,9,20033,,,Ileum,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,D,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619066,,,B
17386,Autocuration,,1,,,3490,8,10209,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,H,,,BAO_0000221,2116.0,CHEMBL619775,,,B
3269,Autocuration,,1,,,3491,8,10209,,,,Affinity against 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619776,,,B
7721,Autocuration,,1,,10141.0,3492,4,104841,,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,H,,Cavia porcellus,BAO_0000224,,CHEMBL619777,,,B
7721,Autocuration,,1,,10141.0,3493,4,104841,,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,H,,Cavia porcellus,BAO_0000224,,CHEMBL619778,,,B
9117,Autocuration,,1,,10141.0,3494,4,104841,,,Ileum,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL619779,,,B
7721,Autocuration,,1,,10141.0,3495,4,104841,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,H,,Cavia porcellus,BAO_0000224,,CHEMBL619780,,,B
7721,Autocuration,,1,,10141.0,3496,4,104841,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,H,,Cavia porcellus,BAO_0000224,,CHEMBL619166,,,B
15796,Autocuration,,1,,10141.0,3497,4,104841,,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,H,,Cavia porcellus,BAO_0000019,,CHEMBL619167,,,F
15796,Autocuration,,1,,10141.0,3498,4,104841,,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,H,,Cavia porcellus,BAO_0000019,,CHEMBL619168,,,F
15650,Expert,,1,,9606.0,3499,9,168,,,Cardiac atrium,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,D,,Homo sapiens,BAO_0000219,2081.0,CHEMBL619169,,,B
15650,Expert,,1,,9606.0,3500,9,168,,,Cardiac atrium,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,D,,Homo sapiens,BAO_0000219,2081.0,CHEMBL619170,,,B
6866,Autocuration,,1,,9606.0,3501,5,104841,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,D,,Homo sapiens,BAO_0000019,,CHEMBL619171,,,F
15650,Expert,,1,,9606.0,3502,9,168,,,Cardiac atrium,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,D,,Homo sapiens,BAO_0000219,2081.0,CHEMBL619172,,,F
10063,Autocuration,,1,,10090.0,3503,0,22226,,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,U,,Mus musculus,BAO_0000019,,CHEMBL619173,,,B
12665,Autocuration,,1,,10090.0,3504,0,22226,,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,U,,Mus musculus,BAO_0000019,,CHEMBL619174,,,B
7504,Autocuration,,1,,,3505,4,104705,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,,H,,,BAO_0000019,,CHEMBL619175,,,B
7504,Autocuration,,1,,,3506,4,104705,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,,H,,,BAO_0000224,,CHEMBL619176,,,B
7038,Autocuration,,1,,,3507,4,104705,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,H,,,BAO_0000019,,CHEMBL619177,,,B
7626,Autocuration,,1,,,3508,4,104705,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,H,,,BAO_0000224,,CHEMBL619178,,,B
7626,Autocuration,,1,,,3509,4,104705,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,H,,,BAO_0000224,,CHEMBL619179,,,B
7185,Autocuration,,1,,,3510,4,104705,,,Stomach,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,H,,,BAO_0000019,945.0,CHEMBL619180,,,F
7185,Autocuration,,1,,,3511,4,104705,,,Stomach,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,H,,,BAO_0000019,945.0,CHEMBL619181,,,F
7185,Autocuration,,1,,,3512,4,104705,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,H,,,BAO_0000019,,CHEMBL619182,,,F
6960,Autocuration,,1,,,3513,4,104705,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,H,,,BAO_0000224,,CHEMBL619183,,,B
6960,Autocuration,,1,,,3514,4,104705,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,H,,,BAO_0000224,,CHEMBL619184,,,B
12416,Autocuration,,1,,,3515,8,10576,,,Hippocampus,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,H,,,BAO_0000221,10000000.0,CHEMBL619185,,,B
15753,Expert,,1,,,3516,8,12198,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,,H,,,BAO_0000357,,CHEMBL619186,,,B
8062,Autocuration,,1,,,3517,4,104705,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,H,,,BAO_0000019,,CHEMBL619187,,,B
9036,Autocuration,,1,,10116.0,3518,5,104705,,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619188,,,B
15067,Autocuration,,1,,10116.0,3519,5,104705,,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL619189,,,B
15753,Expert,,1,,10116.0,3520,9,12198,,,Brain,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,D,,Rattus norvegicus,BAO_0000019,955.0,CHEMBL619190,,,F
15753,Expert,,1,,10116.0,3521,9,12198,,,Cerebellum,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,D,,Rattus norvegicus,BAO_0000221,2037.0,CHEMBL619191,,,F
15295,Autocuration,,1,,10116.0,3522,5,104705,,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619192,,,B
6347,Autocuration,,1,,10116.0,3523,5,104705,,,,Percent binding affinity against 5-hydroxytryptamine receptor,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL619193,,,B
6763,Autocuration,,1,,,3524,0,22226,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,U,,,BAO_0000019,,CHEMBL619194,,,B
12092,Autocuration,,1,,10116.0,3525,5,104705,,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL619195,,,B
1579,Autocuration,,1,,10116.0,3526,5,104705,,,,Affinity against 5-hydroxytryptamine receptor was determined,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL619196,,,B
1579,Autocuration,,1,,10116.0,3527,5,104705,,,Stomach,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,D,,Rattus norvegicus,BAO_0000019,945.0,CHEMBL619197,,,B
5963,Expert,,1,,9606.0,3528,9,121,,In vitro,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,D,,Homo sapiens,BAO_0000219,,CHEMBL619198,,,B
5963,Expert,,1,,9606.0,3529,9,121,,In vitro,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,D,,Homo sapiens,BAO_0000219,,CHEMBL875081,,,B
5030,Autocuration,,1,,,3530,8,18065,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,H,,,BAO_0000357,,CHEMBL884712,,,B
15796,Expert,,1,,,3531,8,121,,,,Inhibition of 5-hydroxytryptamine reuptake,,H,,,BAO_0000357,,CHEMBL884710,,,B
15413,Autocuration,,1,,,3532,8,18065,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,H,,,BAO_0000019,,CHEMBL619199,,,F
15413,Autocuration,,1,,,3533,8,18065,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,H,,,BAO_0000019,,CHEMBL619200,,,F
15413,Autocuration,,1,,,3534,8,18065,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,H,,,BAO_0000019,,CHEMBL619201,,,F
12409,Autocuration,,1,,,3535,8,18065,,,,Tested for 5-hydroxytryptamine receptor uptake,,H,,,BAO_0000019,,CHEMBL619202,,,F
16909,Expert,,1,,9606.0,3536,9,51,CHO,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL619203,,,B
16909,Expert,,1,,9606.0,3537,9,51,,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,D,,Homo sapiens,BAO_0000019,,CHEMBL619204,,,F
15629,Autocuration,,1,,9606.0,3538,8,10576,,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,H,,Homo sapiens,BAO_0000249,,CHEMBL619205,,,B
15629,Autocuration,,1,,,3539,8,10576,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,H,,,BAO_0000357,,CHEMBL619206,,,B
15629,Expert,,1,,,3540,8,10576,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,H,,,BAO_0000249,,CHEMBL619207,,,B
10034,Autocuration,,1,,,3541,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL619208,,,F
10034,Autocuration,,1,,,3542,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL619209,,,F
10034,Autocuration,,1,,,3543,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL619210,,,F
10034,Autocuration,,1,,,3544,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL619211,,,F
10034,Autocuration,,1,,,3545,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL619212,,,F
10034,Autocuration,,1,,,3546,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL620681,,,F
10034,Autocuration,,1,,,3547,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL620682,,,F
10034,Autocuration,,1,,,3548,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL620683,,,F
10034,Autocuration,,1,,,3549,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL620684,,,F
10034,Autocuration,,1,,,3550,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL620685,,,F
10034,Autocuration,,1,,,3551,8,10825,,,Striatum,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,H,,,BAO_0000019,2435.0,CHEMBL620686,,,F
10034,Autocuration,,1,,,3552,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620687,,,F
10034,Autocuration,,1,,,3553,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620688,,,F
10034,Autocuration,,1,,,3554,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620689,,,F
10034,Autocuration,,1,,,3555,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620690,,,F
10034,Autocuration,,1,,,3556,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620691,,,F
10034,Autocuration,,1,,,3557,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620692,,,F
10034,Autocuration,,1,,,3558,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL620693,,,F
1274,Expert,,1,,,3559,8,168,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620694,,,B
17358,Autocuration,,1,,,3560,8,168,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,H,,,BAO_0000019,,CHEMBL857986,,,F
14532,Autocuration,,1,,,3561,8,168,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,H,,,BAO_0000357,,CHEMBL620695,,,B
16989,Expert,,1,,,3562,8,168,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620696,,,B
17200,Autocuration,,1,,,3563,8,168,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,H,,,BAO_0000357,,CHEMBL620697,,,B
15779,Autocuration,,1,,,3564,8,168,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,H,,,BAO_0000357,,CHEMBL620698,,,B
15779,Autocuration,,1,,,3565,8,168,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,H,,,BAO_0000357,,CHEMBL620699,,,B
15779,Autocuration,,1,,,3566,8,168,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,H,,,BAO_0000357,,CHEMBL620700,,,B
15650,Autocuration,,1,,,3567,8,168,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,H,643.0,,BAO_0000219,,CHEMBL620701,,,B
15650,Autocuration,,1,,,3568,8,168,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,H,643.0,,BAO_0000219,,CHEMBL875082,,,B
15650,Autocuration,,1,,,3569,8,168,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,H,643.0,,BAO_0000219,,CHEMBL620702,,,B
15650,Autocuration,,1,,,3570,8,168,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,H,643.0,,BAO_0000219,,CHEMBL620703,,,B
17046,Autocuration,,1,,,3571,8,168,C6,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,H,673.0,,BAO_0000219,,CHEMBL620704,,,B
17046,Expert,,1,,,3572,8,168,C6,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,H,673.0,,BAO_0000219,,CHEMBL620705,,,B
15650,Expert,,1,,,3573,8,168,C6,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,H,673.0,,BAO_0000219,,CHEMBL620706,,,B
17046,Expert,,1,,,3574,8,168,C6,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,H,673.0,,BAO_0000219,,CHEMBL620707,,,B
17066,Expert,,1,,,3575,8,10624,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,H,,,BAO_0000357,,CHEMBL620708,,,B
17200,Autocuration,,1,,,3576,8,105,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,H,,,BAO_0000357,,CHEMBL620709,,,B
16146,Expert,,1,,9606.0,3577,9,10624,,,,Binding affinity against 5-hydroxytryptamine 5A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620710,,,B
15250,Autocuration,,1,,,3578,8,10624,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL620711,,,B
6491,Expert,,1,,9606.0,3579,9,10624,,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620712,,,B
17066,Expert,,1,,9606.0,3580,9,10624,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620713,,,B
17066,Expert,,1,,9606.0,3581,9,10624,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL620714,,,B
4234,Expert,,1,,9606.0,3582,9,10624,,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620715,,,B
6013,Autocuration,,1,,,3583,8,10624,,,,Binding affinity towards 5-HT5A receptor,,H,,,BAO_0000357,,CHEMBL620716,,,B
17175,Expert,,1,,,3584,8,10624,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,H,,,BAO_0000357,,CHEMBL620717,,,B
15818,Autocuration,,1,,,3585,8,10624,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,H,,,BAO_0000357,,CHEMBL618072,,,B
6166,Autocuration,,1,,,3586,8,10624,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,,H,,,BAO_0000357,,CHEMBL857987,,,B
15779,Autocuration,,1,,,3587,8,10624,HEK293,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL618073,,,B
15779,Autocuration,,1,,,3588,8,10624,HEK293,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,H,722.0,,BAO_0000219,,CHEMBL618074,,,B
5213,Autocuration,,1,,,3589,8,10624,HEK293,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,H,722.0,,BAO_0000219,,CHEMBL618075,,,B
17066,Expert,,1,,10090.0,3590,9,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,D,,Mus musculus,BAO_0000357,,CHEMBL618076,,,B
17066,Expert,,1,,10090.0,3591,9,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,D,,Mus musculus,BAO_0000357,,CHEMBL618077,,,B
17066,Expert,,1,,10090.0,3592,9,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,D,,Mus musculus,BAO_0000357,,CHEMBL618078,,,B
17066,Expert,,1,,10090.0,3593,9,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,D,,Mus musculus,BAO_0000357,,CHEMBL881821,,,B
17066,Expert,,1,,10090.0,3594,9,10625,,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,D,,Mus musculus,BAO_0000357,,CHEMBL618079,,,B
17175,Expert,,1,,,3595,8,10625,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,H,,,BAO_0000357,,CHEMBL618080,,,B
16190,Autocuration,,1,,,3596,8,10576,HEK293,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,H,722.0,,BAO_0000219,,CHEMBL618081,,,B
16190,Autocuration,,1,,,3597,8,10626,HEK293,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,H,722.0,,BAO_0000219,,CHEMBL618082,,,B
4820,Expert,,1,,,3598,8,10624,,,,Binding affinity towards 5-HT5a receptor,,H,,,BAO_0000357,,CHEMBL618083,,,B
17066,Expert,,1,,9606.0,3599,9,10624,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL618084,,,B
17066,Expert,,1,,,3600,8,10624,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,H,,,BAO_0000357,,CHEMBL618085,,,B
17175,Expert,,1,,,3601,8,10624,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,H,,,BAO_0000357,,CHEMBL618086,,,B
16633,Autocuration,,1,,,3602,8,10624,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,,H,,,BAO_0000357,,CHEMBL875092,,,B
16633,Autocuration,,1,,,3603,8,10624,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,H,,,BAO_0000357,,CHEMBL618087,,,B
16700,Autocuration,,1,,,3604,8,10624,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,H,,,BAO_0000357,,CHEMBL872926,,,B
4639,Autocuration,,1,,10141.0,3605,4,104714,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618088,,,F
5486,Autocuration,,1,,,3606,4,104714,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,H,,,BAO_0000223,,CHEMBL618089,,,B
16146,Expert,,1,,9606.0,3607,9,10627,,,,Inhibition of human 5-hydroxytryptamine 6 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL618090,,,B
17273,Expert,,1,,9606.0,3608,9,10627,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL618091,,,B
17687,Autocuration,,1,,,3609,8,10627,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL618092,,,B
6491,Expert,,1,,9606.0,3610,9,10627,,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL618093,,,B
16190,Expert,,1,,,3611,8,10627,HeLa,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,H,308.0,,BAO_0000219,,CHEMBL618094,,,B
17066,Expert,,1,,9606.0,3612,9,10627,,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL618095,,,B
17066,Expert,,1,,9606.0,3613,9,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL875093,,,B
17066,Expert,,1,,9606.0,3614,9,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL618096,,,B
17066,Expert,,1,,9606.0,3615,9,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,D,,Homo sapiens,BAO_0000357,,CHEMBL618118,,,B
3555,Expert,,1,,9606.0,3616,9,10627,,,,Binding affinity against 5-hydroxytryptamine 6 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL618119,,,B
5808,Expert,,1,,,3617,8,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL618120,,,B
6013,Autocuration,,1,,,3618,8,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL618121,,,B
15818,Expert,,1,,,3619,8,10627,HEK293,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,H,722.0,,BAO_0000219,,CHEMBL618122,,,B
16209,Autocuration,,1,,,3620,8,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,H,,,BAO_0000357,,CHEMBL618123,,,B
3935,Expert,,1,,,3621,8,10627,HEK293,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,H,722.0,,BAO_0000219,,CHEMBL618124,,,B
15818,Autocuration,,1,,,3622,8,10627,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL618125,,,B
3805,Expert,,1,,9606.0,3623,9,10627,HEK293,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL618126,,,B
16441,Expert,,1,,,3624,8,10627,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,H,,,BAO_0000019,,CHEMBL618236,,,B
16441,Expert,,1,,,3625,8,10627,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,H,,,BAO_0000019,,CHEMBL618237,,,B
6786,Expert,,1,,,3626,8,10627,COS-7,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,H,643.0,,BAO_0000219,,CHEMBL618238,,,B
4234,Expert,,1,,9606.0,3627,9,10627,,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL618239,,,B
17085,Autocuration,,1,,,3628,8,10627,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000019,,CHEMBL618240,,,B
17200,Autocuration,,1,,,3629,8,10627,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,H,,,BAO_0000357,,CHEMBL618241,,,B
17451,Autocuration,,1,,,3630,8,10627,HEK293,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,H,722.0,,BAO_0000219,,CHEMBL859399,,,B
3935,Autocuration,,1,,,3631,8,10627,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,H,,,BAO_0000019,,CHEMBL618242,,,F
5033,Autocuration,,1,,,3632,8,10627,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL857991,,,B
4540,Expert,,1,,,3633,8,10627,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL619951,,,B
4540,Expert,,1,,9606.0,3634,9,10627,HeLa,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL619952,,,B
4540,Expert,,1,,9606.0,3635,9,10627,HeLa,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL619953,,,B
17296,Autocuration,,1,,,3636,8,10627,HeLa,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,H,308.0,,BAO_0000219,,CHEMBL619954,,,B
17296,Autocuration,,1,,,3637,8,10627,HeLa,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,H,308.0,,BAO_0000219,,CHEMBL619955,,,B
17296,Autocuration,,1,,,3638,8,10627,HeLa,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,H,308.0,,BAO_0000219,,CHEMBL619956,,,B
15779,Autocuration,,1,,,3639,8,10627,CHO,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,H,449.0,,BAO_0000219,,CHEMBL619957,,,B
15779,Autocuration,,1,,,3640,8,10627,HEK293,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL619958,,,B
15779,Autocuration,,1,,,3641,8,10627,HEK293,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,H,722.0,,BAO_0000219,,CHEMBL620627,,,B
15779,Autocuration,,1,,,3642,8,10627,HEK293,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,H,722.0,,BAO_0000219,,CHEMBL620628,,,B
15779,Autocuration,,1,,,3643,8,10627,HeLa,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,H,308.0,,BAO_0000219,,CHEMBL620629,,,B
6166,Autocuration,,1,,,3644,8,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620630,,,B
17451,Autocuration,,1,,,3645,8,10627,HeLa,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,H,308.0,,BAO_0000219,,CHEMBL620782,,,B
15316,Autocuration,,1,,,3646,8,10627,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620783,,,B
4199,Expert,,1,,,3647,8,10627,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620784,,,B
15146,Expert,,1,,,3648,8,10627,HeLa,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,H,308.0,,BAO_0000219,,CHEMBL620785,,,B
5213,Autocuration,,1,,,3649,8,10627,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,H,,,BAO_0000357,,CHEMBL857992,,,B
16429,Autocuration,,1,,,3650,8,10627,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,H,,,BAO_0000219,,CHEMBL620786,,,B
14818,Autocuration,,1,,,3651,8,10627,HeLa,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,H,308.0,,BAO_0000219,,CHEMBL620787,,,B
4829,Autocuration,,1,,,3652,8,10627,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,H,308.0,,BAO_0000219,,CHEMBL620788,,,B
4829,Autocuration,,1,,,3653,8,10627,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,H,308.0,,BAO_0000219,,CHEMBL620789,,,B
4829,Autocuration,,1,,,3654,8,10627,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,H,308.0,,BAO_0000219,,CHEMBL620790,,,B
15250,Autocuration,,1,,,3655,8,10628,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL620791,,,B
14423,Autocuration,,1,,,3656,8,10628,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,H,,,BAO_0000019,,CHEMBL620792,,,B
15086,Autocuration,,1,,,3657,8,10628,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620793,,,B
4342,Autocuration,,1,,,3658,8,10628,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,H,,,BAO_0000357,,CHEMBL620794,,,B
16190,Autocuration,,1,,9606.0,3659,9,10627,HeLa,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,D,308.0,Homo sapiens,BAO_0000219,,CHEMBL620795,,,B
4820,Expert,,1,,,3660,8,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620796,,,B
4639,Autocuration,,1,,,3661,8,10627,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,H,,,BAO_0000357,,CHEMBL620797,,,B
17066,Expert,,1,,9606.0,3662,9,10627,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,D,,Homo sapiens,BAO_0000019,,CHEMBL620798,,,F
6011,Autocuration,,1,,,3663,8,10627,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL620799,,,B
17066,Expert,,1,,,3664,8,10627,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620800,,,B
17515,Autocuration,,1,,,3665,8,10627,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,H,,,BAO_0000357,,CHEMBL620801,,,B
5014,Autocuration,,1,,,3666,8,10627,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL875100,,,B
4373,Autocuration,,1,,,3667,8,10627,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,H,,,BAO_0000357,,CHEMBL620802,,,B
17066,Expert,,1,,,3668,8,10627,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000019,,CHEMBL620803,,,F
17066,Expert,,1,,,3669,8,10627,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,H,,,BAO_0000019,,CHEMBL620804,,,F
4373,Autocuration,,1,,,3670,8,10627,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,H,,,BAO_0000357,,CHEMBL620805,,,B
4687,Autocuration,,1,,,3671,8,10627,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620806,,,B
16946,Autocuration,,1,,,3672,8,10627,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,H,,,BAO_0000357,,CHEMBL620807,,,B
16946,Autocuration,,1,,,3673,8,10627,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,H,,,BAO_0000357,,CHEMBL620808,,,B
16633,Autocuration,,1,,,3674,8,10627,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620809,,,B
16633,Autocuration,,1,,,3675,8,10627,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620810,,,B
17066,Expert,,1,,9606.0,3676,9,10627,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620811,,,B
16700,Autocuration,,1,,,3677,8,10627,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,H,,,BAO_0000357,,CHEMBL620812,,,B
3269,Autocuration,,1,,,3678,8,10627,,,,Affinity against 5-hydroxytryptamine 6 receptor,,H,,,BAO_0000357,,CHEMBL620813,,,B
5486,Autocuration,,1,,,3679,8,10627,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,H,,,BAO_0000357,,CHEMBL620814,,,B
16146,Expert,,1,,9606.0,3680,9,10209,,,,Inhibition of human 5-hydroxytryptamine 7 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620815,,,B
5014,Autocuration,,1,,,3681,8,10209,HEK293,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,H,722.0,,BAO_0000219,,CHEMBL620816,,,B
15463,Autocuration,,1,,,3682,8,10209,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620817,,,B
3805,Autocuration,,1,,,3683,8,10209,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,H,,,BAO_0000357,,CHEMBL620818,,,B
5014,Expert,,1,,,3684,8,10209,HEK293,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,H,722.0,,BAO_0000219,,CHEMBL620819,,,B
6491,Expert,,1,,9606.0,3685,9,10209,,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620820,,,B
16190,Autocuration,,1,,,3686,8,10209,CHO,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,H,449.0,,BAO_0000219,,CHEMBL620821,,,B
17066,Expert,,1,,9606.0,3687,9,10209,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620822,,,B
17066,Expert,,1,,9606.0,3688,9,10209,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620823,,,B
3555,Expert,,1,,9606.0,3689,9,10209,,,,Binding affinity against 5-hydroxytryptamine 7 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL620824,,,B
6588,Expert,,1,,,3690,8,10209,CHO,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL620825,,,B
15463,Autocuration,,1,,,3691,8,10209,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,H,,,BAO_0000357,,CHEMBL872930,,,B
6013,Autocuration,,1,,,3692,8,10209,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620826,,,B
16209,Autocuration,,1,,,3693,8,10209,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL620827,,,B
3935,Autocuration,,1,,,3694,8,10209,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620828,,,B
15818,Autocuration,,1,,,3695,8,10209,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620829,,,B
5014,Expert,,1,,,3696,8,10209,HEK293,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,H,722.0,,BAO_0000219,,CHEMBL620830,,,B
16441,Expert,,1,,,3697,8,10209,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,H,,,BAO_0000019,,CHEMBL620831,,,B
16441,Expert,,1,,,3698,8,10209,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,H,,,BAO_0000019,,CHEMBL620832,,,B
4234,Expert,,1,,9606.0,3699,9,10209,,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL621548,,,B
17085,Autocuration,,1,,,3700,8,10209,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000019,,CHEMBL621549,,,B
17200,Autocuration,,1,,,3701,8,10209,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,H,,,BAO_0000357,,CHEMBL621550,,,B
17451,Autocuration,,1,,,3702,8,10209,CHO,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,H,449.0,,BAO_0000219,,CHEMBL621551,,,B
17085,Autocuration,,1,,,3703,8,10209,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,H,,,BAO_0000019,,CHEMBL621552,,,B
5104,Autocuration,,1,,,3704,8,10209,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL857077,,,B
5104,Autocuration,,1,,,3705,8,10209,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,H,,,BAO_0000357,,CHEMBL618158,,,B
5033,Expert,,1,,9606.0,3706,9,10209,COS-7,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,D,643.0,Homo sapiens,BAO_0000219,,CHEMBL618159,,,B
5486,Autocuration,,1,,,3707,8,10209,COS-7,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,H,643.0,,BAO_0000219,,CHEMBL875101,,,B
4540,Expert,,1,,9606.0,3708,9,10209,HEK293,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL618160,,,B
6166,Expert,,1,,,3709,8,10209,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,H,,,BAO_0000357,,CHEMBL618161,,,B
17342,Expert,,1,,,3710,8,10209,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,H,722.0,,BAO_0000219,,CHEMBL618162,,,B
17342,Expert,,1,,,3711,8,10209,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,H,,,BAO_0000357,,CHEMBL618163,,,B
17296,Autocuration,,1,,,3712,8,10209,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,H,,,BAO_0000357,,CHEMBL618164,,,B
16429,Expert,,1,,,3713,8,10209,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,H,,,BAO_0000219,,CHEMBL618165,,,B
15779,Autocuration,,1,,,3714,8,10209,HEK293,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL618166,,,B
15779,Autocuration,,1,,,3715,8,10209,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL857989,,,B
15779,Autocuration,,1,,,3716,8,10209,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL619888,,,B
15779,Autocuration,,1,,,3717,8,10209,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL619889,,,B
15779,Autocuration,,1,,,3718,8,10209,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,H,722.0,,BAO_0000219,,CHEMBL619890,,,B
17451,Autocuration,,1,,,3719,8,10209,CHO,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,H,449.0,,BAO_0000219,,CHEMBL619891,,,B
4199,Autocuration,,1,,,3720,8,10209,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,H,722.0,,BAO_0000219,,CHEMBL619892,,,B
4199,Expert,,1,,,3721,9,10209,HEK293,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,D,722.0,,BAO_0000219,,CHEMBL619893,,,B
4199,Autocuration,,1,,,3722,8,10209,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,H,722.0,,BAO_0000219,,CHEMBL619894,,,B
3680,Intermediate,,1,,,3723,9,10209,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,D,722.0,,BAO_0000219,,CHEMBL619895,,,B
3680,Intermediate,,1,,,3724,9,10209,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,D,,,BAO_0000357,,CHEMBL619896,,,B
15316,Autocuration,,1,,,3725,8,10209,COS-7,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,H,643.0,,BAO_0000219,,CHEMBL619897,,,B
15146,Autocuration,,1,,,3726,8,10209,HEK293,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,H,722.0,,BAO_0000219,,CHEMBL619898,,,B
5213,Expert,,1,,,3727,8,10209,HEK293,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,H,722.0,,BAO_0000219,,CHEMBL619899,,,B
5213,Autocuration,,1,,,3728,8,10209,HEK293,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,H,722.0,,BAO_0000219,,CHEMBL619900,,,B
14818,Expert,,1,,9606.0,3729,9,10209,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL619901,,,B
14818,Autocuration,,1,,,3730,8,10209,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,H,722.0,,BAO_0000219,,CHEMBL620580,,,B
14818,Autocuration,,1,,,3731,8,10209,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,H,722.0,,BAO_0000219,,CHEMBL620581,,,B
4829,Autocuration,,1,,,3732,8,10209,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,H,722.0,,BAO_0000219,,CHEMBL620733,,,B
17200,Autocuration,,1,,9606.0,3733,9,10209,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,D,,Homo sapiens,BAO_0000357,,CHEMBL620734,,,B
17066,Expert,,1,,10090.0,3734,9,10022,,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,D,,Mus musculus,BAO_0000357,,CHEMBL620735,,,B
14025,Autocuration,,1,,9986.0,3735,8,10209,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL620736,,,B
15250,Autocuration,,1,,,3736,8,11923,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,H,449.0,,BAO_0000219,,CHEMBL620737,,,B
16372,Autocuration,,1,,,3737,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,H,449.0,,BAO_0000219,,CHEMBL620738,,,B
16372,Autocuration,,1,,,3738,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,H,449.0,,BAO_0000219,,CHEMBL620739,,,B
16372,Autocuration,,1,,,3739,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,H,449.0,,BAO_0000219,,CHEMBL620740,,,B
16372,Autocuration,,1,,,3740,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,H,449.0,,BAO_0000219,,CHEMBL620741,,,B
16372,Autocuration,,1,,,3741,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,H,449.0,,BAO_0000219,,CHEMBL620742,,,B
16372,Autocuration,,1,,,3742,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,H,449.0,,BAO_0000219,,CHEMBL620743,,,B
16372,Autocuration,,1,,,3743,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,H,449.0,,BAO_0000219,,CHEMBL620744,,,B
16372,Autocuration,,1,,,3744,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,H,449.0,,BAO_0000219,,CHEMBL620745,,,B
16372,Autocuration,,1,,,3745,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,H,449.0,,BAO_0000219,,CHEMBL620746,,,B
16372,Autocuration,,1,,,3746,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,H,449.0,,BAO_0000219,,CHEMBL620747,,,B
16372,Autocuration,,1,,,3747,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,H,449.0,,BAO_0000219,,CHEMBL620748,,,B
16372,Autocuration,,1,,,3748,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,H,449.0,,BAO_0000219,,CHEMBL620749,,,B
17066,Expert,,1,,,3749,8,11923,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620750,,,B
17066,Expert,,1,,10116.0,3750,9,11923,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL620751,,,B
17386,Expert,,1,,,3751,8,11923,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620752,,,B
14423,Autocuration,,1,,,3752,8,11923,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,H,,,BAO_0000019,,CHEMBL872929,,,B
15874,Expert,,1,,10116.0,3753,9,11923,,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL620753,,,B
15874,Expert,,1,,10116.0,3754,9,11923,,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL620754,,,B
16372,Expert,,1,,10116.0,3755,9,11923,CHO,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,D,449.0,Rattus norvegicus,BAO_0000219,,CHEMBL620755,,,B
4622,Autocuration,,1,,,3756,8,11923,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL620756,,,B
15086,Autocuration,,1,,,3757,8,11923,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL620757,,,B
16372,Autocuration,,1,,,3758,8,11923,CHO,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,H,449.0,,BAO_0000219,,CHEMBL620758,,,B
16372,Autocuration,,1,,,3759,8,11923,CHO,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,H,449.0,,BAO_0000219,,CHEMBL620759,,,B
16372,Autocuration,,1,,,3760,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,H,449.0,,BAO_0000219,,CHEMBL620760,,,B
16372,Autocuration,,1,,,3761,8,11923,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,H,449.0,,BAO_0000219,,CHEMBL620761,,,B
17386,Autocuration,,1,,,3762,8,11923,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,H,,,BAO_0000221,2116.0,CHEMBL620762,,,F
17386,Autocuration,,1,,,3763,8,11923,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,H,,,BAO_0000221,2116.0,CHEMBL620763,,,F
17386,Autocuration,,1,,,3764,8,11923,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,H,,,BAO_0000221,2116.0,CHEMBL620764,,,F
5831,Expert,,1,,10116.0,3765,9,11923,,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL857990,,Membranes,B
4342,Autocuration,,1,,,3766,8,11923,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,H,,,BAO_0000357,,CHEMBL620765,,,B
17319,Expert,,1,,,3767,8,11923,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,H,,,BAO_0000357,,CHEMBL620766,,,B
17342,Expert,,1,,,3768,8,11923,,,Hypothalamus,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,H,,,BAO_0000019,1898.0,CHEMBL620767,,,B
17342,Autocuration,,1,,,3769,8,11923,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,H,,,BAO_0000357,,CHEMBL620768,,,B
3680,Expert,,1,,,3770,8,11923,,,Hypothalamus,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,H,,,BAO_0000249,1898.0,CHEMBL619051,,,B
3680,Expert,,1,,,3771,8,11923,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619052,,,B
17319,Expert,,1,,10116.0,3772,9,11923,HEK293,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,D,722.0,Rattus norvegicus,BAO_0000219,,CHEMBL619053,,,F
17319,Expert,,1,,10116.0,3773,9,11923,HEK293,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,D,722.0,Rattus norvegicus,BAO_0000219,,CHEMBL619703,,,F
17319,Autocuration,,1,,10116.0,3774,9,11923,HEK293,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,D,722.0,Rattus norvegicus,BAO_0000219,,CHEMBL619704,,,F
4820,Expert,,1,,,3775,8,10209,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619851,,,B
4639,Autocuration,,1,,,3776,8,10209,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,H,,,BAO_0000357,,CHEMBL619852,,,B
6011,Autocuration,,1,,,3777,8,10209,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,H,,,BAO_0000357,,CHEMBL619853,,,B
17066,Expert,,1,,9606.0,3778,9,10209,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,D,,Homo sapiens,BAO_0000357,,CHEMBL619854,,,B
17066,Expert,,1,,,3779,8,10209,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619855,,,B
17515,Autocuration,,1,,,3780,8,10209,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,H,,,BAO_0000357,,CHEMBL619856,,,B
4373,Autocuration,,1,,,3781,8,10209,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,H,,,BAO_0000357,,CHEMBL619857,,,B
17066,Expert,,1,,,3782,8,10209,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,H,,,BAO_0000019,,CHEMBL619858,,,F
4373,Autocuration,,1,,,3783,8,10209,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,H,,,BAO_0000357,,CHEMBL619859,,,B
4373,Autocuration,,1,,,3784,8,10209,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,H,,,BAO_0000357,,CHEMBL619860,,,B
4687,Autocuration,,1,,,3785,8,10209,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619861,,,B
17342,Expert,,1,,,3786,8,10209,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619862,,,B
16946,Autocuration,,1,,,3787,8,10209,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,H,,,BAO_0000357,,CHEMBL619863,,,B
16946,Autocuration,,1,,,3788,8,10209,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,H,,,BAO_0000357,,CHEMBL619864,,,B
16633,Autocuration,,1,,,3789,8,10209,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL872928,,,B
16633,Autocuration,,1,,,3790,8,10209,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619865,,,B
17066,Expert,,1,,,3791,8,10209,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,H,,,BAO_0000357,,CHEMBL619866,,,B
16700,Autocuration,,1,,,3792,8,10209,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,H,,,BAO_0000357,,CHEMBL619867,,,B
17386,Autocuration,,1,,,3793,8,10209,,,Ileum,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,H,,,BAO_0000221,2116.0,CHEMBL619868,,,B
14080,Autocuration,,1,,,3794,8,55,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,H,,,BAO_0000019,,CHEMBL619869,,,F
14080,Expert,,1,,9606.0,3795,9,55,,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,D,,Homo sapiens,BAO_0000019,,CHEMBL619870,,,F
409,Autocuration,,1,,,3796,8,55,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,H,,,BAO_0000357,,CHEMBL619871,,,B
409,Autocuration,,1,,,3797,8,55,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,,H,,,BAO_0000357,,CHEMBL619872,,,B
409,Autocuration,,1,,,3798,8,55,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,H,,,BAO_0000357,,CHEMBL619873,,,B
11090,Expert,,1,,,3799,8,55,,,Blood,Inhibition of 5-lipoxygenase in human whole blood.,,H,,,BAO_0000357,178.0,CHEMBL619874,,,B
11090,Expert,,1,,,3800,8,55,,,Blood,Inhibition of 5-lipoxygenase in human whole blood.,,H,,,BAO_0000357,178.0,CHEMBL619875,,,B
948,Autocuration,,1,,,3801,8,55,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,H,,,BAO_0000357,,CHEMBL619876,,,B
948,Autocuration,,1,,,3802,8,55,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,H,,,BAO_0000357,,CHEMBL619877,,,B
13622,Expert,,1,,,3803,8,55,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,H,,,BAO_0000219,,CHEMBL619878,,,F
13622,Autocuration,,1,,,3804,8,55,,,Blood,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,H,,,BAO_0000019,178.0,CHEMBL619879,,,F
9637,Autocuration,,1,,,3805,8,55,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,H,,,BAO_0000357,,CHEMBL619880,,,B
11320,Autocuration,,1,,,3806,8,55,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,H,,,BAO_0000357,,CHEMBL619881,,,B
11320,Expert,,1,,,3807,8,55,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619882,,,B
6838,Autocuration,,1,,,3808,8,55,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,H,,,BAO_0000357,,CHEMBL619883,,,B
17667,Expert,,1,,9606.0,3809,9,55,,,Blood,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,D,,Homo sapiens,BAO_0000357,178.0,CHEMBL619884,,,B
12703,Autocuration,,1,,,3810,8,55,,,,In vitro potency against human 5-Lipoxygenase,,H,,,BAO_0000357,,CHEMBL619885,,,B
14312,Expert,,1,,9606.0,3811,9,55,,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,D,,Homo sapiens,BAO_0000019,,CHEMBL619886,,,F
14312,Autocuration,,1,,,3812,8,55,,,Blood,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,H,,,BAO_0000019,178.0,CHEMBL619887,,,F
5364,Autocuration,,1,,,3813,8,55,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,H,,,BAO_0000019,,CHEMBL875097,,,F
951,Autocuration,,1,,,3814,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,H,,,BAO_0000219,,CHEMBL618001,,,B
951,Autocuration,,1,,,3815,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,H,,,BAO_0000219,,CHEMBL618002,,,B
951,Autocuration,,1,,,3816,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,H,,,BAO_0000219,,CHEMBL618003,,,B
951,Autocuration,,1,,,3817,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,H,,,BAO_0000219,,CHEMBL618004,,,B
12365,Autocuration,,1,,,3818,8,55,,,,Inhibition of human 5-lipoxygenase in human cells,,H,,,BAO_0000219,,CHEMBL618005,,,B
10603,Expert,,1,,,3819,8,55,,,,Inhibition of human neutrophil 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618006,,,B
10501,Autocuration,,1,,,3820,8,55,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,H,,,BAO_0000019,,CHEMBL875086,,,B
12281,Expert,,1,,,3821,8,55,,,Blood,Inhibition of 5-lipoxygenase from human whole blood,,H,,,BAO_0000357,178.0,CHEMBL618007,,,B
2567,Autocuration,,1,,,3822,8,55,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,H,,,BAO_0000357,,CHEMBL618008,,,B
2567,Autocuration,,1,,,3823,8,55,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,H,,,BAO_0000219,,CHEMBL618009,,,B
10193,Expert,,1,,,3824,8,55,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618010,,,B
10193,Autocuration,,1,,,3825,8,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,H,,,BAO_0000357,,CHEMBL618011,,,B
13623,Expert,,1,,,3826,8,55,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618012,,,B
12780,Autocuration,,1,,,3827,8,55,,,,Tested against 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL882927,,,B
12780,Autocuration,,1,,,3828,8,55,,,,Tested for activity against 5-Lipoxygenase (5-LO),,H,,,BAO_0000357,,CHEMBL618013,,,B
12780,Autocuration,,1,,,3829,8,55,,,,Tested for activity against 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618014,,,B
11966,Autocuration,,1,,,3830,8,55,,,,Tested for inhibition of 5-HPETE production by human 5-LO,,H,,,BAO_0000357,,CHEMBL618015,,,B
5364,Autocuration,,1,,,3831,8,55,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,H,,,BAO_0000019,,CHEMBL618016,,,F
13165,Expert,,1,,,3832,8,55,,,,Inhibition of Human 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618017,,,B
5364,Autocuration,,1,,,3833,8,55,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,H,,,BAO_0000019,,CHEMBL618018,,,B
11311,Autocuration,,1,,,3834,8,55,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000219,,CHEMBL875087,,,B
11311,Autocuration,,1,,,3835,8,55,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000219,,CHEMBL618019,,,B
14863,Autocuration,,1,,,3836,8,55,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,H,,,BAO_0000019,,CHEMBL618020,,,B
14863,Autocuration,,1,,,3837,8,55,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,H,,,BAO_0000019,,CHEMBL618021,,,B
11087,Autocuration,,1,,,3838,8,55,,,Blood,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,H,,,BAO_0000357,178.0,CHEMBL618022,,,B
455,Autocuration,,1,,,3839,8,55,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,H,,,BAO_0000357,,CHEMBL618023,,,B
13183,Autocuration,,1,,,3840,8,55,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,H,,,BAO_0000357,,CHEMBL618024,,,B
10319,Expert,,1,,,3841,8,55,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,H,,,BAO_0000019,,CHEMBL873950,,,B
10193,Autocuration,,1,,,3842,8,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,H,,,BAO_0000357,,CHEMBL618025,,,B
951,Autocuration,,1,,,3843,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,H,,,BAO_0000219,,CHEMBL618026,,,B
951,Autocuration,,1,,,3844,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,H,,,BAO_0000219,,CHEMBL618027,,,B
951,Autocuration,,1,,,3845,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,H,,,BAO_0000219,,CHEMBL618028,,,B
951,Autocuration,,1,,,3846,8,55,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,H,,,BAO_0000219,,CHEMBL618029,,,B
9859,Expert,,1,,,3847,8,55,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,H,,,BAO_0000357,,CHEMBL618030,,,B
9859,Expert,,1,,,3848,8,55,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,H,,,BAO_0000357,,CHEMBL618031,,,B
9859,Autocuration,,1,,,3849,8,55,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,H,,,BAO_0000357,,CHEMBL618032,,,B
2567,Autocuration,,1,,,3850,8,55,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,H,,,BAO_0000357,,CHEMBL618033,,,B
10193,Autocuration,,1,,,3851,8,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,H,,,BAO_0000357,,CHEMBL618034,,,B
10193,Autocuration,,1,,,3852,8,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,H,,,BAO_0000357,,CHEMBL875088,,,B
949,Autocuration,,1,,,3853,8,55,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,H,,,BAO_0000019,,CHEMBL618035,,,B
949,Autocuration,,1,,,3854,8,55,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,H,,,BAO_0000019,,CHEMBL618036,,,B
10603,Expert,,1,,,3855,8,55,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,H,,,BAO_0000357,,CHEMBL618037,,,B
10603,Expert,,1,,,3856,8,55,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,H,,,BAO_0000357,,CHEMBL618038,,,B
10603,Autocuration,,1,,,3857,8,55,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,H,,,BAO_0000019,,CHEMBL618761,,,F
10603,Expert,,1,,,3858,8,55,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,H,,,BAO_0000357,,CHEMBL618762,,,B
10603,Expert,,1,,,3859,8,55,,,,Inhibition of lipoxygenase at the concentration of 1 uM,,H,,,BAO_0000357,,CHEMBL618763,,,B
10193,Autocuration,,1,,,3860,8,55,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,H,,,BAO_0000357,,CHEMBL618764,,,B
14580,Expert,,1,,9606.0,3861,9,55,,,,Inhibition of 5-Lipoxygenase (5-LOX),,D,,Homo sapiens,BAO_0000357,,CHEMBL618765,,,B
11090,Expert,,1,,,3862,8,17087,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,H,,,BAO_0000357,,CHEMBL618766,,,B
11090,Expert,,1,,,3863,8,17087,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,H,,,BAO_0000357,,CHEMBL618767,,,B
6339,Autocuration,,1,,,3864,8,17087,,,,Inhibitory activity against lipoxygenase-2 in mice,,H,,,BAO_0000357,,CHEMBL619380,,,B
6339,Expert,,1,,,3865,8,17087,,,,Inhibitory activity against murine lipoxygenase-2.,,H,,,BAO_0000357,,CHEMBL619381,,,B
12281,Expert,,1,,10090.0,3866,9,17087,,,,Inhibition of 5-lipoxygenase from mouse macrophage,,D,,Mus musculus,BAO_0000357,,CHEMBL619382,,,B
11311,Autocuration,,1,,,3867,8,17087,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,H,,,BAO_0000357,,CHEMBL619383,,,B
11089,Autocuration,,1,,9823.0,3868,8,55,,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,H,,Sus scrofa,BAO_0000019,,CHEMBL619384,,,B
10091,Autocuration,,1,,9823.0,3869,8,55,,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,H,,Sus scrofa,BAO_0000019,,CHEMBL619385,,,B
14352,Autocuration,,1,,9986.0,3870,8,55,,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,H,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL882928,,,B
13329,Expert,,1,,10116.0,3871,9,12166,,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619386,,,B
13329,Autocuration,,1,,,3872,8,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,H,,,BAO_0000019,,CHEMBL619387,,,B
13329,Autocuration,,1,,,3873,8,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,H,,,BAO_0000019,,CHEMBL619388,,,B
13329,Autocuration,,1,,,3874,8,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,H,,,BAO_0000019,,CHEMBL619389,,,B
13329,Expert,,1,,,3875,8,12166,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,H,,,BAO_0000019,,CHEMBL619390,,,B
13329,Expert,,1,,,3876,8,12166,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,H,,,BAO_0000019,,CHEMBL619391,,,B
13329,Autocuration,,1,,,3877,8,12166,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,H,,,BAO_0000019,,CHEMBL619392,,,B
11311,Autocuration,,1,,,3878,8,12166,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,H,,,BAO_0000019,,CHEMBL619393,,,B
11311,Autocuration,,1,,,3879,8,12166,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,H,,,BAO_0000019,,CHEMBL619394,,,B
105,Autocuration,,1,,,3880,8,12166,RBL-1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,H,702.0,,BAO_0000219,,CHEMBL619395,,,B
105,Autocuration,,1,,,3881,8,12166,RBL-1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,H,702.0,,BAO_0000219,,CHEMBL619396,,,B
9138,Autocuration,,1,,,3882,8,12166,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,H,,,BAO_0000357,,CHEMBL619397,,,B
9138,Autocuration,,1,,,3883,8,12166,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,H,,,BAO_0000357,,CHEMBL619398,,,B
9138,Autocuration,,1,,,3884,8,12166,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,H,,,BAO_0000357,,CHEMBL619399,,,B
14427,Autocuration,,1,,,3885,8,12166,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,H,,,BAO_0000357,,CHEMBL619400,,,B
13329,Autocuration,,1,,,3886,8,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,H,,,BAO_0000019,,CHEMBL619401,,,B
13329,Autocuration,,1,,,3887,8,12166,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,H,,,BAO_0000019,,CHEMBL619402,,,B
14427,Expert,,1,,10116.0,3888,9,12166,RBL-2H3,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,D,663.0,Rattus norvegicus,BAO_0000219,,CHEMBL619403,,,B
14427,Autocuration,,1,,,3889,8,12166,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,H,,,BAO_0000357,,CHEMBL619404,,,B
14427,Autocuration,,1,,,3890,8,12166,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,H,,,BAO_0000357,,CHEMBL619405,,,B
10293,Expert,,1,,,3891,8,12166,RBL-1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,H,702.0,,BAO_0000219,,CHEMBL619406,,,B
338,Expert,,1,,10116.0,3892,9,12166,RBL-1,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL619407,,,B
303,Autocuration,,1,,,3893,8,12166,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,H,,,BAO_0000357,,CHEMBL619408,,,B
303,Autocuration,,1,,,3894,8,12166,RBL-1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,H,702.0,,BAO_0000219,,CHEMBL619409,,,B
9247,Expert,,1,,,3895,8,12166,RBL-1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,H,702.0,,BAO_0000219,,CHEMBL619410,,,B
9247,Autocuration,,1,,,3896,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,H,702.0,,BAO_0000219,,CHEMBL619753,,,B
137,Autocuration,,1,,,3897,8,12166,RBL-1,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,H,702.0,,BAO_0000219,,CHEMBL619754,,,B
11481,Expert,,1,,,3898,8,12166,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619903,,,B
11481,Expert,,1,,,3899,8,12166,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,H,,,BAO_0000357,,CHEMBL619904,,,B
9029,Expert,,1,,,3900,8,12166,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,H,,,BAO_0000357,,CHEMBL619905,,,B
1701,Autocuration,,1,,,3901,8,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,H,,,BAO_0000019,,CHEMBL619906,,,B
1701,Autocuration,,1,,,3902,8,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,H,,,BAO_0000019,,CHEMBL619907,,,B
1701,Autocuration,,1,,,3903,8,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,H,,,BAO_0000019,,CHEMBL619908,,,B
1701,Autocuration,,1,,,3904,8,12166,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,H,,,BAO_0000019,,CHEMBL619909,,,B
13358,Expert,,1,,,3905,8,12166,RBL-1,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,H,702.0,,BAO_0000219,,CHEMBL619910,,,F
1175,Expert,,1,,,3906,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL882929,,,B
8797,Expert,,1,,,3907,8,12166,RBL-1,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,H,702.0,,BAO_0000219,,CHEMBL619911,,,B
8797,Autocuration,,1,,,3908,8,12166,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,H,,,BAO_0000019,,CHEMBL619912,,,B
577,Expert,,1,,10116.0,3909,9,12166,,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL619913,,,B
9295,Expert,,1,,,3910,8,12166,RBL-1,,,In vitro inhibitory activity against RBL-1 5-LO,,H,702.0,,BAO_0000219,,CHEMBL619914,,,B
9295,Autocuration,,1,,,3911,8,12166,RBL-1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,H,702.0,,BAO_0000219,,CHEMBL619915,,,B
9295,Autocuration,,1,,,3912,8,12166,RBL-1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,H,702.0,,BAO_0000219,,CHEMBL619916,,,B
9295,Autocuration,,1,,,3913,8,12166,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,H,,,BAO_0000218,,CHEMBL619917,,,B
9295,Autocuration,,1,,,3914,8,12166,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,H,,,BAO_0000357,,CHEMBL619918,,,B
216,Autocuration,,1,,,3915,8,12166,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,H,,,BAO_0000218,,CHEMBL619919,,,B
11090,Autocuration,,1,,,3916,8,12166,RBL-1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,H,702.0,,BAO_0000219,,CHEMBL883710,,,B
11090,Autocuration,,1,,,3917,8,12166,,,Blood,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,H,,,BAO_0000019,178.0,CHEMBL619920,,,B
10091,Expert,,1,,,3918,8,12166,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619921,,,B
10274,Autocuration,,1,,,3919,8,12166,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,H,,,BAO_0000019,,CHEMBL619922,,,F
13622,Autocuration,,1,,,3920,8,12166,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,H,,,BAO_0000219,,CHEMBL619923,,,F
12118,Expert,,1,,,3921,8,12166,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,H,702.0,,BAO_0000219,,CHEMBL619924,,,B
12576,Expert,,1,,,3922,8,12166,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,H,,,BAO_0000357,,CHEMBL619925,,,B
9546,Expert,,1,,,3923,8,12166,RBL-1,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL619926,,,B
9521,Autocuration,,1,,,3924,8,12166,RBL-1,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL619927,,,B
10626,Expert,,1,,,3925,8,12166,RBL-1,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,H,702.0,,BAO_0000219,,CHEMBL619928,,,B
9225,Autocuration,,1,,,3926,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase,,H,702.0,,BAO_0000219,,CHEMBL619929,,,B
9225,Autocuration,,1,,,3927,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,H,702.0,,BAO_0000219,,CHEMBL875089,,,B
9225,Autocuration,,1,,,3928,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,H,702.0,,BAO_0000219,,CHEMBL619930,,,B
9225,Autocuration,,1,,,3929,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,H,702.0,,BAO_0000219,,CHEMBL619931,,,B
9225,Autocuration,,1,,,3930,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,H,702.0,,BAO_0000219,,CHEMBL619932,,,B
9225,Autocuration,,1,,,3931,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,H,702.0,,BAO_0000219,,CHEMBL619933,,,B
9225,Autocuration,,1,,,3932,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,H,702.0,,BAO_0000219,,CHEMBL619934,,,B
9225,Autocuration,,1,,,3933,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,H,702.0,,BAO_0000219,,CHEMBL619935,,,B
9225,Autocuration,,1,,,3934,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,H,702.0,,BAO_0000219,,CHEMBL619936,,,B
9225,Autocuration,,1,,,3935,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,H,702.0,,BAO_0000219,,CHEMBL619937,,,B
9225,Autocuration,,1,,,3936,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,H,702.0,,BAO_0000219,,CHEMBL619938,,,B
9225,Autocuration,,1,,,3937,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,H,702.0,,BAO_0000219,,CHEMBL619939,,,B
9225,Autocuration,,1,,,3938,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,H,702.0,,BAO_0000219,,CHEMBL619940,,,B
9225,Autocuration,,1,,,3939,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,H,702.0,,BAO_0000219,,CHEMBL875090,,,B
9225,Autocuration,,1,,,3940,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,H,702.0,,BAO_0000219,,CHEMBL619941,,,B
9225,Autocuration,,1,,,3941,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,H,702.0,,BAO_0000219,,CHEMBL619942,,,B
9225,Autocuration,,1,,,3942,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,H,702.0,,BAO_0000219,,CHEMBL883711,,,B
9225,Autocuration,,1,,,3943,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,H,702.0,,BAO_0000219,,CHEMBL619943,,,B
9225,Autocuration,,1,,,3944,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,H,702.0,,BAO_0000219,,CHEMBL619944,,,B
9225,Autocuration,,1,,,3945,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,H,702.0,,BAO_0000219,,CHEMBL619945,,,B
9225,Autocuration,,1,,,3946,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,H,702.0,,BAO_0000219,,CHEMBL619946,,,B
9225,Autocuration,,1,,,3947,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,H,702.0,,BAO_0000219,,CHEMBL619947,,,B
9225,Autocuration,,1,,,3948,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,H,702.0,,BAO_0000219,,CHEMBL619948,,,B
9225,Autocuration,,1,,,3949,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,H,702.0,,BAO_0000219,,CHEMBL619949,,,B
9401,Expert,,1,,,3950,8,12166,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,H,,,BAO_0000019,,CHEMBL619950,,,B
10325,Autocuration,,1,,,3951,8,12166,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,H,,,BAO_0000019,,CHEMBL618050,,,B
1556,Expert,,1,,,3952,8,12166,RBL-2H3,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,H,663.0,,BAO_0000219,,CHEMBL875091,,,F
1556,Expert,,1,,,3953,8,12166,RBL-2H3,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,H,663.0,,BAO_0000219,,CHEMBL618051,,,F
961,Expert,,1,,10116.0,3954,9,12166,RBL-1,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL618052,,,B
6838,Autocuration,,1,,,3955,8,12166,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,H,,,BAO_0000019,,CHEMBL618053,,,B
10325,Expert,,1,,,3956,8,12166,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,H,,,BAO_0000019,,CHEMBL618054,,,B
9209,Expert,,1,,10116.0,3957,9,12166,RBL-1,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL618055,,,B
11520,Expert,,1,,,3958,8,12166,RBL-1,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,H,702.0,,BAO_0000219,,CHEMBL618056,,,B
137,Autocuration,,1,,,3959,8,12166,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,,H,,,BAO_0000357,,CHEMBL618057,,,B
4717,Autocuration,,1,,,3960,8,12166,RBL-1,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL618058,,,B
10636,Expert,,1,,,3961,8,12166,RBL-1,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,H,702.0,,BAO_0000219,,CHEMBL618059,,,B
14312,Expert,,1,,10116.0,3962,9,12166,,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL618060,,,F
1203,Autocuration,,1,,,3963,8,12166,RBL-1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,H,702.0,,BAO_0000219,,CHEMBL618061,,,B
1203,Autocuration,,1,,,3964,8,12166,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,H,,,BAO_0000019,,CHEMBL618062,,,B
13622,Expert,,1,,,3965,8,12166,RBL-1,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,H,702.0,,BAO_0000219,,CHEMBL618063,,,B
9793,Autocuration,,1,,,3966,8,12166,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,H,,,BAO_0000357,,CHEMBL618064,,,B
1143,Expert,,1,,10116.0,3967,9,12166,RBL-1,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL618065,,,B
11854,Expert,,1,,10116.0,3968,9,12166,RBL-1,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL618066,,,B
3595,Autocuration,,1,,,3969,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,H,702.0,,BAO_0000219,,CHEMBL618067,,,B
3595,Autocuration,,1,,,3970,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,H,702.0,,BAO_0000219,,CHEMBL618068,,,B
10501,Expert,,1,,10116.0,3971,9,12166,RBL-1,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL618069,,,B
12526,Expert,,1,,,3972,8,12166,RBL-1,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,702.0,,BAO_0000219,,CHEMBL618070,,,B
10034,Autocuration,,1,,,3973,8,10825,,,Limbic system,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL618071,,,F
10034,Autocuration,,1,,,3974,8,10825,,,Limbic system,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,H,,,BAO_0000019,349.0,CHEMBL619247,,,F
10034,Autocuration,,1,,,3975,8,10825,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,H,,,BAO_0000019,,CHEMBL619248,,,F
10046,Autocuration,,1,,,3976,8,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,H,,,BAO_0000221,10000000.0,CHEMBL619249,,,B
10046,Autocuration,,1,,,3977,8,10576,,,Hippocampus,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,H,,,BAO_0000221,10000000.0,CHEMBL619250,,,B
10046,Autocuration,,1,,,3978,8,10577,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,H,,,BAO_0000019,,CHEMBL619251,,,B
12079,Autocuration,,1,,9615.0,3979,8,55,,,Blood,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,H,,Canis lupus familiaris,BAO_0000019,178.0,CHEMBL619252,,,F
12079,Autocuration,,1,,,3980,8,55,,,Blood,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,H,,,BAO_0000019,178.0,CHEMBL619253,,,F
11311,Autocuration,,1,,,3981,8,12166,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000219,,CHEMBL619254,,,B
12338,Expert,,1,,,3982,8,17140,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,H,,,BAO_0000219,,CHEMBL619255,,,B
12143,Expert,,1,,,3983,8,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,H,,,BAO_0000219,,CHEMBL619256,,,B
12143,Autocuration,,1,,,3984,8,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,H,,,BAO_0000219,,CHEMBL875418,,,B
12143,Expert,,1,,,3985,8,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,H,,,BAO_0000219,,CHEMBL619257,,,B
12143,Autocuration,,1,,,3986,8,17140,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,H,,,BAO_0000219,,CHEMBL619258,,,B
12365,Expert,,1,,,3987,8,17140,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,H,,,BAO_0000357,,CHEMBL619259,,,B
13500,Expert,,1,,,3988,8,17140,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,H,,,BAO_0000357,,CHEMBL619260,,,B
12832,Autocuration,,1,,9615.0,3989,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619261,,,F
12832,Autocuration,,1,,9615.0,3990,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619263,,,F
12832,Autocuration,,1,,9615.0,3991,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619264,,,F
12832,Autocuration,,1,,9615.0,3992,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619265,,,F
12832,Autocuration,,1,,9615.0,3993,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619266,,,F
12832,Autocuration,,1,,9615.0,3994,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619902,,,F
12832,Autocuration,,1,,9615.0,3995,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620058,,,F
12832,Autocuration,,1,,9615.0,3996,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620059,,,F
12832,Autocuration,,1,,9615.0,3997,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620060,,,F
12832,Autocuration,,1,,9615.0,3998,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620061,,,F
12832,Autocuration,,1,,9615.0,3999,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620062,,,F
12832,Autocuration,,1,,9615.0,4000,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620063,,,F
12832,Autocuration,,1,,9615.0,4001,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620064,,,F
12832,Autocuration,,1,,9615.0,4002,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620065,,,F
12832,Autocuration,,1,,9615.0,4003,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620066,,,F
12832,Autocuration,,1,,9615.0,4004,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620067,,,F
12832,Autocuration,,1,,9615.0,4005,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620068,,,F
12832,Autocuration,,1,,9615.0,4006,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620069,,,F
12832,Autocuration,,1,,9615.0,4007,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620070,,,F
12832,Autocuration,,1,,9615.0,4008,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620071,,,F
12832,Autocuration,,1,,9615.0,4009,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620072,,,F
12832,Autocuration,,1,,9615.0,4010,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620036,,,F
12832,Autocuration,,1,,9615.0,4011,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL857702,,,F
12832,Autocuration,,1,,9615.0,4012,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620037,,,F
12832,Autocuration,,1,,9615.0,4013,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620038,,,F
12832,Autocuration,,1,,9615.0,4014,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620039,,,F
12832,Autocuration,,1,,9615.0,4015,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620040,,,F
12832,Autocuration,,1,,9615.0,4016,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620041,,,F
12832,Autocuration,,1,,9615.0,4017,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620042,,,F
12832,Autocuration,,1,,9615.0,4018,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620043,,,F
12832,Autocuration,,1,,9615.0,4019,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620044,,,F
12832,Autocuration,,1,,9615.0,4020,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620045,,,F
12832,Autocuration,,1,,9615.0,4021,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620046,,,F
12832,Autocuration,,1,,9615.0,4022,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620047,,,F
12832,Autocuration,,1,,9615.0,4023,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620048,,,F
12832,Autocuration,,1,,9615.0,4024,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL857703,,,F
12832,Autocuration,,1,,9615.0,4025,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620049,,,F
12832,Autocuration,,1,,9615.0,4026,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620050,,,F
12832,Autocuration,,1,,9615.0,4027,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL620051,,,F
12832,Autocuration,,1,,9615.0,4028,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619213,,,F
12832,Autocuration,,1,,9615.0,4029,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619214,,,F
12832,Autocuration,,1,,9615.0,4030,8,55,,In vivo,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619804,,,F
12832,Autocuration,,1,,9615.0,4031,8,55,,In vivo,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619805,,,F
12832,Autocuration,,1,,9615.0,4032,8,55,,In vivo,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619806,,,F
12832,Autocuration,,1,,9615.0,4033,8,55,,In vivo,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619807,,,F
12832,Autocuration,,1,,9615.0,4034,8,55,,In vivo,Blood,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619808,,,F
3595,Autocuration,,1,,9615.0,4035,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL619809,,,B
3595,Autocuration,,1,,9615.0,4036,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL619810,,,B
3595,Autocuration,,1,,9615.0,4037,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL619811,,,B
3595,Autocuration,,1,,9615.0,4038,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL620769,,,B
3595,Autocuration,,1,,9615.0,4039,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL620770,,,B
3595,Autocuration,,1,,9615.0,4040,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL620771,,,B
3595,Autocuration,,1,,9615.0,4041,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL620772,,,B
3595,Autocuration,,1,,9615.0,4042,8,55,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,H,,Canis lupus familiaris,BAO_0000218,,CHEMBL620773,,,B
9203,Autocuration,,1,,10141.0,4043,8,55,,,,Ability to inhibit 5-lipoxygenase in guinea pig,,H,,Cavia porcellus,BAO_0000357,,CHEMBL620774,,,B
82,Expert,,1,,10141.0,4044,8,55,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,H,,Cavia porcellus,BAO_0000357,,CHEMBL620775,,,B
11090,Autocuration,,1,,10141.0,4045,8,55,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,H,,Cavia porcellus,BAO_0000357,,CHEMBL620776,,,B
12832,Autocuration,,1,,10141.0,4046,8,55,,,Blood,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,H,,Cavia porcellus,BAO_0000218,178.0,CHEMBL620777,,,B
1065,Autocuration,,1,,10141.0,4047,8,55,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,H,,Cavia porcellus,BAO_0000357,,CHEMBL620778,,,B
1065,Autocuration,,1,,10141.0,4048,8,55,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,H,,Cavia porcellus,BAO_0000357,,CHEMBL620779,,,B
12832,Expert,,1,,10141.0,4049,8,55,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL621500,,,B
12832,Expert,,1,,10141.0,4050,8,55,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL621501,,,B
12832,Autocuration,,1,,10141.0,4051,8,55,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618098,,,B
10504,Autocuration,,1,,10141.0,4052,8,55,,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618099,,,B
7788,Autocuration,,1,,10141.0,4053,8,55,,,,Inhibitory activity against 5-lipoxygenase,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618100,,,B
10001,Autocuration,,1,,10141.0,4054,8,55,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618101,,,B
10193,Autocuration,,1,,10141.0,4055,8,55,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618102,,,B
13243,Autocuration,,1,,10141.0,4056,8,55,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618103,,,B
13243,Autocuration,,1,,10141.0,4057,8,55,,,,Inhibitory activity uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618104,,,B
969,Autocuration,,1,,10141.0,4058,8,55,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,H,,Cavia porcellus,BAO_0000219,,CHEMBL883712,,,B
10001,Autocuration,,1,,10141.0,4059,8,55,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618105,,,B
7788,Autocuration,,1,,10141.0,4060,8,55,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618106,,,B
10001,Autocuration,,1,,10141.0,4061,8,55,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618107,,,B
10193,Autocuration,,1,,10141.0,4062,8,55,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618108,,,B
13243,Autocuration,,1,,10141.0,4063,8,55,,,,Inhibitory activity uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618109,,,B
13243,Autocuration,,1,,10141.0,4064,8,55,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618110,,,B
13243,Expert,,1,,10141.0,4065,8,55,,,,Inhibitory activity uM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618111,,,B
13243,Autocuration,,1,,10141.0,4066,8,55,,,,Inhibitory activity uM,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618112,,,F
10504,Autocuration,,1,,10141.0,4067,8,55,,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,H,,Cavia porcellus,BAO_0000019,,CHEMBL618113,,,B
7788,Autocuration,,1,,10141.0,4068,8,55,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,H,,Cavia porcellus,BAO_0000357,,CHEMBL618114,,,B
10546,Expert,,1,,10141.0,4069,8,55,,,Ileum,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,H,,Cavia porcellus,BAO_0000221,2116.0,CHEMBL620871,,,F
13183,Autocuration,,1,,,4070,8,55,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,H,,,BAO_0000357,,CHEMBL620872,,,B
13183,Autocuration,,1,,,4071,8,55,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,H,,,BAO_0000357,,CHEMBL620873,,,B
2578,Autocuration,,1,,,4072,8,55,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,H,,,BAO_0000357,,CHEMBL620874,,,B
12780,Expert,,1,,,4073,8,55,,,,In vitro inhibition of human 5-Lipoxygenase.,,H,,,BAO_0000357,,CHEMBL620875,,,B
7411,Autocuration,,1,,10116.0,4074,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620876,,Microsomes,B
7411,Autocuration,,1,,10116.0,4075,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620877,,Microsomes,B
7411,Autocuration,,1,,10116.0,4076,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL857854,,Microsomes,B
7411,Autocuration,,1,,10116.0,4077,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620878,,Microsomes,B
7411,Autocuration,,1,,10116.0,4078,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620879,,Microsomes,B
7411,Autocuration,,1,,10116.0,4079,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620880,,Microsomes,B
7411,Autocuration,,1,,10116.0,4080,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620881,,Microsomes,B
7411,Autocuration,,1,,10116.0,4081,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620882,,Microsomes,B
7411,Autocuration,,1,,10116.0,4082,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620883,,Microsomes,B
7411,Autocuration,,1,,10116.0,4083,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620884,,Microsomes,B
7411,Autocuration,,1,,10116.0,4084,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620885,,Microsomes,B
7411,Autocuration,,1,,10116.0,4085,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620886,,Microsomes,B
7411,Autocuration,,1,,10116.0,4086,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620887,,Microsomes,B
7411,Autocuration,,1,,10116.0,4087,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618039,,Microsomes,B
7411,Autocuration,,1,,10116.0,4088,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618040,,Microsomes,B
7411,Autocuration,,1,,10116.0,4089,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618041,,Microsomes,B
7411,Autocuration,,1,,10116.0,4090,0,22226,,,Liver,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618216,,Microsomes,B
7411,Autocuration,,1,,10116.0,4091,0,22226,,,Liver,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618217,,Microsomes,B
7411,Autocuration,,1,,10116.0,4092,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618218,,Microsomes,B
7411,Autocuration,,1,,10116.0,4093,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618219,,Microsomes,B
7411,Autocuration,,1,,10116.0,4094,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618220,,Microsomes,B
7411,Autocuration,,1,,10116.0,4095,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618221,,Microsomes,B
7411,Autocuration,,1,,10116.0,4096,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618222,,Microsomes,B
7411,Autocuration,,1,,10116.0,4097,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618223,,Microsomes,B
7411,Autocuration,,1,,10116.0,4098,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618224,,Microsomes,B
7411,Autocuration,,1,,10116.0,4099,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618225,,Microsomes,B
7411,Autocuration,,1,,10116.0,4100,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618226,,Microsomes,B
7411,Autocuration,,1,,10116.0,4101,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618227,,Microsomes,B
7411,Autocuration,,1,,10116.0,4102,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618228,,Microsomes,B
7411,Autocuration,,1,,10116.0,4103,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618229,,Microsomes,B
7411,Autocuration,,1,,10116.0,4104,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618230,,Microsomes,B
7411,Autocuration,,1,,10116.0,4105,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618231,,Microsomes,B
7411,Autocuration,,1,,10116.0,4106,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618232,,Microsomes,B
7411,Autocuration,,1,,10116.0,4107,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618233,,Microsomes,B
7411,Autocuration,,1,,10116.0,4108,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618234,,Microsomes,B
7411,Autocuration,,1,,10116.0,4109,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618235,,Microsomes,B
7411,Autocuration,,1,,10116.0,4110,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618115,,Microsomes,B
7411,Autocuration,,1,,10116.0,4111,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618116,,Microsomes,B
7411,Autocuration,,1,,10116.0,4112,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL618117,,Microsomes,B
7411,Autocuration,,1,,10116.0,4113,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619968,,Microsomes,B
7411,Autocuration,,1,,10116.0,4114,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619969,,Microsomes,B
7411,Autocuration,,1,,10116.0,4115,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619970,,Microsomes,B
7411,Autocuration,,1,,10116.0,4116,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619971,,Microsomes,B
7411,Autocuration,,1,,10116.0,4117,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619972,,Microsomes,B
7411,Autocuration,,1,,10116.0,4118,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619973,,Microsomes,B
7411,Autocuration,,1,,10116.0,4119,0,22226,,,Liver,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619974,,Microsomes,B
7411,Autocuration,,1,,10116.0,4120,0,22226,,,Liver,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619975,,Microsomes,B
7411,Autocuration,,1,,10116.0,4121,0,22226,,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,U,,Rattus norvegicus,BAO_0000251,,CHEMBL619976,,Microsomes,B
7411,Autocuration,,1,,10116.0,4122,0,22226,,,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619977,,Microsomes,B
7411,Autocuration,,1,,10116.0,4123,0,22226,,,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619978,,Microsomes,B
7411,Autocuration,,1,,10116.0,4124,0,22226,,,Liver,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619979,,Microsomes,B
7411,Autocuration,,1,,10116.0,4125,0,22226,,,Liver,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619980,,Microsomes,B
7411,Autocuration,,1,,10116.0,4126,0,22226,,,Liver,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619981,,Microsomes,B
10797,Intermediate,,1,,9606.0,4127,1,80433,RPMI-8226,,,In vitro inhibition of 7226/S myeloma cancer cell line,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619982,,,F
6881,Intermediate,,1,,9606.0,4128,1,80698,BEL-7404 tumor cell line,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,N,993.0,Homo sapiens,BAO_0000219,,CHEMBL619983,,,F
3838,Intermediate,,1,,9606.0,4129,1,80640,786-0,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL620031,,,F
3838,Intermediate,,1,,9606.0,4130,1,80640,786-0,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL620032,,,F
12981,Expert,,1,,10029.0,4131,1,81264,V79,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,N,505.0,Cricetulus griseus,BAO_0000219,,CHEMBL620033,,,F
12981,Expert,,1,,10029.0,4132,1,81264,V79,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,N,505.0,Cricetulus griseus,BAO_0000219,,CHEMBL620034,,,F
7653,Intermediate,,1,,10116.0,4133,1,80635,7800C1 cell line,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,N,1119.0,Rattus norvegicus,BAO_0000219,,CHEMBL620035,,,F
7653,Intermediate,,1,,10116.0,4134,1,80635,7800C1 cell line,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,N,1119.0,Rattus norvegicus,BAO_0000219,,CHEMBL618318,,,F
7653,Intermediate,,1,,10116.0,4135,1,80635,7800C1 cell line,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,N,1119.0,Rattus norvegicus,BAO_0000219,,CHEMBL618319,,,F
7653,Intermediate,,1,,10116.0,4136,1,80635,7800C1 cell line,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,N,1119.0,Rattus norvegicus,BAO_0000219,,CHEMBL618320,,,F
7653,Intermediate,,1,,10116.0,4137,1,80635,7800C1 cell line,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,N,1119.0,Rattus norvegicus,BAO_0000219,,CHEMBL618321,,,F
7653,Intermediate,,1,,10116.0,4138,1,80635,7800C1 cell line,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,N,1119.0,Rattus norvegicus,BAO_0000219,,CHEMBL883118,,,F
17229,Intermediate,,1,,9606.0,4139,1,80640,786-0,,,In vitro antitumor activity against renal 786-0 tumor cell lines,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL883795,,,F
12858,Intermediate,,1,,9606.0,4140,1,80640,786-0,,,Cytotoxic activity against 786-0 Renal cancer cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL618322,,,F
16325,Intermediate,,1,,9606.0,4141,1,80640,786-0,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL618323,,,F
16325,Intermediate,,1,,9606.0,4142,1,80640,786-0,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL618324,,,F
5858,Intermediate,,1,,9606.0,4143,1,80640,786-0,,,In vitro antitumor activity against human renal 786-0 cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL618325,,,F
16325,Intermediate,,1,,9606.0,4144,1,80640,786-0,,,Inhibition of Renal cancer in 786-0 cancer cell lines,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL875416,,,F
14696,Intermediate,,1,,9606.0,4145,1,80640,786-0,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL618326,,,F
3786,Intermediate,,1,,9606.0,4146,1,80640,786-0,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL618327,,,F
14696,Intermediate,,1,,9606.0,4147,1,80640,786-0,,,inhibition of the growth of renal cancer(786-0) cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619215,,,F
14769,Intermediate,,1,,9606.0,4148,1,80640,786-0,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619216,,,F
15354,Intermediate,,1,,9606.0,4149,1,80640,786-0,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619217,,,F
14255,Intermediate,,1,,9606.0,4150,1,80640,786-0,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619218,,,F
14255,Intermediate,,1,,9606.0,4151,1,80640,786-0,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619219,,,F
14255,Intermediate,,1,,9606.0,4152,1,80640,786-0,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619220,,,F
14696,Intermediate,,1,,9606.0,4153,1,80640,786-0,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619221,,,F
12016,Intermediate,,1,,9606.0,4154,1,80640,786-0,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619222,,,F
2597,Intermediate,,1,,9606.0,4155,1,80640,786-0,,,Compound was tested for growth inhibitory activity against 786-0 cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL857454,,,F
12526,Autocuration,,1,,,4156,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL619223,,,B
12526,Autocuration,,1,,,4157,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,H,702.0,,BAO_0000219,,CHEMBL619224,,,B
14799,Autocuration,,1,,,4158,8,12166,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,H,,,BAO_0000019,,CHEMBL619225,,,B
3595,Expert,,1,,,4159,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,H,702.0,,BAO_0000219,,CHEMBL619226,,,B
3595,Expert,,1,,,4160,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,H,702.0,,BAO_0000219,,CHEMBL619227,,,B
12767,Autocuration,,1,,,4161,8,12166,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619228,,,B
10997,Autocuration,,1,,,4162,8,12166,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,H,,,BAO_0000219,,CHEMBL619229,,,B
11388,Autocuration,,1,,,4163,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,H,702.0,,BAO_0000219,,CHEMBL619230,,,B
167,Autocuration,,1,,,4164,8,12166,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,H,,,BAO_0000357,,CHEMBL619231,,,B
167,Autocuration,,1,,,4165,8,12166,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,H,,,BAO_0000357,,CHEMBL619232,,,B
13744,Expert,,1,,,4166,8,12166,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,H,,,BAO_0000357,,CHEMBL619233,,,B
1630,Autocuration,,1,,,4167,8,12166,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619234,,,B
1630,Autocuration,,1,,,4168,8,12166,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,H,,,BAO_0000357,,CHEMBL619235,,,B
969,Expert,,1,,10116.0,4169,9,12166,,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,D,,Rattus norvegicus,BAO_0000019,,CHEMBL619236,,,B
13621,Autocuration,,1,,,4170,8,12166,RBL-1,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL619237,,,B
10089,Autocuration,,1,,,4171,8,12166,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,H,,,BAO_0000357,,CHEMBL619238,,,B
10193,Expert,,1,,,4172,8,12166,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619239,,,B
11966,Autocuration,,1,,,4173,8,12166,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,H,,,BAO_0000357,,CHEMBL619240,,,B
12251,Autocuration,,1,,,4174,8,12166,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,H,,,BAO_0000019,,CHEMBL875417,,,B
211,Autocuration,,1,,,4175,8,12166,RBL-1,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,H,702.0,,BAO_0000219,,CHEMBL619241,,,B
12251,Expert,,1,,,4176,8,12166,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,H,,,BAO_0000019,,CHEMBL619242,,,F
12495,Autocuration,,1,,,4177,8,12166,RBL-1,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL883796,,,B
414,Autocuration,,1,,,4178,8,12166,,,,Tested for its inhibitory activity against 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL619243,,,B
414,Autocuration,,1,,,4179,8,12166,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,H,,,BAO_0000357,,CHEMBL619244,,,B
10325,Expert,,1,,,4180,8,12166,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,H,,,BAO_0000019,,CHEMBL619245,,,B
11966,Expert,,1,,,4181,8,12166,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,H,,,BAO_0000019,,CHEMBL619246,,,B
165,Expert,,1,,,4182,8,12166,RBL-1,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,H,702.0,,BAO_0000219,,CHEMBL619984,,,B
165,Autocuration,,1,,,4183,8,12166,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,H,702.0,,BAO_0000219,,CHEMBL619985,,,B
165,Autocuration,,1,,,4184,8,12166,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,H,702.0,,BAO_0000219,,CHEMBL619986,,,B
165,Expert,,1,,,4185,8,12166,RBL-1,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,H,702.0,,BAO_0000219,,CHEMBL619987,,,B
11311,Autocuration,,1,,,4186,8,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,H,,,BAO_0000218,,CHEMBL619988,,,B
11311,Autocuration,,1,,,4187,8,12166,RBL-1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,H,702.0,,BAO_0000219,,CHEMBL619989,,,B
11311,Autocuration,,1,,,4188,8,12166,RBL-1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,H,702.0,,BAO_0000219,,CHEMBL619990,,,B
11311,Autocuration,,1,,,4189,8,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000219,,CHEMBL619991,,,B
11311,Autocuration,,1,,,4190,8,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,H,,,BAO_0000219,,CHEMBL619992,,,B
11311,Autocuration,,1,,,4191,8,12166,,In vivo,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,H,,,BAO_0000218,,CHEMBL619993,,,B
11311,Autocuration,,1,,,4192,8,12166,RBL-2H3,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,H,663.0,,BAO_0000219,,CHEMBL619994,,,F
11311,Autocuration,,1,,,4193,8,12166,RBL-2H3,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,H,663.0,,BAO_0000219,,CHEMBL619995,,,F
11311,Autocuration,,1,,,4194,8,12166,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,H,,,BAO_0000019,,CHEMBL619996,,,B
11732,Autocuration,,1,,,4195,8,12166,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,H,,,BAO_0000019,,CHEMBL619997,,,B
11732,Expert,,1,,,4196,8,12166,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,H,,,BAO_0000019,,CHEMBL619998,,,B
11087,Expert,,1,,,4197,8,12166,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,H,,,BAO_0000019,,CHEMBL619999,,,B
11087,Autocuration,,1,,,4198,8,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,H,,,BAO_0000019,,CHEMBL620000,,,B
11087,Autocuration,,1,,,4199,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,H,702.0,,BAO_0000219,,CHEMBL620001,,,B
11087,Expert,,1,,10116.0,4200,9,12166,,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL620002,,,B
496,Autocuration,,1,,,4201,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,H,702.0,,BAO_0000219,,CHEMBL620003,,,B
13986,Expert,,1,,,4202,8,12166,RBL-1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,H,702.0,,BAO_0000219,,CHEMBL620004,,,F
11520,Autocuration,,1,,,4203,8,12166,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL874063,,,B
10293,Autocuration,,1,,,4204,8,12166,RBL-1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,H,702.0,,BAO_0000219,,CHEMBL620005,,,B
303,Autocuration,,1,,,4205,8,12166,RBL-1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,H,702.0,,BAO_0000219,,CHEMBL620006,,,B
303,Autocuration,,1,,,4206,8,12166,RBL-1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,H,702.0,,BAO_0000219,,CHEMBL620007,,,B
9247,Autocuration,,1,,,4207,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL620008,,,B
9247,Expert,,1,,10116.0,4208,9,12166,RBL-1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL620009,,,B
9247,Autocuration,,1,,,4209,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,H,702.0,,BAO_0000219,,CHEMBL620010,,,B
9247,Autocuration,,1,,,4210,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,H,702.0,,BAO_0000219,,CHEMBL620011,,,B
9247,Autocuration,,1,,,4211,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,H,702.0,,BAO_0000219,,CHEMBL620677,,,B
9247,Autocuration,,1,,,4212,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,H,702.0,,BAO_0000219,,CHEMBL620678,,,B
9247,Autocuration,,1,,,4213,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,H,702.0,,BAO_0000219,,CHEMBL620679,,,B
9247,Autocuration,,1,,,4214,8,12166,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,H,702.0,,BAO_0000219,,CHEMBL620680,,,B
11481,Expert,,1,,10116.0,4215,9,12166,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,D,,Rattus norvegicus,BAO_0000357,,CHEMBL620838,,,B
105,Autocuration,,1,,,4216,8,12166,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,H,,,BAO_0000357,,CHEMBL620839,,,B
9029,Expert,,1,,,4217,8,12166,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,H,,,BAO_0000357,,CHEMBL620840,,,B
1175,Expert,,1,,,4218,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,H,702.0,,BAO_0000219,,CHEMBL620841,,,B
12118,Autocuration,,1,,,4219,8,12166,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,H,702.0,,BAO_0000219,,CHEMBL620842,,,B
12118,Autocuration,,1,,,4220,8,12166,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,H,702.0,,BAO_0000219,,CHEMBL620843,,,B
12118,Autocuration,,1,,,4221,8,12166,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,H,702.0,,BAO_0000219,,CHEMBL620844,,,B
9225,Autocuration,,1,,,4222,8,12166,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,H,702.0,,BAO_0000219,,CHEMBL620845,,,B
9401,Autocuration,,1,,,4223,8,12166,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,H,,,BAO_0000019,,CHEMBL620846,,,B
137,Autocuration,,1,,,4224,8,12166,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,H,,,BAO_0000357,,CHEMBL873951,,,B
137,Autocuration,,1,,,4225,8,12166,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,H,,,BAO_0000357,,CHEMBL620847,,,B
4717,Autocuration,,1,,,4226,8,12166,RBL-1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,H,702.0,,BAO_0000219,,CHEMBL620848,,,B
3595,Autocuration,,1,,,4227,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL620849,,,B
10501,Autocuration,,1,,,4228,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,H,702.0,,BAO_0000219,,CHEMBL620850,,,B
10501,Autocuration,,1,,,4229,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,H,702.0,,BAO_0000219,,CHEMBL620851,,,B
10501,Autocuration,,1,,,4230,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,H,702.0,,BAO_0000219,,CHEMBL620852,,,B
12526,Autocuration,,1,,,4231,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,702.0,,BAO_0000219,,CHEMBL875098,,,B
14799,Expert,,1,,10116.0,4232,9,12166,RBL-1,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL620853,,,B
14799,Autocuration,,1,,,4233,8,12166,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,H,,,BAO_0000019,,CHEMBL620854,,,B
3595,Autocuration,,1,,,4234,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL620855,,,B
3595,Expert,,1,,,4235,8,12166,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL839884,,,B
12526,Autocuration,,1,,,4236,8,12166,RBL-1,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,702.0,,BAO_0000219,,CHEMBL620856,,,B
12526,Autocuration,,1,,,4237,8,12166,RBL-1,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,H,702.0,,BAO_0000219,,CHEMBL620857,,,B
10193,Autocuration,,1,,,4238,8,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,H,,,BAO_0000019,,CHEMBL620858,,,B
10193,Autocuration,,1,,,4239,8,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,H,,,BAO_0000019,,CHEMBL620859,,,B
10193,Autocuration,,1,,,4240,8,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,H,,,BAO_0000019,,CHEMBL620860,,,B
10193,Autocuration,,1,,,4241,8,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,H,,,BAO_0000019,,CHEMBL620861,,,B
9138,Expert,,1,,,4242,8,12166,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,H,,,BAO_0000357,,CHEMBL620862,,,B
9138,Autocuration,,1,,,4243,8,12166,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,H,,,BAO_0000357,,CHEMBL620863,,,B
11966,Autocuration,,1,,,4244,8,12166,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,H,,,BAO_0000019,,CHEMBL620864,,,B
165,Autocuration,,1,,,4245,8,12166,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,H,702.0,,BAO_0000219,,CHEMBL620865,,,B
165,Autocuration,,1,,,4246,8,12166,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,H,702.0,,BAO_0000219,,CHEMBL620866,,,B
11311,Autocuration,,1,,,4247,8,12166,RBL-2H3,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,H,663.0,,BAO_0000219,,CHEMBL620867,,,B
11311,Autocuration,,1,,,4248,8,12166,RBL-2H3,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,H,663.0,,BAO_0000219,,CHEMBL620868,,,B
11311,Autocuration,,1,,,4249,8,12166,RBL-2H3,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,H,663.0,,BAO_0000219,,CHEMBL620869,,,F
11311,Autocuration,,1,,,4250,8,12166,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,H,,,BAO_0000019,,CHEMBL873952,,,F
11311,Autocuration,,1,,,4251,8,12166,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL875099,,,B
11311,Autocuration,,1,,,4252,8,12166,RBL-2H3,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,H,663.0,,BAO_0000219,,CHEMBL620870,,,F
11087,Autocuration,,1,,,4253,8,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,H,,,BAO_0000019,,CHEMBL618261,,,B
11087,Autocuration,,1,,,4254,8,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,H,,,BAO_0000019,,CHEMBL618262,,,B
11087,Autocuration,,1,,,4255,8,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,H,,,BAO_0000019,,CHEMBL619428,,,B
11087,Autocuration,,1,,,4256,8,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,H,,,BAO_0000019,,CHEMBL619429,,,B
11087,Autocuration,,1,,,4257,8,12166,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,H,,,BAO_0000019,,CHEMBL619430,,,B
496,Autocuration,,1,,,4258,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,H,702.0,,BAO_0000219,,CHEMBL620017,,,B
496,Autocuration,,1,,,4259,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL620018,,,B
13986,Autocuration,,1,,,4260,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,H,702.0,,BAO_0000219,,CHEMBL620019,,,F
13986,Autocuration,,1,,,4261,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,H,702.0,,BAO_0000219,,CHEMBL620020,,,F
13986,Autocuration,,1,,,4262,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,H,702.0,,BAO_0000219,,CHEMBL620021,,,F
13986,Autocuration,,1,,,4263,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,H,702.0,,BAO_0000219,,CHEMBL620022,,,F
13986,Autocuration,,1,,,4264,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,H,702.0,,BAO_0000219,,CHEMBL620023,,,F
13986,Autocuration,,1,,,4265,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,H,702.0,,BAO_0000219,,CHEMBL620024,,,F
13986,Autocuration,,1,,,4266,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,H,702.0,,BAO_0000219,,CHEMBL620025,,,F
13986,Autocuration,,1,,,4267,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,H,702.0,,BAO_0000219,,CHEMBL620026,,,F
13986,Autocuration,,1,,,4268,8,12166,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,H,702.0,,BAO_0000219,,CHEMBL620027,,,F
13986,Expert,,1,,10116.0,4269,9,12166,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL620028,,,F
10193,Autocuration,,1,,,4270,8,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL620029,,,B
9295,Autocuration,,1,,,4271,8,12166,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,H,,,BAO_0000357,,CHEMBL620030,,,B
4717,Autocuration,,1,,,4272,8,12166,RBL-1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,H,702.0,,BAO_0000219,,CHEMBL875415,,,B
4717,Autocuration,,1,,,4273,8,12166,RBL-1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,H,702.0,,BAO_0000219,,CHEMBL618256,,,B
11854,Autocuration,,1,,,4274,8,12166,RBL-1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,H,702.0,,BAO_0000219,,CHEMBL618257,,,B
11854,Autocuration,,1,,,4275,8,12166,RBL-1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL618258,,,B
11854,Autocuration,,1,,,4276,8,12166,RBL-1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,H,702.0,,BAO_0000219,,CHEMBL618259,,,B
10193,Autocuration,,1,,,4277,8,12166,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,H,,,BAO_0000019,,CHEMBL618260,,,B
9295,Autocuration,,1,,,4278,8,12166,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,H,702.0,,BAO_0000219,,CHEMBL618215,,,B
9295,Autocuration,,1,,,4279,8,12166,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,H,702.0,,BAO_0000219,,CHEMBL618390,,,B
9295,Autocuration,,1,,,4280,8,12166,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,H,702.0,,BAO_0000219,,CHEMBL618391,,,B
9295,Autocuration,,1,,,4281,8,12166,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,H,702.0,,BAO_0000219,,CHEMBL618392,,,B
165,Autocuration,,1,,,4282,8,12166,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,H,702.0,,BAO_0000219,,CHEMBL618393,,,B
11311,Autocuration,,1,,,4283,8,12166,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,H,,,BAO_0000219,,CHEMBL618394,,,B
10489,Expert,,1,,9606.0,4284,8,12166,RBL-1,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,H,702.0,Homo sapiens,BAO_0000219,,CHEMBL618395,,,B
10489,Expert,,1,,10116.0,4285,9,12166,RBL-1,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL618396,,,B
10489,Expert,,1,,10116.0,4286,9,12166,RBL-1,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,D,702.0,Rattus norvegicus,BAO_0000219,,CHEMBL858253,,,B
14799,Autocuration,,1,,10116.0,4287,9,12166,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL618397,,,B
9295,Autocuration,,1,,3847.0,4288,8,12054,,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,H,,Glycine max,BAO_0000357,,CHEMBL618398,,,B
16811,Autocuration,,1,,,4289,0,22226,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,U,,,BAO_0000019,,CHEMBL618399,,,B
168,Expert,,1,,,4290,8,55,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,H,,,BAO_0000357,,CHEMBL618400,,,B
6309,Autocuration,,1,,,4291,8,55,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,H,,,BAO_0000357,,CHEMBL618401,,,B
6309,Autocuration,,1,,,4292,8,55,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,H,,,BAO_0000357,,CHEMBL618402,,,B
3092,Autocuration,,1,,,4293,8,55,RBL-1,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,H,702.0,,BAO_0000219,,CHEMBL876400,,,B
168,Expert,,1,,,4294,8,55,,,,Inhibitory activity against 5-lipoxygenase.,,H,,,BAO_0000357,,CHEMBL618403,,,B
168,Autocuration,,1,,,4295,8,55,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,H,,,BAO_0000357,,CHEMBL618404,,,B
168,Autocuration,,1,,,4296,8,55,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,H,,,BAO_0000357,,CHEMBL618405,,,B
168,Autocuration,,1,,,4297,8,55,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,H,,,BAO_0000357,,CHEMBL618406,,,B
12338,Expert,,1,,,4298,8,55,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,H,,,BAO_0000019,,CHEMBL618407,,,F
4501,Autocuration,,1,,,4299,8,55,,,,Tested for the inhibitory activity against 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618408,,,B
1132,Autocuration,,1,,,4300,8,55,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,H,,,BAO_0000357,,CHEMBL618409,,,B
2117,Autocuration,,1,,,4301,8,55,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,H,,,BAO_0000357,,CHEMBL618410,,,B
168,Autocuration,,1,,,4302,8,55,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,H,,,BAO_0000357,,CHEMBL618411,,,B
168,Autocuration,,1,,,4303,8,55,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,H,,,BAO_0000357,,CHEMBL618412,,,B
13575,Autocuration,,1,,,4304,8,12166,RBL-1,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,H,702.0,,BAO_0000219,,CHEMBL618413,,,B
11089,Autocuration,,1,,,4305,8,12166,,,,,,H,,,BAO_0000357,,CHEMBL618414,,,B
216,Autocuration,,1,,,4306,8,10102,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,H,,,BAO_0000357,,CHEMBL618415,,,B
13165,Autocuration,,1,,,4307,8,10102,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,H,,,BAO_0000019,,CHEMBL618416,,,B
3278,Autocuration,,1,,,4308,8,10102,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,H,,,BAO_0000357,,CHEMBL876401,,,B
3278,Expert,,1,,,4309,8,10102,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,H,,,BAO_0000357,,CHEMBL618417,,,B
11966,Autocuration,,1,,,4310,8,10102,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,H,,,BAO_0000357,,CHEMBL618418,,,B
175,Autocuration,,1,,,4311,8,10102,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,H,,,BAO_0000357,,CHEMBL618419,,,B
175,Autocuration,,1,,,4312,8,10102,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,H,,,BAO_0000357,,CHEMBL618420,,,B
13449,Autocuration,,1,,,4313,8,10102,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,H,,,BAO_0000357,,CHEMBL618421,,,B
12014,Autocuration,,1,,,4314,8,11238,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,H,,,BAO_0000019,,CHEMBL618422,,,B
12014,Autocuration,,1,,,4315,8,11238,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,H,,,BAO_0000019,,CHEMBL618423,,,B
12014,Autocuration,,1,,,4316,8,11238,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,H,,,BAO_0000019,,CHEMBL618424,,,B
99,Intermediate,,1,,,4317,2,100284,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,S,,,BAO_0000220,,CHEMBL618425,,,B
4349,Autocuration,,1,,9606.0,4318,0,22226,,,,The dark toxicity against 543 human galactophore carcinoma cells,,U,,Homo sapiens,BAO_0000019,,CHEMBL618426,,,F
4071,Expert,,1,,9606.0,4319,1,80623,Panel (56 tumour cell lines),,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,N,390.0,Homo sapiens,BAO_0000219,,CHEMBL618427,,,F
17589,Expert,,1,,9606.0,4320,1,80008,5637,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL618428,,,F
15002,Intermediate,,1,,9606.0,4321,1,80008,5637,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL618429,,,F
13958,Intermediate,,1,,9606.0,4322,1,80008,5637,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL618430,,,F
17589,Expert,,1,,9606.0,4323,1,80008,5637,,,Growth inhibition against human 5637 cell lines,,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL618431,,,F
16748,Expert,,1,,9606.0,4324,1,80008,5637,,,Antitumor activity against human bladder carcinoma 5637 cells.,,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL883799,,,F
16747,Intermediate,,1,,9606.0,4325,1,80008,5637,,,Antitumor activity against human bladder carcinoma 5637 cells,,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL618432,,,F
16747,Intermediate,,1,,9606.0,4326,1,80008,5637,,,Antitumor activity against human bladder carcinoma 5637 cells,,N,345.0,Homo sapiens,BAO_0000219,,CHEMBL618433,,,F
15285,Expert,,1,,9913.0,4327,9,10443,,,,In vitro inhibition of bovine trypsin(Trp).,,D,,Bos taurus,BAO_0000357,,CHEMBL618434,,,B
3726,Expert,,1,,9527.0,4328,8,240,CV-1,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,H,407.0,Cercopithecidae,BAO_0000219,,CHEMBL618435,,,B
5033,Autocuration,,1,,,4329,8,10577,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,H,,,BAO_0000357,,CHEMBL876402,,,B
11756,Autocuration,,1,,,4330,6,104698,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,H,,,BAO_0000019,,CHEMBL618436,,,F
11953,Autocuration,,1,,,4331,0,22226,,In vivo,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,U,,,BAO_0000218,,CHEMBL618437,,,F
5033,Intermediate,,1,,10141.0,4332,9,20033,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,D,,Cavia porcellus,BAO_0000357,,CHEMBL618438,,,B
11347,Expert,,1,,10116.0,4333,8,17045,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,H,,Rattus norvegicus,BAO_0000251,,CHEMBL883800,,Microsomes,A
11347,Expert,,1,,10116.0,4334,8,17045,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,H,,Rattus norvegicus,BAO_0000251,,CHEMBL618439,,Microsomes,A
1229,Intermediate,,1,,,4335,0,22226,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,U,,,BAO_0000019,,CHEMBL618440,,,F
1229,Intermediate,,1,,,4336,0,22226,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,U,,,BAO_0000019,,CHEMBL618441,,,F
17588,Expert,,1,,5691.0,4337,8,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,H,,Trypanosoma brucei,BAO_0000019,,CHEMBL618442,,,B
17588,Autocuration,,1,,5691.0,4338,8,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,H,,Trypanosoma brucei,BAO_0000019,,CHEMBL618443,,,B
17588,Expert,,1,,9940.0,4339,8,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,H,,Ovis aries,BAO_0000019,,CHEMBL619158,,,B
17588,Autocuration,,1,,9940.0,4340,8,11938,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,H,,Ovis aries,BAO_0000019,,CHEMBL620974,,,B
16485,Autocuration,,1,,,4341,8,11938,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,H,,,BAO_0000357,,CHEMBL620975,,,B
4337,Intermediate,,1,,9606.0,4342,0,22226,,,,Average inhibitory concentration against 60 human cell lines was reported,,U,,Homo sapiens,BAO_0000019,,CHEMBL620976,,,F
4112,Expert,,1,,9606.0,4343,0,22226,,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,U,,Homo sapiens,BAO_0000019,,CHEMBL620977,,,F
16160,Intermediate,,1,,9606.0,4344,1,80315,Panel NCI-60 (60 carcinoma cell lines),,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,N,542.0,Homo sapiens,BAO_0000219,,CHEMBL620978,,,F
16160,Intermediate,,1,,9606.0,4345,1,80315,Panel NCI-60 (60 carcinoma cell lines),,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,N,542.0,Homo sapiens,BAO_0000219,,CHEMBL620979,,,F
17376,Expert,,1,,,4346,1,80315,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth inhibitory activity against 60-cell panel,,N,542.0,,BAO_0000219,,CHEMBL620980,,,F
17376,Expert,,1,,,4347,1,80315,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth lethal concentration against 60-cell panel,,N,542.0,,BAO_0000219,,CHEMBL620981,,,F
17376,Expert,,1,,,4348,1,80315,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,N,542.0,,BAO_0000219,,CHEMBL620982,,,F
17376,Expert,,1,,,4349,1,80315,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,N,542.0,,BAO_0000219,,CHEMBL620983,,,F
3241,Autocuration,,1,,,4350,4,104775,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,H,,,BAO_0000019,,CHEMBL620984,,,F
3241,Autocuration,,1,,,4351,4,104775,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,H,,,BAO_0000019,,CHEMBL620985,,,F
3725,Expert,,1,,,4352,8,275,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,H,,,BAO_0000357,,CHEMBL620986,,,B
10805,Expert,,1,,5833.0,4353,1,50425,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,N,,Plasmodium falciparum,BAO_0000218,,CHEMBL620987,,,F
10805,Expert,,1,,5833.0,4354,1,50425,,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,N,,Plasmodium falciparum,BAO_0000218,,CHEMBL620988,,,F
10805,Expert,,1,,5833.0,4355,1,50425,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,N,,Plasmodium falciparum,BAO_0000218,,CHEMBL620989,,,F
10805,Expert,,1,,5833.0,4356,1,50425,,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,N,,Plasmodium falciparum,BAO_0000218,,CHEMBL620990,,,F
10805,Intermediate,,1,,5833.0,4357,1,50425,,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,N,,Plasmodium falciparum,BAO_0000218,,CHEMBL620991,,,F
10144,Intermediate,,1,,10090.0,4358,1,80628,6C3HED,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL620992,,,F
10144,Intermediate,,1,,10090.0,4359,1,80628,6C3HED,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL620993,,,F
10144,Intermediate,,1,,10090.0,4360,1,80628,6C3HED,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL620994,,,F
10144,Intermediate,,1,,10090.0,4361,1,80628,6C3HED,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL620995,,,F
10144,Intermediate,,1,,10090.0,4362,1,80628,6C3HED,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL620996,,,F
10144,Intermediate,,1,,10090.0,4363,1,80628,6C3HED,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL875581,,,F
10685,Autocuration,,1,,10090.0,4364,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL620997,,,F
10685,Autocuration,,1,,10090.0,4365,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL620998,,,F
10685,Autocuration,,1,,10090.0,4366,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,U,,Mus musculus,BAO_0000218,,CHEMBL620999,,,F
10685,Autocuration,,1,,10090.0,4367,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL621000,,,F
10685,Autocuration,,1,,10090.0,4368,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL621001,,,F
10685,Autocuration,,1,,10090.0,4369,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL621002,,,F
10685,Autocuration,,1,,10090.0,4370,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL621003,,,F
10685,Autocuration,,1,,10090.0,4371,0,22224,,In vivo,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,U,,Mus musculus,BAO_0000218,,CHEMBL621004,,,F
10685,Autocuration,,1,,10090.0,4372,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,U,,Mus musculus,BAO_0000218,,CHEMBL621005,,,F
10685,Autocuration,,1,,10090.0,4373,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,U,,Mus musculus,BAO_0000218,,CHEMBL621006,,,F
10685,Autocuration,,1,,10090.0,4374,0,22224,,In vivo,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL621007,,,F
10144,Autocuration,,1,,10090.0,4375,0,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,U,,Mus musculus,BAO_0000218,,CHEMBL621008,,,F
10144,Autocuration,,1,,10090.0,4376,0,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,U,,Mus musculus,BAO_0000218,,CHEMBL621009,,,F
10144,Autocuration,,1,,10090.0,4377,0,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,U,,Mus musculus,BAO_0000218,,CHEMBL857705,,,F
10144,Autocuration,,1,,10090.0,4378,0,22224,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,U,,Mus musculus,BAO_0000218,,CHEMBL619828,,,F
10685,Autocuration,,1,,10090.0,4379,0,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,U,,Mus musculus,BAO_0000218,,CHEMBL619829,,,F
10685,Autocuration,,1,,10090.0,4380,0,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,U,,Mus musculus,BAO_0000218,,CHEMBL619830,,,F
10685,Autocuration,,1,,10090.0,4381,0,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,U,,Mus musculus,BAO_0000218,,CHEMBL619831,,,F
10685,Autocuration,,1,,10090.0,4382,0,22224,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,U,,Mus musculus,BAO_0000218,,CHEMBL619832,,,F
10685,Autocuration,,1,,10090.0,4383,0,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,U,,Mus musculus,BAO_0000218,,CHEMBL619833,,,A
10685,Autocuration,,1,,10090.0,4384,0,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,U,,Mus musculus,BAO_0000218,,CHEMBL619834,,,A
10685,Autocuration,,1,,10090.0,4385,0,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,U,,Mus musculus,BAO_0000218,,CHEMBL619835,,,A
10685,Autocuration,,1,,10090.0,4386,0,22224,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,U,,Mus musculus,BAO_0000218,,CHEMBL619836,,,A
8831,Intermediate,,1,,10090.0,4387,1,80628,6C3HED,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,N,850.0,Mus musculus,BAO_0000218,,CHEMBL619837,,,F
11704,Autocuration,,1,,,4388,0,22224,,In vivo,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,U,,,BAO_0000218,,CHEMBL619838,,,F
11704,Intermediate,,1,,10090.0,4389,1,50594,,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,N,,Mus musculus,BAO_0000218,,CHEMBL619839,,,A
10685,Intermediate,,1,,10090.0,4390,1,80628,6C3HED,In vivo,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL619840,,,F
10685,Intermediate,,1,,10090.0,4391,1,80628,6C3HED,In vivo,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,N,850.0,Mus musculus,BAO_0000218,,CHEMBL619841,,,F
11368,Expert,,1,,10090.0,4392,1,80628,6C3HED,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,N,850.0,Mus musculus,BAO_0000218,,CHEMBL857704,,,F
11368,Intermediate,,1,,10090.0,4393,1,80628,6C3HED,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,N,850.0,Mus musculus,BAO_0000218,,CHEMBL619842,,,F
11368,Expert,,1,,10090.0,4394,1,80628,6C3HED,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,N,850.0,Mus musculus,BAO_0000218,,CHEMBL619843,,,F
17763,Autocuration,,1,,1280.0,4395,0,22226,,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,U,,Staphylococcus aureus,BAO_0000019,,CHEMBL619844,,,B
7411,Autocuration,,1,,10116.0,4396,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL857855,,Microsomes,B
7411,Autocuration,,1,,10116.0,4397,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619845,,Microsomes,B
7411,Autocuration,,1,,10116.0,4398,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619846,,Microsomes,B
7411,Autocuration,,1,,10116.0,4399,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619847,,Microsomes,B
7411,Autocuration,,1,,10116.0,4400,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL619848,,Microsomes,B
7411,Autocuration,,1,,10116.0,4401,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620893,,Microsomes,B
7411,Autocuration,,1,,10116.0,4402,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620894,,Microsomes,B
7411,Autocuration,,1,,10116.0,4403,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620895,,Microsomes,B
7411,Autocuration,,1,,10116.0,4404,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620896,,Microsomes,B
7411,Autocuration,,1,,10116.0,4405,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620897,,Microsomes,B
7411,Autocuration,,1,,10116.0,4406,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620898,,Microsomes,B
7411,Autocuration,,1,,10116.0,4407,0,22226,,,Liver,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,U,,Rattus norvegicus,BAO_0000251,2107.0,CHEMBL620899,,Microsomes,B
347,Autocuration,,1,,9527.0,4408,0,22224,,In vivo,Plasma,The apparent total plasma clearance in monkey,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL620900,,,A
3341,Autocuration,,1,,9527.0,4409,0,22224,,In vivo,,Compound was evaluated for Hepatic clearance in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620901,,,A
17853,Autocuration,,1,,9527.0,4410,0,22224,,In vivo,,Lower clearance in monkey (i.v.) at 0.5 mpk,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620902,,,A
4514,Autocuration,,1,,9527.0,4411,0,22224,,In vivo,,Plasma clearance in rhesus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620903,,,A
6062,Autocuration,,1,,9527.0,4412,0,22224,,In vivo,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620904,,,A
6821,Autocuration,,1,,9527.0,4413,0,22224,,In vivo,,Plasma clearance of compound was determined in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620905,,,A
6057,Autocuration,,1,,9527.0,4414,0,22224,,In vivo,,Plasma clearance was calculated in rhesus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620906,,,A
5145,Autocuration,,1,,9527.0,4415,0,22224,,In vivo,,Plasma clearance in rhesus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL875420,,,A
6641,Autocuration,,1,,9527.0,4416,0,22224,,In vivo,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620907,,,A
5472,Autocuration,,1,,9527.0,4417,0,22224,,In vivo,,Plasma clearance was evaluated in rhesus,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620908,,,A
4257,Autocuration,,1,,9527.0,4418,0,22224,,In vivo,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620909,,,A
5546,Autocuration,,1,,9527.0,4419,0,22224,,In vivo,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620910,,,A
5334,Autocuration,,1,,9527.0,4420,0,22224,,In vivo,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620911,,,A
5334,Autocuration,,1,,9527.0,4421,0,22224,,In vivo,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620912,,,A
17509,Autocuration,,1,,9527.0,4422,0,22224,,In vivo,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620913,,,A
6535,Autocuration,,1,,9527.0,4423,0,22224,,In vivo,,Cmax in monkey after administration of 1 mg/kg iv,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620914,,,A
5668,Autocuration,,1,,9527.0,4424,0,22224,,In vivo,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620915,,,A
5922,Autocuration,,1,,9527.0,4425,0,22224,,In vivo,,Cmax in cynomolgus monkey by iv administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620916,,,A
5922,Autocuration,,1,,9527.0,4426,0,22224,,In vivo,,Cmax in cynomolgus monkey by po administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620917,,,A
6078,Autocuration,,1,,9527.0,4427,0,22224,,In vivo,,Cmax value evaluated in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620918,,,A
2661,Autocuration,,1,,9527.0,4428,0,22224,,In vivo,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620919,,,A
3249,Autocuration,,1,,9527.0,4429,0,22224,,In vivo,Plasma,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL620920,,,A
3249,Autocuration,,1,,9527.0,4430,0,22224,,In vivo,Plasma,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL620921,,,A
5553,Autocuration,,1,,9527.0,4431,0,22224,,In vivo,Plasma,Maximal plasma concentration in squirrel monkeys,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL620922,,,A
1916,Autocuration,,1,,9527.0,4432,0,22224,,In vivo,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620923,,,A
6227,Autocuration,,1,,9527.0,4433,0,22224,,In vivo,Plasma,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL620924,,,A
4809,Autocuration,,1,,9527.0,4434,0,22224,,In vivo,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620925,,,A
5355,Autocuration,,1,,9527.0,4435,0,22224,,In vivo,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620926,,,A
5355,Autocuration,,1,,9527.0,4436,0,22224,,In vivo,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620927,,,A
5355,Autocuration,,1,,9527.0,4437,0,22224,,In vivo,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620928,,,A
5355,Autocuration,,1,,9527.0,4438,0,22224,,In vivo,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620929,,,A
6221,Autocuration,,1,,9527.0,4439,0,22224,,In vivo,Plasma,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL620930,,,A
167,Autocuration,,1,,9527.0,4440,0,22224,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620931,,,A
167,Autocuration,,1,,9527.0,4441,0,22224,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620932,,,A
4257,Autocuration,,1,,9443.0,4442,0,22224,,In vivo,,Absolute bioavailability was evaluated in monkey,,U,,monkey,BAO_0000218,,CHEMBL620933,,,A
6221,Autocuration,,1,,9443.0,4443,0,22224,,In vivo,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,U,,monkey,BAO_0000218,,CHEMBL620934,,,A
17667,Autocuration,,1,,9443.0,4444,0,22224,,In vivo,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,U,,monkey,BAO_0000218,,CHEMBL620935,,,A
17267,Autocuration,,1,,9544.0,4445,0,22224,,In vivo,,Bioavailability of compound was determined in rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620936,,,A
4256,Autocuration,,1,,38020.0,4446,0,22224,,In vivo,,Bioavailability determined after oral administration in marmoset,,U,,marmosets,BAO_0000218,,CHEMBL620937,,,A
4256,Autocuration,,1,,9541.0,4447,0,22224,,In vivo,,Oral bioavailability in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL620938,,,A
17853,Autocuration,,1,,9443.0,4448,0,22224,,In vivo,,Bioavailability in monkey (p.o.) at 2.0 mpk,,U,,monkey,BAO_0000218,,CHEMBL620939,,,A
16365,Autocuration,,1,,9443.0,4449,0,22224,,In vivo,,Bioavailability was evaluated after oral administration in monkey,,U,,monkey,BAO_0000218,,CHEMBL620940,,,A
1916,Autocuration,,1,,9541.0,4450,0,22224,,In vivo,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL620941,,,A
5334,Autocuration,,1,,9544.0,4451,0,22224,,In vivo,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,,Macaca mulatta,BAO_0000218,,CHEMBL620942,,,A
5334,Autocuration,,1,,9544.0,4452,0,22224,,In vivo,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,,Macaca mulatta,BAO_0000218,,CHEMBL620943,,,A
17592,Autocuration,,1,,9443.0,4453,0,22224,,In vivo,,Bioavailability of the compound was determined in monkey,,U,,monkey,BAO_0000218,,CHEMBL620944,,,A
1399,Autocuration,,1,,9521.0,4454,0,22224,,In vivo,,Bioavailability in squirrel monkey (dose 5 mg/kg),,U,,Saimiri sciureus,BAO_0000218,,CHEMBL620945,,,A
4809,Autocuration,,1,,9443.0,4455,0,22224,,In vivo,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,,monkey,BAO_0000218,,CHEMBL620946,,,A
3341,Autocuration,,1,,9443.0,4456,0,22224,,In vivo,,Oral bioavailability in monkey,,U,,monkey,BAO_0000218,,CHEMBL620947,,,A
64,Autocuration,,1,,9521.0,4457,0,22224,,In vivo,,Compound was tested for bioavailability in squirrel monkey,,U,,Saimiri sciureus,BAO_0000218,,CHEMBL620948,,,A
5005,Autocuration,,1,,9544.0,4458,0,22224,,In vivo,,Oral bioavailability in Rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620949,,,A
5005,Autocuration,,1,,9544.0,4459,0,22224,,In vivo,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,U,,Macaca mulatta,BAO_0000218,,CHEMBL620950,,,A
5237,Autocuration,,1,,9541.0,4460,0,22224,,In vivo,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL620951,,,A
5237,Autocuration,,1,,9541.0,4461,0,22224,,In vivo,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL620952,,,A
5302,Autocuration,,1,,9443.0,4462,0,22224,,In vivo,,Oral bioavailability in monkey (dose 5 mg/kg),,U,,monkey,BAO_0000218,,CHEMBL875421,,,A
17667,Autocuration,,1,,9443.0,4463,0,22224,,In vivo,,Oral bioavailability of compound at 5 mg/kg in monkey,,U,,monkey,BAO_0000218,,CHEMBL620953,,,A
6161,Intermediate,,1,,9615.0,4464,1,50588,,In vivo,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873491,,,A
6161,Intermediate,,1,,9615.0,4465,1,50588,,In vivo,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620954,,,A
3854,Intermediate,,1,,9615.0,4466,1,50588,,,Plasma,Plasma half life determined,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620955,,,A
993,Intermediate,,1,,9615.0,4467,1,50588,,,Plasma,Plasma half life in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618097,,,A
4514,Intermediate,,1,,9615.0,4468,1,50588,,,Plasma,Plasma half-life in Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618268,,,A
5334,Intermediate,,1,,9615.0,4469,1,50588,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618269,,,A
5334,Intermediate,,1,,9615.0,4470,1,50588,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618270,,,A
1466,Intermediate,,1,,9615.0,4471,1,50588,,In vivo,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618271,,,A
1466,Intermediate,,1,,9615.0,4472,1,50588,,In vivo,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873493,,,A
5313,Intermediate,,1,,9615.0,4473,1,50588,,,,Tested for the half life period in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621031,,,A
5313,Intermediate,,1,,9615.0,4474,1,50588,,In vivo,,Tested for the half life period in dog at dosage of 10 mpk,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621032,,,A
3880,Intermediate,,1,,9615.0,4475,1,50588,,,,The compound was tested for half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621033,,,A
3639,Intermediate,,1,,9615.0,4476,1,50588,,,Plasma,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621034,,,A
3880,Intermediate,,1,,9615.0,4477,1,50588,,,,The half life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621035,,,A
3918,Intermediate,,1,,9615.0,4478,1,50588,,,Plasma,The plasma half-life in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621036,,,A
16452,Intermediate,,1,,9615.0,4479,1,50588,,,Plasma,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621037,,,A
17796,Intermediate,,1,,9615.0,4480,1,50588,,,,Half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619812,,,A
5983,Intermediate,,1,,9615.0,4481,1,50588,,In vivo,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619813,,,A
1466,Intermediate,,1,,9615.0,4482,1,50588,,In vivo,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873335,,,A
16456,Intermediate,,1,,9615.0,4483,1,50588,,In vivo,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619814,,,A
6113,Expert,,1,,9669.0,4484,1,50506,,In vivo,,Cmax in ferrets after 30 mg/kg oral dose,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL619815,,,A
6113,Expert,,1,,9669.0,4485,1,50506,,In vivo,,Emesis in ferrets at 30 mg/kg oral dose,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL619816,,,F
17796,Autocuration,,1,,9541.0,4486,0,22224,,In vivo,,Bioavailability in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL619817,,,A
17796,Intermediate,,1,,9541.0,4487,1,100710,,In vivo,,Volume of distribution in cynomolgus,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL619818,,,A
5308,Autocuration,,1,,10141.0,4488,0,22224,,,Plasma,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,U,,Cavia porcellus,BAO_0000218,1969.0,CHEMBL619819,,,A
4877,Autocuration,,1,,10141.0,4489,0,22224,,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,U,,Cavia porcellus,BAO_0000218,,CHEMBL619820,,,A
4876,Autocuration,,1,,10141.0,4490,0,22224,,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,U,,Cavia porcellus,BAO_0000218,,CHEMBL875419,,,A
4878,Autocuration,,1,,10141.0,4491,0,22224,,In vivo,Plasma,AUC in guinea pig after 3mg/kg oral dose,,U,,Cavia porcellus,BAO_0000218,1969.0,CHEMBL619821,,,A
5308,Autocuration,,1,,10141.0,4492,0,22224,,In vivo,,Bioavailability in guinea pig was tested,,U,,Cavia porcellus,BAO_0000218,,CHEMBL619822,,,A
4877,Autocuration,,1,,10141.0,4493,0,22224,,In vivo,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,U,,Cavia porcellus,BAO_0000218,,CHEMBL619823,,,A
4876,Autocuration,,1,,10141.0,4494,0,22224,,In vivo,,Tested for the oral bioavailability of the compound,,U,,Cavia porcellus,BAO_0000218,,CHEMBL619824,,,A
4876,Autocuration,,1,,10141.0,4495,0,22224,,In vivo,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,U,,Cavia porcellus,BAO_0000218,,CHEMBL619825,,,A
5308,Autocuration,,1,,10141.0,4496,0,22224,,In vivo,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,U,,Cavia porcellus,BAO_0000218,,CHEMBL619826,,,A
4877,Autocuration,,1,,10141.0,4497,0,22224,,In vivo,Lung,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,U,,Cavia porcellus,BAO_0000218,2048.0,CHEMBL619827,,,A
4878,Autocuration,,1,,10141.0,4498,0,22224,,In vivo,,Cmax in guinea pig after 3mg/kg oral dose,,U,,Cavia porcellus,BAO_0000218,,CHEMBL618167,,,A
5689,Autocuration,,1,,10141.0,4499,0,22224,,,Blood,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,178.0,CHEMBL618168,,,A
5689,Autocuration,,1,,10141.0,4500,0,22224,,,Brain,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,955.0,CHEMBL618169,,,A
5689,Autocuration,,1,,10141.0,4501,0,22224,,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,,CHEMBL618170,,,A
5689,Autocuration,,1,,10141.0,4502,0,22224,,,Intestine,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,160.0,CHEMBL618171,,,A
5689,Autocuration,,1,,10141.0,4503,0,22224,,,Kidney,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,2113.0,CHEMBL618172,,,A
5689,Autocuration,,1,,10141.0,4504,0,22224,,,Liver,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,2107.0,CHEMBL618173,,,A
5689,Autocuration,,1,,10141.0,4505,0,22224,,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,,CHEMBL618174,,,A
5689,Autocuration,,1,,10141.0,4506,0,22224,,,Spleen,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,U,,Cavia porcellus,BAO_0000019,2106.0,CHEMBL875408,,,A
14465,Autocuration,,1,,10141.0,4507,0,22224,,In vivo,,Elimination T1/2 in Guinea pig (PO dose),,U,,Cavia porcellus,BAO_0000218,,CHEMBL839827,,,A
5689,Autocuration,,1,,10141.0,4508,0,22224,,,,Partition coefficient was measured as -log (counts per min ),,U,,Cavia porcellus,BAO_0000019,,CHEMBL618175,,,A
611,Autocuration,,1,,10141.0,4509,0,22224,,In vivo,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,U,,Cavia porcellus,BAO_0000218,,CHEMBL618176,,,A
611,Autocuration,,1,,10141.0,4510,0,22224,,In vivo,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,U,,Cavia porcellus,BAO_0000218,,CHEMBL618177,,,A
14465,Autocuration,,1,,10141.0,4511,0,22224,,In vivo,,Elimination T1/2 in Guinea pig (PO dose),,U,,Cavia porcellus,BAO_0000218,,CHEMBL618178,,,A
4876,Autocuration,,1,,10141.0,4512,0,22224,,In vivo,,"Tested for the half life period of the compound, intravenously",,U,,Cavia porcellus,BAO_0000218,,CHEMBL618179,,,A
5689,Autocuration,,1,,10141.0,4513,0,22224,,,,Half-life was measured,,U,,Cavia porcellus,BAO_0000019,,CHEMBL873489,,,A
7515,Autocuration,,1,,10141.0,4514,0,22224,,,,The time required for onset of inotropy after addition of a single dose of delta F75,,U,,Cavia porcellus,BAO_0000019,,CHEMBL618180,,,A
17667,Autocuration,,1,,10141.0,4515,0,22224,,In vivo,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,U,,Cavia porcellus,BAO_0000218,,CHEMBL618181,,,A
17667,Autocuration,,1,,10141.0,4516,0,22224,,In vivo,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,U,,Cavia porcellus,BAO_0000218,,CHEMBL618182,,,A
4727,Autocuration,,1,,10029.0,4517,0,22224,,In vivo,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,U,,Cricetulus griseus,BAO_0000218,,CHEMBL618183,,,A
10107,Intermediate,,1,,10090.0,4518,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,,CHEMBL618184,,,A
10107,Intermediate,,1,,10090.0,4519,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,,CHEMBL618185,,,A
10107,Intermediate,,1,,10090.0,4520,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,,CHEMBL618186,,,A
10107,Intermediate,,1,,10090.0,4521,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,,CHEMBL618187,,,A
10107,Intermediate,,1,,10090.0,4522,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL618188,,,A
10107,Intermediate,,1,,10090.0,4523,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,,CHEMBL875409,,,A
10107,Intermediate,,1,,10090.0,4524,1,50594,,In vivo,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,,CHEMBL618189,,,A
3655,Intermediate,,1,,10090.0,4525,1,50594,,In vivo,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL618190,,,A
3655,Intermediate,,1,,10090.0,4526,1,50594,,In vivo,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL618191,,,A
3655,Intermediate,,1,,10090.0,4527,1,50594,,In vivo,Blood,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL618192,,,A
3655,Intermediate,,1,,10090.0,4528,1,50594,,In vivo,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL618193,,,A
3655,Intermediate,,1,,10090.0,4529,1,50594,,In vivo,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL618194,,,A
3655,Intermediate,,1,,10090.0,4530,1,50594,,In vivo,Bone,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL618195,,,A
3655,Intermediate,,1,,10090.0,4531,1,50594,,In vivo,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618196,,,A
3655,Intermediate,,1,,10090.0,4532,1,50594,,In vivo,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618197,,,A
3655,Intermediate,,1,,10090.0,4533,1,50594,,In vivo,Brain,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618198,,,A
3655,Intermediate,,1,,10090.0,4534,1,50594,,In vivo,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL618199,,,A
3655,Intermediate,,1,,10090.0,4535,1,50594,,In vivo,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL618200,,,A
3655,Intermediate,,1,,10090.0,4536,1,50594,,In vivo,Heart,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL618201,,,A
3655,Intermediate,,1,,10090.0,4537,1,50594,,In vivo,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL618202,,,A
3655,Intermediate,,1,,10090.0,4538,1,50594,,In vivo,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL618203,,,A
3655,Intermediate,,1,,10090.0,4539,1,50594,,In vivo,Intestine,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL618204,,,A
3655,Intermediate,,1,,10090.0,4540,1,50594,,In vivo,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618205,,,A
3655,Intermediate,,1,,10090.0,4541,1,50594,,In vivo,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618206,,,A
3655,Intermediate,,1,,10090.0,4542,1,50594,,In vivo,Kidney,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618207,,,A
3655,Intermediate,,1,,10090.0,4543,1,50594,,In vivo,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618208,,,A
3655,Intermediate,,1,,10090.0,4544,1,50594,,In vivo,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618932,,,A
3655,Intermediate,,1,,10090.0,4545,1,50594,,In vivo,Liver,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618933,,,A
3655,Intermediate,,1,,10090.0,4546,1,50594,,In vivo,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL618934,,,A
3655,Intermediate,,1,,10090.0,4547,1,50594,,In vivo,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL618935,,,A
3655,Intermediate,,1,,10090.0,4548,1,50594,,In vivo,Lung,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL618936,,,A
3655,Intermediate,,1,,10090.0,4549,1,50594,,In vivo,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL618937,,,A
3655,Intermediate,,1,,10090.0,4550,1,50594,,In vivo,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL618938,,,A
3655,Intermediate,,1,,10090.0,4551,1,50594,,In vivo,Muscle tissue,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL619104,,,A
3655,Intermediate,,1,,10090.0,4552,1,50594,,In vivo,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL619105,,,A
3655,Intermediate,,1,,10090.0,4553,1,50594,,In vivo,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL619106,,,A
3655,Intermediate,,1,,10090.0,4554,1,50594,,In vivo,Spleen,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL619107,,,A
3655,Intermediate,,1,,10090.0,4555,1,50594,,In vivo,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL875410,,,A
3655,Intermediate,,1,,10090.0,4556,1,50594,,In vivo,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL619108,,,A
3655,Intermediate,,1,,10090.0,4557,1,50594,,In vivo,Stomach,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL619109,,,A
16597,Intermediate,,1,,10090.0,4558,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,N,,Mus musculus,BAO_0000218,,CHEMBL619110,,,A
16597,Intermediate,,1,,10090.0,4559,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,N,,Mus musculus,BAO_0000218,,CHEMBL619111,,,F
16597,Intermediate,,1,,10090.0,4560,1,50594,,In vivo,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL619112,,,A
16597,Intermediate,,1,,10090.0,4561,1,50594,,In vivo,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL619113,,,A
17764,Intermediate,,1,,10090.0,4562,1,50594,,In vivo,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL619114,,,A
17764,Intermediate,,1,,10090.0,4563,1,50594,,In vivo,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL619115,,,F
3830,Intermediate,,1,,9606.0,4564,1,81034,A2780,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619116,,,F
3829,Intermediate,,1,,9606.0,4565,1,81034,A2780,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619117,,,F
2040,Intermediate,,1,,9606.0,4566,1,81034,A2780,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619118,,,F
15684,Intermediate,,1,,9606.0,4567,1,81034,A2780,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619119,,,F
15684,Intermediate,,1,,9606.0,4568,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619120,,,F
15684,Intermediate,,1,,9606.0,4569,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619121,,,F
15684,Intermediate,,1,,9606.0,4570,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619122,,,F
15684,Intermediate,,1,,9606.0,4571,1,81034,A2780,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619123,,,F
15684,Intermediate,,1,,9606.0,4572,1,81034,A2780,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619124,,,F
2859,Intermediate,,1,,9606.0,4573,1,81034,A2780,,,Compound was evaluated for cytotoxicity against A2780 cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619125,,,F
5618,Intermediate,,1,,9606.0,4574,1,81034,A2780,,,In vitro inhibitory activity against human tumor cell line A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL875411,,,F
15684,Intermediate,,1,,9606.0,4575,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619126,,,F
15684,Intermediate,,1,,9606.0,4576,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619127,,,F
15684,Intermediate,,1,,9606.0,4577,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619128,,,F
15684,Intermediate,,1,,9606.0,4578,1,81034,A2780,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619129,,,F
2113,Intermediate,,1,,9606.0,4579,1,81034,A2780,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619130,,,F
2113,Intermediate,,1,,9606.0,4580,1,81034,A2780,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619131,,,F
16745,Intermediate,,1,,9606.0,4581,1,81034,A2780,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619132,,,F
16597,Expert,,1,,9606.0,4582,1,81034,A2780,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL619133,,,F
15684,Intermediate,,1,,9606.0,4583,1,81034,A2780,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619134,,,F
15684,Intermediate,,1,,9606.0,4584,1,81034,A2780,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619135,,,F
2040,Intermediate,,1,,9606.0,4585,1,81034,A2780,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619136,,,F
2040,Intermediate,,1,,9606.0,4586,1,81034,A2780,,,Relative resistance factor in A2780 cisplatin-resistant line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619137,,,F
16165,Intermediate,,1,,9606.0,4587,1,81034,A2780,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL883713,,,F
16165,Intermediate,,1,,9606.0,4588,1,81034,A2780,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL875412,,,F
16597,Expert,,1,,9606.0,4589,1,81034,A2780,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL619138,,,F
16597,Expert,,1,,9606.0,4590,1,81034,A2780,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL619262,,,F
3992,Intermediate,,1,,9606.0,4591,1,81034,A2780,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619139,,,F
10553,Intermediate,,1,,9606.0,4592,1,81034,A2780,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619140,,,F
15608,Intermediate,,1,,9606.0,4593,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619141,,,F
15608,Intermediate,,1,,9606.0,4594,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619142,,,F
15608,Intermediate,,1,,9606.0,4595,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619143,,,F
15608,Intermediate,,1,,9606.0,4596,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619144,,,F
15608,Intermediate,,1,,9606.0,4597,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619145,,,F
15608,Intermediate,,1,,9606.0,4598,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619146,,,F
15569,Intermediate,,1,,9606.0,4599,1,81034,A2780,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619147,,,F
17420,Intermediate,,1,,9606.0,4600,1,81034,A2780,,,Antiproliferative effect of compound on A2780/DX cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619148,,,F
17420,Intermediate,,1,,9606.0,4601,1,81034,A2780,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619149,,,F
15099,Intermediate,,1,,9606.0,4602,1,81034,A2780,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619150,,,F
15099,Intermediate,,1,,9606.0,4603,1,81034,A2780,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619151,,,F
17672,Intermediate,,1,,9606.0,4604,1,81034,A2780,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL883794,,,F
17672,Intermediate,,1,,9606.0,4605,1,81034,A2780,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619152,,,F
17270,Intermediate,,1,,9606.0,4606,1,81034,A2780,,,In vitro cytotoxicity against A2780ADR cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619153,,,F
17270,Intermediate,,1,,9606.0,4607,1,81034,A2780,,,In vitro cytotoxicity against A2780CIS cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619154,,,F
5574,Intermediate,,1,,9606.0,4608,1,81034,A2780,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619155,,,F
2113,Intermediate,,1,,9606.0,4609,1,81034,A2780,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619156,,,F
16913,Intermediate,,1,,9606.0,4610,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619157,,,F
16913,Intermediate,,1,,9606.0,4611,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619797,,,F
17839,Autocuration,,1,,9544.0,4612,0,22224,,In vivo,,Oral bioavailability of compound in rhesus macaques,,U,,Macaca mulatta,BAO_0000218,,CHEMBL619798,,,A
6821,Autocuration,,1,,9443.0,4613,0,22224,,In vivo,,Oral bioavailability in monkey,,U,,monkey,BAO_0000218,,CHEMBL619799,,,A
6078,Autocuration,,1,,9443.0,4614,0,22224,,In vivo,,Oral bioavailability evaluated in monkey,,U,,monkey,BAO_0000218,,CHEMBL619800,,,A
6535,Autocuration,,1,,9443.0,4615,0,22224,,In vivo,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,U,,monkey,BAO_0000218,,CHEMBL619801,,,A
4449,Autocuration,,1,,9544.0,4616,0,22224,,In vivo,,Oral bioavailability in Rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL619802,,,A
6057,Autocuration,,1,,9544.0,4617,0,22224,,In vivo,,Oral bioavailability was calculated in rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL619803,,,A
5922,Autocuration,,1,,9541.0,4618,0,22224,,In vivo,,Oral bioavailability in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL619965,,,A
5940,Autocuration,,1,,9443.0,4619,0,22224,,In vivo,,Oral bioavailability in monkey,,U,,monkey,BAO_0000218,,CHEMBL619966,,,A
6265,Autocuration,,1,,9443.0,4620,0,22224,,In vivo,,Oral bioavailability in monkey,,U,,monkey,BAO_0000218,,CHEMBL619967,,,A
6265,Autocuration,,1,,9443.0,4621,0,22224,,In vivo,,Oral bioavailability in monkey (dose 1 mg/kg),,U,,monkey,BAO_0000218,,CHEMBL620073,,,A
6265,Autocuration,,1,,9443.0,4622,0,22224,,In vivo,,Oral bioavailability in monkey (dose 5 mg/kg),,U,,monkey,BAO_0000218,,CHEMBL620074,,,A
5940,Autocuration,,1,,9443.0,4623,0,22224,,In vivo,,Oral bioavailability in monkey,,U,,monkey,BAO_0000218,,CHEMBL620075,,,A
5940,Autocuration,,1,,9443.0,4624,0,22224,,In vivo,,Oral bioavailability in monkey,,U,,monkey,BAO_0000218,,CHEMBL620076,,,A
4514,Autocuration,,1,,9544.0,4625,0,22224,,In vivo,,Oral bioavailability in rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620077,,,A
5546,Autocuration,,1,,9544.0,4626,0,22224,,In vivo,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620078,,,A
5553,Autocuration,,1,,9521.0,4627,0,22224,,In vivo,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,U,,Saimiri sciureus,BAO_0000218,,CHEMBL620079,,,A
6641,Autocuration,,1,,9443.0,4628,0,22224,,In vivo,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,,monkey,BAO_0000218,,CHEMBL620080,,,A
5472,Autocuration,,1,,9544.0,4629,0,22224,,In vivo,,Oral bioavailability in Rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620081,,,A
5668,Autocuration,,1,,9544.0,4630,0,22224,,In vivo,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,U,,Macaca mulatta,BAO_0000218,,CHEMBL620082,,,A
5711,Autocuration,,1,,9443.0,4631,0,22224,,In vivo,,Oral bioavailability in monkey at 10 mg/kg of the compound,,U,,monkey,BAO_0000218,,CHEMBL620083,,,A
5145,Autocuration,,1,,9544.0,4632,0,22224,,In vivo,,Bioavailability in Rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620084,,,A
3443,Autocuration,,1,,9527.0,4633,0,22224,,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620085,,,A
3443,Autocuration,,1,,9527.0,4634,0,22224,,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL874595,,,A
3249,Autocuration,,1,,9527.0,4635,0,22224,,In vivo,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL873352,,,A
3249,Autocuration,,1,,9527.0,4636,0,22224,,In vivo,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620086,,,A
5355,Autocuration,,1,,9527.0,4637,0,22224,,In vivo,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620087,,,A
5355,Autocuration,,1,,9527.0,4638,0,22224,,In vivo,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620088,,,A
5355,Autocuration,,1,,9527.0,4639,0,22224,,In vivo,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620089,,,A
4809,Autocuration,,1,,9527.0,4640,0,22224,,In vivo,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620090,,,A
4809,Autocuration,,1,,9527.0,4641,0,22224,,In vivo,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620091,,,A
14294,Autocuration,,1,,9527.0,4642,0,22224,,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,U,,Cercopithecidae,BAO_0000251,,CHEMBL620092,,Microsomes,A
14294,Autocuration,,1,,9527.0,4643,0,22224,,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,U,,Cercopithecidae,BAO_0000251,,CHEMBL620093,,Microsomes,A
14294,Autocuration,,1,,9527.0,4644,0,22224,,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,U,,Cercopithecidae,BAO_0000251,,CHEMBL620094,,Microsomes,A
14294,Autocuration,,1,,9527.0,4645,0,22224,,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,U,,Cercopithecidae,BAO_0000251,,CHEMBL620095,,Microsomes,A
3443,Autocuration,,1,,9527.0,4646,0,22224,,In vivo,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620096,,,A
3443,Autocuration,,1,,9527.0,4647,0,22224,,In vivo,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620097,,,A
11271,Autocuration,,1,,9527.0,4648,0,22224,,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,U,,Cercopithecidae,BAO_0000019,,CHEMBL620098,,,A
3443,Autocuration,,1,,9527.0,4649,0,22224,,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620099,,,A
3443,Autocuration,,1,,9527.0,4650,0,22224,,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620100,,,A
6821,Autocuration,,1,,9527.0,4651,0,22224,,,,Elimination Half-life of compound was determined in monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL620101,,,A
17267,Autocuration,,1,,9527.0,4652,0,22224,,,,Half life of compound was determined in rhesus monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL620102,,,A
5819,Autocuration,,1,,9527.0,4653,0,22224,,,Plasma,Half life in monkey plasma,,U,,Cercopithecidae,BAO_0000366,1969.0,CHEMBL620103,,,A
5819,Autocuration,,1,,9527.0,4654,0,22224,,,Plasma,Half life in monkey plasma; Not detected,,U,,Cercopithecidae,BAO_0000366,1969.0,CHEMBL620104,,,A
1916,Autocuration,,1,,9527.0,4655,0,22224,,In vivo,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL874596,,,A
17509,Autocuration,,1,,9527.0,4656,0,22224,,In vivo,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL873490,,,A
1399,Autocuration,,1,,9527.0,4657,0,22224,,,,Terminal half life of the compound.,,U,,Cercopithecidae,BAO_0000019,,CHEMBL620105,,,A
1916,Autocuration,,1,,9527.0,4658,0,22224,,In vivo,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620780,,,A
4809,Autocuration,,1,,9527.0,4659,0,22224,,In vivo,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL620781,,,A
5546,Autocuration,,1,,9527.0,4660,0,22224,,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620956,,,A
3443,Autocuration,,1,,9527.0,4661,0,22224,,,Urine,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,1088.0,CHEMBL620957,,,A
3443,Autocuration,,1,,9527.0,4662,0,22224,,,Urine,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,1088.0,CHEMBL620958,,,A
4257,Autocuration,,1,,9527.0,4663,0,22224,,In vivo,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620959,,,A
6221,Autocuration,,1,,9527.0,4664,0,22224,,In vivo,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620960,,,A
5472,Autocuration,,1,,9527.0,4665,0,22224,,In vivo,,Volume of distribution was evaluated in rhesus,,U,,Cercopithecidae,BAO_0000218,,CHEMBL620961,,,A
4727,Autocuration,,1,,10029.0,4666,0,22224,,In vivo,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,U,,Cricetulus griseus,BAO_0000218,,CHEMBL620962,,,A
4727,Autocuration,,1,,10029.0,4667,0,22224,,In vivo,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,U,,Cricetulus griseus,BAO_0000218,,CHEMBL620963,,,A
4727,Autocuration,,1,,10029.0,4668,0,22224,,In vivo,,Bioavailability in hamster was determined,,U,,Cricetulus griseus,BAO_0000218,,CHEMBL620964,,,A
4727,Autocuration,,1,,10029.0,4669,0,22224,,In vivo,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,U,,Cricetulus griseus,BAO_0000218,,CHEMBL620965,,,A
4727,Autocuration,,1,,10029.0,4670,0,22224,,In vivo,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,U,,Cricetulus griseus,BAO_0000218,,CHEMBL620966,,,A
4727,Autocuration,,1,,10029.0,4671,0,22224,,,Blood,Half life of compound was determined in hamster blood,,U,,Cricetulus griseus,BAO_0000221,178.0,CHEMBL620967,,,A
1452,Autocuration,,1,,9823.0,4672,0,22224,,,,Michaelis-Menten constant of the compound.,,U,,Sus scrofa,BAO_0000019,,CHEMBL620968,,,A
1452,Autocuration,,1,,9823.0,4673,0,22224,,,,Vmax value was measured at 0 uM concentration of silyl ether.,,U,,Sus scrofa,BAO_0000019,,CHEMBL874597,,,A
1452,Autocuration,,1,,9823.0,4674,0,22224,,,,Vmax value was measured at 10 uM concentration of silyl ether.,,U,,Sus scrofa,BAO_0000019,,CHEMBL620969,,,A
1452,Autocuration,,1,,9823.0,4675,0,22224,,,,Vmax value was measured at 5 uM concentration of silyl ether.,,U,,Sus scrofa,BAO_0000019,,CHEMBL620970,,,A
11706,Expert,,1,,9606.0,4676,9,235,,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,D,,Homo sapiens,BAO_0000357,,CHEMBL620971,,,B
1916,Autocuration,,1,,9606.0,4677,0,22224,,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,U,,Homo sapiens,BAO_0000218,,CHEMBL620972,,,A
17791,Autocuration,,1,,9606.0,4678,0,22224,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,U,,Homo sapiens,BAO_0000019,,CHEMBL620973,,,A
7766,Autocuration,,1,,9606.0,4679,0,22224,,,,Active metabolite of ifosfamide determined in humans; A-Active,,U,,Homo sapiens,BAO_0000019,,CHEMBL618243,,,A
6567,Autocuration,,1,,9606.0,4680,0,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,U,,Homo sapiens,BAO_0000019,,CHEMBL618244,,,A
6567,Autocuration,,1,,9606.0,4681,0,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,U,,Homo sapiens,BAO_0000019,,CHEMBL618245,,,A
6567,Autocuration,,1,,9606.0,4682,0,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,U,,Homo sapiens,BAO_0000019,,CHEMBL618246,,,A
6567,Autocuration,,1,,9606.0,4683,0,22224,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,U,,Homo sapiens,BAO_0000019,,CHEMBL618247,,,A
17791,Autocuration,,1,,9606.0,4684,0,22224,,,,Compound was evaluated for oral bioavailability in human,,U,,Homo sapiens,BAO_0000218,,CHEMBL618248,,,A
7766,Autocuration,,1,,9606.0,4685,0,22224,,,Urine,Metabolite of ifosfamide determined in urine; NF-Not found,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618249,,,A
6852,Autocuration,,1,,9606.0,4686,0,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,U,,Homo sapiens,BAO_0000019,,CHEMBL618250,,,A
6852,Autocuration,,1,,9606.0,4687,0,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,U,,Homo sapiens,BAO_0000019,,CHEMBL874598,,,A
6852,Autocuration,,1,,9606.0,4688,0,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,U,,Homo sapiens,BAO_0000019,,CHEMBL618251,,,A
6852,Autocuration,,1,,9606.0,4689,0,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,U,,Homo sapiens,BAO_0000019,,CHEMBL618252,,,A
6852,Autocuration,,1,,9606.0,4690,0,22224,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,U,,Homo sapiens,BAO_0000019,,CHEMBL618253,,,A
6852,Autocuration,,1,,9606.0,4691,0,22224,,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,U,,Homo sapiens,BAO_0000019,,CHEMBL618254,,,A
6852,Autocuration,,1,,9606.0,4692,0,22224,,,,Percent of compound in healthy individuals (Group D),,U,,Homo sapiens,BAO_0000019,,CHEMBL618255,,,A
4397,Autocuration,,1,,9606.0,4693,0,22224,,,Liver,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618983,,Microsomes,A
17409,Autocuration,,1,,9606.0,4694,0,22224,,,,Binding towards human plasma protein at 10 uM,,U,,Homo sapiens,BAO_0000019,,CHEMBL618984,,,A
17409,Autocuration,,1,,9606.0,4695,0,22224,,,,Binding towards human plasma protein at 100 uM,,U,,Homo sapiens,BAO_0000019,,CHEMBL618985,,,A
17176,Autocuration,,1,,9606.0,4696,0,22224,,,,Human plasma protein binding activity was determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL618986,,,A
15444,Autocuration,,1,,9606.0,4697,0,22224,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,U,,Homo sapiens,BAO_0000019,,CHEMBL618987,,,A
17267,Autocuration,,1,,9606.0,4698,0,22224,,,,Percent binding of compound towards human plasma protein was determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL618988,,,A
5944,Autocuration,,1,,9606.0,4699,0,22224,,In vitro,Liver,Plasma clearance in human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618989,,Microsomes,A
5668,Autocuration,,1,,9606.0,4700,0,22224,,In vitro,Liver,In vitro intrinsic clearance in human liver microsome,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618990,,Microsomes,A
5669,Autocuration,,1,,9606.0,4701,0,22224,,In vitro,Liver,In vitro intrinsic clearance in human liver microsome,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618991,,Microsomes,A
5041,Autocuration,,1,,9606.0,4702,0,22224,,In vitro,,In vitro microsome metabolism clearance in human was determined,,U,,Homo sapiens,BAO_0000251,,CHEMBL876725,,Microsomes,A
5041,Autocuration,,1,,9606.0,4703,0,22224,,In vitro,,In vitro microsome metabolism clearance in human was determined; High,,U,,Homo sapiens,BAO_0000251,,CHEMBL618992,,Microsomes,A
5041,Autocuration,,1,,9606.0,4704,0,22224,,In vitro,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,U,,Homo sapiens,BAO_0000251,,CHEMBL618993,,Microsomes,A
5676,Autocuration,,1,,9606.0,4705,0,22224,,In vitro,Liver,Pharmacokinetic property (clearance) in human liver microsome,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618994,,Microsomes,A
5944,Autocuration,,1,,9606.0,4706,0,22224,,In vitro,Liver,Plasma clearance in human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618995,,Microsomes,A
17538,Autocuration,,1,,9606.0,4707,0,22224,,In vitro,Liver,In vitro clearance in human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618996,,Microsomes,A
6331,Autocuration,,1,,9606.0,4708,0,22224,,In vitro,Liver,Intrinsic clearance in human liver microsomes was determined,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618997,,Microsomes,A
5948,Autocuration,,1,,9606.0,4709,0,22224,,In vitro,Liver,Intrinsic clearance in human liver microsomes was determined,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618998,,Microsomes,A
5965,Autocuration,,1,,9606.0,4710,0,22224,,In vivo,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,U,,Homo sapiens,BAO_0000218,,CHEMBL618999,,,A
1916,Autocuration,,1,,9606.0,4711,0,22224,,In vivo,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,U,,Homo sapiens,BAO_0000218,,CHEMBL620223,,,A
5965,Autocuration,,1,,9606.0,4712,0,22224,,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,U,,Homo sapiens,BAO_0000218,,CHEMBL620224,,,A
1299,Autocuration,,1,,9606.0,4713,0,22224,,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,U,,Homo sapiens,BAO_0000019,,CHEMBL620225,,,A
1299,Autocuration,,1,,9606.0,4714,0,22224,,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,U,,Homo sapiens,BAO_0000019,,CHEMBL620226,,,A
7766,Autocuration,,1,,9606.0,4715,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL620227,,,A
7766,Autocuration,,1,,9606.0,4716,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL876726,,,A
7766,Autocuration,,1,,9606.0,4717,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL620228,,,A
7766,Autocuration,,1,,9606.0,4718,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL620229,,,A
17764,Intermediate,,1,,10090.0,4719,1,50594,,In vivo,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620230,,,F
17764,Intermediate,,1,,10090.0,4720,1,50594,,In vivo,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620231,,,F
17764,Intermediate,,1,,10090.0,4721,1,50594,,In vivo,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620232,,,F
17764,Intermediate,,1,,10090.0,4722,1,50594,,In vivo,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620233,,,F
14294,Intermediate,,1,,10090.0,4723,1,50594,,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,N,,Mus musculus,BAO_0000218,,CHEMBL620234,,,A
14294,Intermediate,,1,,10090.0,4724,1,50594,,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,N,,Mus musculus,BAO_0000218,,CHEMBL620235,,,A
14294,Intermediate,,1,,10090.0,4725,1,50594,,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,N,,Mus musculus,BAO_0000218,,CHEMBL620236,,,A
6251,Intermediate,,1,,10090.0,4726,1,50594,,,Liver,In vitro metabolic potential in mouse liver microsomes,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL620237,,,A
17582,Intermediate,,1,,10090.0,4727,1,50594,,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,N,,Mus musculus,BAO_0000218,,CHEMBL620238,,,A
17811,Intermediate,,1,,10090.0,4728,1,50594,,,Adrenal gland,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,N,,Mus musculus,BAO_0000218,2369.0,CHEMBL620239,,,A
17811,Intermediate,,1,,10090.0,4729,1,50594,,,Brain,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL620240,,,A
17811,Intermediate,,1,,10090.0,4730,1,50594,,,Brain,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL620241,,,A
17811,Intermediate,,1,,10090.0,4731,1,50594,,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,N,,Mus musculus,BAO_0000218,,CHEMBL876727,,,A
17811,Intermediate,,1,,10090.0,4732,1,50594,,,Kidney,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL620242,,,A
17811,Intermediate,,1,,10090.0,4733,1,50594,,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,N,,Mus musculus,BAO_0000218,,CHEMBL620243,,,A
5288,Intermediate,,1,,10090.0,4734,1,50594,,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620244,,,A
2717,Intermediate,,1,,10090.0,4735,1,50594,,,Serum,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,N,,Mus musculus,BAO_0000218,1977.0,CHEMBL620245,,,A
2717,Intermediate,,1,,10090.0,4736,1,50594,,,Serum,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,N,,Mus musculus,BAO_0000218,1977.0,CHEMBL620246,,,A
2717,Intermediate,,1,,10090.0,4737,1,50594,,,Serum,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,N,,Mus musculus,BAO_0000218,1977.0,CHEMBL620247,,,A
17753,Intermediate,,1,,10090.0,4738,1,50594,,In vivo,Plasma,Half life of compound was determined in plasma of mice at 24 mg/Kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL620248,,,A
17753,Intermediate,,1,,10090.0,4739,1,50594,,In vivo,Plasma,Half life of compound was determined in plasma of mice at 40 mg/Kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL873497,,,A
17753,Intermediate,,1,,10090.0,4740,1,50594,,In vivo,Plasma,Half life of compound was determined in plasma of mice at 5 mg/Kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL620249,,,A
17764,Intermediate,,1,,10090.0,4741,1,50594,,In vivo,,Half life after intraperitoneal administration in mice at 18 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620250,,,F
17764,Intermediate,,1,,10090.0,4742,1,50594,,In vivo,,Half life after intraperitoneal administration in mice at 23 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620251,,,F
17764,Intermediate,,1,,10090.0,4743,1,50594,,In vivo,,Half life after intraperitoneal administration in mice at 25 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620252,,,F
17764,Intermediate,,1,,10090.0,4744,1,50594,,In vivo,,Half life after intraperitoneal administration in mice at 26 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620253,,,F
17764,Intermediate,,1,,10090.0,4745,1,50594,,In vivo,,Half life after intravenous administration in mice at 23 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620254,,,F
17764,Intermediate,,1,,10090.0,4746,1,50594,,In vivo,,Half life after intravenous administration in mice at 24 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620255,,,A
16597,Intermediate,,1,,10090.0,4747,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,N,,Mus musculus,BAO_0000218,,CHEMBL620256,,,A
2675,Intermediate,,1,,10090.0,4748,1,50594,,In vivo,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL876728,,,A
2675,Intermediate,,1,,10090.0,4749,1,50594,,In vivo,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL620257,,,A
16597,Intermediate,,1,,10090.0,4750,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,N,,Mus musculus,BAO_0000218,,CHEMBL620258,,,A
4890,Intermediate,,1,,10090.0,4751,1,50594,,In vivo,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,N,,Mus musculus,BAO_0000218,,CHEMBL620259,,,A
429,Intermediate,,1,,10090.0,4752,1,50594,,In vivo,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620260,,,A
17837,Intermediate,,1,,10090.0,4753,1,50594,,In vivo,Blood,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL620261,,,A
16597,Intermediate,,1,,10090.0,4754,1,50594,,In vivo,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL620262,,,A
16597,Intermediate,,1,,10090.0,4755,1,50594,,In vivo,,Half life at a dose of 10 mg/kg peroral administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL620263,,,A
6619,Intermediate,,1,,10090.0,4756,1,50594,,,,Half life in ob/ob mice,,N,,Mus musculus,BAO_0000218,,CHEMBL620264,,,A
4066,Intermediate,,1,,10090.0,4757,1,50594,,In vivo,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL620265,,,A
4239,Intermediate,,1,,10090.0,4758,1,50594,,,,Half-life was measured in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL620266,,,A
5969,Intermediate,,1,,10090.0,4759,1,50594,,In vivo,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620267,,,A
8999,Intermediate,,1,,10090.0,4760,1,50594,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,N,,Mus musculus,BAO_0000218,,CHEMBL619364,,,A
8999,Intermediate,,1,,10090.0,4761,1,50594,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,N,,Mus musculus,BAO_0000218,,CHEMBL619365,,,A
17641,Intermediate,,1,,10090.0,4762,1,50594,,,Brain,T2 in brain of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL619366,,,A
17641,Intermediate,,1,,10090.0,4763,1,50594,,,Kidney,T2 in kidney of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL619367,,,A
17641,Intermediate,,1,,10090.0,4764,1,50594,,,Liver,T2 in liver of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL619368,,,A
17641,Intermediate,,1,,10090.0,4765,1,50594,,,Lung,T2 in lungs of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL619369,,,A
17641,Intermediate,,1,,10090.0,4766,1,50594,,,Spleen,T2 in spleen of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL876729,,,A
16597,Intermediate,,1,,10090.0,4767,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,N,,Mus musculus,BAO_0000218,,CHEMBL619370,,,A
4890,Intermediate,,1,,10090.0,4768,1,50594,,In vivo,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,N,,Mus musculus,BAO_0000218,,CHEMBL619371,,,A
429,Intermediate,,1,,10090.0,4769,1,50594,,In vivo,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL619372,,,A
429,Intermediate,,1,,10090.0,4770,1,50594,,In vivo,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL620012,,,A
5969,Intermediate,,1,,10090.0,4771,1,50594,,In vivo,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620013,,,A
16913,Intermediate,,1,,9606.0,4772,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL620014,,,F
16913,Intermediate,,1,,9606.0,4773,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL620015,,,F
16913,Intermediate,,1,,9606.0,4774,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621010,,,F
16913,Intermediate,,1,,9606.0,4775,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621011,,,F
16913,Intermediate,,1,,9606.0,4776,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621012,,,F
16913,Intermediate,,1,,9606.0,4777,1,81034,A2780,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621013,,,F
17270,Intermediate,,1,,9606.0,4778,1,81034,A2780,,,In vitro cytotoxicity against A2780TAX cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621014,,,F
5618,Intermediate,,1,,9606.0,4779,1,80017,A2780cisR,,,In vitro inhibitory activity against human tumor cell line A2780cis,,N,481.0,Homo sapiens,BAO_0000219,,CHEMBL618154,,,F
17777,Expert,,1,,9606.0,4780,1,81034,A2780,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618155,,,F
16112,Intermediate,,1,,9606.0,4781,1,80017,A2780cisR,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,N,481.0,Homo sapiens,BAO_0000219,,CHEMBL618156,,,F
15748,Intermediate,,1,,9606.0,4782,1,80017,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,N,481.0,Homo sapiens,BAO_0000219,,CHEMBL618157,,,F
6633,Intermediate,,1,,9606.0,4783,1,81034,A2780,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618328,,,F
16930,Intermediate,,1,,9606.0,4784,1,81034,A2780,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618329,,,F
17496,Intermediate,,1,,9606.0,4785,1,81034,A2780,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618330,,,F
12989,Expert,,1,,9606.0,4786,1,81034,A2780,,,In vitro antitumor activity against A2780cisR cell line.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618331,,,F
4840,Intermediate,,1,,9606.0,4787,1,81034,A2780,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618332,,,F
12989,Expert,,1,,9606.0,4788,1,81034,A2780,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618333,,,F
16745,Intermediate,,1,,9606.0,4789,1,80017,A2780cisR,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,N,481.0,Homo sapiens,BAO_0000219,,CHEMBL618334,,,F
16597,Expert,,1,,9606.0,4790,1,81034,A2780,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618335,,,F
16547,Expert,,1,,10116.0,4791,9,11736,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,D,,Rattus norvegicus,BAO_0000019,,CHEMBL618336,,,B
16547,Expert,,1,,,4792,8,11736,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,H,,,BAO_0000019,,CHEMBL618337,,,F
16547,Expert,,1,,10116.0,4793,9,11736,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,D,,Rattus norvegicus,BAO_0000019,,CHEMBL618338,,,F
15856,Expert,,1,,9606.0,4794,9,278,HEK293,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL618339,,,F
15856,Expert,,1,,9606.0,4795,9,278,HEK293,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,D,722.0,Homo sapiens,BAO_0000219,,CHEMBL618340,,,F
16547,Expert,,1,,10090.0,4796,9,11831,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,D,,Mus musculus,BAO_0000019,,CHEMBL618341,,,B
16547,Expert,,1,,,4797,8,11831,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,H,,,BAO_0000019,,CHEMBL618342,,,F
16547,Expert,,1,,10090.0,4798,9,11831,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,D,,Mus musculus,BAO_0000019,,CHEMBL618343,,,F
17402,Expert,,1,,,4799,8,280,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,H,,,BAO_0000357,,CHEMBL621038,,,B
11746,Autocuration,,1,,9606.0,4800,0,22226,T-cells,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,U,574.0,Homo sapiens,BAO_0000219,,CHEMBL621039,,,F
11746,Autocuration,,1,,9606.0,4801,0,22226,T-cells,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,U,574.0,Homo sapiens,BAO_0000219,,CHEMBL621040,,,F
5455,Intermediate,,1,,9606.0,4802,1,80018,A-375,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621041,,,F
2068,Intermediate,,1,,9606.0,4803,1,80018,A-375,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621042,,,F
2683,Intermediate,,1,,9606.0,4804,1,80018,A-375,,,In vitro antitumor activity against A375cell line extracted form melanoma,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621043,,,F
15313,Expert,,1,,9606.0,4805,1,80018,A-375,,,Inhibition of cell growth in (A375) melan cell line,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621044,,,F
13739,Intermediate,,1,,9606.0,4806,1,80018,A-375,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621045,,,F
13739,Intermediate,,1,,9606.0,4807,1,80018,A-375,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621046,,,F
14750,Intermediate,,1,,9606.0,4808,1,80018,A-375,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL621047,,,F
14777,Intermediate,,1,,9606.0,4809,1,80019,A-427,,,Antiproliferative activity measured against A427 human lung carcinoma,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621048,,,F
14777,Intermediate,,1,,9606.0,4810,1,80019,A-427,,,Antiproliferative activity measured against A427 human lung carcinoma,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL883798,,,F
17672,Intermediate,,1,,9606.0,4811,1,80019,A-427,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621049,,,F
14368,Intermediate,,1,,9606.0,4812,1,80019,A-427,,,Inhibition of large cell lung carcinoma (A427),,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621050,,,F
14368,Intermediate,,1,,9606.0,4813,1,80019,A-427,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621051,,,F
13866,Intermediate,,1,,9606.0,4814,1,80019,A-427,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621052,,,F
2545,Intermediate,,1,,9606.0,4815,1,80019,A-427,,,Inhibitory concentration in human lung carcinoma A427 cell line,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621053,,,F
2545,Intermediate,,1,,9606.0,4816,1,80019,A-427,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL621054,,,F
6062,Autocuration,,1,,9527.0,4817,0,22224,,In vivo,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621055,,,A
4578,Autocuration,,1,,9527.0,4818,0,22224,,In vivo,,Tested for volume of distribution upon iv administration to african green monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL876398,,,A
17592,Autocuration,,1,,9527.0,4819,0,22224,,In vivo,,Volume of distribution in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621056,,,A
5005,Autocuration,,1,,9544.0,4820,0,22224,,In vivo,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,,Macaca mulatta,BAO_0000218,,CHEMBL621057,,,A
5005,Autocuration,,1,,9544.0,4821,0,22224,,In vivo,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,U,,Macaca mulatta,BAO_0000218,,CHEMBL621058,,,A
5922,Autocuration,,1,,9527.0,4822,0,22224,,In vivo,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621059,,,A
5355,Autocuration,,1,,9527.0,4823,0,22224,,In vivo,,The distribution volume after intravenous administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621060,,,A
5355,Autocuration,,1,,9527.0,4824,0,22224,,In vivo,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621061,,,A
5355,Autocuration,,1,,9527.0,4825,0,22224,,In vivo,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621062,,,A
6057,Autocuration,,1,,9527.0,4826,0,22224,,In vivo,,Volume displacement was calculated in rhesus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621063,,,A
5145,Autocuration,,1,,9527.0,4827,0,22224,,In vivo,,Volume of distribution in steady state was determined in rhesus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621064,,,A
6821,Autocuration,,1,,9527.0,4828,0,22224,,In vivo,,Volume of distribution of compound was determined in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621065,,,A
5334,Autocuration,,1,,9527.0,4829,0,22224,,In vivo,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,,Cercopithecidae,BAO_0000218,,CHEMBL621066,,,A
5334,Autocuration,,1,,9527.0,4830,0,22224,,In vivo,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,,Cercopithecidae,BAO_0000218,,CHEMBL621067,,,A
6641,Autocuration,,1,,9527.0,4831,0,22224,,In vivo,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,,Cercopithecidae,BAO_0000218,,CHEMBL621068,,,A
2661,Autocuration,,1,,9527.0,4832,0,22224,,In vivo,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL876399,,,A
6535,Autocuration,,1,,9527.0,4833,0,22224,,In vivo,,Volume distribution in monkey after administration of 1 mg/kg iv,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621069,,,A
4809,Autocuration,,1,,9527.0,4834,0,22224,,In vivo,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL621070,,,A
6062,Autocuration,,1,,9527.0,4835,0,22224,,In vivo,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621071,,,A
3443,Autocuration,,1,,9527.0,4836,0,22224,,In vivo,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621072,,,A
4578,Autocuration,,1,,9527.0,4837,0,22224,,In vivo,,Oral systemic bioavailability upon iv administration to african green monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618209,,,A
4809,Autocuration,,1,,9527.0,4838,0,22224,,In vivo,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL618210,,,A
11271,Autocuration,,1,,9527.0,4839,0,22224,,,,Baboon plasma free fraction. ,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618211,,,A
6057,Autocuration,,1,,9527.0,4840,0,22224,,,,Area under the curve was calculated in rhesus monkey after iv administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618212,,,A
6057,Autocuration,,1,,9527.0,4841,0,22224,,,,Area under the curve was calculated in rhesus monkey after peroral administration,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618213,,,A
17853,Autocuration,,1,,9527.0,4842,0,22224,,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618214,,,A
5302,Autocuration,,1,,9527.0,4843,0,22224,,In vivo,,Half life period in monkey after 5 mg/kg dose,,U,,Cercopithecidae,BAO_0000218,,CHEMBL873492,,,A
4257,Autocuration,,1,,9527.0,4844,0,22224,,In vivo,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618272,,,A
4257,Autocuration,,1,,9527.0,4845,0,22224,,In vivo,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618273,,,A
13501,Autocuration,,1,,9527.0,4846,0,22224,,In vivo,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL618274,,,A
5394,Autocuration,,1,,9527.0,4847,0,22224,,In vivo,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618275,,,A
2661,Autocuration,,1,,9527.0,4848,0,22224,,In vivo,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618276,,,A
3341,Autocuration,,1,,9527.0,4849,0,22224,,,,Compound was evaluated for terminal half life in monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618277,,,A
3045,Autocuration,,1,,9527.0,4850,0,22224,,In vivo,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618278,,,A
5005,Autocuration,,1,,9544.0,4851,0,22224,,In vivo,Plasma,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL618279,,,A
4847,Autocuration,,1,,9527.0,4852,0,22224,,,,Half life of compound was determined in squirrel monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618280,,,A
4256,Autocuration,,1,,9541.0,4853,0,22224,,In vivo,,Half life after iv administration in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL618281,,,A
6535,Autocuration,,1,,9527.0,4854,0,22224,,In vivo,Plasma,Half life in monkey plasma after administration of 1 mg/kg iv,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL618282,,,A
6057,Autocuration,,1,,9527.0,4855,0,22224,,,,Half life was calculated in rhesus monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618283,,,A
17592,Autocuration,,1,,9527.0,4856,0,22224,,,,Half life in monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618284,,,A
6641,Autocuration,,1,,9527.0,4857,0,22224,,In vivo,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,U,,Cercopithecidae,BAO_0000218,,CHEMBL618285,,,A
5472,Autocuration,,1,,9527.0,4858,0,22224,,,,Half life was evaluated in rhesus,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618286,,,A
6221,Autocuration,,1,,9527.0,4859,0,22224,,In vivo,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618287,,,A
5668,Autocuration,,1,,9527.0,4860,0,22224,,In vivo,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618288,,,A
4809,Autocuration,,1,,9527.0,4861,0,22224,,In vivo,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,U,,Cercopithecidae,BAO_0000218,,CHEMBL876393,,,A
5546,Autocuration,,1,,9527.0,4862,0,22224,,In vivo,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618289,,,A
5553,Autocuration,,1,,9527.0,4863,0,22224,,In vivo,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618290,,,A
6078,Autocuration,,1,,9527.0,4864,0,22224,,,,Half-life was calculated in monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618291,,,A
5147,Autocuration,,1,,9527.0,4865,0,22224,,,,Half-life in Squirrel monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618292,,,A
5145,Autocuration,,1,,9527.0,4866,0,22224,,,,Half-life in rhesus monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618293,,,A
6062,Autocuration,,1,,9527.0,4867,0,22224,,In vivo,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618294,,,A
5355,Autocuration,,1,,9527.0,4868,0,22224,,In vivo,,Half-life period after intravenous administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618295,,,A
5355,Autocuration,,1,,9527.0,4869,0,22224,,In vivo,,Half-life period after oral administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618296,,,A
5355,Autocuration,,1,,9527.0,4870,0,22224,,In vivo,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618297,,,A
7766,Autocuration,,1,,9606.0,4871,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618298,,,A
7766,Autocuration,,1,,9606.0,4872,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618299,,,A
7766,Autocuration,,1,,9606.0,4873,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618300,,,A
7766,Autocuration,,1,,9606.0,4874,0,22224,,,Urine,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618301,,,A
7766,Autocuration,,1,,9606.0,4875,0,22224,,,Urine,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618302,,,A
7766,Autocuration,,1,,9606.0,4876,0,22224,,,Urine,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL876394,,,A
7766,Autocuration,,1,,9606.0,4877,0,22224,,,Urine,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618303,,,A
7766,Autocuration,,1,,9606.0,4878,0,22224,,,Urine,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618304,,,A
1916,Autocuration,,1,,9606.0,4879,0,22224,,In vivo,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,U,,Homo sapiens,BAO_0000218,,CHEMBL618305,,,A
16643,Autocuration,,1,,9606.0,4880,0,22224,,In vivo,,Oral bioavailability in human,,U,,Homo sapiens,BAO_0000218,,CHEMBL618306,,,A
17248,Autocuration,,1,,9606.0,4881,0,22224,,,,Compound was tested for human plasma protein binding,,U,,Homo sapiens,BAO_0000019,,CHEMBL618307,,,A
17248,Autocuration,,1,,9606.0,4882,0,22224,,,,Compound was tested for human plasma protein binding; Not determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL618308,,,A
6241,Autocuration,,1,,9606.0,4883,0,22224,,,,Protein binding activity of compound in human plasma; % Free,,U,,Homo sapiens,BAO_0000019,,CHEMBL618309,,,A
17716,Autocuration,,1,,9606.0,4884,0,22224,,,,Unbound fraction (plasma),,U,,Homo sapiens,BAO_0000019,,CHEMBL618310,,,A
17605,Autocuration,,1,,9606.0,4885,0,22224,,,Plasma,Half life for the hydrolysis of compound in human blood serum,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL873353,,,A
17625,Autocuration,,1,,9606.0,4886,0,22224,,,Plasma,Half life period in human plasma using phosphate buffer (0.08 M),,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618311,,,A
17625,Autocuration,,1,,9606.0,4887,0,22224,,,Plasma,Half life period in human plasma using phosphate buffer (0.1 M),,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618312,,,A
17747,Autocuration,,1,,9606.0,4888,0,22224,,,Plasma,Half-life in human plasma was determined,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618313,,,A
15613,Autocuration,,1,,9606.0,4889,0,22224,,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,U,,Homo sapiens,BAO_0000019,,CHEMBL618314,,,A
354,Autocuration,,1,,9606.0,4890,0,22224,,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,U,,Homo sapiens,BAO_0000019,,CHEMBL618315,,,A
3741,Autocuration,,1,,9606.0,4891,0,22224,,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,U,,Homo sapiens,BAO_0000019,,CHEMBL618316,,,A
3741,Autocuration,,1,,9606.0,4892,0,22224,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,U,,Homo sapiens,BAO_0000019,,CHEMBL618317,,,A
3741,Autocuration,,1,,9606.0,4893,0,22224,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,U,,Homo sapiens,BAO_0000019,,CHEMBL620138,,,A
17599,Autocuration,,1,,9606.0,4894,0,22224,,,,Partition coefficient (logP),,U,,Homo sapiens,BAO_0000019,,CHEMBL858280,,,A
5486,Autocuration,,1,,9606.0,4895,0,22224,,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,U,,Homo sapiens,BAO_0000019,,CHEMBL620139,,,A
5600,Autocuration,,1,,9606.0,4896,0,22224,,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,U,,Homo sapiens,BAO_0000251,,CHEMBL620140,,Microsomes,A
14294,Autocuration,,1,,9606.0,4897,0,22224,,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,U,,Homo sapiens,BAO_0000019,,CHEMBL620141,,,A
14294,Autocuration,,1,,9606.0,4898,0,22224,,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,U,,Homo sapiens,BAO_0000019,,CHEMBL620142,,,A
14294,Autocuration,,1,,9606.0,4899,0,22224,,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,U,,Homo sapiens,BAO_0000019,,CHEMBL620143,,,A
14294,Autocuration,,1,,9606.0,4900,0,22224,,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,U,,Homo sapiens,BAO_0000251,,CHEMBL620144,,Microsomes,A
14294,Autocuration,,1,,9606.0,4901,0,22224,,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,U,,Homo sapiens,BAO_0000251,,CHEMBL620145,,Microsomes,A
14294,Autocuration,,1,,9606.0,4902,0,22224,,,,Metabolism of compound in human microsomes; Trace,,U,,Homo sapiens,BAO_0000251,,CHEMBL620146,,Microsomes,A
6260,Autocuration,,1,,9606.0,4903,0,22224,,,Liver,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL620147,,Microsomes,A
6187,Autocuration,,1,,9606.0,4904,0,22224,,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,U,,Homo sapiens,BAO_0000251,,CHEMBL620148,,Microsomes,A
6251,Autocuration,,1,,9606.0,4905,0,22224,,,Liver,In vitro metabolic potential in human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL620149,,Microsomes,A
3246,Autocuration,,1,,9606.0,4906,0,22224,,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,U,,Homo sapiens,BAO_0000019,,CHEMBL876412,,,A
17313,Autocuration,,1,,9606.0,4907,0,22224,,,,Tested for human plasma protein binding of the compound; Not tested,,U,,Homo sapiens,BAO_0000019,,CHEMBL619352,,,A
6227,Autocuration,,1,,9606.0,4908,0,22224,,,,Compound was tested for percent protein binding (PB) in human,,U,,Homo sapiens,BAO_0000019,,CHEMBL619353,,,A
5530,Autocuration,,1,,9606.0,4909,0,22224,,,Plasma,Protein binding in human plasma,,U,,Homo sapiens,BAO_0000019,1969.0,CHEMBL619354,,,A
6108,Autocuration,,1,,9606.0,4910,0,22224,,,,Permeability coefficient (B to A) in Caco-2 cell,,U,,Homo sapiens,BAO_0000019,,CHEMBL619355,,,A
6108,Autocuration,,1,,9606.0,4911,0,22224,,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,U,,Homo sapiens,BAO_0000019,,CHEMBL619356,,,A
2774,Autocuration,,1,,9606.0,4912,0,22224,,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,U,,Homo sapiens,BAO_0000019,,CHEMBL619357,,,A
16643,Autocuration,,1,,9606.0,4913,0,22224,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,,U,,Homo sapiens,BAO_0000019,,CHEMBL619358,,,A
17582,Autocuration,,1,,9606.0,4914,0,22224,Caco-2,,,Cellular permeability of compound was determined in Caco-2 cells; High,,U,495.0,Homo sapiens,BAO_0000219,,CHEMBL619359,,,A
6838,Autocuration,,1,,9606.0,4915,0,22224,Caco-2,,,Permeability in Caco-2 cells of compound,,U,495.0,Homo sapiens,BAO_0000219,,CHEMBL619360,,,A
6108,Autocuration,,1,,9606.0,4916,0,22224,,,,Permeability coefficient (A to B) in Caco-2 cell,,U,,Homo sapiens,BAO_0000019,,CHEMBL619361,,,A
6108,Autocuration,,1,,9606.0,4917,0,22224,,,,Permeability coefficient (B to A) in Caco-2 cell,,U,,Homo sapiens,BAO_0000019,,CHEMBL619362,,,A
6108,Autocuration,,1,,9606.0,4918,0,22224,,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,U,,Homo sapiens,BAO_0000019,,CHEMBL619363,,,A
2146,Autocuration,,1,,9606.0,4919,0,22224,,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,U,,Homo sapiens,BAO_0000019,,CHEMBL618942,,,A
4514,Autocuration,,1,,9606.0,4920,0,22224,,,,Compound was tested for protein binding in human plasma,,U,,Homo sapiens,BAO_0000019,,CHEMBL618943,,,A
6108,Autocuration,,1,,9606.0,4921,0,22224,,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,U,,Homo sapiens,BAO_0000019,,CHEMBL618944,,,A
7766,Autocuration,,1,,9606.0,4922,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL618945,,,A
5969,Intermediate,,1,,10090.0,4923,1,50594,,In vivo,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618946,,,A
3277,Intermediate,,1,,10090.0,4924,1,50594,,In vivo,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,,Mus musculus,BAO_0000218,,CHEMBL876413,,,A
3802,Intermediate,,1,,10090.0,4925,1,50594,,In vivo,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL618947,,,A
2862,Intermediate,,1,,10090.0,4926,1,50594,,In vivo,Plasma,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL618948,,,A
6348,Intermediate,,1,,10090.0,4927,1,50594,,In vivo,Plasma,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL618949,,,A
17764,Intermediate,,1,,10090.0,4928,1,50594,,In vivo,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618950,,,F
5781,Intermediate,,1,,10090.0,4929,1,50594,,In vivo,,Tmax after oral administration at 30 mg/kg in ICR mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL618951,,,A
17764,Intermediate,,1,,10090.0,4930,1,50594,,In vivo,,Tmax after peroral administration in mice at 2.4 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618952,,,A
4066,Intermediate,,1,,10090.0,4931,1,50594,,In vivo,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618953,,,A
17641,Intermediate,,1,,10090.0,4932,1,50594,,In vivo,Brain,Tmax in brain of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618954,,,A
17641,Intermediate,,1,,10090.0,4933,1,50594,,In vivo,Kidney,Tmax in kidney of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618955,,,A
17641,Intermediate,,1,,10090.0,4934,1,50594,,In vivo,Liver,Tmax in liver of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618956,,,A
17641,Intermediate,,1,,10090.0,4935,1,50594,,In vivo,Lung,Tmax in lungs of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL618957,,,A
17764,Intermediate,,1,,10090.0,4936,1,50594,,In vivo,,Tmax in mice at 18 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL618958,,,F
17764,Intermediate,,1,,10090.0,4937,1,50594,,In vivo,,Tmax in mice at 23 uM/kg i.v. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL618959,,,F
17764,Intermediate,,1,,10090.0,4938,1,50594,,In vivo,,Tmax in mice at 25 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL618960,,,F
17764,Intermediate,,1,,10090.0,4939,1,50594,,In vivo,,Tmax in mice at 26 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL876723,,,F
17641,Intermediate,,1,,10090.0,4940,1,50594,,In vivo,Spleen,Tmax in spleen of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618961,,,A
16597,Intermediate,,1,,10090.0,4941,1,50594,,In vivo,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL618962,,,A
16597,Intermediate,,1,,10090.0,4942,1,50594,,In vivo,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL618963,,,A
5951,Intermediate,,1,,10090.0,4943,1,50594,,,,Tmax value in IRC mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618964,,,A
5506,Intermediate,,1,,10090.0,4944,1,50594,,In vivo,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618965,,,A
5506,Intermediate,,1,,10090.0,4945,1,50594,,In vivo,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618966,,,A
429,Intermediate,,1,,10090.0,4946,1,50594,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL618967,,,A
429,Intermediate,,1,,10090.0,4947,1,50594,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL618968,,,A
4066,Intermediate,,1,,10090.0,4948,1,50594,,,Urine,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL618969,,,A
17734,Intermediate,,1,,10090.0,4949,1,50594,,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618970,,,A
17734,Intermediate,,1,,10090.0,4950,1,50594,,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618971,,,A
6062,Intermediate,,1,,10090.0,4951,1,50594,,In vivo,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618972,,,A
5969,Intermediate,,1,,10090.0,4952,1,50594,,In vivo,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618973,,,A
5969,Intermediate,,1,,10090.0,4953,1,50594,,In vivo,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618974,,,A
5969,Intermediate,,1,,10090.0,4954,1,50594,,In vivo,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL618975,,,A
5980,Intermediate,,1,,10090.0,4955,1,50594,,In vivo,,Vd in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL618976,,,A
17592,Intermediate,,1,,10090.0,4956,1,50594,,In vivo,,Volume of distribution in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL618977,,,A
6348,Intermediate,,1,,10090.0,4957,1,50594,,In vivo,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,,Mus musculus,BAO_0000218,,CHEMBL876724,,,A
17753,Intermediate,,1,,10090.0,4958,1,50594,,In vivo,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618978,,,A
17753,Intermediate,,1,,10090.0,4959,1,50594,,In vivo,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618979,,,A
17753,Intermediate,,1,,10090.0,4960,1,50594,,In vivo,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL618980,,,A
4239,Intermediate,,1,,10090.0,4961,1,50594,,In vivo,,Pharmacokinetic property (vdss) was measured in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL618981,,,A
2862,Intermediate,,1,,10090.0,4962,1,50594,,In vivo,,Value distribution upon iv administration in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL618982,,,A
17734,Intermediate,,1,,10090.0,4963,1,50594,,In vivo,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL620150,,,A
2675,Intermediate,,1,,10090.0,4964,1,50594,,In vivo,,Volume of distribution was evaluated in mice after intravenous administration,,N,,Mus musculus,BAO_0000218,,CHEMBL620151,,,A
2675,Intermediate,,1,,10090.0,4965,1,50594,,In vivo,,Volume of distribution was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL620152,,,A
17837,Intermediate,,1,,10090.0,4966,1,50594,,In vivo,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620153,,,A
5727,Intermediate,,1,,10090.0,4967,1,50594,,In vivo,,Steady state volume of distribution was determined in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL876395,,,A
17852,Intermediate,,1,,10090.0,4968,1,50594,,In vivo,,Volume distribution (steady state) of compound was determined in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL620154,,,A
17764,Intermediate,,1,,10090.0,4969,1,50594,,In vivo,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620155,,,A
16597,Intermediate,,1,,10090.0,4970,1,50594,,In vivo,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL620156,,,A
6062,Intermediate,,1,,10090.0,4971,1,50594,,In vivo,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL620157,,,A
16438,Intermediate,,1,,10090.0,4972,1,50594,,In vivo,Kidney,Biodistribution of compound (oxidized form) in in kidney tissue,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL620158,,,A
16438,Intermediate,,1,,10090.0,4973,1,50594,,In vivo,Blood,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL620159,,,A
16438,Intermediate,,1,,10090.0,4974,1,50594,,In vivo,Blood,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL620160,,,A
16438,Intermediate,,1,,10090.0,4975,1,50594,,In vivo,Blood,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL620161,,,A
10708,Intermediate,,1,,9606.0,4976,1,80019,A-427,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL620162,,,F
16597,Expert,,1,,9606.0,4977,1,80852,A-431,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL620163,,,F
16062,Expert,,1,,9606.0,4978,1,80852,A-431,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL620833,,,F
16062,Expert,,1,,9606.0,4979,1,80852,A-431,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL876396,,,F
16958,Expert,,1,,9606.0,4980,1,80852,A-431,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL620834,,,F
6700,Expert,,1,,9606.0,4981,1,80852,A-431,,,Inhibition of A431 human carcinoma cell proliferation,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL620835,,,F
17226,Expert,,1,,9606.0,4982,1,80852,A-431,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL620836,,,F
6828,Intermediate,,1,,9606.0,4983,1,80852,A-431,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL620837,,,F
12314,Intermediate,,1,,9606.0,4984,1,80852,A-431,,,In vitro cytotoxicity against epidermoid carcinoma cell line,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621017,,,F
13412,Expert,,1,,9606.0,4985,9,9,A-431,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,D,500.0,Homo sapiens,BAO_0000218,,CHEMBL621018,,,F
13299,Intermediate,,1,,9606.0,4986,1,80852,A-431,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621019,,,F
17420,Intermediate,,1,,9606.0,4987,1,80852,A-431,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621020,,,F
13678,Intermediate,,1,,9606.0,4988,1,80852,A-431,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621021,,,F
14171,Expert,,1,,,4989,8,9,A-431,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,H,500.0,,BAO_0000219,,CHEMBL621022,,,F
6333,Expert,,1,,9606.0,4990,1,80852,A-431,,,Tested for antiproliferative activity against human A431 cells,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621023,,,F
2356,Expert,,1,,9606.0,4991,9,9,A-431,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621024,,,F
15578,Expert,,1,,9606.0,4992,1,80852,A-431,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621025,,,F
5126,Expert,,1,,9606.0,4993,1,80852,A-431,,,Inhibition of A431 cell proliferation,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621026,,,F
6844,Expert,,1,,9606.0,4994,1,80852,A-431,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621027,,,F
6844,Expert,,1,,9606.0,4995,1,80852,A-431,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL876397,,,F
4925,Intermediate,,1,,9606.0,4996,1,80852,A-431,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL883797,,,F
4925,Intermediate,,1,,9606.0,4997,1,80852,A-431,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621028,,,F
13978,Intermediate,,1,,9606.0,4998,1,80852,A-431,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621029,,,F
16786,Intermediate,,1,,9606.0,4999,1,80852,A-431,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621030,,,F
13412,Expert,,1,,,5000,8,9,A-431,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,H,500.0,,BAO_0000219,,CHEMBL621147,,,F
17824,Intermediate,,1,,9606.0,5001,1,80852,A-431,,,In vivo antiproliferative activity against A431 cell line,,N,500.0,Homo sapiens,BAO_0000218,,CHEMBL621148,,,F
12751,Expert,,1,,9606.0,5002,9,9,A-431,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621149,,,F
12380,Expert,,1,,9606.0,5003,1,80852,A-431,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621150,,,F
4959,Expert,,1,,9606.0,5004,9,9,A-431,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621151,,,F
6333,Intermediate,,1,,9606.0,5005,1,80852,A-431,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621152,,,F
6333,Intermediate,,1,,9606.0,5006,1,80852,A-431,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621153,,,F
6333,Intermediate,,1,,9606.0,5007,1,80852,A-431,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL884000,,,F
5296,Expert,,1,,9606.0,5008,9,9,,,,Inhibition of EGFR overexpressing A431 cell proliferation,,D,,Homo sapiens,BAO_0000019,,CHEMBL621154,,,F
12624,Expert,,1,,9606.0,5009,1,80852,A-431,,,Inhibition of A431 cell proliferation,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621155,,,F
14926,Expert,,1,,9606.0,5010,9,9,A-431,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621156,,,F
14926,Expert,,1,,9606.0,5011,9,9,A-431,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621157,,,F
14926,Expert,,1,,,5012,8,9,A-431,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,H,500.0,,BAO_0000219,,CHEMBL621158,,,F
15144,Intermediate,,1,,9606.0,5013,1,80852,A-431,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621159,,,F
15144,Intermediate,,1,,9606.0,5014,1,80852,A-431,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621160,,,F
5245,Intermediate,,1,,9606.0,5015,1,80852,A-431,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621161,,,F
5245,Intermediate,,1,,9606.0,5016,1,80852,A-431,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621162,,,F
5245,Intermediate,,1,,9606.0,5017,1,80852,A-431,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621163,,,F
5245,Intermediate,,1,,9606.0,5018,1,80852,A-431,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621164,,,F
5245,Intermediate,,1,,9606.0,5019,1,80852,A-431,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621165,,,F
5922,Autocuration,,1,,9527.0,5020,0,22224,,,,Half-life period in cynomolgus monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619159,,,A
1116,Autocuration,,1,,9527.0,5021,0,22224,,In vitro,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,U,,Cercopithecidae,BAO_0000366,1969.0,CHEMBL619160,,,A
17853,Autocuration,,1,,9527.0,5022,0,22224,,In vivo,,Longer half-life in monkey (i.v.) at 0.5 mpk,,U,,Cercopithecidae,BAO_0000218,,CHEMBL619161,,,A
993,Autocuration,,1,,9527.0,5023,0,22224,,,Plasma,Plasma half life in monkey,,U,,Cercopithecidae,BAO_0000366,1969.0,CHEMBL619162,,,A
4514,Autocuration,,1,,9527.0,5024,0,22224,,,Plasma,Plasma half-life in rhesus monkey,,U,,Cercopithecidae,BAO_0000366,1969.0,CHEMBL619163,,,A
5334,Autocuration,,1,,9527.0,5025,0,22224,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL619164,,,A
5334,Autocuration,,1,,9527.0,5026,0,22224,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL619320,,,A
4578,Autocuration,,1,,9527.0,5027,0,22224,,In vivo,,Tested for half life upon iv administration to african green monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL619321,,,A
2661,Autocuration,,1,,9527.0,5028,0,22224,,In vivo,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL873336,,,A
5355,Autocuration,,1,,9527.0,5029,0,22224,,In vivo,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL619322,,,A
5355,Autocuration,,1,,9527.0,5030,0,22224,,In vivo,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL619323,,,A
5355,Autocuration,,1,,9527.0,5031,0,22224,,In vivo,,The time for peak concentration value after oral administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL619324,,,A
11271,Autocuration,,1,,9527.0,5032,0,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619325,,,A
11271,Autocuration,,1,,9527.0,5033,0,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL876411,,,A
11271,Autocuration,,1,,9527.0,5034,0,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619326,,,A
11271,Autocuration,,1,,9527.0,5035,0,22224,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619327,,,A
11271,Autocuration,,1,,9527.0,5036,0,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619328,,,A
11271,Autocuration,,1,,9527.0,5037,0,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619329,,,A
11271,Autocuration,,1,,9527.0,5038,0,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619330,,,A
11271,Autocuration,,1,,9527.0,5039,0,22224,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619331,,,A
11271,Autocuration,,1,,9527.0,5040,0,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619332,,,A
11271,Autocuration,,1,,9527.0,5041,0,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619333,,,A
11271,Autocuration,,1,,9527.0,5042,0,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619334,,,A
11271,Autocuration,,1,,9527.0,5043,0,22224,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619335,,,A
11271,Autocuration,,1,,9527.0,5044,0,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619336,,,A
11271,Autocuration,,1,,9527.0,5045,0,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619337,,,A
11271,Autocuration,,1,,9527.0,5046,0,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619338,,,A
11271,Autocuration,,1,,9527.0,5047,0,22224,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,U,,Cercopithecidae,BAO_0000019,,CHEMBL619339,,,A
5809,Intermediate,,1,,10116.0,5048,1,50597,,In vivo,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619340,,,A
17720,Intermediate,,1,,10116.0,5049,1,50597,,In vivo,Plasma,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873496,,,A
3546,Intermediate,,1,,10116.0,5050,1,50597,,,Plasma,AUC value in rat after IV administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL619341,,,A
3546,Intermediate,,1,,10116.0,5051,1,50597,,,Plasma,AUC value in rat after oral administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL619342,,,A
3546,Intermediate,,1,,10116.0,5052,1,50597,,In vivo,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619343,,,A
3546,Intermediate,,1,,10116.0,5053,1,50597,,In vivo,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619344,,,A
3546,Intermediate,,1,,10116.0,5054,1,50597,,In vivo,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619345,,,A
3546,Intermediate,,1,,10116.0,5055,1,50597,,,,Vc value in rat after IV administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619346,,,A
3546,Intermediate,,1,,10116.0,5056,1,50597,,In vivo,,Half life period in rat after IV administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619347,,,A
10625,Autocuration,,1,,9557.0,5057,0,22224,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,U,,Papio hamadryas,BAO_0000019,,CHEMBL619348,,,A
10625,Autocuration,,1,,9557.0,5058,0,22224,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,U,,Papio hamadryas,BAO_0000019,,CHEMBL619349,,,A
10625,Autocuration,,1,,9557.0,5059,0,22224,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,U,,Papio hamadryas,BAO_0000019,,CHEMBL619350,,,A
10625,Autocuration,,1,,9557.0,5060,0,22224,,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,U,,Papio hamadryas,BAO_0000019,,CHEMBL619351,,,A
10625,Autocuration,,1,,9557.0,5061,0,22224,,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,U,,Papio hamadryas,BAO_0000019,,CHEMBL875953,,,A
10625,Autocuration,,1,,9557.0,5062,0,22224,,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,U,,Papio hamadryas,BAO_0000019,,CHEMBL621716,,,A
10625,Autocuration,,1,,9557.0,5063,0,22224,,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,U,,Papio hamadryas,BAO_0000019,,CHEMBL621717,,,A
10625,Autocuration,,1,,9557.0,5064,0,22224,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,U,,Papio hamadryas,BAO_0000019,,CHEMBL621718,,,A
3510,Autocuration,,1,,9615.0,5065,0,22224,,,,Area under curve after 1 mpk peroral administration to beagles,,U,,beagle,BAO_0000019,,CHEMBL621719,,,A
3510,Autocuration,,1,,9615.0,5066,0,22224,,,,Area under curve after 2 mpk peroral administration to beagles,,U,,beagle,BAO_0000019,,CHEMBL621720,,,A
3510,Autocuration,,1,,9615.0,5067,0,22224,,In vivo,,Cmax value after 1 mpk peroral administration to beagles,,U,,beagle,BAO_0000218,,CHEMBL621721,,,A
7766,Autocuration,,1,,9606.0,5068,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL621722,,,A
7766,Autocuration,,1,,9606.0,5069,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL621723,,,A
7766,Autocuration,,1,,9606.0,5070,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL621724,,,A
7766,Autocuration,,1,,9606.0,5071,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL623443,,,A
7766,Autocuration,,1,,9606.0,5072,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL623444,,,A
7766,Autocuration,,1,,9606.0,5073,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL623445,,,A
7766,Autocuration,,1,,9606.0,5074,0,22224,,,Urine,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,U,,Homo sapiens,BAO_0000019,1088.0,CHEMBL623446,,,A
16643,Autocuration,,1,,9606.0,5075,0,22224,,,Liver,Metabolic stability observed at 30 min after administration in human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL623447,,Microsomes,A
6852,Autocuration,,1,,9606.0,5076,0,22224,,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,U,,Homo sapiens,BAO_0000019,,CHEMBL623448,,,A
6852,Autocuration,,1,,9606.0,5077,0,22224,,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,U,,Homo sapiens,BAO_0000019,,CHEMBL623449,,,A
6852,Autocuration,,1,,9606.0,5078,0,22224,,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,U,,Homo sapiens,BAO_0000019,,CHEMBL623450,,,A
6567,Autocuration,,1,,9606.0,5079,0,22224,,,Liver,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL623451,,Microsomes,A
6570,Autocuration,,1,,9606.0,5080,0,22224,,,,Metabolic stability (% remaining at 30 mins) in human S9.,,U,,Homo sapiens,BAO_0000019,,CHEMBL623452,,,A
6570,Autocuration,,1,,9606.0,5081,0,22224,,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL623453,,,A
5237,Autocuration,,1,,9606.0,5082,0,22224,,,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL623454,,Microsomes,A
5237,Autocuration,,1,,9606.0,5083,0,22224,,,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL623455,,Microsomes,A
5237,Autocuration,,1,,9606.0,5084,0,22224,,,Liver,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624371,,Microsomes,A
5202,Autocuration,,1,,9606.0,5085,0,22224,,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,U,,Homo sapiens,BAO_0000218,,CHEMBL624372,,,A
5481,Autocuration,,1,,9606.0,5086,0,22224,,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,U,,Homo sapiens,BAO_0000019,,CHEMBL624373,,,A
5481,Autocuration,,1,,9606.0,5087,0,22224,,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,U,,Homo sapiens,BAO_0000019,,CHEMBL624374,,,A
3956,Autocuration,,1,,9606.0,5088,0,22224,,,,The percent remaining in human plasma after 30 min was determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL624556,,,A
5074,Autocuration,,1,,9606.0,5089,0,22224,,,Plasma,Conversion rate of the prodrug in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL624557,,,A
5074,Autocuration,,1,,9606.0,5090,0,22224,,,Plasma,Conversion rate of the prodrug in human plasma; ND means no data,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL624558,,,A
4727,Autocuration,,1,,9606.0,5091,0,22224,,,Blood,Half life of compound was determined in human blood,,U,,Homo sapiens,BAO_0000221,178.0,CHEMBL624559,,,A
5965,Autocuration,,1,,9606.0,5092,0,22224,,,,Half life of compound was determined in man with once daily dosing,,U,,Homo sapiens,BAO_0000019,,CHEMBL624560,,,A
5732,Autocuration,,1,,9606.0,5093,0,22224,,In vitro,,Half life in human microsomes,,U,,Homo sapiens,BAO_0000251,,CHEMBL624561,,Microsomes,A
5819,Autocuration,,1,,9606.0,5094,0,22224,,,Plasma,Half life in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL624562,,,A
5819,Autocuration,,1,,9606.0,5095,0,22224,,,Plasma,Half life in human plasma; Not detected,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL624563,,,A
1916,Autocuration,,1,,9606.0,5096,0,22224,,In vivo,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,U,,Homo sapiens,BAO_0000218,,CHEMBL624564,,,A
6597,Autocuration,,1,,9606.0,5097,0,22224,,In vitro,Liver,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624565,,Microsomes,A
5229,Autocuration,,1,,9606.0,5098,0,22224,,,Plasma,Half-life in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL875152,,,A
5229,Autocuration,,1,,9606.0,5099,0,22224,,,Plasma,Half-life of the parent prodrug in plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL624566,,,A
2192,Autocuration,,1,,9606.0,5100,0,22224,,In vitro,Plasma,In vitro half life in human plasma was determined,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL873805,,,A
3032,Autocuration,,1,,9606.0,5101,0,22224,,In vitro,Liver,The compound was tested In Vitro for half life in human liver microsomes.,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624567,,Microsomes,A
1916,Autocuration,,1,,9606.0,5102,0,22224,,In vivo,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,U,,Homo sapiens,BAO_0000218,,CHEMBL624568,,,A
17716,Autocuration,,1,,9606.0,5103,0,22224,,In vivo,,Observed volume of distribution,,U,,Homo sapiens,BAO_0000218,,CHEMBL624569,,,A
15778,Autocuration,,1,,9606.0,5104,0,22224,,In vivo,,Oral bioavailability in human,,U,,Homo sapiens,BAO_0000218,,CHEMBL624570,,,A
17313,Autocuration,,1,,9606.0,5105,0,22224,,,,Tested for human plasma protein binding of the compound,,U,,Homo sapiens,BAO_0000019,,CHEMBL624571,,,A
4231,Autocuration,,1,,9606.0,5106,0,22224,,,,"First order rate constant, k was determined in human plasma",,U,,Homo sapiens,BAO_0000019,,CHEMBL624572,,,A
4755,Autocuration,,1,,9606.0,5107,0,22224,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,U,,Homo sapiens,BAO_0000019,,CHEMBL624573,,,A
4755,Autocuration,,1,,9606.0,5108,0,22224,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,U,,Homo sapiens,BAO_0000019,,CHEMBL875153,,,A
16907,Autocuration,,1,,9606.0,5109,0,22224,,,Liver,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624574,,Microsomes,A
10839,Autocuration,,1,,9606.0,5110,0,22224,,,,The compound was tested for the plasma binding in human,,U,,Homo sapiens,BAO_0000019,,CHEMBL624575,,,A
10839,Autocuration,,1,,9606.0,5111,0,22224,,,,Plasma protein binding (human),,U,,Homo sapiens,BAO_0000019,,CHEMBL624576,,,A
3199,Autocuration,,1,,9606.0,5112,0,22224,,In vitro,Liver,Compound was evaluated for half-life in human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624577,,Microsomes,A
1345,Autocuration,,1,,9606.0,5113,0,22224,,In vitro,Blood,Half life measured in vitro for its stability in human blood,,U,,Homo sapiens,BAO_0000221,178.0,CHEMBL624578,,,A
4297,Autocuration,,1,,9606.0,5114,0,22224,,,Serum,Half life in human serum,,U,,Homo sapiens,BAO_0000019,1977.0,CHEMBL622796,,,A
4297,Autocuration,,1,,9606.0,5115,0,22224,,,Serum,Half life in human serum; ND=not determined,,U,,Homo sapiens,BAO_0000019,1977.0,CHEMBL622797,,,A
4297,Autocuration,,1,,9606.0,5116,0,22224,,,,Half life were determined in CEM-SS cell extract in decomposition step 1,,U,,Homo sapiens,BAO_0000019,,CHEMBL622798,,,A
4297,Autocuration,,1,,9606.0,5117,0,22224,,,,Half life were determined in CEM-SS cell extract in decomposition step 2,,U,,Homo sapiens,BAO_0000019,,CHEMBL622799,,,A
4231,Autocuration,,1,,9606.0,5118,0,22224,,,Plasma,Half life of the in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL622800,,,A
5633,Autocuration,,1,,9606.0,5119,0,22224,,In vitro,,Half life period in human hepatic S9 fraction was determined,,U,,Homo sapiens,BAO_0000220,,CHEMBL622801,,S9,A
5633,Autocuration,,1,,9606.0,5120,0,22224,,In vitro,Liver,Half life period in human liver microsome was determined,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL622802,,Microsomes,A
17791,Autocuration,,1,,9606.0,5121,0,22224,,,,Half life period was determined; 6-7,,U,,Homo sapiens,BAO_0000019,,CHEMBL622803,,,A
17791,Autocuration,,1,,9606.0,5122,0,22224,,,,Half life period was evaluated in human,,U,,Homo sapiens,BAO_0000019,,CHEMBL875154,,,A
3160,Autocuration,,1,,9606.0,5123,0,22224,,,Plasma,Half life time in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL622804,,,A
16438,Intermediate,,1,,10090.0,5124,1,50594,,In vivo,Brain,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622805,,,A
16438,Intermediate,,1,,10090.0,5125,1,50594,,In vivo,Heart,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622611,,,A
16438,Intermediate,,1,,10090.0,5126,1,50594,,In vivo,Heart,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622612,,,A
16438,Intermediate,,1,,10090.0,5127,1,50594,,In vivo,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL875160,,,A
16438,Intermediate,,1,,10090.0,5128,1,50594,,In vivo,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL622613,,,A
16438,Intermediate,,1,,10090.0,5129,1,50594,,In vivo,Kidney,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL622614,,,A
16438,Intermediate,,1,,10090.0,5130,1,50594,,In vivo,Liver,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL622615,,,A
16438,Intermediate,,1,,10090.0,5131,1,50594,,In vivo,Liver,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL622616,,,A
16438,Intermediate,,1,,10090.0,5132,1,50594,,In vivo,Liver,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL622617,,,A
16438,Intermediate,,1,,10090.0,5133,1,50594,,In vivo,Spleen,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL622618,,,A
16438,Intermediate,,1,,10090.0,5134,1,50594,,In vivo,Spleen,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL622619,,,A
16438,Intermediate,,1,,10090.0,5135,1,50594,,In vivo,Spleen,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL622620,,,A
16438,Intermediate,,1,,10090.0,5136,1,50594,,In vivo,Brain,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622621,,,A
16438,Intermediate,,1,,10090.0,5137,1,50594,,In vivo,Blood,Biodistribution of compound (oxidized form) in blood tissue,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622622,,,A
16438,Intermediate,,1,,10090.0,5138,1,50594,,In vivo,Blood,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622623,,,A
16438,Intermediate,,1,,10090.0,5139,1,50594,,In vivo,Blood,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622624,,,A
16438,Intermediate,,1,,10090.0,5140,1,50594,,In vivo,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622625,,,A
16438,Intermediate,,1,,10090.0,5141,1,50594,,In vivo,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622626,,,A
16438,Intermediate,,1,,10090.0,5142,1,50594,,In vivo,Blood,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622627,,,A
16438,Intermediate,,1,,10090.0,5143,1,50594,,In vivo,Brain,Biodistribution of compound (oxidized form) in brain tissue of mice,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622628,,,A
16438,Intermediate,,1,,10090.0,5144,1,50594,,In vivo,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622629,,,A
16438,Intermediate,,1,,10090.0,5145,1,50594,,In vivo,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622630,,,A
16438,Intermediate,,1,,10090.0,5146,1,50594,,In vivo,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622631,,,A
16438,Intermediate,,1,,10090.0,5147,1,50594,,In vivo,Brain,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622632,,,A
16438,Intermediate,,1,,10090.0,5148,1,50594,,In vivo,Brain,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622633,,,A
16438,Intermediate,,1,,10090.0,5149,1,50594,,In vivo,Heart,Biodistribution of compound (oxidized form) in heart tissue of mice,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622634,,,A
16438,Intermediate,,1,,10090.0,5150,1,50594,,In vivo,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622635,,,A
16438,Intermediate,,1,,10090.0,5151,1,50594,,In vivo,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL875161,,,A
16438,Intermediate,,1,,10090.0,5152,1,50594,,In vivo,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622636,,,A
16438,Intermediate,,1,,10090.0,5153,1,50594,,In vivo,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL623335,,,A
16438,Intermediate,,1,,10090.0,5154,1,50594,,In vivo,Heart,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL623336,,,A
16438,Intermediate,,1,,10090.0,5155,1,50594,,In vivo,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623337,,,A
16438,Intermediate,,1,,10090.0,5156,1,50594,,In vivo,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623338,,,A
16438,Intermediate,,1,,10090.0,5157,1,50594,,In vivo,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623339,,,A
16438,Intermediate,,1,,10090.0,5158,1,50594,,In vivo,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623524,,,A
16438,Intermediate,,1,,10090.0,5159,1,50594,,In vivo,Kidney,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623525,,,A
16438,Intermediate,,1,,10090.0,5160,1,50594,,In vivo,Liver,Biodistribution of compound (oxidized form) in liver tissue,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623526,,,A
16438,Intermediate,,1,,10090.0,5161,1,50594,,In vivo,Liver,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623527,,,A
16438,Intermediate,,1,,10090.0,5162,1,50594,,In vivo,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623528,,,A
5245,Intermediate,,1,,9606.0,5163,1,80852,A-431,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL624615,,,F
5245,Intermediate,,1,,9606.0,5164,1,80852,A-431,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621672,,,F
16289,Expert,,1,,,5165,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,N,500.0,,BAO_0000218,,CHEMBL621673,,,F
16289,Expert,,1,,,5166,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,N,500.0,,BAO_0000218,,CHEMBL621674,,,F
16093,Expert,,1,,9606.0,5167,9,9,A-431,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL884002,,,F
16825,Intermediate,,1,,9606.0,5168,1,80852,A-431,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621850,,,F
4848,Intermediate,,1,,9606.0,5169,1,80852,A-431,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL621851,,,F
14827,Expert,,1,,9606.0,5170,9,9,A-431,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621852,,,F
14827,Expert,,1,,9606.0,5171,9,9,A-431,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL621853,,,F
16289,Expert,,1,,,5172,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,N,500.0,,BAO_0000218,,CHEMBL621854,,,F
16289,Expert,,1,,,5173,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,N,500.0,,BAO_0000218,,CHEMBL621855,,,F
16289,Expert,,1,,,5174,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,N,500.0,,BAO_0000218,,CHEMBL623724,,,F
16289,Expert,,1,,,5175,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,N,500.0,,BAO_0000218,,CHEMBL623725,,,F
16289,Expert,,1,,,5176,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,N,500.0,,BAO_0000218,,CHEMBL623726,,,F
16289,Expert,,1,,9606.0,5177,9,9,A-431,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL623727,,,F
16289,Expert,,1,,,5178,8,9,A-431,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,H,500.0,,BAO_0000219,,CHEMBL623728,,,F
16289,Expert,,1,,,5179,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,N,500.0,,BAO_0000218,,CHEMBL623729,,,F
16289,Expert,,1,,,5180,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,N,500.0,,BAO_0000218,,CHEMBL623730,,,F
16289,Expert,,1,,,5181,1,80852,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,N,500.0,,BAO_0000218,,CHEMBL623731,,,F
14555,Expert,,1,,10090.0,5182,1,80852,A-431,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,500.0,Mus musculus,BAO_0000218,,CHEMBL623732,,,F
14555,Expert,,1,,10090.0,5183,1,80852,A-431,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,500.0,Mus musculus,BAO_0000218,,CHEMBL623733,,,F
14555,Expert,,1,,10090.0,5184,1,80852,A-431,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,500.0,Mus musculus,BAO_0000218,,CHEMBL623734,,,F
14555,Expert,,1,,10090.0,5185,1,80852,A-431,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,N,500.0,Mus musculus,BAO_0000218,,CHEMBL623735,,,F
1937,Expert,,1,,9606.0,5186,1,80852,A-431,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL623736,,,F
13739,Intermediate,,1,,9606.0,5187,1,80852,A-431,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL623737,,,F
3558,Intermediate,,1,,9606.0,5188,1,80852,A-431,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL623738,,,F
3558,Intermediate,,1,,9606.0,5189,1,80852,A-431,,,Dose giving a 50% decrease in the living cell number (A437 cells),,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL875168,,,F
17686,Expert,,1,,9606.0,5190,1,80682,A549,,,In vitro inhibitory concentration against proliferation of A459 cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623739,,,F
5305,Intermediate,,1,,9606.0,5191,1,80682,A549,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623740,,,F
3614,Intermediate,,1,,9606.0,5192,1,80682,A549,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624424,,,F
17229,Intermediate,,1,,9606.0,5193,1,80021,A498,,,In vitro antitumor activity against renal A498 tumor cell lines,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624425,,,F
15935,Intermediate,,1,,9606.0,5194,1,80021,A498,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624426,,,F
15935,Intermediate,,1,,9606.0,5195,1,80021,A498,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624427,,,F
15560,Intermediate,,1,,9606.0,5196,1,80021,A498,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624428,,,F
13891,Intermediate,,1,,9606.0,5197,1,80021,A498,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624429,,,F
13891,Intermediate,,1,,9606.0,5198,1,80021,A498,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624620,,,F
13788,Intermediate,,1,,9606.0,5199,1,80021,A498,,,Cytotoxicity on kidney carcinoma (A-498) cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624621,,,F
15403,Intermediate,,1,,9606.0,5200,1,80021,A498,,,Compound was evaluated against Human cell line renal A498,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624622,,,F
1009,Intermediate,,1,,9606.0,5201,1,80021,A498,,,Compound was tested for inhibition of A498 human renal cancer cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624623,,,F
1043,Intermediate,,1,,9606.0,5202,1,80021,A498,,,Growth inhibitory activity against A498 human cancer cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL874365,,,F
5858,Intermediate,,1,,9606.0,5203,1,80021,A498,,,In vitro antitumor activity against human renal A498 cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624624,,,F
5958,Intermediate,,1,,9606.0,5204,1,80021,A498,,,In vitro cytotoxic activity against renal (A498) cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624625,,,F
5506,Intermediate,,1,,9606.0,5205,1,80021,A498,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624626,,,F
12781,Intermediate,,1,,9606.0,5206,1,80021,A498,,,Tested for cytostatic activity against renal A498 cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624627,,,F
14399,Intermediate,,1,,9606.0,5207,1,80021,A498,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL883157,,,F
5958,Expert,,1,,9606.0,5208,1,80021,A498,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624628,,,F
3510,Autocuration,,1,,9615.0,5209,0,22224,,In vivo,,Cmax value after 2 mpk peroral administration to beagles,,U,,beagle,BAO_0000218,,CHEMBL624629,,,A
3510,Autocuration,,1,,9615.0,5210,0,22224,,In vivo,,Bioavailability,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL623551,beagle,,A
3510,Autocuration,,1,,9615.0,5211,0,22224,,In vivo,,Bioavailability after 1 mpk peroral administration to beagles,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL623552,beagle,,A
3510,Autocuration,,1,,9615.0,5212,0,22224,,In vivo,,Bioavailability after 2 mpk peroral administration to beagles,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL623553,beagle,,A
3085,Autocuration,,1,,9913.0,5213,0,22224,,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,U,,Bos taurus,BAO_0000019,,CHEMBL623554,,,A
3085,Autocuration,,1,,9913.0,5214,0,22224,,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,U,,Bos taurus,BAO_0000019,,CHEMBL623555,,,A
3085,Autocuration,,1,,9913.0,5215,0,22224,,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,U,,Bos taurus,BAO_0000019,,CHEMBL623556,,,A
9372,Autocuration,,1,,9913.0,5216,0,22224,,,,Solubility against bovine alpha-chymotrypsin,,U,,Bos taurus,BAO_0000019,,CHEMBL623557,,,A
3085,Autocuration,,1,,9913.0,5217,0,22224,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,U,,Bos taurus,BAO_0000019,,CHEMBL623558,,,A
3085,Autocuration,,1,,9913.0,5218,0,22224,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,U,,Bos taurus,BAO_0000019,,CHEMBL623559,,,A
1469,Autocuration,,1,,9913.0,5219,0,22224,,,Spleen,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,U,,Bos taurus,BAO_0000221,2106.0,CHEMBL623560,,,A
4297,Autocuration,,1,,9913.0,5220,0,22224,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,U,,Bos taurus,BAO_0000019,,CHEMBL623561,,,A
4297,Autocuration,,1,,9913.0,5221,0,22224,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,U,,Bos taurus,BAO_0000019,,CHEMBL623562,,,A
17585,Autocuration,,1,,9913.0,5222,0,22224,,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,U,,Bos taurus,BAO_0000019,,CHEMBL623563,,,A
1336,Autocuration,,1,,9913.0,5223,0,22224,,,Spleen,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,U,,Bos taurus,BAO_0000221,2106.0,CHEMBL623564,,,A
3085,Autocuration,,1,,9913.0,5224,0,22224,,,,Half life in presence of 2 mg/mL BSA at pH 8.8,,U,,Bos taurus,BAO_0000019,,CHEMBL873806,,,A
2857,Autocuration,,1,,9913.0,5225,0,22224,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,U,,Bos taurus,BAO_0000019,,CHEMBL623565,,,A
2857,Autocuration,,1,,9913.0,5226,0,22224,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,U,,Bos taurus,BAO_0000019,,CHEMBL623566,,,A
2857,Autocuration,,1,,9913.0,5227,0,22224,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,U,,Bos taurus,BAO_0000019,,CHEMBL623567,,,A
1540,Autocuration,,1,,9913.0,5228,0,22224,,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,U,,Bos taurus,BAO_0000019,,CHEMBL623568,,,A
6316,Intermediate,,1,,9615.0,5229,1,50588,,,Plasma,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623569,,,A
17594,Intermediate,,1,,9615.0,5230,1,50588,,,Plasma,AUC after administration at 100 mg/kg/day in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623570,,,A
4953,Intermediate,,1,,9615.0,5231,1,50588,,,Plasma,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624254,,,A
16907,Intermediate,,1,,9615.0,5232,1,50588,,,Plasma,AUC value after 15 mg/kg iv dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624255,,,A
16907,Intermediate,,1,,9615.0,5233,1,50588,,,Plasma,AUC value after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624256,,,A
2959,Intermediate,,1,,9615.0,5234,1,50588,,,Plasma,AUC value after administration of 4 mg/Kg oral dose in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624257,,,A
17594,Intermediate,,1,,9615.0,5235,1,50588,,,Plasma,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624258,,,A
5356,Intermediate,,1,,9615.0,5236,1,50588,,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875277,,,A
16807,Intermediate,,1,,9615.0,5237,1,50588,,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622667,,,A
4527,Intermediate,,1,,9615.0,5238,1,50588,,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622668,,,A
4527,Intermediate,,1,,9615.0,5239,1,50588,,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622669,,,A
15660,Intermediate,,1,,9615.0,5240,1,50588,,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622670,,,A
15660,Intermediate,,1,,9615.0,5241,1,50588,,,,Area under curve determined in dogs after oral administration of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622671,,,A
5802,Intermediate,,1,,9615.0,5242,1,50588,,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622672,,,A
3598,Expert,,1,,9615.0,5243,1,50588,,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622673,,,A
3598,Expert,,1,,9615.0,5244,1,50588,,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622674,,,A
5944,Intermediate,,1,,9615.0,5245,1,50588,,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622675,,,A
5944,Intermediate,,1,,9615.0,5246,1,50588,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622676,,,A
5944,Intermediate,,1,,9615.0,5247,1,50588,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622677,,,A
5944,Intermediate,,1,,9615.0,5248,1,50588,,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622678,,,A
4186,Intermediate,,1,,9615.0,5249,1,50588,,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622679,,,A
5007,Intermediate,,1,,9615.0,5250,1,50588,,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622680,,,A
5668,Intermediate,,1,,9615.0,5251,1,50588,,,,Area under curve was determine after peroral administration at 10 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622681,,,A
5668,Intermediate,,1,,9615.0,5252,1,50588,,,,Area under curve was determine after peroral administration at 5 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875278,,,A
5006,Intermediate,,1,,9615.0,5253,1,50588,,,,Area under curve was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622682,,,A
5006,Intermediate,,1,,9615.0,5254,1,50588,,,,Area under curve in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622683,,,A
3771,Intermediate,,1,,9615.0,5255,1,50588,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622684,,,A
3771,Intermediate,,1,,9615.0,5256,1,50588,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622685,,,A
3771,Intermediate,,1,,9615.0,5257,1,50588,,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622686,,,A
1916,Intermediate,,1,,9615.0,5258,1,50588,,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618344,,,A
5302,Intermediate,,1,,9615.0,5259,1,50588,,,,Area under curve value in dog at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875582,,,A
5600,Intermediate,,1,,9615.0,5260,1,50588,,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618345,,,A
5600,Intermediate,,1,,9615.0,5261,1,50588,,,,Area under curve was determined after 0.3 mg/kg po administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618346,,,A
17764,Intermediate,,1,,9615.0,5262,1,50588,,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618347,,,A
4368,Intermediate,,1,,9615.0,5263,1,50588,,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618348,,,A
5318,Autocuration,,1,,9606.0,5264,0,22224,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,U,,Homo sapiens,BAO_0000019,,CHEMBL618349,,,A
5318,Autocuration,,1,,9606.0,5265,0,22224,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,U,,Homo sapiens,BAO_0000019,,CHEMBL618350,,,A
5318,Autocuration,,1,,9606.0,5266,0,22224,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,U,,Homo sapiens,BAO_0000019,,CHEMBL618351,,,A
5318,Autocuration,,1,,9606.0,5267,0,22224,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,U,,Homo sapiens,BAO_0000019,,CHEMBL618352,,,A
14518,Autocuration,,1,,9606.0,5268,0,22224,,,Blood,Time taken to reduce 50% of the concentration of compound in blood plasma,,U,,Homo sapiens,BAO_0000221,178.0,CHEMBL873494,,,A
2209,Autocuration,,1,,9606.0,5269,0,22224,,,Plasma,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618353,,,A
6787,Autocuration,,1,,9606.0,5270,0,22224,,,Plasma,Half life in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618354,,,A
4898,Autocuration,,1,,9606.0,5271,0,22224,,,Plasma,Half life in human plasma was reported,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL875583,,,A
6072,Autocuration,,1,,9606.0,5272,0,22224,,,Serum,Half life in human serum,,U,,Homo sapiens,BAO_0000019,1977.0,CHEMBL618355,,,A
16907,Autocuration,,1,,9606.0,5273,0,22224,,,Plasma,Half life upon exposure to human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618356,,,A
5656,Autocuration,,1,,9606.0,5274,0,22224,,In vitro,,t1/2 in human microsomes,,U,,Homo sapiens,BAO_0000251,,CHEMBL618357,,Microsomes,A
4755,Autocuration,,1,,9606.0,5275,0,22224,,,Plasma,Half life period in 80% human plasma at 37 degree Centigrade,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618358,,,A
17503,Autocuration,,1,,9606.0,5276,0,22224,,,Zone of skin,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,U,,Homo sapiens,BAO_0000221,14.0,CHEMBL618359,,,A
12357,Autocuration,,1,,9606.0,5277,0,22224,,In vitro,Plasma,Half-life measured in in vitro Cathepsin B assay in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618360,,,A
3076,Autocuration,,1,,9606.0,5278,0,22224,,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,U,,Homo sapiens,BAO_0000019,,CHEMBL618361,,,A
6410,Autocuration,,1,,9606.0,5279,0,22224,,In vitro,Liver,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618362,,Microsomes,A
3741,Autocuration,,1,,9606.0,5280,0,22224,,,Plasma,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618363,,,A
3741,Autocuration,,1,,9606.0,5281,0,22224,,,Plasma,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618364,,,A
3741,Autocuration,,1,,9606.0,5282,0,22224,,,Plasma,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL875584,,,A
1540,Autocuration,,1,,9606.0,5283,0,22224,,,,Half-life in the CEM cell extracts,,U,,Homo sapiens,BAO_0000019,,CHEMBL618365,,,A
2905,Autocuration,,1,,9606.0,5284,0,22224,,,Plasma,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL873495,,,A
2905,Autocuration,,1,,9606.0,5285,0,22224,,,Plasma,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618366,,,A
5523,Autocuration,,1,,9606.0,5286,0,22224,,,,Half-life was determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL618367,,,A
1499,Autocuration,,1,,9606.0,5287,0,22224,,,Blood,Half-life (human blood stability),,U,,Homo sapiens,BAO_0000221,178.0,CHEMBL618368,,,A
1499,Autocuration,,1,,9606.0,5288,0,22224,,,Blood,Half-life (human blood stability); no data,,U,,Homo sapiens,BAO_0000221,178.0,CHEMBL618369,,,A
17065,Autocuration,,1,,9606.0,5289,0,22224,,,Plasma,Half-life in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618370,,,A
6861,Autocuration,,1,,9606.0,5290,0,22224,,,,CYP3A4 metabolism half-life (t1/2),,U,,Homo sapiens,BAO_0000019,,CHEMBL618371,,,A
1499,Autocuration,,1,,9606.0,5291,0,22224,,,Blood,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,U,,Homo sapiens,BAO_0000221,178.0,CHEMBL618372,,,A
530,Autocuration,,1,,9606.0,5292,0,22224,,In vitro,Plasma,In vitro half life in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618373,,,A
1116,Autocuration,,1,,9606.0,5293,0,22224,,In vitro,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618374,,,A
6695,Autocuration,,1,,9606.0,5294,0,22224,,In vitro,Plasma,In vitro hydrolysis in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618375,,,A
6695,Autocuration,,1,,9606.0,5295,0,22224,,In vitro,Plasma,In vitro hydrolysis in human plasma; no data,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618376,,,A
10,Autocuration,,1,,9606.0,5296,0,22224,,In vitro,Liver,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL618377,,Microsomes,A
993,Autocuration,,1,,9606.0,5297,0,22224,,,Plasma,Plasma half life in human,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618378,,,A
15429,Autocuration,,1,,9606.0,5298,0,22224,,,Plasma,Stability after incubation with human plasma (at 37 degree C),,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618379,,,A
1675,Autocuration,,1,,9606.0,5299,0,22224,,,Plasma,T1/2 was evaluated in human plasma,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618380,,,A
2209,Autocuration,,1,,9606.0,5300,0,22224,,,Plasma,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618381,,,A
2209,Autocuration,,1,,9606.0,5301,0,22224,,,Plasma,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL618382,,,A
5318,Autocuration,,1,,9606.0,5302,0,22224,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,U,,Homo sapiens,BAO_0000019,,CHEMBL618383,,,A
2412,Autocuration,,1,,9606.0,5303,0,22224,,In vitro,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,U,,Homo sapiens,BAO_0000019,,CHEMBL618384,,,A
2412,Autocuration,,1,,9606.0,5304,0,22224,,In vitro,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL618385,,,A
2906,Autocuration,,1,,9606.0,5305,0,22224,,,Plasma,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL619099,,,A
2906,Autocuration,,1,,9606.0,5306,0,22224,,,Plasma,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL619100,,,A
5495,Autocuration,,1,,9606.0,5307,0,22224,,,,Time taken for 50% to be consumed by serum PON1 was determined,,U,,Homo sapiens,BAO_0000019,,CHEMBL619101,,,A
5495,Autocuration,,1,,9606.0,5308,0,22224,,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,U,,Homo sapiens,BAO_0000019,,CHEMBL619102,,,A
4397,Autocuration,,1,,9606.0,5309,0,22224,,,Liver,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,U,,Homo sapiens,BAO_0000251,2107.0,CHEMBL619103,,Microsomes,A
2413,Autocuration,,1,,10095.0,5310,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL619268,,,A
2413,Autocuration,,1,,10095.0,5311,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL619269,,,A
2413,Autocuration,,1,,10095.0,5312,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL619270,,,A
2413,Autocuration,,1,,10095.0,5313,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL619271,,,A
2413,Autocuration,,1,,10095.0,5314,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL875585,,,A
2413,Autocuration,,1,,10095.0,5315,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL619272,,,A
6058,Intermediate,,1,,9606.0,5316,1,80640,786-0,,,Compound tested for growth inhibition of renal cancer cell line 786-0,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619273,,,F
17708,Intermediate,,1,,9606.0,5317,1,80640,786-0,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619274,,,F
14017,Expert,,1,,9606.0,5318,1,80640,786-0,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619275,,,F
16818,Intermediate,,1,,9606.0,5319,1,80640,786-0,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619276,,,F
16818,Intermediate,,1,,9606.0,5320,1,80640,786-0,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619277,,,F
16818,Intermediate,,1,,9606.0,5321,1,80640,786-0,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619278,,,F
11970,Intermediate,,1,,9606.0,5322,1,80640,786-0,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619279,,,F
12400,Intermediate,,1,,9606.0,5323,1,80640,786-0,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL858458,,,F
12888,Expert,,1,,9606.0,5324,1,80640,786-0,,,Cytotoxic effect on renal cancer line 786-0,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619280,,,F
15300,Intermediate,,1,,9606.0,5325,1,80640,786-0,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619281,,,F
14769,Intermediate,,1,,9606.0,5326,1,80640,786-0,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619282,,,F
15895,Intermediate,,1,,9606.0,5327,1,80640,786-0,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619283,,,F
17376,Intermediate,,1,,9606.0,5328,1,80640,786-0,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619284,,,F
14882,Intermediate,,1,,9606.0,5329,1,80640,786-0,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619285,,,F
14882,Intermediate,,1,,9606.0,5330,1,80640,786-0,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619286,,,F
15176,Intermediate,,1,,9606.0,5331,1,80640,786-0,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619287,,,F
12696,Intermediate,,1,,9606.0,5332,1,80640,786-0,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL857455,,,F
2496,Intermediate,,1,,9606.0,5333,1,80640,786-0,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL883801,,,F
11831,Intermediate,,1,,9606.0,5334,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619288,,,F
11831,Intermediate,,1,,9606.0,5335,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619289,,,F
11831,Intermediate,,1,,9606.0,5336,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619290,,,F
11831,Intermediate,,1,,9606.0,5337,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619291,,,F
11831,Intermediate,,1,,9606.0,5338,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619292,,,F
11831,Intermediate,,1,,9606.0,5339,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619293,,,F
11831,Intermediate,,1,,9606.0,5340,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619294,,,F
11831,Intermediate,,1,,9606.0,5341,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619295,,,F
11831,Intermediate,,1,,9606.0,5342,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619296,,,F
11831,Intermediate,,1,,9606.0,5343,1,80641,791T cell line,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,N,972.0,Homo sapiens,BAO_0000219,,CHEMBL619297,,,F
12782,Intermediate,,1,,9606.0,5344,1,80640,786-0,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,N,391.0,Homo sapiens,BAO_0000219,,CHEMBL619298,,,F
1229,Intermediate,,1,,,5345,0,22226,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,U,,,BAO_0000019,,CHEMBL619299,,,F
15313,Expert,,1,,9606.0,5346,1,80433,RPMI-8226,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619300,,,F
15313,Expert,,1,,9606.0,5347,1,80433,RPMI-8226,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619301,,,F
11544,Intermediate,,1,,9606.0,5348,1,80433,RPMI-8226,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619302,,,F
9424,Intermediate,,1,,9606.0,5349,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619303,,,F
9424,Intermediate,,1,,9606.0,5350,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619304,,,F
9424,Intermediate,,1,,9606.0,5351,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL857706,,,F
9424,Intermediate,,1,,9606.0,5352,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619305,,,F
9424,Intermediate,,1,,9606.0,5353,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619306,,,F
9424,Intermediate,,1,,9606.0,5354,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619307,,,F
9424,Intermediate,,1,,9606.0,5355,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619308,,,F
9424,Intermediate,,1,,9606.0,5356,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619309,,,F
9424,Intermediate,,1,,9606.0,5357,1,80433,RPMI-8226,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL619310,,,F
14769,Intermediate,,1,,9606.0,5358,1,80021,A498,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619311,,,F
15354,Intermediate,,1,,9606.0,5359,1,80021,A498,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619312,,,F
17445,Intermediate,,1,,9606.0,5360,1,80021,A498,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619313,,,F
4337,Intermediate,,1,,9606.0,5361,1,80021,A498,,,In vitro inhibitory concentration against renal cancer cell line A498,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619314,,,F
15277,Intermediate,,1,,9606.0,5362,1,80021,A498,,,Cytotoxicity against A 498 tumor cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619959,,,F
4812,Intermediate,,1,,9606.0,5363,1,80021,A498,,,In vitro antitumor activity against A498 human cancer cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619960,,,F
4812,Intermediate,,1,,9606.0,5364,1,80021,A498,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619961,,,F
4995,Intermediate,,1,,9606.0,5365,1,80021,A498,,,Inhibitory dose required against A498 human tumor cell lines,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619962,,,F
5847,Intermediate,,1,,9606.0,5366,1,80021,A498,,,Anticancer activity against one renal cancer (A498 cell line),,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL875586,,,F
6557,Intermediate,,1,,9606.0,5367,1,80021,A498,,,In vitro cytotoxicity against melanoma A498 cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619963,,,F
2597,Intermediate,,1,,9606.0,5368,1,80021,A498,,,Compound was tested for growth inhibitory activity against A498 cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619964,,,F
6058,Intermediate,,1,,9606.0,5369,1,80021,A498,,,Compound tested for growth inhibition of renal cancer cell line A498,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620108,,,F
17708,Intermediate,,1,,9606.0,5370,1,80021,A498,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620109,,,F
15176,Intermediate,,1,,9606.0,5371,1,80021,A498,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620110,,,F
15300,Intermediate,,1,,9606.0,5372,1,80021,A498,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620111,,,F
11970,Intermediate,,1,,9606.0,5373,1,80021,A498,,,Tested for cytotoxicity against A498 cell lines in renal cancer,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620112,,,F
12400,Intermediate,,1,,9606.0,5374,1,80021,A498,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620113,,,F
12888,Expert,,1,,9606.0,5375,1,80021,A498,,,Cytotoxic effect on renal cancer lines A498,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620114,,,F
3030,Intermediate,,1,,9606.0,5376,1,80021,A498,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620115,,,F
14769,Intermediate,,1,,9606.0,5377,1,80021,A498,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620116,,,F
17376,Intermediate,,1,,9606.0,5378,1,80021,A498,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620117,,,F
16558,Intermediate,,1,,9606.0,5379,1,80021,A498,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620118,,,F
5194,Intermediate,,1,,9606.0,5380,1,80021,A498,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620119,,,F
10708,Intermediate,,1,,9606.0,5381,1,80021,A498,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620120,,,F
16880,Expert,,1,,9606.0,5382,1,80682,A549,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620121,,,F
10196,Intermediate,,1,,9606.0,5383,1,80682,A549,,,Antitumor activity against A549 human lung carcinoma cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620122,,,F
10196,Intermediate,,1,,9606.0,5384,1,80682,A549,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620123,,,F
10196,Intermediate,,1,,9606.0,5385,1,80682,A549,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620124,,,F
12083,Intermediate,,1,,9606.0,5386,1,80682,A549,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620125,,,F
16464,Expert,,1,,9606.0,5387,1,80682,A549,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620126,,,F
16464,Intermediate,,1,,9606.0,5388,1,80682,A549,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL883027,,,F
16470,Expert,,1,,9606.0,5389,1,80682,A549,,,In vitro cytotoxic activity against human lung A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620127,,,F
16470,Intermediate,,1,,9606.0,5390,1,80682,A549,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620128,,,F
16470,Intermediate,,1,,9606.0,5391,1,80682,A549,,,In vitro cytotoxic activity against human lung A549 cell line),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620129,,,F
16470,Intermediate,,1,,9606.0,5392,1,80682,A549,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620130,,,F
16582,Expert,,1,,9606.0,5393,1,80682,A549,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620131,,,F
15935,Intermediate,,1,,9606.0,5394,1,80682,A549,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620132,,,F
15935,Intermediate,,1,,9606.0,5395,1,80682,A549,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620133,,,F
16597,Expert,,1,,9606.0,5396,1,80682,A549,,,Inhibition of A549 human lung carcinoma cell proliferation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620134,,,F
17376,Intermediate,,1,,9606.0,5397,1,80682,A549,,,Inhibitory activity against A549 lung adenocarcinoma cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620135,,,F
16496,Intermediate,,1,,9606.0,5398,1,80682,A549,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620136,,,F
16152,Intermediate,,1,,9606.0,5399,1,80682,A549,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620137,,,F
16152,Intermediate,,1,,9606.0,5400,1,80682,A549,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620268,,,F
16464,Intermediate,,1,,9606.0,5401,1,80682,A549,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620269,,,F
2288,Intermediate,,1,,9606.0,5402,1,80682,A549,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620270,,,F
17350,Intermediate,,1,,9606.0,5403,1,80682,A549,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620271,,,F
4090,Expert,,1,,9606.0,5404,1,80682,A549,,,Inhibition of A549 cancer cell proliferation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620272,,,F
4090,Expert,,1,,9606.0,5405,1,80682,A549,,,Inhibition of A549 cancer cell proliferation (Not tested),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620273,,,F
17350,Intermediate,,1,,9606.0,5406,1,80682,A549,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620274,,,F
4197,Intermediate,,1,,9606.0,5407,1,80682,A549,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620275,,,F
17072,Intermediate,,1,,9606.0,5408,1,80682,A549,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620276,,,F
17072,Intermediate,,1,,9606.0,5409,1,80682,A549,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620277,,,F
5194,Intermediate,,1,,9606.0,5410,1,80682,A549,,,Cytotoxicity against Renal cell lines A549 was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620278,,,F
4257,Intermediate,,1,,9615.0,5411,1,50588,,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620279,,,A
6123,Intermediate,,1,,9615.0,5412,1,50588,,,,Area under curve was determined in dog after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620280,,,A
1337,Intermediate,,1,,9615.0,5413,1,50588,,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620281,,,A
1337,Intermediate,,1,,9615.0,5414,1,50588,,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620282,,,A
8833,Intermediate,,1,,9615.0,5415,1,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621134,,,A
8833,Intermediate,,1,,9615.0,5416,1,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621135,,,A
8833,Intermediate,,1,,9615.0,5417,1,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621136,,,A
8833,Intermediate,,1,,9615.0,5418,1,50588,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621137,,,A
17657,Intermediate,,1,,9615.0,5419,1,50588,,,Plasma,Area under plasma concentration time curve in dog upon oral administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621138,,,A
17650,Intermediate,,1,,9615.0,5420,1,50588,,,Plasma,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL875587,,,A
1977,Intermediate,,1,,9615.0,5421,1,50588,,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621139,,,A
1977,Intermediate,,1,,9615.0,5422,1,50588,,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621140,,,A
3132,Intermediate,,1,,9615.0,5423,1,50588,,,,Area under the curve for the compound was obtained when tested in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621141,,,A
5473,Intermediate,,1,,9615.0,5424,1,50588,,,,Area under the curve at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621142,,,A
5474,Intermediate,,1,,9615.0,5425,1,50588,,,,Area under the curve at a dose of 1 mg/kg (oral),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621143,,,A
5474,Intermediate,,1,,9615.0,5426,1,50588,,,,Area under the curve at i.v. dose of 0.2 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621144,,,A
6062,Intermediate,,1,,9615.0,5427,1,50588,,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621145,,,A
4709,Intermediate,,1,,9615.0,5428,1,50588,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621146,,,A
2652,Intermediate,,1,,9615.0,5429,1,50588,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622567,,,A
2652,Intermediate,,1,,9615.0,5430,1,50588,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622568,,,A
2877,Intermediate,,1,,9615.0,5431,1,50588,,,,Compound was evaluated for area under the curve in dog blood.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622569,,,A
5444,Intermediate,,1,,9615.0,5432,1,50588,,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622570,,,A
5130,Intermediate,,1,,9615.0,5433,1,50588,,,Plasma,AUC in dog after oral dose (1 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622571,,,A
6265,Intermediate,,1,,9615.0,5434,1,50588,,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622572,,,A
4657,Intermediate,,1,,9615.0,5435,1,50588,,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622573,,,A
16367,Intermediate,,1,,9615.0,5436,1,50588,,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622574,,,A
16367,Intermediate,,1,,9615.0,5437,1,50588,,,,Pharmacokinetic parameter AUC after oral administration to dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622575,,,A
9579,Intermediate,,1,,9615.0,5438,1,50588,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622576,,,A
9579,Intermediate,,1,,9615.0,5439,1,50588,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622577,,,A
5983,Intermediate,,1,,9615.0,5440,1,50588,,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622578,,,A
6241,Intermediate,,1,,9615.0,5441,1,50588,,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622579,,,A
5313,Intermediate,,1,,9615.0,5442,1,50588,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622580,,,A
5313,Intermediate,,1,,9615.0,5443,1,50588,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622581,,,A
6642,Intermediate,,1,,9615.0,5444,1,50588,,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622582,,,A
6642,Intermediate,,1,,9615.0,5445,1,50588,,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622583,,,A
6641,Intermediate,,1,,9615.0,5446,1,50588,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622584,,,A
6642,Intermediate,,1,,9615.0,5447,1,50588,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622585,,,A
17791,Intermediate,,1,,9615.0,5448,1,50588,,,,Compound was evaluated for oral bioavailability in dog; 90-100,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622586,,,A
17655,Intermediate,,1,,9615.0,5449,1,50588,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623281,,,A
17655,Intermediate,,1,,9615.0,5450,1,50588,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623282,,,A
6596,Intermediate,,1,,9615.0,5451,1,50588,,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623283,,,A
3880,Intermediate,,1,,9615.0,5452,1,50588,,,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623284,,,A
16367,Intermediate,,1,,9615.0,5453,1,50588,,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623285,,,A
17409,Intermediate,,1,,9615.0,5454,1,50588,,,Plasma,Plasma protein binding towards dog plasma at 10 uM,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623463,,,A
17409,Intermediate,,1,,9615.0,5455,1,50588,,,Plasma,Plasma protein binding towards dog plasma at 100 uM,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL875952,,,A
2959,Intermediate,,1,,9615.0,5456,1,50588,,In vivo,,Bioavailability in dog (dose 4 mg/kg p.o.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621705,,,A
13501,Intermediate,,1,,9615.0,5457,1,50588,,In vivo,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621706,,,A
4527,Intermediate,,1,,9615.0,5458,1,50588,,In vivo,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621707,,,A
15145,Intermediate,,1,,9615.0,5459,1,50588,,In vivo,,Bioavailability in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621708,,,A
4219,Intermediate,,1,,9615.0,5460,1,50588,,In vivo,,Bioavailability,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621709,,,A
17538,Intermediate,,1,,9615.0,5461,1,50588,,In vivo,,Oral bioavailability in dog (dose 10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621710,,,A
17538,Intermediate,,1,,9615.0,5462,1,50588,,In vivo,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621711,,,A
1466,Intermediate,,1,,9615.0,5463,1,50588,,In vivo,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621712,,,A
17650,Intermediate,,1,,9615.0,5464,1,50588,,In vivo,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621713,,,A
3132,Intermediate,,1,,9615.0,5465,1,50588,,In vivo,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621714,,,A
2413,Autocuration,,1,,10095.0,5466,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL621715,,,A
2413,Autocuration,,1,,10095.0,5467,0,22224,,,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,2107.0,CHEMBL623717,,,A
2413,Autocuration,,1,,10095.0,5468,0,22224,,,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,,Mus sp.,BAO_0000218,2107.0,CHEMBL623718,,,A
2413,Autocuration,,1,,10095.0,5469,0,22224,,,Liver,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,2107.0,CHEMBL623719,,,A
2413,Autocuration,,1,,10095.0,5470,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL623720,,,A
2413,Autocuration,,1,,10095.0,5471,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL623721,,,A
2413,Autocuration,,1,,10095.0,5472,0,22224,,,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,2385.0,CHEMBL623722,,,A
2413,Autocuration,,1,,10095.0,5473,0,22224,,,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,,Mus sp.,BAO_0000218,2385.0,CHEMBL623723,,,A
2413,Autocuration,,1,,10095.0,5474,0,22224,,,Muscle tissue,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,2385.0,CHEMBL618543,,,A
2413,Autocuration,,1,,10095.0,5475,0,22224,,,Spleen,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,2106.0,CHEMBL618544,,,A
2413,Autocuration,,1,,10095.0,5476,0,22224,,,Spleen,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,2106.0,CHEMBL875155,,,A
2413,Autocuration,,1,,10095.0,5477,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL618545,,,A
2413,Autocuration,,1,,10095.0,5478,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL618546,,,A
2413,Autocuration,,1,,10095.0,5479,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL623529,,,A
2413,Autocuration,,1,,10095.0,5480,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL623530,,,A
2413,Autocuration,,1,,10095.0,5481,0,22224,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,U,,Mus sp.,BAO_0000218,,CHEMBL621764,,,A
17827,Autocuration,,1,,9527.0,5482,0,22224,,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,,CHEMBL621765,,,A
17827,Autocuration,,1,,9527.0,5483,0,22224,,,Cerebellum,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,2037.0,CHEMBL621766,,,A
17827,Autocuration,,1,,9527.0,5484,0,22224,,,Frontal cortex,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,1870.0,CHEMBL621767,,,A
17827,Autocuration,,1,,9527.0,5485,0,22224,,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,,CHEMBL621768,,,A
17827,Autocuration,,1,,9527.0,5486,0,22224,,,Striatum,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,2435.0,CHEMBL621769,,,A
17827,Autocuration,,1,,9527.0,5487,0,22224,,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,,CHEMBL621770,,,A
17827,Autocuration,,1,,9527.0,5488,0,22224,,,Cerebellum,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,2037.0,CHEMBL621771,,,A
17827,Autocuration,,1,,9527.0,5489,0,22224,,,Frontal cortex,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,1870.0,CHEMBL621772,,,A
17827,Autocuration,,1,,9527.0,5490,0,22224,,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,,CHEMBL621773,,,A
17827,Autocuration,,1,,9527.0,5491,0,22224,,,Striatum,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,U,,Cercopithecidae,BAO_0000019,2435.0,CHEMBL621774,,,A
17791,Autocuration,,1,,9527.0,5492,0,22224,,,,Compound was evaluated for oral bioavailability in rats,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621775,,,A
17667,Autocuration,,1,,9527.0,5493,0,22224,,In vivo,Plasma,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL621776,,,A
17791,Autocuration,,1,,9527.0,5494,0,22224,,,,Half life period was evaluated in monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL621777,,,A
110,Autocuration,,1,,9527.0,5495,0,22224,,In vivo,,Half-life in rhesus monkeys by intravenous administration of dose,,U,,Cercopithecidae,BAO_0000218,,CHEMBL875162,,,A
5781,Intermediate,,1,,10090.0,5496,1,50594,,,Plasma,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL621778,,,A
17734,Intermediate,,1,,10090.0,5497,1,50594,,,Plasma,AUC after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL621779,,,A
17718,Intermediate,,1,,10090.0,5498,1,50594,,,Plasma,AUC value was determined after oral administration,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622479,,,A
4573,Intermediate,,1,,10090.0,5499,1,50594,,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622480,,,A
3277,Intermediate,,1,,10090.0,5500,1,50594,,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,,Mus musculus,BAO_0000218,,CHEMBL622481,,,A
2862,Intermediate,,1,,10090.0,5501,1,50594,,,,Area under curve by ioral administration in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL622482,,,A
2862,Intermediate,,1,,10090.0,5502,1,50594,,,,Area under curve by iv administration in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL622483,,,A
5951,Intermediate,,1,,10090.0,5503,1,50594,,,,Area under curve at 0-8 hr in IRC mice after peroral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL622484,,,A
17729,Intermediate,,1,,10090.0,5504,1,50594,,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622641,,,A
17728,Intermediate,,1,,10090.0,5505,1,50594,,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622642,,,A
17728,Intermediate,,1,,10090.0,5506,1,50594,,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622643,,,A
17729,Intermediate,,1,,10090.0,5507,1,50594,,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622644,,,A
9424,Intermediate,,1,,9606.0,5508,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL622645,,,F
9424,Intermediate,,1,,9606.0,5509,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL622646,,,F
9424,Intermediate,,1,,9606.0,5510,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL621238,,,F
9424,Intermediate,,1,,9606.0,5511,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL621239,,,F
9424,Intermediate,,1,,9606.0,5512,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL621240,,,F
9424,Intermediate,,1,,9606.0,5513,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL621241,,,F
9424,Intermediate,,1,,9606.0,5514,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL621242,,,F
9424,Intermediate,,1,,9606.0,5515,1,80433,RPMI-8226,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620350,,,F
9424,Intermediate,,1,,9606.0,5516,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620351,,,F
9424,Intermediate,,1,,9606.0,5517,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620352,,,F
9424,Intermediate,,1,,9606.0,5518,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620353,,,F
9424,Intermediate,,1,,9606.0,5519,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620354,,,F
9424,Intermediate,,1,,9606.0,5520,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620355,,,F
9424,Intermediate,,1,,9606.0,5521,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620356,,,F
9424,Intermediate,,1,,9606.0,5522,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620357,,,F
9424,Intermediate,,1,,9606.0,5523,1,80433,RPMI-8226,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620358,,,F
9424,Expert,,1,,9606.0,5524,1,80433,RPMI-8226,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620359,,,F
11544,Intermediate,,1,,9606.0,5525,1,80433,RPMI-8226,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620360,,,F
17378,Intermediate,,1,,9606.0,5526,1,80433,RPMI-8226,,,Cytotoxicity of compound against 8226/DOX1V cells,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620361,,,F
17378,Intermediate,,1,,9606.0,5527,1,80433,RPMI-8226,,,Cytotoxicity of compound against 8226/S cells,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620362,,,F
17079,Intermediate,,1,,9606.0,5528,1,80433,RPMI-8226,,,Inhibitory concentration against 8226 myeloma cancer cell line,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620363,,,F
17079,Intermediate,,1,,9606.0,5529,1,80433,RPMI-8226,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,N,741.0,Homo sapiens,BAO_0000219,,CHEMBL620364,,,F
13466,Intermediate,,1,,9606.0,5530,1,80647,833K,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,N,854.0,Homo sapiens,BAO_0000219,,CHEMBL620365,,,F
13466,Intermediate,,1,,9606.0,5531,1,80647,833K,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,N,854.0,Homo sapiens,BAO_0000219,,CHEMBL620366,,,F
2392,Expert,,1,,9606.0,5532,1,80647,833K,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,N,854.0,Homo sapiens,BAO_0000219,,CHEMBL620367,,,F
2392,Intermediate,,1,,9606.0,5533,1,80647,833K,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,N,854.0,Homo sapiens,BAO_0000219,,CHEMBL620368,,,F
6608,Autocuration,,1,,,5534,0,22226,,,,Inhibitory activity against caspase-1,,U,,,BAO_0000019,,CHEMBL620369,,,B
10199,Autocuration,,1,,1351.0,5535,8,45,,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,H,,Enterococcus faecalis,BAO_0000357,,CHEMBL620370,,,B
17749,Intermediate,,1,,9606.0,5536,1,80648,8701-BC,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,N,705.0,Homo sapiens,BAO_0000219,,CHEMBL620371,,,F
17749,Intermediate,,1,,9606.0,5537,1,80648,8701-BC,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,N,705.0,Homo sapiens,BAO_0000219,,CHEMBL620372,,,F
1229,Intermediate,,1,,,5538,0,22226,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,U,,,BAO_0000019,,CHEMBL876492,,,F
1229,Intermediate,,1,,,5539,0,22226,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,U,,,BAO_0000019,,CHEMBL620373,,,F
1229,Intermediate,,1,,,5540,0,22226,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,U,,,BAO_0000019,,CHEMBL620374,,,F
6390,Autocuration,,1,,,5541,0,22226,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,U,,,BAO_0000019,,CHEMBL620375,,,B
16219,Autocuration,,1,,1314.0,5542,0,22226,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,U,,Streptococcus pyogenes,BAO_0000019,,CHEMBL857902,,,F
16219,Autocuration,,1,,1314.0,5543,0,22226,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,U,,Streptococcus pyogenes,BAO_0000019,,CHEMBL620376,,,F
17043,Autocuration,,1,,,5544,8,11922,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,H,,,BAO_0000357,,CHEMBL620377,,,B
6929,Intermediate,,1,,9606.0,5545,1,81115,KB ,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,N,324.0,Homo sapiens,BAO_0000219,,CHEMBL620378,,,F
6929,Intermediate,,1,,9606.0,5546,1,81115,KB ,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,N,324.0,Homo sapiens,BAO_0000219,,CHEMBL620379,,,A
7083,Autocuration,,1,,9606.0,5547,0,22226,,,,In vitro cytotoxicity of compound was tested against 9KB cells.,,U,,Homo sapiens,BAO_0000219,,CHEMBL620380,,,F
12446,Intermediate,,1,,10116.0,5548,1,80653,9L,,,Cytotoxic concentration against 9L cells was determined on day 3,,N,392.0,Rattus norvegicus,BAO_0000219,,CHEMBL884006,,,F
15345,Expert,,1,,10116.0,5549,1,80653,9L,,,Tested in vitro for anticancer activity against 9L cells,,N,392.0,Rattus norvegicus,BAO_0000219,,CHEMBL620381,,,F
15345,Expert,,1,,10116.0,5550,1,80653,9L,,,Tested in vitro for anticancer activity against 9L cells; Not determined,,N,392.0,Rattus norvegicus,BAO_0000219,,CHEMBL620382,,,F
6301,Intermediate,,1,,9606.0,5551,1,80682,A549,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620383,,,F
4833,Intermediate,,1,,9606.0,5552,1,80682,A549,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876493,,,F
4833,Intermediate,,1,,9606.0,5553,1,80682,A549,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620384,,,F
4833,Intermediate,,1,,9606.0,5554,1,80682,A549,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620385,,,F
13330,Expert,,1,,9606.0,5555,1,80682,A549,,,Cytotoxicity against human lung carcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620386,,,F
17517,Expert,,1,,9606.0,5556,9,25,A549,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,D,646.0,Homo sapiens,BAO_0000219,,CHEMBL620387,,,F
17517,Expert,,1,,9606.0,5557,9,25,A549,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,D,646.0,Homo sapiens,BAO_0000219,,CHEMBL621404,,,F
14425,Intermediate,,1,,9606.0,5558,1,80682,A549,,,"In vitro growth inhibition of A549, lung carcinoma",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621405,,,F
14425,Intermediate,,1,,9606.0,5559,1,80682,A549,,,"In vitro growth inhibition of A549, lung carcinoma.",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621406,,,F
5228,Expert,,1,,9606.0,5560,1,80682,A549,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621407,,,F
5351,Intermediate,,1,,9606.0,5561,1,80682,A549,,,Cytotoxic activity against human lung cancer A549 cell line was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621408,,,F
12198,Expert,,1,,9606.0,5562,1,80682,A549,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL885345,,,F
13891,Intermediate,,1,,9606.0,5563,1,80682,A549,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621409,,,F
5677,Expert,,1,,9606.0,5564,1,80682,A549,,,Cytotoxicity in A549 (human carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876034,,,F
13788,Intermediate,,1,,9606.0,5565,1,80682,A549,,,Cytotoxicity on lung carcinoma (A-549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621410,,,F
13384,Expert,,1,,9606.0,5566,1,80682,A549,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621411,,,F
6726,Intermediate,,1,,9606.0,5567,1,80682,A549,,,Effective dose of compound against replication of A549 cell line was evaluated,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621412,,,F
3455,Expert,,1,,9606.0,5568,1,80682,A549,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621413,,,F
5726,Intermediate,,1,,9606.0,5569,1,80682,A549,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621414,,,F
5726,Intermediate,,1,,9606.0,5570,1,80682,A549,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621415,,,F
3936,Intermediate,,1,,9606.0,5571,1,80682,A549,,,The compound was evaluated for antiproliferative activity against A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621416,,,F
14991,Intermediate,,1,,9606.0,5572,1,80682,A549,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621417,,,F
5243,Intermediate,,1,,9606.0,5573,1,80682,A549,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621418,,,F
12858,Intermediate,,1,,9606.0,5574,1,80682,A549,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621419,,,F
6776,Intermediate,,1,,9606.0,5575,1,80682,A549,,,Growth inhibition against A549 cell line was evaluated,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621420,,,F
16558,Intermediate,,1,,9606.0,5576,1,80682,A549,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL875823,,,F
4583,Expert,,1,,9606.0,5577,1,80682,A549,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621421,,,F
13514,Intermediate,,1,,9606.0,5578,1,80682,A549,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621422,,,F
15166,Expert,,1,,9606.0,5579,1,80682,A549,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884014,,,F
13873,Intermediate,,1,,9606.0,5580,1,80682,A549,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621423,,,F
6447,Expert,,1,,9606.0,5581,1,80682,A549,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621424,,,F
2068,Intermediate,,1,,9606.0,5582,1,80682,A549,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621425,,,F
1863,Expert,,1,,9606.0,5583,1,80682,A549,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621426,,,F
13873,Intermediate,,1,,9606.0,5584,1,80682,A549,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621427,,,F
13873,Intermediate,,1,,9606.0,5585,1,80682,A549,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621428,,,F
13873,Expert,,1,,9606.0,5586,1,80682,A549,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621429,,,F
579,Intermediate,,1,,9606.0,5587,1,80682,A549,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621430,,,F
579,Intermediate,,1,,9606.0,5588,1,80682,A549,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621431,,,F
4584,Intermediate,,1,,9606.0,5589,1,80682,A549,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621432,,,F
5421,Expert,,1,,9606.0,5590,1,80682,A549,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621433,,,F
5421,Intermediate,,1,,9606.0,5591,1,80682,A549,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL875824,,,F
5421,Intermediate,,1,,9606.0,5592,1,80682,A549,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621434,,,F
5421,Intermediate,,1,,9606.0,5593,1,80682,A549,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621435,,,F
14188,Intermediate,,1,,9606.0,5594,1,80682,A549,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621436,,,F
14188,Intermediate,,1,,9606.0,5595,1,80682,A549,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621437,,,F
15354,Intermediate,,1,,9606.0,5596,1,80682,A549,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621438,,,F
14253,Expert,,1,,9606.0,5597,1,80682,A549,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621439,,,F
13873,Intermediate,,1,,9606.0,5598,1,80682,A549,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621440,,,F
3043,Intermediate,,1,,9615.0,5599,1,50588,,In vivo,,Oral bioavailability in dog (conscious),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621441,,,A
3045,Intermediate,,1,,9615.0,5600,1,50588,,In vivo,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621442,,,A
3022,Intermediate,,1,,9615.0,5601,1,50588,,In vivo,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621443,,,A
4453,Intermediate,,1,,9615.0,5602,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621444,,,A
1696,Intermediate,,1,,9615.0,5603,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625133,,,A
5045,Intermediate,,1,,9615.0,5604,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625134,,,A
5356,Intermediate,,1,,9615.0,5605,1,50588,,In vivo,,Oral bioavailability in dog (fasted),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625135,,,A
17764,Intermediate,,1,,9615.0,5606,1,50588,,In vivo,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625136,,,A
6448,Intermediate,,1,,9615.0,5607,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625137,,,A
1475,Intermediate,,1,,9615.0,5608,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625138,,,A
3788,Intermediate,,1,,9615.0,5609,1,50588,,In vivo,,Percent bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625139,,,A
3639,Intermediate,,1,,9615.0,5610,1,50588,,In vivo,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL872264,,,A
13397,Intermediate,,1,,9615.0,5611,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625140,,,A
2137,Intermediate,,1,,9615.0,5612,1,50588,,In vivo,,The compound was evaluated for bioavailability in dogs; 34-44,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624436,,,A
2959,Intermediate,,1,,9615.0,5613,1,50588,,In vivo,,Bioavailability in dog (dose 4 mg/kg p.o.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624437,,,A
6448,Intermediate,,1,,9615.0,5614,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL872261,,,A
6084,Intermediate,,1,,9615.0,5615,1,50588,,,,8 hour trough Blood level in dog was measured after administration of compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624438,,,A
3639,Intermediate,,1,,9615.0,5616,1,50588,,In vivo,Plasma,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624439,,,A
6316,Intermediate,,1,,9615.0,5617,1,50588,,,,C24 after oral administration at 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624440,,,A
5238,Intermediate,,1,,9615.0,5618,1,50588,,,,Clearance after oral and iv dosing in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624441,,,A
17796,Intermediate,,1,,9615.0,5619,1,50588,,,Plasma,Clearance of the drug was measured in the plasma of dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624442,,,A
2652,Intermediate,,1,,9615.0,5620,1,50588,,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624443,,,A
5654,Intermediate,,1,,9615.0,5621,1,50588,,In vivo,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624444,,,A
6621,Intermediate,,1,,9615.0,5622,1,50588,,In vivo,,Clearance of compound was determined in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624445,,,A
6505,Intermediate,,1,,9615.0,5623,1,50588,,In vivo,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624446,,,A
5802,Intermediate,,1,,9615.0,5624,1,50588,,In vivo,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624447,,,A
17267,Intermediate,,1,,9615.0,5625,1,50588,,In vivo,,Plasma clearance in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624448,,,A
4521,Intermediate,,1,,9615.0,5626,1,50588,,In vivo,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624449,,,A
6535,Intermediate,,1,,9615.0,5627,1,50588,,In vivo,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624450,,,A
6535,Intermediate,,1,,9615.0,5628,1,50588,,In vivo,,Plasma clearance in dog after administration of 1 mg/kg iv,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875942,,,A
6535,Intermediate,,1,,9615.0,5629,1,50588,,In vivo,,Plasma clearance in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624451,,,A
5542,Intermediate,,1,,9615.0,5630,1,50588,,In vivo,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624452,,,A
5199,Intermediate,,1,,9615.0,5631,1,50588,,In vivo,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624453,,,A
16907,Intermediate,,1,,9615.0,5632,1,50588,,In vivo,,Plasma clearance after 15 mg/kg iv dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624454,,,A
16907,Intermediate,,1,,9615.0,5633,1,50588,,In vivo,,Plasma clearance after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624455,,,A
16367,Intermediate,,1,,9615.0,5634,1,50588,,In vivo,,Plasma administration to dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624456,,,A
5505,Intermediate,,1,,9615.0,5635,1,50588,,In vivo,,Plasma clearance was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624457,,,A
6215,Intermediate,,1,,9615.0,5636,1,50588,,In vivo,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624458,,,A
1466,Intermediate,,1,,9615.0,5637,1,50588,,In vivo,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624459,,,A
5007,Intermediate,,1,,9606.0,5638,2,102164,,In vitro,Liver,Intrinsic clearance in human liver microsomes,,S,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624460,,Microsomes,A
5007,Intermediate,,1,,9606.0,5639,2,102164,,In vitro,Liver,Intrinsic clearance in human liver microsomes,,S,,Homo sapiens,BAO_0000251,2107.0,CHEMBL624461,,Microsomes,A
16452,Intermediate,,1,,9615.0,5640,1,50588,,In vivo,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875943,,,A
16452,Intermediate,,1,,9615.0,5641,1,50588,,In vivo,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624462,,,A
16452,Intermediate,,1,,9615.0,5642,1,50588,,In vivo,,Clearance in dog (dose 1 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624463,,,A
6221,Intermediate,,1,,9615.0,5643,1,50588,,In vivo,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624464,,,A
5007,Intermediate,,1,,9615.0,5644,1,50588,,In vivo,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624465,,,A
5668,Intermediate,,1,,9615.0,5645,1,50588,,In vivo,,Plasma clearance after peroral administration at 10 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624466,,,A
5668,Intermediate,,1,,9615.0,5646,1,50588,,In vivo,,Plasma clearance after peroral administration at 5 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624467,,,A
5668,Intermediate,,1,,9615.0,5647,1,50588,,In vivo,,Plasma clearance after peroral administration at 5 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624468,,,A
15660,Intermediate,,1,,9615.0,5648,1,50588,,In vivo,,Plasma clearance was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624469,,,A
15660,Intermediate,,1,,9615.0,5649,1,50588,,In vivo,,Plasma clearance was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624470,,,A
5983,Intermediate,,1,,9615.0,5650,1,50588,,In vivo,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624471,,,A
5600,Intermediate,,1,,9615.0,5651,1,50588,,In vivo,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624472,,,A
17764,Intermediate,,1,,9615.0,5652,1,50588,,In vivo,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622775,,,A
6039,Intermediate,,1,,9615.0,5653,1,50588,,In vivo,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622776,,,A
6039,Intermediate,,1,,9615.0,5654,1,50588,,In vivo,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622777,,,A
6039,Intermediate,,1,,9615.0,5655,1,50588,,In vivo,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622778,,,A
4368,Intermediate,,1,,9615.0,5656,1,50588,,In vivo,,Clearance by intravenous administration of 1.2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622779,,,A
4305,Intermediate,,1,,9615.0,5657,1,50588,,In vivo,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622780,,,A
1918,Intermediate,,1,,9615.0,5658,1,50588,,In vivo,Plasma,Clearance value was evaluated in dog plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622781,,,A
6005,Intermediate,,1,,9615.0,5659,1,50588,,In vivo,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622782,,,A
4839,Intermediate,,1,,9615.0,5660,1,50588,,In vivo,Plasma,Compound was tested for plasma clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622783,,,A
4239,Intermediate,,1,,9615.0,5661,1,50588,,In vivo,,Pharmacokinetic property (Plasma clearance) was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622784,,,A
17729,Intermediate,,1,,10090.0,5662,1,50594,,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622785,,,A
17728,Intermediate,,1,,10090.0,5663,1,50594,,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622786,,,A
5302,Intermediate,,1,,10090.0,5664,1,50594,,,,Area under curve value in mouse at a dose of 10 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622787,,,A
5506,Intermediate,,1,,10090.0,5665,1,50594,,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,N,,Mus musculus,BAO_0000218,,CHEMBL875949,,,A
5506,Intermediate,,1,,10090.0,5666,1,50594,,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622788,,,A
17764,Intermediate,,1,,10090.0,5667,1,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622789,,,F
17764,Intermediate,,1,,10090.0,5668,1,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622790,,,F
17764,Intermediate,,1,,10090.0,5669,1,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622791,,,F
17764,Intermediate,,1,,10090.0,5670,1,50594,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622792,,,F
17764,Intermediate,,1,,10090.0,5671,1,50594,,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622793,,,A
17753,Intermediate,,1,,10090.0,5672,1,50594,,,,Area under curve was determined for the compound at 24 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622794,,,A
17753,Intermediate,,1,,10090.0,5673,1,50594,,,,Area under curve was determined for the compound at 40 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622795,,,A
17753,Intermediate,,1,,10090.0,5674,1,50594,,,,Area under curve was determined for the compound at 5 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621803,,,A
3132,Intermediate,,1,,10090.0,5675,1,50594,,,,Area under the curve for the compound is obtained at dose 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621804,,,A
3132,Intermediate,,1,,10090.0,5676,1,50594,,,,Area under the curve for the compound was obtained when tested in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL621805,,,A
17837,Intermediate,,1,,10090.0,5677,1,50594,,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621806,,,A
17837,Intermediate,,1,,10090.0,5678,1,50594,,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621807,,,A
6062,Intermediate,,1,,10090.0,5679,1,50594,,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621808,,,A
4066,Intermediate,,1,,10090.0,5680,1,50594,,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621809,,,A
16597,Intermediate,,1,,10090.0,5681,1,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,N,,Mus musculus,BAO_0000218,,CHEMBL621810,,,A
14239,Intermediate,,1,,10090.0,5682,1,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL875164,,,A
14239,Intermediate,,1,,10090.0,5683,1,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621811,,,A
4890,Intermediate,,1,,10090.0,5684,1,50594,,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,N,,Mus musculus,BAO_0000218,,CHEMBL621812,,,A
429,Intermediate,,1,,10090.0,5685,1,50594,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,N,,Mus musculus,BAO_0000218,,CHEMBL621813,,,A
429,Intermediate,,1,,10090.0,5686,1,50594,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,N,,Mus musculus,BAO_0000218,,CHEMBL621814,,,A
5969,Intermediate,,1,,10090.0,5687,1,50594,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621815,,,A
5969,Intermediate,,1,,10090.0,5688,1,50594,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL621816,,,A
5969,Intermediate,,1,,10090.0,5689,1,50594,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL621817,,,A
6091,Intermediate,,1,,10090.0,5690,1,50594,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL621818,,,A
6091,Intermediate,,1,,10090.0,5691,1,50594,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL621819,,,A
6091,Intermediate,,1,,10090.0,5692,1,50594,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621820,,,A
6091,Intermediate,,1,,10090.0,5693,1,50594,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL621821,,,A
6178,Intermediate,,1,,10090.0,5694,1,50594,,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621822,,,A
6178,Intermediate,,1,,10090.0,5695,1,50594,,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL619474,,,A
6619,Intermediate,,1,,10090.0,5696,1,50594,,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,N,,Mus musculus,BAO_0000218,,CHEMBL619475,,,A
6619,Intermediate,,1,,10090.0,5697,1,50594,,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,N,,Mus musculus,BAO_0000218,,CHEMBL619476,,,A
3760,Intermediate,,1,,10090.0,5698,1,50594,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL619477,,,A
3760,Intermediate,,1,,10090.0,5699,1,50594,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL619478,,,A
3760,Intermediate,,1,,10090.0,5700,1,50594,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL619479,,,A
3760,Intermediate,,1,,10090.0,5701,1,50594,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL619480,,,A
3192,Intermediate,,1,,10090.0,5702,1,50594,,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,N,,Mus musculus,BAO_0000218,,CHEMBL619481,,,A
3192,Intermediate,,1,,10090.0,5703,1,50594,,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,N,,Mus musculus,BAO_0000218,,CHEMBL619482,,,A
2675,Intermediate,,1,,10090.0,5704,1,50594,,,,Area under the curve was evaluated in mice after intravenous administration,,N,,Mus musculus,BAO_0000218,,CHEMBL619483,,,A
2675,Intermediate,,1,,10090.0,5705,1,50594,,,,Area under the curve was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL619484,,,A
16597,Intermediate,,1,,10090.0,5706,1,50594,,,Plasma,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL619485,,,A
16597,Intermediate,,1,,10090.0,5707,1,50594,,,Plasma,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL619486,,,A
16597,Intermediate,,1,,10090.0,5708,1,50594,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,N,,Mus musculus,BAO_0000218,,CHEMBL619487,,,A
17734,Intermediate,,1,,10090.0,5709,1,50594,,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL619488,,,A
7767,Intermediate,,1,,10090.0,5710,1,50594,,In vivo,Blood,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL620106,,,A
15345,Intermediate,,1,,,5711,1,80653,9L,,,The compound was tested in vitro for anticancer activity against 9L cells,,N,392.0,,BAO_0000219,,CHEMBL620107,,,F
2181,Autocuration,,1,,10116.0,5712,0,22226,,,,Anti proliferation activity determined; Weak effect,,U,,Rattus norvegicus,BAO_0000019,,CHEMBL620283,,,F
2181,Autocuration,,1,,10116.0,5713,0,22226,,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,U,,Rattus norvegicus,BAO_0000219,,CHEMBL875176,,,F
2181,Autocuration,,1,,10116.0,5714,0,22226,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,U,,Rattus norvegicus,BAO_0000219,,CHEMBL620284,,,F
2181,Autocuration,,1,,10116.0,5715,0,22226,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,U,,Rattus norvegicus,BAO_0000219,,CHEMBL623515,,,F
10486,Autocuration,,1,,10090.0,5716,0,22226,,,,The cytotoxic activity was in vitro tested by 9PS assay method,,U,,Mus musculus,BAO_0000019,,CHEMBL623516,,,F
10486,Autocuration,,1,,10090.0,5717,0,22226,,,,The cytotoxic activity was in vitro tested by 9PS assay method.,,U,,Mus musculus,BAO_0000019,,CHEMBL623517,,,F
15508,Autocuration,,1,,,5718,0,22224,,,,Partition coefficient (logD6.5),,U,,,BAO_0000019,,CHEMBL857878,,,A
5242,Expert,,1,,9606.0,5719,1,81034,A2780,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623518,,,F
16167,Intermediate,,1,,9606.0,5720,1,80018,A-375,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL624195,,,F
4782,Expert,,1,,9606.0,5721,1,80852,A-431,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL624196,,,F
16093,Expert,,1,,9606.0,5722,9,9,A-431,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,D,500.0,Homo sapiens,BAO_0000219,,CHEMBL624197,,,F
2596,Intermediate,,1,,9606.0,5723,1,80021,A498,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL624198,,,F
2596,Intermediate,,1,,9606.0,5724,1,80021,A498,,,in vitro cytotoxicity against A 498 cancer cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL621287,,,F
3239,Intermediate,,1,,9606.0,5725,1,80021,A498,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL621288,,,F
1847,Intermediate,,1,,9606.0,5726,1,80021,A498,,,Cytotoxic activity against A 498 renal cancer cell lines.,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL876496,,,F
10553,Intermediate,,1,,9606.0,5727,1,80021,A498,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL621289,,,F
16219,Autocuration,,1,,1280.0,5728,0,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,U,,Staphylococcus aureus,BAO_0000019,,CHEMBL621290,,,F
16219,Autocuration,,1,,1280.0,5729,0,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,U,,Staphylococcus aureus,BAO_0000019,,CHEMBL621291,,,F
16219,Autocuration,,1,,1280.0,5730,0,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,U,,Staphylococcus aureus,BAO_0000019,,CHEMBL621292,,,F
16219,Autocuration,,1,,1280.0,5731,0,22226,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,U,,Staphylococcus aureus,BAO_0000019,,CHEMBL621293,,,F
4782,Intermediate,,1,,9606.0,5732,1,80682,A549,,,Inhibitory concentration required against A 549 lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621294,,,F
11805,Intermediate,,1,,9606.0,5733,1,80682,A549,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621295,,,F
11805,Intermediate,,1,,9606.0,5734,1,80682,A549,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884007,,,F
2007,Intermediate,,1,,9606.0,5735,1,80682,A549,,,In vitro cytotoxicity against lung cancer A 549 cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621296,,,F
4594,Intermediate,,1,,9606.0,5736,1,80682,A549,,,Compound was tested for its cytotoxicity against A 549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621297,,,F
6018,Expert,,1,,9606.0,5737,1,80682,A549,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL839828,,,F
6018,Intermediate,,1,,9606.0,5738,1,80682,A549,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620397,,,F
3599,Expert,,1,,9606.0,5739,1,80682,A549,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620398,,,F
2551,Intermediate,,1,,9606.0,5740,1,80682,A549,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620399,,,F
16132,Expert,,1,,9606.0,5741,1,80682,A549,,,In vitro inhibition of A549 (human lung cancer) cell growth.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620400,,,F
16132,Intermediate,,1,,9606.0,5742,1,80682,A549,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620401,,,F
2551,Expert,,1,,9606.0,5743,1,80682,A549,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620402,,,F
2551,Expert,,1,,9606.0,5744,1,80682,A549,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620403,,,F
11913,Autocuration,,1,,,5745,0,22226,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,U,,,BAO_0000218,,CHEMBL620404,,,F
12621,Autocuration,,1,,,5746,4,104694,,In vivo,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,H,,,BAO_0000218,,CHEMBL620405,,,F
12621,Autocuration,,1,,,5747,4,104694,,In vivo,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,H,,,BAO_0000218,,CHEMBL620406,,,F
12621,Autocuration,,1,,,5748,4,104694,,In vivo,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,H,,,BAO_0000218,,CHEMBL620407,,,F
12621,Autocuration,,1,,,5749,4,104694,,In vivo,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,H,,,BAO_0000218,,CHEMBL620408,,,F
12621,Autocuration,,1,,,5750,4,104694,,In vivo,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,H,,,BAO_0000218,,CHEMBL620409,,,F
3600,Expert,,1,,9606.0,5751,1,80021,A498,,,Inhibition of A-498 human Renal cell proliferation,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL620410,,,F
1796,Autocuration,,1,,10116.0,5752,0,22226,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,U,,Rattus norvegicus,BAO_0000019,,CHEMBL620411,,,F
1796,Autocuration,,1,,10116.0,5753,0,22226,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,U,,Rattus norvegicus,BAO_0000019,,CHEMBL620412,,,F
1796,Autocuration,,1,,10116.0,5754,0,22226,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,U,,Rattus norvegicus,BAO_0000019,,CHEMBL876596,,,F
16464,Expert,,1,,9606.0,5755,1,80012,A 172,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL620413,,,F
16464,Intermediate,,1,,9606.0,5756,1,80012,A 172,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL620414,,,F
16464,Intermediate,,1,,9606.0,5757,1,80012,A 172,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL620415,,,F
13617,Expert,,1,,9606.0,5758,1,80682,A549,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620416,,,F
4584,Intermediate,,1,,9606.0,5759,1,80682,A549,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620417,,,F
13799,Expert,,1,,9606.0,5760,1,80682,A549,,,Cytotoxic activity evaluated against A549 tumor cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620418,,,F
16726,Intermediate,,1,,9606.0,5761,1,80682,A549,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620419,,,F
16109,Intermediate,,1,,9606.0,5762,1,80682,A549,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620420,,,F
16109,Intermediate,,1,,9606.0,5763,1,80682,A549,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620421,,,F
15474,Intermediate,,1,,9606.0,5764,1,80682,A549,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620422,,,F
6851,Intermediate,,1,,9606.0,5765,1,80682,A549,,,Cytotoxicity of compound against A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620423,,,F
17534,Expert,,1,,9606.0,5766,1,80682,A549,,,Cytotoxicity against human lung cell carcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620424,,,F
2621,Intermediate,,1,,9606.0,5767,1,80682,A549,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620425,,,F
830,Intermediate,,1,,9606.0,5768,1,80682,A549,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620426,,,F
14255,Intermediate,,1,,9606.0,5769,1,80682,A549,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620427,,,F
14255,Intermediate,,1,,9606.0,5770,1,80682,A549,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620428,,,F
1590,Intermediate,,1,,9606.0,5771,1,80682,A549,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620429,,,F
6146,Expert,,1,,9606.0,5772,1,80682,A549,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620430,,,F
17427,Expert,,1,,9606.0,5773,1,80682,A549,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL839887,,,F
5280,Intermediate,,1,,9606.0,5774,1,80682,A549,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620431,,,F
16786,Intermediate,,1,,9606.0,5775,1,80682,A549,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884010,,,F
5895,Intermediate,,1,,9606.0,5776,1,80682,A549,,,In vitro cytotoxicity against A549 (human lung cancer),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620538,,,F
14297,Expert,,1,,9606.0,5777,1,80682,A549,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620539,,,F
17824,Intermediate,,1,,9606.0,5778,1,80682,A549,,,In vivo antiproliferative activity against A549 cell line,,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL623373,,,F
14368,Intermediate,,1,,9606.0,5779,1,80682,A549,,,Inhibition of non-small-cell lung adenocarcinoma (A549),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623374,,,F
14368,Intermediate,,1,,9606.0,5780,1,80682,A549,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623375,,,F
14254,Intermediate,,1,,9606.0,5781,1,80682,A549,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623376,,,F
15897,Intermediate,,1,,9606.0,5782,1,80682,A549,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623377,,,F
13866,Intermediate,,1,,9606.0,5783,1,80682,A549,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623378,,,F
13370,Intermediate,,1,,9606.0,5784,1,80682,A549,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623379,,,F
4862,Intermediate,,1,,9606.0,5785,1,80682,A549,,,Inhibitory activity against A549 lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623380,,,F
4862,Intermediate,,1,,9606.0,5786,1,80682,A549,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623381,,,F
4862,Intermediate,,1,,9606.0,5787,1,80682,A549,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623382,,,F
15970,Intermediate,,1,,9606.0,5788,1,80682,A549,,,Inhibitory concentration against A549 (lung cancer) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623383,,,F
17713,Expert,,1,,9606.0,5789,1,80682,A549,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623384,,,F
4833,Intermediate,,1,,9606.0,5790,1,80682,A549,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623385,,,F
13736,Expert,,1,,9606.0,5791,1,80682,A549,,,Activity against A549 cancer cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623386,,,F
4312,Intermediate,,1,,9606.0,5792,1,80682,A549,,,The compound was evaluated for cytotoxicity against A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884105,,,F
5421,Intermediate,,1,,9606.0,5793,1,80682,A549,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623387,,,F
5421,Intermediate,,1,,9606.0,5794,1,80682,A549,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621568,,,F
14717,Intermediate,,1,,9606.0,5795,1,80682,A549,,,Growth inhibitory activity was measured for human A549 tumor cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621569,,,F
4634,Intermediate,,1,,9606.0,5796,1,80682,A549,,,Inhibitory activity against A549 lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621570,,,F
1149,Intermediate,,1,,9606.0,5797,1,80682,A549,,,Inhibitory activity against A549 cell line; inactive,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621571,,,F
5421,Expert,,1,,9606.0,5798,1,80682,A549,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621572,,,F
5421,Expert,,1,,9606.0,5799,1,80682,A549,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621573,,,F
5421,Intermediate,,1,,9606.0,5800,1,80682,A549,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621574,,,F
3320,Intermediate,,1,,9606.0,5801,1,80682,A549,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621575,,,F
3320,Intermediate,,1,,9606.0,5802,1,80682,A549,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621576,,,F
3320,Intermediate,,1,,9606.0,5803,1,80682,A549,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621577,,,F
3320,Intermediate,,1,,9606.0,5804,1,80682,A549,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621578,,,F
3320,Intermediate,,1,,9606.0,5805,1,80682,A549,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621579,,,F
5726,Intermediate,,1,,9606.0,5806,1,80682,A549,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621580,,,F
17800,Intermediate,,1,,9615.0,5807,1,50588,,In vivo,,Plasma clearance (in vivo) in mongrel dogs was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621581,,,A
5985,Intermediate,,1,,9615.0,5808,1,50588,,In vivo,,Plasma clearance was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621582,,,A
5530,Intermediate,,1,,9615.0,5809,1,50588,,In vivo,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621583,,,A
5530,Intermediate,,1,,9615.0,5810,1,50588,,In vivo,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621584,,,A
4839,Intermediate,,1,,9615.0,5811,1,50588,,In vivo,Plasma,Tested for plasma clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621585,,,A
3639,Intermediate,,1,,9615.0,5812,1,50588,,In vivo,,The compound was tested for clearance in dog plasma.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621586,,,A
4838,Intermediate,,1,,9615.0,5813,1,50588,,In vivo,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875835,,,A
4137,Intermediate,,1,,9615.0,5814,1,50588,,In vivo,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621587,,,A
5017,Intermediate,,1,,9615.0,5815,1,50588,,In vivo,Plasma,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621588,,,A
17538,Intermediate,,1,,9615.0,5816,1,50588,,In vitro,Liver,In vitro clearance in dog liver microsomes,,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL621589,,Microsomes,A
6161,Intermediate,,1,,9615.0,5817,1,50588,,In vivo,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621590,,,A
6161,Intermediate,,1,,9615.0,5818,1,50588,,In vivo,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621591,,,A
1696,Intermediate,,1,,9615.0,5819,1,50588,,In vivo,,Plasma clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621592,,,A
6762,Intermediate,,1,,9615.0,5820,1,50588,,In vivo,,Clearance rate in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621593,,,A
5932,Intermediate,,1,,9615.0,5821,1,50588,,In vivo,Plasma,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621594,,,A
6305,Intermediate,,1,,9615.0,5822,1,50588,,In vivo,,Clearance in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621595,,,A
4942,Intermediate,,1,,9615.0,5823,1,50588,,In vivo,,Plasma clearance in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621596,,,A
4219,Intermediate,,1,,9615.0,5824,1,50588,,In vivo,,Plasma clearance was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621597,,,A
17853,Intermediate,,1,,9615.0,5825,1,50588,,In vivo,,Lower clearance in dog (i.v.) at 0.5 mpk,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621598,,,A
4514,Intermediate,,1,,9615.0,5826,1,50588,,In vivo,,Plasma clearance in Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621599,,,A
6448,Intermediate,,1,,9615.0,5827,1,50588,,In vivo,,Plasma clearance (Clp) in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875836,,,A
6227,Intermediate,,1,,9615.0,5828,1,50588,,In vivo,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621600,,,A
6227,Intermediate,,1,,9615.0,5829,1,50588,,In vivo,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621601,,,A
6062,Intermediate,,1,,9615.0,5830,1,50588,,In vivo,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618474,,,A
6821,Intermediate,,1,,9615.0,5831,1,50588,,In vivo,,Plasma clearance of compound was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618475,,,A
4709,Intermediate,,1,,9615.0,5832,1,50588,,In vivo,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624524,,,A
4521,Intermediate,,1,,9615.0,5833,1,50588,,In vivo,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624525,,,A
5374,Intermediate,,1,,9615.0,5834,1,50588,,In vivo,,Plasma clearance in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624526,,,A
6057,Intermediate,,1,,9615.0,5835,1,50588,,In vivo,,Plasma clearance was calculated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624527,,,A
4727,Intermediate,,1,,9615.0,5836,1,50588,,In vivo,,Plasma clearance at the dose of 2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624528,,,A
5145,Intermediate,,1,,9615.0,5837,1,50588,,In vivo,,Plasma clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624529,,,A
17657,Intermediate,,1,,9615.0,5838,1,50588,,In vivo,,Plasma clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624530,,,A
17657,Intermediate,,1,,9615.0,5839,1,50588,,In vivo,,Plasma clearance in dog; Unable to calculate,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624531,,,A
5145,Intermediate,,1,,9615.0,5840,1,50588,,In vivo,,Plasma clearance in rhesus monkey,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624532,,,A
6642,Intermediate,,1,,9615.0,5841,1,50588,,In vivo,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624533,,,A
6641,Intermediate,,1,,9615.0,5842,1,50588,,In vivo,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624534,,,A
6642,Intermediate,,1,,9615.0,5843,1,50588,,In vivo,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624535,,,A
5472,Intermediate,,1,,9615.0,5844,1,50588,,In vivo,,Plasma clearance was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624536,,,A
5472,Intermediate,,1,,9615.0,5845,1,50588,,In vivo,,Plasma clearance was evaluated in dog; Not tested,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624537,,,A
5472,Intermediate,,1,,9615.0,5846,1,50588,,In vivo,,Plasma clearance was evaluated in rhesus,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624538,,,A
5472,Intermediate,,1,,9615.0,5847,1,50588,,In vivo,,Plasma clearance was evaluated in rhesus; Not tested,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624539,,,A
4257,Intermediate,,1,,9615.0,5848,1,50588,,In vivo,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624540,,,A
6679,Intermediate,,1,,9615.0,5849,1,50588,,In vivo,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624541,,,A
5546,Intermediate,,1,,9615.0,5850,1,50588,,In vivo,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624542,,,A
6348,Intermediate,,1,,9615.0,5851,1,50588,,In vivo,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624543,,,A
5474,Intermediate,,1,,9615.0,5852,1,50588,,In vivo,,Clearance value at a dose of 0.2 mg/kg i.v.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624544,,,A
6316,Intermediate,,1,,9615.0,5853,1,50588,,In vivo,Plasma,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624545,,,A
17594,Intermediate,,1,,9615.0,5854,1,50588,,In vivo,,Cmax after oral dose of compound at 3 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624546,,,A
17594,Intermediate,,1,,9615.0,5855,1,50588,,In vivo,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875957,,,A
5802,Intermediate,,1,,9615.0,5856,1,50588,,In vivo,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624547,,,A
6535,Intermediate,,1,,9615.0,5857,1,50588,,In vivo,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624548,,,A
6535,Intermediate,,1,,9615.0,5858,1,50588,,In vivo,,Cmax in dog after administration of 1 mg/kg iv,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624549,,,A
1466,Intermediate,,1,,9615.0,5859,1,50588,,In vivo,Plasma,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624550,,,A
6505,Intermediate,,1,,9615.0,5860,1,50588,,In vivo,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621613,,,A
5668,Intermediate,,1,,9615.0,5861,1,50588,,In vivo,,Cmax was determine after peroral administration at 10 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621614,,,A
5668,Intermediate,,1,,9615.0,5862,1,50588,,In vivo,,Cmax was determine after peroral administration at 5 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623431,,,A
5668,Intermediate,,1,,9615.0,5863,1,50588,,In vivo,,Cmax was determine after peroral administration at 5 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623432,,,A
5600,Intermediate,,1,,9615.0,5864,1,50588,,In vivo,,Cmax after 0.3 mg/kg po administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623433,,,A
17764,Intermediate,,1,,9615.0,5865,1,50588,,In vivo,,Cmax after peroral administration in dogs at 2.4 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623434,,,A
6123,Intermediate,,1,,9615.0,5866,1,50588,,In vivo,,Cmax in dog after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623435,,,A
6123,Intermediate,,1,,9615.0,5867,1,50588,,In vivo,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623436,,,A
6757,Intermediate,,1,,9615.0,5868,1,50588,,In vivo,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875958,,,A
16907,Intermediate,,1,,9615.0,5869,1,50588,,In vivo,,Cmax value after 15 mg/kg iv dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623437,,,A
7767,Intermediate,,1,,10090.0,5870,1,50594,,In vivo,Blood,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL623438,,,A
7767,Intermediate,,1,,10090.0,5871,1,50594,,In vivo,Blood,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL623439,,,A
7767,Intermediate,,1,,10090.0,5872,1,50594,,In vivo,Bone,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL623440,,,A
7767,Intermediate,,1,,10090.0,5873,1,50594,,In vivo,Bone,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL623441,,,A
7767,Intermediate,,1,,10090.0,5874,1,50594,,In vivo,Bone,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL623442,,,A
7767,Intermediate,,1,,10090.0,5875,1,50594,,In vivo,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,,CHEMBL623469,,,A
7767,Intermediate,,1,,10090.0,5876,1,50594,,In vivo,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,,CHEMBL623470,,,A
7767,Intermediate,,1,,10090.0,5877,1,50594,,In vivo,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,,CHEMBL623471,,,A
7767,Intermediate,,1,,10090.0,5878,1,50594,,In vivo,Heart,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL623472,,,A
7767,Intermediate,,1,,10090.0,5879,1,50594,,In vivo,Heart,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL623473,,,A
7767,Intermediate,,1,,10090.0,5880,1,50594,,In vivo,Heart,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL623474,,,A
7767,Intermediate,,1,,10090.0,5881,1,50594,,In vivo,Kidney,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623475,,,A
7767,Intermediate,,1,,10090.0,5882,1,50594,,In vivo,Kidney,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623476,,,A
7767,Intermediate,,1,,10090.0,5883,1,50594,,In vivo,Kidney,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623477,,,A
7767,Intermediate,,1,,10090.0,5884,1,50594,,In vivo,Intestine,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL621896,,,A
7767,Intermediate,,1,,10090.0,5885,1,50594,,In vivo,Intestine,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL621897,,,A
7767,Intermediate,,1,,10090.0,5886,1,50594,,In vivo,Intestine,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL621898,,,A
7767,Intermediate,,1,,10090.0,5887,1,50594,,In vivo,Liver,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621899,,,A
7767,Intermediate,,1,,10090.0,5888,1,50594,,In vivo,Liver,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621900,,,A
7767,Intermediate,,1,,10090.0,5889,1,50594,,In vivo,Liver,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621901,,,A
7767,Intermediate,,1,,10090.0,5890,1,50594,,In vivo,Lung,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL621902,,,A
7767,Intermediate,,1,,10090.0,5891,1,50594,,In vivo,Lung,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL621903,,,A
7767,Intermediate,,1,,10090.0,5892,1,50594,,In vivo,Lung,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL622587,,,A
7767,Intermediate,,1,,10090.0,5893,1,50594,,In vivo,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL620285,,,A
7767,Intermediate,,1,,10090.0,5894,1,50594,,In vivo,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL875285,,,A
7767,Intermediate,,1,,10090.0,5895,1,50594,,In vivo,Muscle tissue,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL620286,,,A
7767,Intermediate,,1,,10090.0,5896,1,50594,,In vivo,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,,CHEMBL620287,,,A
7767,Intermediate,,1,,10090.0,5897,1,50594,,In vivo,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,,CHEMBL620288,,,A
7767,Intermediate,,1,,10090.0,5898,1,50594,,In vivo,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,,CHEMBL620289,,,A
7767,Intermediate,,1,,10090.0,5899,1,50594,,In vivo,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL620290,,,A
7767,Intermediate,,1,,10090.0,5900,1,50594,,In vivo,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL620291,,,A
7767,Intermediate,,1,,10090.0,5901,1,50594,,In vivo,Intestine,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,160.0,CHEMBL620292,,,A
7767,Intermediate,,1,,10090.0,5902,1,50594,,In vivo,Spleen,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL620293,,,A
7767,Intermediate,,1,,10090.0,5903,1,50594,,In vivo,Spleen,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL620294,,,A
7767,Intermediate,,1,,10090.0,5904,1,50594,,In vivo,Spleen,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618614,,,A
7767,Intermediate,,1,,10090.0,5905,1,50594,,In vivo,Stomach,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL618615,,,A
7767,Intermediate,,1,,10090.0,5906,1,50594,,In vivo,Stomach,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL618616,,,A
2036,Expert,,1,,9606.0,5907,1,80012,A 172,,,Cytotoxicity against A-172 human tumor cell lines,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL618617,,,F
2357,Intermediate,,1,,9606.0,5908,1,80012,A 172,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL618618,,,F
1457,Intermediate,,1,,9606.0,5909,1,80014,A204,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,N,623.0,Homo sapiens,BAO_0000219,,CHEMBL618619,,,F
4379,Intermediate,,1,,9606.0,5910,1,81034,A2780,,,Tested for antiproliferative activity against A-2780 tumoral cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618620,,,F
1093,Intermediate,,1,,9606.0,5911,1,80018,A-375,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL618621,,,F
12152,Intermediate,,1,,9606.0,5912,1,80018,A-375,,,Tested in vitro against A-375 cell line human melanoma,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL618622,,,F
16464,Expert,,1,,9606.0,5913,1,80019,A-427,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618623,,,F
16464,Intermediate,,1,,9606.0,5914,1,80019,A-427,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618624,,,F
16582,Expert,,1,,9606.0,5915,1,80019,A-427,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618625,,,F
16464,Intermediate,,1,,9606.0,5916,1,80019,A-427,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618626,,,F
10413,Intermediate,,1,,9606.0,5917,1,80019,A-427,,,Antitumor activity on A-427 lung carcinoma cell lines,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618627,,,F
6418,Intermediate,,1,,9606.0,5918,1,80019,A-427,,,Cytotoxic activity against human A-427 lung tumor cell line,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618628,,,F
17134,Expert,,1,,9606.0,5919,1,80019,A-427,,,In vitro antitumor effects against human A-427 cell lines.,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618629,,,F
16132,Expert,,1,,9606.0,5920,1,80019,A-427,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618630,,,F
16132,Intermediate,,1,,9606.0,5921,1,80019,A-427,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618631,,,F
16780,Intermediate,,1,,9606.0,5922,1,80019,A-427,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,N,797.0,Homo sapiens,BAO_0000219,,CHEMBL618632,,,F
4085,Expert,,1,,9606.0,5923,1,80852,A-431,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,N,500.0,Homo sapiens,BAO_0000219,,CHEMBL618633,,,F
1276,Intermediate,,1,,9606.0,5924,1,80021,A498,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619315,,,F
3498,Expert,,1,,9606.0,5925,1,80021,A498,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619316,,,F
1169,Intermediate,,1,,9606.0,5926,1,80021,A498,,,Cytotoxicity against human kidney carcinoma A-498cell lines,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619317,,,F
4450,Intermediate,,1,,9606.0,5927,1,80021,A498,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619318,,,F
3311,Intermediate,,1,,9606.0,5928,1,80021,A498,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619319,,,F
4461,Intermediate,,1,,9606.0,5929,1,80021,A498,,,Antitumor cytotoxic activity against A-498 cell line was determined,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619739,,,F
3311,Intermediate,,1,,9606.0,5930,1,80021,A498,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619740,,,F
3311,Intermediate,,1,,9606.0,5931,1,80021,A498,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL883158,,,F
1457,Intermediate,,1,,9606.0,5932,1,80021,A498,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL884012,,,F
3664,Intermediate,,1,,9606.0,5933,1,80021,A498,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619741,,,F
15895,Intermediate,,1,,9606.0,5934,1,80021,A498,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,N,624.0,Homo sapiens,BAO_0000219,,CHEMBL619742,,,F
11843,Intermediate,,1,,9606.0,5935,1,80682,A549,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876610,,,F
11843,Intermediate,,1,,9606.0,5936,1,80682,A549,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619743,,,F
17705,Intermediate,,1,,9606.0,5937,1,80682,A549,,,In vitro antiproliferative activity against human A-549 NSCL cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619744,,,F
17705,Intermediate,,1,,9606.0,5938,1,80682,A549,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619745,,,F
4369,Intermediate,,1,,9606.0,5939,1,80682,A549,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619746,,,F
4369,Intermediate,,1,,9606.0,5940,1,80682,A549,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619747,,,F
4369,Intermediate,,1,,9606.0,5941,1,80682,A549,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619748,,,F
4369,Intermediate,,1,,9606.0,5942,1,80682,A549,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619749,,,F
4369,Intermediate,,1,,9606.0,5943,1,80682,A549,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619750,,,F
4369,Intermediate,,1,,9606.0,5944,1,80682,A549,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624014,,,F
4369,Intermediate,,1,,9606.0,5945,1,80682,A549,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624015,,,F
4787,Expert,,1,,9606.0,5946,1,80682,A549,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL885344,,,F
4787,Intermediate,,1,,9606.0,5947,1,80682,A549,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623224,,,F
6513,Intermediate,,1,,9606.0,5948,1,80682,A549,,,Cytotoxic activity against A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL623225,,,F
6690,Intermediate,,1,,9606.0,5949,1,80682,A549,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622698,,,F
6690,Intermediate,,1,,9606.0,5950,1,80682,A549,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622699,,,F
12263,Expert,,1,,9606.0,5951,1,80682,A549,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622700,,,F
1054,Intermediate,,1,,9606.0,5952,1,80682,A549,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622701,,,F
1359,Intermediate,,1,,9606.0,5953,1,80682,A549,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622702,,,F
3547,Intermediate,,1,,9606.0,5954,1,80682,A549,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622703,,,F
5771,Expert,,1,,9606.0,5955,1,80682,A549,,,Cytotoxic activity towards A-549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622704,,,F
14425,Intermediate,,1,,9606.0,5956,1,80682,A549,,,"In vitro percent inhibition of A549, lung carcinoma.",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622705,,,F
14425,Intermediate,,1,,9606.0,5957,1,80682,A549,,,"In vitro percent inhibition of A549, lung carcinoma",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622706,,,F
14425,Intermediate,,1,,9606.0,5958,1,80682,A549,,,"In vitro percent inhibition of A549, lung carcinoma.",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622707,,,F
14425,Intermediate,,1,,9606.0,5959,1,80682,A549,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622708,,,F
5280,Intermediate,,1,,9606.0,5960,1,80682,A549,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622709,,,F
15176,Intermediate,,1,,9606.0,5961,1,80682,A549,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622710,,,F
15300,Intermediate,,1,,9606.0,5962,1,80682,A549,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622711,,,F
17824,Intermediate,,1,,9606.0,5963,1,80682,A549,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL622712,,,F
17824,Intermediate,,1,,9606.0,5964,1,80682,A549,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL622713,,,F
17824,Intermediate,,1,,9606.0,5965,1,80682,A549,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL622714,,,F
17824,Intermediate,,1,,9606.0,5966,1,80682,A549,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL622715,,,F
17824,Intermediate,,1,,9606.0,5967,1,80682,A549,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL622716,,,F
17824,Intermediate,,1,,9606.0,5968,1,80682,A549,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622717,,,F
17528,Intermediate,,1,,9606.0,5969,1,80682,A549,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL622718,,,F
6870,Expert,,1,,9606.0,5970,1,80682,A549,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622719,,,F
6870,Intermediate,,1,,9606.0,5971,1,80682,A549,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622720,,,F
6870,Intermediate,,1,,9606.0,5972,1,80682,A549,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622721,,,F
6870,Intermediate,,1,,9606.0,5973,1,80682,A549,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622722,,,F
16726,Intermediate,,1,,9606.0,5974,1,80682,A549,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876030,,,F
6170,Intermediate,,1,,9606.0,5975,1,80682,A549,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620206,,,F
6583,Expert,,1,,9606.0,5976,1,80682,A549,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620207,,,F
6583,Expert,,1,,9606.0,5977,1,80682,A549,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620208,,,F
6583,Expert,,1,,9606.0,5978,1,80682,A549,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620209,,,F
6583,Expert,,1,,9606.0,5979,1,80682,A549,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620210,,,F
6583,Expert,,1,,9606.0,5980,1,80682,A549,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621639,,,F
17321,Intermediate,,1,,9606.0,5981,1,80682,A549,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621640,,,F
17528,Expert,,1,,9606.0,5982,1,80682,A549,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621641,,,F
12888,Expert,,1,,9606.0,5983,1,80682,A549,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621642,,,F
4312,Intermediate,,1,,9606.0,5984,1,80682,A549,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621643,,,F
4312,Intermediate,,1,,9606.0,5985,1,80682,A549,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621644,,,F
4312,Intermediate,,1,,9606.0,5986,1,80682,A549,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL621645,,,F
17737,Intermediate,,1,,10090.0,5987,1,80682,A549,,,In vitro antiproliferative activity against A549 cell line,,N,646.0,Mus musculus,BAO_0000219,,CHEMBL621646,,,F
6630,Intermediate,,1,,,5988,1,80682,A549,,,Synergism with indomethacin in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621647,,,F
6630,Intermediate,,1,,,5989,1,80682,A549,,,Synergism with tolmetin in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621648,,,F
6630,Intermediate,,1,,,5990,1,80682,A549,,,Synergism with sulindac in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621649,,,F
6630,Intermediate,,1,,,5991,1,80682,A549,,,Antagonism of indomethacin in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621650,,,F
6630,Intermediate,,1,,,5992,1,80682,A549,,,Antagonism of sulindac in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621651,,,F
6630,Intermediate,,1,,,5993,1,80682,A549,,,Antagonism of tolmetin in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621652,,,F
6630,Intermediate,,1,,,5994,1,80682,A549,,,Synergism with indomethacin in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621653,,,F
6630,Intermediate,,1,,,5995,1,80682,A549,,,Synergism with sulindac in A549 cells,,N,646.0,,BAO_0000219,,CHEMBL621654,,,F
6630,Intermediate,,1,,,5996,1,80682,A549,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,N,646.0,,BAO_0000219,,CHEMBL621655,,,F
16907,Intermediate,,1,,9615.0,5997,1,50588,,In vivo,,Cmax value after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621656,,,A
5944,Intermediate,,1,,9615.0,5998,1,50588,,In vivo,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621657,,,A
5944,Intermediate,,1,,9615.0,5999,1,50588,,In vivo,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621658,,,A
5944,Intermediate,,1,,9615.0,6000,1,50588,,In vivo,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621659,,,A
5944,Intermediate,,1,,9615.0,6001,1,50588,,In vivo,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621660,,,A
2959,Intermediate,,1,,9615.0,6002,1,50588,,In vivo,,Cmax value after administration of 4 mg/Kg oral dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621661,,,A
6241,Intermediate,,1,,9615.0,6003,1,50588,,In vivo,,Cmax value in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621662,,,A
6241,Intermediate,,1,,9615.0,6004,1,50588,,In vivo,,Cmax value in dogs after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621663,,,A
2652,Intermediate,,1,,9615.0,6005,1,50588,,In vivo,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621664,,,A
1806,Intermediate,,1,,9615.0,6006,1,50588,,In vivo,Plasma,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621665,,,A
1806,Intermediate,,1,,9615.0,6007,1,50588,,In vivo,Plasma,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621666,,,A
1021,Intermediate,,1,,9615.0,6008,1,50588,,In vivo,,Concentration maxima after oral dosing in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621667,,,A
1021,Intermediate,,1,,9615.0,6009,1,50588,,In vivo,,Concentration maxima after oral dosing in dogs; not available,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876738,,,A
1021,Intermediate,,1,,9615.0,6010,1,50588,,In vivo,,Concentration maxima after oral dosing in dogs; not available,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621668,,,A
5444,Intermediate,,1,,9615.0,6011,1,50588,,In vivo,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621669,,,A
5444,Intermediate,,1,,9615.0,6012,1,50588,,In vivo,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621670,,,A
5444,Intermediate,,1,,9615.0,6013,1,50588,,In vivo,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621671,,,A
5444,Intermediate,,1,,9615.0,6014,1,50588,,In vivo,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622360,,,A
5444,Intermediate,,1,,9615.0,6015,1,50588,,In vivo,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622361,,,A
5130,Intermediate,,1,,9615.0,6016,1,50588,,In vivo,Plasma,Cmax in dog plasma after oral dose (1 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622362,,,A
3249,Intermediate,,1,,9615.0,6017,1,50588,,In vivo,Plasma,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622363,,,A
5473,Intermediate,,1,,9615.0,6018,1,50588,,In vivo,Plasma,Maximal plasma concentration at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622364,,,A
5474,Intermediate,,1,,9615.0,6019,1,50588,,In vivo,Plasma,Maximal plasma concentration at a dose of 1 mg/kg (oral),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622365,,,A
4657,Intermediate,,1,,9615.0,6020,1,50588,,In vivo,Plasma,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622533,,,A
3031,Intermediate,,1,,9615.0,6021,1,50588,,In vivo,,Maximum concentration of compound in dog was evaluated.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622534,,,A
4527,Intermediate,,1,,9615.0,6022,1,50588,,In vivo,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622535,,,A
4186,Intermediate,,1,,9615.0,6023,1,50588,,In vivo,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876739,,,A
5007,Intermediate,,1,,9615.0,6024,1,50588,,In vivo,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622536,,,A
3132,Intermediate,,1,,9615.0,6025,1,50588,,In vivo,Plasma,Maximum concentration obtained in dog plasma was determined,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622537,,,A
5006,Intermediate,,1,,9615.0,6026,1,50588,,In vivo,,Maximum concentration was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622538,,,A
4727,Intermediate,,1,,9615.0,6027,1,50588,,In vivo,,Maximum concentration at the dose of 2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL627867,,,A
1916,Intermediate,,1,,9615.0,6028,1,50588,,In vivo,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL627868,,,A
1918,Intermediate,,1,,9615.0,6029,1,50588,,In vivo,Plasma,Maximum concentration was evaluated in dog plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627869,,,A
3045,Intermediate,,1,,9615.0,6030,1,50588,,In vivo,,Maximum concentration was evaluated after 75 min after administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL627870,,,A
9579,Intermediate,,1,,9615.0,6031,1,50588,,In vivo,Plasma,Maximum plasma concentration determined in dog after oral administration of 17b,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627871,,,A
9579,Intermediate,,1,,9615.0,6032,1,50588,,In vivo,Plasma,Maximum plasma concentration determined in dog after oral administration of 2b,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627872,,,A
933,Intermediate,,1,,9615.0,6033,1,50588,,In vivo,Plasma,Maximum plasma concentration in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627873,,,A
17839,Intermediate,,1,,9615.0,6034,1,50588,,In vivo,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627874,,,A
17839,Intermediate,,1,,9615.0,6035,1,50588,,In vivo,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627875,,,A
17839,Intermediate,,1,,9615.0,6036,1,50588,,In vivo,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627876,,,A
17839,Intermediate,,1,,9615.0,6037,1,50588,,In vivo,Plasma,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627877,,,A
6348,Intermediate,,1,,9615.0,6038,1,50588,,In vivo,Plasma,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627878,,,A
16367,Intermediate,,1,,9615.0,6039,1,50588,,In vivo,Plasma,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627879,,,A
1337,Intermediate,,1,,9615.0,6040,1,50588,,In vivo,Plasma,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL875355,,,A
1337,Intermediate,,1,,9615.0,6041,1,50588,,In vivo,Plasma,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627880,,,A
5199,Intermediate,,1,,9615.0,6042,1,50588,,In vivo,Plasma,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627881,,,A
17650,Intermediate,,1,,9615.0,6043,1,50588,,In vivo,Plasma,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627882,,,A
6679,Intermediate,,1,,9615.0,6044,1,50588,,In vivo,Plasma,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627883,,,A
5356,Intermediate,,1,,9615.0,6045,1,50588,,In vivo,Plasma,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628526,,,A
5356,Intermediate,,1,,9615.0,6046,1,50588,,In vivo,Plasma,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628527,,,A
6227,Intermediate,,1,,9615.0,6047,1,50588,,In vivo,Plasma,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628528,,,A
6227,Intermediate,,1,,9615.0,6048,1,50588,,In vivo,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628529,,,A
6227,Intermediate,,1,,9615.0,6049,1,50588,,In vivo,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628530,,,A
6227,Intermediate,,1,,9615.0,6050,1,50588,,In vivo,Plasma,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625243,,,A
3598,Expert,,1,,9615.0,6051,1,50588,,In vivo,Plasma,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625244,,,A
4368,Intermediate,,1,,9615.0,6052,1,50588,,In vivo,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625245,,,A
6265,Intermediate,,1,,9615.0,6053,1,50588,,In vivo,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625246,,,A
7767,Intermediate,,1,,10090.0,6054,1,50594,,In vivo,Stomach,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL625247,,,A
7767,Intermediate,,1,,10090.0,6055,1,50594,,In vivo,Urine,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL625248,,,A
7767,Intermediate,,1,,10090.0,6056,1,50594,,In vivo,Urine,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL625249,,,A
7767,Intermediate,,1,,10090.0,6057,1,50594,,In vivo,Urine,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL625250,,,A
17811,Intermediate,,1,,10090.0,6058,1,50594,,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,N,,Mus musculus,BAO_0000218,,CHEMBL625251,,,A
17811,Intermediate,,1,,10090.0,6059,1,50594,,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,N,,Mus musculus,BAO_0000218,,CHEMBL875356,,,A
17827,Intermediate,,1,,10090.0,6060,1,50594,,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,,CHEMBL625252,,,A
17827,Intermediate,,1,,10090.0,6061,1,50594,,,Blood,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL625253,,,A
17827,Intermediate,,1,,10090.0,6062,1,50594,,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,,CHEMBL625254,,,A
17827,Intermediate,,1,,10090.0,6063,1,50594,,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,,CHEMBL625255,,,A
17827,Intermediate,,1,,10090.0,6064,1,50594,,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,,CHEMBL625256,,,A
17827,Intermediate,,1,,10090.0,6065,1,50594,,,Blood,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL625257,,,A
17827,Intermediate,,1,,10090.0,6066,1,50594,,,Blood,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL625258,,,A
17827,Intermediate,,1,,10090.0,6067,1,50594,,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,,CHEMBL625259,,,A
17827,Intermediate,,1,,10090.0,6068,1,50594,,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,N,,Mus musculus,BAO_0000218,,CHEMBL625260,,,A
17827,Intermediate,,1,,10090.0,6069,1,50594,,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,N,,Mus musculus,BAO_0000218,,CHEMBL625261,,,A
17827,Intermediate,,1,,10090.0,6070,1,50594,,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,N,,Mus musculus,BAO_0000218,,CHEMBL625262,,,A
17827,Intermediate,,1,,10090.0,6071,1,50594,,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,N,,Mus musculus,BAO_0000218,,CHEMBL622639,,,A
17257,Intermediate,,1,,10090.0,6072,1,50594,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622640,,,A
17257,Intermediate,,1,,10090.0,6073,1,50594,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,N,,Mus musculus,BAO_0000218,,CHEMBL622812,,,A
17257,Intermediate,,1,,10090.0,6074,1,50594,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622813,,,A
17257,Intermediate,,1,,10090.0,6075,1,50594,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL622814,,,A
17827,Intermediate,,1,,10090.0,6076,1,50594,,,,Time at maximum activity in mice (Radiolabeled compound),,N,,Mus musculus,BAO_0000218,,CHEMBL622815,,,A
3760,Intermediate,,1,,10090.0,6077,1,50594,,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL625342,,,A
3760,Intermediate,,1,,10090.0,6078,1,50594,,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL625343,,,A
17409,Intermediate,,1,,10090.0,6079,1,50594,,,,Binding towards mouse plasma protein at 10 uM,,N,,Mus musculus,BAO_0000218,,CHEMBL877591,,,A
17409,Intermediate,,1,,10090.0,6080,1,50594,,,,Binding towards mouse plasma protein at 100 uM,,N,,Mus musculus,BAO_0000218,,CHEMBL625344,,,A
2675,Intermediate,,1,,10090.0,6081,1,50594,,In vivo,,Bioavailability was evaluated in mice after intravenous administration,,N,,Mus musculus,BAO_0000218,,CHEMBL625345,,,A
2675,Intermediate,,1,,10090.0,6082,1,50594,,In vivo,,Bioavailability was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL625346,,,A
3132,Intermediate,,1,,10090.0,6083,1,50594,,In vivo,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL625347,,,A
3132,Intermediate,,1,,10090.0,6084,1,50594,,In vivo,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL625348,,,A
16597,Intermediate,,1,,10090.0,6085,1,50594,,In vivo,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL625349,,,A
2862,Intermediate,,1,,10090.0,6086,1,50594,,In vivo,,Oral bioavailability in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL625350,,,A
17764,Intermediate,,1,,10090.0,6087,1,50594,,In vivo,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL882952,,,A
846,Intermediate,,1,,10090.0,6088,1,50594,,In vivo,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625351,,,A
846,Intermediate,,1,,10090.0,6089,1,50594,,In vivo,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625352,,,A
846,Intermediate,,1,,10090.0,6090,1,50594,,In vivo,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL877592,,,A
846,Intermediate,,1,,10090.0,6091,1,50594,,In vivo,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625353,,,A
846,Intermediate,,1,,10090.0,6092,1,50594,,In vivo,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625354,,,A
846,Intermediate,,1,,10090.0,6093,1,50594,,In vivo,Brain,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL626019,,,A
846,Intermediate,,1,,10090.0,6094,1,50594,,In vivo,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL626020,,,A
846,Intermediate,,1,,10090.0,6095,1,50594,,In vivo,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL626021,,,A
846,Intermediate,,1,,10090.0,6096,1,50594,,In vivo,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL626022,,,A
846,Intermediate,,1,,10090.0,6097,1,50594,,In vivo,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL626192,,,A
1276,Intermediate,,1,,9606.0,6098,1,80682,A549,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626193,,,F
3498,Expert,,1,,9606.0,6099,1,80682,A549,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626194,,,F
1169,Intermediate,,1,,9606.0,6100,1,80682,A549,,,Cytotoxicity against human lung carcinoma A-549 cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626195,,,F
4450,Intermediate,,1,,9606.0,6101,1,80682,A549,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626196,,,F
358,Intermediate,,1,,9606.0,6102,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626197,,,F
358,Intermediate,,1,,9606.0,6103,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626198,,,F
358,Intermediate,,1,,9606.0,6104,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626199,,,F
358,Intermediate,,1,,9606.0,6105,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626200,,,F
358,Intermediate,,1,,9606.0,6106,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626201,,,F
358,Intermediate,,1,,9606.0,6107,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626202,,,F
358,Intermediate,,1,,9606.0,6108,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626203,,,F
15167,Intermediate,,1,,9606.0,6109,1,80682,A549,,,In vitro cytotoxicity against A-549 human lung cancer cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL626204,,,F
4139,Intermediate,,1,,9606.0,6110,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624701,,,F
833,Intermediate,,1,,9606.0,6111,1,80682,A549,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624702,,,F
15718,Expert,,1,,9606.0,6112,1,80682,A549,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624703,,,F
12373,Intermediate,,1,,9606.0,6113,1,80682,A549,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624704,,,F
637,Intermediate,,1,,9606.0,6114,1,80682,A549,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624705,,,F
14867,Expert,,1,,9606.0,6115,1,80682,A549,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624706,,,F
4461,Intermediate,,1,,9606.0,6116,1,80682,A549,,,Antitumor cytotoxic activity against A-549 cell line was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624707,,,F
5406,Intermediate,,1,,9606.0,6117,1,80682,A549,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624708,,,F
4457,Intermediate,,1,,9606.0,6118,1,80682,A549,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624709,,,F
1386,Expert,,1,,9606.0,6119,1,80682,A549,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884107,,,F
3265,Intermediate,,1,,9606.0,6120,1,80682,A549,,,Antitumoral activity was assayed against A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624710,,,F
2359,Intermediate,,1,,9606.0,6121,1,80682,A549,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624711,,,F
4457,Intermediate,,1,,9606.0,6122,1,80682,A549,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624712,,,F
12454,Expert,,1,,9606.0,6123,1,80682,A549,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624713,,,F
1481,Intermediate,,1,,9606.0,6124,1,80682,A549,,,Compound was tested for inhibition of cell growth of A-549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624714,,,F
1750,Intermediate,,1,,9606.0,6125,1,80682,A549,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624715,,,F
5065,Intermediate,,1,,9606.0,6126,1,80682,A549,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624716,,,F
808,Expert,,1,,9606.0,6127,1,80682,A549,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619505,,,F
16364,Expert,,1,,9606.0,6128,1,80682,A549,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619506,,,F
1847,Intermediate,,1,,9606.0,6129,1,80682,A549,,,Cytotoxic activity against A-549 cell lines.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619507,,,F
1747,Expert,,1,,9606.0,6130,1,80682,A549,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619508,,,F
1003,Intermediate,,1,,9606.0,6131,1,80682,A549,,,Cytotoxicity against human A549 non small cell lung cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619509,,,F
15313,Expert,,1,,9606.0,6132,1,80682,A549,,,Inhibition of cell growth in (A-549) lung cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619510,,,F
3122,Intermediate,,1,,9606.0,6133,1,80682,A549,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619511,,,F
16049,Intermediate,,1,,9606.0,6134,1,80682,A549,,,In vitro antitumor activity against A-549 tumor cells.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619512,,,F
17134,Expert,,1,,9606.0,6135,1,80682,A549,,,In vitro antitumor effects against human A-549 cell lines.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619513,,,F
6406,Intermediate,,1,,9606.0,6136,1,80682,A549,,,In vitro cytotoxic activity of compound against A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619514,,,F
627,Intermediate,,1,,9606.0,6137,1,80682,A549,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619515,,,F
12307,Intermediate,,1,,9606.0,6138,1,80682,A549,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619516,,,F
17861,Intermediate,,1,,9606.0,6139,1,80682,A549,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884005,,,F
6682,Expert,,1,,9606.0,6140,1,80682,A549,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619517,,,F
6663,Intermediate,,1,,9606.0,6141,1,80682,A549,,,Inhibitory concentration of compound against A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619518,,,F
2454,Intermediate,,1,,9606.0,6142,1,80682,A549,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619519,,,F
14709,Intermediate,,1,,9606.0,6143,1,80682,A549,,,cytotoxic activity against leukemia (A-549) cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876489,,,F
15718,Expert,,1,,9606.0,6144,1,80682,A549,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619520,,,F
15718,Intermediate,,1,,9606.0,6145,1,80682,A549,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619521,,,F
17130,Intermediate,,1,,9606.0,6146,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619522,,,F
17130,Intermediate,,1,,9606.0,6147,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619523,,,F
17130,Intermediate,,1,,9606.0,6148,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619524,,,F
17130,Intermediate,,1,,9606.0,6149,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619525,,,F
6630,Intermediate,,1,,,6150,1,80682,A549,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,N,646.0,,BAO_0000219,,CHEMBL619526,,,F
16726,Intermediate,,1,,9606.0,6151,1,80682,A549,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619527,,,F
17846,Intermediate,,1,,9606.0,6152,1,80682,A549,,,Cytotoxicity against A549 cells; No cytotoxicity,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619528,,,F
3415,Expert,,1,,9606.0,6153,1,80682,A549,,,Cytotoxicity against human lung carcinoma (A549) cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619529,,,F
3415,Expert,,1,,9606.0,6154,1,80682,A549,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619530,,,F
5609,Intermediate,,1,,9606.0,6155,1,80682,A549,,,In vitro anticancer activity against human lung (A549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876490,,,F
17206,Intermediate,,1,,9606.0,6156,1,80682,A549,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619531,,,F
17206,Intermediate,,1,,9606.0,6157,1,80682,A549,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619532,,,F
17206,Intermediate,,1,,9606.0,6158,1,80682,A549,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619533,,,F
17206,Intermediate,,1,,9606.0,6159,1,80682,A549,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619534,,,F
17206,Intermediate,,1,,9606.0,6160,1,80682,A549,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620164,,,F
17206,Intermediate,,1,,9606.0,6161,1,80682,A549,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620165,,,F
16295,Expert,,1,,9606.0,6162,1,80682,A549,,,Inhibition of A549 human lung tumor cell proliferation,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620166,,,F
16825,Intermediate,,1,,9606.0,6163,1,80682,A549,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620167,,,F
3439,Expert,,1,,9606.0,6164,1,80682,A549,,,In vitro cytotoxicity against human tumor cell line A549,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620168,,,F
10870,Intermediate,,1,,9606.0,6165,1,80682,A549,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620338,,,F
4845,Intermediate,,1,,9606.0,6166,1,80682,A549,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620339,,,F
5822,Intermediate,,1,,9606.0,6167,1,80682,A549,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620340,,,F
5822,Intermediate,,1,,9606.0,6168,1,80682,A549,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620341,,,F
5822,Intermediate,,1,,9606.0,6169,1,80682,A549,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876491,,,F
16381,Intermediate,,1,,9606.0,6170,1,80682,A549,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620342,,,F
16381,Intermediate,,1,,9606.0,6171,1,80682,A549,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620343,,,F
16381,Intermediate,,1,,9606.0,6172,1,80682,A549,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620344,,,F
5609,Intermediate,,1,,9606.0,6173,1,80682,A549,,,In vitro anticancer activity against human lung (A549) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620345,,,F
4644,Intermediate,,1,,9606.0,6174,1,80682,A549,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620346,,,F
4644,Intermediate,,1,,9606.0,6175,1,80682,A549,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620347,,,F
4644,Intermediate,,1,,9606.0,6176,1,80682,A549,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620348,,,F
4644,Intermediate,,1,,9606.0,6177,1,80682,A549,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620349,,,F
5822,Intermediate,,1,,9606.0,6178,1,80682,A549,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL618667,,,F
3415,Expert,,1,,9606.0,6179,1,80682,A549,,,Percentage inhibition of human lung carcinoma (A549) cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL618668,,,F
16726,Intermediate,,1,,9606.0,6180,1,80682,A549,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876031,,,F
17206,Intermediate,,1,,9606.0,6181,1,80682,A549,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL618759,,,F
17206,Intermediate,,1,,9606.0,6182,1,80682,A549,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL618760,,,F
17206,Intermediate,,1,,9606.0,6183,1,80682,A549,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619000,,,F
17206,Intermediate,,1,,9606.0,6184,1,80682,A549,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619001,,,F
17206,Intermediate,,1,,9606.0,6185,1,80682,A549,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619002,,,F
17206,Intermediate,,1,,9606.0,6186,1,80682,A549,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619003,,,F
17206,Intermediate,,1,,9606.0,6187,1,80682,A549,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619597,,,F
17206,Intermediate,,1,,9606.0,6188,1,80682,A549,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619598,,,F
17206,Intermediate,,1,,9606.0,6189,1,80682,A549,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619599,,,F
17206,Intermediate,,1,,9606.0,6190,1,80682,A549,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619600,,,F
16726,Intermediate,,1,,9606.0,6191,1,80682,A549,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619601,,,F
17206,Intermediate,,1,,9606.0,6192,1,80682,A549,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619602,,,F
17206,Intermediate,,1,,9606.0,6193,1,80682,A549,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619603,,,F
17206,Intermediate,,1,,9606.0,6194,1,80682,A549,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619604,,,F
17206,Intermediate,,1,,9606.0,6195,1,80682,A549,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619605,,,F
6084,Intermediate,,1,,9615.0,6196,1,50588,,In vivo,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619606,,,A
6084,Intermediate,,1,,9615.0,6197,1,50588,,In vivo,,Pharmacokinetic activity (Cmax) in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876032,,,A
4809,Intermediate,,1,,9615.0,6198,1,50588,,In vivo,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619607,,,A
5983,Intermediate,,1,,9615.0,6199,1,50588,,In vivo,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619608,,,A
6251,Intermediate,,1,,9615.0,6200,1,50588,,In vivo,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619609,,,A
5932,Intermediate,,1,,9615.0,6201,1,50588,,In vivo,Plasma,Cmax in dog plasma after 30mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL619610,,,A
4273,Intermediate,,1,,9615.0,6202,1,50588,,In vivo,Blood,Tested for the peak blood level in dog,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619611,,,A
5313,Intermediate,,1,,9615.0,6203,1,50588,,In vivo,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619612,,,A
5313,Intermediate,,1,,9615.0,6204,1,50588,,In vivo,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619613,,,A
6221,Intermediate,,1,,9615.0,6205,1,50588,,In vivo,Blood,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619614,,,A
4709,Intermediate,,1,,9615.0,6206,1,50588,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619615,,,A
167,Intermediate,,1,,9615.0,6207,1,50588,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619616,,,A
6241,Intermediate,,1,,9615.0,6208,1,50588,,,Plasma,Final plasma concentration in dogs after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL619617,,,A
344,Intermediate,,1,,9615.0,6209,1,50588,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619618,,,A
344,Intermediate,,1,,9615.0,6210,1,50588,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876033,,,A
344,Intermediate,,1,,9615.0,6211,1,50588,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619619,,,A
2189,Intermediate,,1,,9615.0,6212,1,50588,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619620,,,A
2189,Intermediate,,1,,9615.0,6213,1,50588,,,Urine,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL619621,,,A
2189,Intermediate,,1,,9615.0,6214,1,50588,,,Urine,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL619622,,,A
2189,Intermediate,,1,,9615.0,6215,1,50588,,,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL618874,,,A
4257,Intermediate,,1,,9615.0,6216,1,50588,,In vivo,,Absolute bioavailability was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618875,,,A
6221,Intermediate,,1,,9615.0,6217,1,50588,,In vivo,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618876,,,A
6215,Intermediate,,1,,9615.0,6218,1,50588,,In vivo,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618877,,,A
17267,Intermediate,,1,,9615.0,6219,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618878,,,A
6621,Intermediate,,1,,9615.0,6220,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618879,,,A
3854,Intermediate,,1,,9615.0,6221,1,50588,,In vivo,,Bioavailability after intravenous administration in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618880,,,A
3854,Intermediate,,1,,9615.0,6222,1,50588,,In vivo,,Bioavailability after peroral administration in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618881,,,A
5007,Intermediate,,1,,9615.0,6223,1,50588,,In vivo,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618882,,,A
4333,Intermediate,,1,,9615.0,6224,1,50588,,In vivo,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624226,,,A
4333,Intermediate,,1,,9615.0,6225,1,50588,,In vivo,Plasma,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624227,,,A
5006,Intermediate,,1,,9615.0,6226,1,50588,,In vivo,,Bioavailability,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624228,,,A
5199,Intermediate,,1,,9615.0,6227,1,50588,,In vivo,,Bioavailability,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624229,,,A
4368,Intermediate,,1,,9615.0,6228,1,50588,,In vivo,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624230,,,A
3771,Intermediate,,1,,9615.0,6229,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624231,,,A
4953,Intermediate,,1,,9615.0,6230,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624232,,,A
5064,Intermediate,,1,,9615.0,6231,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625127,,,A
17657,Intermediate,,1,,9615.0,6232,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625128,,,A
17796,Intermediate,,1,,9615.0,6233,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621675,,,A
17853,Intermediate,,1,,9615.0,6234,1,50588,,In vivo,,Bioavailability in dog (p.o.) at 2.0 mpk,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621676,,,A
4521,Intermediate,,1,,9615.0,6235,1,50588,,In vivo,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621677,,,A
4521,Intermediate,,1,,9615.0,6236,1,50588,,In vivo,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621678,,,A
5006,Intermediate,,1,,9615.0,6237,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621679,,,A
16365,Intermediate,,1,,9615.0,6238,1,50588,,In vivo,,Bioavailability was evaluated after oral administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621680,,,A
1916,Intermediate,,1,,9615.0,6239,1,50588,,In vivo,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621681,,,A
1918,Intermediate,,1,,9615.0,6240,1,50588,,In vivo,,Bioavailability was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876740,,,A
4239,Intermediate,,1,,9615.0,6241,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621682,,,A
6505,Intermediate,,1,,9615.0,6242,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621683,,,A
5334,Intermediate,,1,,9615.0,6243,1,50588,,In vivo,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621684,,,A
5334,Intermediate,,1,,9615.0,6244,1,50588,,In vivo,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621685,,,A
4809,Intermediate,,1,,9615.0,6245,1,50588,,In vivo,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621686,,,A
6348,Intermediate,,1,,9615.0,6246,1,50588,,In vivo,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621687,,,A
6005,Intermediate,,1,,9615.0,6247,1,50588,,In vivo,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621688,,,A
17804,Intermediate,,1,,9615.0,6248,1,50588,,In vivo,,Bioavailability of compound in dog was determined after peroral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621689,,,A
3184,Intermediate,,1,,9615.0,6249,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621690,,,A
1806,Intermediate,,1,,9615.0,6250,1,50588,,In vivo,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621691,,,A
1806,Intermediate,,1,,9615.0,6251,1,50588,,In vivo,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875941,,,A
1806,Intermediate,,1,,9615.0,6252,1,50588,,In vivo,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621692,,,A
4839,Intermediate,,1,,9615.0,6253,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621693,,,A
5017,Intermediate,,1,,9615.0,6254,1,50588,,In vivo,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621694,,,A
846,Intermediate,,1,,10090.0,6255,1,50594,,In vivo,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621695,,,A
846,Intermediate,,1,,10090.0,6256,1,50594,,In vivo,Heart,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621696,,,A
846,Intermediate,,1,,10090.0,6257,1,50594,,In vivo,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621697,,,A
846,Intermediate,,1,,10090.0,6258,1,50594,,In vivo,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621698,,,A
846,Intermediate,,1,,10090.0,6259,1,50594,,In vivo,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623420,,,A
846,Intermediate,,1,,10090.0,6260,1,50594,,In vivo,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623421,,,A
846,Intermediate,,1,,10090.0,6261,1,50594,,In vivo,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623422,,,A
846,Intermediate,,1,,10090.0,6262,1,50594,,In vivo,Kidney,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623423,,,A
846,Intermediate,,1,,10090.0,6263,1,50594,,In vivo,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623424,,,A
846,Intermediate,,1,,10090.0,6264,1,50594,,In vivo,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623425,,,A
846,Intermediate,,1,,10090.0,6265,1,50594,,In vivo,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623426,,,A
846,Intermediate,,1,,10090.0,6266,1,50594,,In vivo,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623427,,,A
846,Intermediate,,1,,10090.0,6267,1,50594,,In vivo,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623428,,,A
846,Intermediate,,1,,10090.0,6268,1,50594,,In vivo,Liver,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL875947,,,A
846,Intermediate,,1,,10090.0,6269,1,50594,,In vivo,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623429,,,A
846,Intermediate,,1,,10090.0,6270,1,50594,,In vivo,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623430,,,A
846,Intermediate,,1,,10090.0,6271,1,50594,,In vivo,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL622588,,,A
846,Intermediate,,1,,10090.0,6272,1,50594,,In vivo,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL622589,,,A
846,Intermediate,,1,,10090.0,6273,1,50594,,In vivo,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL622751,,,A
846,Intermediate,,1,,10090.0,6274,1,50594,,In vivo,Lung,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL622752,,,A
6599,Intermediate,,1,,10090.0,6275,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL622753,,,A
6599,Intermediate,,1,,10090.0,6276,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL622647,,,A
6599,Intermediate,,1,,10090.0,6277,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL875163,,,A
6599,Intermediate,,1,,10090.0,6278,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL622648,,,A
6599,Intermediate,,1,,10090.0,6279,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL622649,,,A
6599,Intermediate,,1,,10090.0,6280,1,50594,CCRF S-180,,Brain,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,955.0,CHEMBL622650,,,A
6599,Intermediate,,1,,10090.0,6281,1,50594,CCRF S-180,,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,955.0,CHEMBL622651,,,A
6599,Intermediate,,1,,10090.0,6282,1,50594,CCRF S-180,,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,955.0,CHEMBL622652,,,A
6599,Intermediate,,1,,10090.0,6283,1,50594,CCRF S-180,,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,955.0,CHEMBL622653,,,A
6599,Intermediate,,1,,10090.0,6284,1,50594,CCRF S-180,,Brain,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,955.0,CHEMBL622654,,,A
6599,Intermediate,,1,,10090.0,6285,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL622655,,,A
6599,Intermediate,,1,,10090.0,6286,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL622656,,,A
6599,Intermediate,,1,,10090.0,6287,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL622657,,,A
6599,Intermediate,,1,,10090.0,6288,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL622658,,,A
6599,Intermediate,,1,,10090.0,6289,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL622659,,,A
6599,Intermediate,,1,,10090.0,6290,1,50594,CCRF S-180,,Kidney,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,2113.0,CHEMBL624630,,,A
6599,Intermediate,,1,,10090.0,6291,1,50594,CCRF S-180,,Kidney,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,2113.0,CHEMBL624631,,,A
6599,Intermediate,,1,,10090.0,6292,1,50594,CCRF S-180,,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,2113.0,CHEMBL624632,,,A
17130,Intermediate,,1,,9606.0,6293,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624633,,,F
17130,Intermediate,,1,,9606.0,6294,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624634,,,F
17130,Intermediate,,1,,9606.0,6295,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624635,,,F
17130,Intermediate,,1,,9606.0,6296,1,80682,A549,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624636,,,F
3263,Expert,,1,,9606.0,6297,1,80682,A549,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL857055,,,F
6663,Expert,,1,,9606.0,6298,1,80682,A549,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624637,,,F
6663,Expert,,1,,9606.0,6299,1,80682,A549,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624638,,,F
6663,Expert,,1,,9606.0,6300,1,80682,A549,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL874366,,,F
6663,Expert,,1,,9606.0,6301,1,80682,A549,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624639,,,F
6663,Expert,,1,,9606.0,6302,1,80682,A549,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624640,,,F
6663,Intermediate,,1,,9606.0,6303,1,80682,A549,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624641,,,F
6663,Intermediate,,1,,9606.0,6304,1,80682,A549,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624642,,,F
6663,Intermediate,,1,,9606.0,6305,1,80682,A549,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624643,,,F
6663,Intermediate,,1,,9606.0,6306,1,80682,A549,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624644,,,F
6663,Intermediate,,1,,9606.0,6307,1,80682,A549,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL624645,,,F
3983,Intermediate,,1,,9606.0,6308,1,80682,A549,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619445,,,F
11141,Expert,,1,,9606.0,6309,1,80682,A549,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL839886,,,F
5076,Intermediate,,1,,9606.0,6310,1,80682,A549,,,Cytotoxic activity of compound against A-549 tumor cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619446,,,F
3311,Intermediate,,1,,9606.0,6311,1,80682,A549,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619447,,,F
3311,Intermediate,,1,,9606.0,6312,1,80682,A549,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619448,,,F
3311,Intermediate,,1,,9606.0,6313,1,80682,A549,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619449,,,F
5076,Intermediate,,1,,9606.0,6314,1,80682,A549,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619450,,,F
4150,Intermediate,,1,,9606.0,6315,1,80682,A549,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619451,,,F
2150,Expert,,1,,9606.0,6316,1,80682,A549,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619452,,,F
4644,Intermediate,,1,,9606.0,6317,1,80682,A549,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619453,,,F
263,Intermediate,,1,,9606.0,6318,1,80682,A549,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL874367,,,F
11333,Intermediate,,1,,9606.0,6319,1,80682,A549,,,Cytotoxic concentration against A-549 tumor cells.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619454,,,F
11333,Intermediate,,1,,9606.0,6320,1,80682,A549,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619455,,,F
15895,Intermediate,,1,,9606.0,6321,1,80682,A549,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619456,,,F
16677,Expert,,1,,470.0,6322,1,50191,,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,N,,Acinetobacter baumannii,BAO_0000218,,CHEMBL619457,,,F
10624,Intermediate,,1,,471.0,6323,1,50192,,,,Activity against Acinetobacter calcoaceticus (AC54),,N,,Acinetobacter calcoaceticus,BAO_0000218,,CHEMBL619458,,,F
16717,Expert,,1,,5059.0,6324,1,50274,,,,In vitro antifungal activity against Aspergillus flavus CM74,,N,,Aspergillus flavus,BAO_0000218,,CHEMBL619459,,,F
16717,Expert,,1,,5059.0,6325,1,50274,,,,In vitro antifungal activity against Aspergillus flavus CM74,,N,,Aspergillus flavus,BAO_0000218,,CHEMBL619460,,,F
5513,Intermediate,,1,,746128.0,6326,1,50416,,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL619461,,,F
15962,Intermediate,,1,,746128.0,6327,1,50416,,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL619462,,,F
15962,Intermediate,,1,,746128.0,6328,1,50416,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL620388,,,F
15962,Intermediate,,1,,746128.0,6329,1,50416,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL620389,,,F
15962,Intermediate,,1,,746128.0,6330,1,50416,,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL620390,,,F
16717,Expert,,1,,746128.0,6331,1,50416,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL620391,,,F
16717,Expert,,1,,746128.0,6332,1,50416,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,N,,Aspergillus fumigatus,BAO_0000218,,CHEMBL621073,,,F
8117,Intermediate,,1,,1655.0,6333,1,50296,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL621074,,,F
8117,Intermediate,,1,,1656.0,6334,1,50366,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL621075,,,F
15472,Intermediate,,1,,6277.0,6335,1,50535,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL619554,,,F
15472,Intermediate,,1,,6277.0,6336,1,50535,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL619555,,,F
16443,Intermediate,,1,,714.0,6337,1,50169,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,N,,Aggregatibacter actinomycetemcomitans,BAO_0000218,,CHEMBL619556,,,F
16443,Intermediate,,1,,714.0,6338,1,50169,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,N,,Aggregatibacter actinomycetemcomitans,BAO_0000218,,CHEMBL619557,,,F
16443,Intermediate,,1,,714.0,6339,1,50169,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,N,,Aggregatibacter actinomycetemcomitans,BAO_0000218,,CHEMBL619558,,,F
17206,Intermediate,,1,,9606.0,6340,1,80682,A549,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619559,,,F
17206,Intermediate,,1,,9606.0,6341,1,80682,A549,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619560,,,F
16381,Intermediate,,1,,9606.0,6342,1,80682,A549,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619561,,,F
16381,Intermediate,,1,,9606.0,6343,1,80682,A549,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619562,,,F
16381,Intermediate,,1,,9606.0,6344,1,80682,A549,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619563,,,F
16381,Intermediate,,1,,9606.0,6345,1,80682,A549,,,GI values against A549 cells (lung cancer),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL857457,,,F
17206,Intermediate,,1,,9606.0,6346,1,80682,A549,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619564,,,F
16325,Intermediate,,1,,9606.0,6347,1,80682,A549,,,Inhibitory activity against A549 human adenocarcinoma,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619565,,,F
10708,Intermediate,,1,,9606.0,6348,1,80682,A549,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL619566,,,F
10708,Intermediate,,1,,9606.0,6349,1,80682,A549,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL619567,,,F
17376,Intermediate,,1,,9606.0,6350,1,80682,A549,,,Inhibitory activity against A549 lung adenocarcinoma cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619568,,,F
17376,Intermediate,,1,,9606.0,6351,1,80682,A549,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619569,,,F
17488,Intermediate,,1,,9606.0,6352,1,80682,A549,,,Cytotoxicity against human A549 lung cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619570,,,F
17404,Intermediate,,1,,9606.0,6353,1,80682,A549,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,N,646.0,Homo sapiens,BAO_0000218,,CHEMBL619571,,,F
10958,Expert,,1,,9606.0,6354,1,80682,A549,,,Growth inhibition of A549 (human lung carcinoma) cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619572,,,F
17099,Expert,,1,,9606.0,6355,1,80682,A549,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619573,,,F
17099,Intermediate,,1,,9606.0,6356,1,80682,A549,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619574,,,F
4096,Intermediate,,1,,9606.0,6357,1,80682,A549,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619575,,,F
4096,Expert,,1,,9606.0,6358,1,80682,A549,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619576,,,F
4096,Intermediate,,1,,9606.0,6359,1,80682,A549,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619577,,,F
2525,Intermediate,,1,,9606.0,6360,1,80682,A549,,,In vitro inhibitory activity against A549 tumor cell culture,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619578,,,F
2525,Intermediate,,1,,9606.0,6361,1,80682,A549,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884009,,,F
5302,Intermediate,,1,,9606.0,6362,1,80682,A549,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619579,,,F
16325,Intermediate,,1,,9606.0,6363,1,80682,A549,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619580,,,F
16939,Intermediate,,1,,9606.0,6364,1,80682,A549,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619581,,,F
17229,Intermediate,,1,,9606.0,6365,1,80682,A549,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619582,,,F
17380,Intermediate,,1,,9606.0,6366,1,80682,A549,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619583,,,F
17380,Intermediate,,1,,9606.0,6367,1,80682,A549,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL876502,,,F
1903,Intermediate,,1,,9606.0,6368,1,80682,A549,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619584,,,F
3838,Intermediate,,1,,9606.0,6369,1,80682,A549,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619585,,,F
14696,Intermediate,,1,,9606.0,6370,1,80682,A549,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619586,,,F
3838,Intermediate,,1,,9606.0,6371,1,80682,A549,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619587,,,F
1522,Intermediate,,1,,9606.0,6372,1,80682,A549,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619588,,,F
12400,Intermediate,,1,,9606.0,6373,1,80682,A549,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619589,,,F
14696,Intermediate,,1,,9606.0,6374,1,80682,A549,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619590,,,F
14769,Intermediate,,1,,9606.0,6375,1,80682,A549,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619591,,,F
14696,Intermediate,,1,,9606.0,6376,1,80682,A549,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619592,,,F
1888,Intermediate,,1,,9606.0,6377,1,80682,A549,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL619593,,,F
12016,Intermediate,,1,,9606.0,6378,1,80682,A549,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620217,,,F
6058,Intermediate,,1,,9606.0,6379,1,80682,A549,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620218,,,F
17708,Intermediate,,1,,9606.0,6380,1,80682,A549,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620219,,,F
12301,Intermediate,,1,,9606.0,6381,1,80682,A549,,,Antitumor activity against A549/ATCC cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL620220,,,F
11970,Intermediate,,1,,9606.0,6382,1,80682,A549,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL625141,,,F
11818,Expert,,1,,9606.0,6383,1,80682,A549,,,In vitro cytotoxicity against A549/ATCC cell line.,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL625142,,,F
12400,Intermediate,,1,,9606.0,6384,1,80682,A549,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL625143,,,F
3381,Intermediate,,1,,9606.0,6385,1,80682,A549,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL625144,,,F
17376,Intermediate,,1,,9606.0,6386,1,80682,A549,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL622474,,,F
10708,Intermediate,,1,,9606.0,6387,1,80682,A549,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,N,646.0,Homo sapiens,BAO_0000219,,CHEMBL884104,,,F
2964,Autocuration,,1,,9606.0,6388,0,22226,,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,U,,Homo sapiens,BAO_0000219,,CHEMBL622475,,,F
5005,Intermediate,,1,,9615.0,6389,0,22224,,In vivo,,Compound was tested for oral bioavailability in dogs,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL622476,,,A
6229,Intermediate,,1,,9615.0,6390,1,50588,,In vivo,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875831,,,A
6229,Intermediate,,1,,9615.0,6391,1,50588,,In vivo,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622477,,,A
5374,Intermediate,,1,,9615.0,6392,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622478,,,A
5374,Intermediate,,1,,9615.0,6393,1,50588,,In vivo,,Compound was tested for the oral bioavailability in dog; No availability,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623172,,,A
6265,Intermediate,,1,,9615.0,6394,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623173,,,A
5654,Intermediate,,1,,9615.0,6395,1,50588,,In vivo,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623174,,,A
5654,Intermediate,,1,,9615.0,6396,1,50588,,In vivo,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623175,,,A
16456,Intermediate,,1,,9615.0,6397,1,50588,,In vivo,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623340,,,A
5302,Intermediate,,1,,9615.0,6398,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623341,,,A
3624,Intermediate,,1,,9615.0,6399,1,50588,,In vivo,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623342,,,A
16452,Intermediate,,1,,9615.0,6400,1,50588,,In vivo,,Oral bioavailability of active FTIs in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623343,,,A
5802,Intermediate,,1,,9615.0,6401,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623344,,,A
3598,Expert,,1,,9615.0,6402,1,50588,,In vivo,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623345,,,A
17839,Intermediate,,1,,9615.0,6403,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875832,,,A
6762,Intermediate,,1,,9615.0,6404,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623346,,,A
6821,Intermediate,,1,,9615.0,6405,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623347,,,A
6821,Intermediate,,1,,9615.0,6406,1,50588,,In vivo,,Oral bioavailability of compound was determined in dog; Not tested,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623348,,,A
5210,Intermediate,,1,,9615.0,6407,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623349,,,A
6227,Intermediate,,1,,9615.0,6408,1,50588,,In vivo,,Oral bioavailability (10 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623350,,,A
761,Intermediate,,1,,9615.0,6409,1,50588,,In vivo,,Oral bioavailability,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623351,,,A
761,Intermediate,,1,,9615.0,6410,1,50588,,In vivo,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623352,,,A
761,Intermediate,,1,,9615.0,6411,1,50588,,In vivo,,Oral bioavailability administered in solution in rats,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623353,,,A
16907,Intermediate,,1,,9615.0,6412,1,50588,,In vivo,,Oral bioavailability after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875833,,,A
5474,Intermediate,,1,,9615.0,6413,1,50588,,In vivo,,Oral bioavailability at a dose of 1 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623354,,,A
6535,Intermediate,,1,,9615.0,6414,1,50588,,In vivo,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623355,,,A
6535,Intermediate,,1,,9615.0,6415,1,50588,,In vivo,,Oral bioavailability in Dog; ND = not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623356,,,A
3352,Intermediate,,1,,9615.0,6416,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623357,,,A
6168,Intermediate,,1,,9615.0,6417,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623358,,,A
5988,Intermediate,,1,,9615.0,6418,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623359,,,A
4942,Intermediate,,1,,9615.0,6419,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623360,,,A
4942,Intermediate,,1,,9615.0,6420,1,50588,,In vivo,,Oral bioavailability in dogs; No data,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623361,,,A
14541,Intermediate,,1,,9615.0,6421,1,50588,,In vivo,,Oral bioavailability measured in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623362,,,A
4449,Intermediate,,1,,9615.0,6422,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623363,,,A
6057,Intermediate,,1,,9615.0,6423,1,50588,,In vivo,,Oral bioavailability was calculated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623364,,,A
5600,Intermediate,,1,,9615.0,6424,1,50588,,In vivo,,Oral bioavailability after 0.3 mg/kg po administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875834,,,A
5542,Intermediate,,1,,9615.0,6425,1,50588,,In vivo,,Oral bioavailability in dog (i.v. dosing),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623365,,,A
5542,Intermediate,,1,,9615.0,6426,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623366,,,A
5546,Intermediate,,1,,9615.0,6427,1,50588,,In vivo,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623367,,,A
4514,Intermediate,,1,,9615.0,6428,1,50588,,In vivo,,Oral bioavailability in Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623368,,,A
3624,Intermediate,,1,,9615.0,6429,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623369,,,A
3854,Intermediate,,1,,9615.0,6430,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623370,,,A
5836,Intermediate,,1,,9615.0,6431,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623371,,,A
5940,Intermediate,,1,,9615.0,6432,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623372,,,A
6168,Intermediate,,1,,9615.0,6433,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621351,,,A
6227,Intermediate,,1,,9615.0,6434,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621352,,,A
6251,Intermediate,,1,,9615.0,6435,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621353,,,A
6448,Intermediate,,1,,9615.0,6436,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621354,,,A
6647,Intermediate,,1,,9615.0,6437,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621355,,,A
5940,Intermediate,,1,,9615.0,6438,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621356,,,A
933,Intermediate,,1,,9615.0,6439,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621357,,,A
5210,Intermediate,,1,,9615.0,6440,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621358,,,A
6642,Intermediate,,1,,9615.0,6441,1,50588,,In vivo,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621359,,,A
6641,Intermediate,,1,,9615.0,6442,1,50588,,In vivo,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621360,,,A
6642,Intermediate,,1,,9615.0,6443,1,50588,,In vivo,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621361,,,A
5472,Intermediate,,1,,9615.0,6444,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621362,,,A
5985,Intermediate,,1,,9615.0,6445,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621363,,,A
15660,Intermediate,,1,,9615.0,6446,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621364,,,A
5530,Intermediate,,1,,9615.0,6447,1,50588,,In vivo,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621166,,,A
5530,Intermediate,,1,,9615.0,6448,1,50588,,In vivo,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621167,,,A
6305,Intermediate,,1,,9615.0,6449,1,50588,,In vivo,,Oral bioavailability (F) in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621168,,,A
5210,Intermediate,,1,,9615.0,6450,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621169,,,A
5238,Intermediate,,1,,9615.0,6451,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875950,,,A
5668,Intermediate,,1,,9615.0,6452,1,50588,,In vivo,,Oral bioavailability in dog (dose 10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621170,,,A
5668,Intermediate,,1,,9615.0,6453,1,50588,,In vivo,,Oral bioavailability after peroral administration at 5 mpk in Dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621171,,,A
5668,Intermediate,,1,,9615.0,6454,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621172,,,A
6084,Intermediate,,1,,9615.0,6455,1,50588,,In vivo,,Oral bioavailability in dog (dose 10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621173,,,A
6599,Intermediate,,1,,10090.0,6456,1,50594,CCRF S-180,,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,2113.0,CHEMBL621174,,,A
6599,Intermediate,,1,,10090.0,6457,1,50594,CCRF S-180,,Kidney,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,2113.0,CHEMBL621175,,,A
6599,Intermediate,,1,,10090.0,6458,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL621176,,,A
6599,Intermediate,,1,,10090.0,6459,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL621177,,,A
6599,Intermediate,,1,,10090.0,6460,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL621178,,,A
6599,Intermediate,,1,,10090.0,6461,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL621179,,,A
6599,Intermediate,,1,,10090.0,6462,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL621180,,,A
6599,Intermediate,,1,,10090.0,6463,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL875951,,,A
6599,Intermediate,,1,,10090.0,6464,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL621181,,,A
6599,Intermediate,,1,,10090.0,6465,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL621182,,,A
6599,Intermediate,,1,,10090.0,6466,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL621183,,,A
6599,Intermediate,,1,,10090.0,6467,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL621184,,,A
6599,Intermediate,,1,,10090.0,6468,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621185,,,A
6599,Intermediate,,1,,10090.0,6469,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621186,,,A
6599,Intermediate,,1,,10090.0,6470,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621187,,,A
6599,Intermediate,,1,,10090.0,6471,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621188,,,A
6599,Intermediate,,1,,10090.0,6472,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621189,,,A
6599,Intermediate,,1,,10090.0,6473,1,50594,CCRF S-180,,Spleen,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,2106.0,CHEMBL621190,,,A
6599,Intermediate,,1,,10090.0,6474,1,50594,CCRF S-180,,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,2106.0,CHEMBL618520,,,A
6599,Intermediate,,1,,10090.0,6475,1,50594,CCRF S-180,,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,2106.0,CHEMBL621739,,,A
6599,Intermediate,,1,,10090.0,6476,1,50594,CCRF S-180,,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,2106.0,CHEMBL621740,,,A
6599,Intermediate,,1,,10090.0,6477,1,50594,CCRF S-180,,Spleen,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,2106.0,CHEMBL621741,,,A
6599,Intermediate,,1,,10090.0,6478,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621742,,,A
6599,Intermediate,,1,,10090.0,6479,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621743,,,A
6599,Intermediate,,1,,10090.0,6480,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621744,,,A
6599,Intermediate,,1,,10090.0,6481,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621745,,,A
6599,Intermediate,,1,,10090.0,6482,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621746,,,A
6599,Intermediate,,1,,10090.0,6483,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621747,,,A
6599,Intermediate,,1,,10090.0,6484,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621748,,,A
6599,Intermediate,,1,,10090.0,6485,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621749,,,A
6599,Intermediate,,1,,10090.0,6486,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621750,,,A
6599,Intermediate,,1,,10090.0,6487,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL621751,,,A
6599,Intermediate,,1,,10090.0,6488,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL621752,,,A
6599,Intermediate,,1,,10090.0,6489,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL621753,,,A
6599,Intermediate,,1,,10090.0,6490,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL875955,,,A
6599,Intermediate,,1,,10090.0,6491,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL621754,,,A
6599,Intermediate,,1,,10090.0,6492,1,50594,CCRF S-180,,Heart,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,948.0,CHEMBL621755,,,A
6599,Intermediate,,1,,10090.0,6493,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL621756,,,A
6599,Intermediate,,1,,10090.0,6494,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL624199,,,A
6599,Intermediate,,1,,10090.0,6495,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL624200,,,A
6599,Intermediate,,1,,10090.0,6496,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL624375,,,A
6599,Intermediate,,1,,10090.0,6497,1,50594,CCRF S-180,,Liver,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,2107.0,CHEMBL624376,,,A
6599,Intermediate,,1,,10090.0,6498,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL624377,,,A
6599,Intermediate,,1,,10090.0,6499,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL624378,,,A
12269,Intermediate,,1,,107673.0,6500,1,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,,aeinetobacter anitrotap,BAO_0000218,,CHEMBL857901,,,F
12269,Intermediate,,1,,107673.0,6501,1,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,CHEMBL875274,,,F
12269,Intermediate,,1,,107673.0,6502,1,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,CHEMBL624379,,,F
12269,Intermediate,,1,,107673.0,6503,1,50067,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,N,,aeinetobacter anitrotap,BAO_0000218,,CHEMBL624380,,,F
10624,Intermediate,,1,,471.0,6504,1,50192,,,,Activity against Acinetobacter calcoaceticus (AC54),,N,,Acinetobacter calcoaceticus,BAO_0000218,,CHEMBL624381,,,F
17216,Intermediate,,1,,28377.0,6505,1,50714,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,N,,Anolis carolinensis,BAO_0000218,,CHEMBL624382,,,F
17216,Intermediate,,1,,28377.0,6506,1,50714,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,N,,Anolis carolinensis,BAO_0000218,,CHEMBL624383,,,F
9560,Intermediate,,1,,1655.0,6507,1,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624384,,,F
9560,Intermediate,,1,,1655.0,6508,1,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624385,,,F
9560,Intermediate,,1,,1655.0,6509,1,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624386,,,F
9560,Intermediate,,1,,1655.0,6510,1,50296,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624387,,,F
9560,Intermediate,,1,,1655.0,6511,1,50296,,,,Plaque bactericidal index against Actinomyces naeslundii 631,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624388,,,F
9560,Intermediate,,1,,1655.0,6512,1,50296,,,,Plaque bactericidal index against Actinomyces naeslundii N/9,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624389,,,F
9560,Intermediate,,1,,1655.0,6513,1,50296,,,,Plaque bactericidal index against Actinomyces naeslundii B74,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL624390,,,F
9560,Intermediate,,1,,1655.0,6514,1,50296,,,,Plaque bactericidal index against Actinomyces naeslundii N/3,,N,,Actinomyces naeslundii,BAO_0000218,,CHEMBL875275,,,F
114,Intermediate,,1,,85549.0,6515,1,50056,,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,N,,Artemia salina,BAO_0000218,,CHEMBL624391,,,F
114,Intermediate,,1,,85549.0,6516,1,50056,,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,N,,Artemia salina,BAO_0000218,,CHEMBL623636,,,F
10841,Intermediate,,1,,6253.0,6517,1,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623637,,,F
10841,Intermediate,,1,,6253.0,6518,1,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623638,,,F
10841,Intermediate,,1,,6253.0,6519,1,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623639,,,F
10841,Intermediate,,1,,6253.0,6520,1,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623640,,,F
10841,Intermediate,,1,,6253.0,6521,1,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623641,,,F
10841,Intermediate,,1,,6253.0,6522,1,50532,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,N,,Ascaris suum,BAO_0000218,,CHEMBL623642,,,F
10841,Intermediate,,1,,6253.0,6523,1,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623643,,,F
10841,Intermediate,,1,,6253.0,6524,1,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623644,,,F
10841,Intermediate,,1,,6253.0,6525,1,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623645,,,F
10841,Intermediate,,1,,6253.0,6526,1,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623646,,,F
10841,Intermediate,,1,,6253.0,6527,1,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623647,,,F
10841,Intermediate,,1,,6253.0,6528,1,50532,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,N,,Ascaris suum,BAO_0000218,,CHEMBL623648,,,F
8117,Intermediate,,1,,1656.0,6529,1,50366,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623649,,,F
8117,Intermediate,,1,,1656.0,6530,1,50366,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623650,,,F
9560,Intermediate,,1,,1656.0,6531,1,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623651,,,F
9560,Expert,,1,,1656.0,6532,1,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623652,,,F
9560,Intermediate,,1,,1656.0,6533,1,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623653,,,F
9560,Intermediate,,1,,1656.0,6534,1,50366,,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623654,,,F
9560,Intermediate,,1,,1656.0,6535,1,50366,,,,Plaque bactericidal index against Actinomyces viscosus 8A06,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623655,,,F
9560,Intermediate,,1,,1656.0,6536,1,50366,,,,Plaque bactericidal index against Actinomyces viscosus M-100,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623656,,,F
9560,Expert,,1,,1656.0,6537,1,50366,,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623657,,,F
9560,Intermediate,,1,,1656.0,6538,1,50366,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623658,,,F
9560,Intermediate,,1,,1656.0,6539,1,50366,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623659,,,F
9560,Intermediate,,1,,1656.0,6540,1,50366,,,,Plaque bactericidal index against Actinomyces viscosus 626,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623660,,,F
9560,Intermediate,,1,,1656.0,6541,1,50366,,,,Plaque bactericidal index against Actinomyces viscosus T14V,,N,,Actinomyces viscosus,BAO_0000218,,CHEMBL623661,,,F
10986,Intermediate,,1,,6277.0,6542,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL875281,,,F
10986,Intermediate,,1,,6277.0,6543,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL623662,,,F
10986,Intermediate,,1,,6277.0,6544,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL623663,,,F
10986,Intermediate,,1,,6277.0,6545,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL623664,,,F
10986,Intermediate,,1,,6277.0,6546,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL623665,,,F
10708,Intermediate,,1,,9606.0,6547,1,80023,A673,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,N,165.0,Homo sapiens,BAO_0000219,,CHEMBL621856,,,F
10708,Intermediate,,1,,9606.0,6548,1,80661,A704,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,N,645.0,Homo sapiens,BAO_0000219,,CHEMBL620432,,,F
416,Autocuration,,1,,10116.0,6549,0,22226,,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,U,,Rattus norvegicus,BAO_0000219,,CHEMBL620433,,,F
14354,Intermediate,,1,,10090.0,6550,1,80024,A9,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL620434,,,F
14354,Intermediate,,1,,10090.0,6551,1,80024,A9,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL620435,,,F
5116,Intermediate,,1,,9606.0,6552,1,80024,A9,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,N,625.0,Homo sapiens,BAO_0000219,,CHEMBL620436,,,F
5116,Intermediate,,1,,9606.0,6553,1,80024,A9,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,N,625.0,Homo sapiens,BAO_0000219,,CHEMBL876597,,,F
15694,Expert,,1,,9606.0,6554,1,81037,Human ovarian carcinoma cell line,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,N,874.0,Homo sapiens,BAO_0000219,,CHEMBL620437,,,F
13038,Expert,,1,,10090.0,6555,1,80024,A9,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,N,625.0,Mus musculus,BAO_0000219,,CHEMBL620438,,,F
13038,Expert,,1,,10090.0,6556,1,80024,A9,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL620439,,,F
10923,Expert,,1,,10090.0,6557,1,80024,A9,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL619657,,,F
10923,Intermediate,,1,,10090.0,6558,1,80024,A9,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL619658,,,F
10923,Intermediate,,1,,10090.0,6559,1,80024,A9,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL619659,,,F
10923,Expert,,1,,,6560,8,10649,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,H,,,BAO_0000019,,CHEMBL619660,,,F
10923,Intermediate,,1,,10090.0,6561,1,80024,A9,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL619661,,,F
10923,Intermediate,,1,,10090.0,6562,1,80024,A9,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,N,625.0,Mus musculus,BAO_0000219,,CHEMBL619662,,,F
8158,Intermediate,,1,,10029.0,6563,1,80663,AA6,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,N,975.0,Cricetulus griseus,BAO_0000219,,CHEMBL619663,,,F
15494,Autocuration,,1,,9606.0,6564,0,22226,,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,U,,Homo sapiens,BAO_0000219,,CHEMBL619664,,,F
15494,Autocuration,,1,,9606.0,6565,0,22226,,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,U,,Homo sapiens,BAO_0000219,,CHEMBL619665,,,F
12348,Intermediate,,1,,9606.0,6566,1,80662,AA5,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,N,974.0,Homo sapiens,BAO_0000219,,CHEMBL883244,,,F
12348,Intermediate,,1,,9606.0,6567,1,80662,AA5,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,N,974.0,Homo sapiens,BAO_0000219,,CHEMBL884011,,,F
2726,Intermediate,,1,,9606.0,6568,1,80662,AA5,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,N,974.0,Homo sapiens,BAO_0000219,,CHEMBL619666,,,F
2726,Intermediate,,1,,9606.0,6569,1,80566,U-937,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,N,379.0,Homo sapiens,BAO_0000219,,CHEMBL619667,,,F
10747,Intermediate,,1,,10029.0,6570,1,80578,UV4,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,N,274.0,Cricetulus griseus,BAO_0000219,,CHEMBL619668,,,F
11005,Expert,,1,,10029.0,6571,1,80089,CHO-AA8,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619669,,,F
12687,Intermediate,,1,,10029.0,6572,1,80089,CHO-AA8,,,Average intracellular compound concentration when the hypoxic SER=1.6,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL876608,,,F
12687,Intermediate,,1,,10029.0,6573,1,80089,CHO-AA8,,,Average intracellular compound concentration when the hypoxic SER=1.6.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619670,,,F
12687,Intermediate,,1,,10029.0,6574,1,80089,CHO-AA8,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619671,,,F
12687,Intermediate,,1,,10029.0,6575,1,80089,CHO-AA8,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619672,,,F
12687,Intermediate,,1,,10029.0,6576,1,80089,CHO-AA8,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619673,,,F
13436,Intermediate,,1,,10029.0,6577,1,80089,CHO-AA8,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619674,,,F
13435,Intermediate,,1,,10029.0,6578,1,80089,CHO-AA8,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619675,,,F
13302,Intermediate,,1,,10029.0,6579,1,80089,CHO-AA8,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619676,,,F
12687,Intermediate,,1,,10029.0,6580,1,80089,CHO-AA8,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619677,,,F
12687,Intermediate,,1,,10029.0,6581,1,80089,CHO-AA8,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619678,,,A
12687,Intermediate,,1,,10029.0,6582,1,80089,CHO-AA8,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619679,,,A
12878,Expert,,1,,10029.0,6583,1,80089,CHO-AA8,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL619680,,,A
12878,Intermediate,,1,,10029.0,6584,1,80089,CHO-AA8,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL621457,,,A
14367,Expert,,1,,10029.0,6585,1,80089,CHO-AA8,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL876609,,,F
14367,Intermediate,,1,,10029.0,6586,1,80089,CHO-AA8,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL621458,,,F
12398,Expert,,1,,36483.0,6587,1,80089,CHO-AA8,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,N,185.0,hampster,BAO_0000219,,CHEMBL621459,,,F
12878,Expert,,1,,10029.0,6588,1,80089,CHO-AA8,,,Aerobic growth inhibition in Chinese hamster cell line AA8,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL621460,,,F
13820,Expert,,1,,10029.0,6589,1,80089,CHO-AA8,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL621461,,,F
13436,Expert,,1,,10029.0,6590,1,80089,CHO-AA8,,,Inhibition of growth under aerobic conditions in AA8 cells,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL621462,,,F
6084,Intermediate,,1,,9615.0,6591,1,50588,,In vivo,,Oral bioavailability in dog (dose 10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621463,,,A
5711,Intermediate,,1,,9615.0,6592,1,50588,,In vivo,,Oral bioavailability in dog at 10 mg/kg of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621464,,,A
4353,Intermediate,,1,,9615.0,6593,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621465,,,A
4353,Intermediate,,1,,9615.0,6594,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621466,,,A
17800,Intermediate,,1,,9615.0,6595,1,50588,,In vivo,,Oral bioavailability in dog (mongrel),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621467,,,A
3994,Intermediate,,1,,9615.0,6596,1,50588,,In vivo,,Oral bioavailability in dog (dose 10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621468,,,A
3994,Intermediate,,1,,9615.0,6597,1,50588,,In vivo,,Oral bioavailability in dog (dose 10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876734,,,F
5145,Intermediate,,1,,9615.0,6598,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618476,,,A
16452,Intermediate,,1,,9615.0,6599,1,50588,,In vivo,,Bioavailability in dog (dose 1 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618477,,,A
16452,Intermediate,,1,,9615.0,6600,1,50588,,In vivo,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618478,,,A
5983,Intermediate,,1,,9615.0,6601,1,50588,,In vivo,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618479,,,A
4273,Intermediate,,1,,9615.0,6602,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618480,,,A
12500,Intermediate,,1,,9615.0,6603,1,50588,,In vivo,,Bioavailability in dog (dose 3-10 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618481,,,A
12500,Intermediate,,1,,9615.0,6604,1,50588,,In vivo,Plasma,The compound was tested for bioavailability of compound in plasma of dog; Complete,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618482,,,A
3639,Intermediate,,1,,9615.0,6605,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618483,,,A
3880,Intermediate,,1,,9615.0,6606,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618484,,,A
4838,Intermediate,,1,,9615.0,6607,1,50588,,In vivo,,Bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618485,,,A
15600,Intermediate,,1,,9615.0,6608,1,50588,,In vivo,,oral bioavailability was measured in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618486,,,A
17248,Intermediate,,1,,9615.0,6609,1,50588,,,,Compound was tested for plasma protein binding in dog; Not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618487,,,A
17248,Intermediate,,1,,9615.0,6610,1,50588,,,,Compound was tested for plasma protein binding of dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618488,,,A
17248,Intermediate,,1,,9615.0,6611,1,50588,,,,Compound was tested for plasma protein binding of dog; Not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876735,,,A
17443,Intermediate,,1,,9615.0,6612,1,50588,,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618489,,,A
4186,Intermediate,,1,,9615.0,6613,1,50588,,In vivo,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618490,,,A
3749,Intermediate,,1,,9615.0,6614,1,50588,,,,Half life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618491,,,A
3249,Intermediate,,1,,9615.0,6615,1,50588,,In vivo,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618492,,,A
3022,Intermediate,,1,,9615.0,6616,1,50588,,,,Half life was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873354,,,A
3749,Intermediate,,1,,9615.0,6617,1,50588,,,,Half life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618493,,,A
2517,Intermediate,,1,,9615.0,6618,1,50588,,In vivo,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618494,,,A
2517,Intermediate,,1,,9615.0,6619,1,50588,,In vivo,Heart,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,,Canis lupus familiaris,BAO_0000218,948.0,CHEMBL618495,,,A
2517,Intermediate,,1,,9615.0,6620,1,50588,,In vivo,Kidney,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,,Canis lupus familiaris,BAO_0000218,2113.0,CHEMBL618496,,,A
2517,Intermediate,,1,,9615.0,6621,1,50588,,In vivo,Liver,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL618497,,,A
2517,Intermediate,,1,,9615.0,6622,1,50588,,In vivo,Lung,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,,Canis lupus familiaris,BAO_0000218,2048.0,CHEMBL618498,,,A
2517,Intermediate,,1,,9615.0,6623,1,50588,,In vivo,Spleen,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,N,,Canis lupus familiaris,BAO_0000218,2106.0,CHEMBL618499,,,A
3639,Intermediate,,1,,9615.0,6624,1,50588,,,,LogP in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876736,,,A
6227,Intermediate,,1,,9615.0,6625,1,50588,,,,Partition coefficient (logP),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618500,,,A
6227,Intermediate,,1,,9615.0,6626,1,50588,,,,Partition coefficient in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL857831,,,A
17764,Intermediate,,1,,9615.0,6627,1,50588,,In vivo,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618501,,,A
4809,Intermediate,,1,,9615.0,6628,1,50588,,In vivo,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618502,,,A
5600,Intermediate,,1,,9615.0,6629,1,50588,,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618503,,,A
14294,Intermediate,,1,,9615.0,6630,1,50588,,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618504,,,A
14294,Intermediate,,1,,9615.0,6631,1,50588,,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618505,,,A
14294,Intermediate,,1,,9615.0,6632,1,50588,,,,Metabolism of compound in dog S9 microsomes; Trace,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618506,,,A
6251,Intermediate,,1,,9615.0,6633,1,50588,,,Liver,In vitro metabolic potential in dog liver microsomes,,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL618507,,,A
3748,Intermediate,,1,,9615.0,6634,1,50588,,In vivo,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876737,,,A
2713,Intermediate,,1,,9615.0,6635,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618508,,,A
6512,Intermediate,,1,,9615.0,6636,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618509,,,A
6679,Intermediate,,1,,9615.0,6637,1,50588,,In vivo,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618510,,,A
3749,Intermediate,,1,,9615.0,6638,1,50588,,In vivo,,The compound was tested for bioavailability in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618511,,,A
3749,Intermediate,,1,,9615.0,6639,1,50588,,In vivo,,The compound was tested for oral bioavailability in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618512,,,A
6742,Intermediate,,1,,9615.0,6640,1,50588,,In vivo,,Oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618513,,,A
6227,Intermediate,,1,,9615.0,6641,1,50588,,,,Compound was tested for percent protein binding (PB) in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618514,,,A
6874,Intermediate,,1,,9615.0,6642,1,50588,,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620052,,,A
2877,Intermediate,,1,,9615.0,6643,1,50588,,In vivo,Plasma,Compound was evaluated for plasma clearance.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620053,,,A
12500,Intermediate,,1,,9615.0,6644,1,50588,,In vivo,Plasma,The compound was tested for plasma clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620054,,,A
12500,Intermediate,,1,,9615.0,6645,1,50588,,In vivo,Plasma,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620055,,,A
4709,Intermediate,,1,,9615.0,6646,1,50588,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620056,,,A
5542,Intermediate,,1,,9615.0,6647,1,50588,,,Liver,In vitro relative rate of metabolism was determined in dog liver microsomes,,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL620057,,,A
17594,Intermediate,,1,,9615.0,6648,1,50588,,In vivo,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618939,,,A
2652,Intermediate,,1,,9615.0,6649,1,50588,,In vivo,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618940,,,A
17764,Intermediate,,1,,9615.0,6650,1,50588,,In vivo,,Half life after intravenous administration in dogs at 1.2 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618941,,,A
6599,Intermediate,,1,,10090.0,6651,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL624473,,,A
6599,Intermediate,,1,,10090.0,6652,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL624474,,,A
6599,Intermediate,,1,,10090.0,6653,1,50594,CCRF S-180,,Lung,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,2048.0,CHEMBL624475,,,A
6599,Intermediate,,1,,10090.0,6654,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL624476,,,A
6599,Intermediate,,1,,10090.0,6655,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL623478,,,A
6599,Intermediate,,1,,10090.0,6656,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL623479,,,A
6599,Intermediate,,1,,10090.0,6657,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL623480,,,A
6599,Intermediate,,1,,10090.0,6658,1,50594,CCRF S-180,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,N,42.0,Mus musculus,BAO_0000218,,CHEMBL623481,,,A
17641,Intermediate,,1,,10090.0,6659,1,50594,,,Brain,C2 in brain of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL623482,,,A
17641,Intermediate,,1,,10090.0,6660,1,50594,,,Kidney,C2 in kidney of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623483,,,A
17641,Intermediate,,1,,10090.0,6661,1,50594,,,Liver,C2 in liver of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623484,,,A
17641,Intermediate,,1,,10090.0,6662,1,50594,,,Lung,C2 in lungs of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623485,,,A
17641,Intermediate,,1,,10090.0,6663,1,50594,,,Spleen,C2 in spleen of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL623486,,,A
17852,Intermediate,,1,,10090.0,6664,1,50594,,In vivo,,Plasma clearance in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623487,,,A
17764,Intermediate,,1,,10090.0,6665,1,50594,,In vivo,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623488,,,A
17837,Intermediate,,1,,10090.0,6666,1,50594,,In vivo,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623489,,,A
2675,Intermediate,,1,,10090.0,6667,1,50594,,In vivo,,Clearance was evaluated in mice after intravenous administration,,N,,Mus musculus,BAO_0000218,,CHEMBL875157,,,A
2675,Intermediate,,1,,10090.0,6668,1,50594,,In vivo,,Clearance was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL623490,,,A
4239,Intermediate,,1,,10090.0,6669,1,50594,,In vivo,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623491,,,A
17753,Intermediate,,1,,10090.0,6670,1,50594,,In vivo,,Plasma clearance of compound was determined at 40 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623492,,,A
17753,Intermediate,,1,,10090.0,6671,1,50594,,In vivo,,Plasma clearance of at 24 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623493,,,A
17753,Intermediate,,1,,10090.0,6672,1,50594,,In vivo,,Plasma clearance at 24 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623494,,,A
17753,Intermediate,,1,,10090.0,6673,1,50594,,In vivo,,Plasma clearance at 5 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623495,,,A
5727,Intermediate,,1,,10090.0,6674,1,50594,,In vivo,,Plasma clearance in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623496,,,A
2862,Intermediate,,1,,10090.0,6675,1,50594,,In vivo,,Plasma clearance value upon iv administration in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623497,,,A
5980,Intermediate,,1,,10090.0,6676,1,50594,,In vivo,Plasma,Total plasma clearance in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623498,,,A
17592,Intermediate,,1,,10090.0,6677,1,50594,,In vivo,,Clearance in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623499,,,A
17718,Intermediate,,1,,10090.0,6678,1,50594,,In vivo,,Clearance value was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL623500,,,A
16597,Intermediate,,1,,10090.0,6679,1,50594,,In vivo,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL623501,,,A
17384,Intermediate,,1,,,6680,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL875158,,,P
6062,Intermediate,,1,,10090.0,6681,1,50594,,In vivo,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623502,,,A
17734,Intermediate,,1,,10090.0,6682,1,50594,,In vivo,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623503,,,A
6348,Intermediate,,1,,10090.0,6683,1,50594,,In vivo,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,,Mus musculus,BAO_0000218,,CHEMBL623504,,,A
5969,Intermediate,,1,,10090.0,6684,1,50594,,In vivo,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623505,,,A
5969,Intermediate,,1,,10090.0,6685,1,50594,,In vivo,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL623506,,,A
5969,Intermediate,,1,,10090.0,6686,1,50594,,In vivo,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL623507,,,A
16597,Intermediate,,1,,10090.0,6687,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,N,,Mus musculus,BAO_0000218,,CHEMBL623508,,,A
5781,Intermediate,,1,,10090.0,6688,1,50594,,In vivo,,Cmax after oral administration at 30 mg/kg in ICR mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623509,,,A
17764,Intermediate,,1,,10090.0,6689,1,50594,,In vivo,,Cmax after peroral administration in mice at 2.4 uM/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL875159,,,A
17641,Intermediate,,1,,10090.0,6690,1,50594,,In vivo,Brain,Cmax in brain of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL623510,,,A
17641,Intermediate,,1,,10090.0,6691,1,50594,,In vivo,Kidney,Cmax in kidney of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL623511,,,A
17641,Intermediate,,1,,10090.0,6692,1,50594,,In vivo,Liver,Cmax in liver of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623512,,,A
17641,Intermediate,,1,,10090.0,6693,1,50594,,In vivo,Lung,Cmax in lungs of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623513,,,A
17764,Intermediate,,1,,10090.0,6694,1,50594,,In vivo,,Cmax in mice at 18 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL623514,,,F
17764,Intermediate,,1,,10090.0,6695,1,50594,,In vivo,,Cmax in mice at 23 uM/kg i.v. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL622609,,,F
17764,Intermediate,,1,,10090.0,6696,1,50594,,In vivo,,Cmax in mice at 24 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL622610,,,F
17764,Intermediate,,1,,10090.0,6697,1,50594,,In vivo,,Cmax in mice at 25 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL621823,,,F
17764,Intermediate,,1,,10090.0,6698,1,50594,,In vivo,,Cmax in mice at 26 uM/kg i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL621824,,,F
17641,Intermediate,,1,,10090.0,6699,1,50594,,In vivo,Spleen,Cmax in spleen of mice at the oral dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL621825,,,A
16597,Intermediate,,1,,10090.0,6700,1,50594,,In vivo,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL621826,,,A
16597,Intermediate,,1,,10090.0,6701,1,50594,,In vivo,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL621827,,,A
5727,Intermediate,,1,,10090.0,6702,1,50594,,In vivo,,Cmax value was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL621828,,,A
5951,Intermediate,,1,,10090.0,6703,1,50594,,In vivo,,Cmax value in IRC mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621829,,,A
5506,Intermediate,,1,,10090.0,6704,1,50594,,In vivo,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621830,,,A
5506,Intermediate,,1,,10090.0,6705,1,50594,,In vivo,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621831,,,A
14239,Intermediate,,1,,10090.0,6706,1,50594,,In vivo,Plasma,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL621832,,,A
4890,Intermediate,,1,,10090.0,6707,1,50594,,In vivo,Plasma,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL624579,,,A
429,Intermediate,,1,,10090.0,6708,1,50594,,In vivo,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL624580,,,A
10986,Intermediate,,1,,6277.0,6709,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL624581,,,F
10986,Intermediate,,1,,6277.0,6710,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL624582,,,F
10986,Intermediate,,1,,6277.0,6711,1,50535,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,N,,Acanthocheilonema viteae,BAO_0000218,,CHEMBL624583,,,F
13227,Intermediate,,1,,9606.0,6712,1,80018,A-375,,,Inhibitory activity against human tumor cell line A0375 melanoma.,,N,455.0,Homo sapiens,BAO_0000219,,CHEMBL624584,,,F
4481,Expert,,1,,10116.0,6713,9,12512,,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,D,,Rattus norvegicus,BAO_0000249,,CHEMBL624585,,Brain membranes,B
16931,Expert,,1,,9606.0,6714,9,114,,,,Forskolin-induced cAMP production at human A1 adenosine receptor,,D,,Homo sapiens,BAO_0000019,,CHEMBL875165,,,F
3850,Autocuration,,1,,,6715,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,H,449.0,,BAO_0000219,,CHEMBL619490,,,F
3850,Autocuration,,1,,,6716,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,H,449.0,,BAO_0000219,,CHEMBL619491,,,F
3850,Expert,,1,,,6717,8,114,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,H,449.0,,BAO_0000219,,CHEMBL619492,,,F
3850,Expert,,1,,,6718,8,114,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,H,449.0,,BAO_0000219,,CHEMBL619493,,,F
3850,Autocuration,,1,,,6719,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,H,449.0,,BAO_0000219,,CHEMBL619494,,,F
3850,Autocuration,,1,,,6720,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,H,449.0,,BAO_0000219,,CHEMBL619495,,,F
3850,Autocuration,,1,,,6721,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,H,449.0,,BAO_0000219,,CHEMBL619496,,,F
3850,Expert,,1,,9606.0,6722,9,114,CHO,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,D,449.0,Homo sapiens,BAO_0000219,,CHEMBL619497,,,F
3850,Autocuration,,1,,,6723,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,H,449.0,,BAO_0000219,,CHEMBL619498,,,F
3850,Autocuration,,1,,,6724,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,H,449.0,,BAO_0000219,,CHEMBL619499,,,F
3850,Expert,,1,,,6725,8,114,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,H,449.0,,BAO_0000219,,CHEMBL619500,,,F
3850,Autocuration,,1,,,6726,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,H,449.0,,BAO_0000219,,CHEMBL619501,,,F
3850,Expert,,1,,,6727,8,114,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,H,449.0,,BAO_0000219,,CHEMBL619502,,,F
3850,Autocuration,,1,,,6728,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,H,449.0,,BAO_0000219,,CHEMBL619503,,,F
3850,Autocuration,,1,,,6729,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,H,449.0,,BAO_0000219,,CHEMBL619504,,,F
3850,Autocuration,,1,,,6730,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,H,449.0,,BAO_0000219,,CHEMBL621298,,,F
3850,Expert,,1,,,6731,8,114,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,H,449.0,,BAO_0000219,,CHEMBL621299,,,F
3850,Autocuration,,1,,,6732,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,H,449.0,,BAO_0000219,,CHEMBL621300,,,F
3850,Autocuration,,1,,,6733,8,114,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,H,449.0,,BAO_0000219,,CHEMBL621301,,,F
3850,Expert,,1,,,6734,8,114,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,H,449.0,,BAO_0000219,,CHEMBL621302,,,F
12680,Intermediate,,1,,9986.0,6735,1,80013,A10,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,N,164.0,Oryctolagus cuniculus,BAO_0000219,,CHEMBL621303,,,F
1313,Autocuration,,1,,10116.0,6736,0,22226,A10,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,U,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL621304,,,F
1313,Autocuration,,1,,10116.0,6737,0,22226,A10,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,U,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL621305,,,F
17567,Intermediate,,1,,10116.0,6738,1,80013,A10,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL621306,,,F
17567,Intermediate,,1,,10116.0,6739,1,80013,A10,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL618444,,,F
11819,Intermediate,,1,,10116.0,6740,1,80013,A10,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL618445,,,F
13436,Intermediate,,1,,10029.0,6741,1,80089,CHO-AA8,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618446,,,F
12687,Intermediate,,1,,10029.0,6742,1,80089,CHO-AA8,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618447,,,F
12651,Intermediate,,1,,10029.0,6743,1,80089,CHO-AA8,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618448,,,F
13300,Intermediate,,1,,10029.0,6744,1,80089,CHO-AA8,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618449,,,F
15296,Intermediate,,1,,10029.0,6745,1,80089,CHO-AA8,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618637,,,F
15328,Intermediate,,1,,10029.0,6746,1,80089,CHO-AA8,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618638,,,F
13302,Intermediate,,1,,10029.0,6747,1,80089,CHO-AA8,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618639,,,F
14367,Expert,,1,,10029.0,6748,1,80089,CHO-AA8,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618640,,,F
17002,Expert,,1,,10029.0,6749,1,80089,CHO-AA8,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618641,,,F
13436,Intermediate,,1,,10029.0,6750,1,80089,CHO-AA8,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618642,,,F
13435,Intermediate,,1,,10029.0,6751,1,80089,CHO-AA8,,,Inhibitory activity against aerobic growth of AA8 cells.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618643,,,F
10503,Intermediate,,1,,10029.0,6752,1,80089,CHO-AA8,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL884013,,,A
10503,Expert,,1,,10029.0,6753,1,80089,CHO-AA8,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622723,,,F
10503,Intermediate,,1,,10029.0,6754,1,80089,CHO-AA8,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622724,,,F
15090,Expert,,1,,10029.0,6755,1,80089,CHO-AA8,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622725,,,F
10368,Expert,,1,,10029.0,6756,1,80089,CHO-AA8,,,Cytotoxicity against AA8 cell line,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622726,,,F
12651,Intermediate,,1,,10029.0,6757,1,80089,CHO-AA8,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622727,,,F
12687,Intermediate,,1,,10029.0,6758,1,80089,CHO-AA8,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622728,,,A
12687,Intermediate,,1,,10029.0,6759,1,80089,CHO-AA8,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622729,,,F
12687,Intermediate,,1,,10029.0,6760,1,80089,CHO-AA8,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622730,,,A
1890,Intermediate,,1,,10029.0,6761,1,80089,CHO-AA8,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622731,,,F
10747,Intermediate,,1,,10029.0,6762,1,80089,CHO-AA8,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622732,,,F
10747,Intermediate,,1,,10029.0,6763,1,80089,CHO-AA8,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622733,,,F
11616,Autocuration,,1,,10029.0,6764,0,22224,,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,U,,Cricetulus griseus,BAO_0000218,,CHEMBL622734,,,F
11616,Expert,,1,,10029.0,6765,1,80089,CHO-AA8,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL622735,,,F
3471,Autocuration,,1,,10029.0,6766,0,22224,CHO-AA8,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618746,,,F
3471,Autocuration,,1,,10029.0,6767,0,22224,CHO-AA8,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618747,,,F
3471,Autocuration,,1,,10029.0,6768,0,22224,CHO-AA8,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL620540,,,F
3471,Autocuration,,1,,10029.0,6769,0,22224,CHO-AA8,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL620541,,,F
3471,Autocuration,,1,,10029.0,6770,0,22224,CHO-AA8,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL620542,,,F
3471,Autocuration,,1,,10029.0,6771,0,22224,CHO-AA8,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL620543,,,F
3471,Autocuration,,1,,10029.0,6772,0,22224,CHO-AA8,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618832,,,F
11616,Expert,,1,,10029.0,6773,1,80089,CHO-AA8,,,Concentration required to reduce AA8 cell survival by 10%,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618833,,,F
2656,Autocuration,,1,,10029.0,6774,0,22224,CHO-AA8,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618834,,,F
10518,Autocuration,,1,,10029.0,6775,0,22224,CHO-AA8,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618835,,,F
10518,Autocuration,,1,,10029.0,6776,0,22224,CHO-AA8,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618836,,,F
10518,Autocuration,,1,,10029.0,6777,0,22224,CHO-AA8,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618837,,,F
10518,Autocuration,,1,,10029.0,6778,0,22224,CHO-AA8,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618838,,,F
16156,Autocuration,,1,,10029.0,6779,0,22224,CHO-AA8,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618839,,,F
2656,Autocuration,,1,,10029.0,6780,0,22224,CHO-AA8,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618840,,,F
11005,Autocuration,,1,,10029.0,6781,0,22224,,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,U,,Cricetulus griseus,BAO_0000019,,CHEMBL618841,,,F
11942,Autocuration,,1,,10029.0,6782,0,22224,CHO-AA8,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618842,,,F
2128,Autocuration,,1,,10029.0,6783,0,22224,CHO-AA8,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL618843,,,F
16907,Intermediate,,1,,9615.0,6784,1,50588,,In vivo,,Half life period after 15 mg/kg iv dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618844,,,A
16907,Intermediate,,1,,9615.0,6785,1,50588,,In vivo,,Half life period after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618845,,,A
9579,Intermediate,,1,,9615.0,6786,1,50588,,In vivo,,Half life was measured after oral 2b administration (tested in 6 dogs),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618846,,,A
9579,Intermediate,,1,,9615.0,6787,1,50588,,In vivo,,Half life was measured in dog after oral 17b administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618847,,,A
9579,Intermediate,,1,,9615.0,6788,1,50588,,In vivo,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618848,,,A
9579,Intermediate,,1,,9615.0,6789,1,50588,,In vivo,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618849,,,A
16907,Intermediate,,1,,9615.0,6790,1,50588,,In vivo,,Tmax value after 15 mg/kg iv dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618850,,,A
16907,Intermediate,,1,,9615.0,6791,1,50588,,In vivo,,Tmax value after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618851,,,A
3184,Intermediate,,1,,9615.0,6792,1,50588,,In vivo,,Compound was evaluated for its half life when administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873815,,,A
5017,Intermediate,,1,,9615.0,6793,1,50588,,In vivo,Plasma,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618852,,,A
6821,Intermediate,,1,,9615.0,6794,1,50588,,,,Elimination Half-life of compound was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618853,,,A
17839,Intermediate,,1,,9615.0,6795,1,50588,,In vivo,,Half life of compound in dog following oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618854,,,A
17267,Intermediate,,1,,9615.0,6796,1,50588,,,,Half life of compound was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618855,,,A
4727,Intermediate,,1,,9615.0,6797,1,50588,,,Blood,Half life of compound was determined in dog blood,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL618856,,,A
5238,Intermediate,,1,,9615.0,6798,1,50588,,In vivo,,Half life after oral and iv dosing in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875827,,,A
4942,Intermediate,,1,,9615.0,6799,1,50588,,,,Half life in dogs in hours,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618857,,,A
6505,Intermediate,,1,,9615.0,6800,1,50588,,In vivo,,Half life on i.v. administration of 2 mg/kg was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618858,,,A
5130,Intermediate,,1,,9615.0,6801,1,50588,,In vivo,,t1/2 in dog after oral dose (1 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618859,,,A
1475,Intermediate,,1,,9615.0,6802,1,50588,,,,Half life was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618860,,,A
17804,Intermediate,,1,,9615.0,6803,1,50588,,In vivo,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618861,,,A
17804,Intermediate,,1,,9615.0,6804,1,50588,,In vivo,,Half life period of compound was determined after peroral administration at 2 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622539,,,A
6084,Intermediate,,1,,9615.0,6805,1,50588,,In vivo,,Half life period (10 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622540,,,A
6084,Intermediate,,1,,9615.0,6806,1,50588,,In vivo,,Half life period (10 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873803,,,A
5542,Intermediate,,1,,9615.0,6807,1,50588,,In vivo,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873804,,,A
5542,Intermediate,,1,,9615.0,6808,1,50588,,In vivo,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624311,,,A
6084,Intermediate,,1,,9615.0,6809,1,50588,,,,Half life period in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624312,,,A
6241,Intermediate,,1,,9615.0,6810,1,50588,,In vivo,,Half life period in dogs after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624313,,,A
1916,Intermediate,,1,,9615.0,6811,1,50588,,In vivo,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624314,,,A
6621,Intermediate,,1,,9615.0,6812,1,50588,,,,Half-life of compound was determined in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624315,,,A
1696,Intermediate,,1,,9615.0,6813,1,50588,,,Plasma,Half-life in dog plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624316,,,A
17800,Intermediate,,1,,9615.0,6814,1,50588,,,,Half-life in mongrel dogs was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624317,,,A
17657,Intermediate,,1,,9615.0,6815,1,50588,,In vivo,,Half-life in dog upon oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624318,,,A
17657,Intermediate,,1,,9615.0,6816,1,50588,,In vivo,,Half-life in dog upon oral administration; Unable to calculate,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624319,,,A
4239,Intermediate,,1,,9615.0,6817,1,50588,,,,Half-life was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624496,,,A
5985,Intermediate,,1,,9615.0,6818,1,50588,,,,Half-life was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624497,,,A
9932,Intermediate,,1,,9615.0,6819,1,50588,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624498,,,A
5199,Intermediate,,1,,9615.0,6820,1,50588,,In vivo,,Oral half life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624499,,,A
5199,Intermediate,,1,,9615.0,6821,1,50588,,In vivo,Plasma,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624500,,,A
1475,Intermediate,,1,,9615.0,6822,1,50588,,,Plasma,Plasma half life was evaluated,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL624501,,,A
1475,Intermediate,,1,,9615.0,6823,1,50588,,,Plasma,Plasma half life was evaluated in Dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623666,,,A
1475,Intermediate,,1,,9615.0,6824,1,50588,,,Plasma,Plasma half life was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623667,,,A
6316,Intermediate,,1,,9615.0,6825,1,50588,,In vivo,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623668,,,A
4883,Intermediate,,1,,9615.0,6826,1,50588,,,,Tested for the half life value in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623669,,,A
4727,Intermediate,,1,,9615.0,6827,1,50588,,In vivo,,Maximum time at the dose of 2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623670,,,A
1916,Intermediate,,1,,9615.0,6828,1,50588,,In vivo,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623671,,,A
1337,Intermediate,,1,,9615.0,6829,1,50588,,In vivo,Blood,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL875945,,,A
1337,Intermediate,,1,,9615.0,6830,1,50588,,In vivo,Blood,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL623672,,,A
6265,Intermediate,,1,,9615.0,6831,1,50588,,In vivo,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623673,,,A
4809,Intermediate,,1,,9615.0,6832,1,50588,,In vivo,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623674,,,A
5983,Intermediate,,1,,9615.0,6833,1,50588,,In vivo,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623675,,,A
5313,Intermediate,,1,,9615.0,6834,1,50588,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL872526,,,A
5313,Intermediate,,1,,9615.0,6835,1,50588,,In vivo,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623676,,,A
17650,Intermediate,,1,,9615.0,6836,1,50588,,In vivo,Plasma,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623677,,,A
5199,Intermediate,,1,,9615.0,6837,1,50588,,In vivo,Plasma,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623678,,,A
933,Intermediate,,1,,9615.0,6838,1,50588,,,Plasma,Time taken for maximum plasma concentration in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623679,,,A
16367,Intermediate,,1,,9615.0,6839,1,50588,,In vivo,,Time to reach Cmax after oral administration to dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623680,,,A
6348,Intermediate,,1,,9615.0,6840,1,50588,,In vivo,Plasma,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623681,,,A
6316,Intermediate,,1,,9615.0,6841,1,50588,,In vivo,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623682,,,A
6215,Intermediate,,1,,9615.0,6842,1,50588,,In vivo,,Tmax after peroral administration (1 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623683,,,A
3598,Expert,,1,,9615.0,6843,1,50588,,In vivo,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623684,,,A
4527,Intermediate,,1,,9615.0,6844,1,50588,,In vivo,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622745,,,A
17764,Intermediate,,1,,9615.0,6845,1,50588,,In vivo,,Tmax after peroral administration in dogs at 2.4 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622746,,,A
5969,Intermediate,,1,,10090.0,6846,1,50594,,In vivo,,In vivo Cmax in mice at dose of 100 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622747,,,A
5969,Intermediate,,1,,10090.0,6847,1,50594,,In vivo,,In vivo Cmax in mice at dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622748,,,A
4573,Intermediate,,1,,10090.0,6848,1,50594,,In vivo,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622749,,,A
3277,Intermediate,,1,,10090.0,6849,1,50594,,In vivo,Plasma,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622750,,,A
17734,Intermediate,,1,,10090.0,6850,1,50594,,In vivo,Plasma,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623411,,,A
3132,Intermediate,,1,,10090.0,6851,1,50594,,In vivo,Plasma,Maximum concentration obtained in mouse plasma was determined,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL875946,,,A
3132,Intermediate,,1,,10090.0,6852,1,50594,,In vivo,Plasma,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623412,,,A
6348,Intermediate,,1,,10090.0,6853,1,50594,,In vivo,Plasma,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623413,,,A
17729,Intermediate,,1,,10090.0,6854,1,50594,,In vivo,Plasma,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623414,,,A
17729,Intermediate,,1,,10090.0,6855,1,50594,,In vivo,Plasma,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623415,,,A
17729,Intermediate,,1,,10090.0,6856,1,50594,,In vivo,Plasma,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623416,,,A
17728,Intermediate,,1,,10090.0,6857,1,50594,,In vivo,Plasma,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623417,,,A
17728,Intermediate,,1,,10090.0,6858,1,50594,,In vivo,Plasma,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623418,,,A
17728,Intermediate,,1,,10090.0,6859,1,50594,,In vivo,Plasma,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623419,,,A
4066,Intermediate,,1,,10090.0,6860,1,50594,,In vivo,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622816,,,A
6178,Intermediate,,1,,10090.0,6861,1,50594,,In vivo,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623313,,,A
6178,Intermediate,,1,,10090.0,6862,1,50594,,In vivo,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623314,,,A
3760,Intermediate,,1,,10090.0,6863,1,50594,,In vivo,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL876788,,,A
3760,Intermediate,,1,,10090.0,6864,1,50594,,In vivo,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623315,,,A
3760,Intermediate,,1,,10090.0,6865,1,50594,,In vivo,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623316,,,A
3760,Intermediate,,1,,10090.0,6866,1,50594,,In vivo,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623317,,,A
5961,Intermediate,,1,,10090.0,6868,1,50594,,In vivo,,Cmax in male mice after 2 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,,CHEMBL623319,,,A
6137,Intermediate,,1,,10090.0,6869,1,50594,,In vivo,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,N,,Mus musculus,BAO_0000218,,CHEMBL623320,,,A
3802,Intermediate,,1,,10090.0,6870,1,50594,,In vivo,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623321,,,A
3535,Intermediate,,1,,10090.0,6871,1,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL623322,,,A
3535,Intermediate,,1,,10090.0,6872,1,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL623323,,,A
3535,Intermediate,,1,,10090.0,6873,1,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL623324,,,A
3535,Intermediate,,1,,10090.0,6874,1,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL623325,,,A
3535,Intermediate,,1,,10090.0,6875,1,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL623326,,,A
3535,Intermediate,,1,,10090.0,6876,1,50594,,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL623327,,,A
2862,Intermediate,,1,,10090.0,6877,1,50594,,,Plasma,Maximum concentration in plasma upon oral administration in mouse,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623328,,,A
2675,Intermediate,,1,,10090.0,6878,1,50594,,,Plasma,Maximum plasma concentration was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623329,,,A
2675,Intermediate,,1,,10090.0,6879,1,50594,,In vivo,Plasma,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623330,,,A
5399,Intermediate,,1,,10090.0,6880,1,50594,,,,Dose at which the compound induced fecal excretion in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL876789,,,A
11819,Expert,,1,,10116.0,6893,1,80013,A10,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL623333,,,F
11819,Expert,,1,,10116.0,6894,1,80013,A10,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL623334,,,F
11819,Expert,,1,,10116.0,6895,1,80013,A10,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL627536,,,F
11819,Expert,,1,,10116.0,6896,1,80013,A10,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL627537,,,F
16361,Intermediate,,1,,10116.0,6897,1,80013,A10,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,N,164.0,Rattus norvegicus,BAO_0000219,,CHEMBL627538,,,F
2288,Intermediate,,1,,9606.0,6898,1,80655,A121,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL884106,,,F
10404,Intermediate,,1,,9606.0,6899,1,80655,A121,,,Anticancer activity against human ovarian carcinoma A121 cells,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625294,,,F
14790,Intermediate,,1,,9606.0,6900,1,80655,A121,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625295,,,F
14790,Intermediate,,1,,9606.0,6901,1,80655,A121,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625296,,,F
14253,Expert,,1,,9606.0,6902,1,80655,A121,,,Growth inhibition of human ovarian carcinoma (A121) cell line,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625297,,,F
13617,Expert,,1,,9606.0,6903,1,80655,A121,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625298,,,F
1003,Intermediate,,1,,9606.0,6904,1,80655,A121,,,Cytotoxicity against human A121 ovarian cells,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625960,,,F
830,Intermediate,,1,,9606.0,6905,1,80655,A121,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625961,,,F
12307,Intermediate,,1,,9606.0,6906,1,80655,A121,,,In vitro cytotoxicity against human ovarian carcinoma A21,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL625962,,,F
14254,Intermediate,,1,,9606.0,6907,1,80655,A121,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL624717,,,F
13370,Intermediate,,1,,9606.0,6908,1,80655,A121,,,Inhibitory activity of compound against human A121 ovarian cell line.,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL624718,,,F
14790,Intermediate,,1,,9606.0,6909,1,80655,A121,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL624719,,,F
3614,Intermediate,,1,,9606.0,6910,1,80655,A121,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,N,393.0,Homo sapiens,BAO_0000219,,CHEMBL624720,,,F
2664,Intermediate,,1,,9606.0,6911,1,80012,A 172,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL624721,,,F
2037,Expert,,1,,9606.0,6912,1,80012,A 172,,,In vitro cytotoxicity against A172 human tumor cell lines.,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL624722,,,F
14539,Intermediate,,1,,9606.0,6913,1,80012,A 172,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL877597,,,F
2836,Intermediate,,1,,9606.0,6914,1,80012,A 172,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL624723,,,F
10708,Intermediate,,1,,9606.0,6915,1,80012,A 172,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,N,622.0,Homo sapiens,BAO_0000219,,CHEMBL624724,,,F
8975,Autocuration,,1,,9615.0,6916,4,104729,,,,Association constant against A2 adenosine receptor,,H,,Canis lupus familiaris,BAO_0000224,,CHEMBL624725,,,B
7645,Intermediate,,1,,,6917,1,80656,A2,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,N,1085.0,fish,BAO_0000219,,CHEMBL624726,,,F
11377,Autocuration,,1,,10116.0,6918,5,104713,,,,Ratio of Ki for adenosine A2 and A1 receptor binding,,D,,Rattus norvegicus,BAO_0000224,,CHEMBL857535,,,B
13528,Expert,,1,,9606.0,6919,1,80014,A204,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,N,623.0,Homo sapiens,BAO_0000219,,CHEMBL624727,,,F
10160,Expert,,1,,9606.0,6920,1,80014,A204,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,N,623.0,Homo sapiens,BAO_0000219,,CHEMBL624728,,,F
15144,Intermediate,,1,,9606.0,6921,1,80015,A2058,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,N,404.0,Homo sapiens,BAO_0000219,,CHEMBL624729,,,F
13160,Intermediate,,1,,9606.0,6922,1,80657,A253 cell line,,,Growth inhibition against Human squamous cell line(A 253),,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL624730,,,F
12898,Intermediate,,1,,9606.0,6923,1,80657,A253 cell line,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL624731,,,F
13069,Intermediate,,1,,9606.0,6924,1,80657,A253 cell line,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL624732,,,F
15984,Intermediate,,1,,9606.0,6925,1,80657,A253 cell line,,,Growth inhibition of A253 cell lines.,,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL883245,,,F
15564,Intermediate,,1,,9606.0,6926,1,80657,A253 cell line,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL624733,,,F
15564,Intermediate,,1,,9606.0,6927,1,80657,A253 cell line,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL624734,,,F
15564,Intermediate,,1,,9606.0,6928,1,80657,A253 cell line,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,N,973.0,Homo sapiens,BAO_0000219,,CHEMBL624735,,,F
4720,Intermediate,,1,,9606.0,6929,1,81034,A2780,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621780,,,F
16112,Intermediate,,1,,9606.0,6930,1,81034,A2780,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL877598,,,F
16597,Expert,,1,,9606.0,6931,1,81034,A2780,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621781,,,F
16378,Intermediate,,1,,9606.0,6932,1,81034,A2780,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621782,,,F
16085,Expert,,1,,9606.0,6933,1,81034,A2780,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621783,,,F
16317,Intermediate,,1,,9606.0,6934,1,81034,A2780,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621784,,,F
15748,Intermediate,,1,,9606.0,6935,1,81034,A2780,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621785,,,F
16597,Expert,,1,,9606.0,6936,1,81034,A2780,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621968,,,F
16597,Expert,,1,,9606.0,6937,1,81034,A2780,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621969,,,F
16597,Expert,,1,,9606.0,6938,1,81034,A2780,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621970,,,F
15608,Intermediate,,1,,9606.0,6939,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621971,,,F
15608,Intermediate,,1,,9606.0,6940,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621972,,,F
15608,Intermediate,,1,,9606.0,6941,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL884108,,,F
15296,Autocuration,,1,,10029.0,6942,0,22224,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,U,,Cricetulus griseus,BAO_0000019,,CHEMBL623826,,,F
10251,Autocuration,,1,,10029.0,6943,0,22224,CHO-AA8,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623827,,,A
10251,Autocuration,,1,,10029.0,6944,0,22224,CHO-AA8,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623828,,,F
10251,Autocuration,,1,,10029.0,6945,0,22224,CHO-AA8,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623829,,,F
10251,Autocuration,,1,,10029.0,6946,0,22224,CHO-AA8,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623830,,,F
11858,Autocuration,,1,,10029.0,6947,0,22224,,,,Growth inhibition against CHO-derived cell line AA8,,U,,Cricetulus griseus,BAO_0000019,,CHEMBL623831,,,F
11858,Autocuration,,1,,10029.0,6948,0,22224,CHO-AA8,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623832,,,F
11616,Expert,,1,,36483.0,6949,1,80089,CHO-AA8,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,N,185.0,hampster,BAO_0000219,,CHEMBL623833,,,F
11616,Expert,,1,,10029.0,6950,1,80089,CHO-AA8,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623834,,,F
10518,Autocuration,,1,,10029.0,6951,0,22224,CHO-AA8,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623835,,,F
11396,Autocuration,,1,,10029.0,6952,0,22224,CHO-AA8,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623836,,,F
10518,Autocuration,,1,,10029.0,6953,0,22224,CHO-AA8,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,U,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623837,,,F
11616,Expert,,1,,10029.0,6954,1,80089,CHO-AA8,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,N,185.0,Cricetulus griseus,BAO_0000219,,CHEMBL623838,,,F
14837,Autocuration,,1,,,6955,8,12675,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,H,,,BAO_0000019,,CHEMBL623839,,,F
14837,Autocuration,,1,,,6956,8,12675,,,,Number of binding sites (n) of isolated serum protein AAG,,H,,,BAO_0000019,,CHEMBL623840,,,F
16037,Intermediate,,1,,,6957,3,22222,,,,Association constant for binding to AATT duplex,,M,,,BAO_0000225,,CHEMBL623841,,,B
16597,Expert,,1,,9606.0,6958,1,100090,ABAE,,,Inhibition of ABAE human fibroblast cell proliferation,,N,416.0,Homo sapiens,BAO_0000219,,CHEMBL623842,,,F
8831,Intermediate,,1,,10090.0,6959,1,80668,AC755,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,N,1064.0,Mus musculus,BAO_0000218,,CHEMBL623843,,,F
13419,Expert,,1,,9986.0,6960,9,102444,,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,D,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL618669,,,F
13419,Expert,,1,,9986.0,6961,9,102444,,In vivo,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,D,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL618670,,,F
15778,Autocuration,,1,,,6962,8,69,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,H,,,BAO_0000357,,CHEMBL618671,,,B
15778,Autocuration,,1,,,6963,8,69,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,H,,,BAO_0000357,,CHEMBL618672,,,B
12988,Intermediate,,1,,9606.0,6964,1,80669,ACH-2 cell line,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,N,978.0,Homo sapiens,BAO_0000219,,CHEMBL618673,,,F
12988,Intermediate,,1,,9606.0,6965,1,80669,ACH-2 cell line,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,N,978.0,Homo sapiens,BAO_0000219,,CHEMBL618674,,,F
12988,Autocuration,,1,,11676.0,6966,0,22224,T cell line,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,U,998.0,Human immunodeficiency virus 1,BAO_0000219,,CHEMBL618675,,,F
12988,Autocuration,,1,,11676.0,6967,0,22224,T cell line,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,U,998.0,Human immunodeficiency virus 1,BAO_0000219,,CHEMBL618676,,,F
12988,Autocuration,,1,,11676.0,6968,0,22224,T cell line,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,U,998.0,Human immunodeficiency virus 1,BAO_0000219,,CHEMBL618677,,,F
11843,Intermediate,,1,,9606.0,6969,1,80025,ACHN,,,Inhibition of growth of renal cancer ACHN cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618678,,,F
16939,Intermediate,,1,,9606.0,6970,1,80025,ACHN,,,Inhibition of growth of ACHN renal cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618679,,,F
4782,Intermediate,,1,,9606.0,6971,1,80025,ACHN,,,Inhibitory concentration required against ACHN renal cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618680,,,F
6310,Expert,,1,,9606.0,6972,1,80025,ACHN,,,Concentration required to inhibit growth of human renal (ACHN) cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618681,,,F
6310,Intermediate,,1,,9606.0,6973,1,80025,ACHN,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618682,,,F
12858,Intermediate,,1,,9606.0,6974,1,80025,ACHN,,,Cytotoxic activity against ACHN Renal cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618683,,,F
17380,Intermediate,,1,,9606.0,6975,1,80025,ACHN,,,Cytotoxicity evaluation against ACHN renal cancer cells,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618684,,,F
5858,Intermediate,,1,,9606.0,6976,1,80025,ACHN,,,In vitro antitumor activity against human renal ACHN cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618685,,,F
3838,Intermediate,,1,,9606.0,6977,1,80025,ACHN,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL876499,,,F
3838,Intermediate,,1,,9606.0,6978,1,80025,ACHN,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618686,,,F
5406,Intermediate,,1,,9606.0,6979,1,80025,ACHN,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618687,,,F
4071,Intermediate,,1,,9606.0,6980,1,80025,ACHN,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618688,,,F
4071,Expert,,1,,9606.0,6981,1,80025,ACHN,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618689,,,F
4071,Intermediate,,1,,9606.0,6982,1,80025,ACHN,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618690,,,F
15002,Intermediate,,1,,9606.0,6983,1,80025,ACHN,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL618691,,,F
14769,Intermediate,,1,,9606.0,6984,1,80025,ACHN,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL619373,,,F
13958,Intermediate,,1,,9606.0,6985,1,80025,ACHN,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL884008,,,F
1665,Intermediate,,1,,9606.0,6986,1,80025,ACHN,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL619374,,,F
15354,Intermediate,,1,,9606.0,6987,1,80025,ACHN,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL619375,,,F
15354,Intermediate,,1,,9606.0,6988,1,80025,ACHN,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL619376,,,F
13978,Intermediate,,1,,9606.0,6989,1,80025,ACHN,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL619377,,,F
6798,Intermediate,,1,,9606.0,6990,1,80025,ACHN,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL619378,,,F
2959,Intermediate,,1,,9615.0,6991,1,50588,,In vivo,,Tmax value after administration of 4 mg/Kg oral dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL872527,,,A
9932,Intermediate,,1,,9615.0,6992,1,50588,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876500,,,A
5546,Intermediate,,1,,9615.0,6993,1,50588,,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619379,,,A
16907,Intermediate,,1,,9615.0,6994,1,50588,,In vivo,,Volume distribution after 15 mg/kg iv dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619538,,,A
16907,Intermediate,,1,,9615.0,6995,1,50588,,In vivo,,Volume distribution after 30 mg/kg po dose in Dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619539,,,A
4257,Intermediate,,1,,9615.0,6996,1,50588,,In vivo,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619540,,,A
4305,Intermediate,,1,,9615.0,6997,1,50588,,In vivo,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619541,,,A
5472,Intermediate,,1,,9615.0,6998,1,50588,,In vivo,,Volume of distribution was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619542,,,A
6062,Intermediate,,1,,9615.0,6999,1,50588,,In vivo,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619543,,,A
3598,Expert,,1,,9615.0,7000,1,50588,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619544,,,A
12500,Intermediate,,1,,9615.0,7001,1,50588,,In vivo,,The compound was tested for volume of distribution in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619545,,,A
12500,Intermediate,,1,,9615.0,7002,1,50588,,In vivo,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619546,,,A
6227,Intermediate,,1,,9615.0,7003,1,50588,,In vivo,,Vd (1 mg/kg) was determined in dog (in vivo),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619547,,,A
6227,Intermediate,,1,,9615.0,7004,1,50588,,In vivo,,Vd in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619548,,,A
4219,Intermediate,,1,,9615.0,7005,1,50588,,In vivo,,Volume distribution was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619549,,,A
1696,Intermediate,,1,,9615.0,7006,1,50588,,In vivo,,Volume of distribution in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619550,,,A
5542,Intermediate,,1,,9615.0,7007,1,50588,,In vivo,,Volume of distribution by as 4 fold increase by iv administration in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876501,,,A
5199,Intermediate,,1,,9615.0,7008,1,50588,,In vivo,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619551,,,A
6348,Intermediate,,1,,9615.0,7009,1,50588,,In vivo,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619552,,,A
4727,Intermediate,,1,,9615.0,7010,1,50588,,In vivo,,Volume distribution at the dose of 2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619553,,,A
16367,Intermediate,,1,,9615.0,7011,1,50588,,In vivo,,Steady state volume of distribution was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618722,,,A
2652,Intermediate,,1,,9615.0,7012,1,50588,,In vivo,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618723,,,A
16452,Intermediate,,1,,9615.0,7013,1,50588,,In vivo,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618724,,,A
16452,Intermediate,,1,,9615.0,7014,1,50588,,In vivo,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618725,,,A
16452,Intermediate,,1,,9615.0,7015,1,50588,,In vivo,,Bioavailability in dog (dose 1 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618726,,,A
5334,Intermediate,,1,,9615.0,7016,1,50588,,In vivo,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618727,,,A
4239,Intermediate,,1,,9615.0,7017,1,50588,,In vivo,,Pharmacokinetic property (vdss) was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624233,,,A
4709,Intermediate,,1,,9615.0,7018,1,50588,,In vivo,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624234,,,A
5600,Intermediate,,1,,9615.0,7019,1,50588,,In vivo,,Vdss was determined after iv 0.1 mg/kg administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624235,,,A
6057,Intermediate,,1,,9615.0,7020,1,50588,,In vivo,,Volume displacement was calculated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624236,,,A
5654,Intermediate,,1,,9615.0,7021,1,50588,,In vivo,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624237,,,A
5505,Intermediate,,1,,9615.0,7022,1,50588,,In vivo,,Volume distribution constant was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624238,,,A
4527,Intermediate,,1,,9615.0,7023,1,50588,,In vivo,,Volume distribution at a dose of 1 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624239,,,A
4521,Intermediate,,1,,9615.0,7024,1,50588,,In vivo,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875829,,,A
4521,Intermediate,,1,,9615.0,7025,1,50588,,In vivo,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624240,,,A
15660,Intermediate,,1,,9615.0,7026,1,50588,,In vivo,,Volume distribution (Vdss) was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624241,,,A
15660,Intermediate,,1,,9615.0,7027,1,50588,,In vivo,,Volume distribution (Vdss) was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624242,,,A
6679,Intermediate,,1,,9615.0,7028,1,50588,,In vivo,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624243,,,A
5145,Intermediate,,1,,9615.0,7029,1,50588,,In vivo,,Volume of distribution in steady state was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624244,,,A
6821,Intermediate,,1,,9615.0,7030,1,50588,,In vivo,,Volume of distribution of compound was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624245,,,A
4137,Intermediate,,1,,9615.0,7031,1,50588,,In vivo,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624246,,,A
5334,Intermediate,,1,,9615.0,7032,1,50588,,In vivo,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624247,,,A
15660,Intermediate,,1,,9615.0,7033,1,50588,,In vivo,,Volume of distribution (Vdss) was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624248,,,A
6642,Intermediate,,1,,9615.0,7034,1,50588,,In vivo,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624249,,,A
6641,Intermediate,,1,,9615.0,7035,1,50588,,In vivo,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624250,,,A
6642,Intermediate,,1,,9615.0,7036,1,50588,,In vivo,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624251,,,A
11659,Intermediate,,1,,9615.0,7037,1,50588,,,,Maximum rate of depolarization of the upstroke of the action potential,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624252,,,A
6448,Intermediate,,1,,9615.0,7038,1,50588,,In vivo,,Steady state volume distribution in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624253,,,A
5474,Intermediate,,1,,9615.0,7039,1,50588,,In vivo,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624950,,,A
1466,Intermediate,,1,,9615.0,7040,1,50588,,In vivo,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624951,,,A
6535,Intermediate,,1,,9615.0,7041,1,50588,,In vivo,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875830,,,A
6535,Intermediate,,1,,9615.0,7042,1,50588,,In vivo,,Volume distribution in dog after administration of 1 mg/kg iv,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624952,,,A
17764,Intermediate,,1,,9615.0,7043,1,50588,,In vivo,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624953,,,A
6215,Intermediate,,1,,9615.0,7044,1,50588,,In vivo,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624954,,,A
6505,Intermediate,,1,,9615.0,7045,1,50588,,In vivo,,Vss on i.v. administration of 2 mg/kg was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624955,,,A
3639,Intermediate,,1,,9615.0,7046,1,50588,,,,Vss was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624956,,,A
3639,Intermediate,,1,,9615.0,7047,1,50588,,,,Vss in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625129,,,A
6062,Intermediate,,1,,9615.0,7048,1,50588,,In vivo,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625130,,,A
4942,Intermediate,,1,,9615.0,7049,1,50588,,In vivo,,Volume distribution in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625131,,,A
17796,Intermediate,,1,,9615.0,7050,1,50588,,In vivo,,Volume of distribution in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625132,,,A
4883,Intermediate,,1,,9615.0,7051,1,50588,,In vivo,,Tested for the oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL872263,,,A
17837,Intermediate,,1,,10090.0,7060,1,50594,,In vivo,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL624336,,,A
17729,Intermediate,,1,,10090.0,7061,1,50594,,In vivo,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL624337,,,A
17729,Intermediate,,1,,10090.0,7062,1,50594,,In vivo,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL624338,,,A
4239,Intermediate,,1,,10090.0,7063,1,50594,,In vivo,,Bioavailability was measured in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL624339,,,A
17592,Intermediate,,1,,10090.0,7064,1,50594,,In vivo,,Bioavailability in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL624340,,,A
6348,Intermediate,,1,,10090.0,7065,1,50594,,In vivo,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,,Mus musculus,BAO_0000218,,CHEMBL624341,,,A
2801,Intermediate,,1,,10090.0,7066,1,50594,,In vivo,,Bioavailability in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL624342,,,A
2801,Intermediate,,1,,10090.0,7067,1,50594,,In vivo,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL624343,,,A
17718,Intermediate,,1,,10090.0,7068,1,50594,,In vivo,,Oral bioavailability in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL624344,,,A
5727,Intermediate,,1,,10090.0,7069,1,50594,,In vivo,,Oral availability at 50 mg/kg po in male mice,,N,,Mus musculus,BAO_0000218,,CHEMBL624345,,,A
5302,Intermediate,,1,,10090.0,7070,1,50594,,In vivo,,Oral bioavailability in mouse (dose 10 mg/kg),,N,,Mus musculus,BAO_0000218,,CHEMBL624346,,,A
3598,Expert,,1,,10090.0,7071,1,50594,,In vivo,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL624347,,,A
5961,Intermediate,,1,,10090.0,7072,1,50594,,In vivo,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,N,,Mus musculus,BAO_0000218,,CHEMBL624348,,,A
6091,Intermediate,,1,,10090.0,7074,1,50594,,In vivo,,Oral bioavailability in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL622754,,,A
6091,Intermediate,,1,,10090.0,7075,1,50594,,In vivo,,Oral bioavailability in vivo in mice;ND=Not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL622755,,,A
5711,Intermediate,,1,,10090.0,7076,1,50594,,In vivo,,Oral bioavailability in mouse at 10 mg/kg of the compound,,N,,Mus musculus,BAO_0000218,,CHEMBL622756,,,A
17728,Intermediate,,1,,10090.0,7077,1,50594,,In vivo,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,N,,Mus musculus,BAO_0000218,,CHEMBL622757,,,A
17728,Intermediate,,1,,10090.0,7078,1,50594,,In vivo,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,N,,Mus musculus,BAO_0000218,,CHEMBL622758,,,A
3802,Intermediate,,1,,10090.0,7079,1,50594,,In vivo,,Tested for bioavailability of the compound,,N,,Mus musculus,BAO_0000218,,CHEMBL622759,,,A
3802,Intermediate,,1,,10090.0,7080,1,50594,,In vivo,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,N,,Mus musculus,BAO_0000218,,CHEMBL622760,,,A
14029,Intermediate,,1,,10090.0,7081,1,50594,,,Plasma,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622761,,,A
14029,Intermediate,,1,,10090.0,7082,1,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by human plasma. ,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622762,,,A
14029,Intermediate,,1,,10090.0,7083,1,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622763,,,A
14029,Intermediate,,1,,10090.0,7084,1,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622764,,,A
14029,Intermediate,,1,,10090.0,7085,1,50594,,,Plasma,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622765,,,A
17753,Intermediate,,1,,10090.0,7086,1,50594,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622766,,,F
17753,Intermediate,,1,,10090.0,7087,1,50594,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622767,,,A
17753,Intermediate,,1,,10090.0,7088,1,50594,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,N,,Mus musculus,BAO_0000218,,CHEMBL622768,,,A
10107,Intermediate,,1,,10090.0,7089,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL875948,,,A
10107,Intermediate,,1,,10090.0,7090,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622769,,,A
10107,Intermediate,,1,,10090.0,7091,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622770,,,A
10107,Intermediate,,1,,10090.0,7092,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622771,,,A
10107,Intermediate,,1,,10090.0,7093,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622772,,,A
10107,Intermediate,,1,,10090.0,7094,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622773,,,A
10107,Intermediate,,1,,10090.0,7095,1,50594,,In vivo,Blood,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622774,,,A
10107,Intermediate,,1,,10090.0,7096,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL621725,,,A
10107,Intermediate,,1,,10090.0,7097,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL621726,,,A
15608,Intermediate,,1,,9606.0,7098,1,81034,A2780,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621727,,,F
3290,Expert,,1,,9606.0,7099,1,81034,A2780,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622413,,,F
2859,Intermediate,,1,,9606.0,7100,1,81034,A2780,,,Compound was evaluated for cytotoxicity against A2780 cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622414,,,F
15688,Expert,,1,,9606.0,7101,1,81034,A2780,,,Inhibition of A2780 cell clonogenic assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622415,,,F
5642,Expert,,1,,9606.0,7102,1,81034,A2780,,,Cytotoxic effect on ovarian cancer cell line (A2780),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL884001,,,F
6633,Intermediate,,1,,9606.0,7103,1,81034,A2780,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622416,,,F
3906,Intermediate,,1,,9606.0,7104,1,81034,A2780,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622417,,,F
6788,Expert,,1,,9606.0,7105,1,81034,A2780,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622590,,,F
17582,Expert,,1,,9606.0,7106,1,81034,A2780,,,Antiproliferative activity against human A2780 cells,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622591,,,F
17764,Expert,,1,,9606.0,7107,1,81034,A2780,,,Inhibition of human A2780 cell proliferation,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622592,,,F
17764,Expert,,1,,9606.0,7108,1,81034,A2780,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622593,,,F
17764,Expert,,1,,9606.0,7109,1,81034,A2780,,,Inhibition of human A2780 cell proliferation (No data),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622594,,,F
2815,Intermediate,,1,,9606.0,7110,1,81034,A2780,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622595,,,F
16930,Intermediate,,1,,9606.0,7111,1,81034,A2780,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622596,,,F
17777,Expert,,1,,9606.0,7112,1,81034,A2780,,,Growth inhibition against A2780 wild-type ovarian cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622597,,,F
17777,Intermediate,,1,,9606.0,7113,1,81034,A2780,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622598,,,F
16936,Autocuration,,1,,9606.0,7114,5,104766,,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,D,,Homo sapiens,BAO_0000019,,CHEMBL622599,,,F
13759,Intermediate,,1,,9606.0,7115,1,81034,A2780,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622600,,,F
13759,Intermediate,,1,,9606.0,7116,1,81034,A2780,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622601,,,F
13759,Intermediate,,1,,9606.0,7117,1,81034,A2780,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622602,,,F
13759,Intermediate,,1,,9606.0,7118,1,81034,A2780,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622603,,,F
15292,Intermediate,,1,,9606.0,7119,1,81034,A2780,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622604,,,F
15292,Intermediate,,1,,9606.0,7120,1,81034,A2780,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622605,,,F
15069,Expert,,1,,9606.0,7121,1,81034,A2780,,,In vitro inhibition of human ovarian cell line A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622606,,,F
15069,Expert,,1,,9606.0,7122,1,81034,A2780,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619463,,,F
14073,Intermediate,,1,,9606.0,7123,1,81034,A2780,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619464,,,F
14553,Expert,,1,,9606.0,7124,1,81034,A2780,,,Concentration required to inhibit A2780-cell growth by 50%,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619465,,,F
13040,Expert,,1,,9606.0,7125,1,81034,A2780,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619466,,,F
6891,Expert,,1,,9606.0,7126,1,81034,A2780,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619467,,,F
15569,Intermediate,,1,,9606.0,7127,1,81034,A2780,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619468,,,F
14190,Expert,,1,,9606.0,7128,1,81034,A2780,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619469,,,F
15014,Expert,,1,,9606.0,7129,1,81034,A2780,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619470,,,F
15014,Intermediate,,1,,9606.0,7130,1,81034,A2780,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619471,,,F
17496,Intermediate,,1,,9606.0,7131,1,81034,A2780,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619472,,,F
13617,Intermediate,,1,,9606.0,7132,1,81034,A2780,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL619473,,,F
13617,Intermediate,,1,,9606.0,7133,1,81034,A2780,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL874368,,,F
13617,Intermediate,,1,,9606.0,7134,1,81034,A2780,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL884003,,,F
13617,Intermediate,,1,,9606.0,7135,1,81034,A2780,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622690,,,F
17672,Intermediate,,1,,9606.0,7136,1,81034,A2780,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622691,,,F
4544,Intermediate,,1,,9606.0,7137,1,81034,A2780,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL622692,,,F
4544,Intermediate,,1,,9606.0,7138,1,81034,A2780,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623406,,,F
16317,Intermediate,,1,,9606.0,7139,1,81034,A2780,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL884004,,,F
15099,Intermediate,,1,,9606.0,7140,1,81034,A2780,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623407,,,F
13978,Intermediate,,1,,9606.0,7141,1,81034,A2780,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623408,,,F
12989,Expert,,1,,9606.0,7142,1,81034,A2780,,,In vitro antitumor activity against A2780 cell line.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623409,,,F
5574,Intermediate,,1,,9606.0,7143,1,81034,A2780,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623410,,,F
13528,Expert,,1,,9606.0,7144,1,81034,A2780,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL623576,,,F
12782,Intermediate,,1,,9606.0,7145,1,80025,ACHN,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623577,,,F
14255,Intermediate,,1,,9606.0,7146,1,80025,ACHN,,,The IC50 value was measured on ACHN cell line in renal tumor type.,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623578,,,F
16364,Intermediate,,1,,9606.0,7147,1,80025,ACHN,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623579,,,F
17376,Expert,,1,,9606.0,7148,1,80025,ACHN,,,In vitro lethal concentration against most sensitive ACHN cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623580,,,F
12016,Intermediate,,1,,9606.0,7149,1,80025,ACHN,,,Tested for cytotoxic activity against renal cancer ACHN cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623581,,,F
6058,Intermediate,,1,,9606.0,7150,1,80025,ACHN,,,Compound tested for growth inhibition of renal cancer cell line ACHN,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL857456,,,F
17708,Intermediate,,1,,9606.0,7151,1,80025,ACHN,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623582,,,F
15176,Intermediate,,1,,9606.0,7152,1,80025,ACHN,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623583,,,F
2806,Intermediate,,1,,9606.0,7153,1,80025,ACHN,,,In vitro anticancer activity against ACHN renal cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623584,,,F
15300,Intermediate,,1,,9606.0,7154,1,80025,ACHN,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623585,,,F
16364,Intermediate,,1,,9606.0,7155,1,80025,ACHN,,,Percent selectivity was evaluated in renal ACHN cell lines,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623586,,,F
13859,Intermediate,,1,,9606.0,7156,1,80025,ACHN,,,In vitro inhibitory activity against renal ACHN cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623587,,,F
11970,Intermediate,,1,,9606.0,7157,1,80025,ACHN,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL875279,,,F
2450,Intermediate,,1,,9606.0,7158,1,80025,ACHN,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623588,,,F
12696,Intermediate,,1,,9606.0,7159,1,80025,ACHN,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623589,,,F
12400,Intermediate,,1,,9606.0,7160,1,80025,ACHN,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623590,,,F
12888,Expert,,1,,9606.0,7161,1,80025,ACHN,,,Cytotoxic effect on renal cancer line ACHN,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623591,,,F
3156,Intermediate,,1,,9606.0,7162,1,80025,ACHN,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623592,,,F
3381,Intermediate,,1,,9606.0,7163,1,80025,ACHN,,,In vitro inhibition of Renal Cancer ACHN cell lines,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623593,,,F
16747,Intermediate,,1,,9606.0,7164,1,80025,ACHN,,,Antitumor activity against human renal adenocarcinoma ACHN cells,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL623594,,,F
16748,Expert,,1,,9606.0,7165,1,80025,ACHN,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621833,,,F
12062,Intermediate,,1,,9606.0,7166,1,80025,ACHN,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621834,,,F
14769,Intermediate,,1,,9606.0,7167,1,80025,ACHN,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621835,,,F
15895,Intermediate,,1,,9606.0,7168,1,80025,ACHN,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621836,,,F
17376,Intermediate,,1,,9606.0,7169,1,80025,ACHN,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621837,,,F
14882,Intermediate,,1,,9606.0,7170,1,80025,ACHN,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL875280,,,F
14882,Intermediate,,1,,9606.0,7171,1,80025,ACHN,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621838,,,F
15661,Intermediate,,1,,9606.0,7172,1,80025,ACHN,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,N,626.0,Homo sapiens,BAO_0000219,,CHEMBL621839,,,F
9680,Autocuration,,1,,,7173,0,22224,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,U,,,BAO_0000019,,CHEMBL621840,,,A
14579,Autocuration,,1,,,7174,8,10647,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,H,,,BAO_0000019,,CHEMBL621841,,,F
17290,Expert,,1,,10358.0,7175,1,50529,HEL,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,N,468.0,Cytomegalovirus,BAO_0000218,,CHEMBL622979,,,F
17290,Intermediate,,1,,10358.0,7176,1,50529,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,N,,Cytomegalovirus,BAO_0000218,,CHEMBL876595,,,F
15891,Autocuration,,1,,,7177,8,12159,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,H,,,BAO_0000357,,CHEMBL620221,,,B
15890,Autocuration,,1,,,7178,8,12159,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,H,,,BAO_0000357,,CHEMBL620222,,,B
3801,Intermediate,,1,,9913.0,7179,1,80670,ADDP cell line,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,N,979.0,Bos taurus,BAO_0000219,,CHEMBL620506,,,F
9222,Intermediate,,1,,10090.0,7180,1,80671,ADJ/PC6,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,N,980.0,Mus musculus,BAO_0000219,,CHEMBL620507,,,F
9222,Intermediate,,1,,10090.0,7181,1,80671,ADJ/PC6,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,N,980.0,Mus musculus,BAO_0000219,,CHEMBL620508,,,F
7257,Intermediate,,1,,10090.0,7182,1,80671,ADJ/PC6,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,N,980.0,Mus musculus,BAO_0000219,,CHEMBL620509,,,F
7257,Intermediate,,1,,10090.0,7183,1,80671,ADJ/PC6,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,N,980.0,Mus musculus,BAO_0000219,,CHEMBL620510,,,F
7257,Intermediate,,1,,10090.0,7184,1,80671,ADJ/PC6,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,N,980.0,Mus musculus,BAO_0000219,,CHEMBL620511,,,A
8084,Intermediate,,1,,10090.0,7185,1,80671,ADJ/PC6,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,N,980.0,Mus musculus,BAO_0000219,,CHEMBL620512,,,F
14943,Autocuration,,1,,10090.0,7186,0,22224,,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,U,,Mus musculus,BAO_0000019,,CHEMBL620513,,,F
14943,Autocuration,,1,,10090.0,7187,0,22224,,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,U,,Mus musculus,BAO_0000019,,CHEMBL620514,,,F
14943,Autocuration,,1,,10090.0,7188,0,22224,,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,U,,Mus musculus,BAO_0000019,,CHEMBL620515,,,F
10524,Autocuration,,1,,1423.0,7189,0,22224,,In vivo,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,U,,Bacillus subtilis,BAO_0000218,,CHEMBL620516,,,A
3546,Intermediate,,1,,9615.0,7190,1,50588,,,Plasma,AUC value in dog after IV administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620517,,,A
3546,Intermediate,,1,,9615.0,7191,1,50588,,,Plasma,AUC value in dog after oral administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620518,,,A
3546,Intermediate,,1,,9615.0,7192,1,50588,,In vivo,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620519,,,A
3546,Intermediate,,1,,9615.0,7193,1,50588,,In vivo,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621386,,,A
3546,Intermediate,,1,,9615.0,7194,1,50588,,In vivo,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621387,,,A
3184,Intermediate,,1,,9615.0,7195,1,50588,,In vivo,,Compound was evaluated for its clearance when administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621388,,,A
16456,Intermediate,,1,,9615.0,7196,1,50588,,In vivo,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621389,,,A
4809,Intermediate,,1,,9615.0,7197,1,50588,,In vivo,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621390,,,A
4219,Intermediate,,1,,,7198,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL621391,,,P
3748,Intermediate,,1,,9615.0,7199,1,50588,,,,Half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621392,,,A
3132,Intermediate,,1,,9615.0,7200,1,50588,,,,Time taken for EC90 was determined when tested in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621393,,,A
4219,Intermediate,,1,,9615.0,7201,1,50588,,,,Half life (iv) was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621394,,,A
16907,Intermediate,,1,,9615.0,7202,1,50588,,,Liver,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL621395,,,A
6057,Intermediate,,1,,9615.0,7203,1,50588,,,,Area under the curve was calculated in dog after iv administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621396,,,A
6057,Intermediate,,1,,9615.0,7204,1,50588,,,,Area under the curve was calculated in dog after peroral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621397,,,A
17853,Intermediate,,1,,9615.0,7205,1,50588,,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621398,,,A
3639,Intermediate,,1,,9615.0,7206,1,50588,,,,pKa was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618818,,,A
14541,Intermediate,,1,,9615.0,7207,1,50588,,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618819,,,A
16456,Intermediate,,1,,9615.0,7208,1,50588,,In vivo,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618820,,,A
16456,Intermediate,,1,,9615.0,7209,1,50588,,In vivo,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873810,,,A
2652,Intermediate,,1,,9615.0,7210,1,50588,,In vivo,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876606,,,A
3624,Intermediate,,1,,9615.0,7211,1,50588,,,,Compound was evaluated for the half-life (t 1/2) in hours,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618821,,,A
1337,Intermediate,,1,,9615.0,7212,1,50588,,In vivo,Blood,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL618822,,,A
1337,Intermediate,,1,,9615.0,7213,1,50588,,In vivo,Blood,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL618823,,,A
4709,Intermediate,,1,,9615.0,7214,1,50588,,In vivo,,Half life after intravenous administration of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618824,,,A
15660,Intermediate,,1,,9615.0,7215,1,50588,,,,Half life was measured in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618825,,,A
5302,Intermediate,,1,,9615.0,7216,1,50588,,In vivo,,Half life period in dog after 5 mg/kg dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618826,,,A
17791,Intermediate,,1,,9615.0,7217,1,50588,,,,Half life period was evaluated in dog; 4-4.8,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618827,,,A
6348,Intermediate,,1,,9615.0,7218,1,50588,,In vivo,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618828,,,A
4257,Intermediate,,1,,9615.0,7219,1,50588,,In vivo,,Half-life was determined in dog after a3 mg/kg of iv dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618829,,,A
3771,Intermediate,,1,,9615.0,7220,1,50588,,,,Half-life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618830,,,A
6305,Intermediate,,1,,9615.0,7221,1,50588,,,,Half life in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618831,,,A
13501,Intermediate,,1,,9615.0,7222,1,50588,,In vivo,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL619489,,,A
17594,Intermediate,,1,,9615.0,7223,1,50588,,In vivo,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619649,,,A
3045,Intermediate,,1,,9615.0,7224,1,50588,,In vivo,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876607,,,A
3043,Intermediate,,1,,9615.0,7225,1,50588,,In vivo,,Compound was evaluated for the half life period after oral administration in conscious dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619650,,,A
4839,Intermediate,,1,,9615.0,7226,1,50588,,,,Compound was tested for half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619651,,,A
4839,Intermediate,,1,,9615.0,7227,1,50588,,,,Compound was tested for its half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619652,,,A
5802,Intermediate,,1,,9615.0,7228,1,50588,,In vivo,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619653,,,A
17839,Intermediate,,1,,9615.0,7229,1,50588,,,,Half life of compound in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619654,,,A
4219,Intermediate,,1,,9615.0,7230,1,50588,,In vivo,,Half life (iv) was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619655,,,A
13966,Intermediate,,1,,9615.0,7231,1,50588,,,Blood,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL619656,,,A
3994,Intermediate,,1,,9615.0,7232,1,50588,,In vivo,Plasma,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL873812,,,A
3994,Intermediate,,1,,9615.0,7233,1,50588,,In vivo,Plasma,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621365,,,F
4453,Intermediate,,1,,9615.0,7234,1,50588,,,,Half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621366,,,A
6535,Intermediate,,1,,9615.0,7235,1,50588,,,Plasma,Half life in dog plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621367,,,A
6535,Intermediate,,1,,9615.0,7236,1,50588,,In vivo,Plasma,Half life in dog plasma after administration of 0.25 mg/kg iv,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621368,,,A
6535,Intermediate,,1,,9615.0,7237,1,50588,,In vivo,Plasma,Half life in dog plasma after administration of 1 mg/kg iv,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621369,,,A
3132,Intermediate,,1,,9615.0,7238,1,50588,,In vivo,Plasma,Half life in dog plasma was determined at dose 10 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621370,,,A
5374,Intermediate,,1,,9615.0,7239,1,50588,,,,Half life in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621371,,,A
5007,Intermediate,,1,,9615.0,7240,1,50588,,In vivo,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621372,,,A
16907,Intermediate,,1,,9615.0,7241,1,50588,,,Plasma,Half life upon exposure to human plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621373,,,A
6057,Intermediate,,1,,9615.0,7242,1,50588,,,,Half life was calculated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621374,,,A
5006,Intermediate,,1,,9615.0,7243,1,50588,,,,Half life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621375,,,A
5473,Intermediate,,1,,9615.0,7244,1,50588,,,,Half life was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621376,,,A
4368,Intermediate,,1,,9615.0,7245,1,50588,,In vivo,,Half life by intravenous administration of 1.2 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619624,,,A
6448,Intermediate,,1,,9615.0,7246,1,50588,,,,Half life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875840,,,A
4353,Intermediate,,1,,9615.0,7247,1,50588,,,,Half life in dog after intra venous administration of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619625,,,A
4353,Intermediate,,1,,9615.0,7248,1,50588,,,,Half life in dog after intra venous administration of the compound; ND means Not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619626,,,A
4353,Intermediate,,1,,9615.0,7249,1,50588,,In vivo,,Half life in dog after po administration of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619627,,,A
4353,Intermediate,,1,,9615.0,7250,1,50588,,In vivo,,Half life in dog after po administration of the compound; ND means Not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873817,,,A
6265,Intermediate,,1,,9615.0,7251,1,50588,,In vivo,,Half life in dog at the single oral dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619628,,,A
5006,Intermediate,,1,,9615.0,7252,1,50588,,,,Half life in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619629,,,A
5356,Intermediate,,1,,9615.0,7253,1,50588,,In vivo,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619630,,,A
405,Intermediate,,1,,9615.0,7254,1,50588,,,,Half life in rat,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619631,,,A
6642,Intermediate,,1,,9615.0,7255,1,50588,,In vivo,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL619632,,,A
10107,Intermediate,,1,,10090.0,7256,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL619633,,,A
10107,Intermediate,,1,,10090.0,7257,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL875841,,,A
10107,Intermediate,,1,,10090.0,7258,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL619634,,,A
10107,Intermediate,,1,,10090.0,7259,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL619635,,,A
10107,Intermediate,,1,,10090.0,7260,1,50594,,In vivo,Bone,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL619636,,,A
10107,Intermediate,,1,,10090.0,7261,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619637,,,A
10107,Intermediate,,1,,10090.0,7262,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619638,,,A
10107,Intermediate,,1,,10090.0,7263,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619639,,,A
10107,Intermediate,,1,,10090.0,7264,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619640,,,A
10107,Intermediate,,1,,10090.0,7265,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619641,,,A
10107,Intermediate,,1,,10090.0,7266,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619642,,,A
10107,Intermediate,,1,,10090.0,7267,1,50594,,In vivo,Gut,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,10000004.0,CHEMBL619643,,,A
10107,Intermediate,,1,,10090.0,7268,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL619644,,,A
10107,Intermediate,,1,,10090.0,7269,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621112,,,A
10107,Intermediate,,1,,10090.0,7270,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621113,,,A
10107,Intermediate,,1,,10090.0,7271,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621114,,,A
10107,Intermediate,,1,,10090.0,7272,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621115,,,A
10107,Intermediate,,1,,10090.0,7273,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621116,,,A
10107,Intermediate,,1,,10090.0,7274,1,50594,,In vivo,Heart,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL621117,,,A
10107,Intermediate,,1,,10090.0,7275,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621118,,,A
10107,Intermediate,,1,,10090.0,7276,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621119,,,A
10107,Intermediate,,1,,10090.0,7277,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621120,,,A
10107,Intermediate,,1,,10090.0,7278,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621757,,,A
10107,Intermediate,,1,,10090.0,7279,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621758,,,A
10107,Intermediate,,1,,10090.0,7280,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621759,,,A
10107,Intermediate,,1,,10090.0,7281,1,50594,,In vivo,Kidney,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621760,,,A
10107,Intermediate,,1,,10090.0,7282,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621761,,,A
10107,Intermediate,,1,,10090.0,7283,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621762,,,A
10107,Intermediate,,1,,10090.0,7284,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621763,,,A
10107,Intermediate,,1,,10090.0,7285,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624502,,,A
10107,Intermediate,,1,,10090.0,7286,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624503,,,A
10107,Intermediate,,1,,10090.0,7287,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624504,,,A
10107,Intermediate,,1,,10090.0,7288,1,50594,,In vivo,Liver,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624505,,,A
10107,Intermediate,,1,,10090.0,7289,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624506,,,A
5895,Intermediate,,1,,9606.0,7290,1,81034,A2780,,,In vitro cytotoxicity against A2780 (human ovarian cancer),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624507,,,F
6338,Intermediate,,1,,9606.0,7291,1,81034,A2780,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624508,,,F
15163,Intermediate,,1,,9606.0,7292,1,81034,A2780,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624509,,,F
15163,Intermediate,,1,,9606.0,7293,1,81034,A2780,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624510,,,F
15000,Expert,,1,,9606.0,7294,1,81034,A2780,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL875956,,,F
15000,Expert,,1,,9606.0,7295,1,81034,A2780,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL839885,,,F
14729,Expert,,1,,9606.0,7296,1,81034,A2780,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624511,,,F
17270,Intermediate,,1,,9606.0,7297,1,81034,A2780,,,In vitro cytotoxicity against A2780 cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624512,,,F
5685,Intermediate,,1,,9606.0,7298,1,81034,A2780,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624513,,,F
3563,Intermediate,,1,,9606.0,7299,1,81034,A2780,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL624514,,,F
17753,Intermediate,,1,,9606.0,7300,1,81034,A2780,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL618547,,,F
16317,Intermediate,,1,,9606.0,7301,1,81034,A2780,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618548,,,F
16936,Intermediate,,1,,9606.0,7302,1,81034,A2780,,,Inhibition of tubulin polymerization in analogy of ca.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618549,,,F
3801,Intermediate,,1,,9606.0,7303,1,81034,A2780,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618550,,,F
6181,Expert,,1,,9606.0,7304,1,81034,A2780,,,Cytotoxic effect in ovarian cancer cell line (A2780),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618551,,,F
5318,Intermediate,,1,,9606.0,7305,1,81034,A2780,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618552,,,F
4840,Intermediate,,1,,9606.0,7306,1,81034,A2780,,,Tested for the cytotoxicity in A2780 ovarian cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618553,,,F
15748,Intermediate,,1,,9606.0,7307,1,81034,A2780,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618554,,,F
15748,Intermediate,,1,,9606.0,7308,1,81034,A2780,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618555,,,F
15748,Intermediate,,1,,,7309,1,80017,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,N,481.0,,BAO_0000219,,CHEMBL618556,,,F
15748,Intermediate,,1,,,7310,1,80017,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,N,481.0,,BAO_0000219,,CHEMBL618557,,,F
15748,Intermediate,,1,,,7311,1,80017,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,N,481.0,,BAO_0000219,,CHEMBL618558,,,F
15748,Intermediate,,1,,,7312,1,80017,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,N,481.0,,BAO_0000219,,CHEMBL618559,,,F
17753,Intermediate,,1,,9606.0,7313,1,81034,A2780,,,In vivo log of cells killed after administration of compound in A2780 cell line,,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL618560,,,F
17753,Intermediate,,1,,9606.0,7314,1,81034,A2780,In vivo,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL618561,,,F
16936,Intermediate,,1,,9606.0,7315,1,81034,A2780,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618562,,,F
16936,Intermediate,,1,,9606.0,7316,1,81034,A2780,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618563,,,F
16936,Intermediate,,1,,9606.0,7317,1,81034,A2780,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618564,,,F
16936,Intermediate,,1,,9606.0,7318,1,81034,A2780,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618565,,,F
17528,Intermediate,,1,,9606.0,7319,1,81034,A2780,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,N,478.0,Homo sapiens,BAO_0000218,,CHEMBL618566,,,F
6633,Intermediate,,1,,9606.0,7320,1,81034,A2780,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618567,,,F
15000,Expert,,1,,9606.0,7321,1,81034,A2780,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618568,,,F
17528,Expert,,1,,9606.0,7322,1,81034,A2780,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL618569,,,F
16936,Intermediate,,1,,9606.0,7323,1,81034,A2780,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621857,,,F
16936,Intermediate,,1,,9606.0,7324,1,81034,A2780,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621858,,,F
16936,Intermediate,,1,,9606.0,7325,1,81034,A2780,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621859,,,F
16936,Intermediate,,1,,9606.0,7326,1,81034,A2780,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621860,,,F
16936,Intermediate,,1,,9606.0,7327,1,81034,A2780,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621861,,,F
16936,Expert,,1,,9606.0,7328,1,81034,A2780,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621862,,,F
16936,Intermediate,,1,,9606.0,7329,1,81034,A2780,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621863,,,F
16936,Intermediate,,1,,9606.0,7330,1,81034,A2780,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621864,,,F
16936,Intermediate,,1,,9606.0,7331,1,81034,A2780,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621865,,,F
17737,Intermediate,,1,,10090.0,7332,1,81034,A2780,,,In vitro antiproliferative activity against A2780 cell line,,N,478.0,Mus musculus,BAO_0000219,,CHEMBL621866,,,F
17764,Expert,,1,,10090.0,7333,1,81034,A2780,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,N,478.0,Mus musculus,BAO_0000219,,CHEMBL621867,,,F
3830,Intermediate,,1,,9606.0,7334,1,81034,A2780,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL621868,,,F
3829,Intermediate,,1,,9606.0,7335,1,81034,A2780,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,N,478.0,Homo sapiens,BAO_0000219,,CHEMBL875282,,,F
3546,Intermediate,,1,,9615.0,7336,1,50588,,,,Vc value in dog after IV administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621869,,,A
3546,Intermediate,,1,,9615.0,7337,1,50588,,In vivo,,Half life period in dog after IV administration at a dose of 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621870,,,A
5668,Autocuration,,1,,9527.0,7338,0,22224,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,U,,Cercopithecidae,BAO_0000019,,CHEMBL621871,,,A
3443,Autocuration,,1,,9527.0,7339,0,22224,,,Plasma,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL621243,,,A
3443,Autocuration,,1,,9527.0,7340,0,22224,,,Plasma,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,1969.0,CHEMBL621244,,,A
4256,Autocuration,,1,,9541.0,7341,0,22224,,In vivo,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL621245,,,A
4256,Autocuration,,1,,9541.0,7342,0,22224,,In vivo,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL621246,,,A
4256,Autocuration,,1,,9541.0,7343,0,22224,,In vivo,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL621247,,,A
4256,Autocuration,,1,,10116.0,7344,0,22224,,In vivo,,Oral Bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL618386,,,A
1916,Autocuration,,1,,9527.0,7345,0,22224,,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618387,,,A
5302,Autocuration,,1,,9527.0,7346,0,22224,,,,Area under curve value in monkey at a dose of 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618388,,,A
4257,Autocuration,,1,,9527.0,7347,0,22224,,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618389,,,A
5355,Autocuration,,1,,9527.0,7348,0,22224,,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618574,,,A
5355,Autocuration,,1,,9527.0,7349,0,22224,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618575,,,A
5355,Autocuration,,1,,9527.0,7350,0,22224,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618576,,,A
6078,Autocuration,,1,,9527.0,7351,0,22224,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618577,,,A
6078,Autocuration,,1,,9527.0,7352,0,22224,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL876487,,,A
6062,Autocuration,,1,,9527.0,7353,0,22224,,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618578,,,A
2661,Autocuration,,1,,9527.0,7354,0,22224,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618579,,,A
2661,Autocuration,,1,,9527.0,7355,0,22224,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618580,,,A
5394,Autocuration,,1,,9527.0,7356,0,22224,,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618581,,,A
4397,Autocuration,,1,,9527.0,7357,0,22224,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618582,,,A
17509,Autocuration,,1,,9527.0,7358,0,22224,,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618583,,,A
17509,Autocuration,,1,,9527.0,7359,0,22224,,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618584,,,A
6641,Autocuration,,1,,9527.0,7360,0,22224,,In vivo,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,U,,Cercopithecidae,BAO_0000218,,CHEMBL618585,,,A
5355,Autocuration,,1,,9527.0,7361,0,22224,,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,U,,Cercopithecidae,BAO_0000218,,CHEMBL618586,,,A
3443,Autocuration,,1,,9527.0,7362,0,22224,,In vivo,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618587,,,A
3443,Autocuration,,1,,9527.0,7363,0,22224,,In vivo,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618588,,,A
17409,Autocuration,,1,,9527.0,7364,0,22224,,,,Binding towards monkey plasma protein at 10 uM,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618589,,,A
17409,Autocuration,,1,,9527.0,7365,0,22224,,,,Binding towards monkey plasma protein at 100 uM,,U,,Cercopithecidae,BAO_0000019,,CHEMBL618590,,,A
1052,Autocuration,,1,,9527.0,7366,0,22224,,In vivo,,Apparent bioavailability in squirrel monkey was determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL872262,,,A
13501,Autocuration,,1,,9527.0,7367,0,22224,,In vivo,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618591,,,A
17509,Autocuration,,1,,9443.0,7368,0,22224,,In vivo,,Bioavailability in monkey (dose 2 mg/kg),,U,,monkey,BAO_0000218,,CHEMBL618592,,,A
5394,Autocuration,,1,,9527.0,7369,0,22224,,In vivo,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL876488,,,A
2661,Autocuration,,1,,9527.0,7370,0,22224,,In vivo,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618593,,,A
11219,Autocuration,,1,,9443.0,7371,0,22224,,In vivo,,Bioavailability in monkey (i.d. dosing),,U,,monkey,BAO_0000218,,CHEMBL618594,,,A
3045,Autocuration,,1,,9527.0,7372,0,22224,,In vivo,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL618595,,,A
17796,Autocuration,,1,,9527.0,7373,0,22224,,,,Clearance of the drug was measured in cynomolgus,,U,,Cercopithecidae,BAO_0000019,,CHEMBL621469,,,A
1399,Autocuration,,1,,9527.0,7374,0,22224,,In vivo,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621470,,,A
2661,Autocuration,,1,,9527.0,7375,0,22224,,In vivo,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621471,,,A
5005,Autocuration,,1,,9544.0,7376,0,22224,,In vivo,Plasma,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL621472,,,A
17267,Autocuration,,1,,9527.0,7377,0,22224,,In vivo,,Plasma clearance in rhesus monkey was determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621473,,,A
6535,Autocuration,,1,,9527.0,7378,0,22224,,In vivo,,Plasma clearance in monkey after administration of 1 mg/kg iv,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621474,,,A
5922,Autocuration,,1,,9527.0,7379,0,22224,,In vivo,,Plasma clearance in cynomolgus monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621475,,,A
6221,Autocuration,,1,,9527.0,7380,0,22224,,In vivo,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,U,,Cercopithecidae,BAO_0000218,,CHEMBL621476,,,A
5668,Autocuration,,1,,9527.0,7381,0,22224,,In vivo,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,U,,Cercopithecidae,BAO_0000218,,CHEMBL624290,,,A
5355,Autocuration,,1,,9527.0,7382,0,22224,,In vivo,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,U,,Cercopithecidae,BAO_0000218,,CHEMBL624291,,,A
5355,Autocuration,,1,,9527.0,7383,0,22224,,In vivo,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL624292,,,A
5355,Autocuration,,1,,9527.0,7384,0,22224,,In vivo,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,U,,Cercopithecidae,BAO_0000218,,CHEMBL624293,,,A
4578,Autocuration,,1,,9527.0,7385,0,22224,,In vivo,,Tested for Clearance upon iv administration to african green monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL624294,,,A
17592,Autocuration,,1,,9527.0,7386,0,22224,,In vivo,,Clearance in monkey,,U,,Cercopithecidae,BAO_0000218,,CHEMBL624295,,,A
6641,Intermediate,,1,,9615.0,7387,1,50588,,In vivo,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624296,,,A
6642,Intermediate,,1,,9615.0,7388,1,50588,,In vivo,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624297,,,A
16367,Intermediate,,1,,9615.0,7389,1,50588,,In vivo,,Half life was evaluated after intravenous administration to dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624298,,,A
5472,Intermediate,,1,,9615.0,7390,1,50588,,,,Half life was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624299,,,A
5474,Intermediate,,1,,9615.0,7391,1,50588,,,,Half life was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624300,,,A
5654,Intermediate,,1,,9615.0,7392,1,50588,,In vivo,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624301,,,A
6227,Intermediate,,1,,9615.0,7393,1,50588,,In vivo,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624302,,,A
6227,Intermediate,,1,,9615.0,7394,1,50588,,In vivo,,Half life period after intravenous administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876026,,,A
6221,Intermediate,,1,,9615.0,7395,1,50588,,In vivo,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624303,,,A
4527,Intermediate,,1,,9615.0,7396,1,50588,,,,Half life period at a dose of 1 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624304,,,A
5668,Intermediate,,1,,9615.0,7397,1,50588,,In vivo,,Half life period was determine after peroral administration at 10 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624305,,,A
5668,Intermediate,,1,,9615.0,7398,1,50588,,In vivo,,Half life period was determine after peroral administration at 5 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624306,,,A
3854,Intermediate,,1,,9615.0,7399,1,50588,,,,Half life period was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624307,,,A
5505,Intermediate,,1,,9615.0,7400,1,50588,,,,Half life period was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624308,,,A
6251,Intermediate,,1,,9615.0,7401,1,50588,,In vivo,,Half life period by iv administration in dog at a dose of 6 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624309,,,A
1918,Intermediate,,1,,9615.0,7402,1,50588,,,,Half life period was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624310,,,A
5546,Intermediate,,1,,9615.0,7403,1,50588,,In vivo,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625003,,,A
4809,Intermediate,,1,,9615.0,7404,1,50588,,In vivo,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625004,,,A
6215,Intermediate,,1,,9615.0,7405,1,50588,,In vivo,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625005,,,A
4527,Intermediate,,1,,9615.0,7406,1,50588,,In vivo,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873813,,,A
17594,Intermediate,,1,,9615.0,7407,1,50588,,In vivo,,Half-life after oral dose of compound at 3 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625006,,,A
17839,Intermediate,,1,,9615.0,7408,1,50588,,In vivo,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625007,,,A
17839,Intermediate,,1,,9615.0,7409,1,50588,,In vivo,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876027,,,A
17839,Intermediate,,1,,9615.0,7410,1,50588,,In vivo,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625008,,,A
17839,Intermediate,,1,,9615.0,7411,1,50588,,In vivo,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625009,,,A
5210,Intermediate,,1,,9615.0,7412,1,50588,,,Plasma,Half-life of compound in plasma of dog was determined,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625010,,,A
5210,Intermediate,,1,,9615.0,7413,1,50588,,,,Half-life of compound was determined in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625011,,,A
2959,Intermediate,,1,,9615.0,7414,1,50588,,In vivo,,Half-life after administration of 4 mg/Kg oral dose in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621553,,,A
4137,Intermediate,,1,,9615.0,7415,1,50588,,In vivo,,Half-life after intravenous administration of 1 mg/kg/h in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621554,,,A
5064,Intermediate,,1,,9615.0,7416,1,50588,,,,Half-life in Dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621555,,,A
5147,Intermediate,,1,,9615.0,7417,1,50588,,,,Half-life in Dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621556,,,A
5145,Intermediate,,1,,9615.0,7418,1,50588,,,,Half-life in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621557,,,A
6123,Intermediate,,1,,9615.0,7419,1,50588,,In vivo,,Half-life in dog after oral administration at 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621558,,,A
6123,Intermediate,,1,,9615.0,7420,1,50588,,In vivo,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621559,,,A
4333,Intermediate,,1,,9615.0,7421,1,50588,,,,Half-life in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621560,,,A
4333,Intermediate,,1,,9615.0,7422,1,50588,,,,Half-life in dogs; ND indicates not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL876028,,,A
12500,Intermediate,,1,,9615.0,7423,1,50588,,,Plasma,Half-life in plasma of dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621561,,,A
12500,Intermediate,,1,,9615.0,7424,1,50588,,,Plasma,Half-life in plasma of dog at dose of 3-10 mgkg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621562,,,A
6005,Intermediate,,1,,9615.0,7425,1,50588,,In vivo,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621563,,,A
6062,Intermediate,,1,,9615.0,7426,1,50588,,In vivo,,Half-life was measured in dog after an iv dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621564,,,A
17650,Intermediate,,1,,9615.0,7427,1,50588,,In vivo,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621565,,,A
5530,Intermediate,,1,,9615.0,7428,1,50588,,In vivo,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621566,,,A
5530,Intermediate,,1,,9615.0,7429,1,50588,,In vivo,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621567,,,A
5600,Intermediate,,1,,9615.0,7430,1,50588,,In vivo,,Half-life of the compound after 0.3 mg/kg po administration in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622978,,,A
6039,Intermediate,,1,,9615.0,7431,1,50588,,In vivo,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL873814,,,A
6039,Intermediate,,1,,9615.0,7432,1,50588,,In vivo,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623219,,,A
6039,Intermediate,,1,,9615.0,7433,1,50588,,In vivo,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624477,,,A
6227,Intermediate,,1,,9615.0,7434,1,50588,,,,t1/2 in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624478,,,A
14541,Intermediate,,1,,9615.0,7435,1,50588,,,,Half-life period measured in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624479,,,A
4521,Intermediate,,1,,9615.0,7436,1,50588,,In vivo,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624480,,,A
4521,Intermediate,,1,,9615.0,7437,1,50588,,In vivo,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623595,,,A
6679,Intermediate,,1,,9615.0,7438,1,50588,,In vivo,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623596,,,A
1116,Intermediate,,1,,9615.0,7439,1,50588,,In vitro,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623597,,,A
5444,Intermediate,,1,,9615.0,7440,1,50588,,In vivo,,In vivo half life period was calculated at 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623598,,,A
5444,Intermediate,,1,,9615.0,7441,1,50588,,In vivo,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623599,,,A
17853,Intermediate,,1,,9615.0,7442,1,50588,,In vivo,,Longer half-life in dog (i.v.) at 0.5 mpk,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623600,,,A
4353,Intermediate,,1,,9615.0,7443,1,50588,,In vivo,,Oral bioavailability in dog (dose 5 uM/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623601,,,A
16452,Intermediate,,1,,9615.0,7444,1,50588,,In vivo,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623602,,,A
16452,Intermediate,,1,,9615.0,7445,1,50588,,In vivo,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623603,,,A
16452,Intermediate,,1,,9615.0,7446,1,50588,,In vivo,,Bioavailability in dog (dose 1 mg/kg i.v.),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623604,,,A
10107,Intermediate,,1,,10090.0,7447,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623605,,,A
10107,Intermediate,,1,,10090.0,7448,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623606,,,A
10107,Intermediate,,1,,10090.0,7449,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623607,,,A
10107,Intermediate,,1,,10090.0,7450,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623608,,,A
10107,Intermediate,,1,,10090.0,7451,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623609,,,A
10107,Intermediate,,1,,10090.0,7452,1,50594,,In vivo,Lung,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL623610,,,A
10107,Intermediate,,1,,10090.0,7453,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623611,,,A
10107,Intermediate,,1,,10090.0,7454,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623612,,,A
10107,Intermediate,,1,,10090.0,7455,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623613,,,A
10107,Intermediate,,1,,10090.0,7456,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623614,,,A
10107,Intermediate,,1,,10090.0,7457,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623615,,,A
10107,Intermediate,,1,,10090.0,7458,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623616,,,A
10107,Intermediate,,1,,10090.0,7459,1,50594,,In vivo,Muscle tissue,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL623617,,,A
10107,Intermediate,,1,,10090.0,7460,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL875944,,,A
10107,Intermediate,,1,,10090.0,7461,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL623618,,,A
10107,Intermediate,,1,,10090.0,7462,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL623619,,,A
10107,Intermediate,,1,,10090.0,7463,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL623620,,,A
10107,Intermediate,,1,,10090.0,7464,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL623621,,,A
10107,Intermediate,,1,,10090.0,7465,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL623622,,,A
10107,Intermediate,,1,,10090.0,7466,1,50594,,In vivo,Zone of skin,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL623623,,,A
10107,Intermediate,,1,,10090.0,7467,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL623624,,,A
10107,Intermediate,,1,,10090.0,7468,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618521,,,A
10107,Intermediate,,1,,10090.0,7469,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618522,,,A
10107,Intermediate,,1,,10090.0,7470,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618523,,,A
10107,Intermediate,,1,,10090.0,7471,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618524,,,A
10107,Intermediate,,1,,10090.0,7472,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL618525,,,A
10107,Intermediate,,1,,10090.0,7473,1,50594,,In vivo,Spleen,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL624586,,,A
10107,Intermediate,,1,,10090.0,7474,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624587,,,A
10107,Intermediate,,1,,10090.0,7475,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624588,,,A
10107,Intermediate,,1,,10090.0,7476,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624589,,,A
10107,Intermediate,,1,,10090.0,7477,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624590,,,A
10107,Intermediate,,1,,10090.0,7478,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624591,,,A
10107,Intermediate,,1,,10090.0,7479,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624592,,,A
10107,Intermediate,,1,,10090.0,7480,1,50594,,In vivo,Stomach,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL624593,,,A
4689,Intermediate,,1,,10116.0,7481,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624594,,,A
4950,Intermediate,,1,,10116.0,7482,1,50597,,In vivo,,Tested for the bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624595,,,A
5328,Intermediate,,1,,10116.0,7483,1,50597,,In vivo,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624596,,,A
406,Intermediate,,1,,10116.0,7484,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624597,,,A
12500,Intermediate,,1,,10116.0,7485,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624598,,,A
12500,Intermediate,,1,,10116.0,7486,1,50597,,In vivo,,Bioavailability in rat (dose 3-10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624599,,,A
5247,Intermediate,,1,,10116.0,7487,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875166,,,A
4186,Intermediate,,1,,10116.0,7488,1,50597,,In vivo,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624600,,,A
4186,Intermediate,,1,,10116.0,7489,1,50597,,In vivo,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624601,,,A
6647,Intermediate,,1,,10116.0,7490,1,50597,,In vivo,,Half life after oral administration was determined in rats at 6 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624602,,,A
6484,Intermediate,,1,,10116.0,7491,1,50597,,,,Half life was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624603,,,A
3249,Intermediate,,1,,10116.0,7492,1,50597,,In vivo,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624604,,,A
6281,Intermediate,,1,,10116.0,7493,1,50597,,In vivo,Plasma,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624605,,,A
3307,Intermediate,,1,,10116.0,7494,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624606,,,A
12058,Intermediate,,1,,10116.0,7495,1,50597,,In vivo,Blood,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624607,,,A
8833,Intermediate,,1,,10116.0,7496,1,50597,,,,Hill coefficient of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624608,,,A
3193,Intermediate,,1,,10116.0,7497,1,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624609,,,A
3193,Intermediate,,1,,10116.0,7498,1,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624610,,,A
3193,Intermediate,,1,,10116.0,7499,1,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624611,,,A
3193,Intermediate,,1,,10116.0,7500,1,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624612,,,A
3193,Intermediate,,1,,10116.0,7501,1,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL875167,,,A
3193,Intermediate,,1,,10116.0,7502,1,50597,,,Blood,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624613,,,A
3193,Intermediate,,1,,10116.0,7503,1,50597,,,Blood,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624614,,,A
5960,Intermediate,,1,,10116.0,7504,1,50597,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624392,,,A
13950,Intermediate,,1,,10116.0,7505,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624393,,,A
13950,Intermediate,,1,,10116.0,7506,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624394,,,A
13950,Intermediate,,1,,10116.0,7507,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624395,,,A
13950,Intermediate,,1,,10116.0,7508,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624396,,,A
13950,Intermediate,,1,,10116.0,7509,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624397,,,A
13950,Intermediate,,1,,10116.0,7510,1,50597,,In vivo,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624398,,,A
13950,Intermediate,,1,,10116.0,7511,1,50597,,In vivo,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624399,,,A
13950,Intermediate,,1,,10116.0,7512,1,50597,,In vivo,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624400,,,A
13950,Intermediate,,1,,10116.0,7513,1,50597,,In vivo,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624401,,,A
13950,Intermediate,,1,,10116.0,7514,1,50597,,In vivo,Thyroid gland,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624402,,,A
9866,Intermediate,,1,,10116.0,7515,1,50597,,In vivo,Blood,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624403,,,A
9866,Intermediate,,1,,10116.0,7516,1,50597,,In vivo,Blood,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624404,,,A
9866,Intermediate,,1,,10116.0,7517,1,50597,,In vivo,Blood,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624405,,,A
9866,Intermediate,,1,,10116.0,7518,1,50597,,In vivo,Bone,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL624406,,,A
9866,Intermediate,,1,,10116.0,7519,1,50597,,In vivo,Bone,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL624407,,,A
9866,Intermediate,,1,,10116.0,7520,1,50597,,In vivo,Bone,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL624408,,,A
9866,Intermediate,,1,,10116.0,7521,1,50597,,In vivo,Heart,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL618644,,,A
9866,Intermediate,,1,,10116.0,7522,1,50597,,In vivo,Heart,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL618645,,,A
9866,Intermediate,,1,,10116.0,7523,1,50597,,In vivo,Heart,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL618646,,,A
9866,Intermediate,,1,,10116.0,7524,1,50597,,In vivo,Kidney,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL618647,,,A
9866,Intermediate,,1,,10116.0,7525,1,50597,,In vivo,Kidney,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL618648,,,A
9866,Intermediate,,1,,10116.0,7526,1,50597,,In vivo,Kidney,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL618649,,,A
9866,Intermediate,,1,,10116.0,7527,1,50597,,In vivo,Liver,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL618650,,,A
9866,Intermediate,,1,,10116.0,7528,1,50597,,In vivo,Liver,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL618651,,,A
9866,Intermediate,,1,,10116.0,7529,1,50597,,In vivo,Liver,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL876497,,,A
9866,Intermediate,,1,,10116.0,7530,1,50597,,In vivo,Lung,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL618652,,,A
9866,Intermediate,,1,,10116.0,7531,1,50597,,In vivo,Lung,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL618653,,,A
9866,Intermediate,,1,,10116.0,7532,1,50597,,In vivo,Lung,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL618654,,,A
6351,Intermediate,,1,,10116.0,7533,1,50597,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618655,,,A
1465,Intermediate,,1,,10116.0,7534,1,50597,,,,Compound was tested for solubility in water,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618656,,,A
5182,Intermediate,,1,,,7535,0,22229,,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,U,,,BAO_0000100,,CHEMBL618657,,,P
17847,Intermediate,,1,,10116.0,7536,1,50597,,,,Solubility was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618658,,,A
15339,Intermediate,,1,,10116.0,7537,1,50597,,,,solubility in water (ug/mL) at 37 degree C.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618659,,,A
5202,Intermediate,,1,,10116.0,7538,1,50597,,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618660,,,A
1088,Intermediate,,1,,10116.0,7539,1,50597,,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618661,,,A
3169,Intermediate,,1,,10116.0,7540,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873807,,,A
5353,Intermediate,,1,,10116.0,7541,1,50597,,,,Half life in Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618662,,,A
2864,Intermediate,,1,,10116.0,7542,1,50597,,In vivo,,Half life period after 3 mg/kg iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618663,,,A
2864,Intermediate,,1,,10116.0,7543,1,50597,,In vivo,,Half life period after 3 mg/kg iv administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618664,,,A
2864,Intermediate,,1,,10116.0,7544,1,50597,,In vivo,,Half life period after 3 mg/kg iv administration in the rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618665,,,A
6362,Intermediate,,1,,10116.0,7545,1,50597,,,,Half life period in female Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876498,,,A
6249,Intermediate,,1,,10116.0,7546,1,50597,,,,Half life period in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618666,,,A
3169,Intermediate,,1,,10116.0,7547,1,50597,,,,Half-life in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620440,,,A
3169,Intermediate,,1,,10116.0,7548,1,50597,,,,Half-life in rats with metabolic oxidation,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620441,,,A
3169,Intermediate,,1,,10116.0,7549,1,50597,,,,Half-life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620442,,,A
17260,Intermediate,,1,,10116.0,7550,1,50597,,In vivo,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620443,,,A
17260,Intermediate,,1,,10116.0,7551,1,50597,,In vivo,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620444,,,A
17260,Intermediate,,1,,10116.0,7552,1,50597,,In vivo,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620445,,,A
17260,Intermediate,,1,,10116.0,7553,1,50597,,In vivo,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620446,,,A
2879,Intermediate,,1,,10116.0,7554,1,50597,,,Plasma,Biological half-life measured in plasma of rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620447,,,A
2879,Intermediate,,1,,10116.0,7555,1,50597,,,Plasma,Biological half-life measured in plasma of rat; 22-25,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621129,,,A
2879,Intermediate,,1,,10116.0,7556,1,50597,,,Plasma,Biological half-life measured in plasma of rat; 9-16,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621130,,,A
3184,Intermediate,,1,,10116.0,7557,1,50597,,In vivo,,Compound was evaluated for its half life when administered intravenously in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873808,,,A
4891,Intermediate,,1,,10116.0,7558,1,50597,,In vivo,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876598,,,A
429,Intermediate,,1,,10116.0,7559,1,50597,,In vivo,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621131,,,A
5656,Intermediate,,1,,10116.0,7560,1,50597,,In vivo,,Half life (T1/2) after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621132,,,A
4413,Intermediate,,1,,10116.0,7561,1,50597,,In vivo,,Half life of compound after iv administration of 20 mg/kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621133,,,A
3598,Expert,,1,,10116.0,7562,1,50597,,In vivo,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621312,,,A
17267,Intermediate,,1,,10116.0,7563,1,50597,,,,Half life of compound was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621313,,,A
4727,Intermediate,,1,,10116.0,7564,1,50597,,,Blood,Half life of compound was determined in rat blood,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621314,,,A
17651,Intermediate,,1,,10116.0,7565,1,50597,,In vivo,,Half life at 1 mg/kg was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621315,,,A
17651,Intermediate,,1,,10116.0,7566,1,50597,,In vivo,,Half life at 10 mg/kg was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621316,,,A
401,Intermediate,,1,,10116.0,7567,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621317,,,A
4942,Intermediate,,1,,10116.0,7568,1,50597,,,,Half life in rats in hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621318,,,A
17735,Intermediate,,1,,10116.0,7569,1,50597,,In vivo,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621319,,,A
6056,Intermediate,,1,,10116.0,7570,1,50597,,In vivo,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621377,,,A
5213,Intermediate,,1,,10116.0,7571,1,50597,,,,Half life was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621378,,,A
6616,Intermediate,,1,,10116.0,7572,1,50597,,In vivo,,Half life after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876599,,,A
5937,Intermediate,,1,,10116.0,7573,1,50597,,In vivo,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621379,,,A
5819,Intermediate,,1,,10116.0,7574,1,50597,,,Plasma,Half life in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621380,,,A
5819,Intermediate,,1,,10116.0,7575,1,50597,,,Plasma,Half life in rat plasma; Not detected,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621381,,,A
6803,Intermediate,,1,,10116.0,7576,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618515,,,A
17804,Intermediate,,1,,10116.0,7577,1,50597,,In vivo,,Half life period of compound was determined after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618516,,,A
17804,Intermediate,,1,,10116.0,7578,1,50597,,In vivo,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618517,,,A
5948,Intermediate,,1,,10116.0,7579,1,50597,,,,Half life period in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618518,,,A
1916,Intermediate,,1,,10116.0,7580,1,50597,,In vivo,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618519,,,A
1916,Intermediate,,1,,10116.0,7581,1,50597,,In vivo,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618698,,,A
1916,Intermediate,,1,,10116.0,7582,1,50597,,In vivo,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618862,,,A
4890,Intermediate,,1,,10116.0,7583,1,50597,,In vivo,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618863,,,A
17764,Intermediate,,1,,10116.0,7584,1,50597,,In vivo,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618864,,,A
4727,Intermediate,,1,,10116.0,7585,1,50597,,In vivo,,Half life time in rat the dose of 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618865,,,A
17509,Intermediate,,1,,10116.0,7586,1,50597,,In vivo,,Half-life 24 hr after 10 mg/kg iv administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618866,,,A
17509,Intermediate,,1,,10116.0,7587,1,50597,,In vivo,,Half-life 24 hr after 2 mg/kg iv administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618867,,,A
6597,Intermediate,,1,,10116.0,7588,1,50597,,,,Half-life consistent with the observed metabolic steady state in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875828,,,A
17735,Intermediate,,1,,10116.0,7589,1,50597,,In vivo,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618868,,,A
6597,Intermediate,,1,,10116.0,7590,1,50597,,,,Half-life for oxidative metabolic stability was determined using male human,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618869,,,A
17670,Intermediate,,1,,10116.0,7591,1,50597,,In vivo,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618870,,,A
1696,Intermediate,,1,,10116.0,7592,1,50597,,,Plasma,Half-life in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618871,,,A
1742,Intermediate,,1,,10116.0,7593,1,50597,,,Plasma,Half-life in rat plasma was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618872,,,A
17800,Intermediate,,1,,10116.0,7594,1,50597,,,,Half-life in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873816,,,A
12923,Autocuration,,1,,,7595,0,22224,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,U,,,BAO_0000218,,CHEMBL618873,,,A
11954,Autocuration,,1,,,7596,0,22224,,,,Area under curve after oral dose of 0.1 mg//kg,,U,,,BAO_0000019,,CHEMBL621602,,,A
11954,Autocuration,,1,,,7597,0,22224,,,,Area under curve after oral dose of 0.3 mg/kg,,U,,,BAO_0000218,,CHEMBL621603,,,A
11954,Autocuration,,1,,,7598,0,22224,,,,Area under curve after oral dose of 1 mg/kg,,U,,,BAO_0000218,,CHEMBL621604,,,A
11954,Autocuration,,1,,,7599,0,22224,,,,Area under curve after oral dose of 10 mg/kg,,U,,,BAO_0000218,,CHEMBL621605,,,A
11954,Autocuration,,1,,,7600,0,22224,,,,Area under curve after oral dose of 23.4 mg/kg,,U,,,BAO_0000218,,CHEMBL621606,,,A
11954,Autocuration,,1,,,7601,0,22224,,,,Area under curve after oral dose of 3 mg/kg,,U,,,BAO_0000218,,CHEMBL621607,,,A
11954,Autocuration,,1,,,7602,0,22224,,,,Area under curve after oral dose of 3.87 mg/kg,,U,,,BAO_0000218,,CHEMBL621608,,,A
5237,Autocuration,,1,,,7603,0,22224,,,,Area under curve was determined,,U,,,BAO_0000019,,CHEMBL621609,,,A
4026,Autocuration,,1,,,7604,0,22224,,,,Area under curve at a dose of 10 mg/kg,,U,,,BAO_0000218,,CHEMBL621610,,,A
5237,Intermediate,,1,,10116.0,7605,1,50597,,,,Area under curve was determined; ND=No data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621611,,,A
14793,Intermediate,,1,,10116.0,7606,1,50597,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621612,,,A
14793,Intermediate,,1,,10116.0,7607,1,50597,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622308,,,A
14793,Intermediate,,1,,10116.0,7608,1,50597,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622309,,,A
14793,Intermediate,,1,,10116.0,7609,1,50597,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622310,,,A
14793,Intermediate,,1,,10116.0,7610,1,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622311,,,A
14793,Intermediate,,1,,10116.0,7611,1,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622312,,,A
14793,Intermediate,,1,,10116.0,7612,1,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622931,,,A
14793,Intermediate,,1,,10116.0,7613,1,50597,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622932,,,A
14793,Intermediate,,1,,10116.0,7614,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622736,,,A
14793,Intermediate,,1,,10116.0,7615,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622737,,,A
14793,Intermediate,,1,,10116.0,7616,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622738,,,A
14793,Intermediate,,1,,10116.0,7617,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622739,,,A
14793,Intermediate,,1,,10116.0,7618,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622740,,,A
14793,Intermediate,,1,,10116.0,7619,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622741,,,A
14793,Intermediate,,1,,10116.0,7620,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622742,,,A
14793,Intermediate,,1,,10116.0,7621,1,50597,,,Plasma,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622743,,,A
11637,Intermediate,,1,,10090.0,7622,1,50594,,,Plasma,AUC in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL622744,,,A
11149,Autocuration,,1,,,7623,0,22224,,,,Area under curve was measured from the graph obtained from concentration Vs time,,U,,,BAO_0000019,,CHEMBL624134,,,A
10016,Autocuration,,1,,,7624,0,22224,,,,Area under curve value of compound per hour after oral administration,,U,,,BAO_0000019,,CHEMBL624135,,,A
17796,Intermediate,,1,,10116.0,7625,1,50597,,,,Area under curve was determined after oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624136,,,A
17796,Intermediate,,1,,10116.0,7626,1,50597,,,,Area under curve was determined after oral administration in rats; No data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624137,,,A
17796,Intermediate,,1,,10116.0,7627,1,50597,,,,Area under curve was determined after oral administration in rats;No data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624320,,,A
12923,Intermediate,,1,,9615.0,7628,1,50588,,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624321,,,A
15372,Intermediate,,1,,10116.0,7629,1,50597,,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624322,,,A
15372,Intermediate,,1,,10116.0,7630,1,50597,,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624323,,,A
15372,Intermediate,,1,,10116.0,7631,1,50597,,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624324,,,A
15372,Intermediate,,1,,10116.0,7632,1,50597,,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624325,,,A
15372,Intermediate,,1,,10116.0,7633,1,50597,,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624326,,,A
15372,Intermediate,,1,,10116.0,7634,1,50597,,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624327,,,A
15372,Intermediate,,1,,10116.0,7635,1,50597,,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624328,,,A
14169,Intermediate,,1,,9615.0,7636,1,50588,,,,Area under curve was determined in Dogs after peroral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL627848,,,A
14169,Intermediate,,1,,10116.0,7637,1,50597,,,,Area under curve was determined in Rats after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627849,,,A
14258,Intermediate,,1,,10116.0,7638,1,50597,,,,Area under curve was determined in carotid blood of rat when administered intradermally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627850,,,A
14258,Intermediate,,1,,10116.0,7639,1,50597,,,,Area under curve was determined in portal blood of rat when administered intradermally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627851,,,A
15011,Intermediate,,1,,10090.0,7640,1,50594,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627852,,,A
15011,Intermediate,,1,,10090.0,7641,1,50594,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627853,,,A
15011,Intermediate,,1,,10090.0,7642,1,50594,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,N,,Mus musculus,BAO_0000218,,CHEMBL627854,,,A
15011,Intermediate,,1,,10090.0,7643,1,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627855,,,A
15011,Intermediate,,1,,10090.0,7644,1,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,N,,Mus musculus,BAO_0000218,,CHEMBL627856,,,A
15011,Intermediate,,1,,10090.0,7645,1,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL875339,,,A
15011,Intermediate,,1,,10090.0,7646,1,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,N,,Mus musculus,BAO_0000218,,CHEMBL627857,,,A
11195,Intermediate,,1,,10116.0,7647,1,50597,,In vivo,Spleen,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627858,,,A
10130,Intermediate,,1,,10116.0,7648,1,50597,,,Blood,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627859,,,A
10130,Intermediate,,1,,10116.0,7649,1,50597,,,Brain,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL627860,,,A
10130,Intermediate,,1,,10116.0,7650,1,50597,,,Heart,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627019,,,A
10130,Intermediate,,1,,10116.0,7651,1,50597,,,Liver,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627020,,,A
10130,Intermediate,,1,,10116.0,7652,1,50597,,,Lung,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627021,,,A
10130,Intermediate,,1,,10116.0,7653,1,50597,,,Muscle tissue,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627022,,,A
10130,Intermediate,,1,,10116.0,7654,1,50597,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627023,,,A
10130,Intermediate,,1,,10116.0,7655,1,50597,,,Spleen,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627024,,,A
10130,Intermediate,,1,,10116.0,7656,1,50597,,,Thyroid gland,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627025,,,A
10130,Intermediate,,1,,10116.0,7657,1,50597,,,Kidney,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627026,,,A
10130,Intermediate,,1,,10116.0,7658,1,50597,,,Blood,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627027,,,A
10130,Intermediate,,1,,10116.0,7659,1,50597,,,Brain,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL627028,,,A
10130,Intermediate,,1,,10116.0,7660,1,50597,,,Heart,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627029,,,A
10130,Intermediate,,1,,10116.0,7661,1,50597,,,Kidney,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627030,,,A
10130,Intermediate,,1,,10116.0,7662,1,50597,,,Liver,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627031,,,A
10130,Intermediate,,1,,10116.0,7663,1,50597,,,Lung,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627032,,,A
10130,Intermediate,,1,,10116.0,7664,1,50597,,,Muscle tissue,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627033,,,A
10130,Intermediate,,1,,10116.0,7665,1,50597,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627034,,,A
10130,Intermediate,,1,,10116.0,7666,1,50597,,,Spleen,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627035,,,A
10130,Intermediate,,1,,10116.0,7667,1,50597,,,Thyroid gland,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627036,,,A
10130,Intermediate,,1,,10116.0,7668,1,50597,,,Blood,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL875340,,,A
10130,Intermediate,,1,,10116.0,7669,1,50597,,,Heart,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627037,,,A
10130,Intermediate,,1,,10116.0,7670,1,50597,,,Kidney,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627038,,,A
10130,Intermediate,,1,,10116.0,7671,1,50597,,,Liver,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627039,,,A
10130,Intermediate,,1,,10116.0,7672,1,50597,,,Muscle tissue,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627040,,,A
10130,Intermediate,,1,,10116.0,7673,1,50597,,,Spleen,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL624663,,,A
10130,Intermediate,,1,,10116.0,7674,1,50597,,,Thyroid gland,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL625963,,,A
10130,Intermediate,,1,,10116.0,7675,1,50597,,,Brain,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL876799,,,A
10130,Intermediate,,1,,10116.0,7676,1,50597,,,Lung,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626133,,,A
10130,Intermediate,,1,,10116.0,7677,1,50597,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626134,,,A
6295,Intermediate,,1,,10116.0,7678,1,50597,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626135,,,A
6296,Intermediate,,1,,10116.0,7679,1,50597,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626136,,,A
6296,Intermediate,,1,,10116.0,7680,1,50597,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626137,,,A
6295,Intermediate,,1,,10116.0,7681,1,50597,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626138,,,A
6296,Intermediate,,1,,10116.0,7682,1,50597,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626139,,,A
17260,Intermediate,,1,,10116.0,7683,1,50597,,In vivo,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626140,,,A
17260,Intermediate,,1,,10116.0,7684,1,50597,,In vivo,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626141,,,A
17686,Intermediate,,1,,10116.0,7685,1,50597,,,,C24h in rat p.o. at 20 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626142,,,A
9866,Intermediate,,1,,10116.0,7686,1,50597,,In vivo,Muscle tissue,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627930,,,A
9866,Intermediate,,1,,10116.0,7687,1,50597,,In vivo,Muscle tissue,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627931,,,A
9866,Intermediate,,1,,10116.0,7688,1,50597,,In vivo,Muscle tissue,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627932,,,A
9866,Intermediate,,1,,10116.0,7689,1,50597,,In vivo,Spleen,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627933,,,A
9866,Intermediate,,1,,10116.0,7690,1,50597,,In vivo,Spleen,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627934,,,A
9866,Intermediate,,1,,10116.0,7691,1,50597,,In vivo,Spleen,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627935,,,A
9866,Intermediate,,1,,10116.0,7692,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627936,,,A
9866,Intermediate,,1,,10116.0,7693,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627937,,,A
9866,Intermediate,,1,,10116.0,7694,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627938,,,A
9866,Intermediate,,1,,10116.0,7695,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627939,,,A
9866,Intermediate,,1,,10116.0,7696,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627940,,,A
9866,Intermediate,,1,,10116.0,7697,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627941,,,A
9866,Intermediate,,1,,10116.0,7698,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL876800,,,A
9866,Intermediate,,1,,10116.0,7699,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627942,,,A
9866,Intermediate,,1,,10116.0,7700,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627943,,,A
9866,Intermediate,,1,,10116.0,7701,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627944,,,A
9866,Intermediate,,1,,10116.0,7702,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627945,,,A
9866,Intermediate,,1,,10116.0,7703,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628584,,,A
9866,Intermediate,,1,,10116.0,7704,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628585,,,A
9866,Intermediate,,1,,10116.0,7705,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628586,,,A
9866,Intermediate,,1,,10116.0,7706,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628587,,,A
9866,Intermediate,,1,,10116.0,7707,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628588,,,A
9866,Intermediate,,1,,10116.0,7708,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628589,,,A
9866,Intermediate,,1,,10116.0,7709,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625304,,,A
9866,Intermediate,,1,,10116.0,7710,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625305,,,A
9866,Intermediate,,1,,10116.0,7711,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625306,,,A
9866,Intermediate,,1,,10116.0,7712,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625307,,,A
9866,Intermediate,,1,,10116.0,7713,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625308,,,A
9866,Intermediate,,1,,10116.0,7714,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627740,,,A
9866,Intermediate,,1,,10116.0,7715,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627741,,,A
9866,Intermediate,,1,,10116.0,7716,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627742,,,A
9866,Intermediate,,1,,10116.0,7717,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627743,,,A
9866,Intermediate,,1,,10116.0,7718,1,50597,,In vivo,Blood,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627744,,,A
9866,Intermediate,,1,,10116.0,7719,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627745,,,A
9866,Intermediate,,1,,10116.0,7720,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627746,,,A
9866,Intermediate,,1,,10116.0,7721,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627747,,,A
9866,Intermediate,,1,,10116.0,7722,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL876810,,,A
9866,Intermediate,,1,,10116.0,7723,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627748,,,A
9866,Intermediate,,1,,10116.0,7724,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627749,,,A
9866,Intermediate,,1,,10116.0,7725,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627750,,,A
9866,Intermediate,,1,,10116.0,7726,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618728,,,A
9866,Intermediate,,1,,10116.0,7727,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618729,,,A
9866,Intermediate,,1,,10116.0,7728,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618730,,,A
9866,Intermediate,,1,,10116.0,7729,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618731,,,A
9866,Intermediate,,1,,10116.0,7730,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618732,,,A
9866,Intermediate,,1,,10116.0,7731,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618733,,,A
9866,Intermediate,,1,,10116.0,7732,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618734,,,A
9866,Intermediate,,1,,10116.0,7733,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618735,,,A
9866,Intermediate,,1,,10116.0,7734,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL876602,,,A
9866,Intermediate,,1,,10116.0,7735,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618736,,,A
9866,Intermediate,,1,,10116.0,7736,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618737,,,A
9866,Intermediate,,1,,10116.0,7737,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618738,,,A
9866,Intermediate,,1,,10116.0,7738,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618739,,,A
9866,Intermediate,,1,,10116.0,7739,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618740,,,A
9866,Intermediate,,1,,10116.0,7740,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618741,,,A
9866,Intermediate,,1,,10116.0,7741,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618742,,,A
9866,Intermediate,,1,,10116.0,7742,1,50597,,In vivo,Bone,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL618743,,,A
17752,Intermediate,,1,,10116.0,7743,1,50597,,In vivo,Plasma,Half-life from rat plasma at a single oral dose of 25 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618744,,,A
5610,Intermediate,,1,,10116.0,7744,1,50597,,,,Half-life in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618745,,,A
5939,Intermediate,,1,,10116.0,7745,1,50597,,In vivo,,Half-life in rat after peroral administration at 10 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620479,,,A
5939,Intermediate,,1,,10116.0,7746,1,50597,,In vivo,,Half-life in rat after peroral administration at 5 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620480,,,A
17771,Intermediate,,1,,10116.0,7747,1,50597,,In vivo,,Half-life in rat at a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620481,,,A
1974,Intermediate,,1,,10116.0,7748,1,50597,,,,Half-life was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620482,,,A
4239,Intermediate,,1,,10116.0,7749,1,50597,,,,Half-life was measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876603,,,A
6681,Intermediate,,1,,10116.0,7750,1,50597,,In vivo,,Half-life period for the compound was determined in rats at 50 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620483,,,A
17752,Intermediate,,1,,10116.0,7751,1,50597,,In vivo,,Half-life period in rats after intravenous administration at 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620484,,,A
6046,Intermediate,,1,,10116.0,7752,1,50597,,In vivo,,Half-life period in rat at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620485,,,A
6685,Intermediate,,1,,10116.0,7753,1,50597,,In vivo,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620486,,,A
6685,Intermediate,,1,,10116.0,7754,1,50597,,In vivo,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620487,,,A
6685,Intermediate,,1,,10116.0,7755,1,50597,,In vivo,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620488,,,A
4727,Intermediate,,1,,10116.0,7756,1,50597,,In vivo,,Half-life time in rat the dose of 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620489,,,A
1088,Intermediate,,1,,10116.0,7757,1,50597,,In vivo,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620490,,,A
5610,Intermediate,,1,,10116.0,7758,1,50597,,In vivo,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620491,,,A
3032,Intermediate,,1,,10116.0,7759,1,50597,,In vivo,Plasma,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876604,,,A
5199,Intermediate,,1,,10116.0,7760,1,50597,,In vivo,,Oral half life was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620492,,,A
14941,Intermediate,,1,,10116.0,7761,1,50597,,In vivo,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620493,,,A
4408,Intermediate,,1,,10116.0,7762,1,50597,,In vivo,,Pharmacokinetic property (t1/2) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620494,,,A
2552,Intermediate,,1,,10116.0,7763,1,50597,,,Plasma,Plasma elimination half-life was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620495,,,A
5199,Intermediate,,1,,10116.0,7764,1,50597,,In vivo,Plasma,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620496,,,A
15662,Intermediate,,1,,10116.0,7765,1,50597,,In vivo,Plasma,Plasma half life was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620497,,,A
1465,Intermediate,,1,,10116.0,7766,1,50597,,,Plasma,Plasma half-life was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620498,,,A
1446,Intermediate,,1,,10116.0,7767,1,50597,,In vivo,Plasma,Plasma half-life following oral administration in Fisher rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620499,,,A
6824,Intermediate,,1,,10116.0,7768,1,50597,,,Plasma,Plasma half-life in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620500,,,A
17533,Intermediate,,1,,10116.0,7769,1,50597,,In vivo,Plasma,Plasmatic Half-life after intravenous administration to rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873809,,,A
5979,Intermediate,,1,,10116.0,7770,1,50597,,In vivo,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620501,,,A
4689,Intermediate,,1,,10116.0,7771,1,50597,,In vivo,,Terminal half life after intravenous administration (1 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620502,,,A
4689,Intermediate,,1,,10116.0,7772,1,50597,,In vivo,,Terminal half life in Rat at a oral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620503,,,A
2463,Intermediate,,1,,10116.0,7773,1,50597,,In vivo,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620504,,,A
4883,Intermediate,,1,,10116.0,7774,1,50597,,In vivo,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876605,,,A
4883,Intermediate,,1,,10116.0,7775,1,50597,,In vivo,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620505,,,A
15662,Intermediate,,1,,10116.0,7776,1,50597,,In vivo,Plasma,plasma half life was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873811,,,A
3598,Expert,,1,,10116.0,7777,1,50597,,In vivo,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624016,,,A
4576,Intermediate,,1,,10116.0,7778,1,50597,,,,Half life of compound determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624017,,,A
4576,Intermediate,,1,,10116.0,7779,1,50597,,,,Mean residence time determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624018,,,A
4576,Intermediate,,1,,10116.0,7780,1,50597,,,,Plasma half life determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624019,,,A
4910,Intermediate,,1,,10116.0,7781,1,50597,,In vivo,Brain,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624020,,,A
4891,Intermediate,,1,,10116.0,7782,1,50597,,In vivo,,Compound was evaluated for pharmacokinetic parameter maximum time period,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624201,,,A
429,Intermediate,,1,,10116.0,7783,1,50597,,In vivo,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL872528,,,A
5974,Intermediate,,1,,10116.0,7784,1,50597,,In vivo,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624202,,,A
5974,Intermediate,,1,,10116.0,7785,1,50597,,In vivo,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624203,,,A
5974,Intermediate,,1,,10116.0,7786,1,50597,,In vivo,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624350,,,A
5974,Intermediate,,1,,10116.0,7787,1,50597,,In vivo,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621320,,,A
17582,Intermediate,,1,,10116.0,7788,1,50597,,In vivo,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621321,,,A
4026,Intermediate,,1,,10116.0,7789,1,50597,,,,Maximum time (Tmax) required to reach Cmax in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621322,,,A
4890,Intermediate,,1,,10116.0,7790,1,50597,,In vivo,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621323,,,A
6571,Intermediate,,1,,10116.0,7791,1,50597,,In vivo,,Maximum time of clearance of compound in rats after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621324,,,A
4727,Intermediate,,1,,10116.0,7792,1,50597,,,,Maximum time at the dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621325,,,A
17651,Intermediate,,1,,10116.0,7793,1,50597,,In vivo,Plasma,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL875837,,,A
17651,Intermediate,,1,,10116.0,7794,1,50597,,In vivo,Plasma,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621326,,,A
14465,Intermediate,,1,,10116.0,7795,1,50597,,In vivo,,Tmax in Guinea pig (PO dose),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621327,,,A
14941,Intermediate,,1,,10116.0,7796,1,50597,,In vivo,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621328,,,A
5960,Intermediate,,1,,10116.0,7797,1,50597,,In vivo,,Pharmacokinetic parameter (Tmax) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621329,,,A
5022,Intermediate,,1,,10116.0,7798,1,50597,,In vivo,,Pharmacokinetic parameter (Tmax) was estimated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621330,,,A
4408,Intermediate,,1,,10116.0,7799,1,50597,,In vivo,,Pharmacokinetic property (Tmax) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621331,,,A
5983,Intermediate,,1,,10116.0,7800,1,50597,,In vivo,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621332,,,A
4689,Intermediate,,1,,10116.0,7801,1,50597,,In vivo,,T max in Rat at a oral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621333,,,A
2792,Intermediate,,1,,10116.0,7802,1,50597,,In vivo,,T max was determined at 10 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621334,,,A
15011,Intermediate,,1,,10090.0,7803,1,50594,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,N,,Mus musculus,BAO_0000218,,CHEMBL621335,,,A
14180,Intermediate,,1,,9615.0,7804,1,50588,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621336,,,A
14180,Intermediate,,1,,10116.0,7805,1,50597,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621337,,,A
14599,Intermediate,,1,,9615.0,7806,1,50588,,,,Area under curve was measured after i.v. administration into Beagle dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621338,,,A
14599,Intermediate,,1,,9615.0,7807,1,50588,,,,Area under curve was measured after iv administration into Beagle dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875838,,,A
14599,Intermediate,,1,,9615.0,7808,1,50588,,,,Area under curve was measured after po administration into Beagle dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621339,,,A
14599,Intermediate,,1,,9615.0,7809,1,50588,,,,Area under curve was measured after po administration into Beagle dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621340,,,A
15675,Autocuration,,1,,,7810,0,22224,,,,Area under curve was measured at peroral dose of 3 mg/kg,,U,,,BAO_0000218,,CHEMBL621341,,,A
12706,Autocuration,,1,,,7811,0,22224,,,,Area under curve was measured by using concentration Vs time,,U,,,BAO_0000019,,CHEMBL621342,,,A
12706,Autocuration,,1,,,7812,0,22224,,,,Area under curve was measured by using concentration Vs time; not tested,,U,,,BAO_0000019,,CHEMBL621343,,,A
9750,Intermediate,,1,,10090.0,7813,1,50594,,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,N,,Mus musculus,BAO_0000218,,CHEMBL621344,,,A
9750,Intermediate,,1,,10090.0,7814,1,50594,,,,Area under curve(AUC) was measured in mice after oral administration.,,N,,Mus musculus,BAO_0000218,,CHEMBL621345,,,A
14691,Autocuration,,1,,,7815,0,22224,,,,Area under curve(AUC) value of the compound,,U,,,BAO_0000019,,CHEMBL621346,,,A
14691,Autocuration,,1,,,7816,0,22224,,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,U,,,BAO_0000218,,CHEMBL621347,,,A
14691,Intermediate,,1,,9615.0,7817,1,50588,,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621348,,,A
2939,Autocuration,,1,,,7818,0,22224,,,Blood,Area under curve(carotid artery) was determined by the availability in blood,,U,,,BAO_0000019,178.0,CHEMBL621349,,,A
2939,Autocuration,,1,,,7819,0,22224,,,Blood,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,U,,,BAO_0000019,178.0,CHEMBL621350,,,A
2939,Autocuration,,1,,,7820,0,22224,,,Blood,Area under curve(carotid artery) was determined by the availability in blood; No data,,U,,,BAO_0000019,178.0,CHEMBL875839,,,A
2939,Autocuration,,1,,,7821,0,22224,,,Blood,Area under curve(portal vein) was determined by the availability in blood,,U,,,BAO_0000019,178.0,CHEMBL620211,,,A
2939,Autocuration,,1,,,7822,0,22224,,,Blood,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,U,,,BAO_0000019,178.0,CHEMBL620212,,,A
2939,Autocuration,,1,,,7823,0,22224,,,Blood,Area under curve(portal vein) was determined by the availability in blood; No data,,U,,,BAO_0000019,178.0,CHEMBL620213,,,A
9552,Intermediate,,1,,9544.0,7824,1,50797,,,Plasma,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,N,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL620214,,,A
9552,Intermediate,,1,,9544.0,7825,1,50797,,,Plasma,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,N,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL620215,,,A
9552,Intermediate,,1,,9544.0,7826,1,50797,,,Plasma,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,N,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL620216,,,A
9552,Intermediate,,1,,9615.0,7827,1,50588,,,Plasma,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620888,,,A
9552,Intermediate,,1,,9615.0,7828,1,50588,,,Plasma,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL620889,,,A
9552,Autocuration,,1,,,7829,0,22224,,,Plasma,Area under plasma concentration vs time curve observed in rats for 0-3 h,,U,,,BAO_0000019,1969.0,CHEMBL620890,,,A
11911,Intermediate,,1,,10116.0,7830,1,50597,,,Plasma,Area under plasma time curve determined in male rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL620891,,,A
16618,Autocuration,,1,,,7831,0,22224,,,,Area under the MAP curve measured over 5 min.,,U,,,BAO_0000019,,CHEMBL620892,,,A
14387,Intermediate,,1,,10090.0,7832,1,50594,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621079,,,A
14387,Intermediate,,1,,10090.0,7833,1,50594,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL621080,,,A
12836,Intermediate,,1,,9615.0,7834,1,50588,,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621081,,,A
12836,Intermediate,,1,,10026.0,7835,1,100712,,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,N,,Cricetinae,BAO_0000218,,CHEMBL621082,,,A
12836,Intermediate,,1,,10116.0,7836,1,50597,,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621083,,,A
14339,Intermediate,,1,,9615.0,7837,1,50588,,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621084,,,A
14339,Intermediate,,1,,9615.0,7838,1,50588,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621085,,,A
14339,Intermediate,,1,,9615.0,7839,1,50588,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621086,,,A
10524,Intermediate,,1,,9615.0,7840,1,50588,,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621087,,,A
9994,Intermediate,,1,,9615.0,7841,1,50588,,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622607,,,A
11325,Intermediate,,1,,9615.0,7842,1,50588,,,,Serum AUC in marmosets (IV dose),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622608,,,A
12536,Autocuration,,1,,,7843,0,22224,,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,U,,,BAO_0000019,,CHEMBL624481,,,A
12536,Autocuration,,1,,,7844,0,22224,,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,U,,,BAO_0000019,,CHEMBL624482,,,A
12536,Autocuration,,1,,,7845,0,22224,,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,U,,,BAO_0000019,,CHEMBL624483,,,A
12536,Autocuration,,1,,,7846,0,22224,,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,U,,,BAO_0000019,,CHEMBL624484,,,A
12536,Autocuration,,1,,,7847,0,22224,,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,U,,,BAO_0000019,,CHEMBL624485,,,A
15556,Intermediate,,1,,10116.0,7848,1,50597,,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624486,,,A
2809,Autocuration,,1,,,7849,0,22224,,,,Area under the curve for the compound was calculated.,,U,,,BAO_0000019,,CHEMBL624487,,,A
9511,Autocuration,,1,,,7850,0,22224,,,,Area under the curve in concentration/ time,,U,,,BAO_0000019,,CHEMBL624488,,,A
12818,Intermediate,,1,,10116.0,7851,1,50597,,,,Area under the curve administered intraintestinal in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624489,,,A
12818,Intermediate,,1,,10116.0,7852,1,50597,,,,Area under the curve administered intravenously in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625184,,,A
15118,Autocuration,,1,,,7853,0,22224,,,,Area under the curve during intravenous administration,,U,,,BAO_0000019,,CHEMBL625185,,,A
15118,Autocuration,,1,,,7854,0,22224,,,,Area under the curve during intravenous administration; Not determined,,U,,,BAO_0000019,,CHEMBL875954,,,A
15118,Autocuration,,1,,,7855,0,22224,,,,Area under the curve during systemic administration,,U,,,BAO_0000019,,CHEMBL625186,,,A
15118,Autocuration,,1,,,7856,0,22224,,,,Area under the curve during systemic administration; Not determined,,U,,,BAO_0000019,,CHEMBL625187,,,A
2632,Autocuration,,1,,,7857,0,22224,,,,Area under the curve was calculated for the compound.,,U,,,BAO_0000019,,CHEMBL625188,,,A
14346,Intermediate,,1,,9615.0,7858,1,50588,,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625189,,,A
14346,Intermediate,,1,,9615.0,7859,1,50588,,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625190,,,A
14346,Intermediate,,1,,10116.0,7860,1,50597,,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621733,,,A
14346,Intermediate,,1,,10116.0,7861,1,50597,,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621734,,,A
11149,Intermediate,,1,,10116.0,7862,1,50597,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621735,,,A
17796,Intermediate,,1,,10116.0,7863,1,50597,,,Plasma,Clearance of the drug was measured in the plasma of rat; No data,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621736,,,A
5247,Intermediate,,1,,10116.0,7864,1,50597,,,Plasma,The pharmacokinetic parameter plasma clearance in vivo in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621737,,,A
4727,Intermediate,,1,,10116.0,7865,1,50597,,,,Plasma clearance at the dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621738,,,A
5654,Intermediate,,1,,10116.0,7866,1,50597,,In vivo,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622806,,,A
5654,Intermediate,,1,,10116.0,7867,1,50597,,In vivo,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623519,,,A
17260,Intermediate,,1,,10116.0,7868,1,50597,,In vivo,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623520,,,A
17065,Intermediate,,1,,10116.0,7869,1,50597,,In vivo,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623521,,,A
17671,Intermediate,,1,,10116.0,7870,1,50597,,In vivo,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623522,,,A
6672,Intermediate,,1,,10116.0,7871,1,50597,,In vivo,,Clearance rate in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623523,,,A
6673,Intermediate,,1,,10116.0,7872,1,50597,,In vivo,,Clearance rate in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623690,,,A
5978,Intermediate,,1,,10116.0,7873,1,50597,,In vivo,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623691,,,A
5978,Intermediate,,1,,10116.0,7874,1,50597,,In vivo,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623692,,,A
5978,Intermediate,,1,,10116.0,7875,1,50597,,In vivo,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623693,,,A
5978,Intermediate,,1,,10116.0,7876,1,50597,,In vivo,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623694,,,A
4413,Intermediate,,1,,10116.0,7877,1,50597,,In vivo,,Clearance of compound after iv administration of 20 mg/kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623695,,,A
2661,Intermediate,,1,,10116.0,7878,1,50597,,In vivo,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623696,,,A
2661,Intermediate,,1,,10116.0,7879,1,50597,,In vivo,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623697,,,A
5005,Intermediate,,1,,9544.0,7880,0,22224,,In vivo,Plasma,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL623698,,,A
5005,Intermediate,,1,,10116.0,7881,0,22224,,In vivo,Plasma,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,U,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623699,,,A
15765,Intermediate,,1,,10116.0,7882,1,50597,,In vivo,,Mean (%CV) PK parameters for CL(mL/min/kg).,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623700,,,A
3747,Intermediate,,1,,10116.0,7883,1,50597,,In vivo,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623701,,,A
16366,Intermediate,,1,,10116.0,7884,1,50597,,In vivo,Plasma,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623702,,,A
4199,Intermediate,,1,,10116.0,7885,1,50597,,In vivo,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623703,,,A
17267,Intermediate,,1,,10116.0,7886,1,50597,,In vivo,,Plasma clearance in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623704,,,A
6535,Intermediate,,1,,10116.0,7887,1,50597,,In vivo,,Plasma clearance in rat after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623705,,,A
6535,Intermediate,,1,,10116.0,7888,1,50597,,In vivo,,Plasma clearance in rat after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623706,,,A
5041,Intermediate,,1,,10116.0,7889,1,50597,,In vivo,,Plasma clearance was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623707,,,A
5960,Intermediate,,1,,10116.0,7890,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623708,,,A
5937,Intermediate,,1,,10116.0,7891,1,50597,,In vivo,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623709,,,A
5871,Intermediate,,1,,10116.0,7892,1,50597,,In vivo,,Plasma clearance in rat by iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623710,,,A
5874,Intermediate,,1,,10116.0,7893,1,50597,,In vivo,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623711,,,A
6504,Intermediate,,1,,10116.0,7894,1,50597,,In vivo,,Plasma clearance in rat p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623712,,,A
6803,Intermediate,,1,,10116.0,7895,1,50597,,In vivo,,Plasma clearance in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623713,,,A
5041,Intermediate,,1,,10116.0,7896,1,50597,,In vivo,,Plasma clearance was determined; ND denotes no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623714,,,A
5041,Intermediate,,1,,10116.0,7897,1,50597,,In vivo,,Plasma clearance was determined; ND denotes not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623715,,,A
1916,Intermediate,,1,,10116.0,7898,1,50597,,In vivo,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623716,,,A
5199,Intermediate,,1,,10116.0,7899,1,50597,,In vivo,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622980,,,A
16367,Intermediate,,1,,10116.0,7900,1,50597,,In vivo,,Plasma administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622981,,,A
6362,Intermediate,,1,,10116.0,7901,1,50597,,In vivo,,Plasma clearance of the compound in female Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622982,,,A
15662,Intermediate,,1,,10116.0,7902,1,50597,,In vivo,,Plasma clearance was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622983,,,A
6215,Intermediate,,1,,10116.0,7903,1,50597,,In vivo,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622984,,,A
1466,Intermediate,,1,,10116.0,7904,1,50597,,In vivo,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622985,,,A
15662,Intermediate,,1,,10116.0,7905,1,50597,,In vivo,Plasma,plasma clearance was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623631,,,A
4723,Intermediate,,1,,10116.0,7906,1,50597,,In vivo,,In vivo CL/F determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623632,,,A
2792,Intermediate,,1,,10116.0,7907,1,50597,,In vivo,Plasma,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623633,,,A
2792,Intermediate,,1,,10116.0,7908,1,50597,,In vivo,Plasma,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623634,,,A
5213,Intermediate,,1,,10116.0,7909,1,50597,,In vivo,,Compound was tested for the lower blood clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623635,,,A
4687,Intermediate,,1,,10116.0,7910,1,50597,,In vivo,,Evaluated for the low clearance in rat (in vivo),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621195,,,A
3371,Intermediate,,1,,10116.0,7911,1,50597,,In vivo,,Pharmacokinetic property (CLb)of the compound was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621196,,,A
4690,Intermediate,,1,,10116.0,7912,1,50597,,In vivo,,Rapid clearance after intravenous administration in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875287,,,A
5702,Intermediate,,1,,10116.0,7913,1,50597,,In vivo,,Clearance measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621197,,,A
740,Intermediate,,1,,10116.0,7914,1,50597,,In vivo,Plasma,Compound was evaluated for plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621198,,,A
4853,Intermediate,,1,,10116.0,7915,1,50597,,In vivo,Plasma,Low plasma clearance was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621199,,,A
5789,Intermediate,,1,,10116.0,7916,1,50597,,In vivo,,Pharmacokinetic property (Clp) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621200,,,A
4527,Intermediate,,1,,10116.0,7917,1,50597,,In vivo,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621201,,,A
4527,Intermediate,,1,,10116.0,7918,1,50597,,In vivo,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621202,,,A
6518,Intermediate,,1,,10116.0,7919,1,50597,,In vivo,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621203,,,A
6518,Intermediate,,1,,10116.0,7920,1,50597,,In vivo,,Plasma clearance after IV dosing at 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621204,,,A
9866,Intermediate,,1,,10116.0,7921,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621205,,,A
9866,Intermediate,,1,,10116.0,7922,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621206,,,A
9866,Intermediate,,1,,10116.0,7923,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621207,,,A
9866,Intermediate,,1,,10116.0,7924,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621208,,,A
9866,Intermediate,,1,,10116.0,7925,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621209,,,A
9866,Intermediate,,1,,10116.0,7926,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL876484,,,A
9866,Intermediate,,1,,10116.0,7927,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621210,,,A
9866,Intermediate,,1,,10116.0,7928,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621211,,,A
9866,Intermediate,,1,,10116.0,7929,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621212,,,A
9866,Intermediate,,1,,10116.0,7930,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621213,,,A
9866,Intermediate,,1,,10116.0,7931,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621214,,,A
9866,Intermediate,,1,,10116.0,7932,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621215,,,A
9866,Intermediate,,1,,10116.0,7933,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621216,,,A
9866,Intermediate,,1,,10116.0,7934,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621217,,,A
9866,Intermediate,,1,,10116.0,7935,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621218,,,A
9866,Intermediate,,1,,10116.0,7936,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621219,,,A
9866,Intermediate,,1,,10116.0,7937,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621220,,,A
9866,Intermediate,,1,,10116.0,7938,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621221,,,A
9866,Intermediate,,1,,10116.0,7939,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621222,,,A
9866,Intermediate,,1,,10116.0,7940,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621223,,,A
9866,Intermediate,,1,,10116.0,7941,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL876485,,,A
9866,Intermediate,,1,,10116.0,7942,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621224,,,A
9866,Intermediate,,1,,10116.0,7943,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621225,,,A
9866,Intermediate,,1,,10116.0,7944,1,50597,,In vivo,Heart,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621226,,,A
9866,Intermediate,,1,,10116.0,7945,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621227,,,A
9866,Intermediate,,1,,10116.0,7946,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621228,,,A
9866,Intermediate,,1,,10116.0,7947,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621229,,,A
9866,Intermediate,,1,,10116.0,7948,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621230,,,A
9866,Intermediate,,1,,10116.0,7949,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621231,,,A
9866,Intermediate,,1,,10116.0,7950,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621232,,,A
9866,Intermediate,,1,,10116.0,7951,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621233,,,A
9866,Intermediate,,1,,10116.0,7952,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621234,,,A
9866,Intermediate,,1,,10116.0,7953,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621235,,,A
9866,Intermediate,,1,,10116.0,7954,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621236,,,A
9866,Intermediate,,1,,10116.0,7955,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621237,,,A
9866,Intermediate,,1,,10116.0,7956,1,50597,,In vivo,Kidney,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL876486,,,A
9866,Intermediate,,1,,10116.0,7957,1,50597,,In vivo,Intestine,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622436,,,A
9866,Intermediate,,1,,10116.0,7958,1,50597,,In vivo,Intestine,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622437,,,A
9866,Intermediate,,1,,10116.0,7959,1,50597,,In vivo,Intestine,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622438,,,A
9866,Intermediate,,1,,10116.0,7960,1,50597,,In vivo,Liver,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622439,,,A
9866,Intermediate,,1,,10116.0,7961,1,50597,,In vivo,Liver,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622440,,,A
9866,Intermediate,,1,,10116.0,7962,1,50597,,In vivo,Liver,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622441,,,A
9866,Intermediate,,1,,10116.0,7963,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622442,,,A
9866,Intermediate,,1,,10116.0,7964,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622443,,,A
9866,Intermediate,,1,,10116.0,7965,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622444,,,A
9866,Intermediate,,1,,10116.0,7966,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622445,,,A
9866,Intermediate,,1,,10116.0,7967,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622446,,,A
9866,Intermediate,,1,,10116.0,7968,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622447,,,A
9866,Intermediate,,1,,10116.0,7969,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622448,,,A
9866,Intermediate,,1,,10116.0,7970,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622449,,,A
9866,Intermediate,,1,,10116.0,7971,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622450,,,A
9866,Intermediate,,1,,10116.0,7972,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622451,,,A
9866,Intermediate,,1,,10116.0,7973,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622452,,,A
9866,Intermediate,,1,,10116.0,7974,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622453,,,A
9866,Intermediate,,1,,10116.0,7975,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622454,,,A
9866,Intermediate,,1,,10116.0,7976,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622455,,,A
9866,Intermediate,,1,,10116.0,7977,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL876024,,,A
2792,Intermediate,,1,,10116.0,7978,1,50597,,In vivo,,T max was determined at 3 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622456,,,A
15078,Intermediate,,1,,10116.0,7979,1,50597,,In vivo,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622457,,,A
15078,Intermediate,,1,,10116.0,7980,1,50597,,In vivo,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622458,,,A
15022,Intermediate,,1,,10116.0,7981,1,50597,,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622459,,,A
15022,Intermediate,,1,,10116.0,7982,1,50597,,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873343,,,A
15022,Intermediate,,1,,10116.0,7983,1,50597,,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622460,,,A
4576,Intermediate,,1,,10116.0,7984,1,50597,,,Plasma,Time for maximum plasma concentration determined in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622461,,,A
6681,Intermediate,,1,,10116.0,7985,1,50597,,In vivo,Plasma,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622462,,,A
16365,Intermediate,,1,,10116.0,7986,1,50597,,In vivo,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622463,,,A
16365,Intermediate,,1,,10116.0,7987,1,50597,,In vivo,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622464,,,A
16365,Intermediate,,1,,10116.0,7988,1,50597,,In vivo,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622465,,,A
16365,Intermediate,,1,,10116.0,7989,1,50597,,In vivo,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622466,,,A
16365,Intermediate,,1,,10116.0,7990,1,50597,,In vivo,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622467,,,A
6824,Intermediate,,1,,10116.0,7991,1,50597,,,Plasma,Time of maximum plasma concentration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622468,,,A
6685,Intermediate,,1,,10116.0,7992,1,50597,,,Plasma,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876025,,,A
6685,Intermediate,,1,,10116.0,7993,1,50597,,,Plasma,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622469,,,A
6685,Intermediate,,1,,10116.0,7994,1,50597,,,Plasma,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622470,,,A
15662,Intermediate,,1,,10116.0,7995,1,50597,,In vivo,,Time required to reach maximum concentration (Cmax) after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622471,,,A
1742,Intermediate,,1,,10116.0,7996,1,50597,,,Plasma,Time required to reach maximum concentration in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622472,,,A
2774,Intermediate,,1,,10116.0,7997,1,50597,,In vivo,Plasma,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622473,,,A
5199,Intermediate,,1,,10116.0,7998,1,50597,,In vivo,Plasma,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624282,,,A
12873,Intermediate,,1,,10116.0,7999,1,50597,,In vivo,Plasma,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624283,,,A
12873,Intermediate,,1,,10116.0,8000,1,50597,,In vivo,Plasma,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624284,,,A
1916,Intermediate,,1,,10116.0,8001,1,50597,,In vivo,Plasma,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624285,,,A
16367,Intermediate,,1,,10116.0,8002,1,50597,,In vivo,,Time to reach Cmax after oral administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624286,,,A
16366,Intermediate,,1,,10116.0,8003,1,50597,,In vivo,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624287,,,A
216,Intermediate,,1,,10116.0,8004,1,50597,,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624288,,,A
6410,Intermediate,,1,,10116.0,8005,1,50597,,In vivo,Plasma,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624289,,,A
6410,Intermediate,,1,,10116.0,8006,1,50597,,In vivo,Plasma,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873344,,,A
6215,Intermediate,,1,,10116.0,8007,1,50597,,In vivo,,Tmax after peroral administration (10 mg/kg) was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619623,,,A
3598,Expert,,1,,10116.0,8008,1,50597,,In vivo,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621399,,,A
4527,Intermediate,,1,,10116.0,8009,1,50597,,In vivo,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621400,,,A
17670,Intermediate,,1,,10116.0,8010,1,50597,,In vivo,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621401,,,A
1465,Intermediate,,1,,10116.0,8011,1,50597,,,,Tmax was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621402,,,A
2552,Intermediate,,1,,10116.0,8012,1,50597,,,,Tmax was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621403,,,A
5656,Intermediate,,1,,10116.0,8013,1,50597,,In vivo,,Tmax after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621121,,,A
17764,Intermediate,,1,,10116.0,8014,1,50597,,In vivo,,Tmax after peroral administration in rats at 2.4 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL872525,,,A
5610,Intermediate,,1,,10116.0,8015,1,50597,,,,Tmax in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621122,,,A
6046,Intermediate,,1,,10116.0,8016,1,50597,,In vivo,,Tmax in rat at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621123,,,A
5874,Intermediate,,1,,10116.0,8017,1,50597,,In vivo,,Tmax in rat by po administration at a dose of 40 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621124,,,A
17596,Intermediate,,1,,10116.0,8018,1,50597,,,,Tmax in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621125,,,A
17804,Intermediate,,1,,10116.0,8019,1,50597,,In vivo,,Tmax was measured in rats after peroral administration at 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621126,,,A
1908,Intermediate,,1,,10116.0,8020,1,50597,,In vivo,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621127,,,A
2959,Intermediate,,1,,10116.0,8021,1,50597,,In vivo,,Tmax value after administration of 20 mg/Kg oral dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621128,,,A
6757,Intermediate,,1,,10116.0,8022,1,50597,,In vivo,,Tmax value at a dose of 10 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618263,,,A
6757,Intermediate,,1,,10116.0,8023,1,50597,,In vivo,,Tmax value at a dose of 100 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618264,,,A
6757,Intermediate,,1,,10116.0,8024,1,50597,,In vivo,,Tmax value at a dose of 50 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618265,,,A
4186,Intermediate,,1,,10116.0,8025,1,50597,,In vivo,Plasma,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618266,,,A
15662,Intermediate,,1,,10116.0,8026,1,50597,,In vivo,,time required to reach maximum concentration (Cmax) after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618267,,,A
429,Intermediate,,1,,10116.0,8027,1,50597,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL618450,,,A
429,Intermediate,,1,,10116.0,8028,1,50597,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL618451,,,A
5546,Intermediate,,1,,10116.0,8029,1,50597,,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618452,,,A
3173,Intermediate,,1,,10116.0,8030,1,50597,,,Urine,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL618453,,,A
3173,Intermediate,,1,,10116.0,8031,1,50597,,,Urine,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL618454,,,A
3173,Intermediate,,1,,10116.0,8032,1,50597,,,Urine,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL618455,,,A
4257,Intermediate,,1,,10116.0,8033,1,50597,,In vivo,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618456,,,A
6011,Intermediate,,1,,10116.0,8034,1,50597,,In vivo,,Compound distribution in rat tissues was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618457,,,A
5472,Intermediate,,1,,10116.0,8035,1,50597,,In vivo,,Volume of distribution was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618458,,,A
14346,Intermediate,,1,,10116.0,8036,1,50597,,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618459,,,A
14346,Intermediate,,1,,10116.0,8037,1,50597,,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876733,,,A
14346,Intermediate,,1,,9615.0,8038,1,50588,,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL618460,,,A
14346,Intermediate,,1,,10116.0,8039,1,50597,,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618461,,,A
15469,Autocuration,,1,,,8040,0,22224,,,,Area under the curve was determined after oral administration (300 uM/Kg),,U,,,BAO_0000019,,CHEMBL618462,,,A
14346,Intermediate,,1,,10116.0,8041,1,50597,,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618463,,,A
14346,Intermediate,,1,,10116.0,8042,1,50597,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618464,,,A
14346,Intermediate,,1,,10116.0,8043,1,50597,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618465,,,A
14346,Intermediate,,1,,10116.0,8044,1,50597,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618466,,,A
14346,Intermediate,,1,,10116.0,8045,1,50597,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618467,,,A
15372,Intermediate,,1,,10116.0,8046,1,50597,,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618468,,,A
12935,Intermediate,,1,,9615.0,8047,1,50588,,,Plasma,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618469,,,A
12935,Intermediate,,1,,9615.0,8048,1,50588,,,Plasma,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL618470,,,A
14813,Autocuration,,1,,,8049,0,22224,,,,Plasma drug AUC in rat (PO dose),,U,,,BAO_0000218,,CHEMBL618471,,,A
15792,Intermediate,,1,,10090.0,8050,1,50594,,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,N,,Mus musculus,BAO_0000218,,CHEMBL618472,,,A
3579,Autocuration,,1,,,8051,0,22224,,,,Area under was determined at a dose of 30 mg/kg,,U,,,BAO_0000218,,CHEMBL618473,,,A
12487,Intermediate,,1,,9669.0,8052,1,50506,,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL621699,,,A
12487,Intermediate,,1,,10116.0,8053,1,50597,,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621700,,,A
12487,Intermediate,,1,,10116.0,8054,1,50597,,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621701,,,A
12487,Intermediate,,1,,9669.0,8055,1,50506,,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL621702,,,A
12487,Intermediate,,1,,9615.0,8056,1,50588,,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621703,,,A
12487,Intermediate,,1,,9615.0,8057,1,50588,,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL621704,,,A
12902,Intermediate,,1,,10116.0,8058,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624259,,,A
12902,Intermediate,,1,,10116.0,8059,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624260,,,A
12902,Intermediate,,1,,10116.0,8060,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624430,,,A
12902,Intermediate,,1,,10116.0,8061,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624431,,,A
12902,Intermediate,,1,,10116.0,8062,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624432,,,A
12902,Intermediate,,1,,10116.0,8063,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624433,,,A
12902,Intermediate,,1,,10116.0,8064,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624434,,,A
12902,Intermediate,,1,,10116.0,8065,1,50597,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624435,,,A
12745,Intermediate,,1,,10090.0,8066,1,50594,,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,N,,Mus musculus,BAO_0000218,,CHEMBL618570,,,A
12745,Intermediate,,1,,10090.0,8067,1,50594,,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,,Mus musculus,BAO_0000218,,CHEMBL618571,,,A
12745,Intermediate,,1,,10090.0,8068,1,50594,,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,N,,Mus musculus,BAO_0000218,,CHEMBL618572,,,A
12745,Intermediate,,1,,10090.0,8069,1,50594,,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,,Mus musculus,BAO_0000218,,CHEMBL618573,,,A
12745,Intermediate,,1,,10090.0,8070,1,50594,,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,N,,Mus musculus,BAO_0000218,,CHEMBL619267,,,A
12745,Intermediate,,1,,10090.0,8071,1,50594,,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,,Mus musculus,BAO_0000218,,CHEMBL619431,,,A
12745,Intermediate,,1,,10090.0,8072,1,50594,,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,N,,Mus musculus,BAO_0000218,,CHEMBL619432,,,A
12745,Intermediate,,1,,10090.0,8073,1,50594,,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,N,,Mus musculus,BAO_0000218,,CHEMBL619433,,,A
13298,Autocuration,,1,,,8074,0,22224,,,Plasma,AUC in mice after oral dose (50 mg/kg),,U,,,BAO_0000218,1969.0,CHEMBL619434,,,A
12226,Intermediate,,1,,10090.0,8075,1,50594,,,Serum,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,N,,Mus musculus,BAO_0000218,1977.0,CHEMBL619435,,,A
12634,Autocuration,,1,,,8076,0,22224,,,Plasma,AUC (0-4 hr) ug/ml/h,,U,,,BAO_0000019,1969.0,CHEMBL619436,,,A
14810,Intermediate,,1,,10116.0,8077,1,50597,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619437,,,A
13889,Autocuration,,1,,,8078,0,22224,,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,U,,,BAO_0000218,,CHEMBL619438,,,A
10018,Intermediate,,1,,10090.0,8079,1,50594,,,,Compound was evaluated for Area under curve in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL619439,,,A
8758,Intermediate,,1,,10116.0,8080,1,50597,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619440,,,A
8758,Autocuration,,1,,,8081,0,22224,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,U,,,BAO_0000218,,CHEMBL619441,,,F
8758,Intermediate,,1,,10116.0,8082,1,50597,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619442,,,A
2249,Autocuration,,1,,,8083,0,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,U,,,BAO_0000019,,CHEMBL875156,,,A
2249,Autocuration,,1,,,8084,0,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,U,,,BAO_0000019,,CHEMBL619443,,,A
2249,Autocuration,,1,,,8085,0,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,U,,,BAO_0000019,,CHEMBL619444,,,A
2249,Autocuration,,1,,,8086,0,22224,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,U,,,BAO_0000019,,CHEMBL623464,,,A
15115,Intermediate,,1,,10090.0,8087,1,50594,,,,Compound was evaluated for area under curve when administered through oral route in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL623465,,,A
6518,Intermediate,,1,,10116.0,8088,1,50597,,In vivo,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623466,,,A
6518,Intermediate,,1,,10116.0,8089,1,50597,,In vivo,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623467,,,A
6249,Intermediate,,1,,10116.0,8090,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623468,,,A
2463,Intermediate,,1,,10116.0,8091,1,50597,,In vivo,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622660,,,A
4969,Intermediate,,1,,10116.0,8092,1,50597,,In vivo,,Plasma clearance rate in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622661,,,A
17720,Intermediate,,1,,10116.0,8093,1,50597,,In vivo,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622662,,,F
3457,Intermediate,,1,,10116.0,8094,1,50597,,In vivo,,Pharmacokinetic property (total body clearance) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622663,,,A
5983,Intermediate,,1,,10116.0,8095,1,50597,,In vivo,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622664,,,A
6295,Intermediate,,1,,10116.0,8096,1,50597,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622665,,,A
6296,Intermediate,,1,,10116.0,8097,1,50597,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622666,,,A
17686,Intermediate,,1,,10116.0,8098,1,50597,,In vivo,,Cl in rat i.v. at 2 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621615,,,A
17764,Intermediate,,1,,10116.0,8099,1,50597,,In vivo,,Clearance of compound after intravenous administration in rats at 24 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621616,,,A
5503,Intermediate,,1,,10116.0,8100,1,50597,,In vivo,,Clearance was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621617,,,A
4368,Intermediate,,1,,10116.0,8101,1,50597,,In vivo,,Clearance by intravenous administration of 3.4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621618,,,A
6005,Intermediate,,1,,10116.0,8102,1,50597,,In vivo,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621619,,,A
5031,Intermediate,,1,,10116.0,8103,1,50597,,In vivo,,Clearance rate after i.v. administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621620,,,A
4890,Intermediate,,1,,10116.0,8104,1,50597,,In vivo,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621786,,,A
5182,Intermediate,,1,,10116.0,8105,1,50597,,In vivo,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621787,,,A
5979,Intermediate,,1,,10116.0,8106,1,50597,,In vivo,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621788,,,A
5656,Intermediate,,1,,10116.0,8107,1,50597,,In vivo,,Clearance (Cl) after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621789,,,A
17804,Intermediate,,1,,10116.0,8108,1,50597,,In vivo,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621790,,,A
4839,Intermediate,,1,,10116.0,8109,1,50597,,In vivo,Plasma,Compound was tested for plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621791,,,A
5041,Intermediate,,1,,10116.0,8110,1,50597,,In vitro,,In vitro microsome metabolism clearance in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621792,,Microsomes,A
5041,Intermediate,,1,,10116.0,8111,1,50597,,In vitro,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621793,,Microsomes,A
5974,Intermediate,,1,,10116.0,8112,1,50597,,In vivo,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621794,,,A
5496,Intermediate,,1,,10116.0,8113,1,50597,,In vivo,Plasma,In vivo plasma clearance was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621795,,,A
5739,Intermediate,,1,,10116.0,8114,1,50597,,In vivo,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621796,,,A
5676,Intermediate,,1,,10116.0,8115,1,50597,Hepatocyte,In vivo,Liver,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,N,401.0,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621797,,,A
4239,Intermediate,,1,,10116.0,8116,1,50597,,In vivo,,Pharmacokinetic property (Plasma clearance) was measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621798,,,A
5676,Intermediate,,1,,10116.0,8117,1,50597,,In vivo,,Pharmacokinetic property (clearance) in rat i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621799,,,A
1918,Intermediate,,1,,10116.0,8118,1,50597,,In vivo,,"Plasma Clearance was evaluated in rats, iv",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621800,,,A
17800,Intermediate,,1,,10116.0,8119,1,50597,,In vivo,,Plasma clearance (in vivo) in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621801,,,A
6056,Intermediate,,1,,10116.0,8120,1,50597,,In vivo,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621802,,,A
5496,Intermediate,,1,,10116.0,8121,1,50597,,In vivo,,Plasma clearance was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618596,,,A
5939,Intermediate,,1,,10116.0,8122,1,50597,,In vivo,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618597,,,A
5939,Intermediate,,1,,10116.0,8123,1,50597,,In vivo,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618598,,,A
17752,Intermediate,,1,,10116.0,8124,1,50597,,In vivo,,Plasma clearance in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618599,,,A
4576,Intermediate,,1,,10116.0,8125,1,50597,,In vivo,,Plasma clearance rate determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618600,,,A
6011,Intermediate,,1,,10116.0,8126,1,50597,,In vivo,,Plasma clearance was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618601,,,A
5510,Intermediate,,1,,10116.0,8127,1,50597,,In vivo,,Plasma clearance was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618602,,,A
5948,Intermediate,,1,,10116.0,8128,1,50597,,In vivo,,Plasma clearance value in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618603,,,A
6125,Intermediate,,1,,10116.0,8129,1,50597,,Ex vivo,Liver,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL618604,,,A
4839,Intermediate,,1,,10116.0,8130,1,50597,,In vivo,,Clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618605,,,A
17686,Intermediate,,1,,10116.0,8131,1,50597,,In vivo,,Total body clearance in rat i.v. at 2 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618606,,,A
6571,Intermediate,,1,,10116.0,8132,1,50597,,In vivo,,Clearance of compound in rats after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618607,,,A
3364,Intermediate,,1,,10116.0,8133,1,50597,,In vivo,,Clearance after iv administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618608,,,A
13569,Intermediate,,1,,10116.0,8134,1,50597,,In vivo,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618609,,,A
13569,Intermediate,,1,,10116.0,8135,1,50597,,In vivo,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618610,,,A
13569,Intermediate,,1,,10116.0,8136,1,50597,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618611,,,A
13569,Intermediate,,1,,10116.0,8137,1,50597,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618612,,,A
13569,Intermediate,,1,,10116.0,8138,1,50597,,In vivo,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618613,,,A
13569,Intermediate,,1,,10116.0,8139,1,50597,,In vivo,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621076,,,A
13569,Intermediate,,1,,10116.0,8140,1,50597,,In vivo,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621077,,,A
17670,Intermediate,,1,,10116.0,8141,1,50597,,In vivo,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621078,,,A
5970,Intermediate,,1,,10116.0,8142,1,50597,,In vivo,,Clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621251,,,A
6495,Intermediate,,1,,10116.0,8143,1,50597,,In vivo,,Clearance in rat after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621252,,,A
4590,Intermediate,,1,,10116.0,8144,1,50597,,In vivo,,Clearance in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621253,,,A
6193,Intermediate,,1,,10116.0,8145,1,50597,,In vivo,,Clearance rate following an oral dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621254,,,A
2832,Intermediate,,1,,10116.0,8146,1,50597,,In vivo,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621255,,,A
1052,Intermediate,,1,,10116.0,8147,1,50597,,In vivo,Plasma,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621256,,,A
9866,Intermediate,,1,,10116.0,8148,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621257,,,A
9866,Intermediate,,1,,10116.0,8149,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621258,,,A
9866,Intermediate,,1,,10116.0,8150,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621259,,,A
9866,Intermediate,,1,,10116.0,8151,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621260,,,A
9866,Intermediate,,1,,10116.0,8152,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL876494,,,A
9866,Intermediate,,1,,10116.0,8153,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621261,,,A
9866,Intermediate,,1,,10116.0,8154,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621262,,,A
9866,Intermediate,,1,,10116.0,8155,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621263,,,A
9866,Intermediate,,1,,10116.0,8156,1,50597,,In vivo,Liver,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621264,,,A
9866,Intermediate,,1,,10116.0,8157,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621265,,,A
9866,Intermediate,,1,,10116.0,8158,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621266,,,A
9866,Intermediate,,1,,10116.0,8159,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621267,,,A
9866,Intermediate,,1,,10116.0,8160,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621268,,,A
9866,Intermediate,,1,,10116.0,8161,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621269,,,A
9866,Intermediate,,1,,10116.0,8162,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621270,,,A
9866,Intermediate,,1,,10116.0,8163,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621271,,,A
9866,Intermediate,,1,,10116.0,8164,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621272,,,A
9866,Intermediate,,1,,10116.0,8165,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621273,,,A
9866,Intermediate,,1,,10116.0,8166,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621274,,,A
9866,Intermediate,,1,,10116.0,8167,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL876495,,,A
9866,Intermediate,,1,,10116.0,8168,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621275,,,A
9866,Intermediate,,1,,10116.0,8169,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621276,,,A
9866,Intermediate,,1,,10116.0,8170,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621277,,,A
9866,Intermediate,,1,,10116.0,8171,1,50597,,In vivo,Intestine,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621278,,,A
9866,Intermediate,,1,,10116.0,8172,1,50597,,In vivo,Intestine,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621279,,,A
9866,Intermediate,,1,,10116.0,8173,1,50597,,In vivo,Intestine,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621280,,,A
9866,Intermediate,,1,,10116.0,8174,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621281,,,A
9866,Intermediate,,1,,10116.0,8175,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621282,,,A
9866,Intermediate,,1,,10116.0,8176,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621283,,,A
9866,Intermediate,,1,,10116.0,8177,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621284,,,A
9866,Intermediate,,1,,10116.0,8178,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621285,,,A
9866,Intermediate,,1,,10116.0,8179,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621286,,,A
9866,Intermediate,,1,,10116.0,8180,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL623220,,,A
9866,Intermediate,,1,,10116.0,8181,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL623221,,,A
9866,Intermediate,,1,,10116.0,8182,1,50597,,In vivo,Spleen,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL876029,,,A
9866,Intermediate,,1,,10116.0,8183,1,50597,,In vivo,Stomach,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL623222,,,A
9866,Intermediate,,1,,10116.0,8184,1,50597,,In vivo,Stomach,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL623223,,,A
9866,Intermediate,,1,,10116.0,8185,1,50597,,In vivo,Stomach,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL621445,,,A
13950,Intermediate,,1,,10116.0,8186,1,50597,,In vivo,Blood,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621446,,,A
13950,Intermediate,,1,,10116.0,8187,1,50597,,In vivo,Blood,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621447,,,A
13950,Intermediate,,1,,10116.0,8188,1,50597,,In vivo,Blood,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL619681,,,A
13950,Intermediate,,1,,10116.0,8189,1,50597,,In vivo,Blood,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL619682,,,A
13950,Intermediate,,1,,10116.0,8190,1,50597,,In vivo,Blood,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL619683,,,A
13950,Intermediate,,1,,10116.0,8191,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619684,,,A
13950,Intermediate,,1,,10116.0,8192,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619685,,,A
13950,Intermediate,,1,,10116.0,8193,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619686,,,A
13950,Intermediate,,1,,10116.0,8194,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619687,,,A
13950,Intermediate,,1,,10116.0,8195,1,50597,,In vivo,Brain,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619688,,,A
13950,Intermediate,,1,,10116.0,8196,1,50597,,In vivo,Heart,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL619689,,,A
13950,Intermediate,,1,,10116.0,8197,1,50597,,In vivo,Heart,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL619690,,,A
13950,Intermediate,,1,,10116.0,8198,1,50597,,In vivo,Heart,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL619691,,,A
6062,Intermediate,,1,,10116.0,8199,1,50597,,In vivo,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619692,,,A
3598,Expert,,1,,10116.0,8200,1,50597,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619693,,,A
1908,Intermediate,,1,,10116.0,8201,1,50597,,In vivo,,Vc value after IV dose at a dose of 5 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619694,,,A
17596,Intermediate,,1,,10116.0,8202,1,50597,,In vivo,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619695,,,A
4891,Intermediate,,1,,10116.0,8203,1,50597,,In vivo,,Compound was evaluated for pharmacokinetic parameter volume of distribution,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619696,,,A
740,Intermediate,,1,,10116.0,8204,1,50597,,In vivo,,Compound was evaluated for volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619697,,,A
16366,Intermediate,,1,,10116.0,8205,1,50597,,In vivo,,Steady state volume distribution was determined; steady state(ss),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619698,,,A
3364,Intermediate,,1,,10116.0,8206,1,50597,,In vivo,,Steady state volume of distribution after iv administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619699,,,A
2552,Intermediate,,1,,10116.0,8207,1,50597,,In vivo,,Steady state volume of distribution dosing at 3 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619700,,,A
406,Intermediate,,1,,10116.0,8208,1,50597,,In vivo,,The compound was evaluated for volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619701,,,A
12500,Intermediate,,1,,10116.0,8209,1,50597,,In vivo,,The compound was tested for volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL619702,,,A
12500,Intermediate,,1,,10116.0,8210,1,50597,,In vivo,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620335,,,A
5656,Intermediate,,1,,10116.0,8211,1,50597,,In vivo,,Volume distribution (VD) after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620336,,,A
17671,Intermediate,,1,,10116.0,8212,1,50597,,In vivo,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620337,,,A
1094,Intermediate,,1,,10116.0,8213,1,50597,,In vivo,,Volume distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620520,,,A
5833,Intermediate,,1,,10116.0,8214,1,50597,,In vivo,,Volume distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620521,,,A
5939,Intermediate,,1,,10116.0,8215,1,50597,,In vivo,,Volume distribution in rat after peroral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875825,,,A
5939,Intermediate,,1,,10116.0,8216,1,50597,,In vivo,,Volume distribution in rat after peroral administration at 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620522,,,A
6005,Intermediate,,1,,10116.0,8217,1,50597,,In vivo,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620523,,,A
1696,Intermediate,,1,,10116.0,8218,1,50597,,In vivo,,Volume of distribution in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620524,,,A
6672,Intermediate,,1,,10116.0,8219,1,50597,,In vivo,,Volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620525,,,A
6673,Intermediate,,1,,10116.0,8220,1,50597,,In vivo,,Volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620526,,,A
5871,Intermediate,,1,,10116.0,8221,1,50597,,In vivo,,Volume of distribution in rat by iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620527,,,A
6803,Intermediate,,1,,10116.0,8222,1,50597,,In vivo,,Volume of distribution in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620528,,,A
5199,Intermediate,,1,,10116.0,8223,1,50597,,In vivo,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620529,,,A
4727,Intermediate,,1,,10116.0,8224,1,50597,,,,Volume distribution at the dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620530,,,A
16367,Intermediate,,1,,10116.0,8225,1,50597,,In vivo,,Steady state volume of distribution was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620531,,,A
5005,Intermediate,,1,,9544.0,8226,0,22224,,In vivo,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620532,,,A
5005,Intermediate,,1,,10116.0,8227,0,22224,,In vivo,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL620533,,,A
5005,Intermediate,,1,,10116.0,8228,0,22224,,In vivo,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL620534,,,A
15765,Intermediate,,1,,10116.0,8229,1,50597,,In vivo,,Mean (%CV) PK parameters for Vdss(mL/kg).,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620535,,,A
2792,Intermediate,,1,,10116.0,8230,1,50597,,In vivo,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875826,,,A
2792,Intermediate,,1,,10116.0,8231,1,50597,,In vivo,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620536,,,A
5334,Intermediate,,1,,10116.0,8232,1,50597,,In vivo,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620537,,,A
5334,Intermediate,,1,,10116.0,8233,1,50597,,In vivo,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618526,,,A
5739,Intermediate,,1,,10116.0,8234,1,50597,,In vivo,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618527,,,A
5789,Intermediate,,1,,10116.0,8235,1,50597,,In vivo,,Pharmacokinetic property (Vdss) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618528,,,A
4239,Intermediate,,1,,10116.0,8236,1,50597,,In vivo,,Pharmacokinetic property (vdss) was measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618529,,,A
4709,Intermediate,,1,,10116.0,8237,1,50597,,In vivo,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618530,,,A
6642,Intermediate,,1,,10116.0,8238,1,50597,,In vivo,,Volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618531,,,A
5247,Intermediate,,1,,10116.0,8239,1,50597,,In vivo,,The pharmacokinetic parameter volume of distribution in vivo in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618532,,,A
17720,Intermediate,,1,,10116.0,8240,1,50597,,In vivo,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618533,,,F
17686,Intermediate,,1,,10116.0,8241,1,50597,,In vivo,,Vdss in rat i.v. at 2 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618534,,,A
4689,Intermediate,,1,,10116.0,8242,1,50597,,In vivo,,Volume distribution after intravenous administration (1 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618535,,,A
5654,Intermediate,,1,,10116.0,8243,1,50597,,In vivo,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618536,,,A
5654,Intermediate,,1,,10116.0,8244,1,50597,,In vivo,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618537,,,A
4527,Intermediate,,1,,10116.0,8245,1,50597,,In vivo,,Volume distribution at a dose of 10 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618538,,,A
4521,Intermediate,,1,,10116.0,8246,1,50597,,In vivo,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618539,,,A
6057,Intermediate,,1,,10116.0,8247,1,50597,,In vivo,,Volume distribution was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618540,,,A
5510,Intermediate,,1,,10116.0,8248,1,50597,,In vivo,,Volume distribution was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618541,,,A
2938,Intermediate,,1,,10116.0,8249,1,50597,,In vivo,,Volume of distribution after intravenous administration was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618542,,,A
6679,Intermediate,,1,,10116.0,8250,1,50597,,In vivo,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622544,,,A
6685,Intermediate,,1,,10116.0,8251,1,50597,,In vivo,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622545,,,A
6685,Intermediate,,1,,10116.0,8252,1,50597,,In vivo,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622546,,,A
6685,Intermediate,,1,,10116.0,8253,1,50597,,In vivo,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622547,,,A
5145,Intermediate,,1,,10116.0,8254,1,50597,,In vivo,,Volume of distribution in steady state was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622548,,,A
6467,Intermediate,,1,,10116.0,8255,1,50597,,In vivo,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622549,,,A
6467,Intermediate,,1,,10116.0,8256,1,50597,,In vivo,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622550,,,A
15115,Intermediate,,1,,10090.0,8257,1,50594,,,,Compound was evaluated for area under curve when administered through oral route to mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL622551,,,A
8758,Intermediate,,1,,10116.0,8258,1,50597,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622552,,,A
8758,Intermediate,,1,,10116.0,8259,1,50597,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622553,,,A
8267,Autocuration,,1,,,8260,0,22224,,In vivo,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,U,,,BAO_0000218,,CHEMBL622554,,,F
8267,Intermediate,,1,,9615.0,8261,1,50588,,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622555,,,A
14239,Intermediate,,1,,10090.0,8262,1,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622556,,,A
14239,Intermediate,,1,,10090.0,8263,1,50594,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL622557,,,A
10754,Intermediate,,1,,10090.0,8264,1,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622558,,,A
10754,Intermediate,,1,,10090.0,8265,1,50594,,,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622559,,,A
10754,Intermediate,,1,,9615.0,8266,1,50588,,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622560,,,A
14681,Intermediate,,1,,10116.0,8267,1,50597,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622561,,,A
14681,Intermediate,,1,,10116.0,8268,1,50597,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622562,,,A
14681,Intermediate,,1,,10116.0,8269,1,50597,,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622563,,,A
13118,Autocuration,,1,,,8270,0,22224,,,,Concentration of compound in Central nervous system,,U,,,BAO_0000019,,CHEMBL622564,,,A
13118,Autocuration,,1,,,8271,0,22224,,,,Concentration of compound in Central nervous system; Not detectable,,U,,,BAO_0000019,,CHEMBL622565,,,A
13318,Intermediate,,1,,10090.0,8272,1,50594,,,,"Concentration of diester in the blood, following oral administration in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL622566,,,A
13318,Intermediate,,1,,10090.0,8273,1,50594,,,,"Concentration of monoester in the blood, following oral administration in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL624515,,,A
13318,Intermediate,,1,,10090.0,8274,1,50594,,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL624516,,,A
15692,Autocuration,,1,,,8275,0,22224,,,,Evaluated for Pharmacokinetic property: Area under the curve,,U,,,BAO_0000019,,CHEMBL624517,,,A
14839,Intermediate,,1,,10090.0,8276,1,50594,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,N,,Mus musculus,BAO_0000218,,CHEMBL624518,,,A
14839,Intermediate,,1,,9541.0,8277,1,100710,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624519,,,A
14839,Intermediate,,1,,9541.0,8278,1,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624520,,,A
14839,Intermediate,,1,,9541.0,8279,1,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624521,,,A
14839,Intermediate,,1,,9541.0,8280,1,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624522,,,A
14839,Intermediate,,1,,9541.0,8281,1,100710,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624523,,,A
14839,Intermediate,,1,,9541.0,8282,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624409,,,A
14839,Intermediate,,1,,9541.0,8283,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624410,,,A
14839,Intermediate,,1,,9541.0,8284,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL624411,,,A
14839,Intermediate,,1,,9541.0,8285,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623531,,,A
14839,Intermediate,,1,,9541.0,8286,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623532,,,A
14839,Intermediate,,1,,9541.0,8287,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623533,,,A
14839,Intermediate,,1,,9541.0,8288,1,100710,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623534,,,A
14839,Intermediate,,1,,10090.0,8289,1,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,N,,Mus musculus,BAO_0000218,,CHEMBL623535,,,A
14839,Intermediate,,1,,10090.0,8290,1,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,N,,Mus musculus,BAO_0000218,,CHEMBL623536,,,A
14839,Intermediate,,1,,10090.0,8291,1,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,N,,Mus musculus,BAO_0000218,,CHEMBL623537,,,A
14839,Intermediate,,1,,10090.0,8292,1,50594,,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,N,,Mus musculus,BAO_0000218,,CHEMBL623538,,,A
14839,Intermediate,,1,,10090.0,8293,1,50594,,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,N,,Mus musculus,BAO_0000218,,CHEMBL623539,,,A
14839,Intermediate,,1,,10090.0,8294,1,50594,,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,N,,Mus musculus,BAO_0000218,,CHEMBL623540,,,A
14839,Intermediate,,1,,10090.0,8295,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,N,,Mus musculus,BAO_0000218,,CHEMBL623541,,,A
14839,Intermediate,,1,,10090.0,8296,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL623542,,,A
14839,Intermediate,,1,,10090.0,8297,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL623543,,,A
14839,Intermediate,,1,,10090.0,8298,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,N,,Mus musculus,BAO_0000218,,CHEMBL623544,,,A
14839,Intermediate,,1,,10090.0,8299,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL623545,,,A
14839,Intermediate,,1,,10090.0,8300,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL623546,,,A
5408,Intermediate,,1,,10116.0,8301,1,50597,,In vivo,Plasma,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623547,,,A
6827,Intermediate,,1,,10116.0,8302,1,50597,,In vivo,,High i.v. clearance in Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623548,,,A
17538,Intermediate,,1,,10116.0,8303,1,50597,,In vitro,Liver,In vitro clearance in rat liver microsomes,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623549,,Microsomes,A
6331,Intermediate,,1,,10116.0,8304,1,50597,,In vitro,Liver,Intrinsic clearance in rat liver microsomes was determined,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623550,,Microsomes,A
5948,Intermediate,,1,,10116.0,8305,1,50597,Hepatocyte,In vitro,Liver,Intrinsic clearance in rat hepatocytes was determined,,N,401.0,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL875276,,,A
4026,Intermediate,,1,,10116.0,8306,1,50597,,In vivo,,Plasma Clearance was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621872,,,A
6647,Intermediate,,1,,10116.0,8307,1,50597,,In vivo,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621873,,,A
1696,Intermediate,,1,,10116.0,8308,1,50597,,In vivo,,Plasma clearance in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621874,,,A
6597,Intermediate,,1,,10116.0,8309,1,50597,,In vivo,,Plasma clearance in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621875,,,A
347,Intermediate,,1,,10116.0,8310,1,50597,,In vivo,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621876,,,A
16423,Intermediate,,1,,10116.0,8311,1,50597,,In vivo,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621877,,,A
2879,Intermediate,,1,,10116.0,8312,1,50597,,In vivo,,Plasma clearance was measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621878,,,A
4883,Intermediate,,1,,10116.0,8313,1,50597,,In vivo,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621879,,,A
5328,Intermediate,,1,,10116.0,8314,1,50597,,In vivo,Plasma,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621880,,,A
5160,Intermediate,,1,,10116.0,8315,1,50597,,In vivo,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621881,,,A
17582,Intermediate,,1,,10116.0,8316,1,50597,,In vivo,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621882,,,A
17651,Intermediate,,1,,10116.0,8317,1,50597,,In vivo,,Total clearance at 1 mg/kg was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875283,,,A
17651,Intermediate,,1,,10116.0,8318,1,50597,,In vivo,,Total clearance at 10 mg/kg was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621883,,,A
6596,Intermediate,,1,,10116.0,8319,1,50597,,In vivo,,Clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621884,,,A
4796,Intermediate,,1,,10116.0,8320,1,50597,,In vivo,,Plasma clearance rate determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621885,,,A
6850,Intermediate,,1,,10116.0,8321,1,50597,,In vivo,,Clearance of compound in rat was evaluated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621886,,,A
5932,Intermediate,,1,,10116.0,8322,1,50597,,In vivo,Plasma,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621887,,,A
3371,Intermediate,,1,,10116.0,8323,1,50597,,In vivo,,Pharmacokinetic property (blood clearance) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621888,,,A
2083,Intermediate,,1,,10116.0,8324,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621889,,,A
4942,Intermediate,,1,,10116.0,8325,1,50597,,In vivo,,Plasma clearance in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621890,,,A
6838,Intermediate,,1,,10116.0,8326,1,50597,,In vitro,Liver,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621891,,Microsomes,A
5353,Intermediate,,1,,10116.0,8327,1,50597,,In vivo,,Clearance in Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621892,,,A
6641,Intermediate,,1,,10116.0,8328,1,50597,,In vivo,,Clearance rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621893,,,A
6641,Intermediate,,1,,10116.0,8329,1,50597,,In vivo,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621894,,,A
6641,Intermediate,,1,,10116.0,8330,1,50597,,In vivo,,Clearance rat; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621895,,,A
6444,Intermediate,,1,,10116.0,8331,1,50597,,In vivo,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875284,,,A
6444,Intermediate,,1,,10116.0,8332,1,50597,,In vivo,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618699,,,A
6444,Intermediate,,1,,10116.0,8333,1,50597,,In vivo,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618700,,,A
6211,Intermediate,,1,,10116.0,8334,1,50597,,In vivo,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618701,,,A
12873,Intermediate,,1,,10116.0,8335,1,50597,,In vivo,Plasma,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876600,,,A
6570,Intermediate,,1,,10116.0,8336,1,50597,,In vivo,,Clearance of compound in rat after 1 mg/kg i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618702,,,A
3341,Intermediate,,1,,10116.0,8337,1,50597,,In vivo,,Compound was evaluated for Hepatic clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618703,,,A
4891,Intermediate,,1,,10116.0,8338,1,50597,,In vivo,,In vivo clearance after 5 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618704,,,A
1094,Intermediate,,1,,10116.0,8339,1,50597,,In vivo,Plasma,Compound was tested for plasma clearance in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618705,,,A
2938,Intermediate,,1,,10116.0,8340,1,50597,,In vivo,,Hepatic clearance after intravenous administration was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618706,,,A
17853,Intermediate,,1,,10116.0,8341,1,50597,,In vivo,,Lower clearance in rat (i.v.) at 0.5 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618707,,,A
6049,Intermediate,,1,,10116.0,8342,1,50597,,In vivo,Plasma,Pharmacokinetic parameter expressed as plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618708,,,A
5789,Intermediate,,1,,10116.0,8343,1,50597,,In vivo,,Pharmacokinetic property (Clp) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618709,,,A
4514,Intermediate,,1,,10116.0,8344,1,50597,,In vivo,,Plasma clearance in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618710,,,A
6448,Intermediate,,1,,10116.0,8345,1,50597,,In vivo,,Plasma clearance (Clp) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618711,,,A
6062,Intermediate,,1,,10116.0,8346,1,50597,,In vivo,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618712,,,A
5710,Intermediate,,1,,10116.0,8347,1,50597,,In vivo,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618713,,,A
4709,Intermediate,,1,,10116.0,8348,1,50597,,In vivo,,Plasma clearance after intravenous administration of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618714,,,A
4521,Intermediate,,1,,10116.0,8349,1,50597,,In vivo,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618715,,,A
1742,Intermediate,,1,,10116.0,8350,1,50597,,In vivo,,Plasma clearance in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618716,,,A
6057,Intermediate,,1,,10116.0,8351,1,50597,,In vivo,,Plasma clearance measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876601,,,A
6057,Intermediate,,1,,10116.0,8352,1,50597,,In vivo,,Plasma clearance was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618717,,,A
5145,Intermediate,,1,,10116.0,8353,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618718,,,A
5833,Intermediate,,1,,10116.0,8354,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618719,,,A
6453,Intermediate,,1,,10116.0,8355,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618720,,,A
6640,Intermediate,,1,,10116.0,8356,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618721,,,A
6305,Intermediate,,1,,10116.0,8357,1,50597,,In vivo,,Plasma clearance in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621477,,,A
6642,Intermediate,,1,,10116.0,8358,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621478,,,A
5472,Intermediate,,1,,10116.0,8359,1,50597,,In vivo,,Plasma clearance was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621479,,,A
5472,Intermediate,,1,,10116.0,8360,1,50597,,In vivo,,Plasma clearance was evaluated in rat; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621480,,,A
5144,Intermediate,,1,,10116.0,8361,1,50597,,In vivo,,Plasma clearance rate was determined for the compound in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621481,,,A
6685,Intermediate,,1,,10116.0,8362,1,50597,,In vivo,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621482,,,A
6685,Intermediate,,1,,10116.0,8363,1,50597,,In vivo,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621483,,,A
6685,Intermediate,,1,,10116.0,8364,1,50597,,In vivo,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621484,,,A
13950,Intermediate,,1,,10116.0,8365,1,50597,,In vivo,Heart,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621485,,,A
13950,Intermediate,,1,,10116.0,8366,1,50597,,In vivo,Heart,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL621486,,,A
13950,Intermediate,,1,,10116.0,8367,1,50597,,In vivo,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621487,,,A
13950,Intermediate,,1,,10116.0,8368,1,50597,,In vivo,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621488,,,A
13950,Intermediate,,1,,10116.0,8369,1,50597,,In vivo,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621489,,,A
13950,Intermediate,,1,,10116.0,8370,1,50597,,In vivo,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621490,,,A
13950,Intermediate,,1,,10116.0,8371,1,50597,,In vivo,Intestine,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL621491,,,A
13950,Intermediate,,1,,10116.0,8372,1,50597,,In vivo,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621492,,,A
13950,Intermediate,,1,,10116.0,8373,1,50597,,In vivo,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621493,,,A
13950,Intermediate,,1,,10116.0,8374,1,50597,,In vivo,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621494,,,A
13950,Intermediate,,1,,10116.0,8375,1,50597,,In vivo,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621495,,,A
13950,Intermediate,,1,,10116.0,8376,1,50597,,In vivo,Kidney,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621496,,,A
13950,Intermediate,,1,,10116.0,8377,1,50597,,In vivo,Liver,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621497,,,A
13950,Intermediate,,1,,10116.0,8378,1,50597,,In vivo,Liver,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621498,,,A
13950,Intermediate,,1,,10116.0,8379,1,50597,,In vivo,Liver,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621499,,,A
13950,Intermediate,,1,,10116.0,8380,1,50597,,In vivo,Liver,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL618634,,,A
13950,Intermediate,,1,,10116.0,8381,1,50597,,In vivo,Liver,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL618635,,,A
13950,Intermediate,,1,,10116.0,8382,1,50597,,In vivo,Lung,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL618636,,,A
13950,Intermediate,,1,,10116.0,8383,1,50597,,In vivo,Lung,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL619737,,,A
13950,Intermediate,,1,,10116.0,8384,1,50597,,In vivo,Lung,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL619738,,,A
13950,Intermediate,,1,,10116.0,8385,1,50597,,In vivo,Lung,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624329,,,A
13950,Intermediate,,1,,10116.0,8386,1,50597,,In vivo,Lung,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624330,,,A
13950,Intermediate,,1,,10116.0,8387,1,50597,,In vivo,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624331,,,A
13950,Intermediate,,1,,10116.0,8388,1,50597,,In vivo,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624332,,,A
13950,Intermediate,,1,,10116.0,8389,1,50597,,In vivo,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624333,,,A
13950,Intermediate,,1,,10116.0,8390,1,50597,,In vivo,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624334,,,A
13950,Intermediate,,1,,10116.0,8391,1,50597,,In vivo,Muscle tissue,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624335,,,A
13950,Intermediate,,1,,10116.0,8392,1,50597,,In vivo,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL620016,,,A
13950,Intermediate,,1,,10116.0,8393,1,50597,,In vivo,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL620169,,,A
13950,Intermediate,,1,,10116.0,8394,1,50597,,In vivo,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL620170,,,A
13950,Intermediate,,1,,10116.0,8395,1,50597,,In vivo,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL620171,,,A
13950,Intermediate,,1,,10116.0,8396,1,50597,,In vivo,Spleen,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL620172,,,A
13950,Intermediate,,1,,10116.0,8397,1,50597,,In vivo,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL620173,,,A
13950,Intermediate,,1,,10116.0,8398,1,50597,,In vivo,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL620174,,,A
13950,Intermediate,,1,,10116.0,8399,1,50597,,In vivo,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL620175,,,A
13950,Intermediate,,1,,10116.0,8400,1,50597,,In vivo,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL620176,,,A
13950,Intermediate,,1,,10116.0,8401,1,50597,,In vivo,Stomach,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL620177,,,A
13950,Intermediate,,1,,10116.0,8402,1,50597,,,Cerebellum,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL620178,,,A
13950,Intermediate,,1,,10116.0,8403,1,50597,,,Cerebellum,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL620179,,,A
13950,Intermediate,,1,,10116.0,8404,1,50597,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620180,,,A
6570,Intermediate,,1,,10116.0,8405,1,50597,,In vivo,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620181,,,A
6571,Intermediate,,1,,10116.0,8406,1,50597,,In vivo,,Volume of distribution of compound in rats after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620182,,,A
6453,Intermediate,,1,,10116.0,8407,1,50597,,In vivo,,Volume of distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620183,,,A
6444,Intermediate,,1,,10116.0,8408,1,50597,,In vivo,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620184,,,A
6444,Intermediate,,1,,10116.0,8409,1,50597,,In vivo,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620185,,,A
6444,Intermediate,,1,,10116.0,8410,1,50597,,In vivo,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620186,,,A
5353,Intermediate,,1,,10116.0,8411,1,50597,,In vivo,,Volume of distribution was determined in Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620187,,,A
5334,Intermediate,,1,,10116.0,8412,1,50597,,In vivo,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620188,,,A
5334,Intermediate,,1,,10116.0,8413,1,50597,,In vivo,,Volume of distribution was reported in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620189,,,A
6641,Intermediate,,1,,10116.0,8414,1,50597,,In vivo,,Volumes of distribution in rat after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620190,,,A
6641,Intermediate,,1,,10116.0,8415,1,50597,,In vivo,,Volumes of distribution in rat after po administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620191,,,A
6641,Intermediate,,1,,10116.0,8416,1,50597,,In vivo,,Volumes of distribution in rat after po administration; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620192,,,A
5676,Intermediate,,1,,10116.0,8417,1,50597,,In vivo,,Pharmacokinetic property (Volume) in rat i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620193,,,A
6410,Intermediate,,1,,10116.0,8418,1,50597,,In vivo,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620194,,,A
17670,Intermediate,,1,,10116.0,8419,1,50597,,In vivo,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876730,,,A
6495,Intermediate,,1,,10116.0,8420,1,50597,,In vivo,,Volume distribution in rat after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620195,,,A
5408,Intermediate,,1,,10116.0,8421,1,50597,,In vivo,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620196,,,A
4883,Intermediate,,1,,10116.0,8422,1,50597,,In vivo,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620197,,,A
6647,Intermediate,,1,,10116.0,8423,1,50597,,In vivo,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620198,,,A
6495,Intermediate,,1,,10116.0,8424,1,50597,,In vivo,,Volume of distribution in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620199,,,A
2661,Intermediate,,1,,10116.0,8425,1,50597,,In vivo,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620200,,,A
2661,Intermediate,,1,,10116.0,8426,1,50597,,In vivo,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620201,,,A
5974,Intermediate,,1,,10116.0,8427,1,50597,,In vivo,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620202,,,A
5974,Intermediate,,1,,10116.0,8428,1,50597,,In vivo,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620203,,,A
5974,Intermediate,,1,,10116.0,8429,1,50597,,In vivo,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620204,,,A
5974,Intermediate,,1,,10116.0,8430,1,50597,,In vivo,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620205,,,A
5960,Intermediate,,1,,10116.0,8431,1,50597,,In vivo,,Pharmacokinetic parameter (Vss) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624664,,,A
5676,Intermediate,,1,,10116.0,8432,1,50597,,In vivo,,Pharmacokinetic property (Volume) in rat i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624665,,,A
5948,Intermediate,,1,,10116.0,8433,1,50597,,,,Pharmacokinetic property (Vss) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624666,,,A
5979,Intermediate,,1,,10116.0,8434,1,50597,,In vivo,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624667,,,A
5978,Intermediate,,1,,10116.0,8435,1,50597,,In vivo,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624668,,,A
5978,Intermediate,,1,,10116.0,8436,1,50597,,In vivo,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624669,,,A
5978,Intermediate,,1,,10116.0,8437,1,50597,,In vivo,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624670,,,A
5978,Intermediate,,1,,10116.0,8438,1,50597,,In vivo,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624671,,,A
6448,Intermediate,,1,,10116.0,8439,1,50597,,In vivo,,Steady state volume distribution in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624672,,,A
12873,Intermediate,,1,,10116.0,8440,1,50597,,In vivo,Plasma,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624673,,,A
4576,Intermediate,,1,,10116.0,8441,1,50597,,In vivo,,Steady state volume of distribution determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624674,,,A
17582,Intermediate,,1,,10116.0,8442,1,50597,,In vivo,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624675,,,A
1466,Intermediate,,1,,10116.0,8443,1,50597,,In vivo,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621728,,,A
5182,Intermediate,,1,,10116.0,8444,1,50597,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621729,,,A
5182,Intermediate,,1,,10116.0,8445,1,50597,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621730,,,A
6535,Intermediate,,1,,10116.0,8446,1,50597,,In vivo,,Volume distribution in rat after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621731,,,A
6535,Intermediate,,1,,10116.0,8447,1,50597,,In vivo,,Volume distribution in rat after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621732,,,A
5041,Intermediate,,1,,10116.0,8448,1,50597,,In vivo,,Volume in steady state distribution value was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621908,,,A
5041,Intermediate,,1,,10116.0,8449,1,50597,,In vivo,,Volume in steady state distribution value was determined; ND denotes no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875347,,,A
5041,Intermediate,,1,,10116.0,8450,1,50597,,In vivo,,Volume in steady state distribution value was determined; ND denotes not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621909,,,A
17065,Intermediate,,1,,10116.0,8451,1,50597,,In vivo,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621910,,,A
6597,Intermediate,,1,,10116.0,8452,1,50597,,In vivo,,Volume of distribution at steady state was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621911,,,A
15662,Intermediate,,1,,10116.0,8453,1,50597,,In vivo,,Volume of distribution at steady state was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621912,,,A
6485,Intermediate,,1,,10116.0,8454,1,50597,,In vivo,,Volume of distribution in steady state was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621913,,,A
17655,Intermediate,,1,,10116.0,8455,1,50597,,In vivo,,Volume of distribution in steady state was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621914,,,A
6616,Intermediate,,1,,10116.0,8456,1,50597,,In vivo,,Volume of distribution after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621915,,,A
1916,Intermediate,,1,,10116.0,8457,1,50597,,In vivo,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621916,,,A
16438,Intermediate,,1,,10090.0,8458,1,50594,,In vivo,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621917,,,A
16438,Intermediate,,1,,10090.0,8459,1,50594,,In vivo,Liver,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL621918,,,A
16438,Intermediate,,1,,10090.0,8460,1,50594,,In vivo,Spleen,Biodistribution of compound (oxidized form) in spleen tissue,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL621919,,,A
16438,Intermediate,,1,,10090.0,8461,1,50594,,In vivo,Spleen,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL621920,,,A
16438,Intermediate,,1,,10090.0,8462,1,50594,,In vivo,Spleen,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL621921,,,A
16438,Intermediate,,1,,10090.0,8463,1,50594,,In vivo,Spleen,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL622401,,,A
16438,Intermediate,,1,,10090.0,8464,1,50594,,In vivo,Spleen,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL875348,,,A
16438,Intermediate,,1,,10090.0,8465,1,50594,,In vivo,Spleen,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL622402,,,A
16438,Intermediate,,1,,10090.0,8466,1,50594,,In vivo,Blood,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622403,,,A
16438,Intermediate,,1,,10090.0,8467,1,50594,,In vivo,Blood,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,178.0,CHEMBL622404,,,A
16438,Intermediate,,1,,10090.0,8468,1,50594,,In vivo,Brain,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622405,,,A
16438,Intermediate,,1,,10090.0,8469,1,50594,,In vivo,Brain,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622406,,,A
16438,Intermediate,,1,,10090.0,8470,1,50594,,In vivo,Brain,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622407,,,A
16438,Intermediate,,1,,10090.0,8471,1,50594,,In vivo,Heart,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622408,,,A
16438,Intermediate,,1,,10090.0,8472,1,50594,,In vivo,Heart,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622409,,,A
16438,Intermediate,,1,,10090.0,8473,1,50594,,In vivo,Heart,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,948.0,CHEMBL622410,,,A
16438,Intermediate,,1,,10090.0,8474,1,50594,,In vivo,Kidney,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL622411,,,A
16438,Intermediate,,1,,10090.0,8475,1,50594,,In vivo,Kidney,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL627864,,,A
16438,Intermediate,,1,,10090.0,8476,1,50594,,In vivo,Kidney,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL627865,,,A
16438,Intermediate,,1,,10090.0,8477,1,50594,,In vivo,Liver,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL627866,,,A
16438,Intermediate,,1,,10090.0,8478,1,50594,,In vivo,Liver,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL627751,,,A
16438,Intermediate,,1,,10090.0,8479,1,50594,,In vivo,Spleen,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL627752,,,A
16438,Intermediate,,1,,10090.0,8480,1,50594,,In vivo,Spleen,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL627753,,,A
16438,Intermediate,,1,,10090.0,8481,1,50594,,In vivo,Spleen,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL627754,,,A
12467,Intermediate,,1,,10090.0,8482,1,50594,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,N,,Mus musculus,BAO_0000218,,CHEMBL627755,,,A
17208,Intermediate,,1,,10090.0,8483,1,50594,,In vivo,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627756,,,A
17208,Intermediate,,1,,10090.0,8484,1,50594,,In vivo,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627757,,,A
17208,Intermediate,,1,,10090.0,8485,1,50594,,In vivo,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627758,,,A
17208,Intermediate,,1,,10090.0,8486,1,50594,,In vivo,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627759,,,A
17208,Intermediate,,1,,10090.0,8487,1,50594,,In vivo,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627760,,,A
17208,Intermediate,,1,,10090.0,8488,1,50594,,In vivo,Brain,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627761,,,A
17208,Intermediate,,1,,10090.0,8489,1,50594,,In vivo,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,948.0,CHEMBL876811,,,A
17208,Intermediate,,1,,10090.0,8490,1,50594,,In vivo,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,948.0,CHEMBL627762,,,A
17208,Intermediate,,1,,10090.0,8491,1,50594,,In vivo,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,948.0,CHEMBL627763,,,A
17208,Intermediate,,1,,10090.0,8492,1,50594,,In vivo,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,948.0,CHEMBL627764,,,A
17208,Intermediate,,1,,10090.0,8493,1,50594,,In vivo,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,948.0,CHEMBL627765,,,A
17208,Intermediate,,1,,10090.0,8494,1,50594,,In vivo,Heart,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,948.0,CHEMBL627766,,,A
17208,Intermediate,,1,,10090.0,8495,1,50594,,In vivo,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL627767,,,A
17208,Intermediate,,1,,10090.0,8496,1,50594,,In vivo,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL627768,,,A
17208,Intermediate,,1,,10090.0,8497,1,50594,,In vivo,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL628422,,,A
17208,Intermediate,,1,,10090.0,8498,1,50594,,In vivo,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL628423,,,A
5089,Intermediate,,1,,10116.0,8499,1,50597,,In vivo,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628424,,,A
5089,Intermediate,,1,,10116.0,8500,1,50597,,In vivo,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628425,,,A
4257,Intermediate,,1,,10116.0,8501,1,50597,,In vivo,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628426,,,A
6679,Intermediate,,1,,10116.0,8502,1,50597,,In vivo,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628427,,,A
5546,Intermediate,,1,,10116.0,8503,1,50597,,In vivo,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626938,,,A
6141,Intermediate,,1,,10116.0,8504,1,50597,,In vivo,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626939,,,A
5334,Intermediate,,1,,10116.0,8505,1,50597,,In vivo,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626940,,,A
5334,Intermediate,,1,,10116.0,8506,1,50597,,In vivo,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626941,,,A
5334,Intermediate,,1,,10116.0,8507,1,50597,,In vivo,,Plasma clearance was reported in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626942,,,A
4689,Intermediate,,1,,10116.0,8508,1,50597,,In vivo,,Plasma clearance after intravenous administration (1 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876812,,,A
6848,Intermediate,,1,,10116.0,8509,1,50597,,In vivo,,Plasma clearance of compound in rats was evaluated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626943,,,A
6848,Intermediate,,1,,10116.0,8510,1,50597,,In vivo,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626944,,,A
6467,Intermediate,,1,,10116.0,8511,1,50597,,In vivo,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626945,,,A
6467,Intermediate,,1,,10116.0,8512,1,50597,,In vivo,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626946,,,A
4956,Intermediate,,1,,10116.0,8513,1,50597,,In vivo,,Plasma clearance rate in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626856,,,A
5529,Intermediate,,1,,10116.0,8514,1,50597,,In vivo,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626857,,,A
406,Intermediate,,1,,10116.0,8515,1,50597,,In vivo,Plasma,The compound was evaluated for plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626858,,,A
17655,Intermediate,,1,,10116.0,8516,1,50597,,In vivo,Plasma,Total plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627018,,,A
3293,Intermediate,,1,,10116.0,8517,1,50597,,In vivo,Blood,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625331,,,A
4075,Intermediate,,1,,10116.0,8518,1,50597,,In vivo,Blood,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625332,,,A
2792,Intermediate,,1,,10116.0,8519,1,50597,,In vivo,,C max was determined at 10 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877590,,,A
2792,Intermediate,,1,,10116.0,8520,1,50597,,In vivo,,C max was determined at 3 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625333,,,A
17594,Intermediate,,1,,10116.0,8521,1,50597,,In vivo,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625334,,,A
17594,Intermediate,,1,,10116.0,8522,1,50597,,In vivo,,Cmax after single intravenous bolus of 1 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625335,,,A
4762,Intermediate,,1,,10116.0,8523,1,50597,,In vivo,,Cmax of compound at 5 mg/kg after po administration was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625336,,,A
17509,Intermediate,,1,,10116.0,8524,1,50597,,In vivo,,Cmax 24 hr after 10 mg/kg oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625337,,,A
17509,Intermediate,,1,,10116.0,8525,1,50597,,In vivo,,Cmax 24 hr after 2 mg/kg oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625338,,,A
1466,Intermediate,,1,,10116.0,8526,1,50597,,In vivo,Plasma,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625339,,,A
6535,Intermediate,,1,,10116.0,8527,1,50597,,In vivo,,Cmax in rat after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625340,,,A
6535,Intermediate,,1,,10116.0,8528,1,50597,,In vivo,,Cmax in rat after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625341,,,A
3169,Intermediate,,1,,10116.0,8529,1,50597,,In vivo,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622687,,,A
6515,Intermediate,,1,,10116.0,8530,1,50597,,In vivo,Plasma,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622688,,,A
11149,Intermediate,,1,,10116.0,8531,1,50597,,In vivo,Blood,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622689,,,A
11149,Intermediate,,1,,10116.0,8532,1,50597,,In vivo,Blood,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL620295,,,A
17858,Intermediate,,1,,10116.0,8533,1,50597,,In vivo,,Cmax after 10 mg/kg oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620296,,,A
6518,Intermediate,,1,,10116.0,8534,1,50597,,In vivo,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620297,,,A
6518,Intermediate,,1,,10116.0,8535,1,50597,,In vivo,,Cmax after IV dosing at 1 mg/kg in rat; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620298,,,A
4426,Intermediate,,1,,10116.0,8536,1,50597,,In vivo,,Cmax after oral administration at 20 mpk in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620299,,,A
4426,Intermediate,,1,,10116.0,8537,1,50597,,In vivo,,Cmax after oral administration at 20 mpk in rats; Not performed.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620300,,,A
4426,Intermediate,,1,,10116.0,8538,1,50597,,In vivo,,Cmax after oral administration at 20 mpk in rats d; Not performed.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620301,,,A
5656,Intermediate,,1,,10116.0,8539,1,50597,,In vivo,,Cmax after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620302,,,A
6518,Intermediate,,1,,10116.0,8540,1,50597,,In vivo,,Cmax after oral administration at a dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620303,,,A
6518,Intermediate,,1,,10116.0,8541,1,50597,,In vivo,,Cmax after oral administration at a dose of 4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620304,,,A
6113,Intermediate,,1,,10116.0,8542,1,50597,,In vivo,,Cmax in rats after 20 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620305,,,A
17764,Intermediate,,1,,10116.0,8543,1,50597,,In vivo,,Cmax after peroral administration in rats at 2.4 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620306,,,A
4756,Intermediate,,1,,10116.0,8544,1,50597,,In vivo,,Cmax at the dose of 2 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620307,,,A
4756,Intermediate,,1,,10116.0,8545,1,50597,,In vivo,,Cmax at the dose of 5 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620308,,,A
6402,Intermediate,,1,,10116.0,8546,1,50597,,In vivo,,Cmax by administering at 20 mg/kg p.o. in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620309,,,A
5610,Intermediate,,1,,10116.0,8547,1,50597,,In vivo,,Cmax in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620310,,,A
5207,Intermediate,,1,,10116.0,8548,1,50597,,In vivo,,Cmax in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620311,,,A
6011,Intermediate,,1,,10116.0,8549,1,50597,,In vivo,,Cmax in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620312,,,A
6504,Intermediate,,1,,10116.0,8550,1,50597,,In vivo,,Cmax in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620313,,,A
6046,Intermediate,,1,,10116.0,8551,1,50597,,In vivo,,Cmax in rat at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620314,,,A
6504,Intermediate,,1,,10116.0,8552,1,50597,,In vivo,,Cmax in rat at the dose of 1 mg/kg i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620315,,,A
5874,Intermediate,,1,,10116.0,8553,1,50597,,In vivo,,Cmax in rat by po administration at a dose of 40 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620316,,,A
17686,Intermediate,,1,,10116.0,8554,1,50597,,In vivo,,Cmax in rat p.o. at 20 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620317,,,A
5836,Intermediate,,1,,10116.0,8555,1,50597,,In vivo,,Cmax in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620318,,,A
17596,Intermediate,,1,,10116.0,8556,1,50597,,In vivo,,Cmax in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620319,,,A
16423,Intermediate,,1,,10116.0,8557,1,50597,,In vivo,,Cmax was evaluated after 20 uM/kg of peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620320,,,A
17804,Intermediate,,1,,10116.0,8558,1,50597,,In vivo,,Cmax was measured in rats after peroral administration at 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620321,,,A
1908,Intermediate,,1,,10116.0,8559,1,50597,,In vivo,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620322,,,A
13950,Intermediate,,1,,10116.0,8560,1,50597,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620323,,,A
13950,Intermediate,,1,,10116.0,8561,1,50597,,,Frontal cortex,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,1870.0,CHEMBL620324,,,A
13950,Intermediate,,1,,10116.0,8562,1,50597,,,Frontal cortex,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,1870.0,CHEMBL620325,,,A
13950,Intermediate,,1,,10116.0,8563,1,50597,,,Hippocampus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL620326,,,A
13950,Intermediate,,1,,10116.0,8564,1,50597,,,Hippocampus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL620327,,,A
13950,Intermediate,,1,,10116.0,8565,1,50597,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620328,,,A
13950,Intermediate,,1,,10116.0,8566,1,50597,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620329,,,A
13950,Intermediate,,1,,10116.0,8567,1,50597,,,Midbrain,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,1891.0,CHEMBL620330,,,A
13950,Intermediate,,1,,10116.0,8568,1,50597,,,Midbrain,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,1891.0,CHEMBL875286,,,A
13950,Intermediate,,1,,10116.0,8569,1,50597,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620331,,,A
13950,Intermediate,,1,,10116.0,8570,1,50597,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620332,,,A
13950,Intermediate,,1,,10116.0,8571,1,50597,,,Striatum,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL620333,,,A
13950,Intermediate,,1,,10116.0,8572,1,50597,,,Striatum,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL620334,,,A
16434,Intermediate,,1,,10116.0,8573,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621015,,,A
16434,Intermediate,,1,,10116.0,8574,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621016,,,A
16434,Intermediate,,1,,10116.0,8575,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621191,,,A
16434,Intermediate,,1,,10116.0,8576,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621192,,,A
16434,Intermediate,,1,,10116.0,8577,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621193,,,A
16434,Intermediate,,1,,10116.0,8578,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621194,,,A
16434,Intermediate,,1,,10116.0,8579,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624204,,,A
16434,Intermediate,,1,,10116.0,8580,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624205,,,A
16435,Intermediate,,1,,10116.0,8581,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624206,,,A
16435,Intermediate,,1,,10116.0,8582,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624207,,,A
16435,Intermediate,,1,,10116.0,8583,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624208,,,A
16435,Intermediate,,1,,10116.0,8584,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624209,,,A
16435,Intermediate,,1,,10116.0,8585,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624210,,,A
16435,Intermediate,,1,,10116.0,8586,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624211,,,A
16435,Intermediate,,1,,10116.0,8587,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624212,,,A
16435,Intermediate,,1,,10116.0,8588,1,50597,,,Blood,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624213,,,A
16434,Intermediate,,1,,10116.0,8589,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL876611,,,A
16434,Intermediate,,1,,10116.0,8590,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624214,,,A
16434,Intermediate,,1,,10116.0,8591,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624215,,,A
16435,Intermediate,,1,,10116.0,8592,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624216,,,A
16435,Intermediate,,1,,10116.0,8593,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624217,,,A
16435,Intermediate,,1,,10116.0,8594,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624218,,,A
16435,Intermediate,,1,,10116.0,8595,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624219,,,A
16435,Intermediate,,1,,10116.0,8596,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624220,,,A
16435,Intermediate,,1,,10116.0,8597,1,50597,,,Blood,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624221,,,A
16434,Intermediate,,1,,10116.0,8598,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624222,,,A
16434,Intermediate,,1,,10116.0,8599,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624223,,,A
16434,Intermediate,,1,,10116.0,8600,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624224,,,A
16434,Intermediate,,1,,10116.0,8601,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624225,,,A
17764,Intermediate,,1,,10116.0,8602,1,50597,,In vivo,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622420,,,A
5031,Intermediate,,1,,10116.0,8603,1,50597,,In vivo,,Volume of steady state distribution after i.v. administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622421,,,A
6215,Intermediate,,1,,10116.0,8604,1,50597,,In vivo,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622422,,,A
17671,Intermediate,,1,,10116.0,8605,1,50597,,In vivo,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622423,,,A
17752,Intermediate,,1,,10116.0,8606,1,50597,,In vivo,,Vss was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622424,,,A
6596,Intermediate,,1,,10116.0,8607,1,50597,,In vivo,,Vss in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622425,,,A
16423,Intermediate,,1,,10116.0,8608,1,50597,,In vivo,,Vss was evaluated after 10 uM/kg of intra arterial administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876612,,,A
15662,Intermediate,,1,,10116.0,8609,1,50597,,In vivo,,volume of distribution at steady state was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622426,,,A
6062,Intermediate,,1,,10116.0,8610,1,50597,,In vivo,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622427,,,A
5874,Intermediate,,1,,10116.0,8611,1,50597,,In vivo,,Pharmacokinetic (PK) parameter Vz in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622428,,,A
4942,Intermediate,,1,,10116.0,8612,1,50597,,In vivo,,Volume distribution in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622429,,,A
17796,Intermediate,,1,,10116.0,8613,1,50597,,In vivo,,Volume of distribution in rat; No data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622430,,,A
4890,Intermediate,,1,,10116.0,8614,1,50597,,In vivo,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622431,,,A
15765,Intermediate,,1,,10116.0,8615,1,50597,,,Ileum,% absorption predicted from in vitro rat ileum transport studies,,N,,Rattus norvegicus,BAO_0000218,2116.0,CHEMBL622432,,,A
13569,Intermediate,,1,,10116.0,8616,1,50597,,In vivo,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622433,,,A
13569,Intermediate,,1,,10116.0,8617,1,50597,,In vivo,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622434,,,A
13569,Intermediate,,1,,10116.0,8618,1,50597,,In vivo,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622435,,,A
13569,Intermediate,,1,,10116.0,8619,1,50597,,In vivo,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618748,,,A
13569,Intermediate,,1,,10116.0,8620,1,50597,,In vivo,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618749,,,A
13569,Intermediate,,1,,10116.0,8621,1,50597,,In vivo,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618750,,,A
13569,Intermediate,,1,,10116.0,8622,1,50597,,In vivo,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618751,,,A
13569,Intermediate,,1,,10116.0,8623,1,50597,,In vivo,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618752,,,A
4576,Intermediate,,1,,10116.0,8624,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618753,,,A
750,Intermediate,,1,,10116.0,8625,1,50597,,In vivo,Plasma,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL618754,,,A
750,Intermediate,,1,,10116.0,8626,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618755,,,A
4590,Intermediate,,1,,10116.0,8627,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618756,,,A
1716,Intermediate,,1,,10116.0,8628,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618757,,,A
1974,Intermediate,,1,,10116.0,8629,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618758,,,A
4502,Intermediate,,1,,10116.0,8630,1,50597,,In vivo,,Oral bioavailability in rat (dose 30 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621088,,,A
3371,Intermediate,,1,,10116.0,8631,1,50597,,,,Pharmacokinetic property (cLogP) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621089,,,A
9099,Intermediate,,1,,10116.0,8632,1,50597,,,Blood,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621090,,,F
9099,Intermediate,,1,,10116.0,8633,1,50597,,,Blood,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621091,,,F
4590,Intermediate,,1,,10116.0,8634,1,50597,,In vivo,,Clearance in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876731,,,A
3184,Intermediate,,1,,10116.0,8635,1,50597,,In vivo,,Compound was evaluated for its clearance when administered intravenously in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621092,,,A
16456,Intermediate,,1,,10116.0,8636,1,50597,,In vivo,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621093,,,A
4199,Intermediate,,1,,10116.0,8637,1,50597,,,,Blood: Brain distribution ratio is determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621094,,,A
4199,Intermediate,,1,,10116.0,8638,1,50597,,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621095,,,A
4199,Intermediate,,1,,10116.0,8639,1,50597,,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621096,,,A
8677,Intermediate,,1,,10116.0,8640,1,50597,,In vivo,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621097,,,A
7449,Intermediate,,1,,10116.0,8641,1,50597,,,,Percent dose excreted in 0-48 hours administered ip to male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621098,,,F
11977,Intermediate,,1,,10116.0,8642,1,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL621099,,,A
11977,Intermediate,,1,,10116.0,8643,1,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL621100,,,A
11977,Intermediate,,1,,10116.0,8644,1,50597,,,Cerebellum,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL621101,,,A
11977,Intermediate,,1,,10116.0,8645,1,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL621102,,,A
11977,Intermediate,,1,,10116.0,8646,1,50597,,,Cerebellum,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL876732,,,A
11977,Intermediate,,1,,10116.0,8647,1,50597,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621103,,,A
11977,Intermediate,,1,,10116.0,8648,1,50597,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621104,,,A
11977,Intermediate,,1,,10116.0,8649,1,50597,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621105,,,A
11977,Intermediate,,1,,10116.0,8650,1,50597,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621106,,,A
11977,Intermediate,,1,,10116.0,8651,1,50597,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621107,,,A
11977,Intermediate,,1,,10116.0,8652,1,50597,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621108,,,A
11977,Intermediate,,1,,10116.0,8653,1,50597,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621109,,,A
17208,Intermediate,,1,,10090.0,8654,1,50594,,In vivo,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621110,,,A
17208,Intermediate,,1,,10090.0,8655,1,50594,,In vivo,Kidney,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL621111,,,A
17208,Intermediate,,1,,10090.0,8656,1,50594,,In vivo,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL622541,,,A
17208,Intermediate,,1,,10090.0,8657,1,50594,,In vivo,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL622542,,,A
17208,Intermediate,,1,,10090.0,8658,1,50594,,In vivo,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL622543,,,A
17208,Intermediate,,1,,10090.0,8659,1,50594,,In vivo,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624412,,,A
17208,Intermediate,,1,,10090.0,8660,1,50594,,In vivo,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624413,,,A
17208,Intermediate,,1,,10090.0,8661,1,50594,,In vivo,Liver,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL624414,,,A
17208,Intermediate,,1,,10090.0,8662,1,50594,,In vivo,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624415,,,A
17208,Intermediate,,1,,10090.0,8663,1,50594,,In vivo,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624416,,,A
17208,Intermediate,,1,,10090.0,8664,1,50594,,In vivo,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624417,,,A
17208,Intermediate,,1,,10090.0,8665,1,50594,,In vivo,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624418,,,A
17208,Intermediate,,1,,10090.0,8666,1,50594,,In vivo,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624419,,,A
17208,Intermediate,,1,,10090.0,8667,1,50594,,In vivo,Lung,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL624420,,,A
17208,Intermediate,,1,,10090.0,8668,1,50594,,In vivo,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL624421,,,A
17208,Intermediate,,1,,10090.0,8669,1,50594,,In vivo,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL624422,,,A
17208,Intermediate,,1,,10090.0,8670,1,50594,,In vivo,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL624423,,,A
17208,Intermediate,,1,,10090.0,8671,1,50594,,In vivo,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL625123,,,A
17208,Intermediate,,1,,10090.0,8672,1,50594,,In vivo,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL625124,,,A
17208,Intermediate,,1,,10090.0,8673,1,50594,,In vivo,Muscle tissue,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL625125,,,A
17208,Intermediate,,1,,10090.0,8674,1,50594,,In vivo,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,14.0,CHEMBL625126,,,A
17208,Intermediate,,1,,10090.0,8675,1,50594,,In vivo,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,14.0,CHEMBL626947,,,A
17208,Intermediate,,1,,10090.0,8676,1,50594,,In vivo,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,14.0,CHEMBL626948,,,A
17208,Intermediate,,1,,10090.0,8677,1,50594,,In vivo,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,14.0,CHEMBL626949,,,A
17208,Intermediate,,1,,10090.0,8678,1,50594,,In vivo,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,14.0,CHEMBL626950,,,A
17208,Intermediate,,1,,10090.0,8679,1,50594,,In vivo,Zone of skin,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,14.0,CHEMBL626951,,,A
17208,Intermediate,,1,,10090.0,8680,1,50594,,In vivo,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL626952,,,A
17208,Intermediate,,1,,10090.0,8681,1,50594,,In vivo,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL626953,,,A
17208,Intermediate,,1,,10090.0,8682,1,50594,,In vivo,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL626954,,,A
17208,Intermediate,,1,,10090.0,8683,1,50594,,In vivo,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL626955,,,A
17208,Intermediate,,1,,10090.0,8684,1,50594,,In vivo,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL626956,,,A
17208,Intermediate,,1,,10090.0,8685,1,50594,,In vivo,Spleen,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL626957,,,A
17208,Intermediate,,1,,10090.0,8686,1,50594,,In vivo,Blood,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626958,,,A
17208,Intermediate,,1,,10090.0,8687,1,50594,,In vivo,Blood,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626959,,,A
17208,Intermediate,,1,,10090.0,8688,1,50594,,In vivo,Blood,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626960,,,A
17208,Intermediate,,1,,10090.0,8689,1,50594,,In vivo,Blood,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626961,,,A
17208,Intermediate,,1,,10090.0,8690,1,50594,,In vivo,Blood,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL627589,,,A
17208,Intermediate,,1,,10090.0,8691,1,50594,,In vivo,Blood,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL627590,,,A
3132,Intermediate,,1,,10090.0,8692,1,50594,,,,Time taken for EC90 was determined when tested in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL627591,,,A
3132,Intermediate,,1,,10090.0,8693,1,50594,,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627592,,,A
16597,Intermediate,,1,,10090.0,8694,1,50594,,In vivo,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,N,,Mus musculus,BAO_0000218,,CHEMBL627593,,,A
5727,Intermediate,,1,,10090.0,8695,1,50594,,,,Half life in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL627594,,,A
5302,Intermediate,,1,,10090.0,8696,1,50594,,In vivo,,Half life period in mouse after 10 mg/Kg dose,,N,,Mus musculus,BAO_0000218,,CHEMBL876813,,,A
5302,Intermediate,,1,,10090.0,8697,1,50594,,In vivo,,Half life period in mouse after 10 mg/kg dose,,N,,Mus musculus,BAO_0000218,,CHEMBL627595,,,A
6348,Intermediate,,1,,10090.0,8698,1,50594,,In vivo,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,N,,Mus musculus,BAO_0000218,,CHEMBL627596,,,A
5964,Intermediate,,1,,10116.0,8699,1,50597,,In vivo,,Cmax value at 5 mg/kg po was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627597,,,A
6078,Intermediate,,1,,10116.0,8700,1,50597,,In vivo,,Cmax value evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627598,,,A
5206,Intermediate,,1,,10116.0,8701,1,50597,,In vivo,Brain,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL627599,,,A
2959,Intermediate,,1,,10116.0,8702,1,50597,,In vivo,,Cmax value after administration of 20 mg/Kg oral dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627600,,,A
5964,Intermediate,,1,,10116.0,8703,1,50597,,In vivo,,Cmax value at 1 mg/kg po in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627601,,,A
5964,Intermediate,,1,,10116.0,8704,1,50597,,In vivo,,Cmax value at 5 mg/kg po in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627776,,,A
6757,Intermediate,,1,,10116.0,8705,1,50597,,In vivo,,Cmax value at a dose of 10 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627777,,,A
6757,Intermediate,,1,,10116.0,8706,1,50597,,In vivo,,Cmax value at a dose of 100 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627778,,,A
6757,Intermediate,,1,,10116.0,8707,1,50597,,In vivo,,Cmax value at a dose of 50 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627779,,,A
17617,Intermediate,,1,,10116.0,8708,1,50597,,In vivo,,Cmax value in rats at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876814,,,A
1445,Intermediate,,1,,10116.0,8709,1,50597,,In vivo,,Cmax value was evaluated in rats at a dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627780,,,A
6082,Intermediate,,1,,10116.0,8710,1,50597,,In vivo,,Cmax value was determined after peroral administration of 20 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627781,,,A
1446,Intermediate,,1,,10116.0,8711,1,50597,,In vivo,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627782,,,A
5407,Intermediate,,1,,10116.0,8712,1,50597,,In vivo,Plasma,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627783,,,A
2690,Intermediate,,1,,10116.0,8713,1,50597,,In vivo,Plasma,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627784,,,A
2661,Intermediate,,1,,10116.0,8714,1,50597,,In vivo,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627785,,,A
2661,Intermediate,,1,,10116.0,8715,1,50597,,In vivo,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627786,,,A
4891,Intermediate,,1,,10116.0,8716,1,50597,,In vivo,Plasma,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627787,,,A
2807,Intermediate,,1,,10116.0,8717,1,50597,,In vivo,Plasma,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627788,,,A
2807,Intermediate,,1,,10116.0,8718,1,50597,,In vivo,Plasma,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626579,,,A
2807,Intermediate,,1,,10116.0,8719,1,50597,,In vivo,Plasma,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626580,,,A
3634,Intermediate,,1,,10116.0,8720,1,50597,,In vivo,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876815,,,A
1881,Intermediate,,1,,10116.0,8721,1,50597,,In vivo,Plasma,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626581,,,A
1881,Intermediate,,1,,10116.0,8722,1,50597,,In vivo,Plasma,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626582,,,A
429,Intermediate,,1,,10116.0,8723,1,50597,,In vivo,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626583,,,A
5974,Intermediate,,1,,10116.0,8724,1,50597,,In vivo,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626205,,,A
5974,Intermediate,,1,,10116.0,8725,1,50597,,In vivo,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626206,,,A
5974,Intermediate,,1,,10116.0,8726,1,50597,,In vivo,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626207,,,A
5974,Intermediate,,1,,10116.0,8727,1,50597,,In vivo,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623882,,,A
17582,Intermediate,,1,,10116.0,8728,1,50597,,In vivo,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623883,,,A
17582,Intermediate,,1,,10116.0,8729,1,50597,,In vivo,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623884,,,A
3032,Intermediate,,1,,10116.0,8730,1,50597,,In vivo,Plasma,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623885,,,A
6295,Intermediate,,1,,10116.0,8731,1,50597,,In vivo,Plasma,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623886,,,A
6619,Intermediate,,1,,10116.0,8732,1,50597,,In vivo,,Maximal concentration in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623887,,,A
6616,Intermediate,,1,,10116.0,8733,1,50597,,In vivo,,Maximal concentration after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623888,,,A
3249,Intermediate,,1,,10116.0,8734,1,50597,,In vivo,Plasma,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623889,,,A
17791,Intermediate,,1,,10116.0,8735,1,50597,,In vivo,Plasma,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623890,,,A
17791,Intermediate,,1,,10116.0,8736,1,50597,,In vivo,Plasma,Cmax in rat plasma after oral dose (50 mg/Kg),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623891,,,A
1360,Intermediate,,1,,10116.0,8737,1,50597,,In vivo,Plasma,Maximal plasma concentration was determined.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623892,,,A
2552,Intermediate,,1,,10116.0,8738,1,50597,,In vivo,Plasma,Maximal plasma drug concentration was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623893,,,A
6571,Intermediate,,1,,10116.0,8739,1,50597,,In vivo,,Maximal concentration in rats after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877616,,,A
6570,Intermediate,,1,,10116.0,8740,1,50597,,In vivo,,Maximum concentration in rat after 2 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623894,,,A
6567,Intermediate,,1,,10116.0,8741,1,50597,,In vivo,Plasma,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623895,,,A
3031,Intermediate,,1,,10116.0,8742,1,50597,,In vivo,,Maximum concentration of compound in rat was evaluated.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623896,,,A
3436,Intermediate,,1,,10116.0,8743,1,50597,,In vivo,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623897,,,A
3436,Intermediate,,1,,10116.0,8744,1,50597,,In vivo,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623898,,,A
2083,Intermediate,,1,,10116.0,8745,1,50597,,In vivo,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623899,,,A
3436,Intermediate,,1,,10116.0,8746,1,50597,,In vivo,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623900,,,A
4527,Intermediate,,1,,10116.0,8747,1,50597,,In vivo,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623901,,,A
1974,Intermediate,,1,,10116.0,8748,1,50597,,In vivo,,Maximum concentration was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623902,,,A
3307,Intermediate,,1,,10116.0,8749,1,50597,,In vivo,Cerebrospinal fluid,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,N,,Rattus norvegicus,BAO_0000218,1359.0,CHEMBL623903,,,A
3307,Intermediate,,1,,10116.0,8750,1,50597,,In vivo,Plasma,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623904,,,A
1916,Intermediate,,1,,10116.0,8751,1,50597,,In vivo,Plasma,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL877617,,,A
1500,Intermediate,,1,,10116.0,8752,1,50597,,In vivo,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623905,,,A
1500,Intermediate,,1,,10116.0,8753,1,50597,,In vivo,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623906,,,A
4186,Intermediate,,1,,10116.0,8754,1,50597,,In vivo,Plasma,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623907,,,A
16434,Intermediate,,1,,10116.0,8755,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623908,,,A
16434,Intermediate,,1,,10116.0,8756,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623909,,,A
16434,Intermediate,,1,,10116.0,8757,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623910,,,A
16434,Intermediate,,1,,10116.0,8758,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623911,,,A
16435,Intermediate,,1,,10116.0,8759,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623912,,,A
16435,Intermediate,,1,,10116.0,8760,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624616,,,A
16435,Intermediate,,1,,10116.0,8761,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624617,,,A
16435,Intermediate,,1,,10116.0,8762,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624618,,,A
16435,Intermediate,,1,,10116.0,8763,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624619,,,A
16435,Intermediate,,1,,10116.0,8764,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624794,,,A
16435,Intermediate,,1,,10116.0,8765,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624795,,,A
16435,Intermediate,,1,,10116.0,8766,1,50597,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623921,,,A
16434,Intermediate,,1,,10116.0,8767,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623922,,,A
16434,Intermediate,,1,,10116.0,8768,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623923,,,A
16434,Intermediate,,1,,10116.0,8769,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623924,,,A
16435,Intermediate,,1,,10116.0,8770,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623925,,,A
16435,Intermediate,,1,,10116.0,8771,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623926,,,A
16435,Intermediate,,1,,10116.0,8772,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623927,,,A
16435,Intermediate,,1,,10116.0,8773,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623928,,,A
16435,Intermediate,,1,,10116.0,8774,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623929,,,A
16435,Intermediate,,1,,10116.0,8775,1,50597,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623930,,,A
16434,Intermediate,,1,,10116.0,8776,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623931,,,A
16434,Intermediate,,1,,10116.0,8777,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622165,,,A
16434,Intermediate,,1,,10116.0,8778,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621249,,,A
16434,Intermediate,,1,,10116.0,8779,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621250,,,A
16434,Intermediate,,1,,10116.0,8780,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621448,,,A
16434,Intermediate,,1,,10116.0,8781,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621449,,,A
16434,Intermediate,,1,,10116.0,8782,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621450,,,A
16434,Intermediate,,1,,10116.0,8783,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621451,,,A
16435,Intermediate,,1,,10116.0,8784,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621452,,,A
16435,Intermediate,,1,,10116.0,8785,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621453,,,A
16435,Intermediate,,1,,10116.0,8786,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621454,,,A
16435,Intermediate,,1,,10116.0,8787,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621455,,,A
16435,Intermediate,,1,,10116.0,8788,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621456,,,A
16435,Intermediate,,1,,10116.0,8789,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625145,,,A
16435,Intermediate,,1,,10116.0,8790,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL875847,,,A
16435,Intermediate,,1,,10116.0,8791,1,50597,,,Brain,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625146,,,A
16434,Intermediate,,1,,10116.0,8792,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625147,,,A
16434,Intermediate,,1,,10116.0,8793,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625148,,,A
16434,Intermediate,,1,,10116.0,8794,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625149,,,A
16435,Intermediate,,1,,10116.0,8795,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625150,,,A
16435,Intermediate,,1,,10116.0,8796,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625151,,,A
16435,Intermediate,,1,,10116.0,8797,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625152,,,A
16435,Intermediate,,1,,10116.0,8798,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625153,,,A
16435,Intermediate,,1,,10116.0,8799,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625154,,,A
16435,Intermediate,,1,,10116.0,8800,1,50597,,,Brain,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625155,,,A
11977,Intermediate,,1,,10116.0,8801,1,50597,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625156,,,A
11977,Intermediate,,1,,10116.0,8802,1,50597,,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624354,,,A
11977,Intermediate,,1,,10116.0,8803,1,50597,,,Hippocampus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL624355,,,A
11977,Intermediate,,1,,10116.0,8804,1,50597,,,Hippocampus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL624356,,,A
11977,Intermediate,,1,,10116.0,8805,1,50597,,,Hippocampus,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL624357,,,A
11977,Intermediate,,1,,10116.0,8806,1,50597,,,Hippocampus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL624358,,,A
11977,Intermediate,,1,,10116.0,8807,1,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL624359,,,A
11977,Intermediate,,1,,10116.0,8808,1,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL624360,,,A
11977,Intermediate,,1,,10116.0,8809,1,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL624361,,,A
11977,Intermediate,,1,,10116.0,8810,1,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL624362,,,A
11977,Intermediate,,1,,10116.0,8811,1,50597,,,Striatum,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL624363,,,A
11977,Intermediate,,1,,10116.0,8812,1,50597,,In vivo,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624364,,,A
11977,Intermediate,,1,,10116.0,8813,1,50597,,In vivo,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624365,,,A
11977,Intermediate,,1,,10116.0,8814,1,50597,,In vivo,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624366,,,A
11977,Intermediate,,1,,10116.0,8815,1,50597,,In vivo,Blood,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624367,,,A
11977,Intermediate,,1,,10116.0,8816,1,50597,,In vivo,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624368,,,A
11977,Intermediate,,1,,10116.0,8817,1,50597,,In vivo,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624369,,,A
11977,Intermediate,,1,,10116.0,8818,1,50597,,In vivo,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624370,,,A
11977,Intermediate,,1,,10116.0,8819,1,50597,,In vivo,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625069,,,A
11977,Intermediate,,1,,10116.0,8820,1,50597,,In vivo,Brain,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625070,,,A
11977,Intermediate,,1,,10116.0,8821,1,50597,,In vivo,Heart,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626051,,,A
11977,Intermediate,,1,,10116.0,8822,1,50597,,In vivo,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626052,,,A
11977,Intermediate,,1,,10116.0,8823,1,50597,,In vivo,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626053,,,A
11977,Intermediate,,1,,10116.0,8824,1,50597,,In vivo,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626054,,,A
11977,Intermediate,,1,,10116.0,8825,1,50597,,In vivo,Heart,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626055,,,A
11977,Intermediate,,1,,10116.0,8826,1,50597,,In vivo,Kidney,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626056,,,A
11977,Intermediate,,1,,10116.0,8827,1,50597,,In vivo,Kidney,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626057,,,A
11977,Intermediate,,1,,10116.0,8828,1,50597,,In vivo,Kidney,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625193,,,A
11977,Intermediate,,1,,10116.0,8829,1,50597,,In vivo,Kidney,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625194,,,A
11977,Intermediate,,1,,10116.0,8830,1,50597,,In vivo,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625195,,,A
11977,Intermediate,,1,,10116.0,8831,1,50597,,In vivo,Liver,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625196,,,A
11977,Intermediate,,1,,10116.0,8832,1,50597,,In vivo,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625197,,,A
11977,Intermediate,,1,,10116.0,8833,1,50597,,In vivo,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625198,,,A
11977,Intermediate,,1,,10116.0,8834,1,50597,,In vivo,Liver,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627929,,,A
11977,Intermediate,,1,,10116.0,8835,1,50597,,In vivo,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627074,,,A
11977,Intermediate,,1,,10116.0,8836,1,50597,,In vivo,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627075,,,A
11977,Intermediate,,1,,10116.0,8837,1,50597,,In vivo,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627076,,,A
11977,Intermediate,,1,,10116.0,8838,1,50597,,In vivo,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627077,,,A
11977,Intermediate,,1,,10116.0,8839,1,50597,,In vivo,Lung,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627078,,,A
11977,Intermediate,,1,,10116.0,8840,1,50597,,In vivo,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627079,,,A
4573,Intermediate,,1,,10090.0,8841,1,50594,,In vivo,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,N,,Mus musculus,BAO_0000218,,CHEMBL873824,,,A
3132,Intermediate,,1,,10090.0,8842,1,50594,,In vivo,Plasma,Half life in mouse plasma was determined at dose 25 mg/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627080,,,A
17718,Intermediate,,1,,10090.0,8843,1,50594,,,,Half life was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL627081,,,A
17728,Intermediate,,1,,10090.0,8844,1,50594,,In vivo,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL627082,,,A
5961,Intermediate,,1,,10090.0,8845,1,50594,,In vivo,,Half-life in male mice after 1 mg/kg intravenous dose,,N,,Mus musculus,BAO_0000218,,CHEMBL627083,,,A
17731,Intermediate,,1,,10090.0,8847,1,50594,,,Plasma,Half life in mice plasma,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627085,,,A
17592,Intermediate,,1,,10090.0,8848,1,50594,,,,Half life in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL627086,,,A
3132,Intermediate,,1,,10090.0,8849,1,50594,,In vivo,Plasma,Half life in mouse plasma at dose 25 mg/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627087,,,A
17729,Intermediate,,1,,10090.0,8850,1,50594,,In vivo,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL627088,,,A
17729,Intermediate,,1,,10090.0,8851,1,50594,,In vivo,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL627089,,,A
17729,Intermediate,,1,,10090.0,8852,1,50594,,In vivo,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL627090,,,A
3277,Intermediate,,1,,10090.0,8853,1,50594,,In vivo,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,N,,Mus musculus,BAO_0000218,,CHEMBL627091,,,A
3760,Intermediate,,1,,10090.0,8854,1,50594,,In vivo,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL627092,,,A
3760,Intermediate,,1,,10090.0,8855,1,50594,,In vivo,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,N,,Mus musculus,BAO_0000218,,CHEMBL876785,,,A
2862,Intermediate,,1,,10090.0,8856,1,50594,,In vivo,,Half-life by iv administration in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL627093,,,A
2862,Intermediate,,1,,10090.0,8857,1,50594,,In vivo,,Half-life by oral administration in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL627094,,,A
5980,Intermediate,,1,,10090.0,8858,1,50594,,,,Half-life in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL627095,,,A
6159,Intermediate,,1,,10090.0,8859,1,50594,,,Brain,Half-life using mouse brain homogenate,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627096,,,A
6254,Intermediate,,1,,10090.0,8860,1,50594,,,,Half-life was measured in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL627097,,,A
6062,Intermediate,,1,,10090.0,8861,1,50594,,In vivo,,Half-life was measured in mouse after an iv dose of 1 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627098,,,A
1574,Intermediate,,1,,10090.0,8862,1,50594,,,Blood,Half-life period was determined in mouse blood,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL627099,,,A
56,Intermediate,,1,,10090.0,8863,1,50594,,,Brain,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL627100,,,A
993,Intermediate,,1,,10090.0,8864,1,50594,,,Plasma,Plasma half life in mouse,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627101,,,A
6652,Intermediate,,1,,10090.0,8865,1,50594,,,,Stability of the peptide in the presence of mouse serum,,N,,Mus musculus,BAO_0000218,,CHEMBL627102,,,A
17852,Intermediate,,1,,10090.0,8866,1,50594,,,,Terminal half life of compound was determined in mouse,,N,,Mus musculus,BAO_0000218,,CHEMBL627103,,,A
2675,Intermediate,,1,,10090.0,8867,1,50594,,In vivo,,Terminal half life was evaluated in mice after intravenous administration,,N,,Mus musculus,BAO_0000218,,CHEMBL627104,,,A
2675,Intermediate,,1,,10090.0,8868,1,50594,,In vivo,,Terminal half life was evaluated in mice after oral administration,,N,,Mus musculus,BAO_0000218,,CHEMBL627105,,,A
499,Intermediate,,1,,10090.0,8869,1,50594,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,N,,Mus musculus,BAO_0000218,,CHEMBL876786,,,A
499,Intermediate,,1,,10090.0,8870,1,50594,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,N,,Mus musculus,BAO_0000218,,CHEMBL873825,,,A
499,Intermediate,,1,,10090.0,8871,1,50594,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,N,,Mus musculus,BAO_0000218,,CHEMBL627106,,,A
14239,Intermediate,,1,,10090.0,8872,1,50594,,In vivo,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL626336,,,A
5506,Intermediate,,1,,10090.0,8873,1,50594,,In vivo,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,N,,Mus musculus,BAO_0000218,,CHEMBL877462,,,A
5506,Intermediate,,1,,10090.0,8874,1,50594,,In vivo,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,N,,Mus musculus,BAO_0000218,,CHEMBL626337,,,A
17734,Intermediate,,1,,10090.0,8875,1,50594,,,,Half life after intraperitoneal administration of 100 mg/kg in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL626338,,,A
17728,Intermediate,,1,,10090.0,8876,1,50594,,In vivo,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL626339,,,A
17728,Intermediate,,1,,10090.0,8877,1,50594,,In vivo,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL626340,,,A
17728,Intermediate,,1,,10090.0,8878,1,50594,,In vivo,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL625377,,,A
17728,Intermediate,,1,,10090.0,8879,1,50594,,In vivo,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL625378,,,A
17728,Intermediate,,1,,10090.0,8880,1,50594,,In vivo,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,N,,Mus musculus,BAO_0000218,,CHEMBL625379,,,A
14294,Autocuration,,1,,9823.0,8881,0,22224,,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,U,,Sus scrofa,BAO_0000251,,CHEMBL625380,,Microsomes,A
14294,Autocuration,,1,,9823.0,8882,0,22224,,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,U,,Sus scrofa,BAO_0000251,,CHEMBL625381,,Microsomes,A
6056,Autocuration,,1,,9823.0,8883,0,22224,,,,Stability to porcine renal DHP-I,,U,,Sus scrofa,BAO_0000019,,CHEMBL625382,,,A
1317,Autocuration,,1,,9823.0,8884,0,22224,,In vivo,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,U,,Sus scrofa,BAO_0000218,,CHEMBL873828,,,A
1317,Autocuration,,1,,9823.0,8885,0,22224,,In vivo,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,U,,Sus scrofa,BAO_0000218,,CHEMBL625383,,,A
5229,Autocuration,,1,,9823.0,8886,0,22224,,,,Half-life of the parent prodrug in porcine esterase solution,,U,,Sus scrofa,BAO_0000019,,CHEMBL625384,,,A
4231,Autocuration,,1,,9823.0,8887,0,22224,,,,"First order rate constant, k was determined in in pig liver Esterase",,U,,Sus scrofa,BAO_0000019,,CHEMBL625385,,,A
4231,Autocuration,,1,,9823.0,8888,0,22224,,,Liver,Half life of the in pig liver Esterase,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL625386,,,A
5318,Autocuration,,1,,9823.0,8889,0,22224,,,Liver,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623571,,,A
5318,Autocuration,,1,,9823.0,8890,0,22224,,,Liver,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623572,,,A
5318,Autocuration,,1,,9823.0,8891,0,22224,,,Liver,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623573,,,A
3305,Autocuration,,1,,9823.0,8892,0,22224,,,Liver,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623574,,,A
3305,Autocuration,,1,,9823.0,8893,0,22224,,,Liver,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623575,,,A
2842,Autocuration,,1,,9823.0,8894,0,22224,,,Liver,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623749,,,A
2842,Autocuration,,1,,9823.0,8895,0,22224,,,Liver,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623750,,,A
889,Autocuration,,1,,9823.0,8896,0,22224,,In vitro,Liver,Half-life in vitro in pig liver,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623751,,,A
1904,Autocuration,,1,,9823.0,8897,0,22224,,,Liver,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,U,,Sus scrofa,BAO_0000221,2107.0,CHEMBL623752,,,A
4186,Intermediate,,1,,10116.0,8898,1,50597,,In vivo,Plasma,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623753,,,A
2774,Intermediate,,1,,10116.0,8899,1,50597,,In vivo,Plasma,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623754,,,A
1742,Intermediate,,1,,10116.0,8900,1,50597,,In vivo,Plasma,Maximum concentration in rat plasma was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623755,,,A
3169,Intermediate,,1,,10116.0,8901,1,50597,,In vivo,,Maximum concentration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623756,,,A
3169,Intermediate,,1,,10116.0,8902,1,50597,,In vivo,,Maximum concentration in rats at 1-2 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623757,,,A
2081,Intermediate,,1,,10116.0,8903,1,50597,,In vivo,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623758,,,A
3307,Intermediate,,1,,10116.0,8904,1,50597,,In vivo,Brain,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623759,,,A
4727,Intermediate,,1,,10116.0,8905,1,50597,,In vivo,,Maximum concentration at the dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623760,,,A
6597,Intermediate,,1,,10116.0,8906,1,50597,,In vivo,,Maximum concentration was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623761,,,A
16365,Intermediate,,1,,10116.0,8907,1,50597,,In vivo,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623762,,,A
16365,Intermediate,,1,,10116.0,8908,1,50597,,In vivo,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL877594,,,A
16365,Intermediate,,1,,10116.0,8909,1,50597,,In vivo,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623763,,,A
16365,Intermediate,,1,,10116.0,8910,1,50597,,In vivo,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623764,,,A
16365,Intermediate,,1,,10116.0,8911,1,50597,,In vivo,Plasma,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623765,,,A
2591,Intermediate,,1,,10116.0,8912,1,50597,,In vivo,Blood,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623766,,,A
2591,Intermediate,,1,,10116.0,8913,1,50597,,In vivo,Blood,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623767,,,A
2591,Intermediate,,1,,10116.0,8914,1,50597,,In vivo,Blood,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623768,,,A
5978,Intermediate,,1,,10116.0,8915,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623769,,,A
5978,Intermediate,,1,,10116.0,8916,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623770,,,A
5978,Intermediate,,1,,10116.0,8917,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623771,,,A
5978,Intermediate,,1,,10116.0,8918,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623772,,,A
5978,Intermediate,,1,,10116.0,8919,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623773,,,A
5978,Intermediate,,1,,10116.0,8920,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623774,,,A
5978,Intermediate,,1,,10116.0,8921,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623775,,,A
14465,Intermediate,,1,,10116.0,8922,1,50597,,In vivo,,Cmax in rat (PO dose),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623776,,,A
4723,Intermediate,,1,,10116.0,8923,1,50597,,In vivo,Plasma,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622191,,,A
4723,Intermediate,,1,,10116.0,8924,1,50597,,In vivo,Plasma,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622192,,,A
4576,Intermediate,,1,,10116.0,8925,1,50597,,In vivo,Plasma,Maximum plasma concentration determined in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622193,,,A
12873,Intermediate,,1,,10116.0,8926,1,50597,,In vivo,Plasma,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622194,,,A
12873,Intermediate,,1,,10116.0,8927,1,50597,,In vivo,Plasma,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622195,,,A
6824,Intermediate,,1,,10116.0,8928,1,50597,,In vivo,Plasma,Maximum plasma concentration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622196,,,A
17065,Intermediate,,1,,10116.0,8929,1,50597,,In vivo,Plasma,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622197,,,A
2932,Intermediate,,1,,10116.0,8930,1,50597,,In vivo,Plasma,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622198,,,A
2932,Intermediate,,1,,10116.0,8931,1,50597,,In vivo,Plasma,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622199,,,A
2879,Intermediate,,1,,10116.0,8932,1,50597,,In vivo,Plasma,Maximum plasma concentration of compound was measured in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622200,,,A
2864,Intermediate,,1,,10116.0,8933,1,50597,,In vivo,Plasma,Maximum plasma concentration after 20 mg/kg oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622201,,,A
16367,Intermediate,,1,,10116.0,8934,1,50597,,In vivo,Plasma,Maximum plasma concentration after oral administration to rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623990,,,A
17717,Intermediate,,1,,10116.0,8935,1,50597,,In vivo,Plasma,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623991,,,A
17717,Intermediate,,1,,10116.0,8936,1,50597,,In vivo,Plasma,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623992,,,A
17717,Intermediate,,1,,10116.0,8937,1,50597,,In vivo,Plasma,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623993,,,A
17717,Intermediate,,1,,10116.0,8938,1,50597,,In vivo,Plasma,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623994,,,A
17720,Intermediate,,1,,10116.0,8939,1,50597,,In vivo,Plasma,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623995,,,F
17720,Intermediate,,1,,10116.0,8940,1,50597,,In vivo,Plasma,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623996,,,F
17720,Intermediate,,1,,10116.0,8941,1,50597,,In vivo,Plasma,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623997,,,F
4516,Intermediate,,1,,10116.0,8942,1,50597,,In vivo,Plasma,Maximum plasma concentration dosed orally in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623998,,,A
4516,Intermediate,,1,,10116.0,8943,1,50597,,In vivo,Plasma,Maximum plasma concentration dosed orally in rats after 6 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623999,,,A
4516,Intermediate,,1,,10116.0,8944,1,50597,,In vivo,Plasma,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624000,,,A
5199,Intermediate,,1,,10116.0,8945,1,50597,,In vivo,Plasma,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624001,,,A
17538,Intermediate,,1,,10116.0,8946,1,50597,,In vivo,Plasma,Maximum plasma concentration in rat after po administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624002,,,A
6685,Intermediate,,1,,10116.0,8947,1,50597,,In vivo,Plasma,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624003,,,A
6685,Intermediate,,1,,10116.0,8948,1,50597,,In vivo,Plasma,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624004,,,A
16434,Intermediate,,1,,10116.0,8949,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624005,,,A
16434,Intermediate,,1,,10116.0,8950,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624006,,,A
16434,Intermediate,,1,,10116.0,8951,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624007,,,A
16434,Intermediate,,1,,10116.0,8952,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624008,,,A
16434,Intermediate,,1,,10116.0,8953,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624009,,,A
16434,Intermediate,,1,,10116.0,8954,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL874387,,,A
16434,Intermediate,,1,,10116.0,8955,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624010,,,A
16434,Intermediate,,1,,10116.0,8956,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624011,,,A
16435,Intermediate,,1,,10116.0,8957,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624012,,,A
16435,Intermediate,,1,,10116.0,8958,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624013,,,A
16435,Intermediate,,1,,10116.0,8959,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624736,,,A
16435,Intermediate,,1,,10116.0,8960,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624737,,,A
16434,Intermediate,,1,,10116.0,8961,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624738,,,A
16434,Intermediate,,1,,10116.0,8962,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624739,,,A
16434,Intermediate,,1,,10116.0,8963,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624740,,,A
16435,Intermediate,,1,,10116.0,8964,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624896,,,A
16435,Intermediate,,1,,10116.0,8965,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624897,,,A
16435,Intermediate,,1,,10116.0,8966,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624108,,,A
16435,Intermediate,,1,,10116.0,8967,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624109,,,A
16435,Intermediate,,1,,10116.0,8968,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624110,,,A
16435,Intermediate,,1,,10116.0,8969,1,50597,,,Heart,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624111,,,A
16435,Intermediate,,1,,10116.0,8970,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624112,,,A
16435,Intermediate,,1,,10116.0,8971,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624113,,,A
16435,Intermediate,,1,,10116.0,8972,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL619709,,,A
16435,Intermediate,,1,,10116.0,8973,1,50597,,,Heart,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL619710,,,A
16434,Intermediate,,1,,10116.0,8974,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619711,,,A
16434,Intermediate,,1,,10116.0,8975,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619712,,,A
16434,Intermediate,,1,,10116.0,8976,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619713,,,A
16434,Intermediate,,1,,10116.0,8977,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619714,,,A
16434,Intermediate,,1,,10116.0,8978,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619715,,,A
16434,Intermediate,,1,,10116.0,8979,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619716,,,A
16434,Intermediate,,1,,10116.0,8980,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619717,,,A
16434,Intermediate,,1,,10116.0,8981,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619718,,,A
16435,Intermediate,,1,,10116.0,8982,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619719,,,A
16435,Intermediate,,1,,10116.0,8983,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL875329,,,A
16435,Intermediate,,1,,10116.0,8984,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619720,,,A
16435,Intermediate,,1,,10116.0,8985,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619721,,,A
16435,Intermediate,,1,,10116.0,8986,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619722,,,A
16435,Intermediate,,1,,10116.0,8987,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619723,,,A
16435,Intermediate,,1,,10116.0,8988,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619724,,,A
16435,Intermediate,,1,,10116.0,8989,1,50597,,,Kidney,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619725,,,A
16434,Intermediate,,1,,10116.0,8990,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619726,,,A
16434,Intermediate,,1,,10116.0,8991,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619727,,,A
16434,Intermediate,,1,,10116.0,8992,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619728,,,A
16435,Intermediate,,1,,10116.0,8993,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL619729,,,A
11977,Intermediate,,1,,10116.0,8994,1,50597,,In vivo,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL619730,,,A
11977,Intermediate,,1,,10116.0,8995,1,50597,,In vivo,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL619731,,,A
11977,Intermediate,,1,,10116.0,8996,1,50597,,In vivo,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL619732,,,A
11977,Intermediate,,1,,10116.0,8997,1,50597,,In vivo,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL619733,,,A
11977,Intermediate,,1,,10116.0,8998,1,50597,,In vivo,Muscle tissue,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL619734,,,A
11977,Intermediate,,1,,10116.0,8999,1,50597,,In vivo,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL619735,,,A
11977,Intermediate,,1,,10116.0,9000,1,50597,,In vivo,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL875330,,,A
11977,Intermediate,,1,,10116.0,9001,1,50597,,In vivo,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL628465,,,A
11977,Intermediate,,1,,10116.0,9002,1,50597,,In vivo,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL628466,,,A
11977,Intermediate,,1,,10116.0,9003,1,50597,,In vivo,Zone of skin,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL628467,,,A
11977,Intermediate,,1,,10116.0,9004,1,50597,,In vivo,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL628468,,,A
11977,Intermediate,,1,,10116.0,9005,1,50597,,In vivo,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL628469,,,A
11977,Intermediate,,1,,10116.0,9006,1,50597,,In vivo,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL628470,,,A
11977,Intermediate,,1,,10116.0,9007,1,50597,,In vivo,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL628471,,,A
11977,Intermediate,,1,,10116.0,9008,1,50597,,In vivo,Spleen,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL628472,,,A
11977,Intermediate,,1,,10116.0,9009,1,50597,,In vivo,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL625191,,,A
11977,Intermediate,,1,,10116.0,9010,1,50597,,In vivo,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL625192,,,A
11977,Intermediate,,1,,10116.0,9011,1,50597,,In vivo,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL875337,,,A
11977,Intermediate,,1,,10116.0,9012,1,50597,,In vivo,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626341,,,A
11977,Intermediate,,1,,10116.0,9013,1,50597,,In vivo,Thyroid gland,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626342,,,A
11977,Intermediate,,1,,10116.0,9014,1,50597,,In vivo,Liver,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621943,,,A
3748,Intermediate,,1,,10116.0,9015,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621944,,,A
15765,Intermediate,,1,,10116.0,9016,1,50597,,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621945,,,A
4871,Intermediate,,1,,10116.0,9017,1,50597,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621946,,,A
4871,Intermediate,,1,,10116.0,9018,1,50597,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621947,,,A
4872,Intermediate,,1,,10116.0,9019,1,50597,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621948,,,A
4872,Intermediate,,1,,10116.0,9020,1,50597,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621949,,,A
5413,Intermediate,,1,,10116.0,9021,1,50597,,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621950,,,A
5413,Intermediate,,1,,10116.0,9022,1,50597,,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621951,,,A
15272,Intermediate,,1,,10116.0,9023,1,50597,,In vivo,Blood,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621952,,,A
4689,Intermediate,,1,,10116.0,9024,1,50597,,,Liver,Stability (%) in rat liver microsomes,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621953,,,A
6057,Intermediate,,1,,10116.0,9025,1,50597,,,,Area under curve was calculated after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621954,,,A
6057,Intermediate,,1,,10116.0,9026,1,50597,,,,Area under the curve was calculated after iv administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621955,,,A
6057,Intermediate,,1,,10116.0,9027,1,50597,,,,Area under the curve was calculated in rat after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621956,,,A
6211,Intermediate,,1,,10116.0,9028,1,50597,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621957,,,A
5710,Intermediate,,1,,10116.0,9029,1,50597,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621958,,,A
5710,Intermediate,,1,,10116.0,9030,1,50597,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621959,,,A
17853,Intermediate,,1,,10116.0,9031,1,50597,,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621960,,,A
17853,Intermediate,,1,,10116.0,9032,1,50597,,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621961,,,A
15765,Intermediate,,1,,10116.0,9033,1,50597,,,,p value of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621962,,,A
15765,Intermediate,,1,,10116.0,9034,1,50597,,,,p value of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876787,,,F
15765,Intermediate,,1,,10116.0,9035,1,50597,,,,p value of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621963,,,A
6175,Intermediate,,1,,10116.0,9036,1,50597,,,Stomach,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL622637,,,A
6175,Intermediate,,1,,10116.0,9037,1,50597,,,Stomach,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL622638,,,A
6175,Intermediate,,1,,10116.0,9038,1,50597,,,Stomach,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL626561,,,A
7991,Autocuration,,1,,9986.0,9039,0,22224,,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL626562,,,F
429,Autocuration,,1,,9986.0,9040,0,22224,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626563,,,A
429,Autocuration,,1,,9986.0,9041,0,22224,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626564,,,A
6253,Autocuration,,1,,9986.0,9042,0,22224,,In vivo,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626565,,,A
6253,Autocuration,,1,,9986.0,9043,0,22224,,In vivo,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626566,,,A
3615,Autocuration,,1,,9986.0,9044,0,22224,,In vivo,,Clearance rate in rabbits,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626567,,,A
4059,Autocuration,,1,,9986.0,9045,0,22224,,In vivo,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626568,,,A
5124,Autocuration,,1,,9986.0,9046,0,22224,,In vivo,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626569,,,A
5124,Autocuration,,1,,9986.0,9047,0,22224,,In vivo,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626570,,,A
5124,Autocuration,,1,,9986.0,9048,0,22224,,In vivo,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626571,,,A
429,Autocuration,,1,,9986.0,9049,0,22224,,In vivo,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626572,,,A
4059,Autocuration,,1,,9986.0,9050,0,22224,,In vivo,Plasma,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,U,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL626573,,,A
9659,Autocuration,,1,,9986.0,9051,0,22224,,,Liver,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,U,,Oryctolagus cuniculus,BAO_0000251,2107.0,CHEMBL626574,,Microsomes,A
9659,Autocuration,,1,,9986.0,9052,0,22224,,,Liver,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,U,,Oryctolagus cuniculus,BAO_0000251,2107.0,CHEMBL626575,,Microsomes,A
3639,Autocuration,,1,,9986.0,9053,0,22224,,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626576,,,A
3639,Autocuration,,1,,9986.0,9054,0,22224,,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626577,,,A
3639,Autocuration,,1,,9986.0,9055,0,22224,,In vivo,,The compound was tested for its bioavailability in rabbit (by oral dosage).,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626578,,,A
5124,Autocuration,,1,,9986.0,9056,0,22224,,In vivo,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625263,,,A
5124,Autocuration,,1,,9986.0,9057,0,22224,,In vivo,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625264,,,A
5124,Autocuration,,1,,9986.0,9058,0,22224,,In vivo,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625265,,,A
14294,Autocuration,,1,,9986.0,9059,0,22224,,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,U,,Oryctolagus cuniculus,BAO_0000251,,CHEMBL625266,,Microsomes,A
14294,Autocuration,,1,,9986.0,9060,0,22224,,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,U,,Oryctolagus cuniculus,BAO_0000251,,CHEMBL876796,,Microsomes,A
429,Autocuration,,1,,9986.0,9061,0,22224,,In vivo,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625267,,,A
5124,Autocuration,,1,,9986.0,9062,0,22224,,In vivo,Plasma,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL625268,,,A
5124,Autocuration,,1,,9986.0,9063,0,22224,,In vivo,Plasma,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL625269,,,A
5124,Autocuration,,1,,9986.0,9064,0,22224,,In vivo,Plasma,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL624689,,,A
429,Autocuration,,1,,9986.0,9065,0,22224,,In vivo,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL624690,,,A
429,Autocuration,,1,,9986.0,9066,0,22224,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,U,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL624691,,,A
429,Autocuration,,1,,9986.0,9067,0,22224,,,Urine,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,U,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL624692,,,A
4059,Autocuration,,1,,9986.0,9068,0,22224,,In vivo,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL624693,,,A
4137,Autocuration,,1,,9986.0,9069,0,22224,,In vivo,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL624694,,,A
11672,Autocuration,,1,,9986.0,9070,0,22224,,In vitro,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,U,,Oryctolagus cuniculus,BAO_0000221,,CHEMBL877596,,,A
12886,Autocuration,,1,,9986.0,9071,0,22224,,,,Time within which only 10% of the drug was degraded,,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL624695,,,A
3853,Autocuration,,1,,9986.0,9072,0,22224,,,Liver,Half life period in rabbit liver homogenate,,U,,Oryctolagus cuniculus,BAO_0000221,2107.0,CHEMBL624696,,,A
3615,Autocuration,,1,,9986.0,9073,0,22224,,,,Half life value in rabbits,,U,,Oryctolagus cuniculus,BAO_0000019,,CHEMBL624697,,,A
6253,Autocuration,,1,,9986.0,9074,0,22224,,In vivo,Blood,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,U,,Oryctolagus cuniculus,BAO_0000218,178.0,CHEMBL624698,,,A
6253,Autocuration,,1,,9986.0,9075,0,22224,,In vivo,Blood,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,U,,Oryctolagus cuniculus,BAO_0000218,178.0,CHEMBL624699,,,A
6077,Autocuration,,1,,9986.0,9076,0,22224,,In vivo,,Half-life period in rabbits following intravenous administration at 2 mg/kg,,U,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL624700,,,A
17617,Intermediate,,1,,10116.0,9077,1,50597,,,Plasma,AUC 0-8 hr value in rats at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622903,,,A
17594,Intermediate,,1,,10116.0,9078,1,50597,,,Plasma,AUC after administration at 2000 mg/kg/day in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622904,,,A
6149,Intermediate,,1,,10116.0,9079,1,50597,,,Plasma,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622905,,,A
17260,Intermediate,,1,,10116.0,9080,1,50597,,,Plasma,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622906,,,A
17260,Intermediate,,1,,10116.0,9081,1,50597,,,Plasma,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622907,,,A
6644,Intermediate,,1,,10116.0,9082,1,50597,,,Plasma,AUC in rat after oral administration at 10.5 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622908,,,A
6644,Intermediate,,1,,10116.0,9083,1,50597,,,Plasma,AUC in rat after oral administration at 11.2 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622909,,,A
6644,Intermediate,,1,,10116.0,9084,1,50597,,,Plasma,AUC in rat after oral administration at 9.7 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622910,,,A
6495,Intermediate,,1,,10116.0,9085,1,50597,,,Brain,AUC in rat brain after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622911,,,A
6504,Intermediate,,1,,10116.0,9086,1,50597,,,Plasma,AUC in rat p.o.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622912,,,A
17686,Intermediate,,1,,10116.0,9087,1,50597,,,Plasma,AUC in rat p.o. at 20 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622913,,,A
6495,Intermediate,,1,,10116.0,9088,1,50597,,,Plasma,AUC in rat plasma after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622914,,,A
216,Intermediate,,1,,10116.0,9089,1,50597,,,Plasma,AUC in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622915,,,A
1908,Intermediate,,1,,10116.0,9090,1,50597,,,Plasma,AUC value after IV dose at a dose of 5 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622916,,,A
1908,Intermediate,,1,,10116.0,9091,1,50597,,,Plasma,AUC value after oral dose at a dose of 10 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622917,,,A
6685,Intermediate,,1,,10116.0,9092,1,50597,,In vivo,Plasma,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622918,,,A
216,Intermediate,,1,,10116.0,9093,1,50597,,In vivo,Plasma,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622919,,,A
6049,Intermediate,,1,,10116.0,9094,1,50597,,In vivo,Plasma,Maximum plasma concentration was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622920,,,A
2463,Intermediate,,1,,10116.0,9095,1,50597,,In vivo,Plasma,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622921,,,A
6679,Intermediate,,1,,10116.0,9096,1,50597,,In vivo,Plasma,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622922,,,A
6681,Intermediate,,1,,10116.0,9097,1,50597,,In vivo,Plasma,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622923,,,A
4890,Intermediate,,1,,10116.0,9098,1,50597,,In vivo,Plasma,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL877604,,,A
6410,Intermediate,,1,,10116.0,9099,1,50597,,In vivo,Plasma,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622924,,,A
6410,Intermediate,,1,,10116.0,9100,1,50597,,In vivo,Plasma,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622925,,,A
16366,Intermediate,,1,,10116.0,9101,1,50597,,In vivo,Plasma,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622926,,,A
6227,Intermediate,,1,,10116.0,9102,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623625,,,A
3598,Expert,,1,,10116.0,9103,1,50597,,In vivo,Plasma,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623626,,,A
1465,Intermediate,,1,,10116.0,9104,1,50597,,In vivo,Plasma,Maximum plasma drug concentration was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623627,,,A
4368,Intermediate,,1,,10116.0,9105,1,50597,,In vivo,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623628,,,A
15662,Intermediate,,1,,10116.0,9106,1,50597,,In vivo,Plasma,Mean peak plasma concentration was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623629,,,A
15662,Intermediate,,1,,10116.0,9107,1,50597,,In vivo,Plasma,Mean peak plasma concentration was observed after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623630,,,A
5355,Intermediate,,1,,10116.0,9108,1,50597,,In vivo,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623804,,,A
5355,Intermediate,,1,,10116.0,9109,1,50597,,In vivo,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623805,,,A
1567,Intermediate,,1,,10116.0,9110,1,50597,,In vivo,Plasma,Peak oral plasma concentration was determined in rats by oral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623806,,,A
4026,Intermediate,,1,,10116.0,9111,1,50597,,In vivo,Plasma,Peak plasma concentration (Cmax) was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623807,,,A
6193,Intermediate,,1,,10116.0,9112,1,50597,,In vivo,Plasma,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623808,,,A
4026,Intermediate,,1,,10116.0,9113,1,50597,,In vivo,Plasma,Peak plasma concentration (Cmax) in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623809,,,A
6485,Intermediate,,1,,10116.0,9114,1,50597,,In vivo,Plasma,Peak plasma concentration at 1 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623810,,,A
17655,Intermediate,,1,,10116.0,9115,1,50597,,In vivo,Plasma,Peak plasma concentration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623811,,,A
14941,Intermediate,,1,,10116.0,9116,1,50597,,In vivo,Plasma,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623812,,,A
5394,Intermediate,,1,,10116.0,9117,1,50597,,In vivo,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877605,,,A
4408,Intermediate,,1,,10116.0,9118,1,50597,,In vivo,,Pharmacokinetic property (Cmax) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623813,,,A
5983,Intermediate,,1,,10116.0,9119,1,50597,,In vivo,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623814,,,A
4878,Intermediate,,1,,10116.0,9120,1,50597,,In vivo,,Cmax in rat after 3mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623815,,,A
5862,Intermediate,,1,,10116.0,9121,1,50597,,In vivo,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623816,Sprague-Dawley,,A
4517,Intermediate,,1,,10116.0,9122,1,50597,,In vivo,,Cmax in rats after 20 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623145,,,A
5932,Intermediate,,1,,10116.0,9123,1,50597,,In vivo,Plasma,Cmax in rat plasma after 30mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623146,,,A
5436,Intermediate,,1,,10116.0,9124,1,50597,,In vivo,Plasma,Plasma concentration after oral administration of 100 mg/kg to rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623147,,,A
4910,Intermediate,,1,,10116.0,9125,1,50597,,In vivo,Brain,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623042,,,A
4950,Intermediate,,1,,10116.0,9126,1,50597,,In vivo,,Tested for the Cmax in rat at 10 mg/kg per orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623043,,,A
15078,Intermediate,,1,,10116.0,9127,1,50597,,In vivo,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623044,,,A
15078,Intermediate,,1,,10116.0,9128,1,50597,,In vivo,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623045,,,A
3360,Intermediate,,1,,10116.0,9129,1,50597,,In vivo,,Bioavailability as oral Cmax in rats at 30 mins,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623046,,,A
3360,Intermediate,,1,,10116.0,9130,1,50597,,In vivo,,Bioavailability as oral Cmax in rats at 6hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623226,,,A
15022,Intermediate,,1,,10116.0,9131,1,50597,,In vivo,,The maximum concentration of compound was measured at the dose of 100 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623227,,,A
15022,Intermediate,,1,,10116.0,9132,1,50597,,In vivo,,The maximum concentration of compound was measured at the dose of 300 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623228,,,A
15022,Intermediate,,1,,10116.0,9133,1,50597,,In vivo,,The maximum concentration of compound was measured at the dose of 30 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623229,,,A
5160,Intermediate,,1,,10116.0,9134,1,50597,,In vivo,Plasma,The maximum plasma levels for the compounds were determined by LC-MS.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623230,,,A
15662,Intermediate,,1,,10116.0,9135,1,50597,,In vivo,Plasma,mean peak plasma concentration was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623231,,,A
15662,Intermediate,,1,,10116.0,9136,1,50597,,In vivo,Plasma,mean peak plasma concentration was observed after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623232,,,A
4709,Intermediate,,1,,10116.0,9137,1,50597,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623233,,,A
3535,Intermediate,,1,,10116.0,9138,1,50597,,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623234,,,A
3535,Intermediate,,1,,10116.0,9139,1,50597,,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623235,,,A
3535,Intermediate,,1,,10116.0,9140,1,50597,,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623236,,,A
3535,Intermediate,,1,,10116.0,9141,1,50597,,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623237,,,A
3535,Intermediate,,1,,10116.0,9142,1,50597,,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623238,,,A
3535,Intermediate,,1,,10116.0,9143,1,50597,,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623239,,,A
5005,Intermediate,,1,,10116.0,9144,0,22224,,In vivo,Plasma,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,U,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623240,,,A
6326,Intermediate,,1,,10116.0,9145,1,50597,,,Hypothalamus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL623241,,,A
6326,Intermediate,,1,,10116.0,9146,1,50597,,,Hypothalamus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL623242,,,A
6326,Intermediate,,1,,10116.0,9147,1,50597,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874394,,,A
6326,Intermediate,,1,,10116.0,9148,1,50597,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623243,,,A
17411,Intermediate,,1,,10116.0,9149,1,50597,,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623244,,,A
16435,Intermediate,,1,,10116.0,9150,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623245,,,A
16435,Intermediate,,1,,10116.0,9151,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623246,,,A
16435,Intermediate,,1,,10116.0,9152,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623247,,,A
16435,Intermediate,,1,,10116.0,9153,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623248,,,A
16435,Intermediate,,1,,10116.0,9154,1,50597,,,Kidney,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623249,,,A
16434,Intermediate,,1,,10116.0,9155,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625072,,,A
16434,Intermediate,,1,,10116.0,9156,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625073,,,A
16434,Intermediate,,1,,10116.0,9157,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625074,,,A
16434,Intermediate,,1,,10116.0,9158,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625075,,,A
16434,Intermediate,,1,,10116.0,9159,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625076,,,A
16434,Intermediate,,1,,10116.0,9160,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625077,,,A
16434,Intermediate,,1,,10116.0,9161,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625078,,,A
16434,Intermediate,,1,,10116.0,9162,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL874395,,,A
16435,Intermediate,,1,,10116.0,9163,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625079,,,A
16435,Intermediate,,1,,10116.0,9164,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625080,,,A
16435,Intermediate,,1,,10116.0,9165,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625081,,,A
16435,Intermediate,,1,,10116.0,9166,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625082,,,A
16435,Intermediate,,1,,10116.0,9167,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625083,,,A
16435,Intermediate,,1,,10116.0,9168,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625084,,,A
16435,Intermediate,,1,,10116.0,9169,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625085,,,A
16435,Intermediate,,1,,10116.0,9170,1,50597,,,Liver,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625086,,,A
16434,Intermediate,,1,,10116.0,9171,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625087,,,A
16434,Intermediate,,1,,10116.0,9172,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625088,,,A
16434,Intermediate,,1,,10116.0,9173,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622205,,,A
16435,Intermediate,,1,,10116.0,9174,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622206,,,A
16435,Intermediate,,1,,10116.0,9175,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622207,,,A
16435,Intermediate,,1,,10116.0,9176,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622366,,,A
16435,Intermediate,,1,,10116.0,9177,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622367,,,A
16435,Intermediate,,1,,10116.0,9178,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL875331,,,A
16435,Intermediate,,1,,10116.0,9179,1,50597,,,Liver,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622368,,,A
16434,Intermediate,,1,,10116.0,9180,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622369,,,A
16434,Intermediate,,1,,10116.0,9181,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622370,,,A
16434,Intermediate,,1,,10116.0,9182,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622371,,,A
16434,Intermediate,,1,,10116.0,9183,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622372,,,A
16434,Intermediate,,1,,10116.0,9184,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622373,,,A
16434,Intermediate,,1,,10116.0,9185,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622374,,,A
16434,Intermediate,,1,,10116.0,9186,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622375,,,A
16434,Intermediate,,1,,10116.0,9187,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622376,,,A
16435,Intermediate,,1,,10116.0,9188,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622377,,,A
16435,Intermediate,,1,,10116.0,9189,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622378,,,A
16435,Intermediate,,1,,10116.0,9190,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622379,,,A
16435,Intermediate,,1,,10116.0,9191,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622380,,,A
16435,Intermediate,,1,,10116.0,9192,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622381,,,A
16435,Intermediate,,1,,10116.0,9193,1,50597,,,Lung,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622382,,,A
16434,Intermediate,,1,,10116.0,9194,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622383,,,A
6175,Intermediate,,1,,10116.0,9195,1,50597,,,Stomach,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL875332,,,A
6175,Intermediate,,1,,10116.0,9196,1,50597,,,Stomach,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL622384,,,A
6175,Intermediate,,1,,10116.0,9197,1,50597,,,Stomach,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL622385,,,A
6175,Intermediate,,1,,10116.0,9198,1,50597,,,Stomach,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL622386,,,A
10839,Intermediate,,1,,10116.0,9199,1,50597,,,,The compound was tested for the plasma binding in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622387,,,A
16459,Intermediate,,1,,10116.0,9200,1,50597,,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622388,,,A
16459,Intermediate,,1,,10116.0,9201,1,50597,,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622389,,,A
16459,Intermediate,,1,,10116.0,9202,1,50597,,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622390,,,A
16459,Intermediate,,1,,10116.0,9203,1,50597,,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622391,,,A
16459,Intermediate,,1,,10116.0,9204,1,50597,,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622392,,,A
16459,Intermediate,,1,,10116.0,9205,1,50597,,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622393,,,A
3278,Intermediate,,1,,10116.0,9206,1,50597,,,,Plasma level at 2 hr after administration of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622394,,,A
3278,Intermediate,,1,,10116.0,9207,1,50597,,,,plasma level at 2 hr after administration of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622395,,,A
4684,Intermediate,,1,,10116.0,9208,1,50597,,,Serum,Stability in rat serum measured as % recovery at 1 min,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL622396,,,A
4684,Intermediate,,1,,10116.0,9209,1,50597,,,Serum,Stability in rat serum measured as % recovery at 10 min,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624894,,,A
4684,Intermediate,,1,,10116.0,9210,1,50597,,,Serum,Stability in rat serum measured as % recovery at 10 mins,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624895,,,A
4684,Intermediate,,1,,10116.0,9211,1,50597,,,Serum,Stability in rat serum measured as % recovery at 2 hr,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624058,,,A
4684,Intermediate,,1,,10116.0,9212,1,50597,,,Serum,Stability in rat serum measured as % recovery at 3 min,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624059,,,A
4684,Intermediate,,1,,10116.0,9213,1,50597,,,Serum,Stability in rat serum measured as % recovery at 3 mins,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624060,,,A
4684,Intermediate,,1,,10116.0,9214,1,50597,,,Serum,Stability in rat serum measured as % recovery at 5 min,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624061,,,A
4684,Intermediate,,1,,10116.0,9215,1,50597,,,Serum,Stability in rat serum measured as % recovery at 5 mins,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL624062,,,A
16456,Intermediate,,1,,10116.0,9216,1,50597,,In vivo,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624063,,,A
16456,Intermediate,,1,,10116.0,9217,1,50597,,In vivo,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624064,,,A
723,Intermediate,,1,,10116.0,9218,1,50597,,,Plasma,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624065,,,A
723,Intermediate,,1,,10116.0,9219,1,50597,,,Plasma,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624066,,,A
5160,Intermediate,,1,,10116.0,9220,1,50597,,In vivo,,Half life tested in mature male rat at a dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877490,,,A
4709,Intermediate,,1,,10116.0,9221,1,50597,,In vivo,,Half life after intravenous administration of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874442,,,A
5633,Intermediate,,1,,10116.0,9222,1,50597,,In vivo,,Half life period after administration (30 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626890,,,A
5302,Intermediate,,1,,10116.0,9223,1,50597,,In vivo,,Half life period in rat after 5 mg/Kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626891,,,A
5302,Intermediate,,1,,10116.0,9224,1,50597,,In vivo,,Half life period in rat after 5 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626892,,,A
17791,Intermediate,,1,,10116.0,9225,1,50597,,,,Half life period was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626893,,,A
17791,Intermediate,,1,,10116.0,9226,1,50597,,,,Half life period was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626894,,,A
17791,Intermediate,,1,,10116.0,9227,1,50597,,,,Half life period was evaluated in rat; 0.5-1.0,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626895,,,A
17791,Intermediate,,1,,10116.0,9228,1,50597,,,,Half life period was evaluated in rat; 5.9-7.5,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626896,,,A
14512,Intermediate,,1,,10116.0,9229,1,50597,,,Plasma,Half-life in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626897,,,A
6230,Intermediate,,1,,10116.0,9230,1,50597,,,,Half-life time in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626898,,,A
3364,Intermediate,,1,,10116.0,9231,1,50597,,In vivo,,Terminal half-life after iv administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626899,,,A
6874,Intermediate,,1,,10116.0,9232,1,50597,,In vivo,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626900,,,A
857,Intermediate,,1,,10116.0,9233,1,50597,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626901,,,A
858,Intermediate,,1,,10116.0,9234,1,50597,,In vivo,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626902,,,A
858,Intermediate,,1,,10116.0,9235,1,50597,,In vivo,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626903,,,A
5355,Intermediate,,1,,10116.0,9236,1,50597,,In vivo,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874443,,,A
5355,Intermediate,,1,,10116.0,9237,1,50597,,In vivo,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626904,,,A
6305,Intermediate,,1,,10116.0,9238,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626905,,,A
13501,Intermediate,,1,,10116.0,9239,1,50597,,In vivo,Plasma,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873830,,,A
17594,Intermediate,,1,,10116.0,9240,1,50597,,In vivo,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626906,,,A
4186,Intermediate,,1,,10116.0,9241,1,50597,,In vivo,Plasma,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631076,,,A
2932,Intermediate,,1,,10116.0,9242,1,50597,,,Plasma,Biological half-life was measured in plasma of rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631077,,,A
17065,Intermediate,,1,,10116.0,9243,1,50597,,In vivo,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631078,,,A
15765,Intermediate,,1,,10116.0,9244,1,50597,,In vivo,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631079,,,A
2713,Intermediate,,1,,10116.0,9245,1,50597,,In vivo,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631080,,,A
2661,Intermediate,,1,,10116.0,9246,1,50597,,In vivo,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631081,,,A
2661,Intermediate,,1,,10116.0,9247,1,50597,,In vivo,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631239,,,A
740,Intermediate,,1,,10116.0,9248,1,50597,,,Plasma,Compound was evaluated for plasma half life in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631240,,,A
6597,Intermediate,,1,,10116.0,9249,1,50597,,,Plasma,AUC value at a dose of 5 mg/kg (p.o.) in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631241,,,A
2959,Intermediate,,1,,10116.0,9250,1,50597,,,Plasma,AUC value after administration of 20 mg/Kg oral dose in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631242,,,A
17594,Intermediate,,1,,10116.0,9251,1,50597,,,Plasma,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631243,,,A
17596,Intermediate,,1,,10116.0,9252,1,50597,,,Plasma,AUC0-96 after administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL874444,,,A
17594,Intermediate,,1,,10116.0,9253,1,50597,,,Plasma,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631244,,,A
3293,Intermediate,,1,,10116.0,9254,1,50597,,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631245,,,A
6757,Intermediate,,1,,10116.0,9255,1,50597,,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627162,,,A
6757,Intermediate,,1,,10116.0,9256,1,50597,,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627163,,,A
6757,Intermediate,,1,,10116.0,9257,1,50597,,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627164,,,A
5979,Intermediate,,1,,10116.0,9258,1,50597,,,Kidney,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627165,,,A
5979,Intermediate,,1,,10116.0,9259,1,50597,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627166,,,A
5979,Intermediate,,1,,10116.0,9260,1,50597,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627167,,,A
4026,Intermediate,,1,,10116.0,9261,1,50597,,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627822,,,A
5355,Intermediate,,1,,10116.0,9262,1,50597,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627823,,,A
5355,Intermediate,,1,,10116.0,9263,1,50597,,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627824,,,A
5355,Intermediate,,1,,10116.0,9264,1,50597,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627825,,,A
5633,Intermediate,,1,,10116.0,9265,1,50597,,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627826,,,A
1716,Intermediate,,1,,10116.0,9266,1,50597,,,,Area under curve (Pharmacokinetic property) was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627827,,,A
1716,Intermediate,,1,,10116.0,9267,1,50597,,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627828,,,A
4689,Intermediate,,1,,10116.0,9268,1,50597,,,,Area under curve after intravenous administration (1 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627829,,,A
4527,Intermediate,,1,,10116.0,9269,1,50597,,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627830,,,A
4527,Intermediate,,1,,10116.0,9270,1,50597,,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627831,,,A
15662,Intermediate,,1,,10116.0,9271,1,50597,,,,Area under curve in male SD rats was observed after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627832,,,A
4413,Intermediate,,1,,10116.0,9272,1,50597,,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627833,,,A
3598,Expert,,1,,10116.0,9273,1,50597,,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627834,,,A
3598,Expert,,1,,10116.0,9274,1,50597,,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628004,,,A
5964,Intermediate,,1,,10116.0,9275,1,50597,,,,Area under curve at 5 mg/kg po was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628005,,,A
4689,Intermediate,,1,,10116.0,9276,1,50597,,,,Area under curve in Rat at a oral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628006,,,A
4186,Intermediate,,1,,10116.0,9277,1,50597,,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628007,,,A
5510,Intermediate,,1,,10116.0,9278,1,50597,,,,Area under curve was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625676,,,A
17858,Intermediate,,1,,10116.0,9279,1,50597,,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631309,,,A
17804,Intermediate,,1,,10116.0,9280,1,50597,,,,Area under curve after intravenous administration at 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631310,,,A
6106,Intermediate,,1,,10116.0,9281,1,50597,,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631311,,,A
5964,Intermediate,,1,,10116.0,9282,1,50597,,,,Area under curve at 4 hr in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631312,,,A
4026,Intermediate,,1,,10116.0,9283,1,50597,,,,Area under curve at a dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631313,,,A
4756,Intermediate,,1,,10116.0,9284,1,50597,,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631314,,,A
4756,Intermediate,,1,,10116.0,9285,1,50597,,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631315,,,A
5862,Intermediate,,1,,10116.0,9286,1,50597,,,,Area under curve for a 2-mpk po dose in SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631316,,,A
5862,Intermediate,,1,,10116.0,9287,1,50597,,,,Area under curve in SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631317,,,A
6644,Intermediate,,1,,10116.0,9288,1,50597,,,,Area under curve in rat after oral administration at 13 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874471,,,A
5871,Intermediate,,1,,10116.0,9289,1,50597,,,,Area under curve in rat by po administration at 0-24 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631318,,,A
5919,Intermediate,,1,,10116.0,9290,1,50597,,,Plasma,Area under curve in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631319,,,A
5939,Intermediate,,1,,10116.0,9291,1,50597,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631320,,,A
5939,Intermediate,,1,,10116.0,9292,1,50597,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631321,,,A
10,Intermediate,,1,,10116.0,9293,1,50597,,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631322,,,A
11149,Intermediate,,1,,10116.0,9294,1,50597,,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631323,,,A
5302,Intermediate,,1,,10116.0,9295,1,50597,,,,Area under curve value in rat at a dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631324,,,A
17796,Intermediate,,1,,10116.0,9296,1,50597,,,,Area under curve was determined after oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631325,,,A
4890,Intermediate,,1,,10116.0,9297,1,50597,,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631326,,,A
6011,Intermediate,,1,,10116.0,9298,1,50597,,,,Area under curve was determined after peroral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631327,,,A
5375,Intermediate,,1,,10116.0,9299,1,50597,,,,Area under curve was determined at a dose 30 mpk administered orally.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631328,,,A
17764,Intermediate,,1,,10116.0,9300,1,50597,,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631329,,,A
4368,Intermediate,,1,,10116.0,9301,1,50597,,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627217,,,A
5610,Intermediate,,1,,10116.0,9302,1,50597,,,,Area under curve was determined in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626352,,,A
5833,Intermediate,,1,,10116.0,9303,1,50597,,,,Area under curve was determined in rat after PO administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626353,,,A
4257,Intermediate,,1,,10116.0,9304,1,50597,,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626354,,,A
5937,Intermediate,,1,,10116.0,9305,1,50597,,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626355,,,A
5932,Intermediate,,1,,10116.0,9306,1,50597,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626356,,,A
5932,Intermediate,,1,,10116.0,9307,1,50597,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626357,,,A
17411,Intermediate,,1,,10116.0,9308,1,50597,,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626358,,,A
17411,Intermediate,,1,,10116.0,9309,1,50597,,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626359,,,A
17771,Intermediate,,1,,10116.0,9310,1,50597,,,Plasma,Peak plasma concentration in rat at a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626360,,,A
1628,Intermediate,,1,,10116.0,9311,1,50597,,,,Plasma concentration at 2 hr in rats was evaluated.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626361,,,A
1628,Intermediate,,1,,10116.0,9312,1,50597,,,,Plasma concentration at 2 hr in rats was evaluated; Not available,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626362,,,A
17411,Intermediate,,1,,10116.0,9313,1,50597,,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626363,,,A
4910,Intermediate,,1,,10116.0,9314,1,50597,,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626970,,,A
4910,Intermediate,,1,,10116.0,9315,1,50597,,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626971,,,A
4910,Intermediate,,1,,10116.0,9316,1,50597,,,Plasma,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626972,,,A
4910,Intermediate,,1,,10116.0,9317,1,50597,,,Plasma,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626973,,,A
4910,Intermediate,,1,,10116.0,9318,1,50597,,,Plasma,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626974,,,A
4910,Intermediate,,1,,10116.0,9319,1,50597,,,Plasma,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL874592,,,A
5510,Intermediate,,1,,10116.0,9320,1,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626975,,,A
5510,Intermediate,,1,,10116.0,9321,1,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626976,,,A
5510,Intermediate,,1,,10116.0,9322,1,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626977,,,A
5510,Intermediate,,1,,10116.0,9323,1,50597,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626978,,,A
16427,Intermediate,,1,,10116.0,9324,1,50597,,,,PK study was carried to determine the relative absorption ranking in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626979,,,A
4689,Intermediate,,1,,10116.0,9325,1,50597,,In vivo,Plasma,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626980,,,A
11450,Intermediate,,1,,10116.0,9326,1,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626981,,,A
11450,Intermediate,,1,,10116.0,9327,1,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626982,,,A
11450,Intermediate,,1,,10116.0,9328,1,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626983,,,A
11450,Intermediate,,1,,10116.0,9329,1,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622522,,,A
11450,Intermediate,,1,,10116.0,9330,1,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622523,,,A
11450,Intermediate,,1,,10116.0,9331,1,50597,,,Blood,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622524,,,A
11450,Intermediate,,1,,10116.0,9332,1,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622525,,,A
11450,Intermediate,,1,,10116.0,9333,1,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622526,,,A
11450,Intermediate,,1,,10116.0,9334,1,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619849,,,A
11450,Intermediate,,1,,10116.0,9335,1,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL619850,,,A
11450,Intermediate,,1,,10116.0,9336,1,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623864,,,A
11450,Intermediate,,1,,10116.0,9337,1,50597,,,Brain,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623865,,,A
11450,Intermediate,,1,,10116.0,9338,1,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623866,,,A
11450,Intermediate,,1,,10116.0,9339,1,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623867,,,A
11450,Intermediate,,1,,10116.0,9340,1,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL877615,,,A
11450,Intermediate,,1,,10116.0,9341,1,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623868,,,A
11450,Intermediate,,1,,10116.0,9342,1,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623869,,,A
11450,Intermediate,,1,,10116.0,9343,1,50597,,,Heart,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623870,,,A
16434,Intermediate,,1,,10116.0,9344,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL623871,,,A
16434,Intermediate,,1,,10116.0,9345,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL623872,,,A
16435,Intermediate,,1,,10116.0,9346,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622129,,,A
16435,Intermediate,,1,,10116.0,9347,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622130,,,A
16435,Intermediate,,1,,10116.0,9348,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622131,,,A
16435,Intermediate,,1,,10116.0,9349,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622132,,,A
16435,Intermediate,,1,,10116.0,9350,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622133,,,A
16435,Intermediate,,1,,10116.0,9351,1,50597,,,Lung,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622134,,,A
16435,Intermediate,,1,,10116.0,9352,1,50597,,,Lung,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622135,,,A
16435,Intermediate,,1,,10116.0,9353,1,50597,,,Lung,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622136,,,A
16434,Intermediate,,1,,10116.0,9354,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622137,,,A
16434,Intermediate,,1,,10116.0,9355,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622138,,,A
16434,Intermediate,,1,,10116.0,9356,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623017,,,A
16434,Intermediate,,1,,10116.0,9357,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623018,,,A
16434,Intermediate,,1,,10116.0,9358,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623019,,,A
16434,Intermediate,,1,,10116.0,9359,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623020,,,A
16434,Intermediate,,1,,10116.0,9360,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623021,,,A
16434,Intermediate,,1,,10116.0,9361,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623022,,,A
16435,Intermediate,,1,,10116.0,9362,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623023,,,A
16435,Intermediate,,1,,10116.0,9363,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623024,,,A
16435,Intermediate,,1,,10116.0,9364,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623025,,,A
16435,Intermediate,,1,,10116.0,9365,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620545,,,A
16435,Intermediate,,1,,10116.0,9366,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620546,,,A
16435,Intermediate,,1,,10116.0,9367,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620547,,,A
16435,Intermediate,,1,,10116.0,9368,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620548,,,A
16435,Intermediate,,1,,10116.0,9369,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620549,,,A
16434,Intermediate,,1,,10116.0,9370,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620550,,,A
16434,Intermediate,,1,,10116.0,9371,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620551,,,A
16434,Intermediate,,1,,10116.0,9372,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620552,,,A
16435,Intermediate,,1,,10116.0,9373,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620553,,,A
16435,Intermediate,,1,,10116.0,9374,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620554,,,A
16435,Intermediate,,1,,10116.0,9375,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL875845,,,A
16435,Intermediate,,1,,10116.0,9376,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620555,,,A
16435,Intermediate,,1,,10116.0,9377,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620556,,,A
16435,Intermediate,,1,,10116.0,9378,1,50597,,,Muscle tissue,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620557,,,A
16434,Intermediate,,1,,10116.0,9379,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620558,,,A
16434,Intermediate,,1,,10116.0,9380,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620559,,,A
16434,Intermediate,,1,,10116.0,9381,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622939,,,A
16434,Intermediate,,1,,10116.0,9382,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622940,,,A
16434,Intermediate,,1,,10116.0,9383,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622941,,,A
16434,Intermediate,,1,,10116.0,9384,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622942,,,A
16434,Intermediate,,1,,10116.0,9385,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622943,,,A
16434,Intermediate,,1,,10116.0,9386,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622944,,,A
16435,Intermediate,,1,,10116.0,9387,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622945,,,A
16435,Intermediate,,1,,10116.0,9388,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622946,,,A
3341,Intermediate,,1,,10116.0,9389,1,50597,,,,Compound was evaluated for terminal half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622947,,,A
3634,Intermediate,,1,,10116.0,9390,1,50597,,In vivo,Plasma,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622948,,,A
3634,Intermediate,,1,,10116.0,9391,1,50597,,In vivo,Plasma,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622949,,,A
4839,Intermediate,,1,,10116.0,9392,1,50597,,,,Compound was tested for its half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622950,,,A
5005,Intermediate,,1,,9544.0,9393,0,22224,,In vivo,Plasma,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,U,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL622951,,,A
5005,Intermediate,,1,,10116.0,9394,0,22224,,,Plasma,Compound was tested for its plasma half life in Sprague Dawley rats,,U,,Rattus norvegicus,BAO_0000366,1969.0,CHEMBL622952,,,A
5005,Intermediate,,1,,10116.0,9395,0,22224,,,Plasma,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,U,,Rattus norvegicus,BAO_0000366,1969.0,CHEMBL622953,,,A
1094,Intermediate,,1,,10116.0,9396,1,50597,,,Plasma,Compound was tested for plasma half-life period in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873818,,,A
5031,Intermediate,,1,,10116.0,9397,1,50597,,In vivo,,Elimination half life after i.v. administration of compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622954,,,A
6518,Intermediate,,1,,10116.0,9398,1,50597,,In vivo,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622955,,,A
6518,Intermediate,,1,,10116.0,9399,1,50597,,In vivo,,Elimination half-life after IV dosing at 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875229,,,A
6518,Intermediate,,1,,10116.0,9400,1,50597,,In vivo,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622956,,,A
6518,Intermediate,,1,,10116.0,9401,1,50597,,In vivo,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622957,,,A
5408,Intermediate,,1,,10116.0,9402,1,50597,,In vivo,Brain,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622958,,,A
5408,Intermediate,,1,,10116.0,9403,1,50597,,In vivo,Plasma,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622959,,,A
5408,Intermediate,,1,,10116.0,9404,1,50597,,In vivo,Brain,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622960,,,A
5408,Intermediate,,1,,10116.0,9405,1,50597,,In vivo,Plasma,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622961,,,A
4687,Intermediate,,1,,10116.0,9406,1,50597,,In vivo,,Evaluated for the half life in rat (in vivo),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622962,,,A
6640,Intermediate,,1,,10116.0,9407,1,50597,,,,Hafl life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622963,,,A
6640,Intermediate,,1,,10116.0,9408,1,50597,,,,Hafl life rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622964,,,A
6641,Intermediate,,1,,10116.0,9409,1,50597,,,,Hafl life rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622965,,,A
6640,Intermediate,,1,,10116.0,9410,1,50597,,,,Hafl life rat; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622966,,,A
6641,Intermediate,,1,,10116.0,9411,1,50597,,,,Hafl life rat; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622967,,,A
17411,Intermediate,,1,,10116.0,9412,1,50597,,In vivo,Kidney,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622968,,,A
17411,Intermediate,,1,,10116.0,9413,1,50597,,In vivo,Liver,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622969,,,A
17411,Intermediate,,1,,10116.0,9414,1,50597,,In vivo,Lung,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL875327,,,A
6570,Intermediate,,1,,10116.0,9415,1,50597,,In vivo,,Half life in rat after 1 mg/kg i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628638,,,A
6570,Intermediate,,1,,10116.0,9416,1,50597,,In vivo,,Half life in rat after 2 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628639,,,A
17411,Intermediate,,1,,10116.0,9417,1,50597,,In vivo,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625840,,,A
4722,Intermediate,,1,,10116.0,9418,1,50597,,In vivo,,Half life of 10 mg/kg oral dose determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625841,,,A
5978,Intermediate,,1,,10116.0,9419,1,50597,,In vivo,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625842,,,A
5978,Intermediate,,1,,10116.0,9420,1,50597,,In vivo,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625843,,,A
5978,Intermediate,,1,,10116.0,9421,1,50597,,In vivo,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625844,,,A
5978,Intermediate,,1,,10116.0,9422,1,50597,,In vivo,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873822,,,A
5978,Intermediate,,1,,10116.0,9423,1,50597,,In vivo,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625845,,,A
5978,Intermediate,,1,,10116.0,9424,1,50597,,In vivo,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627059,,,A
5978,Intermediate,,1,,10116.0,9425,1,50597,,In vivo,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627060,,,A
5978,Intermediate,,1,,10116.0,9426,1,50597,,In vivo,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627061,,,A
4762,Intermediate,,1,,10116.0,9427,1,50597,,In vivo,,Half life of compound at 5 mg/kg after po administration was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627709,,,A
5327,Intermediate,,1,,10116.0,9428,1,50597,,In vivo,,Half life of compound determined after intravenous administration to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627710,,,A
4847,Intermediate,,1,,10116.0,9429,1,50597,,,,Half life of compound was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627711,,,A
17720,Intermediate,,1,,10116.0,9430,1,50597,,In vivo,Plasma,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627712,,,A
4723,Intermediate,,1,,10116.0,9431,1,50597,,In vivo,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627713,,,A
4723,Intermediate,,1,,10116.0,9432,1,50597,,In vivo,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627714,,,A
4256,Intermediate,,1,,9541.0,9433,0,22224,,In vivo,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL627889,,,A
4256,Intermediate,,1,,10116.0,9434,0,22224,,In vivo,,Half life determined in rat by intravenous administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL627890,,,A
4722,Intermediate,,1,,10116.0,9435,1,50597,,In vivo,,Half life determined in rats after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627891,,,A
6535,Intermediate,,1,,10116.0,9436,1,50597,,In vivo,Plasma,Half life in rat plasma after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627892,,,A
6535,Intermediate,,1,,10116.0,9437,1,50597,,In vivo,Plasma,Half life in rat plasma after administration of 2 mg/kg iv,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627893,,,A
1435,Intermediate,,1,,10116.0,9438,1,50597,,,Plasma,Half life in rat plasma was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627894,,,A
1435,Intermediate,,1,,10116.0,9439,1,50597,,,Plasma,Half life in rat plasma was determined; NA means not applicable,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627895,,,A
5206,Intermediate,,1,,10116.0,9440,1,50597,,,,Half life in rat was tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627896,,,A
6080,Intermediate,,1,,10116.0,9441,1,50597,,,Plasma,Half life measured in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627897,,,A
4449,Intermediate,,1,,10116.0,9442,1,50597,,,,Half life recorded in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627898,,,A
6057,Intermediate,,1,,10116.0,9443,1,50597,,,,Half life was calculated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627899,,,A
6057,Intermediate,,1,,10116.0,9444,1,50597,,,,Half life was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873823,,,A
3747,Intermediate,,1,,10116.0,9445,1,50597,,,,Half life was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627900,,,A
17858,Intermediate,,1,,10116.0,9446,1,50597,,In vivo,,Half life after 10 mg/kg oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627901,,,A
16365,Intermediate,,1,,10116.0,9447,1,50597,,In vivo,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627902,,,A
16365,Intermediate,,1,,10116.0,9448,1,50597,,In vivo,,Half life after administering orally a dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627903,,,A
5031,Intermediate,,1,,10116.0,9449,1,50597,,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627904,,,A
4722,Intermediate,,1,,10116.0,9450,1,50597,,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627905,,,A
6078,Intermediate,,1,,10116.0,9451,1,50597,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627906,,,A
6078,Intermediate,,1,,10116.0,9452,1,50597,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627907,,,A
6078,Intermediate,,1,,10116.0,9453,1,50597,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876783,,,A
6078,Intermediate,,1,,10116.0,9454,1,50597,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627908,,,A
17065,Intermediate,,1,,10116.0,9455,1,50597,,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627909,,,A
1353,Intermediate,,1,,10116.0,9456,1,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627910,,,A
1353,Intermediate,,1,,10116.0,9457,1,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627911,,,A
1353,Intermediate,,1,,10116.0,9458,1,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627912,,,A
1353,Intermediate,,1,,10116.0,9459,1,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627913,,,A
1353,Intermediate,,1,,10116.0,9460,1,50597,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627914,,,A
16423,Intermediate,,1,,10116.0,9461,1,50597,,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627915,,,A
16423,Intermediate,,1,,10116.0,9462,1,50597,,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627916,,,A
6062,Intermediate,,1,,10116.0,9463,1,50597,,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627917,,,A
6056,Intermediate,,1,,10116.0,9464,1,50597,,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627918,,,A
5182,Intermediate,,1,,10116.0,9465,1,50597,,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627919,,,A
6410,Intermediate,,1,,10116.0,9466,1,50597,,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627920,,,A
6410,Intermediate,,1,,10116.0,9467,1,50597,,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627921,,,A
4723,Intermediate,,1,,10116.0,9468,1,50597,,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627922,,,A
4723,Intermediate,,1,,10116.0,9469,1,50597,,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876784,,,A
4723,Intermediate,,1,,10116.0,9470,1,50597,,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627923,,,A
4723,Intermediate,,1,,10116.0,9471,1,50597,,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626208,,,A
4723,Intermediate,,1,,10116.0,9472,1,50597,,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626209,,,A
4723,Intermediate,,1,,10116.0,9473,1,50597,,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626210,,,A
2463,Intermediate,,1,,10116.0,9474,1,50597,,,Plasma,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627994,,,A
4709,Intermediate,,1,,10116.0,9475,1,50597,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627995,,,A
4075,Intermediate,,1,,10116.0,9476,1,50597,,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627996,,,A
5394,Intermediate,,1,,10116.0,9477,1,50597,,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627997,,,A
2661,Intermediate,,1,,10116.0,9478,1,50597,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627998,,,A
2661,Intermediate,,1,,10116.0,9479,1,50597,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628640,,,A
2661,Intermediate,,1,,10116.0,9480,1,50597,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628641,,,A
2661,Intermediate,,1,,10116.0,9481,1,50597,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628642,,,A
17791,Intermediate,,1,,10116.0,9482,1,50597,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628643,,,A
2591,Intermediate,,1,,10116.0,9483,1,50597,,,,Compound was tested for area under curve in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628644,,,A
6567,Intermediate,,1,,10116.0,9484,1,50597,,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628645,,,A
6211,Intermediate,,1,,10116.0,9485,1,50597,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628646,,,A
5529,Intermediate,,1,,10116.0,9486,1,50597,,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628647,,,A
5408,Intermediate,,1,,10116.0,9487,1,50597,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628648,,,A
5408,Intermediate,,1,,10116.0,9488,1,50597,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625358,,,A
5408,Intermediate,,1,,10116.0,9489,1,50597,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625359,,,A
5408,Intermediate,,1,,10116.0,9490,1,50597,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625360,,,A
429,Intermediate,,1,,10116.0,9491,1,50597,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625361,,,A
429,Intermediate,,1,,10116.0,9492,1,50597,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625362,,,A
429,Intermediate,,1,,10116.0,9493,1,50597,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625363,,,A
4796,Intermediate,,1,,10116.0,9494,1,50597,,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625364,,,A
5974,Intermediate,,1,,10116.0,9495,1,50597,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625365,,,A
5974,Intermediate,,1,,10116.0,9496,1,50597,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625366,,,A
5974,Intermediate,,1,,10116.0,9497,1,50597,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625367,,,A
11450,Intermediate,,1,,10116.0,9498,1,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625368,,,A
11450,Intermediate,,1,,10116.0,9499,1,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625369,,,A
11450,Intermediate,,1,,10116.0,9500,1,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625370,,,A
11450,Intermediate,,1,,10116.0,9501,1,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625371,,,A
11450,Intermediate,,1,,10116.0,9502,1,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625372,,,A
11450,Intermediate,,1,,10116.0,9503,1,50597,,,Kidney,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625373,,,A
11450,Intermediate,,1,,10116.0,9504,1,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625374,,,A
11450,Intermediate,,1,,10116.0,9505,1,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL877593,,,A
11450,Intermediate,,1,,10116.0,9506,1,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625375,,,A
11450,Intermediate,,1,,10116.0,9507,1,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625376,,,A
11450,Intermediate,,1,,10116.0,9508,1,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621973,,,A
11450,Intermediate,,1,,10116.0,9509,1,50597,,,Liver,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621974,,,A
11450,Intermediate,,1,,10116.0,9510,1,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL621975,,,A
11450,Intermediate,,1,,10116.0,9511,1,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622166,,,A
11450,Intermediate,,1,,10116.0,9512,1,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622167,,,A
11450,Intermediate,,1,,10116.0,9513,1,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622168,,,A
11450,Intermediate,,1,,10116.0,9514,1,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622169,,,A
11450,Intermediate,,1,,10116.0,9515,1,50597,,,Lung,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622170,,,A
11450,Intermediate,,1,,10116.0,9516,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622171,,,A
11450,Intermediate,,1,,10116.0,9517,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622172,,,A
11450,Intermediate,,1,,10116.0,9518,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622173,,,A
11450,Intermediate,,1,,10116.0,9519,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622174,,,A
11450,Intermediate,,1,,10116.0,9520,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622175,,,A
11450,Intermediate,,1,,10116.0,9521,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622176,,,A
11450,Intermediate,,1,,10116.0,9522,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622177,,,A
11450,Intermediate,,1,,10116.0,9523,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622178,,,A
11450,Intermediate,,1,,10116.0,9524,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622179,,,A
11450,Intermediate,,1,,10116.0,9525,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622180,,,A
16435,Intermediate,,1,,10116.0,9526,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622181,,,A
16435,Intermediate,,1,,10116.0,9527,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622182,,,A
16435,Intermediate,,1,,10116.0,9528,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622183,,,A
16435,Intermediate,,1,,10116.0,9529,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622184,,,A
16435,Intermediate,,1,,10116.0,9530,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622185,,,A
16435,Intermediate,,1,,10116.0,9531,1,50597,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622186,,,A
16434,Intermediate,,1,,10116.0,9532,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622187,,,A
16434,Intermediate,,1,,10116.0,9533,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625002,,,A
16434,Intermediate,,1,,10116.0,9534,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622090,,,A
16435,Intermediate,,1,,10116.0,9535,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622091,,,A
16435,Intermediate,,1,,10116.0,9536,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622092,,,A
16435,Intermediate,,1,,10116.0,9537,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622093,,,A
16435,Intermediate,,1,,10116.0,9538,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622094,,,A
16435,Intermediate,,1,,10116.0,9539,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622095,,,A
16435,Intermediate,,1,,10116.0,9540,1,50597,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622264,,,A
16434,Intermediate,,1,,10116.0,9541,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622265,,,A
16434,Intermediate,,1,,10116.0,9542,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622266,,,A
16434,Intermediate,,1,,10116.0,9543,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622267,,,A
16434,Intermediate,,1,,10116.0,9544,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622268,,,A
16434,Intermediate,,1,,10116.0,9545,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622269,,,A
16434,Intermediate,,1,,10116.0,9546,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625071,,,A
16434,Intermediate,,1,,10116.0,9547,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621621,,,A
16434,Intermediate,,1,,10116.0,9548,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621622,,,A
16435,Intermediate,,1,,10116.0,9549,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621623,,,A
16435,Intermediate,,1,,10116.0,9550,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621624,,,A
16435,Intermediate,,1,,10116.0,9551,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621625,,,A
16435,Intermediate,,1,,10116.0,9552,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621626,,,A
16435,Intermediate,,1,,10116.0,9553,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621627,,,A
16435,Intermediate,,1,,10116.0,9554,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621628,,,A
16435,Intermediate,,1,,10116.0,9555,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL875328,,,A
16435,Intermediate,,1,,10116.0,9556,1,50597,,,Spleen,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621629,,,A
16434,Intermediate,,1,,10116.0,9557,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621630,,,A
16434,Intermediate,,1,,10116.0,9558,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621631,,,A
16434,Intermediate,,1,,10116.0,9559,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621632,,,A
16435,Intermediate,,1,,10116.0,9560,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621633,,,A
16435,Intermediate,,1,,10116.0,9561,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621634,,,A
16435,Intermediate,,1,,10116.0,9562,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621635,,,A
16435,Intermediate,,1,,10116.0,9563,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621636,,,A
16435,Intermediate,,1,,10116.0,9564,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621637,,,A
16435,Intermediate,,1,,10116.0,9565,1,50597,,,Spleen,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL621638,,,A
16434,Intermediate,,1,,10116.0,9566,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618883,,,A
16434,Intermediate,,1,,10116.0,9567,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618884,,,A
16434,Intermediate,,1,,10116.0,9568,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628627,,,A
16434,Intermediate,,1,,10116.0,9569,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628628,,,A
16434,Intermediate,,1,,10116.0,9570,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628629,,,A
16365,Intermediate,,1,,10116.0,9571,1,50597,,In vivo,,Half life after administering orally a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628630,,,A
16365,Intermediate,,1,,10116.0,9572,1,50597,,In vivo,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628631,,,A
16365,Intermediate,,1,,10116.0,9573,1,50597,,In vivo,,Half life after administering intravenously a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628632,,,A
526,Intermediate,,1,,10116.0,9574,1,50597,,In vivo,,Half life after oral dosing in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628633,,,A
16365,Intermediate,,1,,10116.0,9575,1,50597,,In vivo,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628634,,,A
4368,Intermediate,,1,,10116.0,9576,1,50597,,In vivo,,Half life by intravenous administration of 3.4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627789,,,A
3371,Intermediate,,1,,10116.0,9577,1,50597,,,,Half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627790,,,A
6448,Intermediate,,1,,10116.0,9578,1,50597,,,,Half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627791,,,A
6453,Intermediate,,1,,10116.0,9579,1,50597,,,,Half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627792,,,A
4353,Intermediate,,1,,10116.0,9580,1,50597,,In vivo,,Half life in rat after intravenous administration of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627793,,,A
4353,Intermediate,,1,,10116.0,9581,1,50597,,In vivo,Plasma,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627794,,,A
4353,Intermediate,,1,,10116.0,9582,1,50597,,In vivo,,Half life in rat after po administration of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627795,,,A
4353,Intermediate,,1,,10116.0,9583,1,50597,,In vivo,,Half life in rat after po administration of the compound; ND means Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627796,,,A
4353,Intermediate,,1,,10116.0,9584,1,50597,,In vivo,Plasma,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL875335,,,A
4353,Intermediate,,1,,10116.0,9585,1,50597,,In vivo,Plasma,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627797,,,A
5789,Intermediate,,1,,10116.0,9586,1,50597,,In vivo,,Half life in rat i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627798,,,A
17686,Intermediate,,1,,10116.0,9587,1,50597,,In vivo,,Half life in rat i.v. at 2 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627799,,,A
6495,Intermediate,,1,,10116.0,9588,1,50597,,,,Half life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627800,,,A
484,Intermediate,,1,,10116.0,9589,1,50597,,In vivo,,Half life in rats after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627801,,,A
6467,Intermediate,,1,,10116.0,9590,1,50597,,In vivo,,Half life in rats at the dose of 1.0 mpk by i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627802,,,A
6642,Expert,,1,,10116.0,9591,1,50597,,,,Half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627803,,,A
16367,Intermediate,,1,,10116.0,9592,1,50597,,In vivo,,Half life was evaluated after intravenous administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873820,,,A
1369,Intermediate,,1,,10116.0,9593,1,50597,,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627804,,,A
5472,Intermediate,,1,,10116.0,9594,1,50597,,,,Half life was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627805,,,A
6049,Intermediate,,1,,10116.0,9595,1,50597,,,,Half life was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627806,,,A
5472,Intermediate,,1,,10116.0,9596,1,50597,,,,Half life was evaluated in rat; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627107,,,A
16366,Intermediate,,1,,10116.0,9597,1,50597,,In vivo,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627108,,,A
11149,Intermediate,,1,,10116.0,9598,1,50597,,In vivo,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627109,,,A
11149,Intermediate,,1,,10116.0,9599,1,50597,,In vivo,Blood,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627110,,,A
2891,Intermediate,,1,,9443.0,9600,0,22224,,In vivo,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,U,,Primates,BAO_0000218,,CHEMBL627111,,,A
2891,Intermediate,,1,,9443.0,9601,0,22224,,In vivo,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,U,,Primates,BAO_0000218,,CHEMBL627112,,,A
2891,Intermediate,,1,,10116.0,9602,0,22224,,In vivo,,Half life was measured in rat at dose of 30 mg/kg by iv administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL627113,,,A
2891,Intermediate,,1,,10116.0,9603,0,22224,,In vivo,,Half life was measured in rat at dose of 30 mg/kg by po administration,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL627114,,,A
4026,Intermediate,,1,,10116.0,9604,1,50597,,,,Half life (t1/2) was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627115,,,A
4527,Intermediate,,1,,10116.0,9605,1,50597,,,,Half life period at a dose of 10 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627116,,,A
4527,Intermediate,,1,,10116.0,9606,1,50597,,In vivo,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627117,,,A
5503,Intermediate,,1,,10116.0,9607,1,50597,,,,Half life period was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627118,,,A
4426,Intermediate,,1,,10116.0,9608,1,50597,,In vivo,,Half life period after intravenous administration at 20 mpk in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627119,,,A
4426,Intermediate,,1,,10116.0,9609,1,50597,,In vivo,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627120,,,A
6109,Intermediate,,1,,10116.0,9610,1,50597,,In vivo,,Half life period after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626922,,,A
5654,Intermediate,,1,,10116.0,9611,1,50597,,In vivo,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626923,,,A
5654,Intermediate,,1,,10116.0,9612,1,50597,,In vivo,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626924,,,A
4755,Intermediate,,1,,10116.0,9613,1,50597,,,Plasma,Half life period in 80% rat plasma at 37 degree Centigrade,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626925,,,A
5862,Intermediate,,1,,10116.0,9614,1,50597,,,,Half life period in SD rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626926,,,A
1515,Intermediate,,1,,10116.0,9615,1,50597,,,Plasma,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626927,,,A
1515,Intermediate,,1,,10116.0,9616,1,50597,,,Plasma,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626928,,,A
1515,Intermediate,,1,,10116.0,9617,1,50597,,,Plasma,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626929,,,A
1515,Intermediate,,1,,10116.0,9618,1,50597,,,Plasma,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626930,,,A
5960,Intermediate,,1,,10116.0,9619,1,50597,,,,Half life period in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626931,,,A
6103,Intermediate,,1,,10116.0,9620,1,50597,,,,Half life period in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626932,,,A
6317,Intermediate,,1,,10116.0,9621,1,50597,,,,Half life period in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626933,,,A
6644,Intermediate,,1,,10116.0,9622,1,50597,,In vivo,,Half life period in rat after oral administration at 10.5 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873826,,,A
6644,Intermediate,,1,,10116.0,9623,1,50597,,In vivo,,Half life period in rat after oral administration at 11.2 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626934,,,A
6644,Intermediate,,1,,10116.0,9624,1,50597,,In vivo,,Half life period in rat after oral administration at 13 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626935,,,A
6644,Intermediate,,1,,10116.0,9625,1,50597,,In vivo,,Half life period in rat after oral administration at 9.7 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626936,,,A
5974,Intermediate,,1,,10116.0,9626,1,50597,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626937,,,A
6295,Intermediate,,1,,10116.0,9627,1,50597,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625906,,,A
6296,Intermediate,,1,,10116.0,9628,1,50597,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625907,,,A
16427,Intermediate,,1,,10116.0,9629,1,50597,,,,PK study was carried to determine AUC (area under curve) value in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625908,,,A
16367,Intermediate,,1,,10116.0,9630,1,50597,,,,Pharmacokinetic parameter AUC after intravenous administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625909,,,A
16367,Intermediate,,1,,10116.0,9631,1,50597,,,,Pharmacokinetic parameter AUC after oral administration to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625910,,,A
16365,Intermediate,,1,,10116.0,9632,1,50597,,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625911,,,A
16365,Intermediate,,1,,10116.0,9633,1,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625912,,,A
16365,Intermediate,,1,,10116.0,9634,1,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626538,,,A
16365,Intermediate,,1,,10116.0,9635,1,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876794,,,A
16365,Intermediate,,1,,10116.0,9636,1,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626539,,,A
16365,Intermediate,,1,,10116.0,9637,1,50597,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626540,,,A
5394,Intermediate,,1,,10116.0,9638,1,50597,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626541,,,A
5394,Intermediate,,1,,10116.0,9639,1,50597,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626542,,,A
2792,Intermediate,,1,,10116.0,9640,1,50597,,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626543,,,A
2792,Intermediate,,1,,10116.0,9641,1,50597,,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626544,,,A
2792,Intermediate,,1,,10116.0,9642,1,50597,,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626545,,,A
2792,Intermediate,,1,,10116.0,9643,1,50597,,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626546,,,A
5334,Intermediate,,1,,10116.0,9644,1,50597,,,,Pharmacokinetic parameter area under curve was reported,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626547,,,A
4408,Intermediate,,1,,10116.0,9645,1,50597,,,,Pharmacokinetic property (AUC) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626548,,,A
5983,Intermediate,,1,,10116.0,9646,1,50597,,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626549,,,A
4397,Intermediate,,1,,10116.0,9647,1,50597,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626550,,,A
4397,Intermediate,,1,,10116.0,9648,1,50597,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626551,,,A
5491,Intermediate,,1,,10116.0,9649,1,50597,,,,Pharmacokinetic property was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623777,,,A
5491,Intermediate,,1,,10116.0,9650,1,50597,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623778,,,A
5491,Intermediate,,1,,10116.0,9651,1,50597,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623779,,,A
4199,Intermediate,,1,,10116.0,9652,1,50597,,,Plasma,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623780,,,A
4199,Intermediate,,1,,10116.0,9653,1,50597,,,Plasma,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622015,,,A
4199,Intermediate,,1,,10116.0,9654,1,50597,,,Plasma,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622016,,,A
5173,Intermediate,,1,,10116.0,9655,1,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622017,,,A
5173,Intermediate,,1,,10116.0,9656,1,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622018,,,A
5173,Intermediate,,1,,10116.0,9657,1,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622019,,,A
5173,Intermediate,,1,,10116.0,9658,1,50597,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622020,,,A
16366,Intermediate,,1,,10116.0,9659,1,50597,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622021,,,A
16366,Intermediate,,1,,10116.0,9660,1,50597,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622022,,,A
5327,Intermediate,,1,,10116.0,9661,1,50597,,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622023,,,A
6681,Intermediate,,1,,10116.0,9662,1,50597,,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622024,,,A
12873,Intermediate,,1,,10116.0,9663,1,50597,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622693,,,A
12873,Intermediate,,1,,10116.0,9664,1,50597,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622694,,,A
6685,Intermediate,,1,,10116.0,9665,1,50597,,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622695,,,A
6685,Intermediate,,1,,10116.0,9666,1,50597,,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622696,,,A
6685,Intermediate,,1,,10116.0,9667,1,50597,,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622697,,,A
6619,Intermediate,,1,,10116.0,9668,1,50597,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622874,,,A
6619,Intermediate,,1,,10116.0,9669,1,50597,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622875,,,A
10363,Intermediate,,1,,10116.0,9670,1,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622876,,,A
4796,Intermediate,,1,,10116.0,9671,1,50597,,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622877,,,A
4910,Intermediate,,1,,10116.0,9672,1,50597,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622878,,,A
4910,Intermediate,,1,,10116.0,9673,1,50597,,,Plasma,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622879,,,A
4839,Intermediate,,1,,10116.0,9674,1,50597,,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877602,,,A
15078,Intermediate,,1,,10116.0,9675,1,50597,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622880,,,A
15078,Intermediate,,1,,10116.0,9676,1,50597,,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622881,,,A
15078,Intermediate,,1,,10116.0,9677,1,50597,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622882,,,A
15078,Intermediate,,1,,10116.0,9678,1,50597,,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622883,,,A
11450,Intermediate,,1,,10116.0,9679,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622884,,,A
11450,Intermediate,,1,,10116.0,9680,1,50597,,,Thyroid gland,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622885,,,A
8151,Intermediate,,1,,10116.0,9681,1,50597,,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622886,,,A
8151,Intermediate,,1,,10116.0,9682,1,50597,,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622887,,,A
8151,Intermediate,,1,,10116.0,9683,1,50597,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622888,,,A
8677,Intermediate,,1,,10116.0,9684,1,50597,,In vivo,Blood,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622889,,,A
8677,Intermediate,,1,,10116.0,9685,1,50597,,In vivo,Blood,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622890,,,A
8677,Intermediate,,1,,10116.0,9686,1,50597,,In vivo,Blood,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622891,,,A
8677,Intermediate,,1,,10116.0,9687,1,50597,,In vivo,Blood,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL877603,,,A
8677,Intermediate,,1,,10116.0,9688,1,50597,,In vivo,Brain,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622892,,,A
8677,Intermediate,,1,,10116.0,9689,1,50597,,In vivo,Brain,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622893,,,A
8677,Intermediate,,1,,10116.0,9690,1,50597,,In vivo,Brain,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622894,,,A
8677,Intermediate,,1,,10116.0,9691,1,50597,,In vivo,Brain,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622895,,,A
8677,Intermediate,,1,,10116.0,9692,1,50597,,In vivo,Brain,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622896,,,A
8677,Intermediate,,1,,10116.0,9693,1,50597,,In vivo,Heart,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622897,,,A
8677,Intermediate,,1,,10116.0,9694,1,50597,,In vivo,Heart,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622898,,,A
8677,Intermediate,,1,,10116.0,9695,1,50597,,In vivo,Heart,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622899,,,A
8677,Intermediate,,1,,10116.0,9696,1,50597,,In vivo,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622900,,,A
8677,Intermediate,,1,,10116.0,9697,1,50597,,In vivo,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624114,,,A
8677,Intermediate,,1,,10116.0,9698,1,50597,,In vivo,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624115,,,A
8677,Intermediate,,1,,10116.0,9699,1,50597,,In vivo,Kidney,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624116,,,A
8677,Intermediate,,1,,10116.0,9700,1,50597,,In vivo,Liver,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624117,,,A
8677,Intermediate,,1,,10116.0,9701,1,50597,,In vivo,Liver,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624118,,,A
8677,Intermediate,,1,,10116.0,9702,1,50597,,In vivo,Liver,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624119,,,A
8677,Intermediate,,1,,10116.0,9703,1,50597,,In vivo,Liver,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624120,,,A
8677,Intermediate,,1,,10116.0,9704,1,50597,,In vivo,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624121,,,A
8677,Intermediate,,1,,10116.0,9705,1,50597,,In vivo,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624122,,,A
8677,Intermediate,,1,,10116.0,9706,1,50597,,In vivo,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624123,,,A
8677,Intermediate,,1,,10116.0,9707,1,50597,,In vivo,Lung,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624124,,,A
8677,Intermediate,,1,,10116.0,9708,1,50597,,In vivo,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624125,,,A
8677,Intermediate,,1,,10116.0,9709,1,50597,,In vivo,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624126,,,A
8677,Intermediate,,1,,10116.0,9710,1,50597,,In vivo,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624127,,,A
8677,Intermediate,,1,,10116.0,9711,1,50597,,In vivo,Muscle tissue,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624128,,,A
8677,Intermediate,,1,,10116.0,9712,1,50597,,In vivo,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL624129,,,A
8677,Intermediate,,1,,10116.0,9713,1,50597,,In vivo,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL624130,,,A
8677,Intermediate,,1,,10116.0,9714,1,50597,,In vivo,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL622340,,,A
8677,Intermediate,,1,,10116.0,9715,1,50597,,In vivo,Zone of skin,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL622341,,,A
8677,Intermediate,,1,,10116.0,9716,1,50597,,In vivo,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622342,,,A
8677,Intermediate,,1,,10116.0,9717,1,50597,,In vivo,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622343,,,A
8677,Intermediate,,1,,10116.0,9718,1,50597,,In vivo,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622344,,,A
8677,Intermediate,,1,,10116.0,9719,1,50597,,In vivo,Intestine,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622345,,,A
8677,Intermediate,,1,,10116.0,9720,1,50597,,In vivo,Spleen,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622346,,,A
8677,Intermediate,,1,,10116.0,9721,1,50597,,In vivo,Spleen,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622347,,,A
8677,Intermediate,,1,,10116.0,9722,1,50597,,In vivo,Spleen,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622348,,,A
8677,Intermediate,,1,,10116.0,9723,1,50597,,In vivo,Spleen,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622349,,,A
16434,Intermediate,,1,,10116.0,9724,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622350,,,A
16434,Intermediate,,1,,10116.0,9725,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622351,,,A
16434,Intermediate,,1,,10116.0,9726,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622352,,,A
16435,Intermediate,,1,,10116.0,9727,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622353,,,A
16435,Intermediate,,1,,10116.0,9728,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622354,,,A
16435,Intermediate,,1,,10116.0,9729,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622355,,,A
16435,Intermediate,,1,,10116.0,9730,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622356,,,A
16435,Intermediate,,1,,10116.0,9731,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622357,,,A
16435,Intermediate,,1,,10116.0,9732,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622358,,,A
16435,Intermediate,,1,,10116.0,9733,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622359,,,A
16435,Intermediate,,1,,10116.0,9734,1,50597,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874393,,,A
16434,Intermediate,,1,,10116.0,9735,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622872,,,A
16434,Intermediate,,1,,10116.0,9736,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622873,,,A
16434,Intermediate,,1,,10116.0,9737,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623047,,,A
16435,Intermediate,,1,,10116.0,9738,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623048,,,A
16435,Intermediate,,1,,10116.0,9739,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623049,,,A
16435,Intermediate,,1,,10116.0,9740,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623050,,,A
16435,Intermediate,,1,,10116.0,9741,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623051,,,A
16435,Intermediate,,1,,10116.0,9742,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623052,,,A
16435,Intermediate,,1,,10116.0,9743,1,50597,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626343,,,A
16434,Intermediate,,1,,10116.0,9744,1,50597,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626344,,,A
16434,Intermediate,,1,,10116.0,9745,1,50597,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626345,,,A
16434,Intermediate,,1,,10116.0,9746,1,50597,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626346,,,A
16434,Intermediate,,1,,10116.0,9747,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626347,,,A
16434,Intermediate,,1,,10116.0,9748,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626348,,,A
16434,Intermediate,,1,,10116.0,9749,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626349,,,A
16435,Intermediate,,1,,10116.0,9750,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626350,,,F
16435,Intermediate,,1,,10116.0,9751,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626351,,,A
16435,Intermediate,,1,,10116.0,9752,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627650,,,A
16435,Intermediate,,1,,10116.0,9753,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627651,,,F
16435,Intermediate,,1,,10116.0,9754,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627652,,,A
16435,Intermediate,,1,,10116.0,9755,1,50597,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627653,,,A
13091,Intermediate,,1,,10116.0,9756,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627654,,,A
13091,Intermediate,,1,,10116.0,9757,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627835,,,A
13091,Intermediate,,1,,10116.0,9758,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627836,,,A
13091,Intermediate,,1,,10116.0,9759,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627837,,,A
13091,Intermediate,,1,,10116.0,9760,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627838,,,A
13091,Intermediate,,1,,10116.0,9761,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875338,,,A
13091,Intermediate,,1,,10116.0,9762,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627839,,,A
13091,Intermediate,,1,,10116.0,9763,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627840,,,A
13091,Intermediate,,1,,10116.0,9764,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627841,,,A
13091,Intermediate,,1,,10116.0,9765,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627842,,,A
13091,Intermediate,,1,,10116.0,9766,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627843,,,A
13091,Intermediate,,1,,10116.0,9767,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627844,,,A
13091,Intermediate,,1,,10116.0,9768,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627845,,,A
5874,Intermediate,,1,,10116.0,9769,1,50597,,In vivo,,Half life period in rat by iv administration at a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627846,,,A
1515,Intermediate,,1,,10116.0,9770,1,50597,,,Plasma,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627847,,,A
1515,Intermediate,,1,,10116.0,9771,1,50597,,,Plasma,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873821,,,A
1515,Intermediate,,1,,10116.0,9772,1,50597,,,Plasma,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626079,,,A
1515,Intermediate,,1,,10116.0,9773,1,50597,,,Plasma,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626080,,,A
5491,Intermediate,,1,,10116.0,9774,1,50597,,,Plasma,Half life period was evaluated in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626081,,,A
5491,Intermediate,,1,,10116.0,9775,1,50597,,,Plasma,Half life period was evaluated in rat plasma; Not tested,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL875344,,,A
1918,Intermediate,,1,,10116.0,9776,1,50597,,,,Half life period was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626082,,,A
1918,Intermediate,,1,,10116.0,9777,1,50597,,In vivo,,"Half life period was evaluated in rats, iv",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626250,,,A
6113,Intermediate,,1,,10116.0,9778,1,50597,,In vivo,,Half life period after intravenous administration at 5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626251,,,A
5546,Intermediate,,1,,10116.0,9779,1,50597,,In vivo,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626252,,,A
5553,Intermediate,,1,,10116.0,9780,1,50597,,In vivo,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626253,,,A
4188,Intermediate,,1,,10116.0,9781,1,50597,,,Plasma,Half life stability of compound was evaluated in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626254,,,A
6215,Intermediate,,1,,10116.0,9782,1,50597,,In vivo,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626255,,,A
6141,Intermediate,,1,,10116.0,9783,1,50597,,In vivo,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626256,,,A
5182,Intermediate,,1,,10116.0,9784,1,50597,,In vivo,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626257,,,A
5182,Intermediate,,1,,10116.0,9785,1,50597,,In vivo,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626258,,,A
5710,Intermediate,,1,,10116.0,9786,1,50597,,In vivo,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626259,,,A
5789,Intermediate,,1,,10116.0,9787,1,50597,,In vivo,,Half in rat i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626260,,,A
6011,Intermediate,,1,,10116.0,9788,1,50597,,In vivo,,Half period in rat after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875345,,,A
17594,Intermediate,,1,,10116.0,9789,1,50597,,In vivo,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626261,,,A
12357,Intermediate,,1,,10116.0,9790,1,50597,,In vitro,Liver,Half-life measured in in vitro Cathepsin B assay in rat liver,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626262,,,A
5210,Intermediate,,1,,10116.0,9791,1,50597,,,,Half-life of compound was determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626263,,,A
17596,Intermediate,,1,,10116.0,9792,1,50597,,In vivo,,Half-life at 10 mg/kg in rat upon intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625270,,,A
6672,Intermediate,,1,,10116.0,9793,1,50597,,,,Half-life determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625271,,,A
6673,Intermediate,,1,,10116.0,9794,1,50597,,,,Half-life determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625272,,,A
4910,Intermediate,,1,,10116.0,9795,1,50597,,In vivo,Brain,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625273,,,A
3741,Intermediate,,1,,10116.0,9796,1,50597,,,Plasma,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625274,,,A
17671,Intermediate,,1,,10116.0,9797,1,50597,,In vivo,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625275,,,A
4910,Intermediate,,1,,10116.0,9798,1,50597,,In vivo,Plasma,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625276,,,A
17537,Intermediate,,1,,10116.0,9799,1,50597,,,Plasma,Half-life in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625277,,,A
4965,Intermediate,,1,,10116.0,9800,1,50597,,,Plasma,Half-life in rat plasma was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625278,,,A
17537,Intermediate,,1,,10116.0,9801,1,50597,,,Plasma,Half-life in rat plasma; Not tested,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625279,,,A
6124,Intermediate,,1,,10116.0,9802,1,50597,,,Serum,Half-life in rat serum,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL625280,,,A
6124,Intermediate,,1,,10116.0,9803,1,50597,,,Serum,Half-life in rat serum; na is not available,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL876797,,,A
6078,Intermediate,,1,,10116.0,9804,1,50597,,,,Half-life was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625281,,,A
17668,Intermediate,,1,,10116.0,9805,1,50597,,,Plasma,Half-life was calculated in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL873827,,,A
3185,Intermediate,,1,,10116.0,9806,1,50597,,,,Half-life was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625282,,,A
4883,Intermediate,,1,,10116.0,9807,1,50597,,,,Half-life was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625283,,,A
2959,Intermediate,,1,,10116.0,9808,1,50597,,In vivo,,Half-life after administration of 20 mg/Kg oral dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625284,,,A
4029,Intermediate,,1,,10116.0,9809,1,50597,,In vivo,,Half-life after administration of 3.2 mg/kg intravenously in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625285,,,A
4029,Intermediate,,1,,10116.0,9810,1,50597,,In vivo,,Half-life after intravenous administration in female rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625286,,,A
4029,Intermediate,,1,,10116.0,9811,1,50597,,In vivo,,Half-life after intravenous administration in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625287,,,A
6180,Intermediate,,1,,10116.0,9812,1,50597,,In vivo,,Half-life after intravenous dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625288,,,A
1557,Intermediate,,1,,10116.0,9813,1,50597,,,Liver,Half-life in a rat liver homogenate preparation,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625289,,,A
12500,Intermediate,,1,,10116.0,9814,1,50597,,,Plasma,Half-life in plasma of rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625290,,,A
12500,Intermediate,,1,,10116.0,9815,1,50597,,,Plasma,Half-life in plasma of rat at dose of 3-10 mgkg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876798,,,A
5064,Intermediate,,1,,10116.0,9816,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625291,,,A
5145,Intermediate,,1,,10116.0,9817,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625292,,,A
5147,Intermediate,,1,,10116.0,9818,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625293,,,A
5833,Intermediate,,1,,10116.0,9819,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622832,,,A
6596,Intermediate,,1,,10116.0,9820,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622833,,,A
17655,Intermediate,,1,,10116.0,9821,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622834,,,A
6495,Intermediate,,1,,10116.0,9822,1,50597,,In vivo,,Half-life in rat after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622835,,,A
17538,Intermediate,,1,,10116.0,9823,1,50597,,In vivo,,Half-life in rat after po administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622836,,,A
17538,Intermediate,,1,,10116.0,9824,1,50597,,In vivo,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622837,,,A
10,Intermediate,,1,,10116.0,9825,1,50597,,In vivo,,Half-life in rat at 3 mg/kg dose administered intravenously,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622838,,,A
17669,Intermediate,,1,,10116.0,9826,1,50597,,,Brain,Half-life in rat brain homogenate,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622839,,,A
17065,Intermediate,,1,,10116.0,9827,1,50597,,,Plasma,Half-life in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622840,,,A
4333,Intermediate,,1,,10116.0,9828,1,50597,,,,Half-life in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622841,,,A
6827,Intermediate,,1,,10116.0,9829,1,50597,,,,Half-life in Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622842,,,A
889,Intermediate,,1,,10116.0,9830,1,50597,,In vitro,Plasma,Half-life in vitro in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622843,,,A
889,Intermediate,,1,,10116.0,9831,1,50597,,In vitro,Plasma,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622844,,,A
3747,Intermediate,,1,,10116.0,9832,1,50597,,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622845,,,A
15022,Intermediate,,1,,10116.0,9833,1,50597,,,,The area under the curve of compound was measured at the dose of 100 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622846,,,A
15022,Intermediate,,1,,10116.0,9834,1,50597,,,,The area under the curve of compound was measured at the dose of 300 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622847,,,A
15022,Intermediate,,1,,10116.0,9835,1,50597,,,,The area under the curve of compound was measured at the dose of 30 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622848,,,A
3360,Intermediate,,1,,10116.0,9836,1,50597,,In vivo,,Bioavailability as oral AUC in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622849,,,A
5334,Intermediate,,1,,10116.0,9837,1,50597,,,Plasma,The plasma concentration versus time curve (AUC) was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622850,,,A
17411,Intermediate,,1,,10116.0,9838,1,50597,,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876807,,,A
17411,Intermediate,,1,,10116.0,9839,1,50597,,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622851,,,A
17411,Intermediate,,1,,10116.0,9840,1,50597,,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622852,,,A
6570,Intermediate,,1,,10116.0,9841,1,50597,,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622853,,,A
6570,Intermediate,,1,,10116.0,9842,1,50597,,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622854,,,A
17411,Intermediate,,1,,10116.0,9843,1,50597,,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622855,,,A
14941,Intermediate,,1,,10116.0,9844,1,50597,,,Plasma,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622856,,,A
14941,Intermediate,,1,,10116.0,9845,1,50597,,,Plasma,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622857,,,A
17538,Intermediate,,1,,10116.0,9846,1,50597,,,Plasma,AUC in rat after po administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622858,,,A
17752,Intermediate,,1,,10116.0,9847,1,50597,,,Plasma,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622859,,,A
17509,Intermediate,,1,,10116.0,9848,1,50597,,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622860,,,A
17509,Intermediate,,1,,10116.0,9849,1,50597,,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622861,,,A
17509,Intermediate,,1,,10116.0,9850,1,50597,,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622862,,,A
17509,Intermediate,,1,,10116.0,9851,1,50597,,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622863,,,A
17509,Intermediate,,1,,10116.0,9852,1,50597,,,,Area under curve value 6 hr after po administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623817,,,A
17717,Intermediate,,1,,10116.0,9853,1,50597,,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623818,,,A
17717,Intermediate,,1,,10116.0,9854,1,50597,,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623819,,,A
17717,Intermediate,,1,,10116.0,9855,1,50597,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623820,,,A
17717,Intermediate,,1,,10116.0,9856,1,50597,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623821,,,A
6642,Intermediate,,1,,10116.0,9857,1,50597,,,Plasma,AUC normalized for dose (AUCN) in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623822,,,A
6640,Intermediate,,1,,10116.0,9858,1,50597,,,,Area under curve in rat after p.o. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623823,,,A
6641,Intermediate,,1,,10116.0,9859,1,50597,,,,Area under curve in rat after p.o. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623824,,,A
6641,Intermediate,,1,,10116.0,9860,1,50597,,,,Area under curve in rat after p.o. administration; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623825,,,A
6641,Intermediate,,1,,10116.0,9861,1,50597,,,,Area under curve in rat after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622070,,,A
3603,Intermediate,,1,,10116.0,9862,1,50597,,,,Area under curve (carotid artery) value of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622071,,,A
3550,Intermediate,,1,,10116.0,9863,1,50597,,,,Bioavailability expressed as the area under curve of rat carotid artery,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622072,,,A
15662,Intermediate,,1,,10116.0,9864,1,50597,,,,Area under curve in male SD rats was observed after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622073,,,A
17720,Intermediate,,1,,10116.0,9865,1,50597,,,,Area under curve of the compound was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622074,,,A
5407,Intermediate,,1,,10116.0,9866,1,50597,,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622075,,,A
17752,Intermediate,,1,,10116.0,9867,1,50597,,,Plasma,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622076,,,A
17752,Intermediate,,1,,10116.0,9868,1,50597,,,Plasma,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622077,,,A
3603,Intermediate,,1,,10116.0,9869,1,50597,,,,Area under curve (portal vein) value of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622078,,,A
3550,Intermediate,,1,,10116.0,9870,1,50597,,,,Bioavailability expressed as the area under curve of rat portal vein,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622079,,,A
17655,Intermediate,,1,,10116.0,9871,1,50597,,,Plasma,Area Under plasma concentration time curve in rat upon peroral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622080,,,A
17582,Intermediate,,1,,10116.0,9872,1,50597,,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877612,,,A
17582,Intermediate,,1,,10116.0,9873,1,50597,,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622081,,,A
17791,Intermediate,,1,,10116.0,9874,1,50597,,,,Compound was evaluated for oral bioavailability in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622082,,,A
17791,Intermediate,,1,,10116.0,9875,1,50597,,,,Compound was evaluated for oral bioavailability in rats after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622083,,,A
17791,Intermediate,,1,,10116.0,9876,1,50597,,,,Compound was evaluated for oral bioavailability in rats; 30-80,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622084,,,A
17791,Intermediate,,1,,10116.0,9877,1,50597,,,,Compound was evaluated for oral bioavailability in rats; 50-60,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622085,,,A
17791,Intermediate,,1,,10116.0,9878,1,50597,,,,Compound was evaluated for oral bioavailability in rats; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622086,,,A
17791,Intermediate,,1,,10116.0,9879,1,50597,,,,Compound was evaluated for oral bioavailability in rats; peptide,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622087,,,A
7768,Intermediate,,1,,10116.0,9880,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622088,,,A
7768,Intermediate,,1,,10116.0,9881,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622089,,,A
7768,Intermediate,,1,,10116.0,9882,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623685,,,A
7768,Intermediate,,1,,10116.0,9883,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623686,,,A
8677,Intermediate,,1,,10116.0,9884,1,50597,,In vivo,Stomach,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL623687,,,A
8677,Intermediate,,1,,10116.0,9885,1,50597,,In vivo,Stomach,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL623688,,,A
8677,Intermediate,,1,,10116.0,9886,1,50597,,In vivo,Stomach,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL623689,,,A
8677,Intermediate,,1,,10116.0,9887,1,50597,,In vivo,Stomach,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,945.0,CHEMBL622485,,,A
8677,Intermediate,,1,,10116.0,9888,1,50597,,In vivo,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622486,,,A
8677,Intermediate,,1,,10116.0,9889,1,50597,,In vivo,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL877613,,,A
8677,Intermediate,,1,,10116.0,9890,1,50597,,In vivo,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622487,,,A
8677,Intermediate,,1,,10116.0,9891,1,50597,,In vivo,Thyroid gland,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622488,,,A
8677,Intermediate,,1,,10116.0,9892,1,50597,,In vivo,Heart,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622489,,,A
6899,Intermediate,,1,,10116.0,9893,1,50597,,,Urine,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622490,,,A
6899,Intermediate,,1,,10116.0,9894,1,50597,,,Urine,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622491,,,A
6899,Intermediate,,1,,10116.0,9895,1,50597,,,Liver,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622492,,,A
6899,Intermediate,,1,,10116.0,9896,1,50597,,,Urine,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622493,,,A
6899,Intermediate,,1,,10116.0,9897,1,50597,,,Urine,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622494,,,A
8677,Intermediate,,1,,10116.0,9898,1,50597,,,Muscle tissue,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622495,,,A
6899,Intermediate,,1,,10116.0,9899,1,50597,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622496,,,A
6899,Intermediate,,1,,10116.0,9900,1,50597,,,Urine,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622497,,,A
2189,Intermediate,,1,,10116.0,9901,1,50597,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622498,,,A
2189,Intermediate,,1,,10116.0,9902,1,50597,,,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624918,,,A
2189,Intermediate,,1,,10116.0,9903,1,50597,,,Urine,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624919,,,A
10839,Intermediate,,1,,10116.0,9904,1,50597,,In vivo,Blood,Biodistribution of compound in rat blood after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624920,,,A
10839,Intermediate,,1,,10116.0,9905,1,50597,,In vivo,Blood,Biodistribution of compound in rat blood after 5 min of administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624921,,,A
10839,Intermediate,,1,,10116.0,9906,1,50597,,In vivo,Brain,Biodistribution of compound in rat brain after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624922,,,A
10839,Intermediate,,1,,10116.0,9907,1,50597,,In vivo,Heart,Biodistribution of compound in rat heart after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624923,,,A
10839,Intermediate,,1,,10116.0,9908,1,50597,,In vivo,Heart,Biodistribution of compound in rat heart after 5 min of administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624924,,,A
10839,Intermediate,,1,,10116.0,9909,1,50597,,In vivo,Kidney,Biodistribution of compound in rat kidney after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624925,,,A
10839,Intermediate,,1,,10116.0,9910,1,50597,,In vivo,Kidney,Biodistribution of compound in rat kidney after 5 min of administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624926,,,A
10839,Intermediate,,1,,10116.0,9911,1,50597,,In vivo,Liver,Biodistribution of compound in rat liver after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624927,,,A
10839,Intermediate,,1,,10116.0,9912,1,50597,,In vivo,Liver,Biodistribution of compound in rat liver after 5 min of administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL874402,,,A
10839,Intermediate,,1,,10116.0,9913,1,50597,,In vivo,Lung,Biodistribution of compound in rat lung after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624928,,,A
10839,Intermediate,,1,,10116.0,9914,1,50597,,In vivo,Lung,Biodistribution of compound in rat lung after 5 min of administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624929,,,A
10839,Intermediate,,1,,10116.0,9915,1,50597,,In vivo,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624930,,,A
10839,Intermediate,,1,,10116.0,9916,1,50597,,In vivo,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration.,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624931,,,A
4043,Intermediate,,1,,10116.0,9917,1,50597,,,Heart,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624932,,,A
4043,Intermediate,,1,,10116.0,9918,1,50597,,,Heart,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624933,,,A
4043,Intermediate,,1,,10116.0,9919,1,50597,,,Liver,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624934,,,A
4043,Intermediate,,1,,10116.0,9920,1,50597,,,Liver,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624935,,,A
4043,Intermediate,,1,,10116.0,9921,1,50597,,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624936,,,A
4043,Intermediate,,1,,10116.0,9922,1,50597,,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624937,,,A
4043,Intermediate,,1,,10116.0,9923,1,50597,,,Spleen,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL624938,,,A
4043,Intermediate,,1,,10116.0,9924,1,50597,,,Spleen,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL624939,,,A
4043,Intermediate,,1,,10116.0,9925,1,50597,,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624940,,,A
4043,Intermediate,,1,,10116.0,9926,1,50597,,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874403,,,A
1446,Intermediate,,1,,10116.0,9927,1,50597,,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624941,,,A
9971,Intermediate,,1,,10116.0,9928,1,50597,,,Urine,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624942,,,A
9971,Intermediate,,1,,10116.0,9929,1,50597,,,Urine,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624943,,,A
5765,Intermediate,,1,,10116.0,9930,1,50597,,In vivo,,% Bioavailability after 1 day of the drug administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624944,,,A
5765,Intermediate,,1,,10116.0,9931,1,50597,,In vivo,,% Bioavailability after 4 day of the drug administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624945,,,A
4257,Intermediate,,1,,10116.0,9932,1,50597,,In vivo,,Absolute bioavailability was evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624946,,,A
13091,Intermediate,,1,,10116.0,9933,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624947,,,A
13091,Intermediate,,1,,10116.0,9934,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624948,,,A
13091,Intermediate,,1,,10116.0,9935,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624949,,,A
13091,Intermediate,,1,,10116.0,9936,1,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622025,,,A
13091,Intermediate,,1,,10116.0,9937,1,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622026,,,A
13091,Intermediate,,1,,10116.0,9938,1,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622027,,,A
13091,Intermediate,,1,,10116.0,9939,1,50597,,,Kidney,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622028,,,A
13091,Intermediate,,1,,10116.0,9940,1,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622029,,,A
13091,Intermediate,,1,,10116.0,9941,1,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622208,,,A
13091,Intermediate,,1,,10116.0,9942,1,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622209,,,A
13091,Intermediate,,1,,10116.0,9943,1,50597,,,Liver,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622210,,,A
13091,Intermediate,,1,,10116.0,9944,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622211,,,A
13091,Intermediate,,1,,10116.0,9945,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622212,,,A
13091,Intermediate,,1,,10116.0,9946,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622213,,,A
13091,Intermediate,,1,,10116.0,9947,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874404,,,A
13091,Intermediate,,1,,10116.0,9948,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620452,,,A
13091,Intermediate,,1,,10116.0,9949,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620453,,,A
13091,Intermediate,,1,,10116.0,9950,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL620454,,,A
13091,Intermediate,,1,,10116.0,9951,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624067,,,A
13091,Intermediate,,1,,10116.0,9952,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624068,,,A
13091,Intermediate,,1,,10116.0,9953,1,50597,,,Female gonad,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL624069,,,A
13091,Intermediate,,1,,10116.0,9954,1,50597,,,Female gonad,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL624070,,,A
13091,Intermediate,,1,,10116.0,9955,1,50597,,,Female gonad,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL624071,,,A
13091,Intermediate,,1,,10116.0,9956,1,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL624072,,,A
13091,Intermediate,,1,,10116.0,9957,1,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL624073,,,A
13091,Intermediate,,1,,10116.0,9958,1,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL624788,,,A
13091,Intermediate,,1,,10116.0,9959,1,50597,,,Uterus,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL624789,,,A
13091,Intermediate,,1,,10116.0,9960,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624790,,,A
13091,Intermediate,,1,,10116.0,9961,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624791,,,A
13091,Intermediate,,1,,10116.0,9962,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624792,,,A
13091,Intermediate,,1,,10116.0,9963,1,50597,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624793,,,A
13091,Intermediate,,1,,10116.0,9964,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL877491,,,A
13091,Intermediate,,1,,10116.0,9965,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624957,,,A
13091,Intermediate,,1,,10116.0,9966,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624958,,,A
13091,Intermediate,,1,,10116.0,9967,1,50597,,,Muscle tissue,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624959,,,A
11977,Intermediate,,1,,10116.0,9968,1,50597,,,,Dissociation constant was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624960,,,A
14941,Intermediate,,1,,10116.0,9969,1,50597,,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624961,,,A
15078,Intermediate,,1,,10116.0,9970,1,50597,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624962,,,A
15078,Intermediate,,1,,10116.0,9971,1,50597,,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624963,,,A
4755,Intermediate,,1,,10116.0,9972,1,50597,,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624964,,,A
589,Intermediate,,1,,10116.0,9973,1,50597,,,,LogP value was evaluated in the in situ rat gut perfusion assay,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624965,,,A
17582,Intermediate,,1,,10116.0,9974,1,50597,,In vivo,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624966,,,A
5031,Intermediate,,1,,10116.0,9975,1,50597,,In vivo,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624967,,,A
17764,Intermediate,,1,,10116.0,9976,1,50597,,In vivo,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624968,,,A
17720,Intermediate,,1,,10116.0,9977,1,50597,,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624969,,,A
2862,Expert,,1,,10116.0,9978,1,50597,,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624970,,,F
16423,Intermediate,,1,,10116.0,9979,1,50597,,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624971,,,A
16423,Intermediate,,1,,10116.0,9980,1,50597,,In vivo,,Half-life was evaluated after 20 uM/kg of peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624972,,,A
6005,Intermediate,,1,,10116.0,9981,1,50597,,In vivo,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624973,,,A
2938,Intermediate,,1,,10116.0,9982,1,50597,,,Plasma,Half-life was evaluated in plasma of rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL624974,,,A
6410,Intermediate,,1,,10116.0,9983,1,50597,,In vivo,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624975,,,A
6410,Intermediate,,1,,10116.0,9984,1,50597,,In vivo,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877492,,,A
6062,Intermediate,,1,,10116.0,9985,1,50597,,In vivo,,Half-life was measured in rat after an iv dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624976,,,A
6571,Intermediate,,1,,10116.0,9986,1,50597,,In vivo,,Half-life period of compound in rats after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624977,,,A
3136,Intermediate,,1,,10116.0,9987,1,50597,,,Plasma,Half-life period of compound was measured in rat plasma.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626848,,,A
3136,Intermediate,,1,,10116.0,9988,1,50597,,,Plasma,Half-life period of compound was measured in rat plasma; ND is not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626849,,,A
3136,Intermediate,,1,,10116.0,9989,1,50597,,,Plasma,Half-life period of compound was measured in rat plasma; not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626850,,,A
4521,Intermediate,,1,,10116.0,9990,1,50597,,In vivo,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626851,,,A
5871,Intermediate,,1,,10116.0,9991,1,50597,,In vivo,,Half-life period in rat by iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626852,,,A
6077,Intermediate,,1,,10116.0,9992,1,50597,,In vivo,,Half-life period in rats following intravenous administration at 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626853,,,A
6679,Intermediate,,1,,10116.0,9993,1,50597,,In vivo,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626854,,,A
5144,Intermediate,,1,,10116.0,9994,1,50597,,,,Half-life period was determined for the compound in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627486,,,A
4498,Intermediate,,1,,10116.0,9995,1,50597,,In vivo,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627487,,,A
4498,Intermediate,,1,,10116.0,9996,1,50597,,In vivo,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627488,,,A
1908,Intermediate,,1,,10116.0,9997,1,50597,,In vivo,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627489,,,A
6211,Intermediate,,1,,10116.0,9998,1,50597,,In vivo,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627490,,,A
5529,Intermediate,,1,,10116.0,9999,1,50597,,In vivo,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873829,,,A
6444,Intermediate,,1,,10116.0,10000,1,50597,,In vivo,,Half-life was determined in rat at a dose of 1 mpk i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627655,,,A
6444,Intermediate,,1,,10116.0,10001,1,50597,,In vivo,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625994,,,A
6444,Intermediate,,1,,10116.0,10002,1,50597,,In vivo,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625995,,,A
5207,Intermediate,,1,,10116.0,10003,1,50597,,,,Half-life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625996,,,A
530,Intermediate,,1,,10116.0,10004,1,50597,,In vitro,Plasma,In vitro half life in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625850,,,A
1116,Intermediate,,1,,10116.0,10005,1,50597,,In vitro,Plasma,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625851,,,A
3219,Intermediate,,1,,10116.0,10006,1,50597,,In vitro,,In vitro half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625852,,,A
6109,Intermediate,,1,,10116.0,10007,1,50597,,In vivo,,In vivo half life period after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625853,,,A
17582,Intermediate,,1,,10116.0,10008,1,50597,,In vivo,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625854,,,A
17582,Intermediate,,1,,10116.0,10009,1,50597,,In vivo,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874450,,,A
5974,Intermediate,,1,,10116.0,10010,1,50597,,In vivo,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625855,,,A
5974,Intermediate,,1,,10116.0,10011,1,50597,,In vivo,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625856,,,A
5974,Intermediate,,1,,10116.0,10012,1,50597,,In vivo,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625857,,,A
5974,Intermediate,,1,,10116.0,10013,1,50597,,In vivo,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873831,,,A
17853,Intermediate,,1,,10116.0,10014,1,50597,,In vivo,,Longer half-life in rat (i.v.) at 0.5 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625858,,,A
17853,Intermediate,,1,,10116.0,10015,1,50597,,In vivo,,Longer half-life in rat (p.o.) at 2.0 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625859,,,A
3457,Intermediate,,1,,10116.0,10016,1,50597,,,,Pharmacokinetic property (half life) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625860,,,A
2792,Intermediate,,1,,10116.0,10017,1,50597,,In vivo,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625861,,,A
2792,Intermediate,,1,,10116.0,10018,1,50597,,In vivo,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625862,,,A
2792,Intermediate,,1,,10116.0,10019,1,50597,,In vivo,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625863,,,A
2792,Intermediate,,1,,10116.0,10020,1,50597,,In vivo,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625864,,,A
5739,Intermediate,,1,,10116.0,10021,1,50597,,In vivo,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625865,,,A
15765,Intermediate,,1,,10116.0,10022,1,50597,,In vivo,,Pharmacokinetic half time was determined intravenously in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625866,,,A
6567,Intermediate,,1,,10116.0,10023,1,50597,,In vivo,Plasma,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625867,,,A
2448,Intermediate,,1,,10116.0,10024,1,50597,,,Plasma,Plasma half life of hydrolysis of the compound,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625868,,,A
5423,Intermediate,,1,,10116.0,10025,1,50597,,In vivo,Plasma,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625869,,,A
4853,Intermediate,,1,,10116.0,10026,1,50597,,,Plasma,Plasma half life period was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL874451,,,A
4514,Intermediate,,1,,10116.0,10027,1,50597,,,Plasma,Plasma half-life in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625870,,,A
4514,Intermediate,,1,,10116.0,10028,1,50597,,,Plasma,Plasma half-life in Sprague-Dawley rats; Not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625871,,,A
1500,Intermediate,,1,,10116.0,10029,1,50597,,,Plasma,Plasma half-life in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625872,,,A
1500,Intermediate,,1,,10116.0,10030,1,50597,,,Plasma,Plasma half-life in rats; <MQL,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625873,,,A
5334,Intermediate,,1,,10116.0,10031,1,50597,,,Plasma,Plasma half-life period (0-8 h) was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625874,,,A
5334,Intermediate,,1,,10116.0,10032,1,50597,,,Plasma,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625875,,,A
5334,Intermediate,,1,,10116.0,10033,1,50597,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625876,,,A
5334,Intermediate,,1,,10116.0,10034,1,50597,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631258,,,A
4956,Intermediate,,1,,10116.0,10035,1,50597,,,Plasma,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631259,,,A
4956,Intermediate,,1,,10116.0,10036,1,50597,,,Plasma,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631260,,,A
7768,Intermediate,,1,,10116.0,10037,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631261,,,A
7768,Intermediate,,1,,10116.0,10038,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631262,,,A
7768,Intermediate,,1,,10116.0,10039,1,50597,,,Blood,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631263,,,A
7768,Intermediate,,1,,10116.0,10040,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631264,,,A
7768,Intermediate,,1,,10116.0,10041,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631265,,,A
7768,Intermediate,,1,,10116.0,10042,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631266,,,A
7768,Intermediate,,1,,10116.0,10043,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631267,,,A
7768,Intermediate,,1,,10116.0,10044,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631268,,,A
7768,Intermediate,,1,,10116.0,10045,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631269,,,A
7768,Intermediate,,1,,10116.0,10046,1,50597,,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631270,,,A
7768,Intermediate,,1,,10116.0,10047,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631271,,,A
7768,Intermediate,,1,,10116.0,10048,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631272,,,A
7768,Intermediate,,1,,10116.0,10049,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631273,,,A
7768,Intermediate,,1,,10116.0,10050,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631274,,,A
7768,Intermediate,,1,,10116.0,10051,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631275,,,A
7768,Intermediate,,1,,10116.0,10052,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626984,,,A
7768,Intermediate,,1,,10116.0,10053,1,50597,,,Heart,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626985,,,A
7768,Intermediate,,1,,10116.0,10054,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626986,,,A
7768,Intermediate,,1,,10116.0,10055,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626987,,,A
7768,Intermediate,,1,,10116.0,10056,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626988,,,A
7768,Intermediate,,1,,10116.0,10057,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626989,,,A
7768,Intermediate,,1,,10116.0,10058,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626990,,,A
7768,Intermediate,,1,,10116.0,10059,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626991,,,A
7768,Intermediate,,1,,10116.0,10060,1,50597,,,Liver,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626992,,,A
7768,Intermediate,,1,,10116.0,10061,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626993,,,A
7768,Intermediate,,1,,10116.0,10062,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL874593,,,A
7768,Intermediate,,1,,10116.0,10063,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626994,,,A
7768,Intermediate,,1,,10116.0,10064,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626995,,,A
7768,Intermediate,,1,,10116.0,10065,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626190,,,A
7768,Intermediate,,1,,10116.0,10066,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626191,,,A
7768,Intermediate,,1,,10116.0,10067,1,50597,,,Lung,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626364,,,A
7768,Intermediate,,1,,10116.0,10068,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626365,,,A
7768,Intermediate,,1,,10116.0,10069,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626366,,,A
7768,Intermediate,,1,,10116.0,10070,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626367,,,A
7768,Intermediate,,1,,10116.0,10071,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626368,,,A
7768,Intermediate,,1,,10116.0,10072,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626369,,,A
7768,Intermediate,,1,,10116.0,10073,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626370,,,A
4498,Intermediate,,1,,10116.0,10074,1,50597,,In vivo,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626371,,,A
4498,Intermediate,,1,,10116.0,10075,1,50597,,In vivo,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626372,,,A
3603,Intermediate,,1,,10116.0,10076,1,50597,,In vivo,,Bioavailability after a dose of 10 mg/kg p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626373,,,A
6215,Intermediate,,1,,10116.0,10077,1,50597,,In vivo,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626374,,,A
5710,Intermediate,,1,,10116.0,10078,1,50597,,In vivo,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626375,,,A
5710,Intermediate,,1,,10116.0,10079,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626376,,,A
5676,Intermediate,,1,,10116.0,10080,1,50597,,In vivo,,Bioavailability in rat po was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626377,,,A
17667,Intermediate,,1,,10116.0,10081,1,50597,,In vivo,,Bioavailability of compound at 10 mg/kg in rat after oral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626378,,,A
17667,Intermediate,,1,,10116.0,10082,1,50597,,In vivo,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626379,,,A
6848,Intermediate,,1,,10116.0,10083,1,50597,,In vivo,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626380,,,A
6848,Intermediate,,1,,10116.0,10084,1,50597,,In vivo,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626381,,,A
17267,Intermediate,,1,,10116.0,10085,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626382,,,A
6362,Intermediate,,1,,10116.0,10086,1,50597,,In vivo,,Bioavailability in rat (Sprague-Dawley) (female),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626383,,,A
17671,Intermediate,,1,,10116.0,10087,1,50597,,In vivo,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874652,,,A
17671,Intermediate,,1,,10116.0,10088,1,50597,,In vivo,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626384,,,A
4333,Intermediate,,1,,10116.0,10089,1,50597,,In vivo,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626385,,,A
6077,Intermediate,,1,,10116.0,10090,1,50597,,In vivo,,Bioavailability in rat at an oral dose of 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626386,,,A
3278,Intermediate,,1,,10116.0,10091,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626387,,,A
5964,Intermediate,,1,,10116.0,10092,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626388,,,A
4884,Intermediate,,1,,10116.0,10093,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626389,,,A
4905,Intermediate,,1,,10116.0,10094,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626390,,,A
4884,Intermediate,,1,,10116.0,10095,1,50597,,In vivo,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626391,,,A
6850,Intermediate,,1,,10116.0,10096,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626392,,,A
2864,Intermediate,,1,,10116.0,10097,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626393,,,A
5780,Intermediate,,1,,10116.0,10098,1,50597,,In vivo,,Bioavailability was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623026,,,A
1465,Intermediate,,1,,10116.0,10099,1,50597,,In vivo,,Bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623027,,,A
5199,Intermediate,,1,,10116.0,10100,1,50597,,In vivo,,Bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623028,,,A
5765,Intermediate,,1,,10116.0,10101,1,50597,,In vivo,,Bioavailability in rat after 1 day dosing,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623029,,,A
5765,Intermediate,,1,,10116.0,10102,1,50597,,In vivo,,Bioavailability in rat after 4 day dosing,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623030,,,A
6518,Intermediate,,1,,10116.0,10103,1,50597,,In vivo,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623031,,,A
6518,Intermediate,,1,,10116.0,10104,1,50597,,In vivo,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623032,,,A
6518,Intermediate,,1,,10116.0,10105,1,50597,,In vivo,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623033,,,A
6518,Intermediate,,1,,10116.0,10106,1,50597,,In vivo,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623034,,,A
2083,Intermediate,,1,,10116.0,10107,1,50597,,In vivo,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623035,,,A
17260,Intermediate,,1,,10116.0,10108,1,50597,,In vivo,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623036,,,A
4956,Intermediate,,1,,10116.0,10109,1,50597,,In vivo,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623037,,,A
4368,Intermediate,,1,,10116.0,10110,1,50597,,In vivo,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623038,,,A
17752,Intermediate,,1,,10116.0,10111,1,50597,,In vivo,Plasma,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL874385,,,A
1446,Intermediate,,1,,10116.0,10112,1,50597,,In vivo,,Bioavailability in rat (Fisher) (fasted),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623039,,,A
2891,Intermediate,,1,,9443.0,10113,0,22224,,In vivo,,Bioavailability in monkey after po administration of 10 mg/kg dose,,U,,Primates,BAO_0000218,,CHEMBL623040,,,A
2891,Intermediate,,1,,9443.0,10114,0,22224,,In vivo,,Oral bioavailability in monkey (dose 10 mg/kg),,U,,Primates,BAO_0000218,,CHEMBL623041,,,A
6672,Intermediate,,1,,10116.0,10115,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623741,,,A
6673,Intermediate,,1,,10116.0,10116,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623742,,,A
17655,Intermediate,,1,,10116.0,10117,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623743,,,A
17796,Intermediate,,1,,10116.0,10118,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623744,,,A
17853,Intermediate,,1,,10116.0,10119,1,50597,,In vivo,,Bioavailability in rat (dose 2.0 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623745,,,A
4521,Intermediate,,1,,10116.0,10120,1,50597,,In vivo,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623746,,,A
4940,Intermediate,,1,,10116.0,10121,1,50597,,In vivo,,Oral bioavailability in rat (dose 5 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623747,,,A
2891,Intermediate,,1,,10116.0,10122,0,22224,,In vivo,,Bioavailability in rat after po administration of 30 mg/kg dose,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL623748,,,A
2891,Intermediate,,1,,10116.0,10123,0,22224,,In vivo,,Bioavailability in rat after po administration of 30 mg/kg dose,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL623916,,,A
4521,Intermediate,,1,,10116.0,10124,1,50597,,In vivo,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623917,,,A
17686,Intermediate,,1,,10116.0,10125,1,50597,,In vivo,,Bioavailability in rat (dose 2 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623918,,,A
17796,Intermediate,,1,,10116.0,10126,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874386,,,A
17796,Intermediate,,1,,10116.0,10127,1,50597,,In vivo,Plasma,Bioavailability in rat; Only traces detected in rat plasma,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623919,,,A
5064,Intermediate,,1,,10116.0,10128,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623920,,,A
5147,Intermediate,,1,,10116.0,10129,1,50597,,In vivo,,Bioavailability upon oral administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623148,,,A
1916,Intermediate,,1,,10116.0,10130,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623149,,,A
6049,Intermediate,,1,,10116.0,10131,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623150,,,A
1445,Intermediate,,1,,10116.0,10132,1,50597,,In vivo,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623151,,,A
1445,Intermediate,,1,,10116.0,10133,1,50597,,In vivo,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623152,,,A
2862,Expert,,1,,10116.0,10134,1,50597,,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623153,,,F
2862,Expert,,1,,10116.0,10135,1,50597,,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623154,,,F
4194,Intermediate,,1,,10116.0,10136,1,50597,,,,In vitro and metabolic stability was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623155,,,A
4194,Intermediate,,1,,10116.0,10137,1,50597,,,,In vitro metabolic stability in rat hepatocytes,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623156,,,A
5486,Intermediate,,1,,10116.0,10138,1,50597,,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623157,,,A
17582,Intermediate,,1,,10116.0,10139,1,50597,Hepatocyte,In vitro,Liver,Metabolic rate for compound was observed in rat hepatocytes,,N,401.0,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623158,,,A
5600,Intermediate,,1,,10116.0,10140,1,50597,,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623159,,,A
14294,Intermediate,,1,,10116.0,10141,1,50597,,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874390,,,A
14294,Intermediate,,1,,10116.0,10142,1,50597,,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623160,,,A
14294,Intermediate,,1,,10116.0,10143,1,50597,,,,Metabolism of compound in rat S9 microsomes; Trace,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623161,,,A
17847,Intermediate,,1,,10116.0,10144,1,50597,,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623162,,,A
11020,Intermediate,,1,,10116.0,10145,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623163,,,A
11020,Intermediate,,1,,10116.0,10146,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623164,,,A
11020,Intermediate,,1,,10116.0,10147,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623165,,,A
11020,Intermediate,,1,,10116.0,10148,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623166,,,A
11020,Intermediate,,1,,10116.0,10149,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624983,,,A
11020,Intermediate,,1,,10116.0,10150,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624984,,,A
11020,Intermediate,,1,,10116.0,10151,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624985,,,A
11020,Intermediate,,1,,10116.0,10152,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622970,,,A
11020,Intermediate,,1,,10116.0,10153,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622971,,,A
11020,Intermediate,,1,,10116.0,10154,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622972,,,A
11020,Intermediate,,1,,10116.0,10155,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622973,,,A
11020,Intermediate,,1,,10116.0,10156,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622974,,,A
11020,Intermediate,,1,,10116.0,10157,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622975,,,A
11020,Intermediate,,1,,10116.0,10158,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622976,,,A
11020,Intermediate,,1,,10116.0,10159,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622977,,,A
11020,Intermediate,,1,,10116.0,10160,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624351,,,A
11020,Intermediate,,1,,10116.0,10161,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624352,,,A
11020,Intermediate,,1,,10116.0,10162,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624353,,,A
11020,Intermediate,,1,,10116.0,10163,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622397,,,A
11020,Intermediate,,1,,10116.0,10164,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622398,,,A
11020,Intermediate,,1,,10116.0,10165,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622399,,,A
11020,Intermediate,,1,,10116.0,10166,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622400,,,A
11020,Intermediate,,1,,10116.0,10167,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628428,,,A
11020,Intermediate,,1,,10116.0,10168,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628590,,,A
11020,Intermediate,,1,,10116.0,10169,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628591,,,A
11020,Intermediate,,1,,10116.0,10170,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628592,,,A
11020,Intermediate,,1,,10116.0,10171,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628593,,,A
11020,Intermediate,,1,,10116.0,10172,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875333,,,A
11020,Intermediate,,1,,10116.0,10173,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628594,,,A
4969,Intermediate,,1,,10116.0,10174,1,50597,,,Plasma,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628595,,,A
6737,Intermediate,,1,,10116.0,10175,1,50597,,,Plasma,Stability in rat plasma was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628596,,,A
6737,Intermediate,,1,,10116.0,10176,1,50597,,,Plasma,Stability in rat plasma was determined; ND= no data,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628597,,,A
5089,Intermediate,,1,,10116.0,10177,1,50597,,,Plasma,Tested for plasma half life period in rat (0-8 hr),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628598,,,A
5089,Intermediate,,1,,10116.0,10178,1,50597,,,Plasma,Tested for plasma half life period in rat (0-8 hr); Not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628599,,,A
1466,Intermediate,,1,,10116.0,10179,1,50597,,In vivo,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628600,,,A
1466,Intermediate,,1,,10116.0,10180,1,50597,,In vivo,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628601,,,A
4950,Intermediate,,1,,10116.0,10181,1,50597,,,,Tested for the half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628602,,,A
2412,Intermediate,,1,,10116.0,10182,1,50597,,In vitro,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628603,,,A
2412,Intermediate,,1,,10116.0,10183,1,50597,,In vitro,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628604,,,A
2412,Intermediate,,1,,10116.0,10184,1,50597,,In vitro,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628605,,,A
2412,Intermediate,,1,,10116.0,10185,1,50597,,In vitro,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628606,,,A
2412,Intermediate,,1,,10116.0,10186,1,50597,,In vitro,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628607,,,A
15022,Intermediate,,1,,10116.0,10187,1,50597,,,,The biological half life the compound was measured at the dose of 100 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628608,,,A
15022,Intermediate,,1,,10116.0,10188,1,50597,,,,The biological half life the compound was measured at the dose of 30 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628609,,,A
406,Intermediate,,1,,10116.0,10189,1,50597,,,Plasma,The compound was evaluated for plasma half life period in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628610,,,A
15078,Intermediate,,1,,10116.0,10190,1,50597,,In vivo,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL873819,,,A
15078,Intermediate,,1,,10116.0,10191,1,50597,,In vivo,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628611,,,A
5247,Intermediate,,1,,10116.0,10192,1,50597,,In vivo,,The pharmacokinetic parameter half-life period in vivo in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628612,,,A
5041,Intermediate,,1,,10116.0,10193,1,50597,,In vivo,,"The pharmacokinetic property, Half-life was determined",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628613,,,A
5041,Intermediate,,1,,10116.0,10194,1,50597,,In vivo,,"The pharmacokinetic property, Half-life in rat in vivo",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628614,,,A
5041,Intermediate,,1,,10116.0,10195,1,50597,,In vivo,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628615,,,A
5041,Intermediate,,1,,10116.0,10196,1,50597,,In vivo,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628616,,,A
3918,Intermediate,,1,,10116.0,10197,1,50597,,,Plasma,The plasma half life period in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627924,,,A
2906,Intermediate,,1,,10116.0,10198,1,50597,,,Liver,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627925,,,A
6467,Intermediate,,1,,10116.0,10199,1,50597,,In vivo,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627926,,,A
5510,Intermediate,,1,,10116.0,10200,1,50597,,,,t1/2 (apparent elimination)of the compound was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627927,,,A
3788,Intermediate,,1,,10116.0,10201,1,50597,,,,t1/2 value in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627928,,,A
17796,Intermediate,,1,,10116.0,10202,1,50597,,,,Half life in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627539,,,A
12873,Intermediate,,1,,10116.0,10203,1,50597,,In vivo,Plasma,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876790,,,A
5983,Intermediate,,1,,10116.0,10204,1,50597,,In vivo,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL858186,,,A
15765,Intermediate,,1,,10116.0,10205,1,50597,,,,Half-life period in fasted rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627540,,,A
2661,Intermediate,,1,,10116.0,10206,1,50597,,In vivo,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627541,,,A
2661,Intermediate,,1,,10116.0,10207,1,50597,,In vivo,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627715,,,A
429,Intermediate,,1,,10116.0,10208,1,50597,,In vivo,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627716,,,A
17655,Intermediate,,1,,10116.0,10209,1,50597,,,,Maximum time required to achieve Cmax was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627717,,,A
17717,Intermediate,,1,,10116.0,10210,1,50597,,In vivo,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627718,,,A
17717,Intermediate,,1,,10116.0,10211,1,50597,,In vivo,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627719,,,A
17717,Intermediate,,1,,10116.0,10212,1,50597,,In vivo,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627720,,,A
6570,Intermediate,,1,,10116.0,10213,1,50597,,In vivo,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627721,,,A
6570,Intermediate,,1,,10116.0,10214,1,50597,,In vivo,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627722,,,A
5978,Intermediate,,1,,10116.0,10215,1,50597,,In vivo,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627723,,,A
5978,Intermediate,,1,,10116.0,10216,1,50597,,In vivo,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626058,,,A
5978,Intermediate,,1,,10116.0,10217,1,50597,,In vivo,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626059,,,A
5978,Intermediate,,1,,10116.0,10218,1,50597,,In vivo,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626060,,,A
17720,Intermediate,,1,,10116.0,10219,1,50597,,In vivo,Plasma,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626061,,,A
4723,Intermediate,,1,,10116.0,10220,1,50597,,In vivo,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876791,,,A
4723,Intermediate,,1,,10116.0,10221,1,50597,,In vivo,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626062,,,A
4756,Intermediate,,1,,10116.0,10222,1,50597,,In vivo,,Tmax at the dose of 2 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626063,,,A
4756,Intermediate,,1,,10116.0,10223,1,50597,,In vivo,,Tmax at the dose of 5 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626064,,,A
17720,Intermediate,,1,,10116.0,10224,1,50597,,In vivo,Plasma,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626065,,,A
17720,Intermediate,,1,,10116.0,10225,1,50597,,In vivo,Plasma,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626066,,,A
1466,Intermediate,,1,,10116.0,10226,1,50597,,In vivo,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626067,,,A
7449,Intermediate,,1,,10116.0,10227,1,50597,,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626068,,,F
7449,Intermediate,,1,,10116.0,10228,1,50597,,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626069,,,F
7449,Intermediate,,1,,10116.0,10229,1,50597,,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626070,,,F
7449,Intermediate,,1,,10116.0,10230,1,50597,,,,Percent total excretion of N-methoxyacetaminophen glucuronide,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626071,,,F
7449,Intermediate,,1,,10116.0,10231,1,50597,,,,Percent total excretion of N-methoxyacetaminophen sulfate,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626072,,,F
7449,Intermediate,,1,,10116.0,10232,1,50597,,,,Percent total excretion of acetaminophen,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626073,,,F
7768,Intermediate,,1,,10116.0,10233,1,50597,,,Thyroid gland,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626741,,,A
17655,Intermediate,,1,,10116.0,10234,1,50597,,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626742,,,A
17735,Intermediate,,1,,10116.0,10235,1,50597,,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626743,,,A
5960,Intermediate,,1,,10116.0,10236,1,50597,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876792,,,A
17735,Intermediate,,1,,10116.0,10237,1,50597,,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626744,,,A
7116,Intermediate,,1,,10116.0,10238,1,50597,,,,Compound was tested for antidiuretic activity in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626745,,,A
4878,Intermediate,,1,,10116.0,10239,1,50597,,In vivo,Plasma,AUC in rat after 3mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626746,,,A
5939,Intermediate,,1,,10116.0,10240,1,50597,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626747,,,A
5939,Intermediate,,1,,10116.0,10241,1,50597,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626748,,,A
16367,Intermediate,,1,,10116.0,10242,1,50597,,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626749,,,A
16366,Intermediate,,1,,10116.0,10243,1,50597,,,,Oral Bioavailability was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626750,,,A
4426,Intermediate,,1,,10116.0,10244,1,50597,,,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626751,,,A
4426,Intermediate,,1,,10116.0,10245,1,50597,,,,Oral bioavailability in rat; Not performed.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626913,,,A
5041,Intermediate,,1,,10116.0,10246,1,50597,,,,Bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626914,,,A
5041,Intermediate,,1,,10116.0,10247,1,50597,,,,Bioavailability was determined; ND denotes no data,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626915,,,A
1500,Intermediate,,1,,10116.0,10248,1,50597,,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626916,,,A
1500,Intermediate,,1,,10116.0,10249,1,50597,,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626917,,,A
17409,Intermediate,,1,,10116.0,10250,1,50597,,,,Binding towards rat plasma protein at 10 uM,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626918,,,A
17409,Intermediate,,1,,10116.0,10251,1,50597,,,,Binding towards rat plasma protein at 100 uM,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626919,,,A
2959,Intermediate,,1,,10116.0,10252,1,50597,,In vivo,,Bioavailability in rat (dose 20 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626920,,,A
13501,Intermediate,,1,,10116.0,10253,1,50597,,In vivo,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621976,,,A
6567,Intermediate,,1,,10116.0,10254,1,50597,,In vivo,,Bioavailability in rat after 5 mg/kg oral gavage,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877599,,,A
6571,Intermediate,,1,,10116.0,10255,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621977,,,A
6715,Intermediate,,1,,10116.0,10256,1,50597,,In vivo,,Bioavailability in rat (dose 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621978,,,A
6715,Intermediate,,1,,10116.0,10257,1,50597,,In vivo,,Bioavailability in rat (dose 3 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621979,,,A
2932,Intermediate,,1,,10116.0,10258,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621980,,,A
4171,Intermediate,,1,,10116.0,10259,1,50597,,In vivo,,Bioavailability of the compound in rats after administration of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621981,,,A
17509,Intermediate,,1,,10116.0,10260,1,50597,,In vivo,,Bioavailability after administration of 10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621982,,,A
17509,Intermediate,,1,,10116.0,10261,1,50597,,In vivo,,Bioavailability after administration of 2 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL882953,,,A
4527,Intermediate,,1,,10116.0,10262,1,50597,,In vivo,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621983,,,A
4026,Intermediate,,1,,10116.0,10263,1,50597,,In vivo,,Bioavailability in dogs was determined; high,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621984,,,A
6659,Intermediate,,1,,10116.0,10264,1,50597,,In vivo,,Bioavailability in monkey after intravenous administration at 1 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621985,,,A
6659,Intermediate,,1,,10116.0,10265,1,50597,,In vivo,,Bioavailability in monkey after peroral administration at 10 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621986,,,A
6659,Intermediate,,1,,10116.0,10266,1,50597,,In vivo,,Bioavailability in rat after intravenous administration at 1 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621987,,,A
6659,Intermediate,,1,,10116.0,10267,1,50597,,In vivo,,Bioavailability in rat after intravenous administration at 2 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877600,,,F
6659,Intermediate,,1,,10116.0,10268,1,50597,,In vivo,,Bioavailability in rat after peroral administration at 30 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621988,,,A
6659,Intermediate,,1,,10116.0,10269,1,50597,,In vivo,,Bioavailability in rat after peroral administration at at 100 mpk,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621989,,,F
6597,Intermediate,,1,,10116.0,10270,1,50597,,In vivo,,Bioavailability in rats was evaluated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621990,,,A
1202,Intermediate,,1,,10116.0,10271,1,50597,,In vivo,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621991,,,A
1202,Intermediate,,1,,10116.0,10272,1,50597,,In vivo,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621992,,,A
1202,Intermediate,,1,,10116.0,10273,1,50597,,In vivo,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621993,,,A
1202,Intermediate,,1,,10116.0,10274,1,50597,,In vivo,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621994,,,A
5207,Intermediate,,1,,10116.0,10275,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621995,,,A
5970,Intermediate,,1,,10116.0,10276,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621996,,,A
17538,Intermediate,,1,,10116.0,10277,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621997,,,A
17538,Intermediate,,1,,10116.0,10278,1,50597,,In vivo,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621998,,,A
1466,Intermediate,,1,,10116.0,10279,1,50597,,In vivo,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621999,,,A
2879,Intermediate,,1,,10116.0,10280,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622000,,,A
2879,Intermediate,,1,,10116.0,10281,1,50597,,In vivo,,Bioavailability was measured in rat after oral administration; 2-4,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622001,,,A
2879,Intermediate,,1,,10116.0,10282,1,50597,,In vivo,,Bioavailability was measured in rat after oral administration; 3-7,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622002,,,A
3777,Intermediate,,1,,10116.0,10283,1,50597,,In vivo,,Bioavailability in rat (intraduodenal administration),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622003,,,A
3777,Intermediate,,1,,10116.0,10284,1,50597,,In vivo,,Bioavailability in rat (intraduodenal administration),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877601,,,A
3777,Intermediate,,1,,10116.0,10285,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624871,,,A
3777,Intermediate,,1,,10116.0,10286,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622004,,,A
5423,Intermediate,,1,,10116.0,10287,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL882954,,,A
16365,Intermediate,,1,,10116.0,10288,1,50597,,In vivo,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622005,,,A
16365,Intermediate,,1,,10116.0,10289,1,50597,,In vivo,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622006,,,A
4239,Intermediate,,1,,10116.0,10290,1,50597,,In vivo,,Bioavailability was measured in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622007,,,A
5438,Intermediate,,1,,10116.0,10291,1,50597,,In vivo,,Bioavailability was reported,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622008,,,A
5334,Intermediate,,1,,10116.0,10292,1,50597,,In vivo,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622009,,,A
5334,Intermediate,,1,,10116.0,10293,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622010,,,A
4199,Intermediate,,1,,10116.0,10294,1,50597,,In vivo,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622011,,,A
4199,Intermediate,,1,,10116.0,10295,1,50597,,In vivo,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622012,,,A
4199,Intermediate,,1,,10116.0,10296,1,50597,,In vivo,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622013,,,A
4890,Intermediate,,1,,10116.0,10297,1,50597,,In vivo,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622014,,,A
2792,Intermediate,,1,,10116.0,10298,1,50597,,In vivo,,Bioavailability was determined at 3 mg/kg po dose in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624749,,,A
5529,Intermediate,,1,,10116.0,10299,1,50597,,In vivo,,Oral bioavailability in rat (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624750,,,A
6685,Intermediate,,1,,10116.0,10300,1,50597,,In vivo,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624751,,,A
6685,Intermediate,,1,,10116.0,10301,1,50597,,In vivo,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624752,,,A
6685,Intermediate,,1,,10116.0,10302,1,50597,,In vivo,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624753,,,A
6005,Intermediate,,1,,10116.0,10303,1,50597,,In vivo,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624754,,,A
6410,Intermediate,,1,,10116.0,10304,1,50597,,In vivo,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624755,,,A
6410,Intermediate,,1,,10116.0,10305,1,50597,,In vivo,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624756,,,A
6103,Intermediate,,1,,10116.0,10306,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624757,,,A
6410,Intermediate,,1,,10116.0,10307,1,50597,,In vivo,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624758,,,A
6410,Intermediate,,1,,10116.0,10308,1,50597,,In vivo,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622270,,,A
5353,Intermediate,,1,,10116.0,10309,1,50597,,In vivo,,Bioavailability in rat (Sprague-Dawley),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622271,,,A
4727,Intermediate,,1,,10116.0,10310,1,50597,,In vivo,,Bioavailability in rat at the dose of 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622272,,,A
17804,Intermediate,,1,,10116.0,10311,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622273,,,A
5809,Intermediate,,1,,10116.0,10312,1,50597,,In vivo,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622274,,,A
17804,Intermediate,,1,,10116.0,10313,1,50597,,In vivo,,Bioavailability value of compound in rats was determined after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622275,,,A
3634,Intermediate,,1,,10116.0,10314,1,50597,,In vivo,,Oral bioavailability in rat (dose 20 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622276,,,A
3341,Intermediate,,1,,10116.0,10315,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622277,,,A
2690,Intermediate,,1,,10116.0,10316,1,50597,,In vivo,,Oral bioavailability in rat (dose 5 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622278,,,A
3184,Intermediate,,1,,10116.0,10317,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622279,,,A
740,Intermediate,,1,,10116.0,10318,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622280,,,A
1806,Intermediate,,1,,10116.0,10319,1,50597,,In vivo,,Compound was evaluated for oral bioavailability in rats; 15-27 %,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624083,,,A
4891,Intermediate,,1,,10116.0,10320,1,50597,,In vivo,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624084,,,A
3634,Intermediate,,1,,10116.0,10321,1,50597,,In vivo,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624085,,,A
64,Intermediate,,1,,10116.0,10322,1,50597,,In vivo,,Compound was tested for bioavailability in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624086,,,A
4839,Intermediate,,1,,10116.0,10323,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624087,,,A
1094,Intermediate,,1,,10116.0,10324,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624088,,,A
5005,Intermediate,,1,,9544.0,10325,0,22224,,In vivo,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,U,,Macaca mulatta,BAO_0000218,,CHEMBL624089,,,A
5005,Intermediate,,1,,10116.0,10326,0,22224,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL624090,,,A
4687,Intermediate,,1,,10116.0,10327,1,50597,,In vivo,,Evaluated for the bioavailability in rat (in vivo),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624091,,,A
17804,Intermediate,,1,,10116.0,10328,1,50597,,In vivo,,F value of compound in rats was determined after peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624092,,,A
5974,Intermediate,,1,,10116.0,10329,1,50597,,In vivo,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624093,,,A
5974,Intermediate,,1,,10116.0,10330,1,50597,,In vivo,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624094,,,A
5974,Intermediate,,1,,10116.0,10331,1,50597,,In vivo,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624095,,,A
5974,Intermediate,,1,,10116.0,10332,1,50597,,In vivo,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624096,,,A
1088,Intermediate,,1,,10116.0,10333,1,50597,,In vivo,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624097,,,A
1742,Intermediate,,1,,10116.0,10334,1,50597,,In vivo,,Maximum fall in carotid flow in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624098,,,A
4689,Intermediate,,1,,10116.0,10335,1,50597,,In vivo,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874392,,,A
2463,Intermediate,,1,,10116.0,10336,1,50597,,In vivo,,Oral bioavailability in rat (dose 5 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624099,,,A
5654,Intermediate,,1,,10116.0,10337,1,50597,,In vivo,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624100,,,A
5654,Intermediate,,1,,10116.0,10338,1,50597,,In vivo,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624101,,,A
6874,Intermediate,,1,,10116.0,10339,1,50597,,In vivo,,Oral bioavailability in rat (male Wistar),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624102,,,A
5633,Intermediate,,1,,10116.0,10340,1,50597,,In vivo,,Oral bioavailability after administration (30 mg/kg) in rat; good,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624103,,,A
5496,Intermediate,,1,,10116.0,10341,1,50597,,In vivo,,Oral bioavailability at the dose of 2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624104,,,A
2358,Intermediate,,1,,10116.0,10342,1,50597,,In vivo,,Oral bioavailability determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624105,,,A
16456,Intermediate,,1,,10116.0,10343,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624106,,,A
5302,Intermediate,,1,,10116.0,10344,1,50597,,In vivo,,Oral bioavailability in rat (dose single 10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624107,,,A
5302,Intermediate,,1,,10116.0,10345,1,50597,,In vivo,,Oral bioavailability in rat (dose single 10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623943,,,A
5302,Intermediate,,1,,10116.0,10346,1,50597,,In vivo,,Oral bioavailability in rat (dose 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623944,,,A
11020,Intermediate,,1,,10116.0,10347,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623945,,,A
11020,Intermediate,,1,,10116.0,10348,1,50597,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623946,,,A
11020,Intermediate,,1,,10116.0,10349,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623947,,,A
11020,Intermediate,,1,,10116.0,10350,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623948,,,A
11020,Intermediate,,1,,10116.0,10351,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623949,,,A
11020,Intermediate,,1,,10116.0,10352,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623950,,,A
11020,Intermediate,,1,,10116.0,10353,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874398,,,A
11020,Intermediate,,1,,10116.0,10354,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623951,,,A
11020,Intermediate,,1,,10116.0,10355,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623952,,,A
11020,Intermediate,,1,,10116.0,10356,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623953,,,A
11020,Intermediate,,1,,10116.0,10357,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623954,,,A
11020,Intermediate,,1,,10116.0,10358,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623955,,,A
11020,Intermediate,,1,,10116.0,10359,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623956,,,A
11020,Intermediate,,1,,10116.0,10360,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627807,,,A
11020,Intermediate,,1,,10116.0,10361,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627808,,,A
11020,Intermediate,,1,,10116.0,10362,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627809,,,A
11020,Intermediate,,1,,10116.0,10363,1,50597,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627810,,,A
11020,Intermediate,,1,,10116.0,10364,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627811,,,A
11020,Intermediate,,1,,10116.0,10365,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627812,,,A
11020,Intermediate,,1,,10116.0,10366,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627813,,,A
11020,Intermediate,,1,,10116.0,10367,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627814,,,A
11020,Intermediate,,1,,10116.0,10368,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875336,,,A
11020,Intermediate,,1,,10116.0,10369,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627815,,,A
11020,Intermediate,,1,,10116.0,10370,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627816,,,A
11020,Intermediate,,1,,10116.0,10371,1,50597,,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627817,,,A
11020,Intermediate,,1,,10116.0,10372,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627818,,,A
11020,Intermediate,,1,,10116.0,10373,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627819,,,A
11020,Intermediate,,1,,10116.0,10374,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627820,,,A
11020,Intermediate,,1,,10116.0,10375,1,50597,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627821,,,A
11020,Intermediate,,1,,10116.0,10376,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628464,,,A
11020,Intermediate,,1,,10116.0,10377,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626239,,,A
11020,Intermediate,,1,,10116.0,10378,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626240,,,A
11020,Intermediate,,1,,10116.0,10379,1,50597,,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626241,,,A
11020,Intermediate,,1,,10116.0,10380,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626242,,,A
11020,Intermediate,,1,,10116.0,10381,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626243,,,A
11020,Intermediate,,1,,10116.0,10382,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626244,,,A
11020,Intermediate,,1,,10116.0,10383,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626907,,,A
11020,Intermediate,,1,,10116.0,10384,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626908,,,A
11020,Intermediate,,1,,10116.0,10385,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626909,,,A
11020,Intermediate,,1,,10116.0,10386,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626910,,,A
7449,Intermediate,,1,,10116.0,10387,1,50597,,,,Percent total excretion of acetaminophen cysteine conjugate,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875342,,,F
7449,Intermediate,,1,,10116.0,10388,1,50597,,,,Percent total excretion of acetaminophen glucuronide,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626911,,,F
7449,Intermediate,,1,,10116.0,10389,1,50597,,,,Percent total excretion of acetaminophen sulfate,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626912,,,F
7449,Intermediate,,1,,10116.0,10390,1,50597,,,,Percent total excretion of acetaminophen-mercapturic acid,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627065,,,F
3172,Intermediate,,1,,10116.0,10391,1,50597,,,Urine,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627066,,,A
16456,Intermediate,,1,,10116.0,10392,1,50597,,In vivo,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627067,,,A
10839,Autocuration,,1,,8656.0,10393,0,22224,,In vivo,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration,,U,,ratrat,BAO_0000218,2385.0,CHEMBL627068,,,A
10839,Autocuration,,1,,8656.0,10394,0,22224,,In vivo,Muscle tissue,Biodistribution of compound in rat muscle after 5 min of administration.,,U,,ratrat,BAO_0000218,2385.0,CHEMBL627069,,,A
5334,Autocuration,,1,,9940.0,10395,0,22224,,In vivo,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,,CHEMBL627070,,,A
5334,Autocuration,,1,,9940.0,10396,0,22224,,In vivo,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,,CHEMBL627071,,,A
5334,Autocuration,,1,,9940.0,10397,0,22224,,In vivo,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,,CHEMBL627072,,,A
5334,Autocuration,,1,,9940.0,10398,0,22224,,In vivo,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,,CHEMBL627073,,,A
5334,Autocuration,,1,,9940.0,10399,0,22224,,In vivo,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,,CHEMBL625387,,,A
5334,Autocuration,,1,,9940.0,10400,0,22224,,In vivo,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,,CHEMBL625388,,,A
5334,Autocuration,,1,,9940.0,10401,0,22224,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,1969.0,CHEMBL625389,,,A
5334,Autocuration,,1,,9940.0,10402,0,22224,,In vivo,Plasma,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,U,,Ovis aries,BAO_0000218,1969.0,CHEMBL875343,,,A
1735,Intermediate,,1,,8570.0,10403,1,50497,,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,N,,Serpentes,BAO_0000218,,CHEMBL876795,,,A
1469,Intermediate,,1,,8570.0,10404,1,50497,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,N,,Serpentes,BAO_0000218,,CHEMBL626552,,,A
1336,Intermediate,,1,,8570.0,10405,1,50497,,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,N,,Serpentes,BAO_0000218,,CHEMBL626553,,,A
12403,Autocuration,,1,,9606.0,10406,0,22224,,,Plasma,The human biological plasma half life of the compound,,U,,Homo sapiens,BAO_0000366,1969.0,CHEMBL626554,,,A
8151,Intermediate,,1,,10116.0,10407,1,50597,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626555,,,A
8004,Intermediate,,1,,10116.0,10408,1,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626556,,,A
8004,Intermediate,,1,,10116.0,10409,1,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626557,,,A
8004,Intermediate,,1,,10116.0,10410,1,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626558,,,A
8004,Intermediate,,1,,10116.0,10411,1,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626559,,,A
8004,Intermediate,,1,,10116.0,10412,1,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626560,,,A
8004,Intermediate,,1,,10116.0,10413,1,50597,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876803,,,A
8004,Intermediate,,1,,10116.0,10414,1,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627964,,,A
8004,Intermediate,,1,,10116.0,10415,1,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627965,,,A
8004,Intermediate,,1,,10116.0,10416,1,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627966,,,A
8004,Intermediate,,1,,10116.0,10417,1,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627967,,,A
8004,Intermediate,,1,,10116.0,10418,1,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627968,,,A
8004,Intermediate,,1,,10116.0,10419,1,50597,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627969,,,A
8004,Intermediate,,1,,10116.0,10420,1,50597,,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627970,,,A
8004,Intermediate,,1,,10116.0,10421,1,50597,,,Blood,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627971,,,A
8004,Intermediate,,1,,10116.0,10422,1,50597,,,Blood,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627972,,,A
15917,Expert,,1,,9606.0,10423,9,180,,,,Dissociation constant against binding to human cyclophilin A,,D,,Homo sapiens,BAO_0000357,,CHEMBL856029,,,B
12396,Expert,,1,,9913.0,10424,8,11591,,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,H,,Bos taurus,BAO_0000019,,CHEMBL627973,,,B
7065,Autocuration,,1,,,10425,0,22224,,,,-Log C was determined by performing the electroshock minimum test,,U,,,BAO_0000019,,CHEMBL627974,,,A
7065,Autocuration,,1,,,10426,0,22224,,,,-Log C was determined by performing the foot shock test,,U,,,BAO_0000019,,CHEMBL627975,,,A
7065,Autocuration,,1,,,10427,0,22224,,,,-Log C was determined by performing the incl screen test,,U,,,BAO_0000019,,CHEMBL627976,,,A
7065,Autocuration,,1,,,10428,0,22224,,,,-Log C was determined by performing the maximum electroshock test,,U,,,BAO_0000019,,CHEMBL627977,,,A
7065,Autocuration,,1,,,10429,0,22224,,,,-Log C was determined by performing the pentylenetetrazole test,,U,,,BAO_0000019,,CHEMBL627978,,,A
12415,Autocuration,,1,,,10430,0,22224,,,,Tested for experimental arotinoid inhibitory dose,,U,,,BAO_0000019,,CHEMBL627979,,,A
10256,Autocuration,,1,,,10431,0,22224,,,,Negative log transformed activity,,U,,,BAO_0000019,,CHEMBL876804,,,A
7991,Autocuration,,1,,,10432,0,22224,,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,U,,,BAO_0000019,,CHEMBL627980,,,A
14342,Intermediate,,1,,10141.0,10433,1,50512,,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,N,,Cavia porcellus,BAO_0000218,,CHEMBL627981,,,A
14342,Intermediate,,1,,10141.0,10434,1,50512,,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,N,,Cavia porcellus,BAO_0000218,,CHEMBL627982,,,A
14342,Intermediate,,1,,10141.0,10435,1,50512,,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,N,,Cavia porcellus,BAO_0000218,,CHEMBL627983,,,A
14342,Intermediate,,1,,10141.0,10436,1,50512,,,Ileum,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,N,,Cavia porcellus,BAO_0000218,2116.0,CHEMBL627984,,,A
6047,Autocuration,,1,,,10437,0,22229,,,,Solubility in water was determined; values expressed as -log,,U,,,BAO_0000100,,CHEMBL627985,,,P
17269,Autocuration,,1,,,10438,0,22224,,,,Ratio of Kcat to that of Km was determined,,U,,,BAO_0000019,,CHEMBL627986,,,A
10026,Autocuration,,1,,,10439,0,22224,,,,Observed first order rate constant,,U,,,BAO_0000019,,CHEMBL627987,,,A
14583,Autocuration,,1,,,10440,0,22224,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,U,,,BAO_0000019,,CHEMBL627988,,,A
2661,Intermediate,,1,,10116.0,10441,1,50597,,In vivo,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627989,,,A
2661,Intermediate,,1,,10116.0,10442,1,50597,,In vivo,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627990,,,A
4029,Intermediate,,1,,10116.0,10443,1,50597,,In vivo,,Oral Bioavailability after administration of 10 mg/kg in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876805,,,A
17735,Intermediate,,1,,10116.0,10444,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627991,,,A
4576,Intermediate,,1,,10116.0,10445,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627992,,,A
17582,Intermediate,,1,,10116.0,10446,1,50597,,In vivo,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627993,,,A
17651,Intermediate,,1,,10116.0,10447,1,50597,,In vivo,,Oral bioavailability at 1 mg/kg was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622817,,,A
17651,Intermediate,,1,,10116.0,10448,1,50597,,In vivo,,Oral bioavailability at 10 mg/kg was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622818,,,A
17670,Intermediate,,1,,10116.0,10449,1,50597,,In vivo,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622819,,,A
5045,Intermediate,,1,,10116.0,10450,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL872267,,,A
1696,Intermediate,,1,,10116.0,10451,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622820,,,A
17764,Intermediate,,1,,10116.0,10452,1,50597,,In vivo,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622821,,,A
6448,Intermediate,,1,,10116.0,10453,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622822,,,A
6596,Intermediate,,1,,10116.0,10454,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622823,,,A
17547,Intermediate,,1,,10116.0,10455,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622824,,,A
17771,Intermediate,,1,,10116.0,10456,1,50597,,In vivo,,Oral bioavailability in rat at a dose of 3 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622825,,,A
6495,Intermediate,,1,,10116.0,10457,1,50597,,In vivo,,Oral bioavailability in rat after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622901,,,A
4558,Intermediate,,1,,10116.0,10458,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622902,,,A
17596,Intermediate,,1,,10116.0,10459,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621844,,,A
6827,Intermediate,,1,,10116.0,10460,1,50597,,In vivo,,Oral bioavailability in Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621845,,,A
4026,Intermediate,,1,,10116.0,10461,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621846,,,A
10,Intermediate,,1,,10116.0,10462,1,50597,,In vivo,,Oral bioavailability in rat (dose 30 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621847,,,A
17717,Intermediate,,1,,10116.0,10463,1,50597,,In vivo,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877609,,,A
17717,Intermediate,,1,,10116.0,10464,1,50597,,In vivo,,Bioavailability in rat (dose 3 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621848,,,A
17717,Intermediate,,1,,10116.0,10465,1,50597,,In vivo,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621849,,,A
17717,Intermediate,,1,,10116.0,10466,1,50597,,In vivo,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622030,,,A
4796,Intermediate,,1,,10116.0,10467,1,50597,,In vivo,,Percent oral bioavailability determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622031,,,A
4883,Intermediate,,1,,10116.0,10468,1,50597,,In vivo,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622032,,,A
2137,Intermediate,,1,,10116.0,10469,1,50597,,In vivo,,The compound was evaluated for bioavailability in rats; 32-51,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622033,,,A
2959,Intermediate,,1,,10116.0,10470,1,50597,,In vivo,,Bioavailability in rat (dose 20 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622034,,,A
1361,Intermediate,,1,,10116.0,10471,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622035,,,A
4727,Intermediate,,1,,10116.0,10472,1,50597,,In vivo,,Bioavailability percent in rat at the dose of 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL882966,,,A
16423,Intermediate,,1,,10116.0,10473,1,50597,,In vivo,,Bioavailability was evaluated after 20 uM/kg of peroral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622036,,,A
5206,Intermediate,,1,,10116.0,10474,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622037,,,A
6448,Intermediate,,1,,10116.0,10475,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622038,,,A
17723,Intermediate,,1,,10116.0,10476,1,50597,,In vivo,,Bioavailability in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622039,,,A
17738,Intermediate,,1,,10116.0,10477,1,50597,,In vivo,Blood,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622040,,,A
17738,Intermediate,,1,,10116.0,10478,1,50597,,In vivo,Blood,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622041,,,A
17738,Intermediate,,1,,10116.0,10479,1,50597,,In vivo,Blood,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622042,,,A
17738,Intermediate,,1,,10116.0,10480,1,50597,,In vivo,Blood,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622043,,,A
17738,Intermediate,,1,,10116.0,10481,1,50597,,In vivo,Blood,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622044,,,A
17738,Intermediate,,1,,10116.0,10482,1,50597,,In vivo,Bone,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL622045,,,A
17738,Intermediate,,1,,10116.0,10483,1,50597,,In vivo,Bone,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL622046,,,A
17738,Intermediate,,1,,10116.0,10484,1,50597,,In vivo,Bone,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL622047,,,A
17738,Intermediate,,1,,10116.0,10485,1,50597,,In vivo,Bone,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL877610,,,A
17738,Intermediate,,1,,10116.0,10486,1,50597,,In vivo,Brain,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622048,,,A
17738,Intermediate,,1,,10116.0,10487,1,50597,,In vivo,Brain,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622049,,,A
17738,Intermediate,,1,,10116.0,10488,1,50597,,In vivo,Brain,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622050,,,A
17738,Intermediate,,1,,10116.0,10489,1,50597,,In vivo,Brain,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622051,,,A
17738,Intermediate,,1,,10116.0,10490,1,50597,,In vivo,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622052,,,A
17738,Intermediate,,1,,10116.0,10491,1,50597,,In vivo,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622053,,,A
17738,Intermediate,,1,,10116.0,10492,1,50597,,In vivo,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622054,,,A
17738,Intermediate,,1,,10116.0,10493,1,50597,,In vivo,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622055,,,A
5237,Intermediate,,1,,10116.0,10494,1,50597,,In vivo,,Oral bioavailability in rats was determined; High,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622056,,,A
5503,Intermediate,,1,,10116.0,10495,1,50597,,In vivo,,Oral bioavailability in the rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622057,,,A
15765,Intermediate,,1,,10116.0,10496,1,50597,,In vivo,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628008,,,A
15660,Intermediate,,1,,10116.0,10497,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622058,,,A
5978,Intermediate,,1,,10116.0,10498,1,50597,,In vivo,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622059,,,A
5978,Intermediate,,1,,10116.0,10499,1,50597,,In vivo,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622060,,,A
5978,Intermediate,,1,,10116.0,10500,1,50597,,In vivo,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622061,,,A
5978,Intermediate,,1,,10116.0,10501,1,50597,,In vivo,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622062,,,A
5656,Intermediate,,1,,10116.0,10502,1,50597,,In vivo,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622063,,,A
3598,Expert,,1,,10116.0,10503,1,50597,,In vivo,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877611,,,A
4216,Intermediate,,1,,10116.0,10504,1,50597,,In vivo,,Oral bioavailability of compound in Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622064,,,A
17839,Intermediate,,1,,10116.0,10505,1,50597,,In vivo,,Oral bioavailability of compound in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622065,,,A
6570,Intermediate,,1,,10116.0,10506,1,50597,,In vivo,,Oral bioavailability in rat (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622066,,,A
5334,Intermediate,,1,,10116.0,10507,1,50597,,In vivo,,Oral bioavailability of compound in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622067,,,A
6886,Intermediate,,1,,10116.0,10508,1,50597,,In vivo,,Oral bioavailability of compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622068,,,A
5210,Intermediate,,1,,10116.0,10509,1,50597,,In vivo,,Oral bioavailability of compound was determined in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622069,,,A
4170,Intermediate,,1,,10116.0,10510,1,50597,,In vivo,,Oral bioavailability at a dose of 30 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624796,,,A
6028,Intermediate,,1,,10116.0,10511,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624797,,,A
6028,Intermediate,,1,,10116.0,10512,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623053,,,A
6078,Intermediate,,1,,10116.0,10513,1,50597,,In vivo,,Oral bioavailability evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623054,,,A
6168,Intermediate,,1,,10116.0,10514,1,50597,,In vivo,,Oral bioavailability in fasted rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623055,,,A
6168,Intermediate,,1,,10116.0,10515,1,50597,,In vivo,,Oral bioavailability in fed rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623056,,,A
5160,Intermediate,,1,,10116.0,10516,1,50597,,In vivo,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623057,,,A
6057,Intermediate,,1,,10116.0,10517,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623058,,,A
6535,Intermediate,,1,,10116.0,10518,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623059,,,A
6535,Intermediate,,1,,10116.0,10519,1,50597,,In vivo,,Oral bioavailability in rat after administration of 10 mg/kg po,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623060,,,A
4194,Intermediate,,1,,10116.0,10520,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623061,,,A
6230,Intermediate,,1,,10116.0,10521,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623062,,,A
6619,Intermediate,,1,,10116.0,10522,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623063,,,A
17607,Intermediate,,1,,10116.0,10523,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623064,,,A
4942,Intermediate,,1,,10116.0,10524,1,50597,,In vivo,,Oral bioavailability in ratrs,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623065,,,A
4942,Intermediate,,1,,10116.0,10525,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623066,,,A
6646,Intermediate,,1,,10116.0,10526,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623067,,,A
5237,Intermediate,,1,,10116.0,10527,1,50597,,In vivo,,Oral bioavailability in rats was determined; High,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623068,,,A
6646,Intermediate,,1,,10116.0,10528,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623069,,,A
4449,Intermediate,,1,,10116.0,10529,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623070,,,A
6057,Intermediate,,1,,10116.0,10530,1,50597,,In vivo,,Oral bioavailability was calculated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623071,,,A
2552,Intermediate,,1,,10116.0,10531,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623072,,,A
5496,Intermediate,,1,,10116.0,10532,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623073,,,A
6484,Intermediate,,1,,10116.0,10533,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623074,,,A
6485,Intermediate,,1,,10116.0,10534,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623075,,,A
6616,Intermediate,,1,,10116.0,10535,1,50597,,In vivo,,Oral bioavailability after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623076,,,A
4969,Intermediate,,1,,10116.0,10536,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623077,,,A
5862,Intermediate,,1,,10116.0,10537,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623078,,,A
4514,Intermediate,,1,,10116.0,10538,1,50597,,In vivo,,Oral bioavailability in Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623079,,,A
4514,Intermediate,,1,,10116.0,10539,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623080,,,A
4514,Intermediate,,1,,10116.0,10540,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623081,,,A
5546,Intermediate,,1,,10116.0,10541,1,50597,,In vivo,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623082,,,A
6168,Intermediate,,1,,10116.0,10542,1,50597,,In vivo,,Oral bioavailability in fasted rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874400,,,A
6168,Intermediate,,1,,10116.0,10543,1,50597,,In vivo,,Oral bioavailability in fed rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623083,,,A
3624,Intermediate,,1,,10116.0,10544,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623084,,,A
5213,Intermediate,,1,,10116.0,10545,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623085,,,A
5496,Intermediate,,1,,10116.0,10546,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623086,,,A
5553,Intermediate,,1,,10116.0,10547,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623087,,,A
5833,Intermediate,,1,,10116.0,10548,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623088,,,A
5836,Intermediate,,1,,10116.0,10549,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623089,,,A
5865,Intermediate,,1,,10116.0,10550,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623090,,,A
5960,Intermediate,,1,,10116.0,10551,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623091,,,A
6249,Intermediate,,1,,10116.0,10552,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623092,,,A
6448,Intermediate,,1,,10116.0,10553,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623093,,,A
6453,Intermediate,,1,,10116.0,10554,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874401,,,A
6640,Intermediate,,1,,10116.0,10555,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623094,,,A
17607,Intermediate,,1,,10116.0,10556,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623095,,,A
5939,Intermediate,,1,,10116.0,10557,1,50597,,In vivo,,Oral bioavailability in rat after peroral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623096,,,A
5939,Intermediate,,1,,10116.0,10558,1,50597,,In vivo,,Oral bioavailability in rat after peroral administration at 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624913,,,A
6281,Intermediate,,1,,10116.0,10559,1,50597,,In vivo,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624914,,,A
5874,Intermediate,,1,,10116.0,10560,1,50597,,In vivo,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624915,,,A
5213,Intermediate,,1,,10116.0,10561,1,50597,,In vivo,,Oral bioavailability in rat; Not measured,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624916,,,A
4964,Intermediate,,1,,10116.0,10562,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624917,,,A
11020,Intermediate,,1,,10116.0,10563,1,50597,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625157,,,A
6251,Intermediate,,1,,10116.0,10564,1,50597,,,Liver,In vitro metabolic potential in rat liver microsomes,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625158,,,A
1568,Intermediate,,1,,10116.0,10565,1,50597,,In vivo,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625159,,,A
3032,Intermediate,,1,,10116.0,10566,1,50597,,In vivo,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625160,,,A
3748,Intermediate,,1,,10116.0,10567,1,50597,,In vivo,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625161,,,A
401,Intermediate,,1,,10116.0,10568,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625162,,,A
6512,Intermediate,,1,,10116.0,10569,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625163,,,A
17617,Intermediate,,1,,10116.0,10570,1,50597,,In vivo,,Oral bioavailability in rats at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625164,,,A
6679,Intermediate,,1,,10116.0,10571,1,50597,,In vivo,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625165,,,A
6742,Intermediate,,1,,10116.0,10572,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625166,,,A
589,Intermediate,,1,,10116.0,10573,1,50597,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625167,,,A
589,Intermediate,,1,,10116.0,10574,1,50597,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625168,,,A
3185,Intermediate,,1,,10116.0,10575,1,50597,,In vivo,,Plasma clearance of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625169,,,A
17596,Intermediate,,1,,10116.0,10576,1,50597,,In vivo,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626264,,,A
2713,Intermediate,,1,,10116.0,10577,1,50597,,In vivo,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626265,,,A
12500,Intermediate,,1,,10116.0,10578,1,50597,,In vivo,Plasma,The compound was tested for plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626266,,,A
12500,Intermediate,,1,,10116.0,10579,1,50597,,In vivo,Plasma,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626267,,,A
2713,Intermediate,,1,,10116.0,10580,1,50597,,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626268,,,A
1446,Intermediate,,1,,10116.0,10581,1,50597,,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626269,,,A
6227,Intermediate,,1,,10116.0,10582,1,50597,,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626270,,,A
4709,Intermediate,,1,,10116.0,10583,1,50597,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626271,,,A
5510,Intermediate,,1,,10116.0,10584,1,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626272,,,A
5510,Intermediate,,1,,10116.0,10585,1,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626273,,,A
5510,Intermediate,,1,,10116.0,10586,1,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875346,,,A
5510,Intermediate,,1,,10116.0,10587,1,50597,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626274,,,A
4514,Intermediate,,1,,10116.0,10588,1,50597,,,,Compound was tested for protein binding in rat plasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626275,,,A
2713,Intermediate,,1,,10116.0,10589,1,50597,,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624646,,,A
2713,Intermediate,,1,,10116.0,10590,1,50597,,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624647,,,A
5340,Intermediate,,1,,10116.0,10591,1,50597,,,Liver,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624648,,,A
12058,Intermediate,,1,,10116.0,10592,1,50597,,,,Area under curve ratio was determined (po/iv) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624649,,,A
11195,Intermediate,,1,,10116.0,10593,1,50597,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624650,,,A
11195,Intermediate,,1,,10116.0,10594,1,50597,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624651,,,A
11195,Intermediate,,1,,10116.0,10595,1,50597,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624652,,,A
6495,Intermediate,,1,,10116.0,10596,1,50597,,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624653,,,A
6078,Intermediate,,1,,10116.0,10597,1,50597,,,,Ratio of AUCbrain to AUCplasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624654,,,A
5656,Intermediate,,1,,10116.0,10598,1,50597,,,,Ratio of brain to plasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624655,,,A
4910,Intermediate,,1,,10116.0,10599,1,50597,,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624656,,,A
4910,Intermediate,,1,,10116.0,10600,1,50597,,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624657,,,A
4910,Intermediate,,1,,10116.0,10601,1,50597,,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624658,,,A
10130,Intermediate,,1,,10116.0,10602,1,50597,,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624659,,,A
10130,Intermediate,,1,,10116.0,10603,1,50597,,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624660,,,A
10130,Intermediate,,1,,10116.0,10604,1,50597,,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624661,,,A
5213,Intermediate,,1,,10116.0,10605,1,50597,,,,Steady state brain :blood ratio was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624662,,,A
4910,Intermediate,,1,,10116.0,10606,1,50597,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625199,,,A
4910,Intermediate,,1,,10116.0,10607,1,50597,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625200,,,A
4910,Intermediate,,1,,10116.0,10608,1,50597,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625201,,,A
4910,Intermediate,,1,,10116.0,10609,1,50597,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625202,,,A
2083,Intermediate,,1,,10116.0,10610,1,50597,,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625203,,,A
2082,Intermediate,,1,,10116.0,10611,1,50597,,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625204,,,A
2082,Intermediate,,1,,10116.0,10612,1,50597,,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625205,,,A
6351,Intermediate,,1,,10116.0,10613,1,50597,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625206,,,A
14583,Autocuration,,1,,,10614,0,22224,,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,U,,,BAO_0000019,,CHEMBL625207,,,A
14583,Autocuration,,1,,,10615,0,22224,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,U,,,BAO_0000019,,CHEMBL625208,,,A
4608,Intermediate,,1,,9606.0,10616,1,50587,Caco-2,,,In vivo absorption in Caco-2 cell line monolayers was determined,,N,495.0,Homo sapiens,BAO_0000218,,CHEMBL625209,,,A
13668,Autocuration,,1,,,10617,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625210,,,P
5669,Intermediate,,1,,10116.0,10618,1,50597,,,,Area under curve was determine after peroral administration at 10 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625211,,,A
5669,Intermediate,,1,,9544.0,10619,1,50797,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,N,,Macaca mulatta,BAO_0000218,,CHEMBL625212,,,A
5669,Intermediate,,1,,10116.0,10620,1,50597,,,,Area under curve was determine after peroral administration at 160 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625213,,,A
5669,Intermediate,,1,,10116.0,10621,1,50597,,,,Area under curve was determine after peroral administration at 20 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625214,,,A
5669,Intermediate,,1,,10116.0,10622,1,50597,,,,Area under curve was determine after peroral administration at 50 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874542,,,A
6472,Autocuration,,1,,,10623,0,22229,,,,Calculated partition coefficient (clogP) (AlogP),,U,,,BAO_0000100,,CHEMBL625215,,,P
15106,Autocuration,,1,,,10624,0,22224,,,,Activated partial thromboplastin time measured,,U,,,BAO_0000019,,CHEMBL625216,,,A
15207,Autocuration,,1,,,10625,0,22224,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,U,,,BAO_0000100,,CHEMBL625217,,,P
15207,Autocuration,,1,,,10626,0,22224,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,U,,,BAO_0000100,,CHEMBL625218,,,P
13941,Intermediate,,1,,9615.0,10627,1,50588,,,Plasma,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622864,,,A
13941,Intermediate,,1,,10116.0,10628,1,50597,,,Plasma,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622865,,,A
13941,Intermediate,,1,,10116.0,10629,1,50597,,,Plasma,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622866,,,A
13941,Intermediate,,1,,9615.0,10630,1,50588,,,Plasma,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622867,,,A
15240,Intermediate,,1,,10141.0,10631,1,50512,,,Plasma,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,N,,Cavia porcellus,BAO_0000218,1969.0,CHEMBL876808,,,A
10655,Autocuration,,1,,,10632,0,22224,,,Brain,AUC in brain,,U,,,BAO_0000019,955.0,CHEMBL627725,,,A
10655,Autocuration,,1,,,10633,0,22224,,,Serum,AUC in serum,,U,,,BAO_0000019,1977.0,CHEMBL627726,,,A
6504,Autocuration,,1,,,10634,0,22224,,,Plasma,AUC was determined,,U,,,BAO_0000019,1969.0,CHEMBL627727,,,A
10615,Autocuration,,1,,,10635,0,22224,,,Plasma,AUC of the compound.,,U,,,BAO_0000019,1969.0,CHEMBL627728,,,A
10353,Autocuration,,1,,,10636,0,22224,,,Plasma,AUC value (0-4 hr),,U,,,BAO_0000019,1969.0,CHEMBL627729,,,A
14907,Autocuration,,1,,,10637,0,22224,,,Plasma,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,U,,,BAO_0000019,1969.0,CHEMBL627730,,,A
14907,Autocuration,,1,,,10638,0,22224,,,Plasma,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,U,,,BAO_0000019,1969.0,CHEMBL627731,,,A
14907,Autocuration,,1,,,10639,0,22224,,,Plasma,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,U,,,BAO_0000019,1969.0,CHEMBL627732,,,A
14907,Autocuration,,1,,,10640,0,22224,,,Plasma,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,U,,,BAO_0000019,1969.0,CHEMBL627733,,,A
16359,Intermediate,,1,,10116.0,10641,1,50597,,,Plasma,AUC(area under curve) was determined after intravenous administration in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627734,,,A
16359,Intermediate,,1,,10116.0,10642,1,50597,,,Plasma,AUC(area under curve) was determined after oral administration in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627735,,,A
15240,Intermediate,,1,,10141.0,10643,1,50512,,,Plasma,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,N,,Cavia porcellus,BAO_0000218,1969.0,CHEMBL627736,,,A
15240,Intermediate,,1,,10116.0,10644,1,50597,,,Plasma,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876809,,,A
15469,Autocuration,,1,,,10645,0,22224,,,,Area Under Curve after oral dosing of 100 uM/Kg,,U,,,BAO_0000019,,CHEMBL627737,,,A
15469,Autocuration,,1,,,10646,0,22224,,,,Area Under Curve after oral dosing of 30 uM/Kg,,U,,,BAO_0000019,,CHEMBL627738,,,A
13520,Autocuration,,1,,,10647,0,22224,,,,Area Under Curve was measured by ploting the graph between concentration verses time,,U,,,BAO_0000019,,CHEMBL627739,,,A
17025,Intermediate,,1,,9615.0,10648,1,50588,,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626143,,,A
17025,Autocuration,,1,,314293.0,10649,0,22224,,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,U,,Simiiformes,BAO_0000218,,CHEMBL626144,,,A
17025,Intermediate,,1,,9986.0,10650,1,50592,,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626145,,,A
17025,Intermediate,,1,,10116.0,10651,1,50597,,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626146,,,A
12032,Intermediate,,1,,10116.0,10652,1,50597,,,Blood,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626147,,,A
10291,Autocuration,,1,,,10653,0,22224,,,,Area under curve (AUC) was determined,,U,,,BAO_0000019,,CHEMBL626148,,,A
5767,Autocuration,,1,,,10654,0,22224,,,,Area under curve (AUC) following ip administration at 1 mg/kg,,U,,,BAO_0000218,,CHEMBL626149,,,A
1434,Autocuration,,1,,,10655,0,22224,,,,Area under curve (AUC) was determined; ND is Not determined,,U,,,BAO_0000019,,CHEMBL626150,,,A
14925,Intermediate,,1,,9615.0,10656,1,50588,,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626151,,,A
14925,Intermediate,,1,,9615.0,10657,1,50588,,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626152,,,A
14925,Intermediate,,1,,9615.0,10658,1,50588,,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626153,,,A
1434,Autocuration,,1,,,10659,0,22224,,,,Area under curve (AUR) was determined,,U,,,BAO_0000019,,CHEMBL626154,,,A
11883,Autocuration,,1,,,10660,0,22224,,,,Area under curve at 1 uM/dg administered intravenously,,U,,,BAO_0000019,,CHEMBL626155,,,A
11883,Autocuration,,1,,,10661,0,22224,,,,Area under curve at 10 uM/dg administered perorally,,U,,,BAO_0000019,,CHEMBL626156,,,A
11883,Autocuration,,1,,,10662,0,22224,,,,Area under curve at 2 uM/dg administered intravenously,,U,,,BAO_0000019,,CHEMBL626157,,,A
11883,Autocuration,,1,,,10663,0,22224,,,,Area under curve at 20 uM/dg administered perorally,,U,,,BAO_0000019,,CHEMBL626158,,,A
15233,Intermediate,,1,,9615.0,10664,1,50588,,,,Area under curve at a peroral dose of 3 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626159,,,A
15233,Intermediate,,1,,10116.0,10665,1,50597,,,,Area under curve at a peroral dose of 3 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626160,,,A
15233,Intermediate,,1,,9615.0,10666,1,50588,,,,Area under curve at an iv dose of 1 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626161,,,A
15233,Intermediate,,1,,10116.0,10667,1,50597,,,,Area under curve at an iv dose of 1 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626162,,,A
12978,Autocuration,,1,,,10668,0,22224,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,U,,,BAO_0000019,,CHEMBL626163,,,A
12978,Autocuration,,1,,,10669,0,22224,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,U,,,BAO_0000019,,CHEMBL626164,,,A
11355,Intermediate,,1,,10090.0,10670,1,50594,,,,Area under curve measured as conc vs time after intravenous administration to mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL626165,,,A
11355,Intermediate,,1,,10090.0,10671,1,50594,,,,Area under curve measured as conc vs time after peroral administration to mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL626166,,,A
12923,Intermediate,,1,,9615.0,10672,1,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626167,,,A
12923,Intermediate,,1,,9615.0,10673,1,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626168,,,A
12923,Intermediate,,1,,9615.0,10674,1,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL877463,,,A
12923,Intermediate,,1,,9615.0,10675,1,50588,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626169,,,A
17738,Intermediate,,1,,10116.0,10676,1,50597,,In vivo,Heart,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626170,,,A
17738,Intermediate,,1,,10116.0,10677,1,50597,,In vivo,Heart,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626171,,,A
17738,Intermediate,,1,,10116.0,10678,1,50597,,In vivo,Heart,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626172,,,A
17738,Intermediate,,1,,10116.0,10679,1,50597,,In vivo,Heart,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626173,,,A
17738,Intermediate,,1,,10116.0,10680,1,50597,,In vivo,Kidney,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626174,,,A
17738,Intermediate,,1,,10116.0,10681,1,50597,,In vivo,Kidney,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626175,,,A
17738,Intermediate,,1,,10116.0,10682,1,50597,,In vivo,Kidney,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626176,,,A
17738,Intermediate,,1,,10116.0,10683,1,50597,,In vivo,Kidney,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626177,,,A
17738,Intermediate,,1,,10116.0,10684,1,50597,,In vivo,Kidney,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622499,,,A
17738,Intermediate,,1,,10116.0,10685,1,50597,,In vivo,Liver,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622500,,,A
17738,Intermediate,,1,,10116.0,10686,1,50597,,In vivo,Liver,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622501,,,A
17738,Intermediate,,1,,10116.0,10687,1,50597,,In vivo,Liver,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622502,,,A
17738,Intermediate,,1,,10116.0,10688,1,50597,,In vivo,Liver,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622503,,,A
17738,Intermediate,,1,,10116.0,10689,1,50597,,In vivo,Liver,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL877614,,,A
17738,Intermediate,,1,,10116.0,10690,1,50597,,In vivo,Lung,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624839,,,A
17738,Intermediate,,1,,10116.0,10691,1,50597,,In vivo,Lung,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624840,,,A
17738,Intermediate,,1,,10116.0,10692,1,50597,,In vivo,Lung,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624841,,,A
17738,Intermediate,,1,,10116.0,10693,1,50597,,In vivo,Lung,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624842,,,A
17738,Intermediate,,1,,10116.0,10694,1,50597,,In vivo,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624843,,,A
17738,Intermediate,,1,,10116.0,10695,1,50597,,In vivo,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624844,,,A
17738,Intermediate,,1,,10116.0,10696,1,50597,,In vivo,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624845,,,A
17738,Intermediate,,1,,10116.0,10697,1,50597,,In vivo,Muscle tissue,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL621904,,,A
11195,Intermediate,,1,,10116.0,10698,1,50597,,In vivo,Blood,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621905,,,A
11195,Intermediate,,1,,10116.0,10699,1,50597,,In vivo,Blood,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL874382,,,A
11195,Intermediate,,1,,10116.0,10700,1,50597,,In vivo,Blood,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL621906,,,A
11195,Intermediate,,1,,10116.0,10701,1,50597,,In vivo,Brain,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL621907,,,A
11195,Intermediate,,1,,10116.0,10702,1,50597,,In vivo,Brain,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622096,,,A
11195,Intermediate,,1,,10116.0,10703,1,50597,,In vivo,Brain,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622097,,,A
11195,Intermediate,,1,,10116.0,10704,1,50597,,In vivo,Heart,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622098,,,A
11195,Intermediate,,1,,10116.0,10705,1,50597,,In vivo,Heart,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622099,,,A
11195,Intermediate,,1,,10116.0,10706,1,50597,,In vivo,Heart,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622100,,,A
11195,Intermediate,,1,,10116.0,10707,1,50597,,In vivo,Kidney,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622101,,,A
11195,Intermediate,,1,,10116.0,10708,1,50597,,In vivo,Kidney,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622102,,,A
11195,Intermediate,,1,,10116.0,10709,1,50597,,In vivo,Kidney,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622103,,,A
11195,Intermediate,,1,,10116.0,10710,1,50597,,In vivo,Liver,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622104,,,A
11195,Intermediate,,1,,10116.0,10711,1,50597,,In vivo,Liver,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622105,,,A
11195,Intermediate,,1,,10116.0,10712,1,50597,,In vivo,Liver,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622106,,,A
11195,Intermediate,,1,,10116.0,10713,1,50597,,In vivo,Lung,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622107,,,A
11195,Intermediate,,1,,10116.0,10714,1,50597,,In vivo,Lung,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622108,,,A
11195,Intermediate,,1,,10116.0,10715,1,50597,,In vivo,Lung,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622109,,,A
11195,Intermediate,,1,,10116.0,10716,1,50597,,In vivo,Muscle tissue,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622110,,,A
11195,Intermediate,,1,,10116.0,10717,1,50597,,In vivo,Muscle tissue,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622111,,,A
11195,Intermediate,,1,,10116.0,10718,1,50597,,In vivo,Muscle tissue,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL874383,,,A
11195,Intermediate,,1,,10116.0,10719,1,50597,,In vivo,Zone of skin,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL622112,,,A
11195,Intermediate,,1,,10116.0,10720,1,50597,,In vivo,Zone of skin,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL622113,,,A
11195,Intermediate,,1,,10116.0,10721,1,50597,,In vivo,Zone of skin,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL622114,,,A
11195,Intermediate,,1,,10116.0,10722,1,50597,,In vivo,Spleen,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622115,,,A
11195,Intermediate,,1,,10116.0,10723,1,50597,,In vivo,Spleen,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622116,,,A
6193,Intermediate,,1,,10116.0,10724,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622117,,,A
6803,Intermediate,,1,,10116.0,10725,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622118,,,A
6647,Intermediate,,1,,10116.0,10726,1,50597,,In vivo,,Oral bioavailability in rats at 6 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622119,,,A
6647,Intermediate,,1,,10116.0,10727,1,50597,,In vivo,,Oral bioavailability in rat (dose 6 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622120,,,A
6647,Intermediate,,1,,10116.0,10728,1,50597,,In vivo,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622121,,,A
6640,Intermediate,,1,,10116.0,10729,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622122,,,A
6641,Intermediate,,1,,10116.0,10730,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622123,,,A
6641,Intermediate,,1,,10116.0,10731,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622124,,,A
6642,Intermediate,,1,,10116.0,10732,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622125,,,A
5472,Intermediate,,1,,10116.0,10733,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622126,,,A
6141,Intermediate,,1,,10116.0,10734,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620455,,,A
4390,Intermediate,,1,,10116.0,10735,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620456,,,A
5472,Intermediate,,1,,10116.0,10736,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620457,,,A
5472,Intermediate,,1,,10116.0,10737,1,50597,,In vivo,,Oral bioavailability was evaluated; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620458,,,A
5438,Intermediate,,1,,10116.0,10738,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620459,,,A
4883,Intermediate,,1,,10116.0,10739,1,50597,,In vivo,,Oral bioavailability in rat by oral dosing,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620460,,,A
1908,Intermediate,,1,,10116.0,10740,1,50597,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620461,,,A
4853,Intermediate,,1,,10116.0,10741,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620462,,,A
4853,Intermediate,,1,,10116.0,10742,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620463,,,A
4853,Intermediate,,1,,10116.0,10743,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620464,,,A
4853,Intermediate,,1,,10116.0,10744,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620465,,,A
4853,Intermediate,,1,,10116.0,10745,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620466,,,A
4853,Intermediate,,1,,10116.0,10746,1,50597,,In vivo,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620467,,,A
4853,Intermediate,,1,,10116.0,10747,1,50597,,In vivo,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620468,,,A
12873,Intermediate,,1,,10116.0,10748,1,50597,,In vivo,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620469,,,A
12873,Intermediate,,1,,10116.0,10749,1,50597,,In vivo,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620470,,,A
3169,Intermediate,,1,,10116.0,10750,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620471,,,A
6305,Intermediate,,1,,10116.0,10751,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620472,,,A
4762,Intermediate,,1,,10116.0,10752,1,50597,,In vivo,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620473,,,A
17847,Intermediate,,1,,10116.0,10753,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620474,,,A
6211,Intermediate,,1,,10116.0,10754,1,50597,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620475,,,A
6011,Intermediate,,1,,10116.0,10755,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620476,,,A
6317,Intermediate,,1,,10116.0,10756,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620477,,,A
6644,Intermediate,,1,,10116.0,10757,1,50597,,In vivo,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620478,,,A
6644,Intermediate,,1,,10116.0,10758,1,50597,,In vivo,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618768,,,A
6644,Intermediate,,1,,10116.0,10759,1,50597,,In vivo,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618769,,,A
6644,Intermediate,,1,,10116.0,10760,1,50597,,In vivo,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618770,,,A
6113,Intermediate,,1,,10116.0,10761,1,50597,,In vivo,,Oral bioavailability (dose 20 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618771,,,A
5937,Intermediate,,1,,10116.0,10762,1,50597,,In vivo,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618772,,,A
5711,Intermediate,,1,,10116.0,10763,1,50597,,In vivo,,Oral bioavailability in rat at 10 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618773,,,A
17717,Intermediate,,1,,10116.0,10764,1,50597,,In vivo,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875842,,,A
17717,Intermediate,,1,,10116.0,10765,1,50597,,In vivo,,Bioavailability in rat (dose 3 mg/kg i.v.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618774,,,A
17717,Intermediate,,1,,10116.0,10766,1,50597,,In vivo,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618775,,,A
17717,Intermediate,,1,,10116.0,10767,1,50597,,In vivo,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618776,,,A
4722,Intermediate,,1,,10116.0,10768,1,50597,,In vivo,,Percent bioavailability (F) in rats after iv administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618777,,,A
4722,Intermediate,,1,,10116.0,10769,1,50597,,In vivo,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618778,,,A
4353,Intermediate,,1,,10116.0,10770,1,50597,,In vivo,,Bioavailability in rat (dose 5 uM/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618779,,,A
15662,Intermediate,,1,,10116.0,10771,1,50597,,In vivo,,Oral bioavailability,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618780,,,A
4756,Intermediate,,1,,10116.0,10772,1,50597,,In vivo,,Bioavailability in rat (dose 2 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618781,,,A
4756,Intermediate,,1,,10116.0,10773,1,50597,,In vivo,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618782,,,A
3436,Intermediate,,1,,10116.0,10774,1,50597,,In vivo,,Oral bioavailability in rat (dose 20 mg/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618783,,,A
17800,Intermediate,,1,,10116.0,10775,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618784,,,A
15762,Intermediate,,1,,10116.0,10776,1,50597,,In vivo,,Percent oral bioavailability evaluated in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618785,,,A
5089,Intermediate,,1,,10116.0,10777,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618786,,,A
5089,Intermediate,,1,,10116.0,10778,1,50597,,In vivo,,Percent oral bioavailability in rat; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618787,,,A
3185,Intermediate,,1,,10116.0,10779,1,50597,,In vivo,,Oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618788,,,A
5145,Intermediate,,1,,10116.0,10780,1,50597,,In vivo,,Bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618789,,,A
3457,Intermediate,,1,,10116.0,10781,1,50597,,In vivo,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618790,,,A
3457,Intermediate,,1,,10116.0,10782,1,50597,,In vivo,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618791,,,A
5983,Intermediate,,1,,10116.0,10783,1,50597,,In vivo,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875843,,,A
5739,Intermediate,,1,,10116.0,10784,1,50597,,In vivo,,Oral bioavailability in rat (dose 20 mg/kg p.o.),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL618792,,,A
3579,Intermediate,,1,,10116.0,10785,1,50597,,In vivo,,Cmax at a dose of 30 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623395,,,A
17788,Autocuration,,1,,314293.0,10786,0,22224,,In vivo,,Cmax in monkeys at a dose of 1 mg/kg,,U,,Simiiformes,BAO_0000218,,CHEMBL623396,,,A
14956,Intermediate,,1,,10116.0,10787,1,50597,,In vivo,,Cmax in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623397,,,A
17788,Intermediate,,1,,10116.0,10788,1,50597,,In vivo,,Cmax in rats at a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623398,,,A
9750,Intermediate,,1,,10090.0,10789,1,50594,,In vivo,,Cmax was measured in mice after an oral dose of 50 mg/kg.,,N,,Mus musculus,BAO_0000218,,CHEMBL623399,,,A
12767,Autocuration,,1,,,10790,0,22224,,In vivo,,"Cmax value at a dose of 12.7 uM/kg, po",,U,,,BAO_0000218,,CHEMBL623400,,,A
12767,Autocuration,,1,,,10791,0,22224,,In vivo,,"Cmax value at a dose of 6.3 uM/kg, iv",,U,,,BAO_0000218,,CHEMBL623401,,,A
12767,Autocuration,,1,,,10792,0,22224,,In vivo,,"Cmax value at a dose of 7.1 uM/kg, iv",,U,,,BAO_0000218,,CHEMBL623402,,,A
12703,Autocuration,,1,,,10793,0,22224,,In vivo,,Cmax value of compound was determined after 1 hr,,U,,,BAO_0000218,,CHEMBL623403,,,A
15778,Autocuration,,1,,,10794,0,22224,,In vivo,,Cmax value of the compound,,U,,,BAO_0000218,,CHEMBL623404,,,A
12818,Intermediate,,1,,10116.0,10795,1,50597,,In vivo,,Cmax value administered intraintestinal in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625997,,,A
14964,Intermediate,,1,,10116.0,10796,1,50597,,In vivo,,Cmax value administered perorally was determined in rat; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625998,,,A
15808,Autocuration,,1,,,10797,0,22224,,In vivo,,Cmax value at the dose of 2.3 mg/kg,,U,,,BAO_0000218,,CHEMBL625999,,,A
15808,Autocuration,,1,,,10798,0,22224,,In vivo,,Cmax value at the dose of 5 mg/kg,,U,,,BAO_0000218,,CHEMBL626000,,,A
15778,Autocuration,,1,,,10799,0,22224,,In vivo,,Cmax value in the period of 8 hr after dosing. ,,U,,,BAO_0000218,,CHEMBL626001,,,A
3715,Autocuration,,1,,,10800,0,22224,,In vivo,,Cmax value at a oral dose of 20 mg/kg; Not tested,,U,,,BAO_0000218,,CHEMBL626002,,,A
3715,Autocuration,,1,,,10801,0,22224,,In vivo,,Cmax value at a oral dose of 20 mg/kg,,U,,,BAO_0000218,,CHEMBL626003,,,A
1446,Intermediate,,1,,10116.0,10802,1,50597,,In vivo,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626004,,,A
15240,Intermediate,,1,,10141.0,10803,1,50512,,In vivo,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,N,,Cavia porcellus,BAO_0000218,,CHEMBL626005,,,A
15240,Intermediate,,1,,10116.0,10804,1,50597,,In vivo,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626006,,,A
14810,Intermediate,,1,,10116.0,10805,1,50597,,In vivo,Plasma,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626007,,,A
14239,Intermediate,,1,,10090.0,10806,1,50594,,In vivo,Plasma,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL626008,,,A
12555,Intermediate,,1,,9615.0,10807,1,50588,,In vivo,Liver,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL626009,,,A
10754,Intermediate,,1,,9615.0,10808,1,50588,,In vivo,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626010,,,A
10754,Intermediate,,1,,10090.0,10809,1,50594,,In vivo,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626011,,,A
10754,Intermediate,,1,,10090.0,10810,1,50594,,In vivo,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626012,,,A
10754,Intermediate,,1,,10090.0,10811,1,50594,,In vivo,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626013,,,A
10754,Intermediate,,1,,10090.0,10812,1,50594,,In vivo,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL626014,,,A
10754,Intermediate,,1,,10090.0,10813,1,50594,,In vivo,Blood,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL877496,,,A
14600,Intermediate,,1,,9615.0,10814,1,50588,,In vivo,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626015,,,F
14600,Intermediate,,1,,9615.0,10815,1,50588,,In vivo,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626016,,,F
14600,Intermediate,,1,,9615.0,10816,1,50588,,In vivo,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626017,,,F
13543,Intermediate,,1,,9615.0,10817,1,50588,,In vivo,Plasma,Bioavailability as maximal plasma concentration in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626018,,,A
13543,Intermediate,,1,,9615.0,10818,1,50588,,In vivo,Plasma,Bioavailability as maximal plasma concentration in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626692,,,A
13543,Intermediate,,1,,10116.0,10819,1,50597,,In vivo,Plasma,Bioavailability as maximal plasma concentration in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626693,,,A
13543,Autocuration,,1,,10116.0,10820,0,22224,,In vivo,Plasma,Bioavailability as maximal plasma concentration in rats,,U,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626694,,,A
14600,Intermediate,,1,,9615.0,10821,1,50588,,In vivo,Blood,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL626695,,,A
14600,Intermediate,,1,,9615.0,10822,1,50588,,In vivo,Blood,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL626696,,,A
14600,Intermediate,,1,,9615.0,10823,1,50588,,In vivo,Blood,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL626697,,,A
14600,Intermediate,,1,,9615.0,10824,1,50588,,In vivo,Blood,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL626859,,,A
14600,Intermediate,,1,,9615.0,10825,1,50588,,In vivo,Blood,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL626860,,,A
14600,Intermediate,,1,,9615.0,10826,1,50588,,In vivo,Blood,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL626861,,,A
14681,Intermediate,,1,,10116.0,10827,1,50597,,In vivo,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626296,,,A
15905,Autocuration,,1,,,10828,0,22224,,In vivo,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,U,,,BAO_0000218,,CHEMBL626297,,,A
15905,Autocuration,,1,,,10829,0,22224,,In vivo,Plasma,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,U,,,BAO_0000218,1969.0,CHEMBL626298,,,A
13304,Intermediate,,1,,10116.0,10830,1,50597,,In vivo,Plasma,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626299,,,A
15137,Intermediate,,1,,10116.0,10831,1,50597,,In vivo,Plasma,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626300,,,A
15137,Intermediate,,1,,10116.0,10832,1,50597,,In vivo,Plasma,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626301,,,A
15137,Intermediate,,1,,10116.0,10833,1,50597,,In vivo,Plasma,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626962,,,A
15137,Intermediate,,1,,10116.0,10834,1,50597,,In vivo,Plasma,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626963,,,A
15137,Intermediate,,1,,10116.0,10835,1,50597,,In vivo,Plasma,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626964,,,A
14839,Intermediate,,1,,9541.0,10836,1,100710,,In vivo,Plasma,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL626965,,,A
14839,Intermediate,,1,,10090.0,10837,1,50594,,In vivo,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL626966,,,A
14839,Intermediate,,1,,10090.0,10838,1,50594,,In vivo,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL626967,,,A
14839,Intermediate,,1,,9541.0,10839,1,100710,,In vivo,Plasma,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL626968,,,A
8418,Intermediate,,1,,10116.0,10840,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626969,,,A
8418,Intermediate,,1,,10116.0,10841,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627126,,,A
8418,Intermediate,,1,,10116.0,10842,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631276,,,A
8418,Intermediate,,1,,10116.0,10843,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631277,,,A
8418,Intermediate,,1,,10116.0,10844,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631278,,,A
8418,Intermediate,,1,,10116.0,10845,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL874457,,,A
8418,Intermediate,,1,,10116.0,10846,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631279,,,A
8418,Intermediate,,1,,10116.0,10847,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631280,,,A
8418,Intermediate,,1,,10116.0,10848,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631281,,,A
8418,Intermediate,,1,,10116.0,10849,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631968,,,A
8418,Intermediate,,1,,10116.0,10850,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631969,,,A
8418,Intermediate,,1,,10116.0,10851,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631970,,,A
8418,Intermediate,,1,,10116.0,10852,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631971,,,A
8418,Intermediate,,1,,10116.0,10853,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL631972,,,A
8418,Intermediate,,1,,10116.0,10854,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630435,,,A
8418,Intermediate,,1,,10116.0,10855,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630436,,,A
8418,Intermediate,,1,,10116.0,10856,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630437,,,A
8418,Intermediate,,1,,10116.0,10857,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630438,,,A
8418,Intermediate,,1,,10116.0,10858,1,50597,,,Heart,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630439,,,A
8418,Intermediate,,1,,10116.0,10859,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630440,,,A
8418,Intermediate,,1,,10116.0,10860,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630441,,,A
8418,Intermediate,,1,,10116.0,10861,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630442,,,A
8418,Intermediate,,1,,10116.0,10862,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625234,,,A
8418,Intermediate,,1,,10116.0,10863,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625235,,,A
8418,Intermediate,,1,,10116.0,10864,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625236,,,A
8418,Intermediate,,1,,10116.0,10865,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625237,,,A
8418,Intermediate,,1,,10116.0,10866,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626125,,,A
8418,Intermediate,,1,,10116.0,10867,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626126,,,A
8418,Intermediate,,1,,10116.0,10868,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626127,,,A
8418,Intermediate,,1,,10116.0,10869,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626128,,,A
8418,Intermediate,,1,,10116.0,10870,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626129,,,A
8418,Intermediate,,1,,10116.0,10871,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626130,,,A
8418,Intermediate,,1,,10116.0,10872,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626131,,,A
8418,Intermediate,,1,,10116.0,10873,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626132,,,A
8418,Intermediate,,1,,10116.0,10874,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626752,,,A
8418,Intermediate,,1,,10116.0,10875,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626753,,,A
8418,Intermediate,,1,,10116.0,10876,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626754,,,A
8418,Intermediate,,1,,10116.0,10877,1,50597,,,Kidney,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626755,,,A
8418,Intermediate,,1,,10116.0,10878,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626756,,,A
8418,Intermediate,,1,,10116.0,10879,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626757,,,A
8418,Intermediate,,1,,10116.0,10880,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626758,,,A
8418,Intermediate,,1,,10116.0,10881,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626759,,,A
8418,Intermediate,,1,,10116.0,10882,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626760,,,A
6996,Intermediate,,1,,9615.0,10883,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626394,,,A
6996,Intermediate,,1,,9615.0,10884,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626395,,,A
6996,Intermediate,,1,,9615.0,10885,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626396,,,A
6996,Intermediate,,1,,9615.0,10886,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626397,,,A
6996,Intermediate,,1,,9615.0,10887,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626398,,,A
6996,Intermediate,,1,,9615.0,10888,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626399,,,A
6996,Intermediate,,1,,10116.0,10889,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874653,,,A
6996,Intermediate,,1,,10116.0,10890,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626400,,,A
6996,Intermediate,,1,,10116.0,10891,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626401,,,A
6996,Intermediate,,1,,10116.0,10892,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626402,,,A
6996,Intermediate,,1,,10116.0,10893,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626403,,,A
6996,Intermediate,,1,,10116.0,10894,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626404,,,A
6996,Intermediate,,1,,10116.0,10895,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626405,,,A
6996,Intermediate,,1,,10116.0,10896,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625529,,,A
6996,Intermediate,,1,,10116.0,10897,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625530,,,A
6996,Intermediate,,1,,10116.0,10898,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625531,,,A
6996,Intermediate,,1,,10116.0,10899,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625532,,,A
6996,Intermediate,,1,,10116.0,10900,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625533,,,A
6996,Intermediate,,1,,10116.0,10901,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875474,,,A
6996,Intermediate,,1,,10116.0,10902,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625534,,,A
6996,Intermediate,,1,,10116.0,10903,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625535,,,A
6996,Intermediate,,1,,10116.0,10904,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625536,,,A
6996,Intermediate,,1,,10116.0,10905,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625537,,,A
6996,Intermediate,,1,,10116.0,10906,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625538,,,A
6996,Intermediate,,1,,10116.0,10907,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625539,,,A
6996,Intermediate,,1,,10116.0,10908,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625540,,,A
6996,Intermediate,,1,,10116.0,10909,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625541,,,A
6996,Intermediate,,1,,10116.0,10910,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625542,,,A
6996,Intermediate,,1,,10116.0,10911,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625543,,,A
6996,Intermediate,,1,,10116.0,10912,1,50597,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625544,,,A
6996,Intermediate,,1,,9615.0,10913,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625545,,,A
6996,Intermediate,,1,,9615.0,10914,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625546,,,A
6996,Intermediate,,1,,9615.0,10915,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625547,,,A
6996,Intermediate,,1,,9615.0,10916,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625548,,,A
6996,Intermediate,,1,,9615.0,10917,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625549,,,A
6996,Intermediate,,1,,9615.0,10918,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625550,,,A
6996,Intermediate,,1,,9615.0,10919,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625551,,,A
6996,Intermediate,,1,,9615.0,10920,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875475,,,A
6996,Intermediate,,1,,9615.0,10921,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625552,,,A
6996,Intermediate,,1,,9615.0,10922,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625553,,,A
6996,Intermediate,,1,,9615.0,10923,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625554,,,A
6996,Intermediate,,1,,9615.0,10924,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625555,,,A
6996,Intermediate,,1,,9615.0,10925,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625556,,,A
6996,Intermediate,,1,,9615.0,10926,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624986,,,A
6996,Intermediate,,1,,9615.0,10927,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624987,,,A
6996,Intermediate,,1,,9615.0,10928,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624988,,,A
9025,Intermediate,,1,,9615.0,10929,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624989,,,A
9025,Intermediate,,1,,9615.0,10930,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624990,,,A
9025,Intermediate,,1,,9615.0,10931,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL874391,,,A
9025,Intermediate,,1,,9615.0,10932,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624991,,,A
9025,Intermediate,,1,,9615.0,10933,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624992,,,A
9025,Intermediate,,1,,9615.0,10934,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624993,,,A
9025,Intermediate,,1,,9615.0,10935,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624994,,,A
9025,Intermediate,,1,,9615.0,10936,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624995,,,A
9025,Intermediate,,1,,9615.0,10937,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624996,,,A
9025,Intermediate,,1,,9615.0,10938,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624997,,,A
9025,Intermediate,,1,,9615.0,10939,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624998,,,A
9025,Intermediate,,1,,9615.0,10940,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624999,,,A
9025,Intermediate,,1,,9615.0,10941,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL882955,,,A
9025,Intermediate,,1,,9615.0,10942,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625000,,,A
9025,Intermediate,,1,,9615.0,10943,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625001,,,A
9025,Intermediate,,1,,9615.0,10944,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625089,,,A
9025,Intermediate,,1,,9615.0,10945,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625090,,,A
9025,Intermediate,,1,,9615.0,10946,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625091,,,A
9025,Intermediate,,1,,9615.0,10947,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625092,,,A
9025,Intermediate,,1,,9615.0,10948,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625093,,,A
9025,Intermediate,,1,,9615.0,10949,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625094,,,A
9025,Intermediate,,1,,9615.0,10950,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL625095,,,A
2249,Intermediate,,1,,9615.0,10951,1,50588,,In vivo,,Compound was evaluated for its bioavailability in the dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625096,,,A
2249,Intermediate,,1,,10116.0,10952,1,50597,,In vivo,,Compound was evaluated for its bioavailability in the rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625097,,,A
17515,Autocuration,,1,,,10953,0,22224,,In vivo,,Compound was evaluated for oral bioavailability,,U,,,BAO_0000218,,CHEMBL882956,,,A
14541,Intermediate,,1,,10116.0,10954,1,50597,,In vivo,,Compound was evaluated for percentage of Oral bioavailability in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625098,,,A
12797,Autocuration,,1,,10141.0,10955,0,22224,,In vivo,,Bioavailability in guinea pig,,U,,Cavia porcellus,BAO_0000218,,CHEMBL625099,,,A
12797,Intermediate,,1,,10116.0,10956,1,50597,,In vivo,,Compound was evaluated for the oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625100,,,A
12797,Intermediate,,1,,9615.0,10957,1,50588,,In vivo,,Compound was evaluated for the oral bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625101,,,A
12797,Intermediate,,1,,10116.0,10958,1,50597,,In vivo,,Compound was evaluated for the oral bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874396,,,A
11727,Autocuration,,1,,9615.0,10959,0,22224,,In vivo,,Bioavailability in dog (dosed i.v.),,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL625102,,,F
13249,Intermediate,,1,,9615.0,10960,1,50588,,In vivo,,Compound was tested for in vivo bioavailability in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625103,,,A
13249,Intermediate,,1,,10026.0,10961,1,100712,,In vivo,,Compound was tested for in vivo bioavailability in hamsters,,N,,Cricetinae,BAO_0000218,,CHEMBL625104,,,A
13249,Autocuration,,1,,314293.0,10962,0,22224,,In vivo,,Compound was tested for in vivo bioavailability in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL625105,,,A
13249,Intermediate,,1,,10116.0,10963,1,50597,,In vivo,,Compound was tested for in vivo bioavailability in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625106,,,A
9552,Autocuration,,1,,10090.0,10964,0,22224,,In vivo,,Oral bioavailability in mouse,,U,,Mus musculus,BAO_0000218,,CHEMBL625107,,,A
9552,Intermediate,,1,,10090.0,10965,1,50594,,In vivo,,Compound was tested for percent of oral bioavailability in mice; 56-74,,N,,Mus musculus,BAO_0000218,,CHEMBL625108,,,A
14839,Autocuration,,1,,10090.0,10966,0,22224,,In vivo,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,U,,Mus musculus,BAO_0000218,,CHEMBL625109,,,A
14839,Autocuration,,1,,9541.0,10967,0,22224,,In vivo,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,U,,Macaca fascicularis,BAO_0000218,,CHEMBL625110,,,A
14839,Autocuration,,1,,9541.0,10968,0,22224,,In vivo,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,U,,Macaca fascicularis,BAO_0000218,,CHEMBL625111,,,A
14839,Intermediate,,1,,10090.0,10969,1,50594,,In vivo,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,N,,Mus musculus,BAO_0000218,,CHEMBL625112,,,A
14839,Intermediate,,1,,10090.0,10970,1,50594,,In vivo,,Oral bioavailability in nude mice,,N,,Mus musculus,BAO_0000218,,CHEMBL875334,,,A
11219,Autocuration,,1,,9443.0,10971,0,22224,,In vivo,,Bioavailability in monkey (i.d. dosing),,U,,Primates,BAO_0000218,,CHEMBL628617,,,A
9552,Autocuration,,1,,10116.0,10972,0,22224,,In vivo,,Bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL628618,,,A
11732,Autocuration,,1,,,10973,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,U,,,BAO_0000218,,CHEMBL628619,,,A
11732,Autocuration,,1,,,10974,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,U,,,BAO_0000218,,CHEMBL628620,,,A
14839,Intermediate,,1,,9541.0,10975,1,100710,,In vivo,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL628621,,,A
14839,Intermediate,,1,,9541.0,10976,1,100710,,In vivo,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL628622,,,A
14839,Intermediate,,1,,9541.0,10977,1,100710,,In vivo,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,N,,Macaca fascicularis,BAO_0000218,,CHEMBL628623,,,A
14839,Intermediate,,1,,9541.0,10978,1,100710,,In vivo,Plasma,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL628624,,,A
14839,Intermediate,,1,,10090.0,10979,1,50594,,In vivo,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL628625,,,A
14839,Intermediate,,1,,9541.0,10980,1,100710,,In vivo,Plasma,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL628626,,,A
14839,Intermediate,,1,,10090.0,10981,1,50594,,In vivo,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627041,,,A
14839,Intermediate,,1,,10090.0,10982,1,50594,,In vivo,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627042,,,A
14839,Intermediate,,1,,10090.0,10983,1,50594,,In vivo,Plasma,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627043,,,A
13932,Autocuration,,1,,,10984,0,22224,,In vivo,Plasma,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,U,,,BAO_0000218,1969.0,CHEMBL627044,,,A
11637,Intermediate,,1,,10090.0,10985,1,50594,,In vivo,Plasma,Cmax in mouse plasma,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL627045,,,A
11637,Autocuration,,1,,,10986,0,22224,,In vivo,Plasma,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,U,,,BAO_0000218,1969.0,CHEMBL627046,,,A
13960,Intermediate,,1,,10116.0,10987,1,50597,,In vivo,Plasma,Maximal plasma concentration in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627047,,,A
15905,Intermediate,,1,,10116.0,10988,1,50597,,In vivo,Plasma,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627048,,,A
14062,Intermediate,,1,,10116.0,10989,1,50597,,In vivo,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627049,,,A
14062,Intermediate,,1,,10116.0,10990,1,50597,,In vivo,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627050,,,A
14062,Intermediate,,1,,10116.0,10991,1,50597,,In vivo,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627051,,,A
14062,Intermediate,,1,,10116.0,10992,1,50597,,In vivo,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627052,,,A
14062,Intermediate,,1,,10116.0,10993,1,50597,,In vivo,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627053,,,A
14062,Intermediate,,1,,10116.0,10994,1,50597,,In vivo,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627054,,,A
15011,Intermediate,,1,,10090.0,10995,1,50594,,In vivo,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627055,,,A
15011,Intermediate,,1,,10090.0,10996,1,50594,,In vivo,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627056,,,A
15011,Intermediate,,1,,10090.0,10997,1,50594,,In vivo,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,N,,Mus musculus,BAO_0000218,,CHEMBL627057,,,A
15011,Intermediate,,1,,10090.0,10998,1,50594,,In vivo,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL627058,,,A
15011,Intermediate,,1,,10090.0,10999,1,50594,,In vivo,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL626211,,,A
10291,Autocuration,,1,,,11000,0,22224,,In vivo,,Maximum Concentration of the compound.,,U,,,BAO_0000218,,CHEMBL626212,,,A
14599,Intermediate,,1,,9615.0,11001,1,50588,,In vivo,,Maximum Concentration was measured after iv administration into Beagle dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626213,,,A
14599,Intermediate,,1,,9615.0,11002,1,50588,,In vivo,,Maximum Concentration was measured after iv administration into Beagle dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626214,,,A
14599,Intermediate,,1,,9615.0,11003,1,50588,,In vivo,,Maximum Concentration was measured after po administration into Beagle dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626215,,,A
14599,Intermediate,,1,,9615.0,11004,1,50588,,In vivo,,Maximum Concentration was measured after po administration into Beagle dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626216,,,A
12767,Autocuration,,1,,,11005,0,22224,,In vivo,Blood,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,U,,,BAO_0000218,178.0,CHEMBL626217,,,A
12767,Autocuration,,1,,,11006,0,22224,,In vivo,Blood,Maximum blood level reached after an iv dose of 12.2 uM/kg,,U,,,BAO_0000218,178.0,CHEMBL626218,,,A
12767,Autocuration,,1,,,11007,0,22224,,In vivo,Blood,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,U,,,BAO_0000218,178.0,CHEMBL626219,,,A
12767,Autocuration,,1,,,11008,0,22224,,In vivo,Blood,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,U,,,BAO_0000218,178.0,CHEMBL626220,,,A
12767,Autocuration,,1,,,11009,0,22224,,In vivo,Blood,Maximum blood level reached after an oral dose of 5.0 mg/kg,,U,,,BAO_0000218,178.0,CHEMBL626221,,,A
12767,Autocuration,,1,,,11010,0,22224,,In vivo,Blood,Maximum blood level reached at dose of 10.6 uM/kg orally,,U,,,BAO_0000218,178.0,CHEMBL626222,,,A
14706,Intermediate,,1,,10141.0,11011,1,50512,,In vivo,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,N,,Cavia porcellus,BAO_0000218,,CHEMBL626223,,,A
14706,Intermediate,,1,,10141.0,11012,1,50512,,In vivo,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,N,,Cavia porcellus,BAO_0000218,,CHEMBL626224,,,A
14793,Intermediate,,1,,10116.0,11013,1,50597,,In vivo,Brain,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL626225,,,A
14793,Intermediate,,1,,10116.0,11014,1,50597,,In vivo,Brain,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL626226,,,A
14793,Intermediate,,1,,10116.0,11015,1,50597,,In vivo,Brain,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL626227,,,A
14793,Intermediate,,1,,10116.0,11016,1,50597,,In vivo,Brain,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL626228,,,A
14793,Intermediate,,1,,10116.0,11017,1,50597,,In vivo,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626229,,,A
14793,Intermediate,,1,,10116.0,11018,1,50597,,In vivo,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626921,,,A
14793,Intermediate,,1,,10116.0,11019,1,50597,,In vivo,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876793,,,A
14793,Intermediate,,1,,10116.0,11020,1,50597,,In vivo,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625309,,,A
10524,Intermediate,,1,,1423.0,11021,1,50278,,In vivo,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,N,,Bacillus subtilis,BAO_0000218,,CHEMBL625310,,,A
11871,Autocuration,,1,,314293.0,11022,0,22224,,In vivo,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,U,,Simiiformes,BAO_0000218,,CHEMBL625311,,,A
11871,Intermediate,,1,,10116.0,11023,1,50597,,In vivo,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625312,,,A
3437,Autocuration,,1,,,11024,0,22224,,In vivo,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,U,,,BAO_0000218,,CHEMBL625313,,,A
12038,Intermediate,,1,,10090.0,11025,1,50594,,In vivo,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,N,,Mus musculus,BAO_0000218,,CHEMBL625314,,,A
12038,Intermediate,,1,,10116.0,11026,1,50597,,In vivo,,Maximum concentration in male rats after iv administration of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625315,,,A
8418,Intermediate,,1,,10116.0,11027,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625316,,,A
8418,Intermediate,,1,,10116.0,11028,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625317,,,A
8418,Intermediate,,1,,10116.0,11029,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625318,,,A
8418,Intermediate,,1,,10116.0,11030,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625319,,,A
8418,Intermediate,,1,,10116.0,11031,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625320,,,A
8418,Intermediate,,1,,10116.0,11032,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625321,,,A
8418,Intermediate,,1,,10116.0,11033,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625322,,,A
8418,Intermediate,,1,,10116.0,11034,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL876801,,,A
8418,Intermediate,,1,,10116.0,11035,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625323,,,A
8418,Intermediate,,1,,10116.0,11036,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625324,,,A
8418,Intermediate,,1,,10116.0,11037,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625325,,,A
8418,Intermediate,,1,,10116.0,11038,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625326,,,A
8418,Intermediate,,1,,10116.0,11039,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625327,,,A
8418,Intermediate,,1,,10116.0,11040,1,50597,,,Liver,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625328,,,A
8418,Intermediate,,1,,10116.0,11041,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625329,,,A
8418,Intermediate,,1,,10116.0,11042,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625330,,,A
8418,Intermediate,,1,,10116.0,11043,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627774,,,A
8418,Intermediate,,1,,10116.0,11044,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627775,,,A
8418,Intermediate,,1,,10116.0,11045,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627949,,,A
8418,Intermediate,,1,,10116.0,11046,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627950,,,A
8418,Intermediate,,1,,10116.0,11047,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627951,,,A
8418,Intermediate,,1,,10116.0,11048,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627952,,,A
8418,Intermediate,,1,,10116.0,11049,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627953,,,A
8418,Intermediate,,1,,10116.0,11050,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627954,,,A
8418,Intermediate,,1,,10116.0,11051,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627955,,,A
8418,Intermediate,,1,,10116.0,11052,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627956,,,A
8418,Intermediate,,1,,10116.0,11053,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL876802,,,A
8418,Intermediate,,1,,10116.0,11054,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627957,,,A
8418,Intermediate,,1,,10116.0,11055,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627958,,,A
8418,Intermediate,,1,,10116.0,11056,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627959,,,A
8418,Intermediate,,1,,10116.0,11057,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627960,,,A
8418,Intermediate,,1,,10116.0,11058,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627961,,,A
8418,Intermediate,,1,,10116.0,11059,1,50597,,,Lung,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627962,,,A
9796,Intermediate,,1,,10116.0,11060,1,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627963,,,A
9796,Intermediate,,1,,10116.0,11061,1,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624759,,,A
9796,Intermediate,,1,,10116.0,11062,1,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624760,,,A
9796,Intermediate,,1,,10116.0,11063,1,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624761,,,A
9796,Intermediate,,1,,10116.0,11064,1,50597,,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877607,,,A
9796,Intermediate,,1,,10116.0,11065,1,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624762,,,A
9796,Intermediate,,1,,10116.0,11066,1,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624763,,,A
9796,Intermediate,,1,,10116.0,11067,1,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624764,,,A
9796,Intermediate,,1,,10116.0,11068,1,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624765,,,A
9796,Intermediate,,1,,10116.0,11069,1,50597,,,Liver,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624766,,,A
6996,Intermediate,,1,,9615.0,11070,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624767,,,A
6996,Intermediate,,1,,9615.0,11071,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624768,,,A
6996,Intermediate,,1,,9615.0,11072,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624769,,,A
6996,Intermediate,,1,,9615.0,11073,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624770,,,A
6996,Intermediate,,1,,9615.0,11074,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624771,,,A
6996,Intermediate,,1,,9615.0,11075,1,50588,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624772,,,A
6996,Intermediate,,1,,10116.0,11076,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624773,,,A
6996,Intermediate,,1,,10116.0,11077,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624774,,,A
6996,Intermediate,,1,,10116.0,11078,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624775,,,A
6996,Intermediate,,1,,10116.0,11079,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624776,,,A
6996,Intermediate,,1,,10116.0,11080,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624777,,,A
6996,Intermediate,,1,,10116.0,11081,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624778,,,A
6996,Intermediate,,1,,10116.0,11082,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624779,,,A
6996,Intermediate,,1,,10116.0,11083,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624780,,,A
6996,Intermediate,,1,,10116.0,11084,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624781,,,A
6996,Intermediate,,1,,10116.0,11085,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877608,,,A
6996,Intermediate,,1,,10116.0,11086,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624782,,,A
6996,Intermediate,,1,,10116.0,11087,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624783,,,A
6996,Intermediate,,1,,10116.0,11088,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624784,,,A
6996,Intermediate,,1,,10116.0,11089,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624785,,,A
6996,Intermediate,,1,,10116.0,11090,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624786,,,A
6996,Intermediate,,1,,10116.0,11091,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624787,,,A
6996,Intermediate,,1,,10116.0,11092,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628676,,,A
6996,Intermediate,,1,,10116.0,11093,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621842,,,A
6996,Intermediate,,1,,10116.0,11094,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL621843,,,A
6996,Intermediate,,1,,10116.0,11095,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623873,,,A
6996,Intermediate,,1,,10116.0,11096,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623874,,,A
6996,Intermediate,,1,,10116.0,11097,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623875,,,A
6996,Intermediate,,1,,10116.0,11098,1,50597,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623876,,,A
6996,Intermediate,,1,,9615.0,11099,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623877,,,A
6996,Intermediate,,1,,9615.0,11100,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623878,,,A
6996,Intermediate,,1,,9615.0,11101,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623879,,,A
6996,Intermediate,,1,,9615.0,11102,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623880,,,A
6996,Intermediate,,1,,9615.0,11103,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623881,,,A
6996,Intermediate,,1,,9615.0,11104,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623957,,,A
6996,Intermediate,,1,,9615.0,11105,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623958,,,A
6996,Intermediate,,1,,9615.0,11106,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623959,,,A
6996,Intermediate,,1,,9615.0,11107,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623960,,,A
6996,Intermediate,,1,,9615.0,11108,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623961,,,A
6996,Intermediate,,1,,9615.0,11109,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623962,,,A
6996,Intermediate,,1,,9615.0,11110,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624676,,,A
6996,Intermediate,,1,,9615.0,11111,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624677,,,A
6996,Intermediate,,1,,9615.0,11112,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624678,,,A
6996,Intermediate,,1,,9615.0,11113,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624679,,,A
6996,Intermediate,,1,,9615.0,11114,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624680,,,A
11732,Autocuration,,1,,,11115,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,U,,,BAO_0000218,,CHEMBL624849,,,A
11732,Autocuration,,1,,,11116,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,U,,,BAO_0000218,,CHEMBL624850,,,A
11732,Autocuration,,1,,,11117,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,U,,,BAO_0000218,,CHEMBL874399,,,A
11732,Autocuration,,1,,,11118,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,U,,,BAO_0000218,,CHEMBL624851,,,A
11732,Autocuration,,1,,,11119,0,22224,,In vivo,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,U,,,BAO_0000218,,CHEMBL624852,,,A
13359,Autocuration,,1,,10116.0,11120,0,22224,,In vivo,,Oral bioavailability in rat (dose 10 mg/kg),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL624853,,,A
16618,Autocuration,,1,,10116.0,11121,0,22224,,In vivo,,Oral bioavailability in rat (Sprague-Dawley),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL624854,,,A
13960,Autocuration,,1,,10116.0,11122,0,22224,,In vivo,,Oral bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL624855,,,A
13917,Autocuration,,1,,10116.0,11123,0,22224,,In vivo,,Oral bioavailability in rats was determined in vivo,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL624856,,,A
14266,Autocuration,,1,,9615.0,11124,0,22224,,In vivo,,Oral bioavailability in dog,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL882957,,,A
12359,Autocuration,,1,,314293.0,11125,0,22224,,In vivo,,Oral bioavailability of compound in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL624857,,,A
12359,Intermediate,,1,,10116.0,11126,1,50597,,In vivo,,Oral bioavailability of compound in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622202,,,A
12359,Autocuration,,1,,10116.0,11127,0,22224,,In vivo,,Bioavailability in rat of PMEA prodrug,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL622203,,,A
12359,Intermediate,,1,,10116.0,11128,1,50597,,In vivo,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625522,,,A
10791,Autocuration,,1,,9544.0,11129,0,22224,,In vivo,,Serum conc at 3 hours following 25 mg/kg dose,,U,,Macaca mulatta,BAO_0000218,,CHEMBL622868,,,A
10791,Autocuration,,1,,9544.0,11130,0,22224,,In vivo,Urine,Urine conc 0-5 hours following 25 mg/kg dose,,U,,Macaca mulatta,BAO_0000218,1088.0,CHEMBL622869,,,A
10791,Autocuration,,1,,9544.0,11131,0,22224,,In vivo,Urine,Urine conc 0-24 hours following 25 mg/kg dose,,U,,Macaca mulatta,BAO_0000218,1088.0,CHEMBL622870,,,A
138,Autocuration,,1,,9534.0,11132,0,22224,,In vivo,,Oral bioavailability in African green monkeys; 20-25,,U,,Chlorocebus aethiops,BAO_0000218,,CHEMBL622871,,,A
14521,Intermediate,,1,,9541.0,11133,1,100710,,In vivo,,Oral bioavailability in cynomolgus monkey.,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL620560,,,A
13953,Autocuration,,1,,9615.0,11134,0,22224,,In vivo,,Oral bioavailability in dog,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL620561,,,A
12836,Intermediate,,1,,9615.0,11135,1,50588,,In vivo,,Oral bioavailability in dog at 10 mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620562,,,A
12836,Intermediate,,1,,10026.0,11136,1,100712,,In vivo,,Oral bioavailability in hamster at 10 mg/kg oral dose,,N,,Cricetinae,BAO_0000218,,CHEMBL620563,,,A
12836,Intermediate,,1,,10116.0,11137,1,50597,,In vivo,,Oral bioavailability in rat at 10 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL620564,,,A
14521,Autocuration,,1,,10116.0,11138,0,22224,,In vivo,,Oral bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL872265,,,A
13953,Autocuration,,1,,10116.0,11139,0,22224,,In vivo,,Oral bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL620565,,,A
6799,Autocuration,,1,,9347.0,11140,0,22224,,In vivo,,Oral bioavailability,,U,,Eutheria,BAO_0000218,,CHEMBL620566,,,A
11311,Autocuration,,1,,,11141,0,22224,,In vivo,,Oral bioavailability was determined; range 49-102%,,U,,,BAO_0000218,,CHEMBL620567,,,A
4013,Intermediate,,1,,9615.0,11142,1,50588,,In vivo,,Oral bioavailability was determined in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL620568,,,A
4013,Autocuration,,1,,10116.0,11143,0,22224,,In vivo,,Oral bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL620569,,,A
17591,Autocuration,,1,,9347.0,11144,0,22224,,In vivo,,Oral bioavailability,,U,,Eutheria,BAO_0000218,,CHEMBL620570,,,A
17591,Autocuration,,1,,,11145,0,22224,,In vivo,,Oral bioavailability was determined; Not orally available,,U,,,BAO_0000218,,CHEMBL620571,,,A
15011,Intermediate,,1,,10090.0,11146,1,50594,,In vivo,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,N,,Mus musculus,BAO_0000218,,CHEMBL620572,,,A
15011,Autocuration,,1,,10090.0,11147,0,22224,,In vivo,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,U,,Mus musculus,BAO_0000218,,CHEMBL620573,,,A
15011,Autocuration,,1,,10090.0,11148,0,22224,,In vivo,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,U,,Mus musculus,BAO_0000218,,CHEMBL620574,,,A
9552,Autocuration,,1,,9544.0,11149,0,22224,,In vivo,,Oral bioavailability in Rhesus monkey,,U,,Macaca mulatta,BAO_0000218,,CHEMBL620575,,,A
9552,Autocuration,,1,,9615.0,11150,0,22224,,In vivo,,Oral bioavailability in dog (female mongrel),,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL620576,,,A
3639,Autocuration,,1,,,11151,0,22224,,In vivo,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,U,,,BAO_0000218,,CHEMBL875846,,,A
13397,Autocuration,,1,,9615.0,11152,0,22224,,In vivo,,Oral bioavailability in dog,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL620577,,,A
3031,Autocuration,,1,,,11153,0,22224,,In vivo,,Percentage Bioavailability was evaluated.,,U,,,BAO_0000218,,CHEMBL620578,,,A
12818,Autocuration,,1,,10116.0,11154,0,22224,,In vivo,,Bioavailability in rat administered i.d.,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL620579,,,A
4847,Autocuration,,1,,9347.0,11155,0,22224,,In vivo,,Bioavailability,,U,,Eutheria,BAO_0000218,,CHEMBL621248,,,A
12421,Autocuration,,1,,9615.0,11156,0,22224,,In vivo,,Bioavailability in dog (male Beagle) i.v. administration,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL625390,,,A
11966,Autocuration,,1,,10116.0,11157,0,22224,,In vivo,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625391,,,A
11218,Autocuration,,1,,9443.0,11158,0,22224,,In vivo,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,U,,Primates,BAO_0000218,,CHEMBL872266,,,A
13129,Autocuration,,1,,10116.0,11159,0,22224,,In vivo,,Oral bioavailability in rat (Sprague-Dawley) (male),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625392,,,A
12350,Intermediate,,1,,10116.0,11160,1,50597,,In vivo,,The oral bioavailability was measured on rats after oral administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625393,,,A
2231,Intermediate,,1,,10116.0,11161,1,50597,,In vivo,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625394,,,A
2231,Intermediate,,1,,9544.0,11162,1,50797,,In vivo,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,N,,Macaca mulatta,BAO_0000218,,CHEMBL625395,,,A
12187,Autocuration,,1,,10116.0,11163,0,22224,,In vivo,,Bioavailability in rat (dose 10 mg/kg i.d.),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625396,,,A
12421,Autocuration,,1,,9615.0,11164,0,22224,,In vivo,,Bioavailability in dog (male Beagle) i.v. administration,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL625397,,,A
13256,Intermediate,,1,,10090.0,11165,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL625398,,,A
13256,Intermediate,,1,,10090.0,11166,1,50594,,In vivo,Blood,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL625399,,,A
13256,Intermediate,,1,,10090.0,11167,1,50594,,In vivo,Cerebellum,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2037.0,CHEMBL626074,,,A
13256,Intermediate,,1,,10090.0,11168,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL626075,,,A
2231,Intermediate,,1,,10116.0,11169,1,50597,,In vivo,Plasma,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626076,,,A
2231,Intermediate,,1,,9544.0,11170,1,50797,,In vivo,Plasma,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,N,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL626077,,,A
12178,Intermediate,,1,,10116.0,11171,1,50597,,In vivo,Blood,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626078,,,A
12178,Autocuration,,1,,,11172,0,22224,,In vivo,Blood,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,U,,,BAO_0000218,178.0,CHEMBL625846,,,A
12178,Autocuration,,1,,,11173,0,22224,,In vivo,Blood,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,U,,,BAO_0000218,178.0,CHEMBL625847,,,A
15633,Expert,,1,,10116.0,11174,1,50597,,In vivo,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625848,,,A
14258,Intermediate,,1,,10116.0,11175,1,50597,,In vivo,Plasma,Maximum concentration of compound in plasma administered orally to rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625849,,,A
14224,Intermediate,,1,,9615.0,11176,1,50588,,In vivo,Plasma,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626023,,,A
14224,Intermediate,,1,,9615.0,11177,1,50588,,In vivo,Plasma,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626024,,,A
14224,Intermediate,,1,,9615.0,11178,1,50588,,In vivo,Plasma,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626025,,,A
5566,Autocuration,,1,,,11179,0,22224,,In vivo,,Maximum concentration after 10 mg/kg by oral administration,,U,,,BAO_0000218,,CHEMBL626026,,,A
16935,Autocuration,,1,,,11180,0,22224,,In vivo,,Maximum concentration at a dose of 1.5 mg/kg,,U,,,BAO_0000218,,CHEMBL626027,,,A
16935,Autocuration,,1,,,11181,0,22224,,In vivo,,Maximum concentration at a dose of 2.0 mg/kg,,U,,,BAO_0000218,,CHEMBL626028,,,A
14224,Intermediate,,1,,9615.0,11182,1,50588,,In vivo,Plasma,Maximum concentration in dog plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626029,,,A
12536,Autocuration,,1,,,11183,0,22224,,In vivo,Plasma,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,U,,,BAO_0000218,1969.0,CHEMBL626030,,,A
12536,Autocuration,,1,,,11184,0,22224,,In vivo,Plasma,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,U,,,BAO_0000218,1969.0,CHEMBL626031,,,A
12536,Autocuration,,1,,,11185,0,22224,,In vivo,Plasma,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,U,,,BAO_0000218,1969.0,CHEMBL626032,,,A
12536,Autocuration,,1,,,11186,0,22224,,In vivo,Plasma,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,U,,,BAO_0000218,1969.0,CHEMBL626033,,,A
12536,Autocuration,,1,,,11187,0,22224,,In vivo,Plasma,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,U,,,BAO_0000218,1969.0,CHEMBL626034,,,A
9994,Intermediate,,1,,9615.0,11188,1,50588,,In vivo,Plasma,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626035,,,A
1434,Autocuration,,1,,,11189,0,22224,,In vivo,Plasma,Maximum concentration in plasma at Tmax,,U,,,BAO_0000218,1969.0,CHEMBL626036,,,A
12836,Expert,,1,,9615.0,11190,1,50588,,In vivo,Plasma,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626037,,,A
12836,Intermediate,,1,,10026.0,11191,1,100712,,In vivo,Plasma,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,N,,Cricetinae,BAO_0000218,1969.0,CHEMBL626038,,,A
12836,Intermediate,,1,,10116.0,11192,1,50597,,In vivo,Plasma,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626039,,,A
12545,Intermediate,,1,,10116.0,11193,1,50597,,In vivo,Plasma,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626040,,,A
13856,Intermediate,,1,,9986.0,11194,1,50592,,In vivo,Plasma,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,N,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL626041,,,A
3550,Autocuration,,1,,,11195,0,22224,,In vivo,,Maximum concentration was calculated,,U,,,BAO_0000218,,CHEMBL626042,,,A
2632,Autocuration,,1,,,11196,0,22224,,In vivo,,Maximum concentration was calculated.,,U,,,BAO_0000218,,CHEMBL626043,,,A
5566,Autocuration,,1,,,11197,0,22224,,In vivo,,Maximum concentration at a peroral dose of 10 mg/kg,,U,,,BAO_0000218,,CHEMBL626044,,,A
11883,Autocuration,,1,,,11198,0,22224,,In vivo,,Maximum concentration of the drug at 10 uM/dg administered perorally,,U,,,BAO_0000218,,CHEMBL626045,,,A
11883,Autocuration,,1,,,11199,0,22224,,In vivo,,Maximum concentration of the drug at 2 uM/dg administered intravenously,,U,,,BAO_0000218,,CHEMBL626046,,,A
14122,Intermediate,,1,,9615.0,11200,1,50588,,In vivo,Plasma,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626047,,,A
14122,Intermediate,,1,,10026.0,11201,1,100712,,In vivo,Plasma,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,N,,Cricetinae,BAO_0000218,1969.0,CHEMBL626048,,,A
14122,Intermediate,,1,,10116.0,11202,1,50597,,In vivo,Plasma,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626049,,,A
12542,Intermediate,,1,,10116.0,11203,1,50597,,In vivo,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626050,,,A
12542,Intermediate,,1,,9615.0,11204,1,50588,,In vivo,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL874541,,,A
12542,Intermediate,,1,,10026.0,11205,1,100712,,In vivo,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,N,,Cricetinae,BAO_0000218,1969.0,CHEMBL622826,,,A
12542,Intermediate,,1,,10026.0,11206,1,100712,,In vivo,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,N,,Cricetinae,BAO_0000218,1969.0,CHEMBL622827,,,A
12542,Intermediate,,1,,10116.0,11207,1,50597,,In vivo,Plasma,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622828,,,A
14080,Intermediate,,1,,10116.0,11208,1,50597,,In vivo,Plasma,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622829,,,A
11911,Intermediate,,1,,10116.0,11209,1,50597,,In vivo,,Maximum concentration reached following intravenous administration in male rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876806,,,A
13204,Intermediate,,1,,9615.0,11210,1,50588,,In vivo,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622830,,,A
13204,Intermediate,,1,,10116.0,11211,1,50597,,In vivo,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622831,,,A
14346,Intermediate,,1,,9615.0,11212,1,50588,,In vivo,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626794,,,A
14346,Intermediate,,1,,10116.0,11213,1,50597,,In vivo,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626795,,,A
14346,Intermediate,,1,,10116.0,11214,1,50597,,In vivo,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626796,,,A
14346,Intermediate,,1,,10116.0,11215,1,50597,,In vivo,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626797,,,A
14127,Intermediate,,1,,10116.0,11216,1,50597,,In vivo,,Maximum drug concentration is determined after oral dosing in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626798,,,A
14339,Intermediate,,1,,9615.0,11217,1,50588,,In vivo,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626799,,,A
14339,Intermediate,,1,,9615.0,11218,1,50588,,In vivo,,Maximum observed concentration in oral (5 mg/kg) fed dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626800,,,A
13494,Autocuration,,1,,,11219,0,22224,,In vivo,Plasma,Maximum plasma concentration,,U,,,BAO_0000218,1969.0,CHEMBL626801,,,A
14925,Intermediate,,1,,10116.0,11220,1,50597,,In vivo,Plasma,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876816,,,A
14474,Intermediate,,1,,10116.0,11221,1,50597,,In vivo,Plasma,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626802,,,A
14474,Intermediate,,1,,9615.0,11222,1,50588,,In vivo,Plasma,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626803,,,A
13917,Autocuration,,1,,,11223,0,22224,,In vivo,Plasma,Maximum plasma concentration following oral administration of 30 umol/kg,,U,,,BAO_0000218,1969.0,CHEMBL626804,,,A
9796,Intermediate,,1,,10116.0,11224,1,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626805,,,A
9796,Intermediate,,1,,10116.0,11225,1,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626309,,,A
9796,Intermediate,,1,,10116.0,11226,1,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626310,,,A
9796,Intermediate,,1,,10116.0,11227,1,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626311,,,A
9796,Intermediate,,1,,10116.0,11228,1,50597,,,Plasma,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626312,,,A
9796,Intermediate,,1,,10116.0,11229,1,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626313,,,A
9796,Intermediate,,1,,10116.0,11230,1,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626314,,,A
9796,Intermediate,,1,,10116.0,11231,1,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626315,,,A
9796,Intermediate,,1,,10116.0,11232,1,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626316,,,A
9796,Intermediate,,1,,10116.0,11233,1,50597,,,Uterus,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626317,,,A
8363,Intermediate,,1,,10116.0,11234,1,50597,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626318,,,A
8363,Intermediate,,1,,10116.0,11235,1,50597,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626319,,,A
8363,Intermediate,,1,,10116.0,11236,1,50597,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626320,,,A
8363,Intermediate,,1,,10116.0,11237,1,50597,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875053,,,A
8363,Intermediate,,1,,10116.0,11238,1,50597,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626321,,,A
8363,Intermediate,,1,,10116.0,11239,1,50597,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626322,,,A
8363,Intermediate,,1,,10116.0,11240,1,50597,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626323,,,A
8363,Intermediate,,1,,10116.0,11241,1,50597,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626324,,,A
8363,Intermediate,,1,,10116.0,11242,1,50597,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626325,,,A
8363,Intermediate,,1,,10116.0,11243,1,50597,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626326,,,A
8363,Intermediate,,1,,10116.0,11244,1,50597,,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626327,,,A
8363,Intermediate,,1,,10116.0,11245,1,50597,,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626328,,,A
8684,Intermediate,,1,,10116.0,11246,1,50597,,,Blood,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626329,,,A
8684,Intermediate,,1,,10116.0,11247,1,50597,,,Blood,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626330,,,A
8684,Intermediate,,1,,10116.0,11248,1,50597,,,Blood,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626331,,,A
8684,Intermediate,,1,,10116.0,11249,1,50597,,,Blood,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626332,,,A
8684,Intermediate,,1,,10116.0,11250,1,50597,,,Blood,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626333,,,A
8684,Intermediate,,1,,10116.0,11251,1,50597,,,Blood,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626334,,,A
8684,Intermediate,,1,,10116.0,11252,1,50597,,,Blood,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626335,,,A
8684,Intermediate,,1,,10116.0,11253,1,50597,,,Blood,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624798,,,A
8684,Intermediate,,1,,10116.0,11254,1,50597,,,Brain,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624799,,,A
8684,Intermediate,,1,,10116.0,11255,1,50597,,,Brain,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624800,,,A
8684,Intermediate,,1,,10116.0,11256,1,50597,,,Brain,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624801,,,A
8684,Intermediate,,1,,10116.0,11257,1,50597,,,Brain,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624802,,,A
8684,Intermediate,,1,,10116.0,11258,1,50597,,,Brain,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624803,,,A
8684,Intermediate,,1,,10116.0,11259,1,50597,,,Brain,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624804,,,A
8684,Intermediate,,1,,10116.0,11260,1,50597,,,Brain,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624805,,,A
8684,Intermediate,,1,,10116.0,11261,1,50597,,,Brain,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL624806,,,A
8684,Intermediate,,1,,10116.0,11262,1,50597,,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624807,,,A
8684,Intermediate,,1,,10116.0,11263,1,50597,,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624808,,,A
8684,Intermediate,,1,,10116.0,11264,1,50597,,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624809,,,A
8684,Intermediate,,1,,10116.0,11265,1,50597,,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624810,,,A
8684,Intermediate,,1,,10116.0,11266,1,50597,,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877618,,,A
8684,Intermediate,,1,,10116.0,11267,1,50597,,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624811,,,A
8684,Intermediate,,1,,10116.0,11268,1,50597,,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624812,,,A
8684,Intermediate,,1,,10116.0,11269,1,50597,,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624813,,,A
8684,Intermediate,,1,,10116.0,11270,1,50597,,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624814,,,A
8684,Intermediate,,1,,10116.0,11271,1,50597,,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624815,,,A
8684,Intermediate,,1,,10116.0,11272,1,50597,,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624816,,,A
8684,Intermediate,,1,,10116.0,11273,1,50597,,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624817,,,A
6996,Intermediate,,1,,9615.0,11274,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624818,,,A
6996,Intermediate,,1,,9615.0,11275,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624819,,,A
6996,Intermediate,,1,,9615.0,11276,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624820,,,A
6996,Intermediate,,1,,9615.0,11277,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624821,,,A
6996,Intermediate,,1,,9615.0,11278,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624822,,,A
6996,Intermediate,,1,,9615.0,11279,1,50588,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624823,,,A
15599,Intermediate,,1,,562.0,11280,1,50212,,,,Observed diffusion coefficient in organic solvent for Escherichia coli,,N,,Escherichia coli,BAO_0000218,,CHEMBL624824,,,A
9614,Intermediate,,1,,10116.0,11281,1,50597,,,Blood,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624825,,,A
9614,Intermediate,,1,,10116.0,11282,1,50597,,,Blood,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624826,,,A
9614,Intermediate,,1,,10116.0,11283,1,50597,,,Cardiac atrium,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,2081.0,CHEMBL876817,,,A
9614,Intermediate,,1,,10116.0,11284,1,50597,,,Cardiac atrium,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,2081.0,CHEMBL624827,,,A
9614,Intermediate,,1,,10116.0,11285,1,50597,,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624828,,,A
9614,Intermediate,,1,,10116.0,11286,1,50597,,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624829,,,A
9614,Intermediate,,1,,10116.0,11287,1,50597,,,Liver,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624830,,,A
9614,Intermediate,,1,,10116.0,11288,1,50597,,,Liver,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624831,,,A
9614,Intermediate,,1,,10116.0,11289,1,50597,,,Cardiac atrium,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,2081.0,CHEMBL624832,,,A
9614,Intermediate,,1,,10116.0,11290,1,50597,,,Cardiac atrium,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,2081.0,CHEMBL624833,,,A
9614,Intermediate,,1,,10116.0,11291,1,50597,,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624834,,,A
9614,Intermediate,,1,,10116.0,11292,1,50597,,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624835,,,A
9614,Intermediate,,1,,10116.0,11293,1,50597,,,Spleen,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL624836,,,A
9614,Intermediate,,1,,10116.0,11294,1,50597,,,Spleen,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL624837,,,A
9071,Intermediate,,1,,10116.0,11295,1,50597,,,Blood,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624838,,,A
9071,Intermediate,,1,,10116.0,11296,1,50597,,,Blood,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622188,,,A
9071,Intermediate,,1,,10116.0,11297,1,50597,,,Heart,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622189,,,A
9071,Intermediate,,1,,10116.0,11298,1,50597,,,Heart,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622190,,,A
9071,Intermediate,,1,,10116.0,11299,1,50597,,,Heart,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625170,,,A
9071,Intermediate,,1,,10116.0,11300,1,50597,,,Kidney,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625171,,,A
9071,Intermediate,,1,,10116.0,11301,1,50597,,,Kidney,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625172,,,A
9071,Intermediate,,1,,10116.0,11302,1,50597,,,Kidney,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625173,,,A
9071,Intermediate,,1,,10116.0,11303,1,50597,,,Liver,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625174,,,A
9071,Intermediate,,1,,10116.0,11304,1,50597,,,Liver,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625175,,,A
9071,Intermediate,,1,,10116.0,11305,1,50597,,,Liver,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625176,,,A
9071,Intermediate,,1,,10116.0,11306,1,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625177,,,A
9071,Intermediate,,1,,10116.0,11307,1,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625178,,,A
9071,Intermediate,,1,,10116.0,11308,1,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625179,,,A
9071,Intermediate,,1,,10116.0,11309,1,50597,,,Lung,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625180,,,A
10677,Autocuration,,1,,,11310,0,22224,,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,U,,,BAO_0000218,,CHEMBL625181,,,A
9750,Intermediate,,1,,10090.0,11311,1,50594,,,Urine,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL625182,,,A
8319,Intermediate,,1,,10116.0,11312,1,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625183,,,A
8319,Intermediate,,1,,10116.0,11313,1,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875848,,,A
8319,Intermediate,,1,,10116.0,11314,1,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622260,,,A
8319,Intermediate,,1,,10116.0,11315,1,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622261,,,A
8319,Intermediate,,1,,10116.0,11316,1,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622262,,,A
8319,Intermediate,,1,,10116.0,11317,1,50597,,,Kidney,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622263,,,A
8319,Intermediate,,1,,10116.0,11318,1,50597,,,Kidney,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622418,,,A
8319,Intermediate,,1,,10116.0,11319,1,50597,,,Liver,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622419,,,A
13256,Intermediate,,1,,10090.0,11320,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL623388,,,A
13256,Intermediate,,1,,10090.0,11321,1,50594,,In vivo,Liver,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL623389,,,A
13256,Intermediate,,1,,10090.0,11322,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL623390,,,A
13256,Intermediate,,1,,10090.0,11323,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL623391,,,A
13256,Intermediate,,1,,10090.0,11324,1,50594,,In vivo,Blood,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL623392,,,A
13256,Intermediate,,1,,10090.0,11325,1,50594,,In vivo,Cerebellum,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2037.0,CHEMBL623393,,,A
13256,Intermediate,,1,,10090.0,11326,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL623394,,,A
13256,Intermediate,,1,,10090.0,11327,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL618885,,,A
13256,Intermediate,,1,,10090.0,11328,1,50594,,In vivo,Liver,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618886,,,A
13256,Intermediate,,1,,10090.0,11329,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL618887,,,A
13256,Intermediate,,1,,10090.0,11330,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL619535,,,A
13256,Intermediate,,1,,10090.0,11331,1,50594,,In vivo,Blood,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL619536,,,A
13256,Intermediate,,1,,10090.0,11332,1,50594,,In vivo,Cerebellum,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2037.0,CHEMBL619537,,,A
13256,Intermediate,,1,,10090.0,11333,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL619705,,,A
13256,Intermediate,,1,,10090.0,11334,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL619706,,,A
13256,Intermediate,,1,,10090.0,11335,1,50594,,In vivo,Liver,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL619707,,,A
13256,Intermediate,,1,,10090.0,11336,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL619708,,,A
13256,Intermediate,,1,,10090.0,11337,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL625219,,,A
13256,Intermediate,,1,,10090.0,11338,1,50594,,In vivo,Blood,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,178.0,CHEMBL625220,,,A
13256,Intermediate,,1,,10090.0,11339,1,50594,,In vivo,Cerebellum,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2037.0,CHEMBL625221,,,A
13256,Intermediate,,1,,10090.0,11340,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL625222,,,A
13256,Intermediate,,1,,10090.0,11341,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL625223,,,A
13256,Intermediate,,1,,10090.0,11342,1,50594,,In vivo,Liver,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL625224,,,A
13256,Intermediate,,1,,10090.0,11343,1,50594,,In vivo,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,N,,Mus musculus,BAO_0000218,,CHEMBL625225,,,A
8829,Intermediate,,1,,10116.0,11344,1,50597,,In vivo,Blood,Biodistribution in Rat blood after 24 hours of iv administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625226,,,A
8829,Intermediate,,1,,10116.0,11345,1,50597,,In vivo,Blood,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625227,,,A
8829,Intermediate,,1,,10116.0,11346,1,50597,,In vivo,Blood,Biodistribution in Rat blood after 30 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625228,,,A
8829,Intermediate,,1,,10116.0,11347,1,50597,,In vivo,Blood,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL875354,,,A
8829,Intermediate,,1,,10116.0,11348,1,50597,,In vivo,Blood,Biodistribution in Rat blood after 5 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625229,,,A
8829,Intermediate,,1,,10116.0,11349,1,50597,,In vivo,Blood,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625230,,,A
8829,Intermediate,,1,,10116.0,11350,1,50597,,In vivo,Heart,Biodistribution in Rat heart after 24 hours of iv administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625231,,,A
8829,Intermediate,,1,,10116.0,11351,1,50597,,In vivo,Heart,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625900,,,A
8829,Intermediate,,1,,10116.0,11352,1,50597,,In vivo,Heart,Biodistribution in Rat heart after 30 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625901,,,A
8829,Intermediate,,1,,10116.0,11353,1,50597,,In vivo,Heart,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625902,,,A
8829,Intermediate,,1,,10116.0,11354,1,50597,,In vivo,Heart,Biodistribution in Rat heart after 5 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625903,,,A
8829,Intermediate,,1,,10116.0,11355,1,50597,,In vivo,Heart,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625904,,,A
8829,Intermediate,,1,,10116.0,11356,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 24 hours of iv administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625905,,,A
8829,Intermediate,,1,,10116.0,11357,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627861,,,A
8829,Intermediate,,1,,10116.0,11358,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 30 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627862,,,A
8829,Intermediate,,1,,10116.0,11359,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627863,,,A
8829,Intermediate,,1,,10116.0,11360,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 30 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627769,,,A
13249,Intermediate,,1,,9615.0,11361,1,50588,,In vivo,Plasma,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL627770,,,A
13622,Intermediate,,1,,9541.0,11362,1,100710,,In vivo,,Cmax in cynomolgus monkey (PO dose),,N,,Macaca fascicularis,BAO_0000218,,CHEMBL627771,,,A
13622,Intermediate,,1,,10116.0,11363,1,50597,,In vivo,,Cmax in rat (PO dose),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627772,,,A
13622,Intermediate,,1,,10116.0,11364,1,50597,,In vivo,,Cmax in rat (PO dose),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627773,,,A
13494,Intermediate,,1,,10116.0,11365,1,50597,,In vivo,Plasma,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621922,,,A
12170,Intermediate,,1,,10116.0,11366,1,50597,,In vivo,Plasma,Cmax in rat plasma after oral dose (10 mg/kg),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621923,,,A
12170,Autocuration,,1,,,11367,0,22224,,In vivo,Plasma,Cmax in plasma after oral dose (10 mg/kg),,U,,,BAO_0000218,1969.0,CHEMBL621924,,,A
17025,Intermediate,,1,,9615.0,11368,1,50588,,In vivo,Plasma,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621925,,,A
17025,Autocuration,,1,,314293.0,11369,0,22224,,In vivo,Plasma,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL621926,,,A
17025,Intermediate,,1,,9986.0,11370,1,50592,,In vivo,Plasma,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,N,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL621927,,,A
17025,Intermediate,,1,,10116.0,11371,1,50597,,In vivo,Plasma,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621928,,,A
14187,Intermediate,,1,,10116.0,11372,1,50597,,In vivo,Plasma,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621929,,,A
14816,Intermediate,,1,,10090.0,11373,1,50594,,In vivo,Plasma,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL621930,,,A
17820,Intermediate,,1,,10116.0,11374,1,50597,,In vivo,Plasma,Maximum plasma concentration after oral dosing in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621931,,,A
14380,Autocuration,,1,,,11375,0,22224,,In vivo,Plasma,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621932,,,A
14380,Autocuration,,1,,,11376,0,22224,,In vivo,Plasma,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621933,,,A
14691,Intermediate,,1,,9615.0,11377,1,50588,,In vivo,Plasma,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621934,,,A
14691,Intermediate,,1,,9615.0,11378,1,50588,,In vivo,Plasma,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL621935,,,A
13375,Intermediate,,1,,10116.0,11379,1,50597,,In vivo,Plasma,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL621936,,,A
6236,Autocuration,,1,,,11380,0,22224,,In vivo,Plasma,Maximum plasma concentration was determined,,U,,,BAO_0000218,1969.0,CHEMBL621937,,,A
14380,Autocuration,,1,,,11381,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621938,,,A
14380,Autocuration,,1,,,11382,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621939,,,A
14380,Autocuration,,1,,,11383,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621940,,,A
14380,Autocuration,,1,,,11384,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621941,,,A
14380,Autocuration,,1,,,11385,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL621942,,,A
14380,Autocuration,,1,,,11386,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL626178,,,A
14380,Autocuration,,1,,,11387,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL626179,,,A
14380,Autocuration,,1,,,11388,0,22224,,In vivo,Plasma,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,1969.0,CHEMBL626180,,,A
13622,Intermediate,,1,,10116.0,11389,1,50597,,In vivo,Plasma,Plasma Cmax in rat (PO dose),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626181,,,A
15372,Intermediate,,1,,10116.0,11390,1,50597,,In vivo,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626182,,,A
15372,Intermediate,,1,,10116.0,11391,1,50597,,In vivo,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626183,,,A
15372,Intermediate,,1,,10116.0,11392,1,50597,,In vivo,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626184,,,A
15372,Intermediate,,1,,10116.0,11393,1,50597,,In vivo,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626185,,,A
14925,Intermediate,,1,,9615.0,11394,1,50588,,In vivo,Plasma,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626186,,,A
14925,Intermediate,,1,,9615.0,11395,1,50588,,In vivo,Plasma,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL877589,,,A
11883,Autocuration,,1,,,11396,0,22224,,In vivo,,Maximum concentration of the drug at 1 uM/dg administered intravenously,,U,,,BAO_0000218,,CHEMBL626187,,,A
11883,Autocuration,,1,,,11397,0,22224,,In vivo,,Maximum concentration of the drug at 20 uM/dg administered perorally,,U,,,BAO_0000218,,CHEMBL626188,,,A
13391,Autocuration,,1,,,11398,0,22224,,In vivo,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,U,,,BAO_0000218,,CHEMBL626189,,,A
13391,Autocuration,,1,,,11399,0,22224,,In vivo,Blood,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,U,,,BAO_0000218,178.0,CHEMBL626855,,,A
13391,Autocuration,,1,,,11400,0,22224,,In vivo,Blood,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,U,,,BAO_0000218,178.0,CHEMBL623781,,,A
13391,Autocuration,,1,,,11401,0,22224,,In vivo,Blood,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,U,,,BAO_0000218,178.0,CHEMBL623782,,,A
16360,Intermediate,,1,,10116.0,11402,1,50597,,In vivo,Plasma,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623783,,,A
3673,Intermediate,,1,,9615.0,11403,1,50588,,In vivo,Plasma,Cmax in dog plasma after 1mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623784,,,A
14431,Intermediate,,1,,9615.0,11404,1,50588,,In vivo,Plasma,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623785,,,A
14431,Intermediate,,1,,10116.0,11405,1,50597,,In vivo,Plasma,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623786,,,A
14964,Intermediate,,1,,10116.0,11406,1,50597,,In vivo,,Oral maximum concentration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623787,,,A
14964,Intermediate,,1,,10116.0,11407,1,50597,,In vivo,,Oral maximum concentration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623788,,,A
14209,Intermediate,,1,,10090.0,11408,1,50594,,In vivo,Plasma,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623789,,,A
11355,Intermediate,,1,,10090.0,11409,1,50594,,In vivo,Blood,Peak concentration in blood after intravenous administration to mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL623790,,,A
11355,Intermediate,,1,,10090.0,11410,1,50594,,In vivo,Blood,Peak concentration in blood after peroral administration to mice,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL623791,,,A
11966,Intermediate,,1,,10116.0,11411,1,50597,,In vivo,Plasma,Peak concentration in rat plasma was determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623792,,,A
8918,Autocuration,,1,,314293.0,11412,0,22224,,In vivo,Plasma,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL623793,,,A
8918,Intermediate,,1,,10090.0,11413,1,50594,,In vivo,Plasma,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623794,,,A
8918,Intermediate,,1,,10116.0,11414,1,50597,,In vivo,Plasma,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623795,,,A
8684,Intermediate,,1,,10116.0,11415,1,50597,,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623796,,,A
8684,Intermediate,,1,,10116.0,11416,1,50597,,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623797,,,A
8684,Intermediate,,1,,10116.0,11417,1,50597,,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623798,,,A
8684,Intermediate,,1,,10116.0,11418,1,50597,,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623799,,,A
8684,Intermediate,,1,,10116.0,11419,1,50597,,,Intestine,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624490,,,A
8684,Intermediate,,1,,10116.0,11420,1,50597,,,Intestine,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624491,,,A
8684,Intermediate,,1,,10116.0,11421,1,50597,,,Intestine,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624492,,,A
8684,Intermediate,,1,,10116.0,11422,1,50597,,,Intestine,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624493,,,A
8684,Intermediate,,1,,10116.0,11423,1,50597,,,Intestine,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL877595,,,A
8684,Intermediate,,1,,10116.0,11424,1,50597,,,Intestine,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624494,,,A
8684,Intermediate,,1,,10116.0,11425,1,50597,,,Intestine,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624495,,,A
8684,Intermediate,,1,,10116.0,11426,1,50597,,,Intestine,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL624681,,,A
8684,Intermediate,,1,,10116.0,11427,1,50597,,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624682,,,A
8684,Intermediate,,1,,10116.0,11428,1,50597,,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624683,,,A
8684,Intermediate,,1,,10116.0,11429,1,50597,,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624684,,,A
8684,Intermediate,,1,,10116.0,11430,1,50597,,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624685,,,A
8684,Intermediate,,1,,10116.0,11431,1,50597,,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624686,,,A
8684,Intermediate,,1,,10116.0,11432,1,50597,,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624687,,,A
8684,Intermediate,,1,,10116.0,11433,1,50597,,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624688,,,A
8684,Intermediate,,1,,10116.0,11434,1,50597,,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627161,,,A
8684,Intermediate,,1,,10116.0,11435,1,50597,,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622127,,,A
8684,Intermediate,,1,,10116.0,11436,1,50597,,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622128,,,A
8684,Intermediate,,1,,10116.0,11437,1,50597,,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874384,,,A
8684,Intermediate,,1,,10116.0,11438,1,50597,,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624898,,,A
8684,Intermediate,,1,,10116.0,11439,1,50597,,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624899,,,A
8684,Intermediate,,1,,10116.0,11440,1,50597,,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624900,,,A
8684,Intermediate,,1,,10116.0,11441,1,50597,,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624901,,,A
8684,Intermediate,,1,,10116.0,11442,1,50597,,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624902,,,A
8684,Intermediate,,1,,10116.0,11443,1,50597,,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624903,,,A
8684,Intermediate,,1,,10116.0,11444,1,50597,,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624904,,,A
8684,Intermediate,,1,,10116.0,11445,1,50597,,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624905,,,A
8684,Intermediate,,1,,10116.0,11446,1,50597,,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624906,,,A
8684,Intermediate,,1,,10116.0,11447,1,50597,,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624907,,,A
8684,Intermediate,,1,,10116.0,11448,1,50597,,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624908,,,A
8684,Intermediate,,1,,10116.0,11449,1,50597,,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624909,,,A
8684,Intermediate,,1,,10116.0,11450,1,50597,,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624910,,,A
8684,Intermediate,,1,,10116.0,11451,1,50597,,,Muscle tissue,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624911,,,A
8684,Intermediate,,1,,10116.0,11452,1,50597,,,Muscle tissue,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL874388,,,A
8684,Intermediate,,1,,10116.0,11453,1,50597,,,Muscle tissue,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL624912,,,A
8684,Intermediate,,1,,10116.0,11454,1,50597,,,Muscle tissue,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622930,,,A
8684,Intermediate,,1,,10116.0,11455,1,50597,,,Muscle tissue,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623121,,,A
8684,Intermediate,,1,,10116.0,11456,1,50597,,,Muscle tissue,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623122,,,A
8684,Intermediate,,1,,10116.0,11457,1,50597,,,Muscle tissue,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623123,,,A
8684,Intermediate,,1,,10116.0,11458,1,50597,,,Muscle tissue,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623124,,,A
8684,Intermediate,,1,,10116.0,11459,1,50597,,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623125,,,A
8684,Intermediate,,1,,10116.0,11460,1,50597,,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623126,,,A
8684,Intermediate,,1,,10116.0,11461,1,50597,,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623127,,,A
8684,Intermediate,,1,,10116.0,11462,1,50597,,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623128,,,A
8684,Intermediate,,1,,10116.0,11463,1,50597,,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623129,,,A
8684,Intermediate,,1,,10116.0,11464,1,50597,,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623130,,,A
8684,Intermediate,,1,,10116.0,11465,1,50597,,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623131,,,A
8684,Intermediate,,1,,10116.0,11466,1,50597,,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623132,,,A
8319,Intermediate,,1,,10116.0,11467,1,50597,,,Liver,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623133,,,A
8319,Intermediate,,1,,10116.0,11468,1,50597,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623134,,,A
8319,Intermediate,,1,,10116.0,11469,1,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874389,,,A
8319,Intermediate,,1,,10116.0,11470,1,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623135,,,A
8319,Intermediate,,1,,10116.0,11471,1,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623136,,,A
8319,Intermediate,,1,,10116.0,11472,1,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623137,,,A
8319,Intermediate,,1,,10116.0,11473,1,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623138,,,A
8319,Intermediate,,1,,10116.0,11474,1,50597,,,Kidney,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623139,,,A
8319,Intermediate,,1,,10116.0,11475,1,50597,,,Kidney,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623140,,,A
8319,Intermediate,,1,,10116.0,11476,1,50597,,,Liver,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623141,,,A
8319,Intermediate,,1,,10116.0,11477,1,50597,,,Liver,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623142,,,A
8319,Intermediate,,1,,10116.0,11478,1,50597,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623143,,,A
14571,Intermediate,,1,,10090.0,11479,1,50594,,,Urine,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL623144,,,A
14571,Intermediate,,1,,10116.0,11480,1,50597,,,Urine,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623405,,,A
8319,Intermediate,,1,,10116.0,11481,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624074,,,A
8319,Intermediate,,1,,10116.0,11482,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624075,,,A
8319,Intermediate,,1,,10116.0,11483,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624076,,,A
8319,Intermediate,,1,,10116.0,11484,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624077,,,A
8319,Intermediate,,1,,10116.0,11485,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624078,,,A
8319,Intermediate,,1,,10116.0,11486,1,50597,,,Kidney,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624079,,,A
8319,Intermediate,,1,,10116.0,11487,1,50597,,,Kidney,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624261,,,A
8319,Intermediate,,1,,10116.0,11488,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624262,,,A
8319,Intermediate,,1,,10116.0,11489,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624263,,,A
8319,Intermediate,,1,,10116.0,11490,1,50597,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624264,,,A
8319,Intermediate,,1,,10116.0,11491,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624265,,,A
8319,Intermediate,,1,,10116.0,11492,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624266,,,A
8319,Intermediate,,1,,10116.0,11493,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624267,,,A
8319,Intermediate,,1,,10116.0,11494,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624268,,,A
8319,Intermediate,,1,,10116.0,11495,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875227,,,A
8319,Intermediate,,1,,10116.0,11496,1,50597,,,Kidney,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624269,,,A
8319,Intermediate,,1,,10116.0,11497,1,50597,,,Kidney,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624270,,,A
8319,Intermediate,,1,,10116.0,11498,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624271,,,A
8319,Intermediate,,1,,10116.0,11499,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624272,,,A
8319,Intermediate,,1,,10116.0,11500,1,50597,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624273,,,A
12064,Intermediate,,1,,10116.0,11501,1,50597,,,Urine,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624274,,,A
12064,Intermediate,,1,,10116.0,11502,1,50597,,,Urine,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624275,,,A
12064,Intermediate,,1,,10116.0,11503,1,50597,,,Urine,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624276,,,A
12038,Intermediate,,1,,10116.0,11504,1,50597,,,Urine,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624277,,,A
14314,Autocuration,,1,,,11505,0,22224,,,,% dose converted to 2-amino-5-chlorophenyl sulfate,,U,,,BAO_0000019,,CHEMBL624278,,,A
14314,Autocuration,,1,,,11506,0,22224,,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,U,,,BAO_0000019,,CHEMBL624279,,,A
11488,Intermediate,,1,,10116.0,11507,1,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL624280,,,A
11488,Intermediate,,1,,10116.0,11508,1,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL624281,,,A
11488,Intermediate,,1,,10116.0,11509,1,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL622933,,,A
11488,Intermediate,,1,,10116.0,11510,1,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL622934,,,A
8829,Intermediate,,1,,10116.0,11511,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622935,,,A
8829,Intermediate,,1,,10116.0,11512,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 5 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622936,,,A
8829,Intermediate,,1,,10116.0,11513,1,50597,,In vivo,Liver,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL875228,,,A
8829,Intermediate,,1,,10116.0,11514,1,50597,,In vivo,Lung,Biodistribution in Rat lung after 24 hours of iv administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622937,,,A
8829,Intermediate,,1,,10116.0,11515,1,50597,,In vivo,Lung,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622938,,,A
8829,Intermediate,,1,,10116.0,11516,1,50597,,In vivo,Lung,Biodistribution in Rat lung after 30 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL619736,,,A
8829,Intermediate,,1,,10116.0,11517,1,50597,,In vivo,Lung,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625117,,,A
8829,Intermediate,,1,,10116.0,11518,1,50597,,In vivo,Lung,Biodistribution in Rat lung after 5 minutes of iv administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625118,,,A
8829,Intermediate,,1,,10116.0,11519,1,50597,,In vivo,Lung,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625119,,,A
14972,Intermediate,,1,,10116.0,11520,1,50597,,In vivo,Cerebellum,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL625120,,,A
14972,Intermediate,,1,,10116.0,11521,1,50597,,In vivo,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625121,,,A
14972,Intermediate,,1,,10116.0,11522,1,50597,,In vivo,Thalamus,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,N,,Rattus norvegicus,BAO_0000218,10000006.0,CHEMBL625122,,,A
14608,Intermediate,,1,,10116.0,11523,1,50597,,In vivo,Blood,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL622204,,,A
14608,Intermediate,,1,,10116.0,11524,1,50597,,In vivo,Blood,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL877503,,,A
14608,Intermediate,,1,,10116.0,11525,1,50597,,In vivo,Blood,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627127,,,A
14608,Autocuration,,1,,,11526,0,22224,,In vivo,Hippocampus,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,U,,,BAO_0000218,10000000.0,CHEMBL627128,,,A
14608,Autocuration,,1,,,11527,0,22224,,In vivo,Hippocampus,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,U,,,BAO_0000218,10000000.0,CHEMBL627129,,,A
14608,Autocuration,,1,,,11528,0,22224,,In vivo,Hippocampus,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,U,,,BAO_0000218,10000000.0,CHEMBL627130,,,A
14608,Intermediate,,1,,10116.0,11529,1,50597,,In vivo,Brain,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL627131,,,A
14608,Intermediate,,1,,10116.0,11530,1,50597,,In vivo,Brain,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL627132,,,A
14608,Intermediate,,1,,10116.0,11531,1,50597,,In vivo,Brain,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL627133,,,A
14608,Intermediate,,1,,10116.0,11532,1,50597,,In vivo,Cerebellum,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL627134,,,A
14608,Intermediate,,1,,10116.0,11533,1,50597,,In vivo,Cerebellum,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL627135,,,A
14608,Intermediate,,1,,10116.0,11534,1,50597,,In vivo,Cerebellum,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL627136,,,A
14608,Intermediate,,1,,10116.0,11535,1,50597,,In vivo,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628435,,,A
14608,Intermediate,,1,,10116.0,11536,1,50597,,In vivo,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628436,,,A
14608,Intermediate,,1,,10116.0,11537,1,50597,,In vivo,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628437,,,A
14608,Intermediate,,1,,10116.0,11538,1,50597,,In vivo,Heart,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL628438,,,A
14608,Intermediate,,1,,10116.0,11539,1,50597,,In vivo,Heart,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL628439,,,A
14608,Intermediate,,1,,10116.0,11540,1,50597,,In vivo,Heart,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL628440,,,A
14608,Intermediate,,1,,10116.0,11541,1,50597,,In vivo,Hippocampus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL628441,,,A
14608,Intermediate,,1,,10116.0,11542,1,50597,,In vivo,Hippocampus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL628442,,,A
14608,Intermediate,,1,,10116.0,11543,1,50597,,In vivo,Hippocampus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL628443,,,A
14608,Intermediate,,1,,10116.0,11544,1,50597,,In vivo,Kidney,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628444,,,A
14608,Intermediate,,1,,10116.0,11545,1,50597,,In vivo,Kidney,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628445,,,A
14608,Intermediate,,1,,10116.0,11546,1,50597,,In vivo,Kidney,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL877504,,,A
14608,Intermediate,,1,,10116.0,11547,1,50597,,In vivo,Liver,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628446,,,A
14608,Intermediate,,1,,10116.0,11548,1,50597,,In vivo,Liver,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626874,,,A
14608,Intermediate,,1,,10116.0,11549,1,50597,,In vivo,Liver,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626875,,,A
14608,Intermediate,,1,,10116.0,11550,1,50597,,In vivo,Lung,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626876,,,A
14608,Intermediate,,1,,10116.0,11551,1,50597,,In vivo,Lung,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626877,,,A
14608,Intermediate,,1,,10116.0,11552,1,50597,,In vivo,Lung,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626878,,,A
14608,Intermediate,,1,,10116.0,11553,1,50597,,In vivo,Muscle tissue,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL626879,,,A
8918,Autocuration,,1,,314293.0,11554,0,22224,,In vivo,Plasma,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL626880,,,A
8918,Intermediate,,1,,10090.0,11555,1,50594,,In vivo,Plasma,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL626881,,,A
8918,Intermediate,,1,,10116.0,11556,1,50597,,In vivo,Plasma,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626882,,,A
14470,Intermediate,,1,,9615.0,11557,1,50588,,In vivo,Plasma,Peak plasma concentration was measured in dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626883,,,A
14393,Intermediate,,1,,10116.0,11558,1,50597,,In vivo,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626884,,,A
14886,Intermediate,,1,,10116.0,11559,1,50597,,In vivo,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626885,,,A
14886,Intermediate,,1,,10116.0,11560,1,50597,,In vivo,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626886,,,A
14886,Intermediate,,1,,10116.0,11561,1,50597,,In vivo,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626887,,,A
14393,Intermediate,,1,,10116.0,11562,1,50597,,In vivo,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626888,,,A
13465,Intermediate,,1,,9615.0,11563,1,50588,,In vivo,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626889,,,A
13465,Autocuration,,1,,314293.0,11564,0,22224,,In vivo,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL626761,,,A
13465,Intermediate,,1,,9615.0,11565,1,50588,,In vivo,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626762,,,A
13465,Intermediate,,1,,9615.0,11566,1,50588,,In vivo,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626763,,,A
13465,Intermediate,,1,,10116.0,11567,1,50597,,In vivo,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626764,,,A
13465,Intermediate,,1,,10116.0,11568,1,50597,,In vivo,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626765,,,A
13465,Intermediate,,1,,9615.0,11569,1,50588,,In vivo,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626766,,,A
13465,Intermediate,,1,,10116.0,11570,1,50597,,In vivo,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626767,,,A
13465,Intermediate,,1,,10116.0,11571,1,50597,,In vivo,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626768,,,A
13465,Intermediate,,1,,9615.0,11572,1,50588,,In vivo,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626769,,,A
13465,Intermediate,,1,,9615.0,11573,1,50588,,In vivo,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL874463,,,A
13465,Autocuration,,1,,314293.0,11574,0,22224,,In vivo,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL626770,,,A
13465,Autocuration,,1,,314293.0,11575,0,22224,,In vivo,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,U,,Simiiformes,BAO_0000218,,CHEMBL626771,,,A
13465,Intermediate,,1,,10116.0,11576,1,50597,,In vivo,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626772,,,A
14731,Intermediate,,1,,9541.0,11577,1,100710,,In vivo,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL626773,,,A
14731,Intermediate,,1,,10090.0,11578,1,50594,,In vivo,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,N,,Mus musculus,BAO_0000218,,CHEMBL626774,,,A
13376,Intermediate,,1,,9615.0,11579,1,50588,,In vivo,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626775,,,A
13376,Intermediate,,1,,9615.0,11580,1,50588,,In vivo,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626776,,,A
14443,Intermediate,,1,,10116.0,11581,1,50597,,In vivo,,Maximum concentration (Cmax) in rat when administered orally,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626777,,,A
13465,Autocuration,,1,,314293.0,11582,0,22224,,In vivo,Plasma,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL626778,,,A
16359,Autocuration,,1,,10116.0,11583,0,22224,,In vivo,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,U,,Rattus norvegicus,BAO_0000218,,CHEMBL626779,,,A
16359,Autocuration,,1,,10116.0,11584,0,22224,,In vivo,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,U,,Rattus norvegicus,BAO_0000218,,CHEMBL626780,,,A
15618,Autocuration,,1,,,11585,0,22224,,In vivo,Plasma,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,U,,,BAO_0000218,1969.0,CHEMBL626781,,,A
14554,Intermediate,,1,,10116.0,11586,1,50597,,In vivo,,Pharmacokinetic profile Cmax was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632164,,,A
11537,Intermediate,,1,,9615.0,11587,1,50588,,In vivo,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL632165,,,A
11537,Intermediate,,1,,10090.0,11588,1,50594,,In vivo,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,N,,Mus musculus,BAO_0000218,,CHEMBL632166,,,A
11537,Intermediate,,1,,9615.0,11589,1,50588,,In vivo,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL632167,,,A
11537,Intermediate,,1,,10090.0,11590,1,50594,,In vivo,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,N,,Mus musculus,BAO_0000218,,CHEMBL632168,,,A
2021,Autocuration,,1,,10116.0,11591,0,22224,,In vivo,Plasma,Cmax in rat plasma,,U,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632169,,,A
5932,Intermediate,,1,,9615.0,11592,1,50588,,In vivo,Plasma,Cmax in dog plasma after 30mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL632170,,,A
5932,Intermediate,,1,,10116.0,11593,1,50597,,In vivo,Plasma,Cmax in rat plasma after 30mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632171,,,A
17320,Intermediate,,1,,10116.0,11594,1,50597,,In vivo,Plasma,Plasma level in rats at 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632172,,,A
15831,Intermediate,,1,,10090.0,11595,1,50594,,In vivo,Plasma,Tested for maximum plasma concentration in mice,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL632173,,,A
15078,Intermediate,,1,,10116.0,11596,1,50597,,In vivo,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632174,,,A
14941,Intermediate,,1,,10116.0,11597,1,50597,,In vivo,,The Cmax values in female wistar rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632175,,,A
15343,Intermediate,,1,,9615.0,11598,1,50588,,In vivo,Plasma,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL632176,,,A
15343,Intermediate,,1,,10116.0,11599,1,50597,,In vivo,Plasma,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632177,,,A
14856,Intermediate,,1,,10116.0,11600,1,50597,,In vivo,Plasma,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632178,,,A
13129,Intermediate,,1,,10116.0,11601,1,50597,,In vivo,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632179,,,A
13098,Intermediate,,1,,10116.0,11602,1,50597,,In vivo,Blood,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632180,,,A
13098,Intermediate,,1,,10116.0,11603,1,50597,,In vivo,Blood,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632181,,,A
13098,Intermediate,,1,,10116.0,11604,1,50597,,In vivo,Blood,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632182,,,A
15478,Autocuration,,1,,10090.0,11605,0,22224,,In vivo,Blood,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,U,,Mus musculus,BAO_0000218,178.0,CHEMBL632183,,,A
15341,Intermediate,,1,,9615.0,11606,1,50588,,In vivo,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL632184,,,A
15341,Intermediate,,1,,10116.0,11607,1,50597,,In vivo,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874470,,,A
8684,Intermediate,,1,,10116.0,11608,1,50597,,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631302,,,A
8684,Intermediate,,1,,10116.0,11609,1,50597,,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631303,,,A
8684,Intermediate,,1,,10116.0,11610,1,50597,,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631304,,,A
8684,Intermediate,,1,,10116.0,11611,1,50597,,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631305,,,A
8684,Intermediate,,1,,10116.0,11612,1,50597,,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631306,,,A
8684,Intermediate,,1,,10116.0,11613,1,50597,,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631307,,,A
8684,Intermediate,,1,,10116.0,11614,1,50597,,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631308,,,A
8684,Intermediate,,1,,10116.0,11615,1,50597,,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625557,,,A
8684,Intermediate,,1,,10116.0,11616,1,50597,,,Spleen,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625558,,,A
8684,Intermediate,,1,,10116.0,11617,1,50597,,,Spleen,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625559,,,A
8684,Intermediate,,1,,10116.0,11618,1,50597,,,Spleen,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625560,,,A
8684,Intermediate,,1,,10116.0,11619,1,50597,,,Spleen,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625561,,,A
8684,Intermediate,,1,,10116.0,11620,1,50597,,,Spleen,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625562,,,A
8684,Intermediate,,1,,10116.0,11621,1,50597,,,Spleen,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL875320,,,A
8684,Intermediate,,1,,10116.0,11622,1,50597,,,Spleen,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625563,,,A
8684,Intermediate,,1,,10116.0,11623,1,50597,,,Spleen,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625564,,,A
8684,Intermediate,,1,,10116.0,11624,1,50597,,,Uterus,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL625565,,,A
8684,Intermediate,,1,,10116.0,11625,1,50597,,,Uterus,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL625566,,,A
8684,Intermediate,,1,,10116.0,11626,1,50597,,,Uterus,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL625567,,,A
8684,Intermediate,,1,,10116.0,11627,1,50597,,,Uterus,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL625568,,,A
8684,Intermediate,,1,,10116.0,11628,1,50597,,,Uterus,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL628217,,,A
8684,Intermediate,,1,,10116.0,11629,1,50597,,,Uterus,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL628218,,,A
8684,Intermediate,,1,,10116.0,11630,1,50597,,,Uterus,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL628219,,,A
8684,Intermediate,,1,,10116.0,11631,1,50597,,,Uterus,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL628220,,,A
8926,Autocuration,,1,,,11632,0,22224,,,,Distribution in the blood after 120 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628221,,,A
8926,Autocuration,,1,,,11633,0,22224,,,,Distribution in the blood after 15 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628222,,,A
8926,Autocuration,,1,,,11634,0,22224,,,,Distribution in the blood after 30 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628223,,,A
8926,Autocuration,,1,,,11635,0,22224,,,,Distribution in the blood after 5 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628224,,,A
8926,Autocuration,,1,,,11636,0,22224,,,,Distribution in the blood after 60 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628225,,,A
8926,Autocuration,,1,,,11637,0,22224,,,,Distribution in the blood after 90 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628226,,,A
8926,Autocuration,,1,,,11638,0,22224,,,,Distribution in the bone after 120 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628227,,,A
8926,Autocuration,,1,,,11639,0,22224,,,,Distribution in the bone after 15 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL875481,,,A
8926,Autocuration,,1,,,11640,0,22224,,,,Distribution in the bone after 30 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628228,,,A
8926,Autocuration,,1,,,11641,0,22224,,,,Distribution in the bone after 5 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628229,,,A
8926,Autocuration,,1,,,11642,0,22224,,,,Distribution in the bone after 60 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628230,,,A
8926,Autocuration,,1,,,11643,0,22224,,,,Distribution in the bone after 90 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628231,,,A
8926,Autocuration,,1,,,11644,0,22224,,,,Distribution in the heart after 120 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628232,,,A
8926,Autocuration,,1,,,11645,0,22224,,,,Distribution in the heart after 15 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628233,,,A
8926,Autocuration,,1,,,11646,0,22224,,,,Distribution in the heart after 30 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628234,,,A
8926,Autocuration,,1,,,11647,0,22224,,,,Distribution in the heart after 5 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628235,,,A
8926,Autocuration,,1,,,11648,0,22224,,,,Distribution in the heart after 60 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628236,,,A
8926,Autocuration,,1,,,11649,0,22224,,,,Distribution in the heart after 90 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628237,,,A
8926,Autocuration,,1,,,11650,0,22224,,,,Distribution in the kidneys after 120 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628238,,,A
8926,Autocuration,,1,,,11651,0,22224,,,,Distribution in the kidneys after 15 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628239,,,A
8926,Autocuration,,1,,,11652,0,22224,,,,Distribution in the kidneys after 30 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628240,,,A
8926,Autocuration,,1,,,11653,0,22224,,,,Distribution in the kidneys after 5 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628241,,,A
8926,Autocuration,,1,,,11654,0,22224,,,,Distribution in the kidneys after 60 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628242,,,A
8926,Autocuration,,1,,,11655,0,22224,,,,Distribution in the kidneys after 90 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL875482,,,A
8926,Autocuration,,1,,,11656,0,22224,,,,Distribution in the liver after 120 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628243,,,A
8926,Autocuration,,1,,,11657,0,22224,,,,Distribution in the liver after 15 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628244,,,A
8926,Autocuration,,1,,,11658,0,22224,,,,Distribution in the liver after 30 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628245,,,A
8926,Autocuration,,1,,,11659,0,22224,,,,Distribution in the liver after 5 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628246,,,A
8926,Autocuration,,1,,,11660,0,22224,,,,Distribution in the liver after 60 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628247,,,A
8926,Autocuration,,1,,,11661,0,22224,,,,Distribution in the liver after 90 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628248,,,A
8926,Autocuration,,1,,,11662,0,22224,,,,Distribution in the lung after 120 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628249,,,A
14839,Intermediate,,1,,10090.0,11663,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL625452,,,A
14839,Intermediate,,1,,10090.0,11664,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL625453,,,A
14839,Intermediate,,1,,10090.0,11665,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL625454,,,A
14839,Intermediate,,1,,10090.0,11666,1,50594,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,N,,Mus musculus,BAO_0000218,,CHEMBL623844,,,A
12178,Intermediate,,1,,10116.0,11667,1,50597,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623845,,,A
12178,Intermediate,,1,,10116.0,11668,1,50597,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623846,,,A
12178,Autocuration,,1,,,11669,0,22224,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,U,,,BAO_0000218,,CHEMBL623847,,,A
12186,Intermediate,,1,,9541.0,11670,1,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623848,,,A
12186,Intermediate,,1,,9541.0,11671,1,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623849,,,A
12186,Intermediate,,1,,9541.0,11672,1,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623850,,,A
12186,Intermediate,,1,,9541.0,11673,1,100710,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623851,,,A
12187,Autocuration,,1,,314293.0,11674,0,22224,,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL623852,,,A
12187,Intermediate,,1,,9669.0,11675,1,50506,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL624551,,,A
12187,Intermediate,,1,,9669.0,11676,1,50506,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,N,,Mustela putorius furo,BAO_0000218,,CHEMBL624552,,,A
12187,Autocuration,,1,,314293.0,11677,0,22224,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL624553,,,A
12187,Autocuration,,1,,314293.0,11678,0,22224,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,U,,Simiiformes,BAO_0000218,,CHEMBL624554,,,A
12187,Intermediate,,1,,10116.0,11679,1,50597,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624555,,,A
12187,Intermediate,,1,,10116.0,11680,1,50597,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624741,,,A
14122,Intermediate,,1,,9615.0,11681,1,50588,,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624742,,,A
14122,Intermediate,,1,,10026.0,11682,1,100712,,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,N,,Cricetinae,BAO_0000218,,CHEMBL624743,,,A
14122,Intermediate,,1,,10116.0,11683,1,50597,,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877606,,,A
13391,Autocuration,,1,,,11684,0,22224,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,U,,,BAO_0000218,,CHEMBL624744,,,A
13391,Autocuration,,1,,,11685,0,22224,,,Blood,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,U,,,BAO_0000218,178.0,CHEMBL624745,,,A
13391,Autocuration,,1,,,11686,0,22224,,,Blood,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,U,,,BAO_0000218,178.0,CHEMBL624746,,,A
13391,Autocuration,,1,,,11687,0,22224,,,Blood,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,U,,,BAO_0000218,178.0,CHEMBL624747,,,A
16360,Autocuration,,1,,,11688,0,22224,,,,Oral absorption expressed as Area under curve was determined,,U,,,BAO_0000019,,CHEMBL624748,,,A
3673,Intermediate,,1,,9615.0,11689,1,50588,,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622504,,,A
14122,Intermediate,,1,,9615.0,11690,1,50588,,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622505,,,A
14122,Intermediate,,1,,10026.0,11691,1,100712,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,N,,Cricetinae,BAO_0000218,,CHEMBL622506,,,A
14122,Intermediate,,1,,10026.0,11692,1,100712,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,N,,Cricetinae,BAO_0000218,,CHEMBL622507,,,A
14122,Intermediate,,1,,10116.0,11693,1,50597,,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622508,,,A
13889,Autocuration,,1,,,11694,0,22224,,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,U,,,BAO_0000019,,CHEMBL622509,,,A
14393,Intermediate,,1,,10116.0,11695,1,50597,,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622510,,,A
17279,Intermediate,,1,,10116.0,11696,1,50597,,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622511,,,A
14548,Intermediate,,1,,9541.0,11697,1,100710,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL622512,,,A
14548,Intermediate,,1,,9541.0,11698,1,100710,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL622513,,,A
14548,Intermediate,,1,,9541.0,11699,1,100710,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL622514,,,A
14548,Intermediate,,1,,9615.0,11700,1,50588,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622515,,,A
14548,Intermediate,,1,,9615.0,11701,1,50588,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622516,,,A
14548,Intermediate,,1,,10116.0,11702,1,50597,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622517,,,A
14548,Intermediate,,1,,10116.0,11703,1,50597,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622518,,,A
14548,Intermediate,,1,,10116.0,11704,1,50597,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622519,,,A
14608,Intermediate,,1,,10116.0,11705,1,50597,,In vivo,Muscle tissue,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622520,,,A
14608,Intermediate,,1,,10116.0,11706,1,50597,,In vivo,Muscle tissue,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622521,,,A
14608,Intermediate,,1,,10090.0,11707,1,50594,,In vivo,Zone of skin,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Mus musculus,BAO_0000218,14.0,CHEMBL625113,,,A
14608,Intermediate,,1,,10116.0,11708,1,50597,,In vivo,Zone of skin,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL625114,,,A
14608,Intermediate,,1,,10116.0,11709,1,50597,,In vivo,Zone of skin,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL874397,,,A
14608,Intermediate,,1,,10116.0,11710,1,50597,,In vivo,Spleen,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625115,,,A
14608,Intermediate,,1,,10116.0,11711,1,50597,,In vivo,Spleen,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625116,,,A
14608,Intermediate,,1,,10116.0,11712,1,50597,,In vivo,Spleen,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL623932,,,A
14608,Intermediate,,1,,10116.0,11713,1,50597,,In vivo,Striatum,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL623933,,,A
14608,Intermediate,,1,,10116.0,11714,1,50597,,In vivo,Striatum,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL623934,,,A
14608,Intermediate,,1,,10116.0,11715,1,50597,,In vivo,Striatum,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL623935,,,A
14608,Intermediate,,1,,10116.0,11716,1,50597,,In vivo,Thyroid gland,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL623936,,,A
14608,Intermediate,,1,,10116.0,11717,1,50597,,In vivo,Thyroid gland,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL623937,,,A
14608,Intermediate,,1,,10116.0,11718,1,50597,,In vivo,Thyroid gland,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL623938,,,A
15383,Intermediate,,1,,10090.0,11719,1,50594,,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,,CHEMBL623939,,,A
15383,Intermediate,,1,,10090.0,11720,1,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL623940,,,A
15383,Intermediate,,1,,10090.0,11721,1,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL623941,,,A
15383,Intermediate,,1,,10090.0,11722,1,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL627216,,,A
15383,Intermediate,,1,,10090.0,11723,1,50594,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL623942,,,A
15383,Intermediate,,1,,10090.0,11724,1,50594,,,Brain,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618793,,,A
15383,Intermediate,,1,,10090.0,11725,1,50594,,,Brain,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618794,,,A
15383,Intermediate,,1,,10090.0,11726,1,50594,,,Brain,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL618795,,,A
15383,Intermediate,,1,,10090.0,11727,1,50594,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL618796,,,A
15383,Intermediate,,1,,10090.0,11728,1,50594,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL618797,,,A
15383,Intermediate,,1,,10090.0,11729,1,50594,,,Kidney,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618798,,,A
15383,Intermediate,,1,,10090.0,11730,1,50594,,,Kidney,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618799,,,A
15383,Intermediate,,1,,10090.0,11731,1,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618800,,,A
15383,Intermediate,,1,,10090.0,11732,1,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618801,,,A
15383,Intermediate,,1,,10090.0,11733,1,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618802,,,A
15383,Intermediate,,1,,10090.0,11734,1,50594,,,Kidney,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL618803,,,A
15383,Intermediate,,1,,10090.0,11735,1,50594,,,Liver,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618804,,,A
15383,Intermediate,,1,,10090.0,11736,1,50594,,,Liver,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618805,,,A
15383,Intermediate,,1,,10090.0,11737,1,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618806,,,A
15383,Intermediate,,1,,10090.0,11738,1,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618807,,,A
15383,Intermediate,,1,,10090.0,11739,1,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618808,,,A
15383,Intermediate,,1,,10090.0,11740,1,50594,,,Liver,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL618809,,,A
15383,Intermediate,,1,,10090.0,11741,1,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL618810,,,A
15383,Intermediate,,1,,10090.0,11742,1,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL618811,,,A
15383,Intermediate,,1,,10090.0,11743,1,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL875844,,,A
15383,Intermediate,,1,,10090.0,11744,1,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL618812,,,A
15383,Intermediate,,1,,10090.0,11745,1,50594,,,Muscle tissue,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL618813,,,A
15383,Intermediate,,1,,10090.0,11746,1,50594,,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,,CHEMBL618814,,,A
15383,Intermediate,,1,,10090.0,11747,1,50594,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL618815,,,A
15383,Intermediate,,1,,10090.0,11748,1,50594,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL618816,,,A
15383,Intermediate,,1,,10090.0,11749,1,50594,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL618817,,,A
15383,Intermediate,,1,,10090.0,11750,1,50594,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL620544,,,A
15341,Intermediate,,1,,10116.0,11751,1,50597,,In vivo,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626230,,,A
15341,Intermediate,,1,,10116.0,11752,1,50597,,In vivo,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626231,,,A
15341,Intermediate,,1,,10116.0,11753,1,50597,,In vivo,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626232,,,A
14906,Intermediate,,1,,9615.0,11754,1,50588,,In vivo,Plasma,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626233,,,A
14906,Intermediate,,1,,10116.0,11755,1,50597,,In vivo,Plasma,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626234,,,A
14906,Intermediate,,1,,10116.0,11756,1,50597,,In vivo,Plasma,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL875341,,,A
14215,Intermediate,,1,,9606.0,11757,1,50587,,In vivo,Plasma,The maximum plasma concentration (100 mg/kg) administered orally in human,,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL626235,,,A
14215,Autocuration,,1,,9481.0,11758,0,22224,,In vivo,Plasma,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,U,,Callithrix,BAO_0000218,1969.0,CHEMBL626236,,,A
14215,Autocuration,,1,,314293.0,11759,0,22224,,In vivo,Plasma,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL626237,,,A
14215,Intermediate,,1,,9615.0,11760,1,50588,,In vivo,Plasma,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626238,,,A
14215,Intermediate,,1,,9606.0,11761,1,50587,,In vivo,Plasma,The maximum plasma concentration (200 mg/kg) administered orally in human,,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL622412,,,A
14215,Intermediate,,1,,10116.0,11762,1,50597,,In vivo,Plasma,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623114,,,A
14215,Autocuration,,1,,9481.0,11763,0,22224,,In vivo,Plasma,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,U,,Callithrix,BAO_0000218,1969.0,CHEMBL623115,,,A
14215,Autocuration,,1,,314293.0,11764,0,22224,,In vivo,Plasma,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL623116,,,A
14215,Autocuration,,1,,9615.0,11765,0,22224,,In vivo,Plasma,The maximum plasma concentration (30 mg/kg) administered orally in dog,,U,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623117,,,A
14215,Intermediate,,1,,9606.0,11766,1,50587,,In vivo,Plasma,The maximum plasma concentration (400 mg/kg) administered orally in human,,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL623118,,,A
14215,Intermediate,,1,,10116.0,11767,1,50597,,In vivo,Plasma,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623119,,,A
14215,Intermediate,,1,,10116.0,11768,1,50597,,In vivo,Plasma,The maximum plasma concentration (50 mg/kg) administered orally in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623120,,,A
14215,Intermediate,,1,,9606.0,11769,1,50587,,In vivo,Plasma,The maximum plasma concentration (800 mg/kg) administered orally in human,,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL623286,,,A
14067,Intermediate,,1,,10116.0,11770,1,50597,,In vivo,Plasma,The maximum plasma concentration was measured on rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623287,,,A
12350,Intermediate,,1,,10116.0,11771,1,50597,,In vivo,Plasma,The maximum plasma concentration was measured on rats after oral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623288,,,A
14813,Intermediate,,1,,10116.0,11772,1,50597,,In vivo,Plasma,Plasma drug Cmax in rat (PO dose),,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623289,,,A
12536,Autocuration,,1,,,11773,0,22224,,In vivo,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,U,,,BAO_0000218,,CHEMBL623290,,,A
14169,Intermediate,,1,,9615.0,11774,1,50588,,In vivo,Plasma,maximum Plasma concentration in Dog was determined after Peroral administration,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623291,,,A
14169,Intermediate,,1,,10116.0,11775,1,50597,,In vivo,Plasma,maximum Plasma concentration in Rats was determined after Peroral administration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623292,,,A
15604,Intermediate,,1,,9615.0,11776,1,50588,,In vivo,Plasma,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL623293,,,A
15604,Autocuration,,1,,314293.0,11777,0,22224,,In vivo,Plasma,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL623294,,,A
15604,Intermediate,,1,,10116.0,11778,1,50597,,In vivo,Plasma,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623295,,,A
14387,Intermediate,,1,,10090.0,11779,1,50594,,In vivo,,maximum concentration was measured when administered through oral route in mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623296,,,A
15115,Intermediate,,1,,10090.0,11780,1,50594,,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,N,,Mus musculus,BAO_0000218,,CHEMBL875349,,,A
15115,Autocuration,,1,,314293.0,11781,0,22224,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,U,,Simiiformes,BAO_0000019,,CHEMBL623297,,,A
15115,Autocuration,,1,,314293.0,11782,0,22224,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,U,,Simiiformes,BAO_0000019,,CHEMBL623298,,,A
15115,Autocuration,,1,,314293.0,11783,0,22224,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,U,,Simiiformes,BAO_0000019,,CHEMBL623299,,,A
16359,Intermediate,,1,,10116.0,11784,1,50597,,,,Pharmacokinetic parameter was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623300,,,A
12829,Intermediate,,1,,10090.0,11785,1,50594,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,N,,Mus musculus,BAO_0000218,,CHEMBL623301,,,A
12829,Intermediate,,1,,10090.0,11786,1,50594,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,N,,Mus musculus,BAO_0000218,,CHEMBL623302,,,A
12829,Intermediate,,1,,10090.0,11787,1,50594,,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,N,,Mus musculus,BAO_0000218,,CHEMBL623303,,,A
12829,Intermediate,,1,,10090.0,11788,1,50594,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,N,,Mus musculus,BAO_0000218,,CHEMBL623304,,,A
12829,Intermediate,,1,,10090.0,11789,1,50594,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,N,,Mus musculus,BAO_0000218,,CHEMBL623305,,,A
15137,Intermediate,,1,,10116.0,11790,1,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623306,,,A
15137,Intermediate,,1,,10116.0,11791,1,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623307,,,A
15137,Intermediate,,1,,10116.0,11792,1,50597,,,Plasma,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL623308,,,A
15137,Intermediate,,1,,10090.0,11793,1,50594,,,Plasma,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL623309,,,A
13509,Intermediate,,1,,10090.0,11794,1,50594,,,,Plasma Concentration after 120 min of oral administration to mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623310,,,A
13509,Intermediate,,1,,10090.0,11795,1,50594,,,,Plasma Concentration after 30 min of oral administration to mice,,N,,Mus musculus,BAO_0000218,,CHEMBL623311,,,A
13509,Intermediate,,1,,9541.0,11796,1,100710,,,,Plasma Concentration after 60 min of oral administration to mice,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL623312,,,A
13509,Intermediate,,1,,10090.0,11797,1,50594,,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,,N,,Mus musculus,BAO_0000218,,CHEMBL875350,,,A
13509,Intermediate,,1,,10090.0,11798,1,50594,,,,Plasma Concentration after 90 min of oral administration to mice,,N,,Mus musculus,BAO_0000218,,CHEMBL628635,,,A
12064,Intermediate,,1,,10116.0,11799,1,50597,,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628636,,,A
12064,Intermediate,,1,,10116.0,11800,1,50597,,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628637,,,A
12064,Intermediate,,1,,10116.0,11801,1,50597,,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628058,,,A
10677,Intermediate,,1,,10116.0,11802,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628059,,,A
10677,Intermediate,,1,,10116.0,11803,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628060,,,A
8926,Autocuration,,1,,,11804,0,22224,,,,Distribution in the lung after 15 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628061,,,A
8926,Autocuration,,1,,,11805,0,22224,,,,Distribution in the lung after 30 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628062,,,A
8926,Autocuration,,1,,,11806,0,22224,,,,Distribution in the lung after 5 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628063,,,A
8926,Autocuration,,1,,,11807,0,22224,,,,Distribution in the lung after 60 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628064,,,A
8926,Autocuration,,1,,,11808,0,22224,,,,Distribution in the lung after 90 min of intravenous administration,,U,,,BAO_0000019,,CHEMBL628065,,,A
8926,Autocuration,,1,,,11809,0,22224,,,Muscle tissue,Distribution in the muscle after 120 min of intravenous administration,,U,,,BAO_0000019,2385.0,CHEMBL628066,,,A
8926,Autocuration,,1,,,11810,0,22224,,,Muscle tissue,Distribution in the muscle after 15 min of intravenous administration,,U,,,BAO_0000019,2385.0,CHEMBL628067,,,A
8926,Intermediate,,1,,10090.0,11811,1,50594,,,Muscle tissue,Distribution in the muscle after 30 min of intravenous administration,,N,,Mus musculus,BAO_0000218,2385.0,CHEMBL874646,,,A
8926,Autocuration,,1,,,11812,0,22224,,,Muscle tissue,Distribution in the muscle after 5 min of intravenous administration,,U,,,BAO_0000019,2385.0,CHEMBL628068,,,A
8926,Autocuration,,1,,,11813,0,22224,,,Muscle tissue,Distribution in the muscle after 60 min of intravenous administration,,U,,,BAO_0000019,2385.0,CHEMBL628069,,,A
8926,Autocuration,,1,,,11814,0,22224,,,Muscle tissue,Distribution in the muscle after 90 min of intravenous administration,,U,,,BAO_0000019,2385.0,CHEMBL628070,,,A
8926,Autocuration,,1,,,11815,0,22224,,,Spleen,Distribution in the spleen after 120 min of intravenous administration,,U,,,BAO_0000019,2106.0,CHEMBL628071,,,A
8926,Autocuration,,1,,,11816,0,22224,,,Spleen,Distribution in the spleen after 15 min of intravenous administration,,U,,,BAO_0000019,2106.0,CHEMBL628072,,,A
8926,Autocuration,,1,,,11817,0,22224,,,Spleen,Distribution in the spleen after 30 min of intravenous administration,,U,,,BAO_0000019,2106.0,CHEMBL628073,,,A
8926,Autocuration,,1,,,11818,0,22224,,,Spleen,Distribution in the spleen after 5 min of intravenous administration,,U,,,BAO_0000019,2106.0,CHEMBL628074,,,A
8926,Autocuration,,1,,,11819,0,22224,,,Spleen,Distribution in the spleen after 60 min of intravenous administration,,U,,,BAO_0000019,2106.0,CHEMBL628075,,,A
8926,Autocuration,,1,,,11820,0,22224,,,Spleen,Distribution in the spleen after 90 min of intravenous administration,,U,,,BAO_0000019,2106.0,CHEMBL628076,,,A
7570,Intermediate,,1,,10116.0,11821,1,50597,,,Adrenal cortex,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1235.0,CHEMBL628077,,,A
7570,Intermediate,,1,,10116.0,11822,1,50597,,,Blood,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628078,,,A
7570,Intermediate,,1,,10116.0,11823,1,50597,,,Liver,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628079,,,A
7570,Intermediate,,1,,10116.0,11824,1,50597,,,Female gonad,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL628080,,,A
7570,Intermediate,,1,,10116.0,11825,1,50597,,,Thyroid gland,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL628081,,,A
7570,Intermediate,,1,,10116.0,11826,1,50597,,,Adrenal cortex,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1235.0,CHEMBL628082,,,A
7570,Intermediate,,1,,10116.0,11827,1,50597,,,Blood,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL874647,,,A
7570,Intermediate,,1,,10116.0,11828,1,50597,,,Liver,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626406,,,A
7570,Intermediate,,1,,10116.0,11829,1,50597,,,Female gonad,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL626407,,,A
7570,Intermediate,,1,,10116.0,11830,1,50597,,,Thyroid gland,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626408,,,A
8608,Intermediate,,1,,10116.0,11831,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626409,,,A
8608,Intermediate,,1,,10116.0,11832,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626410,,,A
8608,Intermediate,,1,,10116.0,11833,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626411,,,A
8608,Intermediate,,1,,10116.0,11834,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626412,,,A
8608,Intermediate,,1,,10116.0,11835,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626413,,,A
8608,Intermediate,,1,,10116.0,11836,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626414,,,A
8608,Intermediate,,1,,10116.0,11837,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626415,,,A
8608,Intermediate,,1,,10116.0,11838,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626416,,,A
8608,Intermediate,,1,,10116.0,11839,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627062,,,A
8608,Intermediate,,1,,10116.0,11840,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627063,,,A
8608,Intermediate,,1,,10116.0,11841,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627064,,,A
8608,Intermediate,,1,,10116.0,11842,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627227,,,A
8608,Intermediate,,1,,10116.0,11843,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627228,,,A
8608,Intermediate,,1,,10116.0,11844,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627229,,,A
8608,Intermediate,,1,,10116.0,11845,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625792,,,A
8608,Intermediate,,1,,10116.0,11846,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625793,,,A
8608,Intermediate,,1,,10116.0,11847,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625794,,,A
8608,Intermediate,,1,,10116.0,11848,1,50597,,,Blood,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625795,,,A
13792,Intermediate,,1,,10090.0,11849,1,50594,,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,N,,Mus musculus,BAO_0000218,,CHEMBL625796,,,A
13376,Intermediate,,1,,9615.0,11850,1,50588,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625797,,,A
13376,Intermediate,,1,,9615.0,11851,1,50588,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625798,,,A
14380,Autocuration,,1,,,11852,0,22224,,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL875613,,,A
14380,Autocuration,,1,,,11853,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL625799,,,A
14380,Autocuration,,1,,,11854,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL625800,,,A
14380,Autocuration,,1,,,11855,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL625801,,,A
14380,Autocuration,,1,,,11856,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL625802,,,A
14380,Autocuration,,1,,,11857,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL625803,,,A
14380,Autocuration,,1,,,11858,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,U,,,BAO_0000019,,CHEMBL625804,,,A
14380,Autocuration,,1,,,11859,0,22224,,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,U,,,BAO_0000218,,CHEMBL622530,,,A
13701,Intermediate,,1,,10090.0,11860,1,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,N,,Mus musculus,BAO_0000218,,CHEMBL622531,,,A
13701,Intermediate,,1,,10090.0,11861,1,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL622532,,,A
13701,Intermediate,,1,,10090.0,11862,1,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL623176,,,A
13701,Intermediate,,1,,10090.0,11863,1,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL623177,,,A
13701,Intermediate,,1,,10090.0,11864,1,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL623178,,,A
13701,Intermediate,,1,,10090.0,11865,1,50594,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,N,,Mus musculus,BAO_0000218,,CHEMBL623179,,,A
13701,Intermediate,,1,,10090.0,11866,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL623180,,,A
13701,Intermediate,,1,,10090.0,11867,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL623181,,,A
13701,Intermediate,,1,,10090.0,11868,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL624131,,,A
13701,Intermediate,,1,,10090.0,11869,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL624132,,,A
13701,Intermediate,,1,,10090.0,11870,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL624133,,,A
13701,Intermediate,,1,,10090.0,11871,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,N,,Mus musculus,BAO_0000218,,CHEMBL624846,,,A
13701,Intermediate,,1,,10090.0,11872,1,50594,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL624847,,,A
13701,Intermediate,,1,,10090.0,11873,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL624848,,,A
13701,Intermediate,,1,,10090.0,11874,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625012,,,A
13701,Intermediate,,1,,10090.0,11875,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625013,,,A
13701,Intermediate,,1,,10090.0,11876,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,N,,Mus musculus,BAO_0000218,,CHEMBL625014,,,A
13701,Intermediate,,1,,10090.0,11877,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625015,,,A
13701,Intermediate,,1,,10090.0,11878,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625016,,,A
13701,Intermediate,,1,,10090.0,11879,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,N,,Mus musculus,BAO_0000218,,CHEMBL625017,,,A
13701,Intermediate,,1,,10090.0,11880,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625018,,,A
13701,Intermediate,,1,,10090.0,11881,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625019,,,A
13701,Intermediate,,1,,10090.0,11882,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL625020,,,A
13701,Intermediate,,1,,10090.0,11883,1,50594,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,N,,Mus musculus,BAO_0000218,,CHEMBL625021,,,A
14393,Intermediate,,1,,10116.0,11884,1,50597,,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625022,,,A
14731,Intermediate,,1,,10090.0,11885,1,50594,,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,N,,Mus musculus,BAO_0000218,,CHEMBL625023,,,A
14731,Intermediate,,1,,9541.0,11886,1,100710,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL625024,,,A
14731,Intermediate,,1,,9541.0,11887,1,100710,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL627626,,,A
13758,Autocuration,,1,,,11888,0,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,U,,,BAO_0000218,955.0,CHEMBL627627,,,A
13758,Autocuration,,1,,,11889,0,22224,,,Serum,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,U,,,BAO_0000218,1977.0,CHEMBL627628,,,A
13758,Autocuration,,1,,,11890,0,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,U,,,BAO_0000218,955.0,CHEMBL627629,,,A
13758,Autocuration,,1,,,11891,0,22224,,,Serum,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,U,,,BAO_0000218,1977.0,CHEMBL627630,,,A
16359,Autocuration,,1,,,11892,0,22224,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,U,,,BAO_0000019,,CHEMBL627631,,,A
16359,Autocuration,,1,,,11893,0,22224,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,U,,,BAO_0000218,,CHEMBL629515,,,A
15383,Intermediate,,1,,10090.0,11894,1,50594,,,Spleen,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL629516,,,A
15383,Intermediate,,1,,10090.0,11895,1,50594,,,Spleen,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL629517,,,A
15383,Intermediate,,1,,10090.0,11896,1,50594,,,Spleen,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL629518,,,A
15383,Intermediate,,1,,10090.0,11897,1,50594,,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,N,,Mus musculus,BAO_0000218,,CHEMBL877499,,,A
15383,Intermediate,,1,,10090.0,11898,1,50594,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL629519,,,A
15383,Intermediate,,1,,10090.0,11899,1,50594,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL629520,,,A
15383,Intermediate,,1,,10090.0,11900,1,50594,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,N,,Mus musculus,BAO_0000218,,CHEMBL629521,,,A
14439,Intermediate,,1,,10090.0,11901,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL629522,,,A
14439,Intermediate,,1,,10090.0,11902,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,N,,Mus musculus,BAO_0000218,,CHEMBL629523,,,A
14439,Intermediate,,1,,10090.0,11903,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,N,,Mus musculus,BAO_0000218,,CHEMBL629524,,,A
14439,Intermediate,,1,,10090.0,11904,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL629525,,,A
14439,Intermediate,,1,,10090.0,11905,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL629526,,,A
14439,Intermediate,,1,,10090.0,11906,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,N,,Mus musculus,BAO_0000218,,CHEMBL629527,,,A
14439,Intermediate,,1,,10090.0,11907,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,N,,Mus musculus,BAO_0000218,,CHEMBL629528,,,A
14439,Intermediate,,1,,10090.0,11908,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL629529,,,A
14439,Intermediate,,1,,10090.0,11909,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL629530,,,A
14439,Intermediate,,1,,10090.0,11910,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,N,,Mus musculus,BAO_0000218,,CHEMBL629531,,,A
14439,Intermediate,,1,,10090.0,11911,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,N,,Mus musculus,BAO_0000218,,CHEMBL628656,,,A
14439,Intermediate,,1,,10090.0,11912,1,50594,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL628657,,,A
13751,Intermediate,,1,,10116.0,11913,1,50597,,In vivo,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628658,,,A
13751,Intermediate,,1,,10116.0,11914,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628659,,,A
13751,Intermediate,,1,,10116.0,11915,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877500,,,A
13751,Intermediate,,1,,10116.0,11916,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628660,,,A
13751,Intermediate,,1,,10116.0,11917,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628661,,,A
13751,Intermediate,,1,,10116.0,11918,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628662,,,A
13751,Intermediate,,1,,10116.0,11919,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628663,,,A
13751,Intermediate,,1,,10116.0,11920,1,50597,,In vivo,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628664,,,A
13751,Intermediate,,1,,10116.0,11921,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628665,,,A
13751,Intermediate,,1,,10116.0,11922,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628666,,,A
13751,Intermediate,,1,,10116.0,11923,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628667,,,A
13751,Intermediate,,1,,10116.0,11924,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628668,,,A
13751,Intermediate,,1,,10116.0,11925,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628669,,,A
13751,Intermediate,,1,,10116.0,11926,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628670,,,A
13751,Intermediate,,1,,10116.0,11927,1,50597,,In vivo,Blood,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628671,,,A
13751,Intermediate,,1,,10116.0,11928,1,50597,,In vivo,Bone,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL628672,,,A
13751,Intermediate,,1,,10116.0,11929,1,50597,,In vivo,Bone,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL630300,,,A
13751,Intermediate,,1,,10116.0,11930,1,50597,,In vivo,Bone,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL629787,,,A
13751,Intermediate,,1,,10116.0,11931,1,50597,,In vivo,Bone,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL629788,,,A
13751,Intermediate,,1,,10116.0,11932,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629789,,,A
13751,Intermediate,,1,,10116.0,11933,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629790,,,A
13751,Intermediate,,1,,10116.0,11934,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629791,,,A
13751,Intermediate,,1,,10116.0,11935,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629792,,,A
13751,Intermediate,,1,,10116.0,11936,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629793,,,A
13751,Intermediate,,1,,10116.0,11937,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629794,,,A
10677,Intermediate,,1,,10116.0,11938,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874459,,,A
10677,Intermediate,,1,,10116.0,11939,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629795,,,A
10677,Intermediate,,1,,10116.0,11940,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629796,,,A
10677,Intermediate,,1,,10116.0,11941,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629797,,,A
10677,Intermediate,,1,,10116.0,11942,1,50597,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629798,,,A
10911,Intermediate,,1,,10116.0,11943,1,50597,,In vivo,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2369.0,CHEMBL629799,,,A
10911,Intermediate,,1,,10116.0,11944,1,50597,,In vivo,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2369.0,CHEMBL629800,,,A
10911,Intermediate,,1,,10116.0,11945,1,50597,,In vivo,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2369.0,CHEMBL629801,,,A
10911,Intermediate,,1,,10116.0,11946,1,50597,,In vivo,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,N,,Rattus norvegicus,BAO_0000218,2369.0,CHEMBL629802,,,A
10911,Intermediate,,1,,10116.0,11947,1,50597,,In vivo,Adrenal gland,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2369.0,CHEMBL629803,,,A
10911,Intermediate,,1,,10116.0,11948,1,50597,,In vivo,Blood,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629804,,,A
10911,Intermediate,,1,,10116.0,11949,1,50597,,In vivo,Blood,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629805,,,A
10911,Intermediate,,1,,10116.0,11950,1,50597,,In vivo,Blood,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629806,,,A
10911,Intermediate,,1,,10116.0,11951,1,50597,,In vivo,Blood,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629807,,,A
10911,Intermediate,,1,,10116.0,11952,1,50597,,In vivo,Blood,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629808,,,A
10911,Intermediate,,1,,10116.0,11953,1,50597,,In vivo,Brain,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629809,,,A
10911,Intermediate,,1,,10116.0,11954,1,50597,,In vivo,Brain,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629810,,,A
10911,Intermediate,,1,,10116.0,11955,1,50597,,In vivo,Brain,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629811,,,A
10911,Intermediate,,1,,10116.0,11956,1,50597,,In vivo,Brain,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629812,,,A
10911,Intermediate,,1,,10116.0,11957,1,50597,,In vivo,Brain,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629813,,,A
10911,Intermediate,,1,,10116.0,11958,1,50597,,In vivo,Brain,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL874460,,,A
10911,Intermediate,,1,,10116.0,11959,1,50597,,In vivo,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629814,,,A
10911,Intermediate,,1,,10116.0,11960,1,50597,,In vivo,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629815,,,A
10911,Intermediate,,1,,10116.0,11961,1,50597,,In vivo,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629816,,,A
10911,Intermediate,,1,,10116.0,11962,1,50597,,In vivo,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629817,,,A
10911,Intermediate,,1,,10116.0,11963,1,50597,,In vivo,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626643,,,A
10911,Intermediate,,1,,10116.0,11964,1,50597,,In vivo,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626644,,,A
10911,Intermediate,,1,,10116.0,11965,1,50597,,In vivo,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626806,,,A
10911,Intermediate,,1,,10116.0,11966,1,50597,,In vivo,Kidney,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626807,,,A
10911,Intermediate,,1,,10116.0,11967,1,50597,,In vivo,Liver,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627261,,,A
10911,Intermediate,,1,,10116.0,11968,1,50597,,In vivo,Liver,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627262,,,A
10911,Intermediate,,1,,10116.0,11969,1,50597,,In vivo,Liver,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627263,,,A
10911,Intermediate,,1,,10116.0,11970,1,50597,,In vivo,Liver,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627264,,,A
10911,Intermediate,,1,,10116.0,11971,1,50597,,In vivo,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627265,,,A
10911,Intermediate,,1,,10116.0,11972,1,50597,,In vivo,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627266,,,A
10911,Intermediate,,1,,10116.0,11973,1,50597,,In vivo,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627267,,,A
10911,Intermediate,,1,,10116.0,11974,1,50597,,In vivo,Lung,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627268,,,A
10911,Intermediate,,1,,10116.0,11975,1,50597,,In vivo,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627269,,,A
10911,Intermediate,,1,,10116.0,11976,1,50597,,In vivo,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627270,,,A
8608,Intermediate,,1,,10116.0,11977,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627271,,,A
8608,Intermediate,,1,,10116.0,11978,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627946,,,A
8608,Intermediate,,1,,10116.0,11979,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875472,,,A
8608,Intermediate,,1,,10116.0,11980,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627947,,,A
8608,Intermediate,,1,,10116.0,11981,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627948,,,A
8608,Intermediate,,1,,10116.0,11982,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628113,,,A
8608,Intermediate,,1,,10116.0,11983,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628114,,,A
8608,Intermediate,,1,,10116.0,11984,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628115,,,A
8608,Intermediate,,1,,10116.0,11985,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628116,,,A
8608,Intermediate,,1,,10116.0,11986,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628117,,,A
8608,Intermediate,,1,,10116.0,11987,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628118,,,A
8608,Intermediate,,1,,10116.0,11988,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628119,,,A
8608,Intermediate,,1,,10116.0,11989,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628120,,,A
8608,Intermediate,,1,,10116.0,11990,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628121,,,A
8608,Intermediate,,1,,10116.0,11991,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628122,,,A
8608,Intermediate,,1,,10116.0,11992,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627297,,,A
8608,Intermediate,,1,,10116.0,11993,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627298,,,A
8608,Intermediate,,1,,10116.0,11994,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627299,,,A
8608,Intermediate,,1,,10116.0,11995,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627300,,,A
8608,Intermediate,,1,,10116.0,11996,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627301,,,A
8608,Intermediate,,1,,10116.0,11997,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627302,,,A
8608,Intermediate,,1,,10116.0,11998,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627303,,,A
8608,Intermediate,,1,,10116.0,11999,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627304,,,A
8608,Intermediate,,1,,10116.0,12000,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627305,,,A
8608,Intermediate,,1,,10116.0,12001,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627306,,,A
8608,Intermediate,,1,,10116.0,12002,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623982,,,A
8608,Intermediate,,1,,10116.0,12003,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623983,,,A
8608,Intermediate,,1,,10116.0,12004,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623984,,,A
8608,Intermediate,,1,,10116.0,12005,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623985,,,A
8608,Intermediate,,1,,10116.0,12006,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623986,,,A
8608,Intermediate,,1,,10116.0,12007,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623987,,,A
8608,Intermediate,,1,,10116.0,12008,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623988,,,A
8608,Intermediate,,1,,10116.0,12009,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623989,,,A
8608,Intermediate,,1,,10116.0,12010,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622215,,,A
8608,Intermediate,,1,,10116.0,12011,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622216,,,A
8608,Intermediate,,1,,10116.0,12012,1,50597,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877481,,,A
16359,Autocuration,,1,,,12013,0,22224,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,U,,,BAO_0000218,,CHEMBL622217,,,A
13701,Intermediate,,1,,10090.0,12014,1,50594,,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,N,,Mus musculus,BAO_0000218,,CHEMBL622218,,,A
14554,Intermediate,,1,,10116.0,12015,1,50597,,,,Pharmacokinetic profile AUC was evaluated in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622219,,,A
6241,Autocuration,,1,,,12016,0,22224,,,,Pharmacokinetic property (Area under curve),,U,,,BAO_0000019,,CHEMBL622220,,,A
11537,Intermediate,,1,,9615.0,12017,1,50588,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622221,,,A
11537,Intermediate,,1,,10090.0,12018,1,50594,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,N,,Mus musculus,BAO_0000218,,CHEMBL622222,,,A
11537,Intermediate,,1,,9615.0,12019,1,50588,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL622223,,,A
11537,Intermediate,,1,,10090.0,12020,1,50594,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,N,,Mus musculus,BAO_0000218,,CHEMBL622224,,,A
13118,Autocuration,,1,,,12021,0,22224,,,,Plasma concentration (AUC) was determined,,U,,,BAO_0000019,,CHEMBL622225,,,A
13118,Autocuration,,1,,,12022,0,22224,,,,Plasma concentration (AUC) was determined; Not detectable,,U,,,BAO_0000019,,CHEMBL622226,,,A
9562,Intermediate,,1,,10141.0,12023,1,50512,,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,N,,Cavia porcellus,BAO_0000218,,CHEMBL624154,,,A
10363,Intermediate,,1,,10116.0,12024,1,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624155,,,A
10363,Intermediate,,1,,10116.0,12025,1,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624156,,,A
10363,Intermediate,,1,,10116.0,12026,1,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624157,,,A
10363,Intermediate,,1,,10116.0,12027,1,50597,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624158,,,A
12504,Intermediate,,1,,10116.0,12028,1,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624159,,,A
12504,Intermediate,,1,,10116.0,12029,1,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624160,,,A
12504,Intermediate,,1,,10116.0,12030,1,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624161,,,A
12504,Intermediate,,1,,10116.0,12031,1,50597,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624162,,,A
13317,Intermediate,,1,,9615.0,12032,1,50588,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624163,,,A
15078,Intermediate,,1,,10116.0,12033,1,50597,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624164,,,A
14941,Intermediate,,1,,10116.0,12034,1,50597,,,,The AUC(0-infinity) values in female wistar rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624165,,,A
15078,Intermediate,,1,,10116.0,12035,1,50597,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624166,,,A
15078,Intermediate,,1,,10116.0,12036,1,50597,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624167,,,A
14941,Intermediate,,1,,10116.0,12037,1,50597,,,,The AUC(0-t)values in female wistar rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624168,,,A
14067,Intermediate,,1,,10116.0,12038,1,50597,,,,The Area under the concentration time curve of compound was measured on rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624169,,,A
14215,Intermediate,,1,,9606.0,12039,1,50587,,,,The area under curve (100 mg/kg) administered orally in humans,,N,,Homo sapiens,BAO_0000218,,CHEMBL624170,,,A
14215,Autocuration,,1,,9481.0,12040,0,22224,,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,U,,Callithrix,BAO_0000218,,CHEMBL624171,,,A
14215,Autocuration,,1,,314293.0,12041,0,22224,,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL624172,,,A
14215,Intermediate,,1,,9615.0,12042,1,50588,,,,The area under curve (15 mg/kg) administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624173,,,A
14215,Intermediate,,1,,9606.0,12043,1,50587,,,,The area under curve (200 mg/kg) administered orally in humans,,N,,Homo sapiens,BAO_0000218,,CHEMBL877488,,,A
14215,Intermediate,,1,,10116.0,12044,1,50597,,,,The area under curve (25 mg/kg) administered intravenously in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624174,,,A
14215,Autocuration,,1,,9481.0,12045,0,22224,,,,The area under curve (25 mg/kg) administered orally in marmoset,,U,,Callithrix,BAO_0000218,,CHEMBL624175,,,A
14215,Autocuration,,1,,314293.0,12046,0,22224,,,,The area under curve (25 mg/kg) administered orally in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL624176,,,A
14215,Intermediate,,1,,9615.0,12047,1,50588,,,,The area under curve (30 mg/kg) administered orally in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624177,,,A
14215,Intermediate,,1,,9606.0,12048,1,50587,,,,The area under curve (400 mg/kg) administered orally in humans,,N,,Homo sapiens,BAO_0000218,,CHEMBL624178,,,A
14215,Intermediate,,1,,10116.0,12049,1,50597,,,,The area under curve (50 mg/kg) administered orally in fasted rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624179,,,A
14215,Intermediate,,1,,10116.0,12050,1,50597,,,,The area under curve (50 mg/kg) administered orally in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627689,,,A
14215,Intermediate,,1,,9606.0,12051,1,50587,,,,The area under curve (800 mg/kg) administered orally in humans,,N,,Homo sapiens,BAO_0000218,,CHEMBL627690,,,A
11324,Autocuration,,1,,,12052,0,22224,,,,The compound was evaluated for area under the curve,,U,,,BAO_0000019,,CHEMBL627691,,,A
11324,Autocuration,,1,,9481.0,12053,0,22224,,,,The compound was evaluated for area under the curve in marmosets,,U,,Callithrix,BAO_0000019,,CHEMBL627692,,,A
11324,Autocuration,,1,,9481.0,12054,0,22224,,,,The compound was evaluated for area under the curve in marmosets,,U,,Callithrix,BAO_0000019,,CHEMBL627693,,,A
13875,Intermediate,,1,,10116.0,12055,1,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627694,,,A
13875,Intermediate,,1,,10116.0,12056,1,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627695,,,A
13875,Autocuration,,1,,,12057,0,22224,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,U,,,BAO_0000218,,CHEMBL627696,,,A
13875,Intermediate,,1,,10116.0,12058,1,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627697,,,A
13875,Intermediate,,1,,10116.0,12059,1,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627698,,,A
13875,Intermediate,,1,,10116.0,12060,1,50597,,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627699,,,A
13807,Intermediate,,1,,10116.0,12061,1,50597,,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627700,,,A
14127,Intermediate,,1,,10116.0,12062,1,50597,,,,Total drug exposure is determined after oral dosing in rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627701,,,A
15116,Autocuration,,1,,,12063,0,22224,,,,Total drug exposure (5 mg/kg) when administered intravenously,,U,,,BAO_0000218,,CHEMBL627702,,,A
15116,Autocuration,,1,,,12064,0,22224,,,,Total drug exposure (5 mg/kg) when administered orally,,U,,,BAO_0000218,,CHEMBL627703,,,A
15604,Autocuration,,1,,314293.0,12065,0,22224,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL626873,,,A
15604,Intermediate,,1,,10116.0,12066,1,50597,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629583,,,A
15604,Intermediate,,1,,9615.0,12067,1,50588,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629584,,,A
15604,Intermediate,,1,,9615.0,12068,1,50588,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629585,,,A
13751,Intermediate,,1,,10116.0,12069,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629586,,,A
13751,Intermediate,,1,,10116.0,12070,1,50597,,In vivo,Brain,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL629587,,,A
13751,Intermediate,,1,,10116.0,12071,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629588,,,A
13751,Intermediate,,1,,10116.0,12072,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629589,,,A
13751,Intermediate,,1,,10116.0,12073,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629590,,,A
13751,Intermediate,,1,,10116.0,12074,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629591,,,A
13751,Intermediate,,1,,10116.0,12075,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629592,,,A
13751,Intermediate,,1,,10116.0,12076,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629593,,,A
13751,Intermediate,,1,,10116.0,12077,1,50597,,In vivo,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629594,,,A
13751,Intermediate,,1,,10116.0,12078,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL629595,,,A
13751,Intermediate,,1,,10116.0,12079,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630290,,,A
13751,Intermediate,,1,,10116.0,12080,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627137,,,A
13751,Intermediate,,1,,10116.0,12081,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627138,,,A
13751,Intermediate,,1,,10116.0,12082,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627139,,,A
13751,Intermediate,,1,,10116.0,12083,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627140,,,A
13751,Intermediate,,1,,10116.0,12084,1,50597,,In vivo,Heart,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627141,,,A
13751,Intermediate,,1,,10116.0,12085,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627142,,,A
13751,Intermediate,,1,,10116.0,12086,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627143,,,A
13751,Intermediate,,1,,10116.0,12087,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL874449,,,A
13751,Intermediate,,1,,10116.0,12088,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627144,,,A
13751,Intermediate,,1,,10116.0,12089,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627145,,,A
13751,Intermediate,,1,,10116.0,12090,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627146,,,A
13751,Intermediate,,1,,10116.0,12091,1,50597,,In vivo,Kidney,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627147,,,A
13751,Intermediate,,1,,10116.0,12092,1,50597,,In vivo,Liver,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627148,,,A
13751,Intermediate,,1,,10116.0,12093,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627149,,,A
13751,Intermediate,,1,,10116.0,12094,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL632160,,,A
13751,Intermediate,,1,,10116.0,12095,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL632161,,,A
13751,Intermediate,,1,,10116.0,12096,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL632162,,,A
13751,Intermediate,,1,,10116.0,12097,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL632163,,,A
13751,Intermediate,,1,,10116.0,12098,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL874469,,,A
13751,Intermediate,,1,,10116.0,12099,1,50597,,In vivo,Lung,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627182,,,A
13751,Intermediate,,1,,10116.0,12100,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627183,,,A
13751,Intermediate,,1,,10116.0,12101,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627184,,,A
13751,Intermediate,,1,,10116.0,12102,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627185,,,A
13751,Intermediate,,1,,10116.0,12103,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627186,,,A
13751,Intermediate,,1,,10116.0,12104,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627187,,,A
13751,Intermediate,,1,,10116.0,12105,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627188,,,A
13751,Intermediate,,1,,10116.0,12106,1,50597,,In vivo,Muscle tissue,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627189,,,A
13751,Intermediate,,1,,10116.0,12107,1,50597,,In vivo,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627190,,,A
13751,Intermediate,,1,,10116.0,12108,1,50597,,In vivo,Liver,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627191,,,A
13751,Intermediate,,1,,10116.0,12109,1,50597,,In vivo,Liver,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627192,,,A
13751,Intermediate,,1,,10116.0,12110,1,50597,,In vivo,Liver,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627193,,,A
10911,Intermediate,,1,,10116.0,12111,1,50597,,In vivo,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL874590,,,A
10911,Intermediate,,1,,10116.0,12112,1,50597,,In vivo,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627194,,,A
10911,Intermediate,,1,,10116.0,12113,1,50597,,In vivo,Muscle tissue,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627195,,,A
10911,Intermediate,,1,,10116.0,12114,1,50597,,In vivo,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL627196,,,A
10911,Intermediate,,1,,10116.0,12115,1,50597,,In vivo,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL627197,,,A
10911,Intermediate,,1,,10116.0,12116,1,50597,,In vivo,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL627198,,,A
10911,Intermediate,,1,,10116.0,12117,1,50597,,In vivo,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL627199,,,A
10911,Intermediate,,1,,10116.0,12118,1,50597,,In vivo,Female gonad,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,992.0,CHEMBL627200,,,A
10911,Intermediate,,1,,10116.0,12119,1,50597,,In vivo,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627201,,,A
10911,Intermediate,,1,,10116.0,12120,1,50597,,In vivo,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627202,,,A
10911,Intermediate,,1,,10116.0,12121,1,50597,,In vivo,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627203,,,A
10911,Intermediate,,1,,10116.0,12122,1,50597,,In vivo,Plasma,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627204,,,A
10911,Intermediate,,1,,10116.0,12123,1,50597,,In vivo,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627205,,,A
10911,Intermediate,,1,,10116.0,12124,1,50597,,In vivo,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627206,,,A
10911,Intermediate,,1,,10116.0,12125,1,50597,,In vivo,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627207,,,A
10911,Intermediate,,1,,10116.0,12126,1,50597,,In vivo,Spleen,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627208,,,A
10911,Intermediate,,1,,10116.0,12127,1,50597,,In vivo,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627209,,,A
10911,Intermediate,,1,,10116.0,12128,1,50597,,In vivo,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627210,,,A
10911,Intermediate,,1,,10116.0,12129,1,50597,,In vivo,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627211,,,A
10911,Intermediate,,1,,10116.0,12130,1,50597,,In vivo,Thyroid gland,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627212,,,A
10911,Intermediate,,1,,10116.0,12131,1,50597,,In vivo,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL627213,,,A
10911,Intermediate,,1,,10116.0,12132,1,50597,,In vivo,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626599,,,A
10911,Intermediate,,1,,10116.0,12133,1,50597,,In vivo,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626600,,,A
10911,Intermediate,,1,,10116.0,12134,1,50597,,In vivo,Uterus,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL626601,,,A
8081,Autocuration,,1,,,12135,0,22224,,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,U,,,BAO_0000019,,CHEMBL627484,,,A
17248,Intermediate,,1,,9541.0,12136,1,100710,,,Plasma,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL627485,,,A
17248,Intermediate,,1,,9541.0,12137,1,100710,,,Plasma,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL628147,,,A
17248,Intermediate,,1,,9541.0,12138,1,100710,,,Plasma,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL628148,,,A
17248,Intermediate,,1,,9615.0,12139,1,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628149,,,A
17248,Intermediate,,1,,9615.0,12140,1,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628150,,,A
17248,Intermediate,,1,,9615.0,12141,1,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628318,,,A
17248,Intermediate,,1,,9615.0,12142,1,50588,,,Plasma,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628319,,,A
15592,Intermediate,,1,,9615.0,12143,1,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875609,,,A
7040,Autocuration,,1,,,12144,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,U,,,BAO_0000019,,CHEMBL628320,,,A
7040,Autocuration,,1,,,12145,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,U,,,BAO_0000019,,CHEMBL628321,,,A
7040,Autocuration,,1,,,12146,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,U,,,BAO_0000019,,CHEMBL628322,,,A
7040,Autocuration,,1,,,12147,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,U,,,BAO_0000019,,CHEMBL628323,,,A
7040,Autocuration,,1,,,12148,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,U,,,BAO_0000019,,CHEMBL628324,,,A
7040,Autocuration,,1,,,12149,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,U,,,BAO_0000019,,CHEMBL628325,,,A
7040,Autocuration,,1,,,12150,0,22224,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,U,,,BAO_0000019,,CHEMBL628326,,,A
9614,Intermediate,,1,,9615.0,12151,1,50588,,,Adrenal medulla,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,1236.0,CHEMBL628327,,,A
9614,Intermediate,,1,,9615.0,12152,1,50588,,,Adrenal medulla,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,1236.0,CHEMBL628328,,,A
9614,Intermediate,,1,,9615.0,12153,1,50588,,,Blood,"Concentration of compound in blood of dog 1, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL628329,,,A
8608,Intermediate,,1,,10116.0,12154,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628330,,,A
8608,Intermediate,,1,,10116.0,12155,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628331,,,A
8608,Intermediate,,1,,10116.0,12156,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628332,,,A
8608,Intermediate,,1,,10116.0,12157,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628333,,,A
8608,Intermediate,,1,,10116.0,12158,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628334,,,A
8608,Intermediate,,1,,10116.0,12159,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628335,,,A
8608,Intermediate,,1,,10116.0,12160,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628336,,,A
8608,Intermediate,,1,,10116.0,12161,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628337,,,A
8608,Intermediate,,1,,10116.0,12162,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628338,,,A
8608,Intermediate,,1,,10116.0,12163,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL875610,,,A
8608,Intermediate,,1,,10116.0,12164,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628339,,,A
8608,Intermediate,,1,,10116.0,12165,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628340,,,A
8608,Intermediate,,1,,10116.0,12166,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628341,,,A
8608,Intermediate,,1,,10116.0,12167,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622214,,,A
8608,Intermediate,,1,,10116.0,12168,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623167,,,A
8608,Intermediate,,1,,10116.0,12169,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623168,,,A
8608,Intermediate,,1,,10116.0,12170,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623169,,,A
8608,Intermediate,,1,,10116.0,12171,1,50597,,,Liver,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623170,,,A
8608,Intermediate,,1,,10116.0,12172,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627224,,,A
8608,Intermediate,,1,,10116.0,12173,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL875634,,,A
8608,Intermediate,,1,,10116.0,12174,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627225,,,A
8608,Intermediate,,1,,10116.0,12175,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627226,,,A
8608,Intermediate,,1,,10116.0,12176,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626083,,,A
8608,Intermediate,,1,,10116.0,12177,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626084,,,A
8608,Intermediate,,1,,10116.0,12178,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626085,,,A
8608,Intermediate,,1,,10116.0,12179,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626086,,,A
8608,Intermediate,,1,,10116.0,12180,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626087,,,A
8608,Intermediate,,1,,10116.0,12181,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626088,,,A
8608,Intermediate,,1,,10116.0,12182,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626089,,,A
8608,Intermediate,,1,,10116.0,12183,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626090,,,A
8608,Intermediate,,1,,10116.0,12184,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626091,,,A
8608,Intermediate,,1,,10116.0,12185,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626092,,,A
8608,Intermediate,,1,,10116.0,12186,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626093,,,A
8608,Intermediate,,1,,10116.0,12187,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626094,,,A
8608,Intermediate,,1,,10116.0,12188,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626095,,,A
8608,Intermediate,,1,,10116.0,12189,1,50597,,,Lung,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL626096,,,A
15604,Autocuration,,1,,314293.0,12190,0,22224,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL626097,,,A
15604,Intermediate,,1,,10116.0,12191,1,50597,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626098,,,A
1806,Autocuration,,1,,,12192,0,22224,,,Plasma,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,U,,,BAO_0000218,1969.0,CHEMBL626099,,,A
1806,Autocuration,,1,,,12193,0,22224,,,Plasma,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,U,,,BAO_0000218,1969.0,CHEMBL626100,,,A
17237,Intermediate,,1,,9615.0,12194,1,50588,,,Plasma,AUC 0-inf in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626101,,,A
17237,Intermediate,,1,,10141.0,12195,1,50512,,,Plasma,AUC 0-inf in guinea pig,,N,,Cavia porcellus,BAO_0000218,1969.0,CHEMBL626102,,,A
17237,Intermediate,,1,,9615.0,12196,1,50588,,,Plasma,AUC 0-t in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626103,,,A
17237,Intermediate,,1,,10141.0,12197,1,50512,,,Plasma,AUC 0-t in guinea pig,,N,,Cavia porcellus,BAO_0000218,1969.0,CHEMBL628391,,,A
15194,Intermediate,,1,,10116.0,12198,1,50597,,,,The compound was tested for brain to plasma partition in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628392,,,A
15194,Intermediate,,1,,10116.0,12199,1,50597,,,,The compound was tested for brain to plasma partition in rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628393,,,A
8787,Autocuration,,1,,,12200,0,22224,,,Blood,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,U,,,BAO_0000019,178.0,CHEMBL628394,,,A
17025,Intermediate,,1,,9615.0,12201,1,50588,,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628395,,,A
17025,Autocuration,,1,,314293.0,12202,0,22224,,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,U,,Simiiformes,BAO_0000218,,CHEMBL628396,,,A
17025,Intermediate,,1,,9986.0,12203,1,50592,,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL628397,,,A
17025,Intermediate,,1,,10116.0,12204,1,50597,,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628398,,,A
4236,Intermediate,,1,,9544.0,12205,1,50797,,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,N,,Macaca mulatta,BAO_0000218,,CHEMBL628399,,,A
15343,Intermediate,,1,,9615.0,12206,1,50588,,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628400,,,A
15343,Intermediate,,1,,10116.0,12207,1,50597,,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874907,,,A
17720,Autocuration,,1,,,12208,0,22224,,,,Area under curve of the compound was determined,,U,,,BAO_0000019,,CHEMBL628401,,,A
17788,Autocuration,,1,,314293.0,12209,0,22224,,,Plasma,AUC in monkeys at a dose of 1 mg/kg,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL628402,,,A
17788,Intermediate,,1,,10116.0,12210,1,50597,,,Plasma,AUC in rats at a dose of 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628403,,,A
8778,Autocuration,,1,,,12211,0,22224,,,,Compound was evaluated for the overall absorbance loss at pH of 2,,U,,,BAO_0000019,,CHEMBL628404,,,A
8778,Autocuration,,1,,,12212,0,22224,,,,Compound was evaluated for the overall absorbance loss at pH of 4,,U,,,BAO_0000019,,CHEMBL628405,,,A
8778,Autocuration,,1,,,12213,0,22224,,,,Compound was evaluated for the overall absorbance loss at pH of 7,,U,,,BAO_0000019,,CHEMBL628406,,,A
2249,Intermediate,,1,,10116.0,12214,1,50597,,,,Compound was evaluated for its absorption in the rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628407,,,A
8881,Intermediate,,1,,10116.0,12215,1,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628408,,,A
8881,Intermediate,,1,,10116.0,12216,1,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629171,,,A
8881,Intermediate,,1,,10116.0,12217,1,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629172,,,A
8881,Intermediate,,1,,10116.0,12218,1,50597,,,Urine,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629173,,,A
15286,Intermediate,,1,,10116.0,12219,1,50597,,,,In vitro percent permeability into rat ileum,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629174,,,A
15286,Intermediate,,1,,10116.0,12220,1,50597,,,,In vitro percent permeability into rat ileum; Range is 10-17,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629175,,,A
15286,Intermediate,,1,,10116.0,12221,1,50597,,,,In vitro percent permeability into rat ileum; Range is 10-18,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629176,,,A
15286,Intermediate,,1,,10116.0,12222,1,50597,,,,In vitro percent permeability into rat ileum; Range is 10-19,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629177,,,A
15286,Intermediate,,1,,10116.0,12223,1,50597,,,,In vitro percent permeability into rat ileum; Range is 12-15,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629178,,,A
15286,Intermediate,,1,,10116.0,12224,1,50597,,,,In vitro percent permeability into rat ileum; Range is 13-19,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631869,,,A
15286,Intermediate,,1,,10116.0,12225,1,50597,,,,In vitro percent permeability into rat ileum; Range is 14-17,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631870,,,A
15286,Intermediate,,1,,10116.0,12226,1,50597,,,,In vitro percent permeability into rat ileum; Range is 15-18,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631871,,,A
15286,Intermediate,,1,,10116.0,12227,1,50597,,,,In vitro percent permeability into rat ileum; Range is 2-5,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631872,,,A
15286,Autocuration,,1,,,12228,0,22224,,,Ileum,In vitro percent permeability into rat ileum; Range is 23-42,,U,,,BAO_0000221,2116.0,CHEMBL875775,,,A
15286,Intermediate,,1,,10116.0,12229,1,50597,,,,In vitro percent permeability into rat ileum; Range is 28-36,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631873,,,A
15286,Intermediate,,1,,10116.0,12230,1,50597,,,,In vitro percent permeability into rat ileum; Range is 29-35,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631874,,,A
15286,Intermediate,,1,,10116.0,12231,1,50597,,,,In vitro percent permeability into rat ileum; Range is 46-66,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631875,,,A
15286,Intermediate,,1,,10116.0,12232,1,50597,,,,In vitro percent permeability into rat ileum; Range is 50-68,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631876,,,A
15286,Intermediate,,1,,10116.0,12233,1,50597,,,,In vitro percent permeability into rat ileum; Range is 78-81,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631877,,,A
15286,Intermediate,,1,,10116.0,12234,1,50597,,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631878,,,A
15286,Intermediate,,1,,10116.0,12235,1,50597,,,,In vitro percent permeability into rat ileum; nd indicates not detected,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631879,,,A
15286,Intermediate,,1,,10116.0,12236,1,50597,,,,In vitro percent permeability into rat ileum; nt indicates not detected,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631880,,,A
15286,Intermediate,,1,,10116.0,12237,1,50597,,,,In vitro percent permeability into rat ileum; nt indicates not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631881,,,A
13770,Intermediate,,1,,10116.0,12238,1,50597,,,,Compound was tested for oral absorption in bile-duct cannulated rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631882,,,A
13770,Intermediate,,1,,10116.0,12239,1,50597,,,,Compound was tested for oral absorption in bile-duct cannulated rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630749,,,A
5202,Intermediate,,1,,9606.0,12240,1,50587,,,,Oral absorption using Caco-2 cell monolayers.,,N,,Homo sapiens,BAO_0000218,,CHEMBL630750,,,A
14920,Intermediate,,1,,9606.0,12241,1,50587,,,,Percent of the drug absorbed after administration to humans was determined,,N,,Homo sapiens,BAO_0000218,,CHEMBL630253,,,A
14103,Intermediate,,1,,10116.0,12242,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL630254,,,A
14103,Intermediate,,1,,10116.0,12243,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL630255,,,A
14103,Intermediate,,1,,10116.0,12244,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL630256,,,A
13751,Intermediate,,1,,10116.0,12245,1,50597,,In vivo,Liver,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL875781,,,A
13751,Intermediate,,1,,10116.0,12246,1,50597,,In vivo,Liver,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL630257,,,A
13751,Intermediate,,1,,10116.0,12247,1,50597,,In vivo,Liver,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL630258,,,A
15807,Intermediate,,1,,10116.0,12248,1,50597,,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630259,,,A
15807,Intermediate,,1,,10116.0,12249,1,50597,,,Striatum,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL630260,,,A
15807,Intermediate,,1,,10116.0,12250,1,50597,,,Striatum,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL630261,,,A
14950,Intermediate,,1,,10116.0,12251,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630262,,,A
14950,Intermediate,,1,,10116.0,12252,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630263,,,A
14950,Intermediate,,1,,10116.0,12253,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630264,,,A
14950,Intermediate,,1,,10116.0,12254,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630265,,,A
14950,Intermediate,,1,,10116.0,12255,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630266,,,A
14950,Intermediate,,1,,10116.0,12256,1,50597,,,Kidney,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630267,,,A
14950,Intermediate,,1,,10116.0,12257,1,50597,,,Kidney,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630268,,,A
14950,Intermediate,,1,,10116.0,12258,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630269,,,A
14950,Intermediate,,1,,10116.0,12259,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630270,,,A
14950,Intermediate,,1,,10116.0,12260,1,50597,,,Lung,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630141,,,A
14950,Intermediate,,1,,10116.0,12261,1,50597,,,Lung,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630142,,,A
14950,Intermediate,,1,,10116.0,12262,1,50597,,,Muscle tissue,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630143,,,A
14950,Intermediate,,1,,10116.0,12263,1,50597,,,Muscle tissue,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630144,,,A
14950,Intermediate,,1,,10116.0,12264,1,50597,,,Prostate gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,N,,Rattus norvegicus,BAO_0000218,2367.0,CHEMBL630145,,,A
14950,Intermediate,,1,,10116.0,12265,1,50597,,,Prostate gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,N,,Rattus norvegicus,BAO_0000218,2367.0,CHEMBL630146,,,A
14950,Intermediate,,1,,10116.0,12266,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630147,,,A
14950,Intermediate,,1,,10116.0,12267,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630148,,,A
14950,Intermediate,,1,,10116.0,12268,1,50597,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630149,,,A
14950,Intermediate,,1,,10116.0,12269,1,50597,,,Spleen,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630150,,,A
14950,Intermediate,,1,,10116.0,12270,1,50597,,,Spleen,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630151,,,A
14950,Intermediate,,1,,10116.0,12271,1,50597,,,Thyroid gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL632031,,,A
14950,Intermediate,,1,,10116.0,12272,1,50597,,,Thyroid gland,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL632032,,,A
14950,Intermediate,,1,,10116.0,12273,1,50597,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632033,,,A
14950,Intermediate,,1,,10116.0,12274,1,50597,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632034,,,A
14950,Intermediate,,1,,10116.0,12275,1,50597,,,Muscle tissue,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL632035,,,A
14950,Intermediate,,1,,10116.0,12276,1,50597,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632036,,,A
14950,Intermediate,,1,,10116.0,12277,1,50597,,,Thyroid gland,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL632037,,,A
8631,Intermediate,,1,,10116.0,12278,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632038,,,A
8631,Intermediate,,1,,10116.0,12279,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632039,,,A
8631,Intermediate,,1,,10116.0,12280,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632040,,,A
8631,Intermediate,,1,,10116.0,12281,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL632041,,,A
9614,Intermediate,,1,,9615.0,12282,1,50588,,,Blood,"Concentration of compound in blood of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,178.0,CHEMBL632042,,,A
9614,Intermediate,,1,,9615.0,12283,1,50588,,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL632043,,,A
9614,Intermediate,,1,,9615.0,12284,1,50588,,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL632044,,,A
9614,Intermediate,,1,,9615.0,12285,1,50588,,,Liver,"Concentration of compound in liver of dog 1, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL632045,,,A
9614,Intermediate,,1,,9615.0,12286,1,50588,,,Liver,"Concentration of compound in liver of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL632046,,,A
9614,Intermediate,,1,,9615.0,12287,1,50588,,,Lung,"Concentration of compound in lung of dog 1, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2048.0,CHEMBL632047,,,A
9614,Intermediate,,1,,9615.0,12288,1,50588,,,Lung,"Concentration of compound in lung of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2048.0,CHEMBL632048,,,A
9614,Intermediate,,1,,9615.0,12289,1,50588,,,Muscle tissue,"Concentration of compound in muscle of dog 1, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2385.0,CHEMBL632049,,,A
9614,Intermediate,,1,,9615.0,12290,1,50588,,,Muscle tissue,"Concentration of compound in muscle of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2385.0,CHEMBL876418,,,A
9614,Intermediate,,1,,9615.0,12291,1,50588,,,Spleen,"Concentration of compound in spleen of dog 1,after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2106.0,CHEMBL632050,,,A
9614,Intermediate,,1,,9615.0,12292,1,50588,,,Spleen,"Concentration of compound in spleen of dog 2, after administering intravenously",,N,,Canis lupus familiaris,BAO_0000218,2106.0,CHEMBL632051,,,A
10353,Autocuration,,1,,,12293,0,22224,,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,U,,,BAO_0000218,,CHEMBL632052,,,F
10353,Autocuration,,1,,,12294,0,22224,,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,U,,,BAO_0000218,,CHEMBL632053,,,F
10353,Autocuration,,1,,,12295,0,22224,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,U,,,BAO_0000218,,CHEMBL632054,,,A
10353,Autocuration,,1,,,12296,0,22224,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,U,,,BAO_0000218,,CHEMBL632055,,,F
10353,Autocuration,,1,,,12297,0,22224,,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,U,,,BAO_0000218,,CHEMBL631181,,,F
9196,Autocuration,,1,,,12298,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,U,,,BAO_0000218,,CHEMBL631182,,,A
9196,Autocuration,,1,,,12299,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,U,,,BAO_0000218,,CHEMBL631183,,,A
9196,Autocuration,,1,,,12300,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL631184,,,A
9196,Autocuration,,1,,,12301,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL629774,,,A
9196,Autocuration,,1,,,12302,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,,,BAO_0000218,,CHEMBL629775,,,A
9196,Autocuration,,1,,,12303,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL876549,,,A
9196,Autocuration,,1,,,12304,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL628172,,,A
9196,Autocuration,,1,,,12305,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,U,,,BAO_0000218,,CHEMBL628173,,,A
9196,Autocuration,,1,,,12306,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,U,,,BAO_0000218,,CHEMBL628174,,,A
9196,Autocuration,,1,,,12307,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,U,,,BAO_0000218,,CHEMBL628175,,,A
9196,Autocuration,,1,,,12308,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL628176,,,A
9196,Autocuration,,1,,,12309,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL628177,,,A
9196,Autocuration,,1,,,12310,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL628178,,,A
9196,Autocuration,,1,,,12311,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,U,,,BAO_0000218,,CHEMBL628179,,,A
9196,Autocuration,,1,,,12312,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,U,,,BAO_0000218,,CHEMBL628180,,,A
9196,Autocuration,,1,,,12313,0,22224,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,U,,,BAO_0000218,,CHEMBL628181,,,A
9196,Autocuration,,1,,,12314,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL628182,,,A
9196,Autocuration,,1,,,12315,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,,,BAO_0000218,,CHEMBL628183,,,A
9196,Autocuration,,1,,,12316,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,U,,,BAO_0000218,,CHEMBL628184,,,A
9196,Autocuration,,1,,,12317,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL628185,,,A
9196,Autocuration,,1,,,12318,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL875617,,,A
9196,Autocuration,,1,,,12319,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,U,,,BAO_0000218,,CHEMBL628186,,,A
9196,Autocuration,,1,,,12320,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL628187,,,A
9196,Autocuration,,1,,,12321,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL628188,,,A
9196,Autocuration,,1,,,12322,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,U,,,BAO_0000218,,CHEMBL628189,,,A
9196,Autocuration,,1,,,12323,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,U,,,BAO_0000218,,CHEMBL628190,,,A
9196,Autocuration,,1,,,12324,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL628191,,,A
9196,Autocuration,,1,,,12325,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,U,,,BAO_0000218,,CHEMBL626513,,,A
8608,Intermediate,,1,,10116.0,12326,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626514,,,A
8608,Intermediate,,1,,10116.0,12327,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626515,,,A
8608,Intermediate,,1,,10116.0,12328,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626516,,,A
8608,Intermediate,,1,,10116.0,12329,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626517,,,A
8608,Intermediate,,1,,10116.0,12330,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626518,,,A
8608,Intermediate,,1,,10116.0,12331,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626519,,,A
8608,Intermediate,,1,,10116.0,12332,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626520,,,A
8608,Intermediate,,1,,10116.0,12333,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626521,,,A
8608,Intermediate,,1,,10116.0,12334,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626522,,,A
8608,Intermediate,,1,,10116.0,12335,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626523,,,A
8608,Intermediate,,1,,10116.0,12336,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626524,,,A
8608,Intermediate,,1,,10116.0,12337,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626688,,,A
8608,Intermediate,,1,,10116.0,12338,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626689,,,A
8608,Intermediate,,1,,10116.0,12339,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626690,,,A
8608,Intermediate,,1,,10116.0,12340,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626691,,,A
8608,Intermediate,,1,,10116.0,12341,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL627319,,,A
8608,Intermediate,,1,,10116.0,12342,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624052,,,A
8608,Intermediate,,1,,10116.0,12343,1,50597,,,Thyroid gland,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL624053,,,A
8085,Intermediate,,1,,10116.0,12344,1,50597,,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624054,,,A
8085,Intermediate,,1,,10116.0,12345,1,50597,,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624055,,,A
8085,Intermediate,,1,,10116.0,12346,1,50597,,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624056,,,A
8085,Intermediate,,1,,10116.0,12347,1,50597,,,Uterus,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL624057,,,A
8085,Intermediate,,1,,10116.0,12348,1,50597,,,Uterus,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL622281,,,A
8085,Intermediate,,1,,10116.0,12349,1,50597,,,Uterus,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL622282,,,A
8085,Intermediate,,1,,10116.0,12350,1,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL622283,,,A
8085,Intermediate,,1,,10116.0,12351,1,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL622284,,,A
8085,Intermediate,,1,,10116.0,12352,1,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL622285,,,A
8085,Intermediate,,1,,10116.0,12353,1,50597,,,Uterus,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL622286,,,A
7657,Autocuration,,1,,,12354,0,22224,,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,U,,,BAO_0000100,,CHEMBL622287,,,P
8935,Intermediate,,1,,10090.0,12355,1,50594,,,,Partition coefficient (logD7.4),,N,,Mus musculus,BAO_0000218,,CHEMBL622288,,,A
13792,Intermediate,,1,,10090.0,12356,1,50594,,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,N,,Mus musculus,BAO_0000218,,CHEMBL622289,,,A
13792,Intermediate,,1,,10090.0,12357,1,50594,,,Brain,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622290,,,A
13792,Intermediate,,1,,10090.0,12358,1,50594,,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,N,,Mus musculus,BAO_0000218,,CHEMBL622291,,,A
13792,Intermediate,,1,,10090.0,12359,1,50594,,,Brain,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622292,,,A
13792,Intermediate,,1,,10090.0,12360,1,50594,,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,N,,Mus musculus,BAO_0000218,,CHEMBL622293,,,A
13792,Intermediate,,1,,10090.0,12361,1,50594,,,Brain,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL622294,,,A
13792,Intermediate,,1,,10090.0,12362,1,50594,,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,N,,Mus musculus,BAO_0000218,,CHEMBL622295,,,A
13792,Intermediate,,1,,10116.0,12363,1,50597,,,Brain,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL622296,,,A
14103,Intermediate,,1,,10116.0,12364,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL874409,,,A
14103,Intermediate,,1,,10116.0,12365,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622297,,,A
14103,Intermediate,,1,,10116.0,12366,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622298,,,A
14103,Intermediate,,1,,10116.0,12367,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622299,,,A
14103,Intermediate,,1,,10116.0,12368,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622300,,,A
14103,Intermediate,,1,,10116.0,12369,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622301,,,A
14103,Intermediate,,1,,10116.0,12370,1,50597,,,Plasma,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622302,,,A
14103,Intermediate,,1,,10116.0,12371,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622303,,,A
14103,Intermediate,,1,,10116.0,12372,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622304,,,A
14103,Intermediate,,1,,10116.0,12373,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622305,,,A
14103,Intermediate,,1,,10116.0,12374,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622306,,,A
14103,Intermediate,,1,,10116.0,12375,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626864,,,A
14103,Intermediate,,1,,10116.0,12376,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626865,,,A
14103,Intermediate,,1,,10116.0,12377,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626866,,,A
14103,Intermediate,,1,,10116.0,12378,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626867,,,A
14103,Intermediate,,1,,10116.0,12379,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626868,,,A
14103,Intermediate,,1,,10116.0,12380,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626869,,,A
14103,Intermediate,,1,,10116.0,12381,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626870,,,A
14103,Intermediate,,1,,10116.0,12382,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626871,,,A
14103,Intermediate,,1,,10116.0,12383,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626872,,,A
14103,Intermediate,,1,,10116.0,12384,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632185,,,A
14103,Intermediate,,1,,10116.0,12385,1,50597,,,Plasma,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL632186,,,A
12904,Autocuration,,1,,,12386,0,22224,,,,Amount of acetic acid produced by the compound,,U,,,BAO_0000019,,CHEMBL629310,,,A
12904,Autocuration,,1,,,12387,0,22224,,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,U,,,BAO_0000019,,CHEMBL629311,,,A
9663,Intermediate,,1,,10116.0,12388,1,50597,,,,Log of (Cbrain/Cblood) in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629312,,,A
7652,Autocuration,,1,,,12389,0,22224,,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,U,,,BAO_0000221,,CHEMBL629313,,,A
7652,Autocuration,,1,,,12390,0,22224,,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,U,,,BAO_0000221,,CHEMBL629314,,,A
7652,Autocuration,,1,,,12391,0,22224,,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,U,,,BAO_0000221,,CHEMBL629315,,,A
7652,Autocuration,,1,,,12392,0,22224,,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,U,,,BAO_0000219,,CHEMBL629316,,,B
7652,Autocuration,,1,,,12393,0,22224,,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,U,,,BAO_0000221,,CHEMBL629317,,,A
7652,Autocuration,,1,,,12394,0,22224,,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629318,,,A
7652,Autocuration,,1,,,12395,0,22224,,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL877497,,,A
7652,Autocuration,,1,,,12396,0,22224,,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629319,,,A
7652,Autocuration,,1,,,12397,0,22224,,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629320,,,A
7652,Autocuration,,1,,,12398,0,22224,,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629496,,,A
7652,Autocuration,,1,,,12399,0,22224,,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629497,,,A
7652,Autocuration,,1,,,12400,0,22224,,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629498,,,A
7652,Autocuration,,1,,,12401,0,22224,,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629499,,,A
7652,Autocuration,,1,,,12402,0,22224,,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629500,,,A
7652,Autocuration,,1,,,12403,0,22224,,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629501,,,A
7652,Autocuration,,1,,,12404,0,22224,,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,U,,,BAO_0000019,,CHEMBL629502,,,A
8267,Autocuration,,1,,,12405,0,22224,,In vivo,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,U,,,BAO_0000218,,CHEMBL629503,,,F
8267,Intermediate,,1,,9615.0,12406,1,50588,,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629504,,,A
14479,Autocuration,,1,,,12407,0,22224,,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,U,,,BAO_0000019,,CHEMBL629505,,,A
17515,Autocuration,,1,,,12408,0,22224,,,,Compound was evaluated for total body clearance,,U,,,BAO_0000019,,CHEMBL629506,,,A
17515,Autocuration,,1,,,12409,0,22224,,,,Compound was evaluated for volume of distribution at steady state,,U,,,BAO_0000019,,CHEMBL629507,,,A
8142,Autocuration,,1,,,12410,0,22224,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,U,,,BAO_0000019,,CHEMBL877498,,,A
14849,Autocuration,,1,,,12411,0,22224,,,,Percentage of the diamine which is monoprotonated at pH 7.4,,U,,,BAO_0000019,,CHEMBL629508,,,A
7653,Autocuration,,1,,,12412,0,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,U,,,BAO_0000019,,CHEMBL629509,,,A
8631,Intermediate,,1,,10116.0,12413,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629510,,,A
8631,Intermediate,,1,,10116.0,12414,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629511,,,A
8631,Intermediate,,1,,10116.0,12415,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629512,,,A
8631,Intermediate,,1,,10116.0,12416,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629513,,,A
8631,Intermediate,,1,,10116.0,12417,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629514,,,A
8631,Intermediate,,1,,10116.0,12418,1,50597,,,Blood,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628447,,,A
8631,Intermediate,,1,,10116.0,12419,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628448,,,A
8631,Intermediate,,1,,10116.0,12420,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628449,,,A
8631,Intermediate,,1,,10116.0,12421,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631119,,,A
8631,Intermediate,,1,,10116.0,12422,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631120,,,A
8631,Intermediate,,1,,10116.0,12423,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631121,,,A
8631,Intermediate,,1,,10116.0,12424,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL874458,,,A
8631,Intermediate,,1,,10116.0,12425,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631122,,,A
8631,Intermediate,,1,,10116.0,12426,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631123,,,A
8631,Intermediate,,1,,10116.0,12427,1,50597,,,Blood,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631124,,,A
8631,Intermediate,,1,,10116.0,12428,1,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631125,,,A
8631,Intermediate,,1,,10116.0,12429,1,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631290,,,A
8631,Intermediate,,1,,10116.0,12430,1,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631291,,,A
8631,Intermediate,,1,,10116.0,12431,1,50597,,,Blood,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631292,,,A
8631,Intermediate,,1,,10116.0,12432,1,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631293,,,A
8631,Intermediate,,1,,10116.0,12433,1,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631294,,,A
8631,Intermediate,,1,,10116.0,12434,1,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631295,,,A
8631,Intermediate,,1,,10116.0,12435,1,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631296,,,A
8631,Intermediate,,1,,10116.0,12436,1,50597,,,Blood,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631297,,,A
10263,Autocuration,,1,,,12437,0,22224,,,,Maximum biodistribution (Bmax) was determined.,,U,,,BAO_0000218,,CHEMBL631298,,,A
12364,Intermediate,,1,,10090.0,12438,1,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,N,,Mus musculus,BAO_0000218,,CHEMBL631299,,,A
12364,Intermediate,,1,,10090.0,12439,1,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,N,,Mus musculus,BAO_0000218,,CHEMBL631300,,,A
12364,Intermediate,,1,,10090.0,12440,1,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,N,,Mus musculus,BAO_0000218,,CHEMBL631301,,,A
12364,Intermediate,,1,,10090.0,12441,1,50594,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,N,,Mus musculus,BAO_0000218,,CHEMBL630291,,,A
14793,Autocuration,,1,,,12442,0,22224,,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,,,BAO_0000218,,CHEMBL630292,,,A
14793,Autocuration,,1,,,12443,0,22224,,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,U,,,BAO_0000218,,CHEMBL630293,,,A
14793,Autocuration,,1,,,12444,0,22224,,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL630294,,,A
14793,Autocuration,,1,,,12445,0,22224,,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,U,,,BAO_0000218,,CHEMBL630295,,,A
14793,Autocuration,,1,,,12446,0,22224,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,U,,,BAO_0000218,,CHEMBL630296,,,A
14793,Autocuration,,1,,,12447,0,22224,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626782,,,A
14793,Autocuration,,1,,,12448,0,22224,,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626783,,,A
14793,Autocuration,,1,,,12449,0,22224,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,,,BAO_0000218,,CHEMBL626784,,,A
14793,Autocuration,,1,,,12450,0,22224,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,U,,,BAO_0000218,,CHEMBL626785,,,A
14793,Autocuration,,1,,,12451,0,22224,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626786,,,A
9196,Autocuration,,1,,,12452,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL626787,,,A
9196,Autocuration,,1,,,12453,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,U,,,BAO_0000218,,CHEMBL626788,,,A
9196,Autocuration,,1,,,12454,0,22224,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL625927,,,A
8374,Intermediate,,1,,10116.0,12455,1,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625928,,,A
8374,Intermediate,,1,,10116.0,12456,1,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625929,,,A
8374,Intermediate,,1,,10116.0,12457,1,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625930,,,A
8374,Intermediate,,1,,10116.0,12458,1,50597,,,Blood,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625931,,,A
8374,Intermediate,,1,,10116.0,12459,1,50597,,,Blood,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627230,,,A
8374,Intermediate,,1,,10116.0,12460,1,50597,,,Blood,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627231,,,A
8374,Intermediate,,1,,10116.0,12461,1,50597,,,Blood,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627232,,,A
8374,Intermediate,,1,,10116.0,12462,1,50597,,,Blood,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627233,,,A
8374,Intermediate,,1,,10116.0,12463,1,50597,,,Blood,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL875470,,,A
8374,Intermediate,,1,,10116.0,12464,1,50597,,,Blood,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627234,,,A
8374,Intermediate,,1,,10116.0,12465,1,50597,,,Blood,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627235,,,A
8374,Intermediate,,1,,10116.0,12466,1,50597,,,Blood,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627236,,,A
8374,Intermediate,,1,,10116.0,12467,1,50597,,,Blood,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627237,,,A
8374,Intermediate,,1,,10116.0,12468,1,50597,,,Blood,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627238,,,A
8374,Intermediate,,1,,10116.0,12469,1,50597,,,Blood,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627239,,,A
8374,Intermediate,,1,,10116.0,12470,1,50597,,,Blood,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627240,,,A
8374,Intermediate,,1,,10116.0,12471,1,50597,,,Blood,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627241,,,A
8374,Intermediate,,1,,10116.0,12472,1,50597,,,Blood,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627242,,,A
8374,Intermediate,,1,,10116.0,12473,1,50597,,,Blood,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627243,,,A
8374,Intermediate,,1,,10116.0,12474,1,50597,,,Blood,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627244,,,A
8374,Intermediate,,1,,10116.0,12475,1,50597,,,Blood,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627245,,,A
8374,Intermediate,,1,,10116.0,12476,1,50597,,,Blood,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627246,,,A
8374,Intermediate,,1,,10116.0,12477,1,50597,,,Blood,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627247,,,A
8374,Intermediate,,1,,10116.0,12478,1,50597,,,Blood,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627248,,,A
8374,Intermediate,,1,,10116.0,12479,1,50597,,,Blood,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627249,,,A
8374,Intermediate,,1,,10116.0,12480,1,50597,,,Blood,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625569,,,A
8374,Intermediate,,1,,10116.0,12481,1,50597,,,Blood,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625570,,,A
8374,Intermediate,,1,,10116.0,12482,1,50597,,,Blood,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625571,,,A
8374,Intermediate,,1,,10116.0,12483,1,50597,,,Blood,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625572,,,A
8374,Intermediate,,1,,10116.0,12484,1,50597,,,Blood,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625573,,,A
8374,Intermediate,,1,,10116.0,12485,1,50597,,,Blood,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625574,,,A
8374,Intermediate,,1,,10116.0,12486,1,50597,,,Blood,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626245,,,A
8374,Intermediate,,1,,10116.0,12487,1,50597,,,Blood,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626246,,,A
9196,Autocuration,,1,,,12488,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL626247,,,A
9196,Autocuration,,1,,,12489,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,,,BAO_0000218,,CHEMBL626248,,,A
9196,Autocuration,,1,,,12490,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,U,,,BAO_0000218,,CHEMBL626249,,,A
9196,Autocuration,,1,,,12491,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL626420,,,A
9196,Autocuration,,1,,,12492,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,U,,,BAO_0000218,,CHEMBL626421,,,A
9196,Autocuration,,1,,,12493,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,U,,,BAO_0000218,,CHEMBL626422,,,A
9196,Autocuration,,1,,,12494,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL626423,,,A
9196,Autocuration,,1,,,12495,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL626424,,,A
12023,Intermediate,,1,,9615.0,12496,1,50588,,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626425,,,A
12023,Intermediate,,1,,10116.0,12497,1,50597,,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875476,,,A
12023,Intermediate,,1,,9541.0,12498,1,100710,,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL626426,,,A
10580,Autocuration,,1,,,12499,0,22224,,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,U,,,BAO_0000100,,CHEMBL626427,,,P
10580,Autocuration,,1,,,12500,0,22224,,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,U,,,BAO_0000100,,CHEMBL626428,,,P
16032,Autocuration,,1,,,12501,0,22224,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,U,,,BAO_0000019,,CHEMBL626429,,,A
16032,Autocuration,,1,,,12502,0,22224,,,Urine,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,U,,,BAO_0000019,1088.0,CHEMBL625025,,,A
8594,Intermediate,,1,,10116.0,12503,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625026,,,A
8594,Intermediate,,1,,10116.0,12504,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625027,,,A
8594,Intermediate,,1,,10116.0,12505,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL874410,,,A
8594,Intermediate,,1,,10116.0,12506,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625028,,,A
8594,Intermediate,,1,,10116.0,12507,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625029,,,A
8594,Intermediate,,1,,10116.0,12508,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625030,,,A
8594,Intermediate,,1,,10116.0,12509,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625031,,,A
8594,Intermediate,,1,,10116.0,12510,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625032,,,A
8594,Intermediate,,1,,10116.0,12511,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625033,,,A
8594,Intermediate,,1,,10116.0,12512,1,50597,,,Blood,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625034,,,A
8594,Intermediate,,1,,10116.0,12513,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624872,,,A
8594,Intermediate,,1,,10116.0,12514,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624873,,,A
8594,Intermediate,,1,,10116.0,12515,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624874,,,A
8594,Intermediate,,1,,10116.0,12516,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624875,,,A
8594,Intermediate,,1,,10116.0,12517,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624876,,,A
8594,Intermediate,,1,,10116.0,12518,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624877,,,A
8594,Intermediate,,1,,10116.0,12519,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624878,,,A
8594,Intermediate,,1,,10116.0,12520,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624879,,,A
8594,Intermediate,,1,,10116.0,12521,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624880,,,A
8594,Intermediate,,1,,10116.0,12522,1,50597,,,Heart,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624881,,,A
8594,Intermediate,,1,,10116.0,12523,1,50597,,,Heart,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL624882,,,A
8594,Intermediate,,1,,10116.0,12524,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624883,,,A
8594,Intermediate,,1,,10116.0,12525,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624884,,,A
8594,Intermediate,,1,,10116.0,12526,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624885,,,A
8594,Intermediate,,1,,10116.0,12527,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624886,,,A
8594,Intermediate,,1,,10116.0,12528,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624887,,,A
8594,Intermediate,,1,,10116.0,12529,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624888,,,A
8594,Intermediate,,1,,10116.0,12530,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624889,,,A
8594,Intermediate,,1,,10116.0,12531,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL624890,,,A
8594,Intermediate,,1,,10116.0,12532,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621964,,,A
8594,Intermediate,,1,,10116.0,12533,1,50597,,,Kidney,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL621965,,,A
8594,Intermediate,,1,,10116.0,12534,1,50597,,,Liver,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621966,,,A
8594,Intermediate,,1,,10116.0,12535,1,50597,,,Liver,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL621967,,,A
8594,Intermediate,,1,,10116.0,12536,1,50597,,,Liver,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL622164,,,A
7653,Autocuration,,1,,,12537,0,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,U,,,BAO_0000019,,CHEMBL623097,,,A
7653,Autocuration,,1,,,12538,0,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,U,,,BAO_0000019,,CHEMBL623098,,,A
7653,Autocuration,,1,,,12539,0,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,U,,,BAO_0000019,,CHEMBL623099,,,A
7653,Autocuration,,1,,,12540,0,22224,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,U,,,BAO_0000019,,CHEMBL623100,,,A
9104,Intermediate,,1,,10116.0,12541,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628673,,,A
9104,Intermediate,,1,,10116.0,12542,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628674,,,A
9104,Intermediate,,1,,10116.0,12543,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628675,,,A
9104,Intermediate,,1,,10116.0,12544,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627644,,,A
9104,Intermediate,,1,,10116.0,12545,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627645,,,A
9104,Intermediate,,1,,10116.0,12546,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627646,,,A
9104,Intermediate,,1,,10116.0,12547,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627647,,,A
9104,Intermediate,,1,,10116.0,12548,1,50597,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627648,,,A
12902,Intermediate,,1,,10116.0,12549,1,50597,,,,Free level in rat plasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627649,,,A
6614,Autocuration,,1,,,12550,0,22224,,,,Level reaching in blood plasma of rat or human was determined,,U,,,BAO_0000019,,CHEMBL628313,,,A
9663,Intermediate,,1,,10116.0,12551,1,50597,,,,Log (Cbrain/Cblood) in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628314,,,A
17658,Autocuration,,1,,,12552,0,22224,,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,U,,,BAO_0000019,,CHEMBL628315,,,A
17658,Autocuration,,1,,,12553,0,22224,,,,Mean percentage of compound transport through membrane; expressed as membrane transport,,U,,,BAO_0000019,,CHEMBL628316,,,A
14314,Autocuration,,1,,,12554,0,22224,,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,U,,,BAO_0000218,,CHEMBL628317,,,A
7385,Autocuration,,1,,,12555,0,22224,,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,U,,,BAO_0000019,,CHEMBL628473,,,A
7385,Autocuration,,1,,,12556,0,22224,,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,U,,,BAO_0000019,,CHEMBL628474,,,A
7385,Autocuration,,1,,,12557,0,22224,,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,U,,,BAO_0000019,,CHEMBL628475,,,A
1329,Autocuration,,1,,,12558,0,22224,,,,Net water uptake by a carrier mediated transport (%cm) mechanism,,U,,,BAO_0000019,,CHEMBL628476,,,A
12187,Autocuration,,1,,314293.0,12559,0,22224,,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL628477,,,A
12187,Intermediate,,1,,9669.0,12560,1,50506,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL628478,,,A
12187,Intermediate,,1,,9669.0,12561,1,50506,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,N,,Mustela putorius furo,BAO_0000218,,CHEMBL628479,,,A
12187,Autocuration,,1,,314293.0,12562,0,22224,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL628480,,,A
12187,Autocuration,,1,,314293.0,12563,0,22224,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,U,,Simiiformes,BAO_0000218,,CHEMBL628481,,,A
12187,Intermediate,,1,,10116.0,12564,1,50597,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628482,,,A
12187,Intermediate,,1,,10116.0,12565,1,50597,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628483,,,A
9278,Intermediate,,1,,10116.0,12566,1,50597,,,Plasma,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628484,,,A
9278,Intermediate,,1,,10116.0,12567,1,50597,,,Plasma,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628485,,,A
9278,Intermediate,,1,,9541.0,12568,1,100710,,,Plasma,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL628486,,,A
9278,Intermediate,,1,,9606.0,12569,1,50587,,,Plasma,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL628487,,,A
9278,Intermediate,,1,,10116.0,12570,1,50597,,,Plasma,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628488,,,A
9278,Intermediate,,1,,10116.0,12571,1,50597,,,Plasma,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628489,,,A
9278,Intermediate,,1,,10116.0,12572,1,50597,,,Plasma,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628490,,,A
12186,Intermediate,,1,,9541.0,12573,1,100710,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL628491,,,A
12186,Intermediate,,1,,9541.0,12574,1,100710,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL877507,,,A
12186,Autocuration,,1,,,12575,0,22224,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,U,,,BAO_0000218,,CHEMBL628492,,,A
12041,Autocuration,,1,,314293.0,12576,0,22224,,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,U,,Simiiformes,BAO_0000019,,CHEMBL628493,,,A
12041,Autocuration,,1,,314293.0,12577,0,22224,,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,U,,Simiiformes,BAO_0000019,,CHEMBL628494,,,A
12041,Autocuration,,1,,314293.0,12578,0,22224,,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,U,,Simiiformes,BAO_0000019,,CHEMBL628495,,,A
6737,Intermediate,,1,,9606.0,12579,1,50587,,,,Permeability in Caco-2 assay at 10E-6,,N,,Homo sapiens,BAO_0000218,,CHEMBL628496,,,A
13758,Autocuration,,1,,,12580,0,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,U,,,BAO_0000218,955.0,CHEMBL628497,,,A
13758,Autocuration,,1,,,12581,0,22224,,,Brain,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,U,,,BAO_0000218,955.0,CHEMBL628498,,,A
5676,Autocuration,,1,,,12582,0,22224,,,,Plasma protein binding was determined,,U,,,BAO_0000019,,CHEMBL628499,,,A
14793,Autocuration,,1,,,12583,0,22224,,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL627656,,,A
14793,Autocuration,,1,,,12584,0,22224,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,,,BAO_0000218,,CHEMBL627657,,,A
14793,Autocuration,,1,,,12585,0,22224,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,U,,,BAO_0000218,,CHEMBL626808,,,A
14793,Autocuration,,1,,,12586,0,22224,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626809,,,A
14793,Autocuration,,1,,,12587,0,22224,,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626810,,,A
14793,Autocuration,,1,,,12588,0,22224,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,U,,,BAO_0000218,,CHEMBL626811,,,A
14793,Autocuration,,1,,,12589,0,22224,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,U,,,BAO_0000218,,CHEMBL874465,,,A
14793,Autocuration,,1,,,12590,0,22224,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626812,,,A
14793,Autocuration,,1,,,12591,0,22224,,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626813,,,A
14793,Autocuration,,1,,,12592,0,22224,,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,U,,,BAO_0000218,,CHEMBL626814,,,A
14000,Autocuration,,1,,,12593,0,22224,,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,U,,,BAO_0000019,,CHEMBL626815,,,A
5948,Autocuration,,1,,,12594,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL628566,,,A
13824,Autocuration,,1,,,12595,0,22229,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,U,,,BAO_0000100,,CHEMBL628567,,,P
10778,Autocuration,,1,,,12596,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL628568,,,P
17237,Intermediate,,1,,9615.0,12597,1,50588,,In vivo,,C max in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628569,,,A
17237,Intermediate,,1,,10141.0,12598,1,50512,,In vivo,,C max in guinea pig,,N,,Cavia porcellus,BAO_0000218,,CHEMBL628570,,,A
2809,Autocuration,,1,,,12599,0,22224,,In vivo,,C max value was evaluated,,U,,,BAO_0000218,,CHEMBL628571,,,A
11954,Autocuration,,1,,,12600,0,22224,,In vivo,,Cmax value after oral dose of 0.1 mg//kg,,U,,,BAO_0000218,,CHEMBL628572,,,A
11954,Autocuration,,1,,,12601,0,22224,,In vivo,,Cmax value after oral dose of 0.3 mg/kg,,U,,,BAO_0000218,,CHEMBL628573,,,A
11954,Autocuration,,1,,,12602,0,22224,,In vivo,,Cmax value after oral dose of 1 mg/kg,,U,,,BAO_0000218,,CHEMBL628574,,,A
11954,Autocuration,,1,,,12603,0,22224,,In vivo,,Cmax value after oral dose of 10 mg/kg,,U,,,BAO_0000218,,CHEMBL628575,,,A
11954,Autocuration,,1,,,12604,0,22224,,In vivo,,Cmax value after oral dose of 23.4 mg/kg,,U,,,BAO_0000218,,CHEMBL628576,,,A
11954,Autocuration,,1,,,12605,0,22224,,In vivo,,Cmax value after oral dose of 3 mg/kg,,U,,,BAO_0000218,,CHEMBL628577,,,A
11954,Autocuration,,1,,,12606,0,22224,,In vivo,,Cmax value after oral dose of 3.87 mg/kg,,U,,,BAO_0000218,,CHEMBL628578,,,A
12768,Intermediate,,1,,9615.0,12607,1,50588,,In vivo,,Cmax value in female Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL874466,,,A
12768,Intermediate,,1,,10116.0,12608,1,50597,,In vivo,,Cmax value in male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628579,,,A
12780,Intermediate,,1,,10116.0,12609,1,50597,,In vivo,Plasma,Cmax value in rat plasma when administered 20 mg/kg perorally,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628580,,,A
15592,Intermediate,,1,,9615.0,12610,1,50588,,In vivo,Plasma,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628581,,,A
15592,Intermediate,,1,,9615.0,12611,1,50588,,In vivo,Plasma,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL628582,,,A
17025,Intermediate,,1,,9615.0,12612,1,50588,,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628583,,,A
17025,Autocuration,,1,,314293.0,12613,0,22224,,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,U,,Simiiformes,BAO_0000218,,CHEMBL625782,,,A
17025,Intermediate,,1,,9986.0,12614,1,50592,,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625783,,,A
17025,Intermediate,,1,,10116.0,12615,1,50597,,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625784,,,A
4236,Intermediate,,1,,9544.0,12616,1,50797,,,Plasma,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,N,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL625785,,,A
15791,Intermediate,,1,,10116.0,12617,1,50597,,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625786,,,A
11149,Autocuration,,1,,,12618,0,22224,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,U,,,BAO_0000019,,CHEMBL874467,,,A
15592,Intermediate,,1,,9615.0,12619,1,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625787,,,A
15778,Intermediate,,1,,12721.0,12620,1,50677,,,,cytotoxicity against HIV protease enzyme.,,N,,Human immunodeficiency virus,BAO_0000218,,CHEMBL625964,,,A
12745,Intermediate,,1,,10090.0,12621,1,50594,,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,N,,Mus musculus,BAO_0000218,,CHEMBL625965,,,A
12745,Intermediate,,1,,10090.0,12622,1,50594,,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,N,,Mus musculus,BAO_0000218,,CHEMBL625966,,,A
13941,Intermediate,,1,,9615.0,12623,1,50588,,In vivo,Plasma,The plasma clearance in dog.,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625967,,,A
13941,Intermediate,,1,,10116.0,12624,1,50597,,In vivo,Plasma,The plasma clearance in rat.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625968,,,A
16449,Intermediate,,1,,10116.0,12625,1,50597,,In vivo,Plasma,Clearance from plasma in male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625969,,,A
16449,Intermediate,,1,,9541.0,12626,1,100710,,In vivo,Plasma,Clearance from plasma in male cynomolgus monkeys,,N,,Macaca fascicularis,BAO_0000218,1969.0,CHEMBL625970,,,A
14224,Intermediate,,1,,9615.0,12627,1,50588,,In vivo,Plasma,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625971,,,A
14224,Intermediate,,1,,9615.0,12628,1,50588,,In vivo,Plasma,Clearance of compound in dog plasma,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625972,,,A
14224,Intermediate,,1,,9606.0,12629,1,50587,,In vivo,Plasma,Clearance of compound in human plasma,,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL625973,,,A
14317,Intermediate,,1,,9615.0,12630,1,50588,,In vivo,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625974,,,A
14317,Intermediate,,1,,9615.0,12631,1,50588,,In vivo,,Clearance of compound when administered intravenously as an individual dose to a single dog.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625975,,,A
14224,Intermediate,,1,,9615.0,12632,1,50588,,In vivo,Plasma,"Clearance (10 mg/kg, intravenously) in dog plasma",,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625976,,,A
17237,Intermediate,,1,,9615.0,12633,1,50588,,In vivo,,Clearance value in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625977,,,A
17237,Intermediate,,1,,10141.0,12634,1,50512,,In vivo,,Clearance value in guinea pig,,N,,Cavia porcellus,BAO_0000218,,CHEMBL625978,,,A
14187,Intermediate,,1,,10116.0,12635,1,50597,,In vivo,,Clearance values in rats after iv administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874468,,,A
4806,Autocuration,,1,,,12636,0,22224,,In vivo,Plasma,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,U,,,BAO_0000218,1969.0,CHEMBL625421,,,A
15025,Intermediate,,1,,9986.0,12637,1,50592,,In vivo,,In vivo clearance (5 mg/kg) was determined in rabbits,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625422,,,A
13197,Intermediate,,1,,10116.0,12638,1,50597,,In vivo,,Plasma Clearance rate was determined for the compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625423,,,A
13197,Autocuration,,1,,9520.0,12639,0,22224,,In vivo,,Plasma Clearance rate was determined for the compound in squirrel monkeys,,U,,Saimiri,BAO_0000218,,CHEMBL625424,,,A
13960,Intermediate,,1,,10116.0,12640,1,50597,,In vivo,,Plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625425,,,A
17820,Autocuration,,1,,,12641,0,22224,,In vivo,,Plasma clearance of the compound,,U,,,BAO_0000218,,CHEMBL625426,,,A
14706,Intermediate,,1,,10141.0,12642,1,50512,,In vivo,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,N,,Cavia porcellus,BAO_0000218,,CHEMBL625427,,,A
14706,Intermediate,,1,,10141.0,12643,1,50512,,In vivo,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,N,,Cavia porcellus,BAO_0000218,,CHEMBL625428,,,A
6504,Autocuration,,1,,,12644,0,22224,,In vivo,,Plasma clearance was determined,,U,,,BAO_0000218,,CHEMBL625429,,,A
14925,Intermediate,,1,,9615.0,12645,1,50588,,In vivo,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625430,,,A
13197,Intermediate,,1,,10116.0,12646,1,50597,,In vivo,,Plasma clearance rate was determined for the compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625431,,,A
13197,Autocuration,,1,,9520.0,12647,0,22224,,In vivo,,Plasma clearance rate was determined for the compound in squirrel monkeys,,U,,Saimiri,BAO_0000218,,CHEMBL627307,,,A
3437,Autocuration,,1,,,12648,0,22224,,In vivo,,Slow clearance (CL) was determined,,U,,,BAO_0000218,,CHEMBL627308,,,A
9196,Autocuration,,1,,,12649,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL627309,,,A
9196,Autocuration,,1,,,12650,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,U,,,BAO_0000218,,CHEMBL627310,,,A
9196,Autocuration,,1,,,12651,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,U,,,BAO_0000218,,CHEMBL627311,,,A
9196,Autocuration,,1,,,12652,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL627312,,,A
9196,Autocuration,,1,,,12653,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,U,,,BAO_0000218,,CHEMBL627313,,,A
9196,Autocuration,,1,,,12654,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,U,,,BAO_0000218,,CHEMBL627314,,,A
9196,Autocuration,,1,,,12655,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL627315,,,A
9196,Autocuration,,1,,,12656,0,22224,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL627316,,,A
9196,Autocuration,,1,,,12657,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,U,,,BAO_0000218,,CHEMBL627317,,,A
9196,Autocuration,,1,,,12658,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,U,,,BAO_0000218,,CHEMBL627318,,,A
9196,Autocuration,,1,,,12659,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,U,,,BAO_0000218,,CHEMBL627999,,,A
9196,Autocuration,,1,,,12660,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,U,,,BAO_0000218,,CHEMBL628000,,,A
9196,Autocuration,,1,,,12661,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,U,,,BAO_0000218,,CHEMBL628001,,,A
9196,Autocuration,,1,,,12662,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL628002,,,A
9196,Autocuration,,1,,,12663,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,U,,,BAO_0000218,,CHEMBL625610,,,A
9196,Autocuration,,1,,,12664,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL625611,,,A
9196,Autocuration,,1,,,12665,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,U,,,BAO_0000218,,CHEMBL625612,,,A
9196,Autocuration,,1,,,12666,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,U,,,BAO_0000218,,CHEMBL625613,,,A
9196,Autocuration,,1,,,12667,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,U,,,BAO_0000218,,CHEMBL875479,,,A
9196,Autocuration,,1,,,12668,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,U,,,BAO_0000218,,CHEMBL625614,,,A
9196,Autocuration,,1,,,12669,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,U,,,BAO_0000218,,CHEMBL625615,,,A
9196,Autocuration,,1,,,12670,0,22224,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,U,,,BAO_0000218,,CHEMBL626302,,,A
8374,Intermediate,,1,,10116.0,12671,1,50597,,,Blood,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626303,,,A
8374,Intermediate,,1,,10116.0,12672,1,50597,,,Blood,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627420,,,A
13477,Intermediate,,1,,10116.0,12673,1,50597,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627421,,,A
13477,Intermediate,,1,,10116.0,12674,1,50597,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625695,,,A
13477,Intermediate,,1,,10116.0,12675,1,50597,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625696,,,A
10009,Intermediate,,1,,10090.0,12676,1,50594,,,Brain,Distribution of compound in mice brain was measured after 1 hr,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL875606,,,A
10009,Intermediate,,1,,10090.0,12677,1,50594,,,Brain,Distribution of compound in mice brain was measured after 24 hr r,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625697,,,A
10009,Intermediate,,1,,10090.0,12678,1,50594,,,Brain,Distribution of compound in mice brain was measured after 2 hr,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625698,,,A
10009,Intermediate,,1,,10090.0,12679,1,50594,,,Brain,Distribution of compound in mice brain was measured after 3 hr,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625699,,,A
10009,Intermediate,,1,,10090.0,12680,1,50594,,,Brain,Distribution of compound in mice brain was measured after 6 hr,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL625700,,,A
10009,Intermediate,,1,,10090.0,12681,1,50594,,,,Distribution of compound in mice liver was measured after 1 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL625701,,,A
10009,Intermediate,,1,,10090.0,12682,1,50594,,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,N,,Mus musculus,BAO_0000218,,CHEMBL625702,,,A
10009,Intermediate,,1,,10090.0,12683,1,50594,,,,Distribution of compound in mice liver was measured after 2 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL625703,,,A
10009,Intermediate,,1,,10090.0,12684,1,50594,,,,Distribution of compound in mice liver was measured after 3 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL625704,,,A
10009,Intermediate,,1,,10090.0,12685,1,50594,,,,Distribution of compound in mice liver was measured after 6 hr,,N,,Mus musculus,BAO_0000218,,CHEMBL625705,,,A
8170,Intermediate,,1,,9615.0,12686,1,50588,,,Adrenal medulla,Distribution in dog adrenal medulla 30 min after administration.,,N,,Canis lupus familiaris,BAO_0000218,1236.0,CHEMBL625706,,,A
8170,Intermediate,,1,,9615.0,12687,1,50588,,,Adrenal medulla,Distribution in dog adrenal medulla 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,1236.0,CHEMBL625707,,,A
8170,Intermediate,,1,,9615.0,12688,1,50588,,,,Distribution in female dog Ovary 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625708,,,A
8170,Intermediate,,1,,9615.0,12689,1,50588,,,,Distribution in female dog Ovary 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625709,,,A
8170,Intermediate,,1,,9615.0,12690,1,50588,,,,Distribution in female dog adipose 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624180,,,A
8170,Intermediate,,1,,9615.0,12691,1,50588,,,,Distribution in female dog adipose 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624181,,,A
8170,Intermediate,,1,,9615.0,12692,1,50588,,,Adrenal cortex,Distribution in female dog adrenal cortex 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,1235.0,CHEMBL624182,,,A
8170,Intermediate,,1,,9615.0,12693,1,50588,,,Adrenal cortex,Distribution in female dog adrenal cortex 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,1235.0,CHEMBL624183,,,A
8594,Intermediate,,1,,10116.0,12694,1,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624184,,,A
8594,Intermediate,,1,,10116.0,12695,1,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL877489,,,A
8594,Intermediate,,1,,10116.0,12696,1,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624185,,,A
8594,Intermediate,,1,,10116.0,12697,1,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624186,,,A
8594,Intermediate,,1,,10116.0,12698,1,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624187,,,A
8594,Intermediate,,1,,10116.0,12699,1,50597,,,Liver,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL624188,,,A
8594,Intermediate,,1,,10116.0,12700,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624189,,,A
8594,Intermediate,,1,,10116.0,12701,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624190,,,A
8594,Intermediate,,1,,10116.0,12702,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624191,,,A
8594,Intermediate,,1,,10116.0,12703,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624192,,,A
8594,Intermediate,,1,,10116.0,12704,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624193,,,A
8594,Intermediate,,1,,10116.0,12705,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624194,,,A
8594,Intermediate,,1,,10116.0,12706,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624891,,,A
8594,Intermediate,,1,,10116.0,12707,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624892,,,A
8594,Intermediate,,1,,10116.0,12708,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL624893,,,A
8594,Intermediate,,1,,10116.0,12709,1,50597,,,Lung,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627632,,,A
8594,Intermediate,,1,,10116.0,12710,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627633,,,A
8594,Intermediate,,1,,10116.0,12711,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627634,,,A
8594,Intermediate,,1,,10116.0,12712,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627635,,,A
8594,Intermediate,,1,,10116.0,12713,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627636,,,A
8594,Intermediate,,1,,10116.0,12714,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626816,,,A
8594,Intermediate,,1,,10116.0,12715,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626817,,,A
8594,Intermediate,,1,,10116.0,12716,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626818,,,A
8594,Intermediate,,1,,10116.0,12717,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626819,,,A
8594,Intermediate,,1,,10116.0,12718,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626820,,,A
8594,Intermediate,,1,,10116.0,12719,1,50597,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626821,,,A
8594,Intermediate,,1,,10116.0,12720,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626822,,,A
8594,Intermediate,,1,,10116.0,12721,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626823,,,A
8594,Intermediate,,1,,10116.0,12722,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626824,,,A
8594,Intermediate,,1,,10116.0,12723,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626825,,,A
8594,Intermediate,,1,,10116.0,12724,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626826,,,A
8594,Intermediate,,1,,10116.0,12725,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626827,,,A
8594,Intermediate,,1,,10116.0,12726,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626828,,,A
8594,Intermediate,,1,,10116.0,12727,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626829,,,A
8594,Intermediate,,1,,10116.0,12728,1,50597,,,Thyroid gland,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL626830,,,A
8594,Intermediate,,1,,10116.0,12729,1,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627150,,,A
8594,Intermediate,,1,,10116.0,12730,1,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627151,,,A
8594,Intermediate,,1,,10116.0,12731,1,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627152,,,A
8594,Intermediate,,1,,10116.0,12732,1,50597,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627153,,,A
12904,Autocuration,,1,,,12733,0,22224,,,,Rate of acetate production by the compound was determined,,U,,,BAO_0000019,,CHEMBL627154,,,A
12904,Autocuration,,1,,,12734,0,22224,,,,Rate of acetate production by the compound was determined; Not determined,,U,,,BAO_0000019,,CHEMBL627155,,,A
3730,Autocuration,,1,,,12735,0,22224,,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,U,,,BAO_0000019,,CHEMBL627156,,,A
3627,Autocuration,,1,,,12736,0,22224,,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,U,,,BAO_0000019,,CHEMBL627157,,,A
13799,Intermediate,,1,,9986.0,12737,1,50592,,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL627158,,,A
13799,Intermediate,,1,,9986.0,12738,1,50592,,,Plasma,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,N,,Oryctolagus cuniculus,BAO_0000218,1969.0,CHEMBL627159,,,A
13799,Intermediate,,1,,10090.0,12739,1,50594,,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,N,,Mus musculus,BAO_0000218,,CHEMBL627160,,,A
13799,Intermediate,,1,,10116.0,12740,1,50597,,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628540,,,A
13799,Intermediate,,1,,10116.0,12741,1,50597,,,Plasma,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628541,,,A
13799,Intermediate,,1,,10116.0,12742,1,50597,,,Plasma,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628542,,,A
6629,Autocuration,,1,,,12743,0,22229,,,,Solubility after at a pH 1.2,,U,,,BAO_0000100,,CHEMBL628543,,,P
6629,Autocuration,,1,,,12744,0,22229,,,,Solubility after at pH 1.2,,U,,,BAO_0000100,,CHEMBL628544,,,P
6629,Autocuration,,1,,,12745,0,22229,,,,Solubility after injection of water,,U,,,BAO_0000100,,CHEMBL628545,,,P
14000,Autocuration,,1,,,12746,0,22224,,,,Statistical significance of IC 50 values; Expressed as R value,,U,,,BAO_0000019,,CHEMBL628546,,,A
8267,Autocuration,,1,,,12747,0,22224,,,,Systemic availability with respect to methyldopa was determined,,U,,,BAO_0000019,,CHEMBL874455,,,A
13799,Intermediate,,1,,10116.0,12748,1,50597,,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628547,,,A
13799,Intermediate,,1,,10116.0,12749,1,50597,,,Plasma,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL628548,,,A
7132,Intermediate,,1,,9986.0,12750,1,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628549,,,A
7132,Intermediate,,1,,9986.0,12751,1,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628550,,,A
7132,Intermediate,,1,,9986.0,12752,1,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628551,,,A
7132,Intermediate,,1,,9986.0,12753,1,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628552,,,A
7132,Intermediate,,1,,9986.0,12754,1,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628553,,,A
7132,Intermediate,,1,,9986.0,12755,1,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628554,,,A
7132,Intermediate,,1,,9986.0,12756,1,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628555,,,A
7132,Intermediate,,1,,9986.0,12757,1,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628556,,,A
7132,Intermediate,,1,,9986.0,12758,1,50592,,,Kidney,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,2113.0,CHEMBL628557,,,A
7132,Intermediate,,1,,9986.0,12759,1,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628558,,,A
7132,Intermediate,,1,,9986.0,12760,1,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628559,,,A
7132,Intermediate,,1,,9986.0,12761,1,50592,,,Feces,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628560,,,A
7132,Intermediate,,1,,9986.0,12762,1,50592,,,Urine,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL874456,,,A
7132,Intermediate,,1,,9986.0,12763,1,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628561,,,A
7132,Intermediate,,1,,9986.0,12764,1,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL628562,,,A
7132,Intermediate,,1,,9986.0,12765,1,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628563,,,A
7132,Intermediate,,1,,9986.0,12766,1,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628564,,,A
7132,Intermediate,,1,,9986.0,12767,1,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL628565,,,A
7132,Intermediate,,1,,9986.0,12768,1,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL631248,,,A
7132,Intermediate,,1,,9986.0,12769,1,50592,,,Urine,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL631249,,,A
7132,Intermediate,,1,,9986.0,12770,1,50592,,,Kidney,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,2113.0,CHEMBL627214,,,A
7132,Intermediate,,1,,9986.0,12771,1,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL874591,,,A
7132,Intermediate,,1,,9986.0,12772,1,50592,,,Feces,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL627215,,,A
7132,Intermediate,,1,,9986.0,12773,1,50592,,,Feces,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL625471,,,A
7132,Intermediate,,1,,9986.0,12774,1,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625472,,,A
7132,Intermediate,,1,,9986.0,12775,1,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL625473,,,A
13317,Intermediate,,1,,9615.0,12776,1,50588,,In vivo,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625474,,,A
15341,Intermediate,,1,,9615.0,12777,1,50588,,In vivo,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625475,,,A
15341,Intermediate,,1,,10116.0,12778,1,50597,,In vivo,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625476,,,A
15341,Intermediate,,1,,10116.0,12779,1,50597,,In vivo,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625477,,,A
15341,Intermediate,,1,,10116.0,12780,1,50597,,In vivo,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625478,,,A
12801,Intermediate,,1,,10116.0,12781,1,50597,,In vitro,esophageal tunica muscularis mucosae,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625479,,,A
12801,Intermediate,,1,,10116.0,12782,1,50597,,In vitro,esophageal tunica muscularis mucosae,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625480,,,A
14856,Intermediate,,1,,10116.0,12783,1,50597,,In vivo,Plasma,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625481,,,A
14062,Intermediate,,1,,10116.0,12784,1,50597,,In vivo,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625482,,,A
14062,Intermediate,,1,,10116.0,12785,1,50597,,In vivo,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625483,,,A
14062,Intermediate,,1,,10116.0,12786,1,50597,,In vivo,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625484,,,A
14062,Intermediate,,1,,10116.0,12787,1,50597,,In vivo,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625485,,,A
14346,Intermediate,,1,,9615.0,12788,1,50588,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625486,,,A
14346,Intermediate,,1,,10116.0,12789,1,50597,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625487,,,A
14346,Intermediate,,1,,10116.0,12790,1,50597,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625488,,,A
14346,Intermediate,,1,,10116.0,12791,1,50597,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625489,,,A
14346,Intermediate,,1,,10116.0,12792,1,50597,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625490,,,A
14346,Intermediate,,1,,9615.0,12793,1,50588,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL625491,,,A
14346,Intermediate,,1,,10116.0,12794,1,50597,,In vivo,Plasma,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625492,,,A
15711,Intermediate,,1,,9606.0,12795,1,50587,,In vivo,Plasma,plasma clearance in human,,N,,Homo sapiens,BAO_0000218,1969.0,CHEMBL625493,,,A
14886,Intermediate,,1,,10116.0,12796,1,50597,,In vivo,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625494,,,A
14886,Intermediate,,1,,10116.0,12797,1,50597,,In vivo,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625495,,,A
14886,Intermediate,,1,,10116.0,12798,1,50597,,In vivo,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625496,,,A
4115,Autocuration,,1,,,12799,0,22229,,,,1-Octanol/water partition coefficient measured at 7.4,,U,,,BAO_0000100,,CHEMBL625497,,,P
13733,Autocuration,,1,,,12800,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625498,,,P
12102,Autocuration,,1,,,12801,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL625499,,,A
12676,Autocuration,,1,,,12802,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625500,,,P
13733,Autocuration,,1,,,12803,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625501,,,P
13740,Autocuration,,1,,,12804,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625502,,,P
12766,Autocuration,,1,,,12805,0,22229,,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),,U,,,BAO_0000100,,CHEMBL625503,,,P
2764,Autocuration,,1,,,12806,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625504,,,P
12355,Autocuration,,1,,,12807,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625505,,,P
11314,Autocuration,,1,,,12808,0,22229,,,,Calculated partition coefficient of the compound,,U,,,BAO_0000100,,CHEMBL625506,,,P
12706,Autocuration,,1,,,12809,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL625507,,,A
12645,Autocuration,,1,,,12810,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625508,,,P
13668,Autocuration,,1,,,12811,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625509,,,P
12819,Autocuration,,1,,,12812,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625510,,,P
13668,Autocuration,,1,,,12813,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL883125,,,P
13017,Autocuration,,1,,,12814,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625511,,,P
2448,Autocuration,,1,,,12815,0,22224,,,,Partition coefficient of the compound,,U,,,BAO_0000019,,CHEMBL874650,,,A
11526,Autocuration,,1,,,12816,0,22224,,,,Partition coefficient of the compound,,U,,,BAO_0000019,,CHEMBL625512,,,A
12426,Autocuration,,1,,,12817,0,22224,,,,Partition coefficient of compound was determined,,U,,,BAO_0000019,,CHEMBL625513,,,A
2448,Autocuration,,1,,,12818,0,22224,,,,Partition coefficient was determined,,U,,,BAO_0000019,,CHEMBL625514,,,A
12001,Autocuration,,1,,,12819,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625515,,,P
12426,Autocuration,,1,,,12820,0,22229,,,,partition coefficient of compound was determined,,U,,,BAO_0000100,,CHEMBL625516,,,P
13204,Intermediate,,1,,9615.0,12821,1,50588,,In vivo,,The total body administered intravenously in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625517,,,A
13204,Intermediate,,1,,10116.0,12822,1,50597,,In vivo,,The total body administered intravenously in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625518,,,A
13889,Intermediate,,1,,10090.0,12823,1,50594,,,,Time taken for the administration to female NIH mice weighing 25-30 g.,,N,,Mus musculus,BAO_0000218,,CHEMBL625519,,,A
13889,Autocuration,,1,,,12824,0,22224,,,,Time taken for the administration,,U,,,BAO_0000019,,CHEMBL625520,,,A
17025,Intermediate,,1,,9615.0,12825,1,50588,,In vivo,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL874651,,,A
17025,Autocuration,,1,,314293.0,12826,0,22224,,In vivo,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,U,,Simiiformes,BAO_0000218,,CHEMBL625521,,,A
17025,Intermediate,,1,,9986.0,12827,1,50592,,In vivo,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL623171,,,A
17025,Intermediate,,1,,10116.0,12828,1,50597,,In vivo,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623853,,,A
15067,Autocuration,,1,,,12829,0,22224,,,,Plasma clearance for the compound was determined.,,U,,,BAO_0000019,,CHEMBL623854,,,A
3091,Autocuration,,1,,,12830,0,22224,,,,CLog P value of the compound,,U,,,BAO_0000100,,CHEMBL874405,,,P
15592,Autocuration,,1,,,12831,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL623855,,,P
14738,Autocuration,,1,,,12832,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL623856,,,P
14738,Autocuration,,1,,,12833,0,22224,,,,ClogP value of the compound; nd ='no data',,U,,,BAO_0000100,,CHEMBL623857,,,P
14738,Autocuration,,1,,,12834,0,22224,,,,ClogP value of the compound; nd ='not determined',,U,,,BAO_0000100,,CHEMBL623858,,,P
6076,Autocuration,,1,,,12835,0,22224,,,,CLog P was determined,,U,,,BAO_0000100,,CHEMBL623859,,,P
17840,Autocuration,,1,,,12836,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL839829,,,P
13589,Autocuration,,1,,,12837,0,22224,,,,CLogP was calculated,,U,,,BAO_0000019,,CHEMBL623860,,,A
17655,Autocuration,,1,,,12838,0,22224,,,,CLogP value was determined,,U,,,BAO_0000019,,CHEMBL623861,,,A
5867,Autocuration,,1,,,12839,0,22224,,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,U,,,BAO_0000019,,CHEMBL623862,,,A
5867,Autocuration,,1,,,12840,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL874406,,,P
10783,Autocuration,,1,,,12841,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL623863,,,P
14849,Autocuration,,1,,,12842,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624021,,,P
8170,Intermediate,,1,,9615.0,12843,1,50588,,,Adrenal medulla,Distribution in female dog adrenal medulla 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,1236.0,CHEMBL624022,,,A
8170,Intermediate,,1,,9615.0,12844,1,50588,,,Adrenal medulla,Distribution in female dog adrenal medulla 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,1236.0,CHEMBL624023,,,A
8170,Intermediate,,1,,9615.0,12845,1,50588,,,,Distribution in female dog bile 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624024,,,A
8170,Intermediate,,1,,9615.0,12846,1,50588,,,,Distribution in female dog bile 72 hr after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624025,,,A
8170,Intermediate,,1,,9615.0,12847,1,50588,,,,Distribution in female dog blood 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624026,,,A
8170,Intermediate,,1,,9615.0,12848,1,50588,,,,Distribution in female dog blood 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624027,,,A
8170,Intermediate,,1,,9615.0,12849,1,50588,,,,Distribution in female dog heart 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624028,,,A
8170,Intermediate,,1,,9615.0,12850,1,50588,,,,Distribution in female dog heart 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624029,,,A
8170,Intermediate,,1,,9615.0,12851,1,50588,,,,Distribution in female dog kidney 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624030,,,A
8170,Intermediate,,1,,9615.0,12852,1,50588,,,,Distribution in female dog kidney 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624031,,,A
8170,Intermediate,,1,,9615.0,12853,1,50588,,,Intestine,Distribution in female dog large intestine 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,160.0,CHEMBL624032,,,A
8170,Intermediate,,1,,9615.0,12854,1,50588,,,Intestine,Distribution in female dog large intestine 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,160.0,CHEMBL874407,,,A
8170,Intermediate,,1,,9615.0,12855,1,50588,,,,Distribution in female dog liver 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624033,,,A
8170,Intermediate,,1,,9615.0,12856,1,50588,,,,Distribution in female dog liver 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624034,,,A
8170,Intermediate,,1,,9615.0,12857,1,50588,,,,Distribution in female dog lung 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624035,,,A
8170,Intermediate,,1,,9615.0,12858,1,50588,,,,Distribution in female dog lung 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624036,,,A
8170,Intermediate,,1,,9615.0,12859,1,50588,,,Muscle tissue,Distribution in female dog muscle 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,2385.0,CHEMBL624037,,,A
8170,Intermediate,,1,,9615.0,12860,1,50588,,,Muscle tissue,Distribution in female dog muscle 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,2385.0,CHEMBL624038,,,A
8170,Intermediate,,1,,9615.0,12861,1,50588,,,,Distribution in female dog pancreas 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624039,,,A
8170,Intermediate,,1,,9615.0,12862,1,50588,,,,Distribution in female dog pancreas 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624040,,,A
8170,Intermediate,,1,,9615.0,12863,1,50588,,,Intestine,Distribution in female dog small intestine 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,160.0,CHEMBL624041,,,A
8170,Intermediate,,1,,9615.0,12864,1,50588,,,Intestine,Distribution in female dog small intestine 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,160.0,CHEMBL624042,,,A
8170,Intermediate,,1,,9615.0,12865,1,50588,,,Spleen,Distribution in female dog spleen 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,2106.0,CHEMBL624043,,,A
8170,Intermediate,,1,,9615.0,12866,1,50588,,,Spleen,Distribution in female dog spleen 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,2106.0,CHEMBL624044,,,A
8170,Intermediate,,1,,9615.0,12867,1,50588,,,Stomach,Distribution in female dog stomach 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,945.0,CHEMBL624045,,,A
8170,Intermediate,,1,,9615.0,12868,1,50588,,,Stomach,Distribution in female dog stomach 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,945.0,CHEMBL624046,,,A
8170,Intermediate,,1,,9615.0,12869,1,50588,,,Thyroid gland,Distribution in female dog thyroid 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,2046.0,CHEMBL624047,,,A
8170,Intermediate,,1,,9615.0,12870,1,50588,,,Thyroid gland,Distribution in female dog thyroid 72 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,2046.0,CHEMBL624048,,,A
8170,Intermediate,,1,,9615.0,12871,1,50588,,,Urine,Distribution in female dog urine 24 hours after administration.,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL874408,,,A
8170,Intermediate,,1,,9615.0,12872,1,50588,,,Urine,Distribution in female dog urine 72 hr after administration.,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL624049,,,A
14283,Autocuration,,1,,,12873,0,22224,,,Plasma,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,U,,,BAO_0000218,1969.0,CHEMBL624050,,,A
5623,Autocuration,,1,,,12874,0,22224,,,,Plasma concentration at 7 hr after intravenous dosing,,U,,,BAO_0000019,,CHEMBL624051,,,A
13477,Intermediate,,1,,10116.0,12875,1,50597,,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623278,,,A
13477,Intermediate,,1,,10116.0,12876,1,50597,,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623279,,,A
13477,Intermediate,,1,,10116.0,12877,1,50597,,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623280,,,A
13477,Intermediate,,1,,10116.0,12878,1,50597,,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623963,,,A
13477,Intermediate,,1,,10116.0,12879,1,50597,,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623964,,,A
13477,Intermediate,,1,,10116.0,12880,1,50597,,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623965,,,A
13477,Intermediate,,1,,10116.0,12881,1,50597,,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623966,,,A
13477,Intermediate,,1,,10116.0,12882,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874415,,,A
13477,Intermediate,,1,,10116.0,12883,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623967,,,A
13477,Intermediate,,1,,10116.0,12884,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623968,,,A
13477,Intermediate,,1,,10116.0,12885,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623969,,,A
13477,Intermediate,,1,,10116.0,12886,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628409,,,A
13477,Intermediate,,1,,10116.0,12887,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628410,,,A
13477,Intermediate,,1,,10116.0,12888,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628411,,,A
13477,Intermediate,,1,,10116.0,12889,1,50597,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628412,,,A
12553,Autocuration,,1,,,12890,0,22224,,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,U,,,BAO_0000019,,CHEMBL628413,,,A
14548,Autocuration,,1,,,12891,0,22224,,,Plasma,The concentration in plasmat; Not determined,,U,,,BAO_0000019,1969.0,CHEMBL628414,,,A
14393,Intermediate,,1,,10116.0,12892,1,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in blood,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628415,,,A
14393,Intermediate,,1,,10116.0,12893,1,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628416,,,A
14393,Intermediate,,1,,10116.0,12894,1,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in heart,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628417,,,A
14393,Intermediate,,1,,10116.0,12895,1,50597,,,Liver,Tissue level at 10 mg/kg/po in wistar rats in liver,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL874908,,,A
14393,Intermediate,,1,,10116.0,12896,1,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628418,,,A
14393,Intermediate,,1,,10116.0,12897,1,50597,,,Muscle tissue,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL628419,,,A
14393,Intermediate,,1,,10116.0,12898,1,50597,,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628420,,,A
1629,Autocuration,,1,,,12899,0,22224,,,,Water solubility at 37 degree C.,,U,,,BAO_0000019,,CHEMBL628421,,,A
8194,Autocuration,,1,,,12900,0,22229,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,U,,,BAO_0000100,,CHEMBL626726,,,P
8194,Autocuration,,1,,,12901,0,22229,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,U,,,BAO_0000100,,CHEMBL626727,,,P
8594,Intermediate,,1,,10116.0,12902,1,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626728,,,A
8594,Intermediate,,1,,10116.0,12903,1,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626729,,,A
8594,Intermediate,,1,,10116.0,12904,1,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626730,,,A
8594,Intermediate,,1,,10116.0,12905,1,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626731,,,A
8594,Intermediate,,1,,10116.0,12906,1,50597,,,Blood,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL626732,,,A
8594,Intermediate,,1,,10116.0,12907,1,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626733,,,A
8594,Intermediate,,1,,10116.0,12908,1,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626734,,,A
8594,Intermediate,,1,,10116.0,12909,1,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626735,,,A
8594,Intermediate,,1,,10116.0,12910,1,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL874909,,,A
8594,Intermediate,,1,,10116.0,12911,1,50597,,,Heart,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL626736,,,A
8594,Intermediate,,1,,10116.0,12912,1,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL626737,,,A
8594,Intermediate,,1,,10116.0,12913,1,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630999,,,A
8594,Intermediate,,1,,10116.0,12914,1,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL631000,,,A
8594,Intermediate,,1,,10116.0,12915,1,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL631001,,,A
8594,Intermediate,,1,,10116.0,12916,1,50597,,,Kidney,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL631002,,,A
8594,Intermediate,,1,,10116.0,12917,1,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631003,,,A
8594,Intermediate,,1,,10116.0,12918,1,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631004,,,A
8594,Intermediate,,1,,10116.0,12919,1,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631005,,,A
8594,Intermediate,,1,,10116.0,12920,1,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631006,,,A
8594,Intermediate,,1,,10116.0,12921,1,50597,,,Liver,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631007,,,A
8594,Intermediate,,1,,10116.0,12922,1,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL631008,,,A
8594,Intermediate,,1,,10116.0,12923,1,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL631009,,,A
8594,Intermediate,,1,,10116.0,12924,1,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL631010,,,A
8594,Intermediate,,1,,10116.0,12925,1,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL631011,,,A
8594,Intermediate,,1,,10116.0,12926,1,50597,,,Lung,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL631012,,,A
8594,Intermediate,,1,,10116.0,12927,1,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630271,,,A
8594,Intermediate,,1,,10116.0,12928,1,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630272,,,A
8594,Intermediate,,1,,10116.0,12929,1,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630273,,,A
8594,Intermediate,,1,,10116.0,12930,1,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630274,,,A
8594,Intermediate,,1,,10116.0,12931,1,50597,,,Thyroid gland,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630275,,,A
8594,Intermediate,,1,,10116.0,12932,1,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875782,,,A
8594,Intermediate,,1,,10116.0,12933,1,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630276,,,A
8594,Intermediate,,1,,10116.0,12934,1,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630277,,,A
8594,Intermediate,,1,,10116.0,12935,1,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630278,,,A
8594,Intermediate,,1,,10116.0,12936,1,50597,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630279,,,A
8151,Autocuration,,1,,,12937,0,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,U,,,BAO_0000019,,CHEMBL630280,,,A
8151,Autocuration,,1,,,12938,0,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,U,,,BAO_0000019,,CHEMBL630281,,,A
7132,Intermediate,,1,,9986.0,12939,1,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL630282,,,A
7132,Intermediate,,1,,9986.0,12940,1,50592,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL630283,,,A
5797,Autocuration,,1,,,12941,0,22224,,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,U,,,BAO_0000019,,CHEMBL630284,,,A
7849,Autocuration,,1,,,12942,0,22224,,,,Alkylating activity was determined,,U,,,BAO_0000019,,CHEMBL630285,,,A
14220,Autocuration,,1,,,12943,0,22224,,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,U,,,BAO_0000251,,CHEMBL630286,,Microsomes,A
8650,Intermediate,,1,,9986.0,12944,1,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL630069,,,A
8650,Intermediate,,1,,9986.0,12945,1,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL630070,,,A
8650,Intermediate,,1,,9986.0,12946,1,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL630071,,,A
8650,Intermediate,,1,,9986.0,12947,1,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL630072,,,A
8650,Intermediate,,1,,9986.0,12948,1,50592,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL875110,,,A
7116,Intermediate,,1,,10116.0,12949,1,50597,,,,Compound was tested for antidiuretic activity in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630073,,,A
14131,Autocuration,,1,,,12950,0,22224,,,,Compound was tested for inactivation kinetic values,,U,,,BAO_0000019,,CHEMBL630074,,,A
7415,Autocuration,,1,,,12951,0,22224,,In vivo,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,U,,,BAO_0000218,,CHEMBL630075,,,A
13178,Autocuration,,1,,,12952,0,22224,,,,Dissociation rate calculated from the first-order equation using the t1/2 value,,U,,,BAO_0000019,,CHEMBL630076,,,A
8815,Autocuration,,1,,,12953,0,22229,,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,U,,,BAO_0000100,,CHEMBL630077,,,P
1450,Autocuration,,1,,,12954,0,22229,,,,Aqueous solubility was measured,,U,,,BAO_0000100,,CHEMBL630078,,,P
1450,Autocuration,,1,,,12955,0,22229,,,,Aqueous solubility was measured at a pH 4,,U,,,BAO_0000100,,CHEMBL630079,,,P
1450,Autocuration,,1,,,12956,0,22229,,,,Aqueous solubility (pH 7),,U,,,BAO_0000100,,CHEMBL630080,,,P
1450,Autocuration,,1,,,12957,0,22229,,,,Aqueous solubility was measured at a pH 9,,U,,,BAO_0000100,,CHEMBL630081,,,P
12711,Autocuration,,1,,,12958,0,22224,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,U,,,BAO_0000019,,CHEMBL630082,,,A
12711,Autocuration,,1,,,12959,0,22224,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,U,,,BAO_0000019,,CHEMBL630083,,,A
12711,Autocuration,,1,,,12960,0,22224,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,U,,,BAO_0000019,,CHEMBL630084,,,A
15032,Autocuration,,1,,,12961,0,22229,,,,Aqueous solubility of the compound,,U,,,BAO_0000100,,CHEMBL629198,,,P
9964,Autocuration,,1,,,12962,0,22229,,,,Aqueous solubility at 37 degree Celsius at pH 7.38,,U,,,BAO_0000100,,CHEMBL629199,,,P
14962,Autocuration,,1,,,12963,0,22229,,,,Aqueous solubility in pH 7.4 phosphate buffer,,U,,,BAO_0000100,,CHEMBL629200,,,P
12487,Intermediate,,1,,9615.0,12964,1,50588,,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629201,,,A
12487,Intermediate,,1,,9615.0,12965,1,50588,,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629202,,,A
10026,Intermediate,,1,,9606.0,12966,1,50587,,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,N,,Homo sapiens,BAO_0000218,,CHEMBL875111,,,A
10026,Intermediate,,1,,9606.0,12967,1,50587,,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,N,,Homo sapiens,BAO_0000218,,CHEMBL629203,,,A
10026,Intermediate,,1,,9606.0,12968,1,50587,,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,N,,Homo sapiens,BAO_0000218,,CHEMBL629204,,,A
10026,Intermediate,,1,,9606.0,12969,1,50587,,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,N,,Homo sapiens,BAO_0000218,,CHEMBL629205,,,A
10026,Intermediate,,1,,9606.0,12970,1,50587,,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,N,,Homo sapiens,BAO_0000218,,CHEMBL629206,,,A
10026,Autocuration,,1,,,12971,0,22224,,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,U,,,BAO_0000019,,CHEMBL631185,,,A
7415,Intermediate,,1,,10116.0,12972,1,50597,,,,Compound was evaluated for the average bile flow rat in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631186,,,A
17025,Intermediate,,1,,9986.0,12973,1,50592,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL631187,,,A
17025,Intermediate,,1,,9986.0,12974,1,50592,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL631188,,,A
10184,Autocuration,,1,,,12975,0,22224,,,,Average half life period was determined,,U,,,BAO_0000019,,CHEMBL876419,,,A
10184,Autocuration,,1,,,12976,0,22224,,,,Average half life period was determined,,U,,,BAO_0000019,,CHEMBL631189,,,A
8613,Intermediate,,1,,10298.0,12977,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL631190,,,A
8613,Intermediate,,1,,10298.0,12978,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL631191,,,A
8613,Intermediate,,1,,10298.0,12979,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL631192,,,A
8613,Intermediate,,1,,10298.0,12980,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL632400,,,A
8613,Intermediate,,1,,10298.0,12981,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL630564,,,A
8613,Intermediate,,1,,10298.0,12982,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL630565,,,A
8613,Intermediate,,1,,10298.0,12983,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL630566,,,A
8613,Intermediate,,1,,10298.0,12984,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL631229,,,A
8613,Intermediate,,1,,10298.0,12985,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL631230,,,A
6030,Autocuration,,1,,,12986,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL876428,,,P
6147,Autocuration,,1,,,12987,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631231,,,P
14556,Autocuration,,1,,,12988,0,22229,,,,Calculated partition coefficient (clogP) (MacLogP),,U,,,BAO_0000100,,CHEMBL631232,,,P
768,Autocuration,,1,,,12989,0,22224,,,,Hydrophilicity was determined,,U,,,BAO_0000019,,CHEMBL631233,,,A
14452,Autocuration,,1,,,12990,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631234,,,P
5237,Autocuration,,1,,,12991,0,22224,,,,Increased absorption was determined,,U,,,BAO_0000019,,CHEMBL883126,,,A
14378,Autocuration,,1,,,12992,0,22224,,,,Lipophilicity value was evaluated,,U,,,BAO_0000100,,CHEMBL631235,,,P
14418,Autocuration,,1,,,12993,0,22224,,,,Log P value of the compound.,,U,,,BAO_0000100,,CHEMBL631236,,,P
5249,Autocuration,,1,,,12994,0,22224,,,,Partition coefficient of compound was determined,,U,,,BAO_0000019,,CHEMBL631237,,,A
14621,Autocuration,,1,,,12995,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631238,,,P
12542,Autocuration,,1,,,12996,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL876429,,,P
12542,Autocuration,,1,,,12997,0,22224,,,,Partition coefficient was measured by medchem software; Not calculated,,U,,,BAO_0000019,,CHEMBL631414,,,A
12542,Autocuration,,1,,,12998,0,22224,,,,Partition coefficient was measured by octanol-water using standard shake-flask method,,U,,,BAO_0000100,,CHEMBL631415,,,P
15462,Autocuration,,1,,,12999,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631416,,,P
14884,Autocuration,,1,,,13000,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL631417,,,A
16526,Autocuration,,1,,,13001,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631418,,,P
13693,Autocuration,,1,,,13002,0,22229,,,,The Octanol/Water partition coefficient CLogP,,U,,,BAO_0000100,,CHEMBL631419,,,P
13693,Autocuration,,1,,,13003,0,22224,,,,The pharmacokinetic parameter C Log p was reported,,U,,,BAO_0000019,,CHEMBL631420,,,A
13779,Autocuration,,1,,,13004,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631421,,,P
14772,Autocuration,,1,,,13005,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631422,,,P
14393,Autocuration,,1,,,13006,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL631423,,,P
14793,Intermediate,,1,,10116.0,13007,1,50597,,In vivo,Plasma,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL876430,,,A
14793,Intermediate,,1,,10116.0,13008,1,50597,,In vivo,Plasma,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL631424,,,A
13744,Intermediate,,1,,9615.0,13009,1,50588,,In vivo,Plasma,Compound was administered intravenously in dog to evaluate plasma clearance values,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL631425,,,A
13744,Autocuration,,1,,314293.0,13010,0,22224,,In vivo,Plasma,Compound was administered intravenously in monkey to evaluate plasma clearance values,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL631426,,,A
13744,Intermediate,,1,,10090.0,13011,1,50594,,In vivo,Plasma,Compound was administered intravenously in mouse to evaluate plasma clearance values,,N,,Mus musculus,BAO_0000218,1969.0,CHEMBL631427,,,A
13207,Intermediate,,1,,9615.0,13012,1,50588,,In vivo,Plasma,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL631428,,,A
5669,Intermediate,,1,,9544.0,13013,1,50797,,In vitro,Liver,Intrinsic clearance in Rhesus liver microsome,,N,,Macaca mulatta,BAO_0000218,2107.0,CHEMBL631429,,Microsomes,A
5669,Intermediate,,1,,9615.0,13014,1,50588,,In vitro,Liver,Intrinsic clearance in dog liver microsome,,N,,Canis lupus familiaris,BAO_0000218,2107.0,CHEMBL631430,,Microsomes,A
5669,Intermediate,,1,,10116.0,13015,1,50597,,In vitro,Liver,Intrinsic clearance in rat liver microsome,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631431,,Microsomes,A
4853,Intermediate,,1,,9544.0,13016,1,50797,,In vivo,Plasma,Low plasma clearance was calculated in rhesus monkey,,N,,Macaca mulatta,BAO_0000218,1969.0,CHEMBL631432,,,A
16452,Intermediate,,1,,9615.0,13017,1,50588,,In vivo,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631433,,,A
11954,Autocuration,,1,,,13018,0,22224,,In vivo,,Plasma clearance after intravenous dose of 0.3 mg/kg,,U,,,BAO_0000218,,CHEMBL631434,,,A
11954,Autocuration,,1,,,13019,0,22224,,In vivo,,Plasma clearance after intravenous dose of 1 mg/kg,,U,,,BAO_0000218,,CHEMBL631435,,,A
11954,Autocuration,,1,,,13020,0,22224,,In vivo,,Plasma clearance after intravenous dose of 3 mg/kg,,U,,,BAO_0000218,,CHEMBL631436,,,A
11954,Autocuration,,1,,,13021,0,22224,,In vivo,,Plasma clearance after intravenous dose of 3.87 mg/kg,,U,,,BAO_0000218,,CHEMBL631437,,,A
5669,Intermediate,,1,,10116.0,13022,1,50597,,In vivo,,Plasma clearance after peroral administration at 10 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631438,,,A
5669,Intermediate,,1,,9544.0,13023,1,50797,,In vivo,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,N,,Macaca mulatta,BAO_0000218,,CHEMBL876431,,,A
5669,Intermediate,,1,,9615.0,13024,1,50588,,In vivo,,Plasma clearance after peroral administration at 10 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631439,,,A
13662,Intermediate,,1,,10116.0,13025,1,50597,,In vivo,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631440,,,A
8272,Autocuration,,1,,,13026,0,22224,,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,U,,,BAO_0000019,,CHEMBL631441,,,A
13410,Autocuration,,1,,,13027,0,22224,,,,Critical Micellar concentration was determined,,U,,,BAO_0000019,,CHEMBL631442,,,A
13410,Autocuration,,1,,,13028,0,22224,,,,Critical Micellar concentration of the compound. was determined,,U,,,BAO_0000019,,CHEMBL626525,,,A
12628,Autocuration,,1,,,13029,0,22224,,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,U,,,BAO_0000019,,CHEMBL627168,,,A
9675,Autocuration,,1,,,13030,0,22224,,,,Critical micellar concentration was measured in water by the dye solubilization method,,U,,,BAO_0000019,,CHEMBL875618,,,A
12628,Autocuration,,1,,,13031,0,22224,,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,U,,,BAO_0000019,,CHEMBL626612,,,B
12766,Autocuration,,1,,,13032,0,22224,,,,CMR value (relative to BAY K 8644),,U,,,BAO_0000019,,CHEMBL626613,,,A
7849,Autocuration,,1,,,13033,0,22224,,,,Carbamoylating activity was determined,,U,,,BAO_0000019,,CHEMBL626614,,,A
12187,Autocuration,,1,,314293.0,13034,0,22224,,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,U,,Simiiformes,BAO_0000218,,CHEMBL626615,,,A
2040,Autocuration,,1,,,13035,0,22224,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,U,,,BAO_0000019,,CHEMBL626616,,,A
2040,Autocuration,,1,,,13036,0,22224,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,U,,,BAO_0000019,,CHEMBL626617,,,A
14180,Intermediate,,1,,9615.0,13037,1,50588,,In vivo,Plasma,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626618,,,A
14180,Intermediate,,1,,10116.0,13038,1,50597,,In vivo,Plasma,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626619,,,A
14474,Intermediate,,1,,9615.0,13039,1,50588,,In vivo,,"Clearance rate at 0.46 mg/kg, iv, in dogs",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626620,,,A
14474,Intermediate,,1,,10116.0,13040,1,50597,,In vivo,,"Clearance rate at 5.5 mg/kg, iv, in rat",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626621,,,A
14548,Intermediate,,1,,9541.0,13041,1,100710,,In vivo,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL626622,,,A
14548,Intermediate,,1,,9541.0,13042,1,100710,,In vivo,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL626623,,,A
14548,Intermediate,,1,,9615.0,13043,1,50588,,In vivo,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626624,,,A
14548,Intermediate,,1,,10116.0,13044,1,50597,,In vivo,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626625,,,A
6125,Intermediate,,1,,10116.0,13045,1,50597,,Ex vivo,Liver,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL626626,,,A
6874,Autocuration,,1,,,13046,0,22224,,In vivo,,Tested for the total clearance of the compound,,U,,,BAO_0000218,,CHEMBL626627,,,A
15343,Intermediate,,1,,9615.0,13047,1,50588,,In vivo,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626628,,,A
6236,Autocuration,,1,,,13048,0,22224,,In vivo,,Total body clearance was determined,,U,,,BAO_0000218,,CHEMBL626629,,,A
11510,Intermediate,,1,,10116.0,13049,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626630,,,A
11510,Intermediate,,1,,10116.0,13050,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626631,,,A
8194,Autocuration,,1,,,13051,0,22229,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,U,,,BAO_0000100,,CHEMBL626632,,,P
8194,Autocuration,,1,,,13052,0,22229,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,U,,,BAO_0000100,,CHEMBL626633,,,P
8194,Autocuration,,1,,,13053,0,22229,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,U,,,BAO_0000100,,CHEMBL626634,,,P
8194,Autocuration,,1,,,13054,0,22229,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,U,,,BAO_0000100,,CHEMBL626635,,,P
8194,Autocuration,,1,,,13055,0,22229,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,U,,,BAO_0000100,,CHEMBL626636,,,P
8194,Autocuration,,1,,,13056,0,22229,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,U,,,BAO_0000100,,CHEMBL626637,,,P
13273,Intermediate,,1,,4754.0,13057,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL626638,,,A
13273,Intermediate,,1,,4754.0,13058,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL626639,,,A
13273,Intermediate,,1,,4754.0,13059,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL626640,,,A
13273,Intermediate,,1,,4754.0,13060,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL626641,,,A
13273,Intermediate,,1,,4754.0,13061,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL627272,,,A
13273,Intermediate,,1,,4754.0,13062,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL627273,,,A
13273,Intermediate,,1,,4754.0,13063,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL627441,,,A
13273,Intermediate,,1,,4754.0,13064,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL628355,,,A
13273,Intermediate,,1,,4754.0,13065,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL628356,,,A
13273,Intermediate,,1,,4754.0,13066,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL628357,,,A
13273,Intermediate,,1,,4754.0,13067,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL628358,,,A
13273,Intermediate,,1,,4754.0,13068,1,50339,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,N,,Pneumocystis carinii,BAO_0000218,,CHEMBL622307,,,A
13118,Autocuration,,1,,,13069,0,22224,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,U,,,BAO_0000019,,CHEMBL622527,,,A
13118,Autocuration,,1,,,13070,0,22224,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,U,,,BAO_0000019,,CHEMBL622528,,,A
13118,Autocuration,,1,,,13071,0,22224,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,U,,,BAO_0000019,,CHEMBL622529,,,A
13118,Autocuration,,1,,,13072,0,22224,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,U,,,BAO_0000019,,CHEMBL622992,,,A
13118,Autocuration,,1,,,13073,0,22224,,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,U,,,BAO_0000019,,CHEMBL622993,,,A
13118,Autocuration,,1,,,13074,0,22224,,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,U,,,BAO_0000019,,CHEMBL622994,,,A
10633,Intermediate,,1,,10116.0,13075,1,50597,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622995,,,A
10633,Intermediate,,1,,10116.0,13076,1,50597,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622996,,,A
10633,Intermediate,,1,,10116.0,13077,1,50597,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622997,,,A
10633,Intermediate,,1,,10116.0,13078,1,50597,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622998,,,A
5767,Autocuration,,1,,,13079,0,22224,,,,Cp max following ip administration at 1 mg/kg,,U,,,BAO_0000218,,CHEMBL622999,,,A
3302,Autocuration,,1,,,13080,0,22224,,In vivo,Plasma,Maximum concentration in plasma was reported at 0.5 hour,,U,,,BAO_0000218,1969.0,CHEMBL623000,,,A
3302,Autocuration,,1,,,13081,0,22224,,In vivo,Plasma,Maximum concentration in plasma was reported at 2 hour,,U,,,BAO_0000218,1969.0,CHEMBL623001,,,A
12467,Intermediate,,1,,10090.0,13082,1,50594,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,N,,Mus musculus,BAO_0000218,,CHEMBL623002,,,A
11778,Autocuration,,1,,,13083,0,22229,,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,U,,,BAO_0000100,,CHEMBL623003,,,P
4321,Autocuration,,1,,,13084,0,22224,,,,Steady state concentration was evaluated,,U,,,BAO_0000019,,CHEMBL623004,,,A
14884,Autocuration,,1,,,13085,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL623005,,,A
15234,Autocuration,,1,,,13086,0,22224,,,,Partition coefficient (logD7.4),,U,,,BAO_0000019,,CHEMBL623006,,,A
14198,Intermediate,,1,,10116.0,13087,1,50597,,In vivo,Liver,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623007,,,A
14198,Intermediate,,1,,10116.0,13088,1,50597,,In vivo,Bone,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL623008,,,A
14198,Intermediate,,1,,10116.0,13089,1,50597,,In vivo,Cerebellum,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL876654,,,A
14198,Intermediate,,1,,10116.0,13090,1,50597,,In vivo,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623009,,,A
14198,Intermediate,,1,,10116.0,13091,1,50597,,In vivo,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623010,,,A
14198,Intermediate,,1,,10116.0,13092,1,50597,,In vivo,Heart,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623011,,,A
14198,Intermediate,,1,,10116.0,13093,1,50597,,In vivo,Intestine,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL623012,,,A
8151,Autocuration,,1,,,13094,0,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,U,,,BAO_0000019,,CHEMBL623013,,,A
8151,Autocuration,,1,,,13095,0,22224,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,U,,,BAO_0000019,,CHEMBL623014,,,A
8151,Autocuration,,1,,,13096,0,22224,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,U,,,BAO_0000019,1088.0,CHEMBL623015,,,A
8151,Autocuration,,1,,,13097,0,22224,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,U,,,BAO_0000019,1088.0,CHEMBL623016,,,A
8151,Autocuration,,1,,,13098,0,22224,,,Urine,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,U,,,BAO_0000019,1088.0,CHEMBL624858,,,A
8151,Intermediate,,1,,10116.0,13099,1,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624859,,,A
8151,Intermediate,,1,,10116.0,13100,1,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624860,,,A
8151,Intermediate,,1,,10116.0,13101,1,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624861,,,A
8151,Intermediate,,1,,10116.0,13102,1,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624862,,,A
8151,Intermediate,,1,,10116.0,13103,1,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624863,,,A
8151,Intermediate,,1,,10116.0,13104,1,50597,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876655,,,A
6996,Intermediate,,1,,9615.0,13105,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624864,,,A
6996,Intermediate,,1,,9615.0,13106,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624865,,,A
6996,Intermediate,,1,,9615.0,13107,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624866,,,A
6996,Expert,,1,,9615.0,13108,1,50588,,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624867,,,F
6996,Intermediate,,1,,9615.0,13109,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL624868,,,A
6996,Intermediate,,1,,9615.0,13110,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628450,,,A
6996,Intermediate,,1,,9615.0,13111,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628451,,,A
6996,Intermediate,,1,,9615.0,13112,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628452,,,A
6996,Intermediate,,1,,9615.0,13113,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628453,,,A
6996,Intermediate,,1,,9615.0,13114,1,50588,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628454,,,A
6996,Intermediate,,1,,9615.0,13115,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628455,,,A
6996,Intermediate,,1,,9615.0,13116,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628456,,,A
6996,Intermediate,,1,,9615.0,13117,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628457,,,A
6996,Intermediate,,1,,9615.0,13118,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL877505,,,A
6996,Intermediate,,1,,9615.0,13119,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628458,,,A
6996,Intermediate,,1,,9615.0,13120,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628459,,,A
6996,Intermediate,,1,,9615.0,13121,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628460,,,A
6996,Intermediate,,1,,9615.0,13122,1,50588,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628461,,,A
6996,Autocuration,,1,,,13123,0,22224,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,U,,,BAO_0000218,,CHEMBL628462,,,B
6996,Intermediate,,1,,9615.0,13124,1,50588,,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628463,,,A
6996,Expert,,1,,10116.0,13125,1,50597,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625666,,,F
6996,Autocuration,,1,,,13126,0,22224,,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,U,,,BAO_0000218,,CHEMBL625667,,,B
6996,Expert,,1,,10116.0,13127,1,50597,,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625668,,,A
6996,Intermediate,,1,,10116.0,13128,1,50597,,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625669,,,A
7114,Autocuration,,1,,,13129,0,22224,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,U,,,BAO_0000019,,CHEMBL625670,,,A
7114,Intermediate,,1,,10116.0,13130,1,50597,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625671,,,A
8613,Intermediate,,1,,10298.0,13131,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL625672,,,A
8613,Intermediate,,1,,10298.0,13132,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL625673,,,A
8613,Intermediate,,1,,10298.0,13133,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL625674,,,A
8613,Intermediate,,1,,10298.0,13134,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL625675,,,A
8613,Intermediate,,1,,10298.0,13135,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL627637,,,A
8613,Intermediate,,1,,10298.0,13136,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL627638,,,A
8613,Intermediate,,1,,10298.0,13137,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL627639,,,A
8613,Intermediate,,1,,10298.0,13138,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL627640,,,A
8613,Intermediate,,1,,10298.0,13139,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL627641,,,A
8613,Intermediate,,1,,10298.0,13140,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL627642,,,A
8613,Intermediate,,1,,10298.0,13141,1,50602,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL877506,,,A
8613,Intermediate,,1,,10090.0,13142,1,50594,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,N,,Mus musculus,BAO_0000218,,CHEMBL627275,,,A
11219,Intermediate,,1,,9669.0,13143,1,50506,,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,N,,Mustela putorius furo,BAO_0000218,,CHEMBL627643,,,A
11219,Intermediate,,1,,9669.0,13144,1,50506,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,N,,Mustela putorius furo,BAO_0000218,,CHEMBL631246,,,A
11219,Intermediate,,1,,9669.0,13145,1,50506,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,N,,Mustela putorius furo,BAO_0000218,,CHEMBL631247,,,A
11219,Intermediate,,1,,9669.0,13146,1,50506,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL629532,,,A
11219,Intermediate,,1,,9669.0,13147,1,50506,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL629533,,,A
11219,Intermediate,,1,,9669.0,13148,1,50506,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL629534,,,A
11219,Intermediate,,1,,9669.0,13149,1,50506,,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,N,,Mustela putorius furo,BAO_0000218,,CHEMBL629535,,,A
14837,Autocuration,,1,,,13150,0,22224,,,,Pharmacokinetic parameter :drug bound to plasma was reported,,U,,,BAO_0000019,,CHEMBL625932,,,A
14837,Autocuration,,1,,,13151,0,22224,,,,compound was evaluated for drug bound in plasma,,U,,,BAO_0000019,,CHEMBL625933,,,A
15343,Intermediate,,1,,10116.0,13152,1,50597,,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625934,,,A
13761,Autocuration,,1,,9347.0,13153,0,22224,,,,Bioavailability,,U,,Eutheria,BAO_0000218,,CHEMBL625935,,,A
14810,Intermediate,,1,,10116.0,13154,1,50597,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625936,,,A
14810,Intermediate,,1,,10116.0,13155,1,50597,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625937,,,A
13249,Intermediate,,1,,9615.0,13156,1,50588,,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625938,,,A
9267,Intermediate,,1,,10116.0,13157,1,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,N,,Rattus norvegicus,BAO_0000218,1970.0,CHEMBL625939,,,A
9267,Intermediate,,1,,10116.0,13158,1,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,N,,Rattus norvegicus,BAO_0000218,1970.0,CHEMBL625940,,,A
9267,Intermediate,,1,,10116.0,13159,1,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,N,,Rattus norvegicus,BAO_0000218,1970.0,CHEMBL874464,,,A
9267,Intermediate,,1,,10116.0,13160,1,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,N,,Rattus norvegicus,BAO_0000218,1970.0,CHEMBL625941,,,A
9267,Intermediate,,1,,10116.0,13161,1,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,N,,Rattus norvegicus,BAO_0000218,1970.0,CHEMBL625942,,,A
9267,Intermediate,,1,,10116.0,13162,1,50597,,,Bile,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,N,,Rattus norvegicus,BAO_0000218,1970.0,CHEMBL625943,,,A
15549,Intermediate,,1,,9606.0,13163,1,50587,,,Serum,In vitro protein binding in human serum at 5 ug/ml,,N,,Homo sapiens,BAO_0000218,1977.0,CHEMBL625944,,,A
10929,Autocuration,,1,,,13164,0,22224,,,,Serum protein binding ability was measured,,U,,,BAO_0000019,,CHEMBL625945,,,A
15444,Autocuration,,1,,,13165,0,22224,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,U,,,BAO_0000019,,CHEMBL625946,,,A
12860,Autocuration,,1,,9615.0,13166,0,22224,,In vivo,,Oral bioavailability in dog,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL625947,,,A
12170,Intermediate,,1,,10116.0,13167,1,50597,,In vivo,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625948,,,A
15173,Autocuration,,1,,,13168,0,22224,,In vivo,,Absolute oral bioavailability at an iv dose of 14 mg/kg,,U,,,BAO_0000218,,CHEMBL625949,,,A
15173,Autocuration,,1,,,13169,0,22224,,In vivo,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,U,,,BAO_0000218,,CHEMBL625950,,,A
15173,Autocuration,,1,,9347.0,13170,0,22224,,In vivo,,Oral bioavailability (dose 15 mg/kg i.v.),,U,,Eutheria,BAO_0000218,,CHEMBL625951,,,A
15173,Autocuration,,1,,,13171,0,22224,,In vivo,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,U,,,BAO_0000218,,CHEMBL625952,,,A
15173,Autocuration,,1,,,13172,0,22224,,In vivo,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,U,,,BAO_0000218,,CHEMBL625953,,,A
15173,Autocuration,,1,,,13173,0,22224,,In vivo,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,U,,,BAO_0000218,,CHEMBL625954,,,A
15173,Autocuration,,1,,,13174,0,22224,,In vivo,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,U,,,BAO_0000218,,CHEMBL882959,,,A
11767,Intermediate,,1,,9615.0,13175,1,50588,,In vivo,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625955,,,A
11219,Autocuration,,1,,9669.0,13176,0,22224,,In vivo,,Bioavailability in ferret,,U,,Mustela putorius furo,BAO_0000218,,CHEMBL625956,,,A
12186,Intermediate,,1,,9541.0,13177,1,100710,,In vivo,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL625957,,,A
11510,Intermediate,,1,,10116.0,13178,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625958,,,A
11510,Intermediate,,1,,10116.0,13179,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625959,,,A
11510,Intermediate,,1,,10116.0,13180,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626642,,,A
11510,Intermediate,,1,,10116.0,13181,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631330,,,A
11510,Intermediate,,1,,10116.0,13182,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631331,,,A
11510,Intermediate,,1,,10116.0,13183,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631332,,,A
11510,Intermediate,,1,,10116.0,13184,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631333,,,A
11510,Intermediate,,1,,10116.0,13185,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632018,,,A
11510,Intermediate,,1,,10116.0,13186,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632019,,,A
11510,Intermediate,,1,,10116.0,13187,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632020,,,A
11510,Intermediate,,1,,10116.0,13188,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632021,,,A
11510,Intermediate,,1,,10116.0,13189,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632022,,,A
11510,Intermediate,,1,,10116.0,13190,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632023,,,A
11510,Intermediate,,1,,10116.0,13191,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632024,,,A
11510,Intermediate,,1,,10116.0,13192,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874472,,,A
11510,Intermediate,,1,,10116.0,13193,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632025,,,A
11510,Intermediate,,1,,10116.0,13194,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632026,,,A
11510,Intermediate,,1,,10116.0,13195,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632027,,,A
11510,Intermediate,,1,,10116.0,13196,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632028,,,A
11510,Intermediate,,1,,10116.0,13197,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626430,,,A
11510,Intermediate,,1,,10116.0,13198,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626431,,,A
11510,Intermediate,,1,,10116.0,13199,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626432,,,A
11510,Intermediate,,1,,10116.0,13200,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626433,,,A
11510,Intermediate,,1,,10116.0,13201,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626434,,,A
11510,Intermediate,,1,,10116.0,13202,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627280,,,A
11510,Intermediate,,1,,10116.0,13203,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627281,,,A
11510,Intermediate,,1,,10116.0,13204,1,50597,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627282,,,A
7199,Autocuration,,1,,,13205,0,22224,,,,Total body clearance was measured at given dose,,U,,,BAO_0000019,,CHEMBL627283,,,A
7199,Autocuration,,1,,,13206,0,22224,,,,Total body clearance was measured at given dose.,,U,,,BAO_0000218,,CHEMBL627284,,,A
7095,Intermediate,,1,,10116.0,13207,1,50597,,,,Metabolic clearance from the body in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627285,,,A
7095,Autocuration,,1,,,13208,0,22224,,In vivo,,Renal clearance from the body,,U,,,BAO_0000218,,CHEMBL627286,,,A
7095,Intermediate,,1,,10116.0,13209,1,50597,,In vivo,,Renal clearance from the body in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875477,,,A
12528,Intermediate,,1,,10116.0,13210,1,50597,,In vivo,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627287,,,A
12528,Intermediate,,1,,9615.0,13211,1,50588,,In vivo,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL627288,,,A
7095,Intermediate,,1,,10116.0,13212,1,50597,,,,Total clearance from the body in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627289,,,A
14223,Intermediate,,1,,10116.0,13213,1,50597,,In vivo,Plasma,Clearance into cortex from rat plasma or PBS,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627290,,,A
13569,Autocuration,,1,,,13214,0,22224,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,U,,,BAO_0000218,,CHEMBL627291,,,A
13569,Autocuration,,1,,,13215,0,22224,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,U,,,BAO_0000218,,CHEMBL627292,,,A
13569,Autocuration,,1,,,13216,0,22224,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,U,,,BAO_0000218,,CHEMBL627293,,,A
13569,Autocuration,,1,,,13217,0,22224,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,U,,,BAO_0000218,,CHEMBL627294,,,A
13569,Autocuration,,1,,,13218,0,22224,,In vivo,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,U,,,BAO_0000218,,CHEMBL875478,,,A
13979,Autocuration,,1,,,13219,0,22224,,In vivo,,Clearance was determined,,U,,,BAO_0000218,,CHEMBL627295,,,A
14315,Intermediate,,1,,10090.0,13220,1,50594,,In vivo,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,N,,Mus musculus,BAO_0000218,,CHEMBL627296,,,A
14315,Intermediate,,1,,9986.0,13221,1,50592,,In vivo,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,N,,Oryctolagus cuniculus,BAO_0000218,,CHEMBL626119,,,A
14315,Intermediate,,1,,10116.0,13222,1,50597,,In vivo,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626120,,,A
12174,Intermediate,,1,,10116.0,13223,1,50597,,In vivo,,Clearance in rat after iv dose (100 ug/kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626121,,,A
12797,Autocuration,,1,,10141.0,13224,0,22224,,In vivo,,Clearance in guinea pig,,U,,Cavia porcellus,BAO_0000218,,CHEMBL626122,,,A
12797,Intermediate,,1,,10116.0,13225,1,50597,,In vivo,,Compound was evaluated for clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626123,,,A
12797,Intermediate,,1,,9615.0,13226,1,50588,,In vivo,,Compound was evaluated for the clearance in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL623456,,,A
12797,Intermediate,,1,,10116.0,13227,1,50597,,In vivo,,Compound was evaluated for the clearance in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623457,,,A
11500,Intermediate,,1,,10116.0,13228,1,50597,,In vivo,,Compound was tested in vivo for clearance after iv administration in the rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623458,,,A
15173,Autocuration,,1,,,13229,0,22224,,In vivo,,IV clearance determined at an iv dose of 14 mg/kg,,U,,,BAO_0000218,,CHEMBL623459,,,A
15173,Autocuration,,1,,,13230,0,22224,,In vivo,,IV clearance determined at an iv dose of 15.2 mg/kg,,U,,,BAO_0000218,,CHEMBL875484,,,A
15173,Autocuration,,1,,,13231,0,22224,,In vivo,,IV clearance determined at an iv dose of 15 mg/kg,,U,,,BAO_0000218,,CHEMBL623460,,,A
15173,Autocuration,,1,,,13232,0,22224,,In vivo,,IV clearance determined at an peroral dose of 30 mg/kg.,,U,,,BAO_0000218,,CHEMBL623461,,,A
15173,Autocuration,,1,,,13233,0,22224,,In vivo,,IV clearance determined at an peroral dose of 30.2 mg/kg.,,U,,,BAO_0000218,,CHEMBL623462,,,A
15173,Autocuration,,1,,,13234,0,22224,,In vivo,,IV clearance determined at an peroral dose of 30.3 mg/kg.,,U,,,BAO_0000218,,CHEMBL627386,,,A
14198,Intermediate,,1,,10116.0,13235,1,50597,,In vivo,Kidney,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627387,,,A
14198,Intermediate,,1,,10116.0,13236,1,50597,,In vivo,Liver,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627388,,,A
14198,Intermediate,,1,,10116.0,13237,1,50597,,In vivo,Lung,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627389,,,A
14198,Intermediate,,1,,10116.0,13238,1,50597,,In vivo,Muscle tissue,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627390,,,A
14198,Intermediate,,1,,10116.0,13239,1,50597,,In vivo,Plasma,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627391,,,A
14198,Intermediate,,1,,10116.0,13240,1,50597,,In vivo,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627392,,,A
14198,Intermediate,,1,,10116.0,13241,1,50597,,In vivo,Spleen,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL627393,,,A
14198,Intermediate,,1,,10116.0,13242,1,50597,,In vivo,Trachea,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,3126.0,CHEMBL627394,,,A
14198,Intermediate,,1,,10116.0,13243,1,50597,,In vivo,Bone,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627395,,,A
14198,Intermediate,,1,,10116.0,13244,1,50597,,In vivo,Cerebellum,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL875485,,,A
14198,Intermediate,,1,,10116.0,13245,1,50597,,In vivo,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627396,,,A
14198,Intermediate,,1,,10116.0,13246,1,50597,,In vivo,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627397,,,A
14198,Intermediate,,1,,10116.0,13247,1,50597,,In vivo,Heart,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL627398,,,A
14198,Intermediate,,1,,10116.0,13248,1,50597,,In vivo,Bone,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL627399,,,A
14198,Intermediate,,1,,10116.0,13249,1,50597,,In vivo,Kidney,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627400,,,A
14198,Intermediate,,1,,10116.0,13250,1,50597,,In vivo,Liver,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627401,,,A
14198,Intermediate,,1,,10116.0,13251,1,50597,,In vivo,Lung,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627402,,,A
14198,Intermediate,,1,,10116.0,13252,1,50597,,In vivo,Muscle tissue,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL627403,,,A
14198,Intermediate,,1,,10116.0,13253,1,50597,,In vivo,Plasma,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL627404,,,A
14198,Intermediate,,1,,10116.0,13254,1,50597,,In vivo,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623101,,,A
14198,Intermediate,,1,,10116.0,13255,1,50597,,In vivo,Spleen,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL877480,,,A
14198,Intermediate,,1,,10116.0,13256,1,50597,,In vivo,Trachea,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,3126.0,CHEMBL623102,,,A
14198,Intermediate,,1,,10116.0,13257,1,50597,,In vivo,Bone,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL623103,,,A
14198,Intermediate,,1,,10116.0,13258,1,50597,,In vivo,Cerebellum,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL623104,,,A
14198,Intermediate,,1,,10116.0,13259,1,50597,,In vivo,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623105,,,A
14198,Intermediate,,1,,10116.0,13260,1,50597,,In vivo,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623106,,,A
14198,Intermediate,,1,,10116.0,13261,1,50597,,In vivo,Heart,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL623107,,,A
14198,Intermediate,,1,,10116.0,13262,1,50597,,In vivo,Intestine,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL623108,,,A
14198,Intermediate,,1,,10116.0,13263,1,50597,,In vivo,Kidney,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL623109,,,A
14198,Intermediate,,1,,10116.0,13264,1,50597,,In vivo,Liver,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL623110,,,A
14198,Intermediate,,1,,10116.0,13265,1,50597,,In vivo,Lung,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL623111,,,A
14198,Intermediate,,1,,10116.0,13266,1,50597,,In vivo,Muscle tissue,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625060,,,A
14198,Intermediate,,1,,10116.0,13267,1,50597,,In vivo,Plasma,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625061,,,A
14198,Intermediate,,1,,10116.0,13268,1,50597,,In vivo,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625062,,,A
14198,Intermediate,,1,,10116.0,13269,1,50597,,In vivo,Spleen,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625063,,,A
14198,Intermediate,,1,,10116.0,13270,1,50597,,In vivo,Trachea,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,3126.0,CHEMBL625064,,,A
14198,Intermediate,,1,,10116.0,13271,1,50597,,In vivo,Bone,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,10000001.0,CHEMBL625065,,,A
14198,Intermediate,,1,,10116.0,13272,1,50597,,In vivo,Cerebellum,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL625066,,,A
14198,Intermediate,,1,,10116.0,13273,1,50597,,In vivo,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625067,,,A
14198,Intermediate,,1,,10116.0,13274,1,50597,,In vivo,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625068,,,A
14198,Intermediate,,1,,10116.0,13275,1,50597,,In vivo,Heart,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL622159,,,A
14198,Intermediate,,1,,10116.0,13276,1,50597,,In vivo,Intestine,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,160.0,CHEMBL622160,,,A
14198,Intermediate,,1,,10116.0,13277,1,50597,,In vivo,Kidney,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL622161,,,A
14198,Intermediate,,1,,10116.0,13278,1,50597,,In vivo,Lung,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL622162,,,A
14198,Intermediate,,1,,10116.0,13279,1,50597,,In vivo,Muscle tissue,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL622163,,,A
14198,Intermediate,,1,,10116.0,13280,1,50597,,In vivo,Plasma,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622313,,,A
14198,Intermediate,,1,,10116.0,13281,1,50597,,In vivo,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622314,,,A
14198,Intermediate,,1,,10116.0,13282,1,50597,,In vivo,Spleen,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622315,,,A
14198,Intermediate,,1,,10116.0,13283,1,50597,,In vivo,Trachea,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,N,,Rattus norvegicus,BAO_0000218,3126.0,CHEMBL622316,,,A
15599,Intermediate,,1,,562.0,13284,1,50212,,,,Normal diffusion coefficient in water for Escherichia coli,,N,,Escherichia coli,BAO_0000218,,CHEMBL877486,,,A
8204,Autocuration,,1,,,13285,0,22224,,,,Average max percent decrease in RVR (renal vascular resistance) was determined,,U,,,BAO_0000019,,CHEMBL622317,,,A
8204,Autocuration,,1,,,13286,0,22224,,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,,U,,,BAO_0000019,,CHEMBL622318,,,A
6154,Autocuration,,1,,,13287,0,22224,,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,U,,,BAO_0000019,,CHEMBL622319,,,A
6154,Autocuration,,1,,,13288,0,22224,,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,U,,,BAO_0000019,,CHEMBL622320,,,A
6154,Autocuration,,1,,,13289,0,22224,,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,U,,,BAO_0000019,,CHEMBL622321,,,A
6154,Autocuration,,1,,,13290,0,22224,,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,U,,,BAO_0000019,,CHEMBL622322,,,A
7114,Autocuration,,1,,,13291,0,22224,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,U,,,BAO_0000019,,CHEMBL622323,,,A
7114,Intermediate,,1,,10116.0,13292,1,50597,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622324,,,A
8133,Intermediate,,1,,9615.0,13293,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622325,,,A
8133,Intermediate,,1,,9615.0,13294,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622326,,,A
8133,Intermediate,,1,,9615.0,13295,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL877487,,,A
8133,Intermediate,,1,,9615.0,13296,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622327,,,A
8133,Intermediate,,1,,9615.0,13297,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622328,,,A
8133,Intermediate,,1,,9615.0,13298,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622329,,,A
8133,Intermediate,,1,,9615.0,13299,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622330,,,A
8133,Intermediate,,1,,9615.0,13300,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622331,,,A
8133,Intermediate,,1,,9615.0,13301,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622332,,,A
8133,Intermediate,,1,,9615.0,13302,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622333,,,A
8133,Autocuration,,1,,314293.0,13303,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL627658,,,A
8133,Autocuration,,1,,314293.0,13304,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL630428,,,A
8133,Autocuration,,1,,314293.0,13305,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL630429,,,A
8133,Autocuration,,1,,314293.0,13306,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL630430,,,A
8133,Autocuration,,1,,314293.0,13307,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL630431,,,A
8133,Intermediate,,1,,10116.0,13308,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL630432,,,A
8133,Intermediate,,1,,10116.0,13309,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL630433,,,A
8133,Intermediate,,1,,10116.0,13310,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL630434,,,A
8133,Intermediate,,1,,10116.0,13311,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629372,,,A
8133,Intermediate,,1,,10116.0,13312,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629553,,,A
8133,Intermediate,,1,,10116.0,13313,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629554,,,A
8133,Intermediate,,1,,10116.0,13314,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL874447,,,A
8133,Intermediate,,1,,10116.0,13315,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629555,,,A
8133,Intermediate,,1,,10116.0,13316,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629556,,,A
8133,Intermediate,,1,,10116.0,13317,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629557,,,A
8133,Intermediate,,1,,10116.0,13318,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629558,,,A
8133,Intermediate,,1,,10116.0,13319,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629559,,,A
8133,Intermediate,,1,,10116.0,13320,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629560,,,A
8133,Intermediate,,1,,9615.0,13321,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629561,,,A
8133,Intermediate,,1,,9615.0,13322,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629562,,,A
8133,Intermediate,,1,,9615.0,13323,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629563,,,A
8133,Intermediate,,1,,9615.0,13324,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629564,,,A
8133,Intermediate,,1,,9615.0,13325,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629565,,,A
8133,Intermediate,,1,,9615.0,13326,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629566,,,A
8133,Intermediate,,1,,9615.0,13327,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629567,,,A
8133,Intermediate,,1,,9615.0,13328,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629568,,,A
8133,Intermediate,,1,,9615.0,13329,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629569,,,A
8133,Intermediate,,1,,9615.0,13330,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL629570,,,A
8133,Autocuration,,1,,314293.0,13331,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL629571,,,A
12170,Autocuration,,1,,10116.0,13332,0,22224,,In vivo,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL629572,,,A
12170,Autocuration,,1,,10116.0,13333,0,22224,,In vivo,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL629573,,,A
4985,Autocuration,,1,,9347.0,13334,0,22224,,In vivo,,Bioavailability (dose 20 mg/kg),,U,,Eutheria,BAO_0000218,,CHEMBL629574,,,A
15145,Autocuration,,1,,9615.0,13335,0,22224,,In vivo,,Bioavailability in dog,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL629575,,,A
14080,Autocuration,,1,,10116.0,13336,0,22224,,In vivo,,Bioavailability in rat (Sprague-Dawley) (male),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL874448,,,A
11219,Autocuration,,1,,9443.0,13337,0,22224,,In vivo,,Bioavailability in monkey (dose 10 mg/kg i.d.),,U,,Primates,BAO_0000218,,CHEMBL629576,,,A
15145,Autocuration,,1,,10116.0,13338,0,22224,,In vivo,,Bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL629577,,,A
15145,Autocuration,,1,,10116.0,13339,0,22224,,In vivo,,Bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL629578,,,A
1202,Autocuration,,1,,9615.0,13340,0,22224,,In vivo,,Bioavailability in dog (dose 3.0 mg/kg p.o.),,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL629579,,,A
1202,Autocuration,,1,,9615.0,13341,0,22224,,In vivo,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL882958,,,A
1202,Intermediate,,1,,9598.0,13342,1,50505,,In vivo,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,N,,Pan troglodytes,BAO_0000218,,CHEMBL629580,,,A
4026,Autocuration,,1,,9347.0,13343,0,22224,,In vivo,,Bioavailability,,U,,Eutheria,BAO_0000218,,CHEMBL629581,,,A
1492,Autocuration,,1,,9520.0,13344,0,22224,,In vivo,,Bioavailability in squirrel monkey,,U,,Saimiri,BAO_0000218,,CHEMBL629582,,,A
12793,Intermediate,,1,,9615.0,13345,1,50588,,In vivo,,Bioavailability was evaluated in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628522,,,A
12793,Intermediate,,1,,10026.0,13346,1,100712,,In vivo,,Bioavailability was evaluated in hamster,,N,,Cricetinae,BAO_0000218,,CHEMBL625432,,,A
12793,Autocuration,,1,,10116.0,13347,0,22224,,In vivo,,Bioavailability in rat,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625433,,,A
14793,Intermediate,,1,,10116.0,13348,1,50597,,In vivo,Plasma,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625434,,,A
14793,Intermediate,,1,,10116.0,13349,1,50597,,In vivo,Plasma,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL625435,,,A
14793,Autocuration,,1,,10116.0,13350,0,22224,,In vivo,,Bioavailability in rat (dose 10 mg/kg p.o.),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625436,,,A
14731,Intermediate,,1,,9541.0,13351,1,100710,,In vivo,,Bioavailability was measured in cynomolgus monkeys.,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL874588,,,A
14731,Intermediate,,1,,10090.0,13352,1,50594,,In vivo,,Bioavailability was measured in nude mice.,,N,,Mus musculus,BAO_0000218,,CHEMBL625437,,,A
12187,Autocuration,,1,,9669.0,13353,0,22224,,In vivo,,Bioavailability in ferret (dose 10 mg/kg i.d.),,U,,Mustela putorius furo,BAO_0000218,,CHEMBL625438,,,A
12187,Autocuration,,1,,314293.0,13354,0,22224,,In vivo,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,U,,Simiiformes,BAO_0000218,,CHEMBL625439,,,A
12187,Autocuration,,1,,314293.0,13355,0,22224,,In vivo,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,U,,Simiiformes,BAO_0000218,,CHEMBL625440,,,A
12187,Autocuration,,1,,314293.0,13356,0,22224,,In vivo,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,U,,Simiiformes,BAO_0000218,,CHEMBL625441,,,A
12187,Autocuration,,1,,10116.0,13357,0,22224,,In vivo,,Bioavailability in rat (dose 10 mg/kg i.d.),,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625442,,,A
12187,Intermediate,,1,,10116.0,13358,1,50597,,In vivo,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625443,,,A
17431,Autocuration,,1,,,13359,0,22224,,In vivo,,Bioavailability was determined; extremely poor,,U,,,BAO_0000218,,CHEMBL625444,,,A
13318,Intermediate,,1,,10090.0,13360,1,50594,,In vivo,,% bioavailability in mice after oral administration of prodrug,,N,,Mus musculus,BAO_0000218,,CHEMBL625445,,,A
9025,Intermediate,,1,,9615.0,13361,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625446,,,A
9025,Intermediate,,1,,9615.0,13362,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL882960,,,A
9025,Intermediate,,1,,9615.0,13363,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625447,,,A
9025,Intermediate,,1,,9615.0,13364,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625448,,,A
9025,Intermediate,,1,,9615.0,13365,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625449,,,A
9025,Intermediate,,1,,9615.0,13366,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL874589,,,A
9025,Intermediate,,1,,9615.0,13367,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625450,,,A
9025,Intermediate,,1,,9615.0,13368,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625451,,,A
9025,Intermediate,,1,,9615.0,13369,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626584,,,A
9025,Intermediate,,1,,9615.0,13370,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626585,,,A
9025,Intermediate,,1,,9615.0,13371,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626586,,,A
9025,Intermediate,,1,,9615.0,13372,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626587,,,A
9025,Intermediate,,1,,9615.0,13373,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626588,,,A
9025,Intermediate,,1,,9615.0,13374,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626589,,,A
9025,Intermediate,,1,,9615.0,13375,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626590,,,A
9025,Intermediate,,1,,9615.0,13376,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626591,,,A
9025,Intermediate,,1,,9615.0,13377,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL627181,,,A
9025,Intermediate,,1,,9615.0,13378,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628083,,,A
15173,Autocuration,,1,,,13379,0,22224,,In vivo,,IV clearance determined at an peroral dose of 15 mg/kg.,,U,,,BAO_0000218,,CHEMBL628084,,,A
7732,Expert,,1,,102285.0,13380,1,50064,,In vivo,,Mouse oral clearance was measured against Hymenolepiasis nana.,,N,,Hymenolepis nana,BAO_0000218,,CHEMBL628085,,,F
7732,Expert,,1,,6339.0,13381,1,50545,,In vivo,,Mouse oral clearance was measured against Nematospiroides dubius,,N,,Heligmosomoides polygyrus,BAO_0000218,,CHEMBL628086,,,F
7732,Autocuration,,1,,,13382,0,22224,,In vivo,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,U,,,BAO_0000218,,CHEMBL628087,,,F
7732,Intermediate,,1,,10090.0,13383,1,50594,,In vivo,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,N,,Mus musculus,BAO_0000218,,CHEMBL628088,,,A
7732,Autocuration,,1,,,13384,0,22224,,In vivo,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,U,,,BAO_0000218,,CHEMBL628089,,,B
8328,Autocuration,,1,,,13385,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL628090,,,A
8328,Autocuration,,1,,,13386,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL628091,,,A
8328,Autocuration,,1,,,13387,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL628092,,,A
8328,Autocuration,,1,,,13388,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL628093,,,A
8328,Autocuration,,1,,,13389,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL875607,,,A
8328,Autocuration,,1,,,13390,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL625710,,,A
8328,Autocuration,,1,,,13391,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL625711,,,A
8328,Autocuration,,1,,,13392,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL625712,,,A
8328,Autocuration,,1,,,13393,0,22224,,In vivo,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,U,,,BAO_0000218,,CHEMBL625713,,,A
13376,Intermediate,,1,,9615.0,13394,1,50588,,In vivo,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625714,,,A
13477,Intermediate,,1,,9544.0,13395,1,50797,,In vivo,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,N,,Macaca mulatta,BAO_0000218,,CHEMBL625715,,,A
13477,Intermediate,,1,,10116.0,13396,1,50597,,In vivo,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625716,,,A
13477,Intermediate,,1,,10116.0,13397,1,50597,,In vivo,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625717,,,A
13313,Intermediate,,1,,10116.0,13398,1,50597,,In vivo,,Plasma clearance was determined for the compound in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625718,,,A
12504,Intermediate,,1,,10116.0,13399,1,50597,,In vivo,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625719,,,A
12504,Intermediate,,1,,10116.0,13400,1,50597,,In vivo,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625720,,,A
12504,Intermediate,,1,,10116.0,13401,1,50597,,In vivo,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625721,,,A
12504,Intermediate,,1,,10116.0,13402,1,50597,,In vivo,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625722,,,A
13129,Intermediate,,1,,10116.0,13403,1,50597,,In vivo,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625723,,,A
7732,Intermediate,,1,,6339.0,13404,1,50545,,In vivo,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,N,,Heligmosomoides polygyrus,BAO_0000218,,CHEMBL625724,,,A
7732,Intermediate,,1,,6339.0,13405,1,50545,,In vivo,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,N,,Heligmosomoides polygyrus,BAO_0000218,,CHEMBL625725,,,A
7732,Intermediate,,1,,6339.0,13406,1,50545,,In vivo,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,N,,Heligmosomoides polygyrus,BAO_0000218,,CHEMBL625726,,,A
7732,Intermediate,,1,,6339.0,13407,1,50545,,In vivo,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,N,,Heligmosomoides polygyrus,BAO_0000218,,CHEMBL875608,,,A
7732,Intermediate,,1,,6339.0,13408,1,50545,,In vivo,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,N,,Heligmosomoides polygyrus,BAO_0000218,,CHEMBL625727,,,A
9278,Autocuration,,1,,10116.0,13409,0,22224,,In vivo,Urine,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,U,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625728,,,A
9278,Autocuration,,1,,10116.0,13410,0,22224,,In vivo,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625729,,,A
9278,Autocuration,,1,,10116.0,13411,0,22224,,In vivo,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL625730,,,A
9278,Autocuration,,1,,10116.0,13412,0,22224,,In vivo,Urine,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,U,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625731,,,A
9278,Autocuration,,1,,10116.0,13413,0,22224,,In vivo,Urine,Urinary clearance was determined in rat at 25 mg/kg os dosage,,U,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626417,,,A
9278,Intermediate,,1,,9606.0,13414,1,50587,,In vivo,Urine,Urinary clearance was determined at 100 mg/kg oral dosage in human,,N,,Homo sapiens,BAO_0000218,1088.0,CHEMBL626418,,,A
9278,Intermediate,,1,,9615.0,13415,1,50588,,In vivo,Urine,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL626419,,,A
5932,Intermediate,,1,,9615.0,13416,1,50588,,In vivo,Plasma,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626592,,,A
5932,Intermediate,,1,,10116.0,13417,1,50597,,In vivo,Plasma,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626593,,,A
5182,Intermediate,,1,,10116.0,13418,1,50597,,In vivo,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626594,,,A
10499,Intermediate,,1,,9615.0,13419,1,50588,,In vivo,,Clearance rate in dogs,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625035,,,A
6051,Autocuration,,1,,,13420,0,22224,,In vitro,,Compound was measured for intrinsic clearance,,U,,,BAO_0000019,,CHEMBL625036,,,A
17508,Autocuration,,1,,,13421,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625037,,,P
6228,Autocuration,,1,,,13422,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625038,,,P
6231,Autocuration,,1,,,13423,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625039,,,P
17740,Autocuration,,1,,,13424,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625040,,,P
6495,Autocuration,,1,,,13425,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625041,,,P
2171,Autocuration,,1,,,13426,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625042,,,P
3255,Autocuration,,1,,,13427,0,22224,,,,Partition coefficient of the compound,,U,,,BAO_0000019,,CHEMBL874411,,,A
6821,Autocuration,,1,,,13428,0,22224,,,,Permeability,,U,,,BAO_0000019,,CHEMBL625043,,,A
2685,Autocuration,,1,,,13429,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625044,,,P
17584,Autocuration,,1,,,13430,0,22224,,,,Partition coefficient (logD),,U,,,BAO_0000019,,CHEMBL625045,,,A
13824,Autocuration,,1,,,13431,0,22229,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,U,,,BAO_0000100,,CHEMBL625046,,,P
13824,Autocuration,,1,,,13432,0,22229,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,U,,,BAO_0000100,,CHEMBL625047,,,P
16479,Autocuration,,1,,,13433,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625048,,,P
11997,Autocuration,,1,,,13434,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625049,,,P
2988,Autocuration,,1,,,13435,0,22229,,,,Calculated logarithm of partition coefficient (P) was determined,,U,,,BAO_0000100,,CHEMBL625050,,,P
931,Autocuration,,1,,,13436,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625051,,,P
4381,Autocuration,,1,,,13437,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL874412,,,P
4397,Autocuration,,1,,,13438,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625052,,,P
5889,Autocuration,,1,,,13439,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL625053,,,P
6154,Autocuration,,1,,,13440,0,22224,,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,U,,,BAO_0000019,,CHEMBL623250,,,A
6154,Autocuration,,1,,,13441,0,22224,,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,U,,,BAO_0000019,,CHEMBL623251,,,A
6154,Autocuration,,1,,,13442,0,22224,,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,U,,,BAO_0000019,,CHEMBL623252,,,A
6154,Autocuration,,1,,,13443,0,22224,,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,U,,,BAO_0000019,,CHEMBL623253,,,A
6154,Autocuration,,1,,,13444,0,22224,,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,U,,,BAO_0000019,,CHEMBL623254,,,A
6154,Autocuration,,1,,,13445,0,22224,,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,U,,,BAO_0000019,,CHEMBL623255,,,A
6887,Autocuration,,1,,,13446,0,22224,,,,Percent degradation of compound at a pH of 1 over a 18 hr period,,U,,,BAO_0000019,,CHEMBL626831,,,A
6887,Autocuration,,1,,,13447,0,22224,,,,Percent degradation of compound at pH of 1 over an 18 hr period,,U,,,BAO_0000019,,CHEMBL877494,,,A
14116,Autocuration,,1,,,13448,0,22224,,,,Delta Logarithm of Partition Coefficient value was determined.,,U,,,BAO_0000019,,CHEMBL626832,,,A
11137,Autocuration,,1,,,13449,0,22224,,,,Delta logPoct-cyc,,U,,,BAO_0000019,,CHEMBL626833,,,A
7230,Autocuration,,1,,,13450,0,22224,,,,Lipophilicity estimated on reversed phase TLC,,U,,,BAO_0000100,,CHEMBL626834,,,P
15741,Autocuration,,1,,,13451,0,22224,,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,U,,,BAO_0000019,,CHEMBL626835,,,A
9663,Autocuration,,1,,,13452,0,22224,,,,Delta logPoct-cyc,,U,,,BAO_0000019,,CHEMBL626836,,,A
9663,Autocuration,,1,,,13453,0,22229,,,,Change in logarithm of partition coefficient of the compound,,U,,,BAO_0000100,,CHEMBL626837,,,P
13807,Autocuration,,1,,,13454,0,22224,,,,Delta logD (pH 6.5),,U,,,BAO_0000019,,CHEMBL626838,,,A
13807,Autocuration,,1,,,13455,0,22224,,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,U,,,BAO_0000100,,CHEMBL626839,,,P
17425,Autocuration,,1,,,13456,0,22224,,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,U,,,BAO_0000019,,CHEMBL626840,,,A
12143,Autocuration,,1,,,13457,0,22224,,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,U,,,BAO_0000019,,CHEMBL626841,,,A
12608,Autocuration,,1,,,13458,0,22224,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,U,,,BAO_0000219,,CHEMBL626842,,,A
12608,Autocuration,,1,,,13459,0,22224,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,U,,,BAO_0000219,,CHEMBL626843,,,A
8649,Intermediate,,1,,10116.0,13460,1,50597,,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626844,,,A
8649,Intermediate,,1,,10116.0,13461,1,50597,,,,Amount of deuterium retained was reported after normal workup in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL877495,,,A
8649,Intermediate,,1,,10116.0,13462,1,50597,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626845,,,A
8649,Intermediate,,1,,10116.0,13463,1,50597,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626846,,,A
8649,Intermediate,,1,,10116.0,13464,1,50597,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626847,,,A
8649,Intermediate,,1,,10116.0,13465,1,50597,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628677,,,A
8649,Intermediate,,1,,10116.0,13466,1,50597,,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628678,,,A
9659,Autocuration,,1,,,13467,0,22224,,,,Compound was subjected to electrochemical oxidation,,U,,,BAO_0000019,,CHEMBL628679,,,A
9659,Autocuration,,1,,,13468,0,22224,,,,Compound was subjected to photochemical oxidation,,U,,,BAO_0000019,,CHEMBL628680,,,A
9659,Autocuration,,1,,,13469,0,22224,,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,U,,,BAO_0000019,,CHEMBL628681,,,A
9659,Autocuration,,1,,,13470,0,22224,,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,U,,,BAO_0000019,,CHEMBL628682,,,A
9659,Autocuration,,1,,,13471,0,22224,,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,,U,,,BAO_0000019,,CHEMBL628683,,,A
9607,Intermediate,,1,,10116.0,13472,1,50597,,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628684,,,A
7057,Autocuration,,1,,,13473,0,22229,,,,Dissociation constant (pKa),,U,,,BAO_0000100,,CHEMBL877501,,,P
7057,Autocuration,,1,,,13474,0,22224,,,,Dissociation constant value of the compound; ND means not determined.,,U,,,BAO_0000100,,CHEMBL628685,,,P
7911,Intermediate,,1,,10116.0,13475,1,50597,,,Blood,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628686,,,A
7911,Intermediate,,1,,10116.0,13476,1,50597,,,Blood,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL628687,,,A
7911,Intermediate,,1,,10116.0,13477,1,50597,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628688,,,A
7911,Intermediate,,1,,10116.0,13478,1,50597,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628689,,,A
7911,Intermediate,,1,,10116.0,13479,1,50597,,,Liver,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628690,,,A
7911,Intermediate,,1,,10116.0,13480,1,50597,,,Liver,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL629363,,,A
7911,Intermediate,,1,,10116.0,13481,1,50597,,,Spleen,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL629364,,,A
7911,Intermediate,,1,,10116.0,13482,1,50597,,,Spleen,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL629365,,,A
7911,Intermediate,,1,,10116.0,13483,1,50597,,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629366,,,A
7911,Intermediate,,1,,10116.0,13484,1,50597,,,Urine,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629367,,,A
7911,Intermediate,,1,,10116.0,13485,1,50597,,,Feces,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL629368,,,A
7911,Intermediate,,1,,10116.0,13486,1,50597,,,Urine,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL877502,,,A
13792,Intermediate,,1,,10090.0,13487,1,50594,,,Cerebellum,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,N,,Mus musculus,BAO_0000218,2037.0,CHEMBL629369,,,A
13792,Intermediate,,1,,10090.0,13488,1,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL629370,,,A
8133,Autocuration,,1,,314293.0,13489,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL629371,,,A
8133,Autocuration,,1,,314293.0,13490,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL626276,,,A
8133,Autocuration,,1,,314293.0,13491,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL626277,,,A
8133,Autocuration,,1,,314293.0,13492,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL631250,,,A
8133,Intermediate,,1,,10116.0,13493,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631251,,,A
8133,Intermediate,,1,,10116.0,13494,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631252,,,A
8133,Intermediate,,1,,10116.0,13495,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631253,,,A
8133,Intermediate,,1,,10116.0,13496,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631254,,,A
8133,Intermediate,,1,,10116.0,13497,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631255,,,A
8133,Intermediate,,1,,10116.0,13498,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631256,,,A
8133,Intermediate,,1,,10116.0,13499,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631257,,,A
8133,Intermediate,,1,,10116.0,13500,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628009,,,A
8133,Intermediate,,1,,10116.0,13501,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628010,,,A
8133,Intermediate,,1,,10116.0,13502,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628011,,,A
8133,Intermediate,,1,,10116.0,13503,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628012,,,A
8133,Intermediate,,1,,10116.0,13504,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628013,,,A
8133,Intermediate,,1,,10116.0,13505,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628014,,,A
8133,Intermediate,,1,,9615.0,13506,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628015,,,A
8133,Intermediate,,1,,9615.0,13507,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628016,,,A
8133,Intermediate,,1,,9615.0,13508,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL874461,,,A
8133,Intermediate,,1,,9615.0,13509,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628017,,,A
8133,Intermediate,,1,,9615.0,13510,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628018,,,A
8133,Intermediate,,1,,9615.0,13511,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628019,,,A
8133,Intermediate,,1,,9615.0,13512,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628020,,,A
8133,Intermediate,,1,,9615.0,13513,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628021,,,A
8133,Intermediate,,1,,9615.0,13514,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628022,,,A
8133,Intermediate,,1,,9615.0,13515,1,50588,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL628023,,,A
8133,Autocuration,,1,,314293.0,13516,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL628024,,,A
8133,Autocuration,,1,,314293.0,13517,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL628025,,,A
8133,Autocuration,,1,,314293.0,13518,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL628026,,,A
8133,Autocuration,,1,,314293.0,13519,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL628027,,,A
8133,Autocuration,,1,,314293.0,13520,0,22224,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,U,,Simiiformes,BAO_0000218,1088.0,CHEMBL628028,,,A
8133,Intermediate,,1,,10116.0,13521,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628029,,,A
8133,Intermediate,,1,,10116.0,13522,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628030,,,A
8133,Intermediate,,1,,10116.0,13523,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628031,,,A
8133,Intermediate,,1,,10116.0,13524,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628032,,,A
8133,Intermediate,,1,,10116.0,13525,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628033,,,A
8133,Intermediate,,1,,10116.0,13526,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628034,,,A
8133,Intermediate,,1,,10116.0,13527,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628035,,,A
8133,Intermediate,,1,,10116.0,13528,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628036,,,A
8133,Intermediate,,1,,10116.0,13529,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL874462,,,A
9025,Intermediate,,1,,9615.0,13530,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628037,,,A
9025,Intermediate,,1,,9615.0,13531,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628123,,,A
9025,Intermediate,,1,,9615.0,13532,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628124,,,A
9025,Intermediate,,1,,9615.0,13533,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628125,,,A
9025,Intermediate,,1,,9615.0,13534,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628126,,,A
9025,Intermediate,,1,,9615.0,13535,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628127,,,A
9025,Intermediate,,1,,9615.0,13536,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628128,,,A
9025,Intermediate,,1,,9615.0,13537,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628129,,,A
9025,Intermediate,,1,,9615.0,13538,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628130,,,A
9025,Intermediate,,1,,9615.0,13539,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628131,,,A
9025,Intermediate,,1,,9615.0,13540,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628132,,,A
9025,Intermediate,,1,,9615.0,13541,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628133,,,A
9025,Intermediate,,1,,9615.0,13542,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628134,,,A
9025,Intermediate,,1,,9615.0,13543,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628135,,,A
9025,Intermediate,,1,,9615.0,13544,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628136,,,A
9025,Intermediate,,1,,9615.0,13545,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628137,,,A
9025,Intermediate,,1,,9615.0,13546,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628138,,,A
9025,Intermediate,,1,,9615.0,13547,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628139,,,A
9025,Intermediate,,1,,9615.0,13548,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628140,,,A
9025,Intermediate,,1,,9615.0,13549,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628141,,,A
9025,Intermediate,,1,,9615.0,13550,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628142,,,A
9025,Intermediate,,1,,9615.0,13551,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628143,,,A
9025,Intermediate,,1,,9615.0,13552,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628144,,,A
9025,Intermediate,,1,,9615.0,13553,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628145,,,A
9025,Intermediate,,1,,9615.0,13554,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL628146,,,A
9025,Intermediate,,1,,9615.0,13555,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625355,,,A
9025,Intermediate,,1,,9615.0,13556,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625356,,,A
9025,Intermediate,,1,,9615.0,13557,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625357,,,A
9025,Intermediate,,1,,9615.0,13558,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625527,,,A
9025,Intermediate,,1,,9615.0,13559,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL875473,,,A
9025,Intermediate,,1,,9615.0,13560,1,50588,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL625528,,,A
9025,Intermediate,,1,,10116.0,13561,1,50597,,In vivo,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626304,,,A
9025,Intermediate,,1,,9615.0,13562,1,50588,,In vivo,Artery,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,N,,Canis lupus familiaris,BAO_0000218,1637.0,CHEMBL624138,,,A
6448,Autocuration,,1,,,13563,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624139,,,P
17221,Autocuration,,1,,,13564,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624140,,,P
6545,Autocuration,,1,,,13565,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624141,,,P
577,Autocuration,,1,,,13566,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624142,,,P
6285,Autocuration,,1,,,13567,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624143,,,P
6500,Autocuration,,1,,,13568,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624144,,,P
6716,Autocuration,,1,,,13569,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624145,,,P
13658,Autocuration,,1,,,13570,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624146,,,P
6549,Autocuration,,1,,,13571,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624147,,,P
14685,Autocuration,,1,,,13572,0,22229,,,,Calculated partition coefficient (clogP) (MacLogP),,U,,,BAO_0000100,,CHEMBL883123,,,P
6893,Autocuration,,1,,,13573,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL624148,,,A
3687,Autocuration,,1,,,13574,0,22224,,,,Kinetic parameter was determined,,U,,,BAO_0000019,,CHEMBL874416,,,A
4207,Autocuration,,1,,,13575,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624149,,,P
4626,Autocuration,,1,,,13576,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL624150,,,P
1021,Autocuration,,1,,,13577,0,22224,,,,Lipophilicity was determined,,U,,,BAO_0000100,,CHEMBL624151,,,P
3777,Autocuration,,1,,,13578,0,22224,,,,Lipophilicity was determined,,U,,,BAO_0000100,,CHEMBL624152,,,P
17533,Autocuration,,1,,,13579,0,22224,,,,Lipophilicity was determined,,U,,,BAO_0000100,,CHEMBL622139,,,P
6524,Autocuration,,1,,,13580,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL622140,,,P
17533,Autocuration,,1,,,13581,0,22224,,,,Lipophilicity was determined,,U,,,BAO_0000100,,CHEMBL622141,,,P
6480,Autocuration,,1,,,13582,0,22224,,,,Lipophilicity in octanol-water,,U,,,BAO_0000100,,CHEMBL622142,,,P
17606,Autocuration,,1,,,13583,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL622143,,,P
6863,Autocuration,,1,,,13584,0,22229,,,,Octanol-water partition coefficient was determined,,U,,,BAO_0000100,,CHEMBL622144,,,P
1356,Autocuration,,1,,,13585,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL877473,,,A
3326,Autocuration,,1,,,13586,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL622145,,,P
1356,Autocuration,,1,,,13587,0,22224,,,,Partition coefficient was determined; ND means not determined,,U,,,BAO_0000019,,CHEMBL622146,,,A
12984,Autocuration,,1,,,13588,0,22229,,,,Calculated partition coefficient (clogP),,U,,,BAO_0000100,,CHEMBL622147,,,P
17363,Autocuration,,1,,,13589,0,22224,,,,Partition coefficient of the compound,,U,,,BAO_0000019,,CHEMBL622148,,,A
6827,Autocuration,,1,,,13590,0,22224,,,,Permeability was determined,,U,,,BAO_0000019,,CHEMBL883124,,,A
261,Autocuration,,1,,,13591,0,22229,,,,The compound was evaluated for the partition coefficient,,U,,,BAO_0000100,,CHEMBL622149,,,P
2685,Autocuration,,1,,,13592,0,22224,,,,Partition coefficient (logP),,U,,,BAO_0000019,,CHEMBL622150,,,A
414,Autocuration,,1,,,13593,0,22224,,,,The lipophilicity was reported,,U,,,BAO_0000100,,CHEMBL622151,,,P
15769,Autocuration,,1,,,13594,0,22229,,,,logarithm of the octanol-water partition coefficient for the compound,,U,,,BAO_0000100,,CHEMBL622152,,,P
17248,Autocuration,,1,,,13595,0,22224,,,,Clogp value was determined,,U,,,BAO_0000019,,CHEMBL622153,,,A
16935,Autocuration,,1,,,13596,0,22224,,In vivo,,Clp at a dose of 1.5 mg/kg,,U,,,BAO_0000218,,CHEMBL877474,,,A
16935,Autocuration,,1,,,13597,0,22224,,In vivo,,Clp at a dose of 2.0 mg/kg,,U,,,BAO_0000218,,CHEMBL622154,,,A
14832,Autocuration,,1,,,13598,0,22224,,In vivo,Plasma,"Clp, plasma clearance at a dose of 10 mg/kg",,U,,,BAO_0000218,1969.0,CHEMBL622155,,,A
14832,Autocuration,,1,,,13599,0,22224,,In vivo,Plasma,"Clp, plasma clearance at a dose of 50 mg/kg",,U,,,BAO_0000218,1969.0,CHEMBL622156,,,A
2399,Intermediate,,1,,10116.0,13600,1,50597,,In vivo,Plasma,Compound was tested for plasma clearance in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622157,,,A
2399,Intermediate,,1,,10116.0,13601,1,50597,,In vivo,Plasma,Compound was tested for plasma clearance in rat; Not determined,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622158,,,A
6227,Intermediate,,1,,10116.0,13602,1,50597,,In vivo,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622807,,,A
6227,Intermediate,,1,,9544.0,13603,1,50797,,In vivo,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,N,,Macaca mulatta,BAO_0000218,,CHEMBL622808,,,A
5623,Autocuration,,1,,,13604,0,22224,,In vivo,,Plasma clearance by iv administration at a dose 0.003 ug/mL,,U,,,BAO_0000218,,CHEMBL622809,,,A
4854,Autocuration,,1,,,13605,0,22224,,In vivo,,Plasma clearance determined,,U,,,BAO_0000218,,CHEMBL622810,,,A
4493,Intermediate,,1,,10026.0,13606,1,100712,,In vivo,,Plasma clearance after iv administration at 3 mg/kg in hamster,,N,,Cricetinae,BAO_0000218,,CHEMBL876653,,,A
4493,Intermediate,,1,,10026.0,13607,1,100712,,In vivo,,Plasma clearance after iv administration at 4 mg/kg in hamster,,N,,Cricetinae,BAO_0000218,,CHEMBL622811,,,A
14956,Intermediate,,1,,10116.0,13608,1,50597,,In vivo,,Rate of clearance in rat was determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622986,,,A
15372,Intermediate,,1,,10116.0,13609,1,50597,,In vivo,Plasma,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622987,,,A
15372,Intermediate,,1,,10116.0,13610,1,50597,,In vivo,Plasma,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622988,,,A
15372,Intermediate,,1,,10116.0,13611,1,50597,,In vivo,Plasma,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622989,,,A
15372,Intermediate,,1,,10116.0,13612,1,50597,,In vivo,Plasma,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622990,,,A
15604,Autocuration,,1,,314293.0,13613,0,22224,,In vivo,Plasma,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,U,,Simiiformes,BAO_0000218,1969.0,CHEMBL622991,,,A
15604,Intermediate,,1,,10116.0,13614,1,50597,,In vivo,Plasma,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL622227,,,A
15604,Intermediate,,1,,9615.0,13615,1,50588,,In vivo,Plasma,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL622228,,,A
14964,Intermediate,,1,,10116.0,13616,1,50597,,In vivo,,Clpl value in rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622229,,,A
15240,Intermediate,,1,,10141.0,13617,1,50512,,In vivo,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,N,,Cavia porcellus,BAO_0000218,,CHEMBL622230,,,A
16449,Intermediate,,1,,10116.0,13618,1,50597,,In vivo,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL622231,,,A
16449,Intermediate,,1,,9541.0,13619,1,100710,,In vivo,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,N,,Macaca fascicularis,BAO_0000218,,CHEMBL622232,,,A
12902,Autocuration,,1,,,13620,0,22224,,In vivo,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622233,,,A
12902,Autocuration,,1,,,13621,0,22224,,In vivo,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622234,,,A
12902,Autocuration,,1,,,13622,0,22224,,In vivo,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622235,,,A
12902,Autocuration,,1,,,13623,0,22224,,In vivo,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622236,,,A
12902,Autocuration,,1,,,13624,0,22224,,In vivo,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622237,,,A
12902,Autocuration,,1,,,13625,0,22224,,In vivo,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL877482,,,A
12902,Autocuration,,1,,,13626,0,22224,,In vivo,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622238,,,A
12902,Autocuration,,1,,,13627,0,22224,,In vivo,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,U,,,BAO_0000218,,CHEMBL622239,,,A
11149,Autocuration,,1,,,13628,0,22224,,In vivo,Blood,Cmax was calculated as maximum concentration reached in the blood,,U,,,BAO_0000218,178.0,CHEMBL622240,,,A
11149,Autocuration,,1,,,13629,0,22224,,In vivo,Blood,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,U,,,BAO_0000218,178.0,CHEMBL622241,,,A
5669,Intermediate,,1,,10116.0,13630,1,50597,,In vivo,,Cmax was determine after peroral administration at 10 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631013,,,A
5669,Intermediate,,1,,9544.0,13631,1,50797,,In vivo,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,N,,Macaca mulatta,BAO_0000218,,CHEMBL631014,,,A
5669,Intermediate,,1,,9615.0,13632,1,50588,,In vivo,,Cmax was determine after peroral administration at 10 mpk in dog,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631015,,,A
5669,Intermediate,,1,,10116.0,13633,1,50597,,In vivo,,Cmax was determine after peroral administration at 160 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631016,,,A
5669,Intermediate,,1,,10116.0,13634,1,50597,,In vivo,,Cmax was determine after peroral administration at 20 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631017,,,A
5669,Intermediate,,1,,10116.0,13635,1,50597,,In vivo,,Cmax was determine after peroral administration at 50 mpk in Rat,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631018,,,A
4236,Autocuration,,1,,,13636,0,22224,,In vivo,,Cmax was determined,,U,,,BAO_0000218,,CHEMBL631019,,,A
13792,Intermediate,,1,,10090.0,13637,1,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL875761,,,A
13792,Intermediate,,1,,10090.0,13638,1,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL631020,,,A
13792,Intermediate,,1,,10090.0,13639,1,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL631669,,,A
13792,Intermediate,,1,,10090.0,13640,1,50594,,,Brain,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,N,,Mus musculus,BAO_0000218,955.0,CHEMBL631670,,,A
13792,Intermediate,,1,,10090.0,13641,1,50594,,,Striatum,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,N,,Mus musculus,BAO_0000218,2435.0,CHEMBL631671,,,A
8418,Intermediate,,1,,10116.0,13642,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631672,,,A
8418,Intermediate,,1,,10116.0,13643,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631673,,,A
8418,Intermediate,,1,,10116.0,13644,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631856,,,A
8418,Intermediate,,1,,10116.0,13645,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631857,,,A
8418,Intermediate,,1,,10116.0,13646,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631858,,,A
8418,Intermediate,,1,,10116.0,13647,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631859,,,A
8418,Intermediate,,1,,10116.0,13648,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631860,,,A
8418,Intermediate,,1,,10116.0,13649,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631861,,,A
8418,Intermediate,,1,,10116.0,13650,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631862,,,A
8418,Intermediate,,1,,10116.0,13651,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631863,,,A
8418,Intermediate,,1,,10116.0,13652,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631864,,,A
8418,Intermediate,,1,,10116.0,13653,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631865,,,A
8418,Intermediate,,1,,10116.0,13654,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631866,,,A
8418,Intermediate,,1,,10116.0,13655,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629360,,,A
8418,Intermediate,,1,,10116.0,13656,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629361,,,A
8418,Intermediate,,1,,10116.0,13657,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL629362,,,A
8418,Intermediate,,1,,10116.0,13658,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630740,,,A
8418,Intermediate,,1,,10116.0,13659,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630741,,,A
8418,Intermediate,,1,,10116.0,13660,1,50597,,,Blood,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630742,,,A
8418,Intermediate,,1,,10116.0,13661,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630743,,,A
8418,Intermediate,,1,,10116.0,13662,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630744,,,A
8418,Intermediate,,1,,10116.0,13663,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630745,,,A
8418,Intermediate,,1,,10116.0,13664,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630746,,,A
8418,Intermediate,,1,,10116.0,13665,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630747,,,A
8418,Intermediate,,1,,10116.0,13666,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630748,,,A
8418,Intermediate,,1,,10116.0,13667,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632056,,,A
8418,Intermediate,,1,,10116.0,13668,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632057,,,A
8418,Intermediate,,1,,10116.0,13669,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632058,,,A
8418,Intermediate,,1,,10116.0,13670,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632059,,,A
8418,Intermediate,,1,,10116.0,13671,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632060,,,A
8418,Intermediate,,1,,10116.0,13672,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632061,,,A
8418,Intermediate,,1,,10116.0,13673,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629207,,,A
8418,Intermediate,,1,,10116.0,13674,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629208,,,A
8418,Intermediate,,1,,10116.0,13675,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629209,,,A
8418,Intermediate,,1,,10116.0,13676,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629210,,,A
8418,Intermediate,,1,,10116.0,13677,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629211,,,A
8418,Intermediate,,1,,10116.0,13678,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629212,,,A
8418,Intermediate,,1,,10116.0,13679,1,50597,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629213,,,A
8133,Intermediate,,1,,10116.0,13680,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629214,,,A
8133,Intermediate,,1,,10116.0,13681,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629215,,,A
8133,Intermediate,,1,,10116.0,13682,1,50597,,,Urine,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL635154,,,A
6996,Intermediate,,1,,10116.0,13683,1,50597,,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629216,,,A
6996,Intermediate,,1,,10116.0,13684,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629217,,,A
6996,Intermediate,,1,,10116.0,13685,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629218,,,A
6996,Intermediate,,1,,10116.0,13686,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629219,,,A
6996,Intermediate,,1,,10116.0,13687,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629220,,,A
6996,Intermediate,,1,,10116.0,13688,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629221,,,A
6996,Intermediate,,1,,10116.0,13689,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631127,,,A
6996,Intermediate,,1,,10116.0,13690,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631128,,,A
6996,Intermediate,,1,,10116.0,13691,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631129,,,A
6996,Intermediate,,1,,10116.0,13692,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631130,,,A
6996,Intermediate,,1,,10116.0,13693,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631131,,,A
6996,Intermediate,,1,,10116.0,13694,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631132,,,A
6996,Intermediate,,1,,10116.0,13695,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631133,,,A
6996,Intermediate,,1,,10116.0,13696,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631134,,,A
6996,Intermediate,,1,,10116.0,13697,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875120,,,A
6996,Intermediate,,1,,10116.0,13698,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631135,,,A
6996,Intermediate,,1,,10116.0,13699,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631136,,,A
6996,Intermediate,,1,,10116.0,13700,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631137,,,A
6996,Intermediate,,1,,10116.0,13701,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631138,,,A
6996,Intermediate,,1,,10116.0,13702,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631139,,,A
6996,Intermediate,,1,,10116.0,13703,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631140,,,A
6996,Intermediate,,1,,10116.0,13704,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631141,,,A
6996,Intermediate,,1,,10116.0,13705,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631142,,,A
6996,Intermediate,,1,,10116.0,13706,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631143,,,A
6996,Intermediate,,1,,10116.0,13707,1,50597,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631144,,,A
6996,Intermediate,,1,,9615.0,13708,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631145,,,A
6996,Intermediate,,1,,9615.0,13709,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631146,,,A
6996,Intermediate,,1,,9615.0,13710,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631147,,,A
6996,Intermediate,,1,,9615.0,13711,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631148,,,A
6996,Intermediate,,1,,9615.0,13712,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631149,,,A
6996,Intermediate,,1,,9615.0,13713,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631150,,,A
6996,Intermediate,,1,,9615.0,13714,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631151,,,A
6996,Intermediate,,1,,9615.0,13715,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631152,,,A
6996,Intermediate,,1,,9615.0,13716,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631443,,,A
6996,Intermediate,,1,,9615.0,13717,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631444,,,A
6996,Intermediate,,1,,9615.0,13718,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631445,,,A
6996,Intermediate,,1,,9615.0,13719,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631446,,,A
6996,Intermediate,,1,,9615.0,13720,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631447,,,A
6996,Intermediate,,1,,9615.0,13721,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631448,,,A
6996,Intermediate,,1,,9615.0,13722,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631449,,,A
6996,Intermediate,,1,,9615.0,13723,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL631450,,,A
6996,Intermediate,,1,,9615.0,13724,1,50588,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629724,,,A
9716,Intermediate,,1,,10090.0,13725,1,50594,,In vivo,Zone of skin,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,14.0,CHEMBL629725,,,A
9716,Intermediate,,1,,10090.0,13726,1,50594,,In vivo,Zone of skin,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,14.0,CHEMBL629726,,,A
9716,Intermediate,,1,,10090.0,13727,1,50594,,In vivo,Spleen,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL629727,,,A
9716,Intermediate,,1,,10090.0,13728,1,50594,,In vivo,Spleen,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL630404,,,A
9716,Intermediate,,1,,10090.0,13729,1,50594,,In vivo,Spleen,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL630405,,,A
9716,Intermediate,,1,,10090.0,13730,1,50594,,In vivo,Spleen,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL630406,,,A
9716,Intermediate,,1,,10090.0,13731,1,50594,,In vivo,Stomach,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,945.0,CHEMBL630407,,,A
9716,Intermediate,,1,,10090.0,13732,1,50594,,In vivo,Stomach,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,945.0,CHEMBL630573,,,A
9716,Intermediate,,1,,10090.0,13733,1,50594,,In vivo,Stomach,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,945.0,CHEMBL630574,,,A
9716,Intermediate,,1,,10090.0,13734,1,50594,,In vivo,Stomach,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,945.0,CHEMBL630575,,,A
9716,Intermediate,,1,,10090.0,13735,1,50594,,In vivo,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,,CHEMBL630576,,,A
9716,Intermediate,,1,,10090.0,13736,1,50594,,In vivo,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,,CHEMBL630577,,,A
9716,Intermediate,,1,,10090.0,13737,1,50594,,In vivo,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,,CHEMBL630578,,,A
9716,Intermediate,,1,,10090.0,13738,1,50594,,In vivo,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,N,,Mus musculus,BAO_0000218,,CHEMBL630579,,,A
12192,Intermediate,,1,,10090.0,13739,1,50594,,,Kidney,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL630580,,,A
12192,Intermediate,,1,,10090.0,13740,1,50594,,,Kidney,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL630581,,,A
12192,Intermediate,,1,,10090.0,13741,1,50594,,,Kidney,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL630582,,,A
12192,Intermediate,,1,,10090.0,13742,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,N,,Mus musculus,BAO_0000218,,CHEMBL630583,,,A
12192,Intermediate,,1,,10090.0,13743,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,N,,Mus musculus,BAO_0000218,,CHEMBL630584,,,A
12192,Intermediate,,1,,10090.0,13744,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,N,,Mus musculus,BAO_0000218,,CHEMBL630585,,,A
12192,Intermediate,,1,,10090.0,13745,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,N,,Mus musculus,BAO_0000218,,CHEMBL630586,,,A
12192,Intermediate,,1,,10090.0,13746,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,N,,Mus musculus,BAO_0000218,,CHEMBL630587,,,A
12192,Intermediate,,1,,10090.0,13747,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,N,,Mus musculus,BAO_0000218,,CHEMBL630588,,,A
12192,Intermediate,,1,,10090.0,13748,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,N,,Mus musculus,BAO_0000218,,CHEMBL630589,,,A
12192,Intermediate,,1,,10090.0,13749,1,50594,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,N,,Mus musculus,BAO_0000218,,CHEMBL630590,,,A
12192,Autocuration,,1,,,13750,0,22224,,,Feces,Removal of 238-Plutonium(IV) in feces at 24 h,,U,,,BAO_0000019,1988.0,CHEMBL630591,,,A
12192,Autocuration,,1,,,13751,0,22224,,,Feces,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,U,,,BAO_0000019,1988.0,CHEMBL630592,,,A
12192,Autocuration,,1,,,13752,0,22224,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,U,,,BAO_0000019,,CHEMBL630593,,,A
12192,Autocuration,,1,,,13753,0,22224,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,U,,,BAO_0000019,,CHEMBL630594,,,A
12192,Autocuration,,1,,,13754,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630595,,,A
12192,Autocuration,,1,,,13755,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630596,,,A
12192,Autocuration,,1,,,13756,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-24 h,,U,,,BAO_0000019,1088.0,CHEMBL630597,,,A
12192,Autocuration,,1,,,13757,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630598,,,A
12192,Autocuration,,1,,,13758,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-4 h,,U,,,BAO_0000019,1088.0,CHEMBL630599,,,A
12192,Autocuration,,1,,,13759,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630600,,,A
12192,Autocuration,,1,,,13760,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 4-24 h,,U,,,BAO_0000019,1088.0,CHEMBL630601,,,A
12192,Autocuration,,1,,,13761,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630602,,,A
12192,Autocuration,,1,,,13762,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630603,,,A
12192,Autocuration,,1,,,13763,0,22224,,,Urine,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,U,,,BAO_0000019,1088.0,CHEMBL630604,,,A
12017,Intermediate,,1,,10116.0,13764,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624869,,,A
12017,Intermediate,,1,,10116.0,13765,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL624870,,,A
12017,Intermediate,,1,,10116.0,13766,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623189,,,A
12017,Intermediate,,1,,10116.0,13767,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623190,,,A
12017,Intermediate,,1,,10116.0,13768,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623191,,,A
12017,Intermediate,,1,,10116.0,13769,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623192,,,A
12017,Intermediate,,1,,10116.0,13770,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623193,,,A
12017,Intermediate,,1,,10116.0,13771,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623194,,,A
12017,Intermediate,,1,,10116.0,13772,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623195,,,A
12017,Intermediate,,1,,10116.0,13773,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623196,,,A
11836,Intermediate,,1,,10116.0,13774,1,50597,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623197,,,A
11836,Intermediate,,1,,10116.0,13775,1,50597,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623198,,,A
11836,Intermediate,,1,,10116.0,13776,1,50597,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623199,,,A
11836,Intermediate,,1,,10116.0,13777,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623200,,,A
11836,Intermediate,,1,,10116.0,13778,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623201,,,A
11836,Intermediate,,1,,10116.0,13779,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623202,,,A
11836,Intermediate,,1,,10116.0,13780,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623203,,,A
11836,Intermediate,,1,,10116.0,13781,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623204,,,A
11836,Intermediate,,1,,10116.0,13782,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623205,,,A
11836,Intermediate,,1,,10116.0,13783,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623206,,,A
11836,Intermediate,,1,,10116.0,13784,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623207,,,A
11836,Intermediate,,1,,10116.0,13785,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623208,,,A
11836,Intermediate,,1,,10116.0,13786,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623209,,,A
11836,Intermediate,,1,,10116.0,13787,1,50597,,,Muscle tissue,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL623210,,,A
11836,Intermediate,,1,,10116.0,13788,1,50597,,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623211,,,A
11836,Intermediate,,1,,10116.0,13789,1,50597,,,Uterus,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL623212,,,A
12640,Autocuration,,1,,,13790,0,22224,,,,Tested in vitro for intrinsic activity relative to quinpirole,,U,,,BAO_0000019,,CHEMBL623213,,,A
14218,Autocuration,,1,,,13791,0,22224,,,,"Relative ion enhancement, determined in pulsed ultrafiltration",,U,,,BAO_0000019,,CHEMBL623214,,,A
11296,Autocuration,,1,,,13792,0,22224,,,,% ionization at the pH 7.4 at 37 degree Centigrade,,U,,,BAO_0000019,,CHEMBL623215,,,A
10929,Autocuration,,1,,,13793,0,22224,,,,Percentage ionization was measured,,U,,,BAO_0000019,,CHEMBL623216,,,A
13841,Intermediate,,1,,9913.0,13794,1,50591,,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,N,,Bos taurus,BAO_0000218,,CHEMBL623217,,,A
10431,Autocuration,,1,,,13795,0,22224,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,U,,,BAO_0000019,,CHEMBL623218,,,A
10431,Autocuration,,1,,,13796,0,22224,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,U,,,BAO_0000019,,CHEMBL623913,,,A
10431,Autocuration,,1,,,13797,0,22224,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,U,,,BAO_0000019,,CHEMBL623914,,,A
8826,Autocuration,,1,,,13798,0,22229,,,,Compound was evaluated for the partition coefficient in octanol/water,,U,,,BAO_0000100,,CHEMBL623915,,,P
8826,Autocuration,,1,,,13799,0,22229,,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,U,,,BAO_0000100,,CHEMBL624080,,,P
9884,Autocuration,,1,,,13800,0,22224,,,,Equilibrium constant measured by the pulse radiolysis at pH 7,,U,,,BAO_0000019,,CHEMBL624081,,,A
9827,Intermediate,,1,,9606.0,13801,1,50587,,,,In vitro hydrolytic rate constant determined in human blood,,N,,Homo sapiens,BAO_0000218,,CHEMBL624082,,,A
10009,Intermediate,,1,,9606.0,13802,1,50587,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,N,,Homo sapiens,BAO_0000218,,CHEMBL625054,,,A
10009,Autocuration,,1,,,13803,0,22224,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,U,,,BAO_0000019,,CHEMBL877485,,,A
10009,Intermediate,,1,,10090.0,13804,1,50594,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,N,,Mus musculus,BAO_0000218,,CHEMBL625055,,,A
10009,Intermediate,,1,,10090.0,13805,1,50594,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,N,,Mus musculus,BAO_0000218,,CHEMBL625056,,,A
10009,Intermediate,,1,,9606.0,13806,1,50587,,,,In vitro oxidation of compound in presence of human plasma,,N,,Homo sapiens,BAO_0000218,,CHEMBL625057,,,A
10009,Autocuration,,1,,,13807,0,22224,,,,In vitro oxidation of compound in presence of hydrogen peroxide,,U,,,BAO_0000019,,CHEMBL625058,,,A
10009,Intermediate,,1,,10090.0,13808,1,50594,,,,In vitro oxidation of compound in presence of mouse brain homogenate,,N,,Mus musculus,BAO_0000218,,CHEMBL625059,,,A
10009,Intermediate,,1,,10090.0,13809,1,50594,,,,In vitro oxidation of compound in presence of mouse liver homogenate,,N,,Mus musculus,BAO_0000218,,CHEMBL629536,,,A
11510,Intermediate,,1,,10116.0,13810,1,50597,,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629537,,,A
11510,Intermediate,,1,,10116.0,13811,1,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629538,,,A
11510,Intermediate,,1,,10116.0,13812,1,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629539,,,A
11510,Intermediate,,1,,10116.0,13813,1,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL874445,,,A
11510,Intermediate,,1,,10116.0,13814,1,50597,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629540,,,A
11510,Intermediate,,1,,10116.0,13815,1,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629541,,,A
11510,Intermediate,,1,,10116.0,13816,1,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629542,,,A
11510,Intermediate,,1,,10116.0,13817,1,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630243,,,A
11510,Intermediate,,1,,10116.0,13818,1,50597,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630244,,,A
11510,Intermediate,,1,,10116.0,13819,1,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630245,,,A
11510,Intermediate,,1,,10116.0,13820,1,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630246,,,A
11510,Intermediate,,1,,10116.0,13821,1,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630247,,,A
11510,Intermediate,,1,,10116.0,13822,1,50597,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630248,,,A
13100,Intermediate,,1,,10116.0,13823,1,50597,,In vivo,Blood,Biodistribution in rat blood at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630249,,,A
13100,Intermediate,,1,,10116.0,13824,1,50597,,In vivo,Blood,Biodistribution in rat blood at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630250,,,A
13100,Intermediate,,1,,10116.0,13825,1,50597,,In vivo,Blood,Biodistribution in rat blood at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630251,,,A
13100,Intermediate,,1,,10116.0,13826,1,50597,,In vivo,Blood,Biodistribution in rat blood at 3 hr after dose administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630252,,,A
13100,Intermediate,,1,,10116.0,13827,1,50597,,In vivo,Blood,Biodistribution in rat blood at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL630408,,,A
13100,Intermediate,,1,,10116.0,13828,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630409,,,A
13100,Intermediate,,1,,10116.0,13829,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL874446,,,A
13100,Intermediate,,1,,10116.0,13830,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630410,,,A
13100,Intermediate,,1,,10116.0,13831,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630411,,,A
13100,Intermediate,,1,,10116.0,13832,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630412,,,A
13100,Intermediate,,1,,10116.0,13833,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630413,,,A
13100,Intermediate,,1,,10116.0,13834,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 3 hr after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630414,,,A
13100,Intermediate,,1,,10116.0,13835,1,50597,,In vivo,Cerebellum,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL630415,,,A
13100,Intermediate,,1,,10116.0,13836,1,50597,,In vivo,,Biodistribution in rat cortex at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630416,,,A
13100,Intermediate,,1,,10116.0,13837,1,50597,,In vivo,,Biodistribution in rat cortex at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630417,,,A
13100,Intermediate,,1,,10116.0,13838,1,50597,,In vivo,,Biodistribution in rat cortex at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630418,,,A
13100,Intermediate,,1,,10116.0,13839,1,50597,,In vivo,,Biodistribution in rat cortex at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630419,,,A
13100,Intermediate,,1,,10116.0,13840,1,50597,,In vivo,,Biodistribution in rat cortex at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630420,,,A
13100,Intermediate,,1,,10116.0,13841,1,50597,,In vivo,,Biodistribution in rat cortex at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630421,,,A
13100,Intermediate,,1,,10116.0,13842,1,50597,,In vivo,,Biodistribution in rat cortex at 3 hr after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630422,,,A
13100,Intermediate,,1,,10116.0,13843,1,50597,,In vivo,,Biodistribution in rat cortex at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630423,,,A
13100,Intermediate,,1,,10116.0,13844,1,50597,,In vivo,Heart,Biodistribution in rat heart at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630424,,,A
13100,Intermediate,,1,,10116.0,13845,1,50597,,In vivo,Heart,Biodistribution in rat heart at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630425,,,A
13100,Intermediate,,1,,10116.0,13846,1,50597,,In vivo,Heart,Biodistribution in rat heart at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL629462,,,A
13100,Intermediate,,1,,10116.0,13847,1,50597,,In vivo,Heart,Biodistribution in rat heart at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630426,,,A
13100,Intermediate,,1,,10116.0,13848,1,50597,,In vivo,Heart,Biodistribution in rat heart at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL630427,,,A
13100,Intermediate,,1,,10116.0,13849,1,50597,,In vivo,Heart,Biodistribution in rat heart at 3 hr after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625877,,,A
13100,Intermediate,,1,,10116.0,13850,1,50597,,In vivo,Heart,Biodistribution in rat heart at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625878,,,A
13100,Intermediate,,1,,10116.0,13851,1,50597,,In vivo,Hippocampus,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625879,,,A
13100,Intermediate,,1,,10116.0,13852,1,50597,,In vivo,Hippocampus,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625880,,,A
13100,Intermediate,,1,,10116.0,13853,1,50597,,In vivo,Hippocampus,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625881,,,A
13100,Intermediate,,1,,10116.0,13854,1,50597,,In vivo,Hippocampus,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625882,,,A
13100,Intermediate,,1,,10116.0,13855,1,50597,,In vivo,Hippocampus,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625883,,,A
13100,Intermediate,,1,,10116.0,13856,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625884,,,A
13100,Intermediate,,1,,10116.0,13857,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625885,,,A
13100,Intermediate,,1,,10116.0,13858,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628649,,,A
13100,Intermediate,,1,,10116.0,13859,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628650,,,A
13100,Intermediate,,1,,10116.0,13860,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628651,,,A
13100,Intermediate,,1,,10116.0,13861,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628652,,,A
13100,Intermediate,,1,,10116.0,13862,1,50597,,In vivo,Kidney,Biodistribution in rat kidney at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL628653,,,A
13100,Intermediate,,1,,10116.0,13863,1,50597,,In vivo,Liver,Biodistribution in rat liver at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628654,,,A
13100,Intermediate,,1,,10116.0,13864,1,50597,,In vivo,Liver,Biodistribution in rat liver at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL628655,,,A
13100,Intermediate,,1,,10116.0,13865,1,50597,,In vivo,Liver,Biodistribution in rat liver at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625238,,,A
13100,Intermediate,,1,,10116.0,13866,1,50597,,In vivo,Liver,Biodistribution in rat liver at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625239,,,A
13100,Intermediate,,1,,10116.0,13867,1,50597,,In vivo,Liver,Biodistribution in rat liver at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625240,,,A
13100,Intermediate,,1,,10116.0,13868,1,50597,,In vivo,Liver,Biodistribution in rat liver at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625241,,,A
13100,Intermediate,,1,,10116.0,13869,1,50597,,In vivo,Liver,Biodistribution in rat liver at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625242,,,A
13100,Intermediate,,1,,10116.0,13870,1,50597,,In vivo,Lung,Biodistribution in rat lung at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL874587,,,A
13100,Intermediate,,1,,10116.0,13871,1,50597,,In vivo,Lung,Biodistribution in rat lung at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625405,,,A
13100,Intermediate,,1,,10116.0,13872,1,50597,,In vivo,Lung,Biodistribution in rat lung at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625406,,,A
13100,Intermediate,,1,,10116.0,13873,1,50597,,In vivo,Lung,Biodistribution in rat lung at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625407,,,A
13100,Intermediate,,1,,10116.0,13874,1,50597,,In vivo,Lung,Biodistribution in rat lung at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625408,,,A
13100,Intermediate,,1,,10116.0,13875,1,50597,,In vivo,Lung,Biodistribution in rat lung at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625409,,,A
12361,Intermediate,,1,,10116.0,13876,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625410,,,A
12361,Intermediate,,1,,10116.0,13877,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625411,,,A
12361,Intermediate,,1,,10116.0,13878,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625412,,,A
12361,Intermediate,,1,,10116.0,13879,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625413,,,A
12361,Intermediate,,1,,10116.0,13880,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625414,,,A
12361,Intermediate,,1,,10116.0,13881,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625415,,,A
12361,Intermediate,,1,,10116.0,13882,1,50597,,,Thoracic aorta,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,N,,Rattus norvegicus,BAO_0000218,1515.0,CHEMBL625416,,,A
12712,Intermediate,,1,,10116.0,13883,1,50597,,,Urine,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625417,,,A
7415,Intermediate,,1,,10116.0,13884,1,50597,,,Feces,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL625418,,,A
7415,Intermediate,,1,,10116.0,13885,1,50597,,,Urine,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625419,,,A
7415,Intermediate,,1,,10116.0,13886,1,50597,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625420,,,A
7415,Intermediate,,1,,10116.0,13887,1,50597,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626996,,,A
7415,Intermediate,,1,,10116.0,13888,1,50597,,,Feces,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL626997,,,A
7415,Intermediate,,1,,10116.0,13889,1,50597,,,Urine,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626998,,,A
7415,Intermediate,,1,,10116.0,13890,1,50597,,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626999,,,A
8050,Intermediate,,1,,10090.0,13891,1,50594,,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,N,,Mus musculus,BAO_0000218,,CHEMBL627000,,,A
8050,Intermediate,,1,,10090.0,13892,1,50594,,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,N,,Mus musculus,BAO_0000218,,CHEMBL627001,,,A
8050,Intermediate,,1,,10090.0,13893,1,50594,,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,N,,Mus musculus,BAO_0000218,,CHEMBL627002,,,A
8050,Intermediate,,1,,10090.0,13894,1,50594,,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,N,,Mus musculus,BAO_0000218,,CHEMBL627003,,,A
8050,Intermediate,,1,,10090.0,13895,1,50594,,,Urine,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627004,,,A
8050,Intermediate,,1,,10090.0,13896,1,50594,,,Urine,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627005,,,A
8050,Intermediate,,1,,10090.0,13897,1,50594,,,Urine,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL874594,,,A
8050,Intermediate,,1,,10090.0,13898,1,50594,,,Urine,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627006,,,A
8050,Intermediate,,1,,10090.0,13899,1,50594,,,Urine,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627007,,,A
8050,Intermediate,,1,,10090.0,13900,1,50594,,,Urine,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627884,,,A
8050,Intermediate,,1,,10090.0,13901,1,50594,,,Urine,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627885,,,A
8050,Intermediate,,1,,10090.0,13902,1,50594,,,Urine,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627886,,,A
8050,Intermediate,,1,,10090.0,13903,1,50594,,,Urine,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627887,,,A
8050,Intermediate,,1,,10090.0,13904,1,50594,,,Urine,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627888,,,A
8050,Intermediate,,1,,10090.0,13905,1,50594,,,Urine,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL628057,,,A
8050,Intermediate,,1,,10090.0,13906,1,50594,,,Urine,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627405,,,A
12582,Intermediate,,1,,9615.0,13907,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627406,,,A
12582,Intermediate,,1,,9615.0,13908,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627407,,,A
12582,Intermediate,,1,,9615.0,13909,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627408,,,A
12582,Intermediate,,1,,9615.0,13910,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627409,,,A
12582,Intermediate,,1,,9615.0,13911,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL875486,,,A
12582,Intermediate,,1,,9615.0,13912,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627410,,,A
12582,Intermediate,,1,,9615.0,13913,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627411,,,A
12582,Intermediate,,1,,9615.0,13914,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627412,,,A
12582,Intermediate,,1,,9615.0,13915,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627413,,,A
12582,Intermediate,,1,,9615.0,13916,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627414,,,A
12582,Intermediate,,1,,9615.0,13917,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627415,,,A
12582,Intermediate,,1,,9615.0,13918,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627416,,,A
12582,Intermediate,,1,,9615.0,13919,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627417,,,A
12582,Intermediate,,1,,9615.0,13920,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627418,,,A
12582,Intermediate,,1,,9615.0,13921,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627419,,,A
12582,Intermediate,,1,,9615.0,13922,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627320,,,A
12582,Intermediate,,1,,9615.0,13923,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627321,,,A
12017,Intermediate,,1,,10116.0,13924,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627322,,,A
12017,Intermediate,,1,,10116.0,13925,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627323,,,A
12017,Intermediate,,1,,10116.0,13926,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627491,,,A
12017,Intermediate,,1,,10116.0,13927,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627492,,,A
12017,Intermediate,,1,,10116.0,13928,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL627493,,,A
12017,Intermediate,,1,,10116.0,13929,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627494,,,A
12017,Intermediate,,1,,10116.0,13930,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627495,,,A
12017,Intermediate,,1,,10116.0,13931,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627496,,,A
12017,Intermediate,,1,,10116.0,13932,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627497,,,A
12017,Intermediate,,1,,10116.0,13933,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL627498,,,A
12017,Intermediate,,1,,10116.0,13934,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627499,,,A
12017,Intermediate,,1,,10116.0,13935,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627500,,,A
12017,Intermediate,,1,,10116.0,13936,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627501,,,A
12017,Intermediate,,1,,10116.0,13937,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625616,,,A
12017,Intermediate,,1,,10116.0,13938,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625617,,,A
12017,Intermediate,,1,,10116.0,13939,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625618,,,A
12017,Intermediate,,1,,10116.0,13940,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625619,,,A
12017,Intermediate,,1,,10116.0,13941,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625620,,,A
12017,Intermediate,,1,,10116.0,13942,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625621,,,A
12017,Intermediate,,1,,10116.0,13943,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625622,,,A
12017,Intermediate,,1,,10116.0,13944,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625788,,,A
12017,Intermediate,,1,,10116.0,13945,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625789,,,A
12017,Intermediate,,1,,10116.0,13946,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625790,,,A
12017,Intermediate,,1,,10116.0,13947,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625791,,,A
12017,Intermediate,,1,,10116.0,13948,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL622334,,,A
12017,Intermediate,,1,,10116.0,13949,1,50597,,In vivo,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622335,,,A
12017,Intermediate,,1,,10116.0,13950,1,50597,,In vivo,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622336,,,A
12017,Intermediate,,1,,10116.0,13951,1,50597,,In vivo,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622337,,,A
12017,Intermediate,,1,,10116.0,13952,1,50597,,In vivo,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622338,,,A
12017,Intermediate,,1,,10116.0,13953,1,50597,,In vivo,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL622339,,,A
12017,Intermediate,,1,,10116.0,13954,1,50597,,In vivo,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL624153,,,A
12017,Intermediate,,1,,10116.0,13955,1,50597,,In vivo,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628430,,,A
12017,Intermediate,,1,,10116.0,13956,1,50597,,In vivo,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628431,,,A
12017,Intermediate,,1,,10116.0,13957,1,50597,,In vivo,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628432,,,A
12017,Intermediate,,1,,10116.0,13958,1,50597,,In vivo,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628433,,,A
12017,Intermediate,,1,,10116.0,13959,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL628434,,,A
12017,Intermediate,,1,,10116.0,13960,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL626789,,,A
12017,Intermediate,,1,,10116.0,13961,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL626790,,,A
12017,Intermediate,,1,,10116.0,13962,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL626791,,,A
12017,Intermediate,,1,,10116.0,13963,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL626792,,,A
12017,Intermediate,,1,,10116.0,13964,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL626793,,,A
11510,Intermediate,,1,,10116.0,13965,1,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627436,,,A
11510,Intermediate,,1,,10116.0,13966,1,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627437,,,A
11510,Intermediate,,1,,10116.0,13967,1,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627438,,,A
11510,Intermediate,,1,,10116.0,13968,1,50597,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627439,,,A
11510,Intermediate,,1,,10116.0,13969,1,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627440,,,A
11510,Intermediate,,1,,10116.0,13970,1,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627602,,,A
11510,Intermediate,,1,,10116.0,13971,1,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627603,,,A
11510,Intermediate,,1,,10116.0,13972,1,50597,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627604,,,A
11510,Intermediate,,1,,10116.0,13973,1,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627605,,,A
11510,Intermediate,,1,,10116.0,13974,1,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627606,,,A
11510,Intermediate,,1,,10116.0,13975,1,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627607,,,A
11510,Intermediate,,1,,10116.0,13976,1,50597,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627608,,,A
11510,Intermediate,,1,,10116.0,13977,1,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627609,,,A
11510,Intermediate,,1,,10116.0,13978,1,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627610,,,A
11510,Intermediate,,1,,10116.0,13979,1,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627611,,,A
11510,Intermediate,,1,,10116.0,13980,1,50597,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627612,,,A
8362,Autocuration,,1,,,13981,0,22229,,,,Octanol:water partition coefficient is evaluated,,U,,,BAO_0000100,,CHEMBL627613,,,P
8257,Autocuration,,1,,,13982,0,22224,,,,Partition coefficient in 1-octanol/water system,,U,,,BAO_0000100,,CHEMBL627614,,,P
8257,Autocuration,,1,,,13983,0,22224,,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,,U,,,BAO_0000100,,CHEMBL627615,,,P
9468,Autocuration,,1,,,13984,0,22224,,,,Partition coefficient in octanol/water system was determined,,U,,,BAO_0000100,,CHEMBL627616,,,P
9468,Autocuration,,1,,,13985,0,22224,,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,U,,,BAO_0000100,,CHEMBL627617,,,P
10568,Autocuration,,1,,,13986,0,22224,,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,U,,,BAO_0000019,,CHEMBL627618,,,A
10568,Autocuration,,1,,,13987,0,22224,,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,U,,,BAO_0000019,,CHEMBL627619,,,A
15359,Autocuration,,1,,,13988,0,22224,,,,Pseudo-first-order rate constant of the compound,,U,,,BAO_0000019,,CHEMBL627620,,,A
15359,Autocuration,,1,,,13989,0,22224,,,,Pseudo-first-order rate constant with 1-min time point,,U,,,BAO_0000019,,CHEMBL627621,,,A
15359,Autocuration,,1,,,13990,0,22224,,,,Pseudo-first-order rate constant without 1-min time point,,U,,,BAO_0000019,,CHEMBL627622,,,A
10431,Autocuration,,1,,,13991,0,22224,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,U,,,BAO_0000019,,CHEMBL627623,,,A
10431,Autocuration,,1,,,13992,0,22224,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,U,,,BAO_0000019,,CHEMBL627624,,,A
10431,Autocuration,,1,,,13993,0,22224,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,U,,,BAO_0000019,,CHEMBL627625,,,A
15704,Autocuration,,1,,,13994,0,22224,,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,U,,,BAO_0000019,,CHEMBL628523,,,A
15287,Autocuration,,1,,,13995,0,22224,,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,,U,,,BAO_0000019,,CHEMBL628524,,,A
7516,Autocuration,,1,,,13996,0,22224,,,,The efflux rate constant of the compound,,U,,,BAO_0000019,,CHEMBL628525,,,A
12973,Autocuration,,1,,,13997,0,22224,,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,U,,,BAO_0000019,,CHEMBL625732,,,A
12973,Autocuration,,1,,,13998,0,22224,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,U,,,BAO_0000019,,CHEMBL625733,,,A
12973,Autocuration,,1,,,13999,0,22224,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,U,,,BAO_0000019,,CHEMBL625734,,,F
12973,Autocuration,,1,,,14000,0,22224,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,U,,,BAO_0000019,,CHEMBL625913,,,A
8696,Autocuration,,1,,,14001,0,22224,,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,U,,,BAO_0000019,,CHEMBL625914,,,A
15052,Autocuration,,1,,,14002,0,22224,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,U,,,BAO_0000019,,CHEMBL625915,,,A
15052,Autocuration,,1,,,14003,0,22224,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,U,,,BAO_0000019,,CHEMBL625916,,,A
10503,Autocuration,,1,,,14004,0,22224,,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,U,,,BAO_0000019,,CHEMBL625917,,,A
8354,Autocuration,,1,,,14005,0,22224,,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625918,,,A
8354,Autocuration,,1,,,14006,0,22224,,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625919,,,A
8354,Autocuration,,1,,,14007,0,22224,,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625920,,,A
8354,Autocuration,,1,,,14008,0,22224,,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL874453,,,A
8354,Autocuration,,1,,,14009,0,22224,,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625921,,,A
10503,Autocuration,,1,,,14010,0,22224,,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,U,,,BAO_0000019,,CHEMBL625922,,,A
8354,Autocuration,,1,,,14011,0,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625923,,,A
8354,Autocuration,,1,,,14012,0,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625924,,,A
8354,Autocuration,,1,,,14013,0,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625925,,,A
8354,Autocuration,,1,,,14014,0,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL625926,,,A
13100,Intermediate,,1,,10116.0,14015,1,50597,,In vivo,Lung,Biodistribution in rat lung at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL627704,,,A
13100,Intermediate,,1,,10116.0,14016,1,50597,,In vivo,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627705,,,A
13100,Intermediate,,1,,10116.0,14017,1,50597,,In vivo,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627706,,,A
13100,Intermediate,,1,,10116.0,14018,1,50597,,In vivo,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627707,,,A
13100,Intermediate,,1,,10116.0,14019,1,50597,,In vivo,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627708,,,A
13100,Intermediate,,1,,10116.0,14020,1,50597,,In vivo,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628361,,,A
13100,Intermediate,,1,,10116.0,14021,1,50597,,In vivo,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628362,,,A
13100,Intermediate,,1,,10116.0,14022,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628363,,,A
13100,Intermediate,,1,,10116.0,14023,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628364,,,A
13100,Intermediate,,1,,10116.0,14024,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628365,,,A
13100,Intermediate,,1,,10116.0,14025,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL874454,,,A
13100,Intermediate,,1,,10116.0,14026,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628531,,,A
13100,Intermediate,,1,,10116.0,14027,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628532,,,A
13100,Intermediate,,1,,10116.0,14028,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 3 hr after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628533,,,A
13100,Intermediate,,1,,10116.0,14029,1,50597,,In vivo,Striatum,Biodistribution in rat striatum at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2435.0,CHEMBL628534,,,A
13100,Intermediate,,1,,10116.0,14030,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL628535,,,A
13100,Intermediate,,1,,10116.0,14031,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL628536,,,A
13100,Intermediate,,1,,10116.0,14032,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL628537,,,A
13100,Intermediate,,1,,10116.0,14033,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL628538,,,A
13100,Intermediate,,1,,10116.0,14034,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL628539,,,A
13100,Intermediate,,1,,10116.0,14035,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630297,,,A
13100,Intermediate,,1,,10116.0,14036,1,50597,,In vivo,Thyroid gland,Biodistribution in rat thyroid at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL630298,,,A
13100,Intermediate,,1,,10116.0,14037,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL630299,,,A
13100,Intermediate,,1,,10116.0,14038,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL628094,,,A
13100,Intermediate,,1,,10116.0,14039,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL628095,,,A
13100,Intermediate,,1,,10116.0,14040,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL874648,,,A
13100,Intermediate,,1,,10116.0,14041,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL628096,,,A
13100,Intermediate,,1,,10116.0,14042,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL628097,,,A
13100,Intermediate,,1,,10116.0,14043,1,50597,,In vivo,Brain,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL628098,,,A
13331,Autocuration,,1,,,14044,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,U,,,BAO_0000019,,CHEMBL628099,,,A
13331,Autocuration,,1,,,14045,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,U,,,BAO_0000019,,CHEMBL628100,,,A
13331,Autocuration,,1,,,14046,0,22224,,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,U,,,BAO_0000019,,CHEMBL628101,,,A
13331,Autocuration,,1,,,14047,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,U,,,BAO_0000019,,CHEMBL628102,,,A
13331,Autocuration,,1,,,14048,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,U,,,BAO_0000019,,CHEMBL628103,,,A
13331,Autocuration,,1,,,14049,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,U,,,BAO_0000019,,CHEMBL628104,,,A
13331,Autocuration,,1,,,14050,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,U,,,BAO_0000019,,CHEMBL628105,,,A
13331,Autocuration,,1,,,14051,0,22224,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,U,,,BAO_0000019,,CHEMBL628106,,,A
10086,Intermediate,,1,,10116.0,14052,1,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628107,,,A
10086,Autocuration,,1,,,14053,0,22224,,,Urine,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,U,,,BAO_0000218,1088.0,CHEMBL628108,,,F
10086,Intermediate,,1,,10116.0,14054,1,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628109,,,A
10086,Autocuration,,1,,,14055,0,22224,,,Urine,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,U,,,BAO_0000218,1088.0,CHEMBL625299,,,F
10086,Intermediate,,1,,10116.0,14056,1,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625300,,,A
10086,Intermediate,,1,,10116.0,14057,1,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625301,,,A
10086,Intermediate,,1,,10116.0,14058,1,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625302,,,A
10086,Intermediate,,1,,10116.0,14059,1,50597,,,Urine,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL874649,,,A
13248,Intermediate,,1,,10116.0,14060,1,50597,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625303,,,A
13248,Intermediate,,1,,10116.0,14061,1,50597,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625463,,,A
14527,Intermediate,,1,,9606.0,14062,1,50587,,,Liver,In vitro metabolism in human liver microsomes,,N,,Homo sapiens,BAO_0000218,2107.0,CHEMBL625464,,,A
3008,Intermediate,,1,,9606.0,14063,1,50587,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,N,,Homo sapiens,BAO_0000218,,CHEMBL625465,,,A
12582,Intermediate,,1,,9615.0,14064,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625466,,,A
12582,Intermediate,,1,,9615.0,14065,1,50588,,,Urine,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625467,,,A
12582,Intermediate,,1,,10116.0,14066,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625468,,,A
12582,Intermediate,,1,,10116.0,14067,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625469,,,A
12582,Intermediate,,1,,10116.0,14068,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625470,,,A
12582,Intermediate,,1,,10116.0,14069,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL632418,,,A
12582,Intermediate,,1,,10116.0,14070,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627250,,,A
12582,Intermediate,,1,,10116.0,14071,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627251,,,A
12582,Intermediate,,1,,10116.0,14072,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627252,,,A
12582,Intermediate,,1,,10116.0,14073,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627253,,,A
12582,Intermediate,,1,,10116.0,14074,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627254,,,A
12582,Intermediate,,1,,10116.0,14075,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875471,,,A
12582,Intermediate,,1,,10116.0,14076,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627255,,,A
12582,Intermediate,,1,,10116.0,14077,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627256,,,A
12582,Intermediate,,1,,10116.0,14078,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627257,,,A
12582,Intermediate,,1,,10116.0,14079,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627258,,,A
12582,Intermediate,,1,,10116.0,14080,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627259,,,A
12582,Intermediate,,1,,10116.0,14081,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627260,,,A
12582,Intermediate,,1,,10116.0,14082,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623256,,,A
12582,Intermediate,,1,,10116.0,14083,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL874413,,,A
12582,Intermediate,,1,,10116.0,14084,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623257,,,A
12582,Intermediate,,1,,10116.0,14085,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623258,,,A
12582,Intermediate,,1,,10116.0,14086,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623259,,,A
12582,Intermediate,,1,,10116.0,14087,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623260,,,A
12582,Intermediate,,1,,10116.0,14088,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623261,,,A
12582,Intermediate,,1,,10116.0,14089,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623262,,,A
12582,Intermediate,,1,,10116.0,14090,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623263,,,A
12582,Intermediate,,1,,10116.0,14091,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623264,,,A
12582,Intermediate,,1,,10116.0,14092,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623265,,,A
12582,Intermediate,,1,,10116.0,14093,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623266,,,A
12582,Intermediate,,1,,10116.0,14094,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623267,,,A
12582,Intermediate,,1,,10116.0,14095,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623268,,,A
12582,Intermediate,,1,,10116.0,14096,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623269,,,A
12582,Intermediate,,1,,10116.0,14097,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623270,,,A
12582,Intermediate,,1,,10116.0,14098,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623271,,,A
12582,Intermediate,,1,,10116.0,14099,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623272,,,A
12582,Intermediate,,1,,10116.0,14100,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623273,,,A
12582,Intermediate,,1,,10116.0,14101,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623274,,,A
12582,Intermediate,,1,,10116.0,14102,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL874414,,,A
12582,Intermediate,,1,,10116.0,14103,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623275,,,A
12582,Intermediate,,1,,10116.0,14104,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629150,,,A
12582,Intermediate,,1,,10116.0,14105,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623276,,,A
12582,Intermediate,,1,,10116.0,14106,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623277,,,A
12582,Intermediate,,1,,10116.0,14107,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623112,,,A
12582,Intermediate,,1,,10116.0,14108,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623113,,,A
12582,Intermediate,,1,,10116.0,14109,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623800,,,A
12582,Intermediate,,1,,10116.0,14110,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623801,,,A
12017,Intermediate,,1,,10116.0,14111,1,50597,,In vivo,Spleen,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL623802,,,A
12017,Intermediate,,1,,10116.0,14112,1,50597,,In vivo,Uterus,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL623803,,,A
12017,Intermediate,,1,,10116.0,14113,1,50597,,In vivo,Uterus,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL623970,,,A
12017,Intermediate,,1,,10116.0,14114,1,50597,,In vivo,Uterus,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,995.0,CHEMBL623971,,,A
14045,Intermediate,,1,,10116.0,14115,1,50597,,In vivo,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623972,,,A
14045,Intermediate,,1,,10116.0,14116,1,50597,,In vivo,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623973,,,A
14045,Intermediate,,1,,10116.0,14117,1,50597,,In vivo,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623974,,,A
14045,Intermediate,,1,,10116.0,14118,1,50597,,In vivo,Blood,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL623975,,,A
14045,Intermediate,,1,,10116.0,14119,1,50597,,In vivo,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623976,,,A
14045,Intermediate,,1,,10116.0,14120,1,50597,,In vivo,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623977,,,A
14045,Intermediate,,1,,10116.0,14121,1,50597,,In vivo,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623978,,,A
14045,Intermediate,,1,,10116.0,14122,1,50597,,In vivo,Brain,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL623979,,,A
14045,Intermediate,,1,,10116.0,14123,1,50597,,In vivo,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623980,,,A
14045,Intermediate,,1,,10116.0,14124,1,50597,,In vivo,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL623981,,,A
14045,Intermediate,,1,,10116.0,14125,1,50597,,In vivo,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626278,,,A
14045,Intermediate,,1,,10116.0,14126,1,50597,,In vivo,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626279,,,A
14045,Intermediate,,1,,10090.0,14127,1,50594,,In vivo,,Biodistribution in mice bladder plus excreted urine was determined,,N,,Mus musculus,BAO_0000218,,CHEMBL626280,,,A
14045,Intermediate,,1,,10090.0,14128,1,50594,,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626281,,,A
14045,Intermediate,,1,,10090.0,14129,1,50594,,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626282,,,A
14045,Intermediate,,1,,10090.0,14130,1,50594,,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626283,,,A
14045,Intermediate,,1,,10090.0,14131,1,50594,,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626284,,,A
14045,Intermediate,,1,,10090.0,14132,1,50594,,,Brain,"Percentage biodistribution in mouse brain, 10 minutes post injection",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL626285,,,A
14045,Intermediate,,1,,10090.0,14133,1,50594,,,Brain,"Percentage biodistribution in mouse brain, 30 minutes post injection",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL626286,,,A
14045,Intermediate,,1,,10090.0,14134,1,50594,,,Brain,"Percentage biodistribution in mouse brain, 5 minutes post injection",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL626287,,,A
14045,Intermediate,,1,,10090.0,14135,1,50594,,,Brain,"Percentage biodistribution in mouse brain, 60 minutes post injection",,N,,Mus musculus,BAO_0000218,955.0,CHEMBL626288,,,A
14045,Intermediate,,1,,10090.0,14136,1,50594,,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626289,,,A
14045,Intermediate,,1,,10090.0,14137,1,50594,,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626290,,,A
14045,Intermediate,,1,,10090.0,14138,1,50594,,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL626291,,,A
14045,Intermediate,,1,,10090.0,14139,1,50594,,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL839888,,,A
14045,Intermediate,,1,,10090.0,14140,1,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,N,,Mus musculus,BAO_0000218,160.0,CHEMBL626292,,,A
14045,Intermediate,,1,,10090.0,14141,1,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,N,,Mus musculus,BAO_0000218,160.0,CHEMBL626293,,,A
14045,Intermediate,,1,,10090.0,14142,1,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,N,,Mus musculus,BAO_0000218,160.0,CHEMBL626294,,,A
14045,Intermediate,,1,,10090.0,14143,1,50594,,,Intestine,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,N,,Mus musculus,BAO_0000218,160.0,CHEMBL626295,,,A
14045,Intermediate,,1,,10090.0,14144,1,50594,,,Liver,"Percentage biodistribution in mouse liver, 10 minutes post injection",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL627659,,,A
14045,Intermediate,,1,,10090.0,14145,1,50594,,,Liver,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL627660,,,A
14045,Intermediate,,1,,10090.0,14146,1,50594,,,Liver,"Percentage biodistribution in mouse liver, 5 minutes post injection",,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL627661,,,A
14045,Intermediate,,1,,10090.0,14147,1,50594,,In vivo,Liver,Biodistribution in mice liver at 60 minutes of post injection,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL627662,,,A
14045,Intermediate,,1,,10090.0,14148,1,50594,,In vivo,Lung,Biodistribution in mice lungs at 10 min of post injection,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL627663,,,A
14045,Intermediate,,1,,10090.0,14149,1,50594,,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL627664,,,A
14045,Intermediate,,1,,10090.0,14150,1,50594,,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",,N,,Mus musculus,BAO_0000218,,CHEMBL627665,,,A
14045,Intermediate,,1,,10090.0,14151,1,50594,,In vivo,Lung,Biodistribution in mice lungs at 60 min of post injection,,N,,Mus musculus,BAO_0000218,2048.0,CHEMBL627666,,,A
14045,Intermediate,,1,,10090.0,14152,1,50594,,,Spleen,Percentage biodistribution in mouse spleen,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL627667,,,A
14045,Intermediate,,1,,10090.0,14153,1,50594,,,Stomach,Percentage biodistribution in mouse stomach,,N,,Mus musculus,BAO_0000218,945.0,CHEMBL627668,,,A
11745,Intermediate,,1,,10090.0,14154,1,50594,,,Urine,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,N,,Mus musculus,BAO_0000218,1088.0,CHEMBL627669,,,A
13257,Autocuration,,1,,,14155,0,22224,,In vivo,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,U,,,BAO_0000218,1255.0,CHEMBL627670,,,A
13257,Autocuration,,1,,,14156,0,22224,,In vivo,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,U,,,BAO_0000218,178.0,CHEMBL627671,,,A
13257,Autocuration,,1,,,14157,0,22224,,In vivo,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,U,,,BAO_0000218,1474.0,CHEMBL627672,,,A
13257,Autocuration,,1,,,14158,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,U,,,BAO_0000218,,CHEMBL627673,,,A
13257,Autocuration,,1,,,14159,0,22224,,In vivo,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,U,,,BAO_0000218,2113.0,CHEMBL627674,,,A
13257,Autocuration,,1,,,14160,0,22224,,In vivo,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,U,,,BAO_0000218,2107.0,CHEMBL627675,,,A
13257,Autocuration,,1,,,14161,0,22224,,In vivo,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,U,,,BAO_0000218,2048.0,CHEMBL627676,,,A
13257,Autocuration,,1,,,14162,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,U,,,BAO_0000218,2385.0,CHEMBL627677,,,A
8354,Autocuration,,1,,,14163,0,22224,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL627678,,,A
7095,Intermediate,,1,,10116.0,14164,1,50597,,,Serum,Affinity for protein binding expressed as association constant in fresh rat serum,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL627679,,,A
12185,Autocuration,,1,,,14165,0,22224,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,U,,,BAO_0000019,,CHEMBL627680,,,A
12185,Autocuration,,1,,,14166,0,22224,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,U,,,BAO_0000019,,CHEMBL627681,,,A
12185,Autocuration,,1,,,14167,0,22224,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,U,,,BAO_0000019,,CHEMBL627682,,,A
12185,Autocuration,,1,,,14168,0,22224,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,U,,,BAO_0000019,,CHEMBL627683,,,A
12686,Autocuration,,1,,,14169,0,22224,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,U,,,BAO_0000019,,CHEMBL627684,,,A
12686,Autocuration,,1,,,14170,0,22224,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,U,,,BAO_0000019,,CHEMBL874441,,,A
12686,Autocuration,,1,,,14171,0,22224,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,U,,,BAO_0000019,,CHEMBL627685,,,A
12686,Autocuration,,1,,,14172,0,22224,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,U,,,BAO_0000019,,CHEMBL627686,,,A
8057,Autocuration,,1,,,14173,0,22224,,,,Apparent rate constant Koff for inactivation of dTMP synthase.,,U,,,BAO_0000019,,CHEMBL627687,,,A
15778,Autocuration,,1,,,14174,0,22224,,,,The irreversible inhibitor activity by second order rate equation.,,U,,,BAO_0000019,,CHEMBL627688,,,A
12375,Intermediate,,1,,10116.0,14175,1,50597,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628038,,,A
12375,Intermediate,,1,,10116.0,14176,1,50597,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628039,,,A
12375,Intermediate,,1,,10116.0,14177,1,50597,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628040,,,A
13588,Autocuration,,1,,,14178,0,22224,,,,Dissociation rate calculated from the first-order equation using t1/2 value,,U,,,BAO_0000019,,CHEMBL628041,,,A
15039,Autocuration,,1,,,14179,0,22224,,,,The compound was tested for Binding constant against DNA,,U,,,BAO_0000019,,CHEMBL630226,,,A
9500,Autocuration,,1,,,14180,0,22224,,,,First order rate constant for cyclization of the compound,,U,,,BAO_0000019,,CHEMBL628042,,,A
10014,Autocuration,,1,,,14181,0,22224,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,U,,,BAO_0000019,,CHEMBL625232,,,A
10014,Autocuration,,1,,,14182,0,22224,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,U,,,BAO_0000019,,CHEMBL625233,,,A
568,Autocuration,,1,,,14183,0,22224,,,,Hydrolysis rate constant was determined,,U,,,BAO_0000019,,CHEMBL625979,,,A
10026,Autocuration,,1,,,14184,0,22224,,,,Observed first order rate constant,,U,,,BAO_0000019,,CHEMBL625980,,,A
10281,Autocuration,,1,,,14185,0,22224,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,U,,,BAO_0000019,,CHEMBL625981,,,A
10281,Autocuration,,1,,,14186,0,22224,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,U,,,BAO_0000019,,CHEMBL625982,,,A
9680,Autocuration,,1,,,14187,0,22224,,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,U,,,BAO_0000019,,CHEMBL625983,,,A
13028,Autocuration,,1,,,14188,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625984,,,A
13028,Autocuration,,1,,,14189,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625985,,,A
13028,Autocuration,,1,,,14190,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625986,,,A
13028,Autocuration,,1,,,14191,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625987,,,A
13028,Autocuration,,1,,,14192,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625988,,,A
13028,Autocuration,,1,,,14193,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625989,,,A
13028,Autocuration,,1,,,14194,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625990,,,A
13028,Autocuration,,1,,,14195,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625991,,,A
13028,Autocuration,,1,,,14196,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625992,,,A
13028,Autocuration,,1,,,14197,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL625993,,,A
13028,Autocuration,,1,,,14198,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL631973,,,A
13028,Autocuration,,1,,,14199,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632143,,,A
13028,Autocuration,,1,,,14200,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632144,,,A
13028,Autocuration,,1,,,14201,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632145,,,A
13028,Autocuration,,1,,,14202,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632146,,,A
13028,Autocuration,,1,,,14203,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632147,,,A
13028,Autocuration,,1,,,14204,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632148,,,A
13028,Autocuration,,1,,,14205,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632149,,,A
13028,Autocuration,,1,,,14206,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632150,,,A
13028,Autocuration,,1,,,14207,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL632151,,,A
3008,Intermediate,,1,,9606.0,14208,1,50587,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,N,,Homo sapiens,BAO_0000218,,CHEMBL632152,,,A
4509,Intermediate,,1,,9606.0,14209,1,50587,,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,N,,Homo sapiens,BAO_0000218,,CHEMBL632153,,,A
4509,Intermediate,,1,,9606.0,14210,1,50587,,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,N,,Homo sapiens,BAO_0000218,,CHEMBL632154,,,A
8613,Intermediate,,1,,10298.0,14211,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL632155,,,A
8613,Intermediate,,1,,10298.0,14212,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL632156,,,A
8613,Intermediate,,1,,10298.0,14213,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL632157,,,A
8613,Intermediate,,1,,10298.0,14214,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL632158,,,A
8613,Intermediate,,1,,10298.0,14215,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL632159,,,A
8613,Intermediate,,1,,10298.0,14216,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL626305,,,A
8613,Intermediate,,1,,10298.0,14217,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL626306,,,A
8613,Intermediate,,1,,10298.0,14218,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL626307,,,A
8613,Intermediate,,1,,10298.0,14219,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL626308,,,A
8613,Intermediate,,1,,10298.0,14220,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL626479,,,A
8613,Intermediate,,1,,10298.0,14221,1,50602,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,N,,Human herpesvirus 1,BAO_0000218,,CHEMBL626480,,,A
6021,Autocuration,,1,,,14222,0,22229,,,,Calculated partition coefficient (clogP) (MlogP),,U,,,BAO_0000100,,CHEMBL626481,,,P
9348,Autocuration,,1,,,14223,0,22224,,,,Equipotent potent ratio relative to carbachol (nicotinic activity),,U,,,BAO_0000019,,CHEMBL626482,,,A
15592,Intermediate,,1,,9615.0,14224,1,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626483,,,A
15592,Intermediate,,1,,9615.0,14225,1,50588,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL626484,,,A
15592,Autocuration,,1,,,14226,0,22229,,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,,U,,,BAO_0000100,,CHEMBL626485,,,P
15592,Autocuration,,1,,,14227,0,22229,,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,U,,,BAO_0000100,,CHEMBL626486,,,P
15592,Autocuration,,1,,,14228,0,22229,,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,,U,,,BAO_0000100,,CHEMBL626487,,,P
15592,Intermediate,,1,,9615.0,14229,1,50588,,In vivo,Plasma,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,N,,Canis lupus familiaris,BAO_0000218,1969.0,CHEMBL626488,,,A
7095,Intermediate,,1,,10116.0,14230,1,50597,,,Serum,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,N,,Rattus norvegicus,BAO_0000218,1977.0,CHEMBL626489,,,A
16618,Autocuration,,1,,,14231,0,22224,,,,Area under the MAP curve measured over 5 min; ND means Not determined,,U,,,BAO_0000019,,CHEMBL626490,,,A
16835,Autocuration,,1,,,14232,0,22224,,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,U,,,BAO_0000100,,CHEMBL626491,,,P
15284,Autocuration,,1,,,14233,0,22229,,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,U,,,BAO_0000100,,CHEMBL626492,,,P
15750,Autocuration,,1,,,14234,0,22224,,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,U,,,BAO_0000019,,CHEMBL626493,,,A
16618,Intermediate,,1,,10116.0,14235,1,50597,,In vivo,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626494,,,A
16618,Autocuration,,1,,,14236,0,22224,,In vivo,,Half life after oral tested,,U,,,BAO_0000218,,CHEMBL626495,,,A
15812,Intermediate,,1,,10116.0,14237,1,50597,,,Plasma,Half life was determined in plasma of rat; NT indicates not tested,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626496,,,A
16618,Intermediate,,1,,10116.0,14238,1,50597,,In vivo,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626497,,,A
16618,Autocuration,,1,,,14239,0,22224,,In vivo,,Oral bioavailability after oral tested,,U,,,BAO_0000218,,CHEMBL626498,,,A
13098,Intermediate,,1,,10116.0,14240,1,50597,,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626499,,,A
13098,Intermediate,,1,,10116.0,14241,1,50597,,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626500,,,A
15812,Intermediate,,1,,10116.0,14242,1,50597,,,Plasma,half life was determined in plasma of rat; NT indicates not tested,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626501,,,A
15812,Intermediate,,1,,10116.0,14243,1,50597,,,Plasma,half life was determined in plasma of rat; NT means not tested,,N,,Rattus norvegicus,BAO_0000218,1969.0,CHEMBL626502,,,A
11510,Intermediate,,1,,10116.0,14244,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626503,,,A
11510,Intermediate,,1,,10116.0,14245,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626504,,,A
11510,Intermediate,,1,,10116.0,14246,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626505,,,A
11510,Intermediate,,1,,10116.0,14247,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626506,,,A
11510,Intermediate,,1,,10116.0,14248,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626507,,,A
11510,Intermediate,,1,,10116.0,14249,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626508,,,A
11510,Intermediate,,1,,10116.0,14250,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626509,,,A
11510,Intermediate,,1,,10116.0,14251,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875480,,,A
11510,Intermediate,,1,,10116.0,14252,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626510,,,A
11510,Intermediate,,1,,10116.0,14253,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626511,,,A
11510,Intermediate,,1,,10116.0,14254,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL626512,,,A
11510,Intermediate,,1,,10116.0,14255,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628208,,,A
11510,Intermediate,,1,,10116.0,14256,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628209,,,A
11510,Intermediate,,1,,10116.0,14257,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628210,,,A
11510,Intermediate,,1,,10116.0,14258,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628211,,,A
11510,Intermediate,,1,,10116.0,14259,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628212,,,A
11510,Intermediate,,1,,10116.0,14260,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628213,,,A
12582,Intermediate,,1,,10116.0,14261,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628214,,,A
12582,Intermediate,,1,,10116.0,14262,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628215,,,A
12582,Intermediate,,1,,10116.0,14263,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628216,,,A
12582,Intermediate,,1,,10116.0,14264,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626595,,,A
12582,Intermediate,,1,,10116.0,14265,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626596,,,A
12582,Intermediate,,1,,10116.0,14266,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626597,,,A
12582,Intermediate,,1,,10116.0,14267,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626598,,,A
12582,Intermediate,,1,,10116.0,14268,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622242,,,A
12582,Intermediate,,1,,10116.0,14269,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622243,,,A
12582,Intermediate,,1,,10116.0,14270,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622244,,,A
12582,Intermediate,,1,,10116.0,14271,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622245,,,A
12582,Intermediate,,1,,10116.0,14272,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622246,,,A
12582,Intermediate,,1,,10116.0,14273,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622247,,,A
12582,Intermediate,,1,,10116.0,14274,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622248,,,A
12582,Intermediate,,1,,10116.0,14275,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL877483,,,A
12582,Intermediate,,1,,10116.0,14276,1,50597,,,Urine,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL622249,,,A
12582,Intermediate,,1,,9615.0,14277,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622250,,,A
12582,Intermediate,,1,,9615.0,14278,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622251,,,A
12582,Intermediate,,1,,9615.0,14279,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622252,,,A
12582,Intermediate,,1,,9615.0,14280,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622253,,,A
12582,Intermediate,,1,,9615.0,14281,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622254,,,A
12582,Intermediate,,1,,9615.0,14282,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622255,,,A
12582,Intermediate,,1,,9615.0,14283,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622256,,,A
12582,Intermediate,,1,,9615.0,14284,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622257,,,A
12582,Intermediate,,1,,9615.0,14285,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622258,,,A
12582,Intermediate,,1,,9615.0,14286,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622259,,,A
12582,Intermediate,,1,,9615.0,14287,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622927,,,A
12582,Intermediate,,1,,9615.0,14288,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622928,,,A
12582,Intermediate,,1,,9615.0,14289,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL622929,,,A
12582,Intermediate,,1,,9615.0,14290,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL623182,,,A
12582,Intermediate,,1,,9615.0,14291,1,50588,,,Urine,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL623183,,,A
12582,Intermediate,,1,,10116.0,14292,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623184,,,A
12582,Intermediate,,1,,10116.0,14293,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623185,,,A
12582,Intermediate,,1,,10116.0,14294,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL877484,,,A
12582,Intermediate,,1,,10116.0,14295,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL627274,,,A
12582,Intermediate,,1,,10116.0,14296,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623186,,,A
12582,Intermediate,,1,,10116.0,14297,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623187,,,A
12582,Intermediate,,1,,10116.0,14298,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL623188,,,A
12582,Intermediate,,1,,10116.0,14299,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628055,,,A
12582,Intermediate,,1,,10116.0,14300,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628056,,,A
12582,Intermediate,,1,,10116.0,14301,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628200,,,A
12582,Intermediate,,1,,10116.0,14302,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628201,,,A
12582,Intermediate,,1,,10116.0,14303,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628202,,,A
12582,Intermediate,,1,,10116.0,14304,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628203,,,A
12582,Intermediate,,1,,10116.0,14305,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628204,,,A
12582,Intermediate,,1,,10116.0,14306,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628205,,,A
12582,Intermediate,,1,,10116.0,14307,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628206,,,A
13257,Autocuration,,1,,,14308,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,U,,,BAO_0000218,2367.0,CHEMBL628207,,,A
13257,Autocuration,,1,,,14309,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,U,,,BAO_0000218,2367.0,CHEMBL627220,,,A
13257,Autocuration,,1,,,14310,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL627221,,,A
13257,Autocuration,,1,,,14311,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,U,,,BAO_0000218,2367.0,CHEMBL627222,,,A
13257,Autocuration,,1,,,14312,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,U,,,BAO_0000218,,CHEMBL627223,,,A
13257,Autocuration,,1,,,14313,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL632062,,,A
13257,Autocuration,,1,,,14314,0,22224,,In vivo,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,U,,,BAO_0000218,2106.0,CHEMBL632063,,,A
13257,Autocuration,,1,,,14315,0,22224,,In vivo,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,U,,,BAO_0000218,1255.0,CHEMBL632064,,,A
13257,Autocuration,,1,,,14316,0,22224,,In vivo,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,U,,,BAO_0000218,178.0,CHEMBL632065,,,A
13257,Autocuration,,1,,,14317,0,22224,,In vivo,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,U,,,BAO_0000218,1474.0,CHEMBL632066,,,A
13257,Autocuration,,1,,,14318,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,U,,,BAO_0000218,,CHEMBL632067,,,A
13257,Autocuration,,1,,,14319,0,22224,,In vivo,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,U,,,BAO_0000218,2113.0,CHEMBL629188,,,A
13257,Autocuration,,1,,,14320,0,22224,,In vivo,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,U,,,BAO_0000218,2107.0,CHEMBL629189,,,A
13257,Autocuration,,1,,,14321,0,22224,,In vivo,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,U,,,BAO_0000218,2048.0,CHEMBL629190,,,A
13257,Autocuration,,1,,,14322,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,U,,,BAO_0000218,2385.0,CHEMBL629191,,,A
13257,Autocuration,,1,,,14323,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,U,,,BAO_0000218,2367.0,CHEMBL629192,,,A
13257,Autocuration,,1,,,14324,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL629193,,,A
13257,Autocuration,,1,,,14325,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,U,,,BAO_0000218,2367.0,CHEMBL629194,,,A
13257,Autocuration,,1,,,14326,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,U,,,BAO_0000218,,CHEMBL629195,,,A
13257,Autocuration,,1,,,14327,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL629373,,,A
13257,Autocuration,,1,,,14328,0,22224,,In vivo,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,U,,,BAO_0000218,2106.0,CHEMBL629374,,,A
13257,Autocuration,,1,,,14329,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,U,,,BAO_0000218,2367.0,CHEMBL629375,,,A
13257,Autocuration,,1,,,14330,0,22224,,In vivo,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,U,,,BAO_0000218,1255.0,CHEMBL629376,,,A
13257,Autocuration,,1,,,14331,0,22224,,In vivo,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,U,,,BAO_0000218,178.0,CHEMBL629377,,,A
13257,Autocuration,,1,,,14332,0,22224,,In vivo,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,U,,,BAO_0000218,1474.0,CHEMBL629378,,,A
13257,Autocuration,,1,,,14333,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,U,,,BAO_0000218,,CHEMBL629379,,,A
13257,Autocuration,,1,,,14334,0,22224,,In vivo,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,U,,,BAO_0000218,2113.0,CHEMBL629151,,,A
13257,Autocuration,,1,,,14335,0,22224,,In vivo,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,U,,,BAO_0000218,2107.0,CHEMBL629152,,,A
13257,Autocuration,,1,,,14336,0,22224,,In vivo,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,U,,,BAO_0000218,2048.0,CHEMBL629153,,,A
13257,Autocuration,,1,,,14337,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,U,,,BAO_0000218,2385.0,CHEMBL629154,,,A
13257,Autocuration,,1,,,14338,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,U,,,BAO_0000218,2367.0,CHEMBL629155,,,A
13257,Autocuration,,1,,,14339,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,U,,,BAO_0000218,2367.0,CHEMBL629156,,,A
13257,Autocuration,,1,,,14340,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL629157,,,A
13257,Autocuration,,1,,,14341,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,U,,,BAO_0000218,2367.0,CHEMBL629158,,,A
13257,Autocuration,,1,,,14342,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,U,,,BAO_0000218,,CHEMBL629159,,,A
13257,Autocuration,,1,,,14343,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL629160,,,A
13257,Autocuration,,1,,,14344,0,22224,,In vivo,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,U,,,BAO_0000218,2106.0,CHEMBL629161,,,A
13257,Autocuration,,1,,,14345,0,22224,,In vivo,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,U,,,BAO_0000218,1255.0,CHEMBL629162,,,A
13257,Autocuration,,1,,,14346,0,22224,,In vivo,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,U,,,BAO_0000218,178.0,CHEMBL629163,,,A
13257,Autocuration,,1,,,14347,0,22224,,In vivo,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,U,,,BAO_0000218,1474.0,CHEMBL629164,,,A
13257,Autocuration,,1,,,14348,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,U,,,BAO_0000218,,CHEMBL629165,,,A
13257,Autocuration,,1,,,14349,0,22224,,In vivo,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,U,,,BAO_0000218,2107.0,CHEMBL629166,,,A
13257,Autocuration,,1,,,14350,0,22224,,In vivo,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,U,,,BAO_0000218,2048.0,CHEMBL629167,,,A
13257,Autocuration,,1,,,14351,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,U,,,BAO_0000218,2385.0,CHEMBL629168,,,A
2193,Autocuration,,1,,,14352,0,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,U,,,BAO_0000019,,CHEMBL629169,,,A
2193,Autocuration,,1,,,14353,0,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,U,,,BAO_0000019,,CHEMBL629170,,,A
2193,Autocuration,,1,,,14354,0,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,U,,,BAO_0000019,,CHEMBL631153,,,A
2193,Autocuration,,1,,,14355,0,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,U,,,BAO_0000019,,CHEMBL875121,,,A
2193,Autocuration,,1,,,14356,0,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,U,,,BAO_0000019,,CHEMBL631154,,,A
2193,Autocuration,,1,,,14357,0,22224,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,U,,,BAO_0000019,,CHEMBL631155,,,A
568,Autocuration,,1,,,14358,0,22224,,,,Hydrolysis rate constant was determined,,U,,,BAO_0000019,,CHEMBL631156,,,A
9680,Autocuration,,1,,,14359,0,22224,,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,U,,,BAO_0000019,,CHEMBL631157,,,A
9680,Autocuration,,1,,,14360,0,22224,,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,U,,,BAO_0000019,,CHEMBL631158,,,A
9680,Autocuration,,1,,,14361,0,22224,,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,U,,,BAO_0000019,,CHEMBL631159,,,A
10026,Autocuration,,1,,,14362,0,22224,,,,Observed second order rate constant,,U,,,BAO_0000019,,CHEMBL631160,,,A
10281,Autocuration,,1,,,14363,0,22224,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,U,,,BAO_0000019,,CHEMBL631161,,,A
10014,Autocuration,,1,,,14364,0,22224,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,U,,,BAO_0000019,,CHEMBL631162,,,A
10014,Autocuration,,1,,,14365,0,22224,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,U,,,BAO_0000019,,CHEMBL630313,,,A
9680,Autocuration,,1,,,14366,0,22224,,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,U,,,BAO_0000019,,CHEMBL630314,,,A
9680,Autocuration,,1,,,14367,0,22224,,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,U,,,BAO_0000019,,CHEMBL630315,,,A
13028,Autocuration,,1,,,14368,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630316,,,A
13028,Autocuration,,1,,,14369,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630986,,,A
13028,Autocuration,,1,,,14370,0,22224,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630987,,,A
13028,Autocuration,,1,,,14371,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630988,,,A
13028,Autocuration,,1,,,14372,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630989,,,A
13028,Autocuration,,1,,,14373,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630990,,,A
13028,Autocuration,,1,,,14374,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630991,,,A
13028,Autocuration,,1,,,14375,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630992,,,A
13028,Autocuration,,1,,,14376,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630993,,,A
13028,Autocuration,,1,,,14377,0,22224,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,U,,,BAO_0000019,,CHEMBL630994,,,A
10014,Intermediate,,1,,10116.0,14378,1,50597,,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630995,,,A
9962,Autocuration,,1,,,14379,0,22224,,,,Association constant for compound at 31 degree C was determined,,U,,,BAO_0000019,,CHEMBL629252,,,A
12029,Autocuration,,1,,,14380,0,22224,,,,Calculated antagonist equilibrium dissociation constant of the compound,,U,,,BAO_0000019,,CHEMBL629253,,,A
12029,Autocuration,,1,,,14381,0,22224,,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,U,,,BAO_0000019,,CHEMBL629944,,,A
10583,Intermediate,,1,,10141.0,14382,1,50512,,,Trachea,Dissociation constants vs LTE4 on guinea pig trachea,,N,,Cavia porcellus,BAO_0000218,3126.0,CHEMBL629945,,,A
568,Autocuration,,1,,,14383,0,22224,,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,U,,,BAO_0000019,,CHEMBL629946,,,A
568,Autocuration,,1,,,14384,0,22224,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,U,,,BAO_0000019,,CHEMBL629947,,,A
568,Autocuration,,1,,,14385,0,22224,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,U,,,BAO_0000019,,CHEMBL629948,,,A
568,Autocuration,,1,,,14386,0,22224,,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,U,,,BAO_0000019,,CHEMBL856024,,,A
7493,Autocuration,,1,,,14387,0,22224,,,,Affinity constant KD value was derived from TMP,,U,,,BAO_0000019,,CHEMBL629949,,,A
8371,Autocuration,,1,,,14388,0,22224,,,,Apparent dissociation (binding) rate constant was evaluated,,U,,,BAO_0000019,,CHEMBL629950,,,A
13114,Autocuration,,1,,,14389,0,22224,,,,Dissociation constant (KD) of the compound,,U,,,BAO_0000100,,CHEMBL630127,,,P
15515,Autocuration,,1,,,14390,0,22224,,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,U,,,BAO_0000100,,CHEMBL630128,,,P
522,Autocuration,,1,,,14391,0,22224,,,,Dissociation constant from ESR titration experiments,,U,,,BAO_0000100,,CHEMBL630129,,,P
13888,Autocuration,,1,,,14392,0,22224,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,U,,,BAO_0000019,,CHEMBL630130,,,
2616,Autocuration,,1,,,14393,0,22224,,,,Dissociation constant was evaluated.,,U,,,BAO_0000100,,CHEMBL875234,,,P
3798,Autocuration,,1,,,14394,0,22224,,,,Dissociation constant was reported,,U,,,BAO_0000100,,CHEMBL630131,,,P
8731,Intermediate,,1,,10116.0,14395,1,50597,,,,Dissociation constant was determined in rat pituitary cells.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630132,,,A
11892,Autocuration,,1,,,14396,0,22224,,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,U,,,BAO_0000019,,CHEMBL630133,,,A
11892,Autocuration,,1,,,14397,0,22224,,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,U,,,BAO_0000019,,CHEMBL630134,,,A
2582,Autocuration,,1,,,14398,0,22224,,,,Equilibrium dissociation constant of the compound,,U,,,BAO_0000019,,CHEMBL630135,,,A
11892,Autocuration,,1,,,14399,0,22224,,,,Equilibrium dissociation constant was determined,,U,,,BAO_0000019,,CHEMBL630136,,,A
13396,Autocuration,,1,,,14400,0,22224,,,,Kinetic constant KD was evaluated,,U,,,BAO_0000019,,CHEMBL630137,,,A
603,Autocuration,,1,,,14401,0,22224,,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,U,,,BAO_0000019,,CHEMBL630138,,,A
15673,Autocuration,,1,,,14402,0,22224,,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,U,,,BAO_0000019,,CHEMBL630139,,,A
10368,Autocuration,,1,,,14403,0,22224,,,,Rate constant for hydrolysis in aqueous acetone.,,U,,,BAO_0000019,,CHEMBL630140,,,A
14228,Autocuration,,1,,,14404,0,22224,,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,U,,,BAO_0000019,,CHEMBL875235,,,A
11510,Intermediate,,1,,10116.0,14405,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876439,,,A
11510,Intermediate,,1,,10116.0,14406,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630605,,,A
11510,Intermediate,,1,,10116.0,14407,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630606,,,A
11510,Intermediate,,1,,10116.0,14408,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630607,,,A
11510,Intermediate,,1,,10116.0,14409,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630608,,,A
11510,Intermediate,,1,,10116.0,14410,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630609,,,A
11510,Intermediate,,1,,10116.0,14411,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630610,,,A
11510,Intermediate,,1,,10116.0,14412,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630611,,,A
11510,Intermediate,,1,,10116.0,14413,1,50597,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629552,,,A
11510,Intermediate,,1,,10116.0,14414,1,50597,,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629733,,,A
11510,Intermediate,,1,,10116.0,14415,1,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629734,,,A
11510,Intermediate,,1,,10116.0,14416,1,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629735,,,A
11510,Intermediate,,1,,10116.0,14417,1,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629736,,,A
11510,Intermediate,,1,,10116.0,14418,1,50597,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629737,,,A
11510,Intermediate,,1,,10116.0,14419,1,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629738,,,A
11510,Intermediate,,1,,10116.0,14420,1,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629739,,,A
11510,Intermediate,,1,,10116.0,14421,1,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629740,,,A
11510,Intermediate,,1,,10116.0,14422,1,50597,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629741,,,A
11510,Intermediate,,1,,10116.0,14423,1,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629742,,,A
11510,Intermediate,,1,,10116.0,14424,1,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629743,,,A
11510,Intermediate,,1,,10116.0,14425,1,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629744,,,A
11510,Intermediate,,1,,10116.0,14426,1,50597,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629745,,,A
11510,Intermediate,,1,,10116.0,14427,1,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629746,,,A
11510,Intermediate,,1,,10116.0,14428,1,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629747,,,A
11510,Intermediate,,1,,10116.0,14429,1,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629748,,,A
11510,Intermediate,,1,,10116.0,14430,1,50597,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629749,,,A
11510,Intermediate,,1,,10116.0,14431,1,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629750,,,A
11510,Intermediate,,1,,10116.0,14432,1,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629751,,,A
11510,Intermediate,,1,,10116.0,14433,1,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629752,,,A
11510,Intermediate,,1,,10116.0,14434,1,50597,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629753,,,A
11510,Intermediate,,1,,10116.0,14435,1,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629754,,,A
11510,Intermediate,,1,,10116.0,14436,1,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629755,,,A
11510,Intermediate,,1,,10116.0,14437,1,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629756,,,A
11510,Intermediate,,1,,10116.0,14438,1,50597,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629757,,,A
11510,Intermediate,,1,,10116.0,14439,1,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629758,,,A
11510,Intermediate,,1,,10116.0,14440,1,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629759,,,A
11510,Intermediate,,1,,10116.0,14441,1,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL629760,,,A
11510,Intermediate,,1,,10116.0,14442,1,50597,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876443,,,A
8310,Intermediate,,1,,9615.0,14443,1,50588,,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629761,,,A
8310,Intermediate,,1,,9615.0,14444,1,50588,,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629762,,,A
8310,Intermediate,,1,,10090.0,14445,1,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629763,,,A
8310,Intermediate,,1,,10090.0,14446,1,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629764,,,A
8310,Intermediate,,1,,10090.0,14447,1,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629765,,,A
8310,Intermediate,,1,,10090.0,14448,1,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629766,,,A
8310,Intermediate,,1,,10090.0,14449,1,50594,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629767,,,A
8310,Intermediate,,1,,9615.0,14450,1,50588,,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629768,,,A
8310,Intermediate,,1,,10090.0,14451,1,50594,,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629769,,,A
8310,Intermediate,,1,,9615.0,14452,1,50588,,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629770,,,A
8310,Intermediate,,1,,9615.0,14453,1,50588,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,N,,Canis lupus familiaris,BAO_0000218,,CHEMBL629771,,,A
8310,Intermediate,,1,,10090.0,14454,1,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629772,,,A
8310,Intermediate,,1,,10090.0,14455,1,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL629773,,,A
8310,Intermediate,,1,,10090.0,14456,1,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL625455,,,A
8310,Intermediate,,1,,10090.0,14457,1,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL625456,,,A
8310,Intermediate,,1,,10090.0,14458,1,50594,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,N,,Mus musculus,BAO_0000218,,CHEMBL625457,,,A
12582,Intermediate,,1,,10116.0,14459,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625458,,,A
12582,Intermediate,,1,,10116.0,14460,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625459,,,A
12582,Intermediate,,1,,10116.0,14461,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875483,,,A
12582,Intermediate,,1,,10116.0,14462,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL634779,,,A
12582,Intermediate,,1,,10116.0,14463,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625460,,,A
12582,Intermediate,,1,,10116.0,14464,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626117,,,A
12582,Intermediate,,1,,10116.0,14465,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626118,,,A
12582,Intermediate,,1,,10116.0,14466,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628342,,,A
12582,Intermediate,,1,,10116.0,14467,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628343,,,A
12582,Intermediate,,1,,10116.0,14468,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628344,,,A
12582,Intermediate,,1,,10116.0,14469,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628345,,,A
12582,Intermediate,,1,,10116.0,14470,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628346,,,A
12582,Intermediate,,1,,10116.0,14471,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628347,,,A
12582,Intermediate,,1,,10116.0,14472,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628348,,,A
12582,Intermediate,,1,,10116.0,14473,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628349,,,A
12582,Intermediate,,1,,10116.0,14474,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875611,,,A
12582,Intermediate,,1,,10116.0,14475,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628350,,,A
12582,Intermediate,,1,,10116.0,14476,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628351,,,A
12582,Intermediate,,1,,10116.0,14477,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628352,,,A
12582,Intermediate,,1,,10116.0,14478,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628353,,,A
12582,Intermediate,,1,,10116.0,14479,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628354,,,A
12582,Intermediate,,1,,10116.0,14480,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626667,,,A
12582,Intermediate,,1,,10116.0,14481,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626668,,,A
12582,Intermediate,,1,,10116.0,14482,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626669,,,A
12582,Intermediate,,1,,10116.0,14483,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626670,,,A
12582,Intermediate,,1,,10116.0,14484,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626671,,,A
12582,Intermediate,,1,,10116.0,14485,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626672,,,A
12582,Intermediate,,1,,10116.0,14486,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626673,,,A
12582,Intermediate,,1,,10116.0,14487,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626674,,,A
12582,Intermediate,,1,,10116.0,14488,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626675,,,A
12582,Intermediate,,1,,10116.0,14489,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626676,,,A
12582,Intermediate,,1,,10116.0,14490,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626677,,,A
12582,Intermediate,,1,,10116.0,14491,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626678,,,A
12582,Intermediate,,1,,10116.0,14492,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626679,,,A
12582,Intermediate,,1,,10116.0,14493,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875612,,,A
12582,Intermediate,,1,,10116.0,14494,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626680,,,A
12582,Intermediate,,1,,10116.0,14495,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626681,,,A
12582,Intermediate,,1,,10116.0,14496,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626682,,,A
12582,Intermediate,,1,,10116.0,14497,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626683,,,A
12582,Intermediate,,1,,10116.0,14498,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626684,,,A
12582,Intermediate,,1,,10116.0,14499,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626685,,,A
12582,Intermediate,,1,,10116.0,14500,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626686,,,A
12582,Intermediate,,1,,10116.0,14501,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626687,,,A
12582,Intermediate,,1,,10116.0,14502,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624978,,,A
12582,Intermediate,,1,,10116.0,14503,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624979,,,A
12582,Intermediate,,1,,10116.0,14504,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624980,,,A
12582,Intermediate,,1,,10116.0,14505,1,50597,,,Urine,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL624981,,,A
12582,Intermediate,,1,,9615.0,14506,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL624982,,,A
13257,Autocuration,,1,,,14507,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,U,,,BAO_0000218,2367.0,CHEMBL627564,,,A
13257,Autocuration,,1,,,14508,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,U,,,BAO_0000218,2367.0,CHEMBL627565,,,A
13257,Autocuration,,1,,,14509,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,U,,,BAO_0000218,,CHEMBL627566,,,A
13257,Autocuration,,1,,,14510,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL627567,,,A
13257,Autocuration,,1,,,14511,0,22224,,In vivo,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,U,,,BAO_0000218,2106.0,CHEMBL627568,,,A
13257,Autocuration,,1,,,14512,0,22224,,In vivo,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,U,,,BAO_0000218,2113.0,CHEMBL627569,,,A
13257,Autocuration,,1,,,14513,0,22224,,In vivo,Urinary bladder,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,U,,,BAO_0000218,1255.0,CHEMBL627570,,,A
13257,Autocuration,,1,,,14514,0,22224,,In vivo,Blood,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,U,,,BAO_0000218,178.0,CHEMBL627571,,,A
13257,Autocuration,,1,,,14515,0,22224,,In vivo,Bone element,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,U,,,BAO_0000218,1474.0,CHEMBL627572,,,A
13257,Autocuration,,1,,,14516,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,U,,,BAO_0000218,,CHEMBL627573,,,A
13257,Autocuration,,1,,,14517,0,22224,,In vivo,Kidney,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,U,,,BAO_0000218,2113.0,CHEMBL627574,,,A
13257,Autocuration,,1,,,14518,0,22224,,In vivo,Liver,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,U,,,BAO_0000218,2107.0,CHEMBL627575,,,A
13257,Autocuration,,1,,,14519,0,22224,,In vivo,Lung,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,U,,,BAO_0000218,2048.0,CHEMBL627576,,,A
13257,Autocuration,,1,,,14520,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,U,,,BAO_0000218,2385.0,CHEMBL627577,,,A
13257,Autocuration,,1,,,14521,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,U,,,BAO_0000218,2367.0,CHEMBL627578,,,A
13257,Autocuration,,1,,,14522,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,U,,,BAO_0000218,2367.0,CHEMBL627579,,,A
13257,Autocuration,,1,,,14523,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL627580,,,A
13257,Autocuration,,1,,,14524,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,U,,,BAO_0000218,2367.0,CHEMBL627581,,,A
13257,Autocuration,,1,,,14525,0,22224,,In vivo,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,U,,,BAO_0000218,,CHEMBL627582,,,A
13257,Autocuration,,1,,,14526,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL627583,,,A
13257,Autocuration,,1,,,14527,0,22224,,In vivo,Spleen,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,U,,,BAO_0000218,2106.0,CHEMBL627584,,,A
13257,Autocuration,,1,,,14528,0,22224,,In vivo,Prostate gland,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,U,,,BAO_0000218,2367.0,CHEMBL627585,,,A
13257,Autocuration,,1,,,14529,0,22224,,In vivo,Muscle tissue,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,U,,,BAO_0000218,2385.0,CHEMBL627586,,,A
15413,Intermediate,,1,,10116.0,14530,1,50597,,In vivo,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627587,,,A
15413,Intermediate,,1,,10116.0,14531,1,50597,,In vivo,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL627588,,,A
15413,Intermediate,,1,,10116.0,14532,1,50597,,In vivo,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628250,,,A
15413,Intermediate,,1,,10116.0,14533,1,50597,,In vivo,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628251,,,A
15413,Intermediate,,1,,10116.0,14534,1,50597,,In vivo,Hippocampus,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL628252,,,A
15413,Intermediate,,1,,10116.0,14535,1,50597,,In vivo,Hippocampus,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL628253,,,A
15413,Intermediate,,1,,10116.0,14536,1,50597,,In vivo,Hypothalamus,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL628254,,,A
15413,Intermediate,,1,,10116.0,14537,1,50597,,In vivo,Hypothalamus,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL877493,,,A
15413,Intermediate,,1,,10116.0,14538,1,50597,,In vivo,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628255,,,A
15413,Intermediate,,1,,10116.0,14539,1,50597,,In vivo,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628256,,,A
15413,Intermediate,,1,,10116.0,14540,1,50597,,In vivo,Hippocampus,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL628257,,,A
15413,Intermediate,,1,,10116.0,14541,1,50597,,In vivo,Hypothalamus,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL628258,,,A
15413,Intermediate,,1,,10116.0,14542,1,50597,,In vivo,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628259,,,A
15413,Intermediate,,1,,10116.0,14543,1,50597,,In vivo,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628429,,,A
15413,Intermediate,,1,,10116.0,14544,1,50597,,In vivo,Hippocampus,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL626862,,,A
15413,Intermediate,,1,,10116.0,14545,1,50597,,In vivo,Hypothalamus,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL626863,,,A
15413,Intermediate,,1,,10116.0,14546,1,50597,,In vivo,Cerebellum,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL625886,,,A
15413,Intermediate,,1,,10116.0,14547,1,50597,,In vivo,Cerebellum,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL625887,,,A
15413,Intermediate,,1,,10116.0,14548,1,50597,,In vivo,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625888,,,A
15413,Intermediate,,1,,10116.0,14549,1,50597,,In vivo,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625889,,,A
15413,Intermediate,,1,,10116.0,14550,1,50597,,In vivo,Hippocampus,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625890,,,A
15413,Intermediate,,1,,10116.0,14551,1,50597,,In vivo,Hippocampus,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL625891,,,A
15413,Intermediate,,1,,10116.0,14552,1,50597,,In vivo,Hypothalamus,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL625892,,,A
15413,Intermediate,,1,,10116.0,14553,1,50597,,In vivo,Hypothalamus,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL625893,,,A
15413,Intermediate,,1,,10116.0,14554,1,50597,,In vivo,Cerebellum,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,N,,Rattus norvegicus,BAO_0000218,2037.0,CHEMBL625894,,,A
15413,Intermediate,,1,,10116.0,14555,1,50597,,In vivo,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625895,,,A
12404,Autocuration,,1,,,14556,0,22224,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,U,,,BAO_0000019,,CHEMBL625896,,,A
568,Autocuration,,1,,,14557,0,22224,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,U,,,BAO_0000019,,CHEMBL625897,,,A
568,Autocuration,,1,,,14558,0,22224,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,U,,,BAO_0000019,,CHEMBL625898,,,A
568,Autocuration,,1,,,14559,0,22224,,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,U,,,BAO_0000019,,CHEMBL625899,,,A
12404,Autocuration,,1,,,14560,0,22224,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,U,,,BAO_0000019,,CHEMBL626124,,,A
7624,Intermediate,,1,,562.0,14561,1,50212,,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,N,,Escherichia coli,BAO_0000218,,CHEMBL628500,,,A
7624,Intermediate,,1,,10116.0,14562,1,50597,,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL857856,,,A
7624,Intermediate,,1,,10116.0,14563,1,50597,,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628501,,,A
4643,Autocuration,,1,,,14564,0,22224,,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,U,,,BAO_0000019,,CHEMBL628502,,,A
11532,Autocuration,,1,,,14565,0,22224,,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,U,,,BAO_0000019,,CHEMBL628503,,,A
11018,Autocuration,,1,,,14566,0,22224,,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,U,,,BAO_0000019,,CHEMBL628504,,,A
2276,Autocuration,,1,,,14567,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,U,,,BAO_0000019,,CHEMBL628505,,,A
2276,Autocuration,,1,,,14568,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,U,,,BAO_0000019,,CHEMBL874452,,,A
2276,Autocuration,,1,,,14569,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,U,,,BAO_0000019,,CHEMBL628506,,,A
2276,Autocuration,,1,,,14570,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,U,,,BAO_0000019,,CHEMBL628507,,,A
2276,Autocuration,,1,,,14571,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,U,,,BAO_0000019,,CHEMBL628508,,,A
8949,Autocuration,,1,,,14572,0,22224,,,,Michaelis constant (KM) was evaluated,,U,,,BAO_0000019,,CHEMBL628509,,,A
12404,Autocuration,,1,,,14573,0,22224,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,U,,,BAO_0000019,,CHEMBL628510,,,A
7625,Autocuration,,1,,,14574,0,22224,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,U,,,BAO_0000019,,CHEMBL628511,,,B
7625,Autocuration,,1,,,14575,0,22224,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,U,,,BAO_0000019,,CHEMBL628512,,,B
7625,Autocuration,,1,,,14576,0,22224,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,U,,,BAO_0000019,,CHEMBL628513,,,B
7625,Autocuration,,1,,,14577,0,22224,,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,U,,,BAO_0000019,,CHEMBL628514,,,B
12908,Autocuration,,1,,,14578,0,22224,,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,U,,,BAO_0000019,,CHEMBL628515,,,A
10368,Autocuration,,1,,,14579,0,22224,,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,U,,,BAO_0000019,,CHEMBL628516,,,A
13108,Autocuration,,1,,,14580,0,22224,,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,U,,,BAO_0000019,,CHEMBL628517,,,A
13108,Autocuration,,1,,,14581,0,22224,,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,U,,,BAO_0000019,,CHEMBL628518,,,A
15217,Autocuration,,1,,,14582,0,22224,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,U,,,BAO_0000019,,CHEMBL628519,,,A
15217,Autocuration,,1,,,14583,0,22224,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,U,,,BAO_0000019,,CHEMBL628520,,,A
10933,Autocuration,,1,,,14584,0,22224,,,,Binding constant was determined,,U,,,BAO_0000019,,CHEMBL628521,,,A
2363,Autocuration,,1,,,14585,0,22224,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,U,,,BAO_0000019,,CHEMBL630443,,,A
2363,Autocuration,,1,,,14586,0,22224,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,U,,,BAO_0000019,,CHEMBL630444,,,A
2276,Autocuration,,1,,,14587,0,22224,,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,U,,,BAO_0000019,,CHEMBL857732,,,A
14915,Autocuration,,1,,,14588,0,22224,,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,U,,,BAO_0000100,,CHEMBL630445,,,P
8847,Autocuration,,1,,,14589,0,22224,,,,Catalytic rate constant of the compound,,U,,,BAO_0000019,,CHEMBL630446,,,A
15357,Autocuration,,1,,,14590,0,22224,,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,U,,,BAO_0000019,,CHEMBL630447,,,B
2869,Autocuration,,1,,,14591,0,22224,,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,U,,,BAO_0000019,,CHEMBL630448,,,A
3484,Autocuration,,1,,,14592,0,22224,,,,Catalytic rate constant against phospholipase A2 was determined,,U,,,BAO_0000019,,CHEMBL630449,,,A
1373,Autocuration,,1,,,14593,0,22224,,,,"Compound was evaluated for catalytic constant, Kcat",,U,,,BAO_0000019,,CHEMBL630450,,,A
8142,Autocuration,,1,,,14594,0,22224,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,U,,,BAO_0000019,,CHEMBL630451,,,A
14131,Autocuration,,1,,,14595,0,22224,,,,Kcat calculated from 0.693/T1/2,,U,,,BAO_0000019,,CHEMBL630452,,,A
17269,Autocuration,,1,,,14596,0,22224,,,,Kcat was determined,,U,,,BAO_0000019,,CHEMBL630453,,,A
3485,Autocuration,,1,,,14597,0,22224,,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,U,,,BAO_0000019,,CHEMBL630454,,,A
3485,Autocuration,,1,,,14598,0,22224,,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,U,,,BAO_0000019,,CHEMBL630455,,,A
3485,Autocuration,,1,,,14599,0,22224,,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,U,,,BAO_0000019,,CHEMBL631487,,,A
5962,Autocuration,,1,,,14600,0,22224,,,,Kcat value was determined,,U,,,BAO_0000019,,CHEMBL631488,,,A
3133,Autocuration,,1,,,14601,0,22224,,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,U,,,BAO_0000019,,CHEMBL876440,,,A
3133,Autocuration,,1,,,14602,0,22224,,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,U,,,BAO_0000019,,CHEMBL631489,,,A
2276,Autocuration,,1,,,14603,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,U,,,BAO_0000019,,CHEMBL857742,,,A
2276,Autocuration,,1,,,14604,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,U,,,BAO_0000019,,CHEMBL631490,,,A
2276,Autocuration,,1,,,14605,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,U,,,BAO_0000019,,CHEMBL631491,,,A
2276,Autocuration,,1,,,14606,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,U,,,BAO_0000019,,CHEMBL631492,,,A
2276,Autocuration,,1,,,14607,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,U,,,BAO_0000019,,CHEMBL631493,,,A
4892,Autocuration,,1,,,14608,0,22224,,,,Kinetic parameter for rate of conversion to PABA was determined,,U,,,BAO_0000019,,CHEMBL631494,,,A
3133,Autocuration,,1,,,14609,0,22224,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,U,,,BAO_0000019,,CHEMBL631495,,,A
11488,Intermediate,,1,,10116.0,14610,1,50597,,,Feces,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,N,,Rattus norvegicus,BAO_0000218,1988.0,CHEMBL631496,,,A
11488,Intermediate,,1,,10116.0,14611,1,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631497,,,A
11488,Intermediate,,1,,10116.0,14612,1,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631498,,,A
11488,Intermediate,,1,,10116.0,14613,1,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629776,,,A
11488,Intermediate,,1,,10116.0,14614,1,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629777,,,A
11488,Intermediate,,1,,10116.0,14615,1,50597,,,Urine,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL629778,,,A
11488,Intermediate,,1,,10116.0,14616,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630456,,,A
11488,Intermediate,,1,,10116.0,14617,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630457,,,A
11488,Intermediate,,1,,10116.0,14618,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630458,,,A
11488,Intermediate,,1,,10116.0,14619,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630459,,,A
11488,Intermediate,,1,,10116.0,14620,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630460,,,A
11488,Intermediate,,1,,10116.0,14621,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL876550,,,A
11488,Intermediate,,1,,10116.0,14622,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630461,,,A
11488,Intermediate,,1,,10116.0,14623,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630462,,,A
11488,Intermediate,,1,,10116.0,14624,1,50597,,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630463,,,A
11488,Intermediate,,1,,10116.0,14625,1,50597,,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630464,,,A
11488,Intermediate,,1,,10116.0,14626,1,50597,,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630465,,,A
11488,Intermediate,,1,,10116.0,14627,1,50597,,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630466,,,A
11488,Intermediate,,1,,10116.0,14628,1,50597,,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630467,,,A
11488,Intermediate,,1,,10116.0,14629,1,50597,,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630633,,,A
11488,Intermediate,,1,,10116.0,14630,1,50597,,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630634,,,A
11488,Intermediate,,1,,10116.0,14631,1,50597,,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630635,,,A
11488,Intermediate,,1,,10116.0,14632,1,50597,,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630636,,,A
11488,Intermediate,,1,,10116.0,14633,1,50597,,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630637,,,A
7132,Intermediate,,1,,9986.0,14634,1,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL630638,,,A
7132,Intermediate,,1,,9986.0,14635,1,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL630639,,,A
7132,Intermediate,,1,,9986.0,14636,1,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL630640,,,A
7132,Intermediate,,1,,9986.0,14637,1,50592,,,Feces,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL876551,,,A
7132,Intermediate,,1,,9986.0,14638,1,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL630641,,,A
7132,Intermediate,,1,,9986.0,14639,1,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL630642,,,A
7132,Intermediate,,1,,9986.0,14640,1,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL630643,,,A
7132,Intermediate,,1,,9986.0,14641,1,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL630644,,,A
7132,Intermediate,,1,,9986.0,14642,1,50592,,,Urine,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL630645,,,A
7132,Intermediate,,1,,9986.0,14643,1,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL625599,,,A
7132,Intermediate,,1,,9986.0,14644,1,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL625600,,,A
7132,Intermediate,,1,,9986.0,14645,1,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL625601,,,A
7132,Intermediate,,1,,9986.0,14646,1,50592,,,Feces,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,N,,Oryctolagus cuniculus,BAO_0000218,1988.0,CHEMBL625602,,,A
7132,Intermediate,,1,,9986.0,14647,1,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL627470,,,A
7132,Intermediate,,1,,9986.0,14648,1,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL627471,,,A
7132,Intermediate,,1,,9986.0,14649,1,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL627472,,,A
7132,Intermediate,,1,,9986.0,14650,1,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL627473,,,A
7132,Intermediate,,1,,9986.0,14651,1,50592,,,Urine,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,N,,Oryctolagus cuniculus,BAO_0000218,1088.0,CHEMBL627474,,,A
13925,Intermediate,,1,,10116.0,14652,1,50597,,In vivo,Blood,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627475,,,A
13925,Intermediate,,1,,10116.0,14653,1,50597,,In vivo,Blood,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL627476,,,A
12582,Intermediate,,1,,9615.0,14654,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627477,,,A
12582,Intermediate,,1,,9615.0,14655,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627478,,,A
12582,Intermediate,,1,,9615.0,14656,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627479,,,A
12582,Intermediate,,1,,9615.0,14657,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627480,,,A
12582,Intermediate,,1,,9615.0,14658,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627481,,,A
12582,Intermediate,,1,,9615.0,14659,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627482,,,A
12582,Intermediate,,1,,9615.0,14660,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL627483,,,A
12582,Intermediate,,1,,9615.0,14661,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL875636,,,A
12582,Intermediate,,1,,9615.0,14662,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625764,,,A
12582,Intermediate,,1,,9615.0,14663,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625765,,,A
12582,Intermediate,,1,,9615.0,14664,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625766,,,A
12582,Intermediate,,1,,9615.0,14665,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625767,,,A
12582,Intermediate,,1,,9615.0,14666,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625768,,,A
12582,Intermediate,,1,,9615.0,14667,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625769,,,A
12582,Intermediate,,1,,9615.0,14668,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625770,,,A
12582,Intermediate,,1,,9615.0,14669,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625771,,,A
12582,Intermediate,,1,,9615.0,14670,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625772,,,A
12582,Intermediate,,1,,9615.0,14671,1,50588,,,Urine,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,N,,Canis lupus familiaris,BAO_0000218,1088.0,CHEMBL625773,,,A
12582,Intermediate,,1,,10116.0,14672,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625774,,,A
12582,Intermediate,,1,,10116.0,14673,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625775,,,A
12582,Intermediate,,1,,10116.0,14674,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625776,,,A
12582,Intermediate,,1,,10116.0,14675,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625777,,,A
12582,Intermediate,,1,,10116.0,14676,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625778,,,A
12582,Intermediate,,1,,10116.0,14677,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625779,,,A
12582,Intermediate,,1,,10116.0,14678,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625780,,,A
12582,Intermediate,,1,,10116.0,14679,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL625781,,,A
12582,Intermediate,,1,,10116.0,14680,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875637,,,A
12582,Intermediate,,1,,10116.0,14681,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626473,,,A
12582,Intermediate,,1,,10116.0,14682,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626474,,,A
12582,Intermediate,,1,,10116.0,14683,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626475,,,A
12582,Intermediate,,1,,10116.0,14684,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626476,,,A
12582,Intermediate,,1,,10116.0,14685,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL634397,,,A
12582,Intermediate,,1,,10116.0,14686,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL626477,,,A
12582,Intermediate,,1,,10116.0,14687,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631069,,,A
12582,Intermediate,,1,,10116.0,14688,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631070,,,A
12582,Intermediate,,1,,10116.0,14689,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631071,,,A
12582,Intermediate,,1,,10116.0,14690,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631072,,,A
12582,Intermediate,,1,,10116.0,14691,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631073,,,A
12582,Intermediate,,1,,10116.0,14692,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631074,,,A
12582,Intermediate,,1,,10116.0,14693,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631075,,,A
12582,Intermediate,,1,,10116.0,14694,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631725,,,A
12582,Intermediate,,1,,10116.0,14695,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631726,,,A
12582,Intermediate,,1,,10116.0,14696,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631727,,,A
12582,Intermediate,,1,,10116.0,14697,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631728,,,A
12582,Intermediate,,1,,10116.0,14698,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631729,,,A
12582,Intermediate,,1,,10116.0,14699,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631730,,,A
12582,Intermediate,,1,,10116.0,14700,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631731,,,A
12582,Intermediate,,1,,10116.0,14701,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631910,,,A
15413,Intermediate,,1,,10116.0,14702,1,50597,,In vivo,Hippocampus,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,N,,Rattus norvegicus,BAO_0000218,10000000.0,CHEMBL631911,,,A
15413,Intermediate,,1,,10116.0,14703,1,50597,,In vivo,Hypothalamus,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL631912,,,A
15413,Intermediate,,1,,10116.0,14704,1,50597,,In vivo,Hypothalamus,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,N,,Rattus norvegicus,BAO_0000218,1898.0,CHEMBL631913,,,A
12017,Intermediate,,1,,10116.0,14705,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631914,,,A
12017,Intermediate,,1,,10116.0,14706,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631915,,,A
12017,Intermediate,,1,,10116.0,14707,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL875778,,,A
12017,Intermediate,,1,,10116.0,14708,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631916,,,A
12017,Intermediate,,1,,10116.0,14709,1,50597,,In vivo,Blood,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631917,,,A
12017,Intermediate,,1,,10116.0,14710,1,50597,,In vivo,Blood,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631918,,,A
12017,Intermediate,,1,,10116.0,14711,1,50597,,In vivo,Blood,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631919,,,A
12017,Intermediate,,1,,10116.0,14712,1,50597,,In vivo,Blood,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631920,,,A
12017,Intermediate,,1,,10116.0,14713,1,50597,,In vivo,Blood,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631921,,,A
12017,Intermediate,,1,,10116.0,14714,1,50597,,In vivo,Blood,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631922,,,A
12017,Intermediate,,1,,10116.0,14715,1,50597,,In vivo,Blood,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL631923,,,A
12017,Intermediate,,1,,10116.0,14716,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631924,,,A
12017,Intermediate,,1,,10116.0,14717,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630234,,,A
12017,Intermediate,,1,,10116.0,14718,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630235,,,A
12017,Intermediate,,1,,10116.0,14719,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630236,,,A
12017,Intermediate,,1,,10116.0,14720,1,50597,,In vivo,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630237,,,A
12017,Intermediate,,1,,10116.0,14721,1,50597,,In vivo,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630238,,,A
12017,Intermediate,,1,,10116.0,14722,1,50597,,In vivo,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630239,,,A
12017,Intermediate,,1,,10116.0,14723,1,50597,,In vivo,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630303,,,A
12017,Intermediate,,1,,10116.0,14724,1,50597,,In vivo,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630304,,,A
12017,Intermediate,,1,,10116.0,14725,1,50597,,In vivo,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630305,,,A
12017,Intermediate,,1,,10116.0,14726,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630306,,,A
12017,Intermediate,,1,,10116.0,14727,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630307,,,A
12017,Intermediate,,1,,10116.0,14728,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630308,,,A
12017,Intermediate,,1,,10116.0,14729,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL630309,,,A
12017,Intermediate,,1,,10116.0,14730,1,50597,,In vivo,Kidney,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL629309,,,A
12017,Intermediate,,1,,10116.0,14731,1,50597,,In vivo,Kidney,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL629993,,,A
12017,Intermediate,,1,,10116.0,14732,1,50597,,In vivo,Kidney,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL629994,,,A
12017,Intermediate,,1,,10116.0,14733,1,50597,,In vivo,Kidney,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL629995,,,A
12017,Intermediate,,1,,10116.0,14734,1,50597,,In vivo,Kidney,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL631993,,,A
12017,Intermediate,,1,,10116.0,14735,1,50597,,In vivo,Kidney,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL631994,,,A
12017,Intermediate,,1,,10116.0,14736,1,50597,,In vivo,Kidney,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL631995,,,A
12017,Intermediate,,1,,10116.0,14737,1,50597,,In vivo,Liver,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631996,,,A
12017,Intermediate,,1,,10116.0,14738,1,50597,,In vivo,Liver,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631997,,,A
12017,Intermediate,,1,,10116.0,14739,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631998,,,A
12017,Intermediate,,1,,10116.0,14740,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631999,,,A
12017,Intermediate,,1,,10116.0,14741,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL632000,,,A
12017,Intermediate,,1,,10116.0,14742,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL632001,,,A
12017,Intermediate,,1,,10116.0,14743,1,50597,,In vivo,Liver,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL874424,,,A
12017,Intermediate,,1,,10116.0,14744,1,50597,,In vivo,Liver,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL632002,,,A
12017,Intermediate,,1,,10116.0,14745,1,50597,,In vivo,Liver,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL632003,,,A
3133,Autocuration,,1,,,14746,0,22224,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,U,,,BAO_0000019,,CHEMBL632004,,,A
2742,Autocuration,,1,,,14747,0,22224,,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,U,,,BAO_0000019,,CHEMBL632005,,,A
2742,Autocuration,,1,,,14748,0,22224,,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,,U,,,BAO_0000019,,CHEMBL632006,,,A
2742,Autocuration,,1,,,14749,0,22224,,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,U,,,BAO_0000019,,CHEMBL632007,,,A
2742,Autocuration,,1,,,14750,0,22224,,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,,U,,,BAO_0000019,,CHEMBL632008,,,A
2742,Autocuration,,1,,,14751,0,22224,,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,U,,,BAO_0000019,,CHEMBL632009,,,A
2742,Autocuration,,1,,,14752,0,22224,,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,,U,,,BAO_0000019,,CHEMBL632010,,,A
2742,Autocuration,,1,,,14753,0,22224,,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,U,,,BAO_0000019,,CHEMBL857750,,,A
2742,Autocuration,,1,,,14754,0,22224,,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,,U,,,BAO_0000019,,CHEMBL632011,,,A
2276,Autocuration,,1,,,14755,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,,,BAO_0000019,,CHEMBL632012,,,A
2276,Autocuration,,1,,,14756,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,,,BAO_0000019,,CHEMBL632013,,,A
2276,Autocuration,,1,,,14757,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,U,,,BAO_0000019,,CHEMBL632014,,,A
2276,Autocuration,,1,,,14758,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,,,BAO_0000019,,CHEMBL629622,,,A
2276,Autocuration,,1,,,14759,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,U,,,BAO_0000019,,CHEMBL629623,,,A
2276,Autocuration,,1,,,14760,0,22224,,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,U,,,BAO_0000019,,CHEMBL629624,,,A
17269,Autocuration,,1,,,14761,0,22224,,,,Ratio of Kcat to that of Km was determined,,U,,,BAO_0000019,,CHEMBL629625,,,A
2276,Autocuration,,1,,,14762,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,U,,,BAO_0000019,,CHEMBL629626,,,A
2276,Autocuration,,1,,,14763,0,22224,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,U,,,BAO_0000019,,CHEMBL629627,,,A
15917,Autocuration,,1,,,14764,0,22224,,,,"Compound was evaluated for constant, Kd",,U,,,BAO_0000019,,CHEMBL629628,,,A
10933,Autocuration,,1,,,14765,0,22224,,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,U,,,BAO_0000019,,CHEMBL629629,,,A
10933,Autocuration,,1,,,14766,0,22224,,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,U,,,BAO_0000019,,CHEMBL629630,,,A
14293,Autocuration,,1,,,14767,0,22224,,,,Dissociation Constant of compound determined,,U,,,BAO_0000019,,CHEMBL856030,,,A
6698,Autocuration,,1,,,14768,0,22224,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,U,,,BAO_0000019,,CHEMBL629631,,,B
6698,Autocuration,,1,,,14769,0,22224,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,U,,,BAO_0000019,,CHEMBL629632,,,B
4318,Autocuration,,1,,,14770,0,22224,,,,Dissociation constant of compound with Fructose was determined,,U,,,BAO_0000100,,CHEMBL629633,,,P
4318,Autocuration,,1,,,14771,0,22224,,,,Dissociation constant of compound with Fructose was determined; Not determined,,U,,,BAO_0000100,,CHEMBL629634,,,P
4318,Autocuration,,1,,,14772,0,22224,,,,Dissociation constant of compound with Lactulose was determined,,U,,,BAO_0000100,,CHEMBL629635,,,P
4318,Autocuration,,1,,,14773,0,22224,,,,Dissociation constant of compound with Lactulose was determined; Not determined,,U,,,BAO_0000100,,CHEMBL629636,,,P
14959,Autocuration,,1,,,14774,0,22224,,,,Dissociation constant of the Compound,,U,,,BAO_0000100,,CHEMBL629637,,,P
5913,Autocuration,,1,,,14775,0,22224,,,,Dissociation constant by non-linear regression analysis,,U,,,BAO_0000100,,CHEMBL629638,,,P
14218,Autocuration,,1,,,14776,0,22224,,,,Dissociation constant was determined,,U,,,BAO_0000100,,CHEMBL629639,,,P
10689,Autocuration,,1,,,14777,0,22224,,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,U,,,BAO_0000100,,CHEMBL629640,,,P
13925,Autocuration,,1,,,14778,0,22224,,,,Dissociation constant was determined,,U,,,BAO_0000100,,CHEMBL629641,,,P
16359,Autocuration,,1,,,14779,0,22224,,,,Dissociation constant was determined,,U,,,BAO_0000100,,CHEMBL631344,,,P
10944,Intermediate,,1,,10116.0,14780,1,50597,,,Muscle tissue,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631345,,,A
11080,Autocuration,,1,,,14781,0,22224,,,,The dissociation constant determined by fluorescence displacement assay,,U,,,BAO_0000019,,CHEMBL631346,,,A
17805,Autocuration,,1,,,14782,0,22224,,,,kd value surface plasmon resonance (SPR) method,,U,,,BAO_0000019,,CHEMBL631524,,,A
10944,Intermediate,,1,,10116.0,14783,1,50597,,,Muscle tissue,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631525,,,A
16645,Autocuration,,1,,,14784,0,22224,,,,First dissociation constant of the binding of compound to V30M TTR,,U,,,BAO_0000019,,CHEMBL631526,,,F
16645,Autocuration,,1,,,14785,0,22224,,,,Second dissociation constant of the binding of compound to V30M TTR,,U,,,BAO_0000019,,CHEMBL631527,,,F
7793,Autocuration,,1,,,14786,0,22224,,,,"Compound was evaluated for equilibrium constant, Ke",,U,,,BAO_0000019,,CHEMBL631528,,,A
12199,Autocuration,,1,,,14787,0,22224,,,Hypothalamus,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,U,,,BAO_0000019,1898.0,CHEMBL631529,,,A
12199,Autocuration,,1,,,14788,0,22224,,,Hypothalamus,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,U,,,BAO_0000019,1898.0,CHEMBL631530,,,A
9680,Autocuration,,1,,,14789,0,22224,,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,U,,,BAO_0000019,,CHEMBL631531,,,A
9680,Autocuration,,1,,,14790,0,22224,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,U,,,BAO_0000019,,CHEMBL631532,,,A
9680,Autocuration,,1,,,14791,0,22224,,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,U,,,BAO_0000019,,CHEMBL631533,,,A
13758,Intermediate,,1,,10090.0,14792,1,50594,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL876552,,,A
13758,Intermediate,,1,,10090.0,14793,1,50594,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631534,,,A
13758,Intermediate,,1,,10090.0,14794,1,50594,,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631535,,,A
13758,Intermediate,,1,,10090.0,14795,1,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631536,,,A
13758,Intermediate,,1,,10090.0,14796,1,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631537,,,A
13758,Intermediate,,1,,10090.0,14797,1,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631538,,,A
13758,Intermediate,,1,,10090.0,14798,1,50594,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631539,,,A
13758,Intermediate,,1,,10090.0,14799,1,50594,,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,N,,Mus musculus,BAO_0000218,,CHEMBL631540,,,A
14393,Intermediate,,1,,10116.0,14800,1,50597,,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625637,,,A
14393,Intermediate,,1,,10116.0,14801,1,50597,,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625638,,,A
15078,Intermediate,,1,,10116.0,14802,1,50597,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL625639,,,A
13925,Intermediate,,1,,10116.0,14803,1,50597,,In vivo,Brain,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625640,,,A
13925,Intermediate,,1,,10116.0,14804,1,50597,,In vivo,Brain,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625641,,,A
13925,Intermediate,,1,,10116.0,14805,1,50597,,In vivo,Heart,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625642,,,A
13925,Intermediate,,1,,10116.0,14806,1,50597,,In vivo,Heart,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625643,,,A
13925,Intermediate,,1,,10116.0,14807,1,50597,,In vivo,Kidney,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625644,,,A
13925,Intermediate,,1,,10116.0,14808,1,50597,,In vivo,Kidney,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2113.0,CHEMBL625645,,,A
13925,Intermediate,,1,,10116.0,14809,1,50597,,In vivo,Liver,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625646,,,A
13925,Intermediate,,1,,10116.0,14810,1,50597,,In vivo,Liver,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625647,,,A
13925,Intermediate,,1,,10116.0,14811,1,50597,,In vivo,Lung,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625648,,,A
13925,Intermediate,,1,,10116.0,14812,1,50597,,In vivo,Lung,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL625649,,,A
13925,Intermediate,,1,,10116.0,14813,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625650,,,A
13925,Intermediate,,1,,10116.0,14814,1,50597,,In vivo,Muscle tissue,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL625651,,,A
13925,Intermediate,,1,,10116.0,14815,1,50597,,In vivo,Zone of skin,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL625652,,,A
13925,Intermediate,,1,,10116.0,14816,1,50597,,In vivo,Zone of skin,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,14.0,CHEMBL625653,,,A
13925,Intermediate,,1,,10116.0,14817,1,50597,,In vivo,Spleen,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625654,,,A
13925,Intermediate,,1,,10116.0,14818,1,50597,,In vivo,Spleen,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL625655,,,A
9712,Intermediate,,1,,10116.0,14819,1,50597,,In vivo,Blood,Biodistribution of Compound in rat blood after 15 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625656,,,A
9712,Intermediate,,1,,10116.0,14820,1,50597,,In vivo,Blood,Biodistribution of Compound in rat blood after 2 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,178.0,CHEMBL625657,,,A
9712,Intermediate,,1,,10116.0,14821,1,50597,,In vivo,Brain,Biodistribution of Compound in rat brain after 15 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625658,,,A
9712,Intermediate,,1,,10116.0,14822,1,50597,,In vivo,Brain,Biodistribution of Compound in rat brain after 2 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,955.0,CHEMBL625659,,,A
9712,Intermediate,,1,,10116.0,14823,1,50597,,In vivo,Heart,Biodistribution of Compound in rat heart after 15 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625660,,,A
9712,Intermediate,,1,,10116.0,14824,1,50597,,In vivo,Heart,Biodistribution of Compound in rat heart after 2 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,948.0,CHEMBL625661,,,A
9712,Intermediate,,1,,10116.0,14825,1,50597,,In vivo,Liver,Biodistribution of Compound in rat liver after 15 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625662,,,A
9712,Intermediate,,1,,10116.0,14826,1,50597,,In vivo,Liver,Biodistribution of Compound in rat liver after 2 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL625663,,,A
9712,Intermediate,,1,,10116.0,14827,1,50597,,In vivo,Lung,Biodistribution of Compound in rat lung after 15 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL875621,,,A
9712,Intermediate,,1,,10116.0,14828,1,50597,,In vivo,Lung,Biodistribution of Compound in rat lung after 2 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL628382,,,A
9712,Intermediate,,1,,10116.0,14829,1,50597,,In vivo,Muscle tissue,Biodistribution of Compound in rat muscle after 15 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL628383,,,A
9712,Intermediate,,1,,10116.0,14830,1,50597,,In vivo,Muscle tissue,Biodistribution of Compound in rat muscle after 2 minutes of administration,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL628384,,,A
13925,Intermediate,,1,,10116.0,14831,1,50597,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628385,,,A
13925,Intermediate,,1,,10116.0,14832,1,50597,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875753,,,A
13925,Intermediate,,1,,10116.0,14833,1,50597,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628386,,,A
6941,Intermediate,,1,,10116.0,14834,1,50597,,,,Organ distribution in rat blood 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628387,,,A
6941,Intermediate,,1,,10116.0,14835,1,50597,,,,Organ distribution in rat blood 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628388,,,A
6941,Intermediate,,1,,10116.0,14836,1,50597,,,,Organ distribution in rat blood 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628389,,,A
6941,Intermediate,,1,,10116.0,14837,1,50597,,,,Organ distribution in rat blood 30 min after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL632756,,,A
6941,Intermediate,,1,,10116.0,14838,1,50597,,,,Organ distribution in rat brain 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628390,,,A
6941,Intermediate,,1,,10116.0,14839,1,50597,,,,Organ distribution in rat brain 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631811,,,A
6941,Intermediate,,1,,10116.0,14840,1,50597,,,,Organ distribution in rat brain 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631812,,,A
6941,Intermediate,,1,,10116.0,14841,1,50597,,,,Organ distribution in rat heart 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631813,,,A
6941,Intermediate,,1,,10116.0,14842,1,50597,,,,Organ distribution in rat heart 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631814,,,A
6941,Intermediate,,1,,10116.0,14843,1,50597,,,,Organ distribution in rat heart 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631815,,,A
6941,Intermediate,,1,,10116.0,14844,1,50597,,,,Organ distribution in rat kidney 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631816,,,A
6941,Intermediate,,1,,10116.0,14845,1,50597,,,,Organ distribution in rat kidney 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL875758,,,A
6941,Intermediate,,1,,10116.0,14846,1,50597,,,,Organ distribution in rat kidney 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631817,,,A
6941,Intermediate,,1,,10116.0,14847,1,50597,,,Liver,Organ distribution in rat liver 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631818,,,A
6941,Intermediate,,1,,10116.0,14848,1,50597,,,Liver,Organ distribution in rat liver 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631819,,,A
6941,Intermediate,,1,,10116.0,14849,1,50597,,,Liver,Organ distribution in rat liver 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL631820,,,A
6941,Intermediate,,1,,10116.0,14850,1,50597,,,,Organ distribution in rat lung 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631821,,,A
6941,Intermediate,,1,,10116.0,14851,1,50597,,,,Organ distribution in rat lung 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631822,,,A
6941,Intermediate,,1,,10116.0,14852,1,50597,,,,Organ distribution in rat lung 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL631823,,,A
6941,Intermediate,,1,,10116.0,14853,1,50597,,,Muscle tissue,Organ distribution in rat muscle 2 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631824,,,A
6941,Intermediate,,1,,10116.0,14854,1,50597,,,Muscle tissue,Organ distribution in rat muscle 2 hr after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631825,,,A
6941,Intermediate,,1,,10116.0,14855,1,50597,,,Muscle tissue,Organ distribution in rat muscle 30 minutes after intravenous injection,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631826,,,A
14439,Intermediate,,1,,10090.0,14856,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL631827,,,A
14439,Intermediate,,1,,10090.0,14857,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,N,,Mus musculus,BAO_0000218,,CHEMBL631828,,,A
14439,Intermediate,,1,,10090.0,14858,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,N,,Mus musculus,BAO_0000218,,CHEMBL631829,,,A
12582,Intermediate,,1,,10116.0,14859,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875759,,,A
12582,Intermediate,,1,,10116.0,14860,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631830,,,A
12582,Intermediate,,1,,10116.0,14861,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631831,,,A
12582,Intermediate,,1,,10116.0,14862,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631832,,,A
12582,Intermediate,,1,,10116.0,14863,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631833,,,A
12582,Intermediate,,1,,10116.0,14864,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631834,,,A
12582,Intermediate,,1,,10116.0,14865,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631835,,,A
12582,Intermediate,,1,,10116.0,14866,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631836,,,A
12582,Intermediate,,1,,10116.0,14867,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631837,,,A
12582,Intermediate,,1,,10116.0,14868,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631838,,,A
12582,Intermediate,,1,,10116.0,14869,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631839,,,A
12582,Intermediate,,1,,10116.0,14870,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631840,,,A
12582,Intermediate,,1,,10116.0,14871,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631841,,,A
12582,Intermediate,,1,,10116.0,14872,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631842,,,A
12582,Intermediate,,1,,10116.0,14873,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631843,,,A
12582,Intermediate,,1,,10116.0,14874,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631844,,,A
12582,Intermediate,,1,,10116.0,14875,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631845,,,A
12582,Intermediate,,1,,10116.0,14876,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631846,,,A
12582,Intermediate,,1,,10116.0,14877,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL875760,,,A
12582,Intermediate,,1,,10116.0,14878,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL632199,,,A
12582,Intermediate,,1,,10116.0,14879,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631847,,,A
12582,Intermediate,,1,,10116.0,14880,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL631848,,,A
12582,Intermediate,,1,,10116.0,14881,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628707,,,A
12582,Intermediate,,1,,10116.0,14882,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628708,,,A
12582,Intermediate,,1,,10116.0,14883,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628709,,,A
12582,Intermediate,,1,,10116.0,14884,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628710,,,A
12582,Intermediate,,1,,10116.0,14885,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628711,,,A
12582,Intermediate,,1,,10116.0,14886,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628712,,,A
12582,Intermediate,,1,,10116.0,14887,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628713,,,A
12582,Intermediate,,1,,10116.0,14888,1,50597,,,Urine,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,N,,Rattus norvegicus,BAO_0000218,1088.0,CHEMBL628714,,,A
7415,Intermediate,,1,,10116.0,14889,1,50597,,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,N,,Rattus norvegicus,BAO_0000218,,CHEMBL628715,,,A
7313,Autocuration,,1,,,14890,0,22224,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,U,,,BAO_0000019,,CHEMBL629179,,,A
7313,Autocuration,,1,,,14891,0,22224,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,U,,,BAO_0000019,,CHEMBL629180,,,A
7313,Autocuration,,1,,,14892,0,22224,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,U,,,BAO_0000019,,CHEMBL875108,,,A
7570,Autocuration,,1,,,14893,0,22224,,,Adrenal cortex,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,U,,,BAO_0000019,1235.0,CHEMBL629181,,,A
7570,Autocuration,,1,,,14894,0,22224,,,Adrenal cortex,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,U,,,BAO_0000019,1235.0,CHEMBL629182,,,A
7570,Autocuration,,1,,,14895,0,22224,,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629183,,,A
7570,Autocuration,,1,,,14896,0,22224,,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629184,,,A
7570,Autocuration,,1,,,14897,0,22224,,,Adrenal cortex,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,U,,,BAO_0000019,1235.0,CHEMBL629185,,,A
7570,Autocuration,,1,,,14898,0,22224,,,Adrenal cortex,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,U,,,BAO_0000019,1235.0,CHEMBL629186,,,A
7570,Autocuration,,1,,,14899,0,22224,,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629187,,,A
7570,Autocuration,,1,,,14900,0,22224,,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629887,,,A
7570,Autocuration,,1,,,14901,0,22224,,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629888,,,A
7570,Autocuration,,1,,,14902,0,22224,,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629889,,,A
7570,Autocuration,,1,,,14903,0,22224,,,Adrenal cortex,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,U,,,BAO_0000019,1235.0,CHEMBL629890,,,A
7570,Autocuration,,1,,,14904,0,22224,,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629891,,,A
7570,Autocuration,,1,,,14905,0,22224,,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629892,,,A
7570,Autocuration,,1,,,14906,0,22224,,,Adrenal cortex,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,U,,,BAO_0000019,1235.0,CHEMBL629893,,,A
7570,Autocuration,,1,,,14907,0,22224,,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629894,,,A
7570,Autocuration,,1,,,14908,0,22224,,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,U,,,BAO_0000019,,CHEMBL629895,,,A
14122,Autocuration,,1,,9615.0,14909,0,22224,,In vivo,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,U,,Canis lupus familiaris,BAO_0000218,,CHEMBL875109,,,A
16449,Autocuration,,1,,9541.0,14910,0,22224,,In vivo,,Absolute bioavailability in male cynomolgus monkeys,,U,,Macaca fascicularis,BAO_0000218,,CHEMBL629896,,,A
16449,Autocuration,,1,,10116.0,14911,0,22224,,In vivo,,Absolute bioavailability in maleSprague-Dawley rats,,U,,Rattus norvegicus,BAO_0000218,,CHEMBL629897,,,A
12017,Intermediate,,1,,10116.0,14912,1,50597,,In vivo,Liver,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL629898,,,A
12017,Intermediate,,1,,10116.0,14913,1,50597,,In vivo,Liver,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL630057,,,A
12017,Intermediate,,1,,10116.0,14914,1,50597,,In vivo,Liver,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2107.0,CHEMBL630058,,,A
12017,Intermediate,,1,,10116.0,14915,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630059,,,A
12017,Intermediate,,1,,10116.0,14916,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630060,,,A
12017,Intermediate,,1,,10116.0,14917,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630061,,,A
12017,Intermediate,,1,,10116.0,14918,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630062,,,A
12017,Intermediate,,1,,10116.0,14919,1,50597,,In vivo,Lung,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630063,,,A
12017,Intermediate,,1,,10116.0,14920,1,50597,,In vivo,Lung,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630064,,,A
12017,Intermediate,,1,,10116.0,14921,1,50597,,In vivo,Lung,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630065,,,A
12017,Intermediate,,1,,10116.0,14922,1,50597,,In vivo,Lung,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630066,,,A
12017,Intermediate,,1,,10116.0,14923,1,50597,,In vivo,Lung,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630067,,,A
12017,Intermediate,,1,,10116.0,14924,1,50597,,In vivo,Lung,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2048.0,CHEMBL630068,,,A
12017,Intermediate,,1,,10116.0,14925,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631113,,,A
12017,Intermediate,,1,,10116.0,14926,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631114,,,A
12017,Intermediate,,1,,10116.0,14927,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631115,,,A
12017,Intermediate,,1,,10116.0,14928,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL631116,,,A
12017,Intermediate,,1,,10116.0,14929,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630528,,,A
12017,Intermediate,,1,,10116.0,14930,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630529,,,A
12017,Intermediate,,1,,10116.0,14931,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630530,,,A
12017,Intermediate,,1,,10116.0,14932,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630531,,,A
12017,Intermediate,,1,,10116.0,14933,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630532,,,A
12017,Intermediate,,1,,10116.0,14934,1,50597,,In vivo,Muscle tissue,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2385.0,CHEMBL630533,,,A
15045,Intermediate,,1,,10090.0,14935,1,50594,,In vivo,Blood,Biodistribution in normal mice blood after 120 hr,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL630534,,,A
15045,Intermediate,,1,,10090.0,14936,1,50594,,In vivo,Blood,Biodistribution in normal mice blood after 24 hr,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL630535,,,A
15045,Intermediate,,1,,10090.0,14937,1,50594,,In vivo,Blood,Biodistribution in normal mice blood after 4 hr,,N,,Mus musculus,BAO_0000218,178.0,CHEMBL630536,,,A
15045,Intermediate,,1,,10090.0,14938,1,50594,,In vivo,Bone,Biodistribution in normal mice bone after 120 hr,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL630537,,,A
15045,Intermediate,,1,,10090.0,14939,1,50594,,In vivo,Bone,Biodistribution in normal mice bone after 24 hr,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL630538,,,A
15045,Intermediate,,1,,10090.0,14940,1,50594,,In vivo,Bone,Biodistribution in normal mice bone after 4 hr,,N,,Mus musculus,BAO_0000218,10000001.0,CHEMBL630539,,,A
15045,Intermediate,,1,,10090.0,14941,1,50594,,In vivo,Heart,Biodistribution in normal mice heart after 120 hr,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL630540,,,A
15045,Intermediate,,1,,10090.0,14942,1,50594,,In vivo,Heart,Biodistribution in normal mice heart after 24 hr,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL630541,,,A
15045,Intermediate,,1,,10090.0,14943,1,50594,,In vivo,Heart,Biodistribution in normal mice heart after 4 hr,,N,,Mus musculus,BAO_0000218,948.0,CHEMBL630542,,,A
15045,Intermediate,,1,,10090.0,14944,1,50594,,In vivo,Kidney,Biodistribution in normal mice kidney after 120 hr,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL630543,,,A
15045,Intermediate,,1,,10090.0,14945,1,50594,,In vivo,Kidney,Biodistribution in normal mice kidney after 24 hr,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL630544,,,A
15045,Intermediate,,1,,10090.0,14946,1,50594,,In vivo,Kidney,Biodistribution in normal mice kidney after 4 hr,,N,,Mus musculus,BAO_0000218,2113.0,CHEMBL630545,,,A
15045,Intermediate,,1,,10090.0,14947,1,50594,,In vivo,Liver,Biodistribution in normal mice liver after 120 hr,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL630546,,,A
15045,Intermediate,,1,,10090.0,14948,1,50594,,In vivo,Liver,Biodistribution in normal mice liver after 24 hr,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL630547,,,A
15045,Intermediate,,1,,10090.0,14949,1,50594,,In vivo,Liver,Biodistribution in normal mice liver after 4 hr,,N,,Mus musculus,BAO_0000218,2107.0,CHEMBL630548,,,A
15045,Intermediate,,1,,10090.0,14950,1,50594,,In vivo,Spleen,Biodistribution in normal mice spleen after 120 hr,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL630549,,,A
15045,Intermediate,,1,,10090.0,14951,1,50594,,In vivo,Spleen,Biodistribution in normal mice spleen after 24 hr,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL630550,,,A
15045,Intermediate,,1,,10090.0,14952,1,50594,,In vivo,Spleen,Biodistribution in normal mice spleen after 4 hr,,N,,Mus musculus,BAO_0000218,2106.0,CHEMBL876426,,,A
12017,Intermediate,,1,,10116.0,14953,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630551,,,A
12017,Intermediate,,1,,10116.0,14954,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630552,,,A
12017,Intermediate,,1,,10116.0,14955,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630553,,,A
12017,Intermediate,,1,,10116.0,14956,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630554,,,A
12017,Intermediate,,1,,10116.0,14957,1,50597,,In vivo,Spleen,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630555,,,A
12017,Intermediate,,1,,10116.0,14958,1,50597,,In vivo,Spleen,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630556,,,A
12017,Intermediate,,1,,10116.0,14959,1,50597,,In vivo,Spleen,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630557,,,A
12017,Intermediate,,1,,10116.0,14960,1,50597,,In vivo,Spleen,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630558,,,A
12017,Intermediate,,1,,10116.0,14961,1,50597,,In vivo,Spleen,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630559,,,A
12017,Intermediate,,1,,10116.0,14962,1,50597,,In vivo,Spleen,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2106.0,CHEMBL630560,,,A
12017,Intermediate,,1,,10116.0,14963,1,50597,,In vivo,Thyroid gland,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,N,,Rattus norvegicus,BAO_0000218,2046.0,CHEMBL876427,,,A
14941,Intermediate,,1,,10116.0,14964,1,50597,,,,The Kel values in female wistar rats.,,N,,Rattus norvegicus,BAO_0000218,,CHEMBL630561,,,A
4646,Autocuration,,1,,,14965,0,22224,,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,U,,,BAO_0000019,,CHEMBL630562,,,A
8847,Autocuration,,1,,,14966,0,22224,,,,Hydrolysis rate constant of the compound,,U,,,BAO_0000019,,CHEMBL630563,,,A
11778,Autocuration,,1,,,14967,0,22229,,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,U,,,BAO_0000100,,CHEMBL629673,,,P
2363,Autocuration,,1,,,14968,0,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,U,,,BAO_0000019,,CHEMBL629674,,,A
2363,Autocuration,,1,,,14969,0,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,U,,,BAO_0000019,,CHEMBL629675,,,A
2363,Autocuration,,1,,,14970,0,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,U,,,BAO_0000019,,CHEMBL629676,,,A
2363,Autocuration,,1,,,14971,0,22224,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,U,,,BAO_0000019,,CHEMBL629677,,,A
8371,Autocuration,,1,,,14972,0,22224,,,,Apparent inactivation rate constant was evaluated,,U,,,BAO_0000019,,CHEMBL629678,,,A
14883,Autocuration,,1,,,14973,0,22224,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,U,,,BAO_0000019,,CHEMBL629679,,,A
14883,Autocuration,,1,,,14974,0,22224,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,U,,,BAO_0000019,,CHEMBL629680,,,A
4643,Autocuration,,1,,,14975,0,22224,,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,U,,,BAO_0000019,,CHEMBL629681,,,A
3519,Autocuration,,1,,,14976,0,22224,,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,U,,,BAO_0000019,,CHEMBL629682,,,A
10600,Autocuration,,1,,,14977,0,22224,,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,U,,,BAO_0000019,,CHEMBL629683,,,A
8501,Autocuration,,1,,,14978,0,22224,,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,U,,,BAO_0000019,,CHEMBL629684,,,F
8505,Autocuration,,1,,,14979,0,22224,,,,Dissociation constant was determined,,U,,,BAO_0000100,,CHEMBL629685,,,P
9778,Autocuration,,1,,,14980,0,22224,,,,Dissociation constant was determined,,U,,,BAO_0000100,,CHEMBL629686,,,P
9778,Autocuration,,1,,,14981,0,22224,,,,Dissociation constant at pH 7.4,,U,,,BAO_0000100,,CHEMBL872932,,,P
9778,Autocuration,,1,,,14982,0,22224,,,,Dissociation constant in presence of 1 mM dithiothreitol,,U,,,BAO_0000100,,CHEMBL629687,,,P
13007,Autocuration,,1,,,14983,0,22224,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,U,,,BAO_0000019,,CHEMBL872931,,,A
13007,Autocuration,,1,,,14984,0,22224,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,U,,,BAO_0000019,,CHEMBL628151,,,A
13007,Autocuration,,1,,,14985,0,22224,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,U,,,BAO_0000019,,CHEMBL628152,,,A
13007,Autocuration,,1,,,14986,0,22224,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,U,,,BAO_0000019,,CHEMBL628153,,,A
11482,Autocuration,,1,,,14987,0,22224,,,,Kinetic constant for aromatization of androstenedione,,U,,,BAO_0000019,,CHEMBL628154,,,A
11482,Autocuration,,1,,,14988,0,22224,,,,Kinetic constant for aromatization of testosterone,,U,,,BAO_0000019,,CHEMBL628155,,,A
2303,Autocuration,,1,,,14989,0,22224,,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,U,,,BAO_0000019,,CHEMBL628156,,,A
11964,Autocuration,,1,,,14990,0,22224,,,,Local inhibition constant was determined,,U,,,BAO_0000019,,CHEMBL628157,,,A
3140,Intermediate,,1,,4932.0,14991,1,50347,,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,N,,Saccharomyces cerevisiae,BAO_0000218,,CHEMBL857533,,,A
10650,Autocuration,,1,,,14992,0,22224,,,,Dissociation constant value of the compound,,U,,,BAO_0000100,,CHEMBL628158,,,P
4667,Autocuration,,1,,,14993,0,22224,,,Cornea,In vitro permeability through cornea without epithelium,,U,,,BAO_0000019,964.0,CHEMBL628159,,,A
4667,Autocuration,,1,,,14994,0,22224,,,Cornea,In vitro permeability through intact cornea,,U,,,BAO_0000019,964.0,CHEMBL875616,,,A
9199,Intermediate,,1,,9986.0,14995,1,50592,,,Cornea,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,N,,Oryctolagus cuniculus,BAO_0000218,964.0,CHEMBL628160,,,A
11966,Autocuration,,1,,,14996,0,22224,,,,Rate of enzyme inactivation for the compound was determined,,U,,,BAO_0000019,,CHEMBL628161,,,A
4667,Autocuration,,1,,,14997,0,22224,,,Cornea,In vitro permeability through cornea without epithelium,,U,,,BAO_0000019,964.0,CHEMBL628162,,,A
4667,Autocuration,,1,,,14998,0,22224,,,Cornea,In vitro permeability through intact cornea,,U,,,BAO_0000019,964.0,CHEMBL628163,,,A
8354,Autocuration,,1,,,14999,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628164,,,A
8354,Autocuration,,1,,,15000,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628165,,,A
8354,Autocuration,,1,,,15001,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628166,,,A
8354,Autocuration,,1,,,15002,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628167,,,A
8354,Autocuration,,1,,,15003,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628168,,,A
8354,Autocuration,,1,,,15004,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628169,,,A
8354,Autocuration,,1,,,15005,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628170,,,A
8354,Autocuration,,1,,,15006,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628171,,,A
8354,Autocuration,,1,,,15007,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL627434,,,A
8354,Autocuration,,1,,,15008,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL627435,,,A
8354,Autocuration,,1,,,15009,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628110,,,A
8354,Autocuration,,1,,,15010,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628111,,,A
8354,Autocuration,,1,,,15011,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628112,,,A
8354,Autocuration,,1,,,15012,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628260,,,A
8354,Autocuration,,1,,,15013,0,22224,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,U,,,BAO_0000019,,CHEMBL628261,,,A
14439,Intermediate,,1,,10090.0,15014,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,N,,Mus musculus,BAO_0000218,,CHEMBL628262,,,A
14439,Intermediate,,1,,9606.0,15015,1,50587,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,N,,Homo sapiens,BAO_0000218,,CHEMBL628263,,,A
14439,Intermediate,,1,,10090.0,15016,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL628264,,,A
14439,Intermediate,,1,,10090.0,15017,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,N,,Mus musculus,BAO_0000218,,CHEMBL628265,,,A
14439,Intermediate,,1,,10090.0,15018,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,N,,Mus musculus,BAO_0000218,,CHEMBL628266,,,A
14439,Intermediate,,1,,10090.0,15019,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,N,,Mus musculus,BAO_0000218,,CHEMBL628267,,,A
14439,Intermediate,,1,,10090.0,15020,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,N,,Mus musculus,BAO_0000218,,CHEMBL628268,,,A
14439,Intermediate,,1,,10090.0,15021,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,N,,Mus musculus,BAO_0000218,,CHEMBL628269,,,A
14439,Intermediate,,1,,10090.0,15022,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,N,,Mus musculus,BAO_0000218,,CHEMBL628270,,,A
14439,Intermediate,,1,,10090.0,15023,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,N,,Mus musculus,BAO_0000218,,CHEMBL628271,,,A
14439,Intermediate,,1,,10090.0,15024,1,50594,,In vivo,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,N,,Mus musculus,BAO_0000218,,CHEMBL628272,,,A
